<SEC-DOCUMENT>0001144204-17-018352.txt : 20170403
<SEC-HEADER>0001144204-17-018352.hdr.sgml : 20170403
<ACCEPTANCE-DATETIME>20170403073626
ACCESSION NUMBER:		0001144204-17-018352
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		63
CONFORMED PERIOD OF REPORT:	20161231
FILED AS OF DATE:		20170403
DATE AS OF CHANGE:		20170403

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Moleculin Biotech, Inc.
		CENTRAL INDEX KEY:			0001659617
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				474671999
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37758
		FILM NUMBER:		17732307

	BUSINESS ADDRESS:	
		STREET 1:		2575 WEST BELLFORT
		STREET 2:		SUITE 333
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77054
		BUSINESS PHONE:		713-300-5160

	MAIL ADDRESS:	
		STREET 1:		2575 WEST BELLFORT
		STREET 2:		SUITE 333
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77054
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>v462503_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>UNITED
STATES </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>SECURITIES
AND EXCHANGE COMMISSION </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C., 20549 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>FORM 10-K
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Wingdings"><B>x</B></FONT><B>
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 50%; font-size: 10pt; text-align: center"><font style="font-size: 10pt"><b>For the fiscal year ended December 31, 2016</b></font></td>
    <td style="width: 50%; font-size: 10pt; text-align: center"><font style="font-size: 10pt"><b>Commission File Number: 001-37758</b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><IMG SRC="pg1img1_10k.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Moleculin
Biotech, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified
in its charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="width: 34%; text-align: center"><font style="font-size: 10pt"><b>Delaware</b></font></td>
    <TD NOWRAP STYLE="width: 32%; text-align: center"><font style="font-size: 10pt"><b>2834</b></font></td>
    <TD NOWRAP STYLE="width: 34%; text-align: center"><font style="font-size: 10pt"><b>47-4671997</b></font></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="text-align: center"><font style="font-size: 10pt"><b>(State or Other Jurisdiction of</b></font></td>
    <TD NOWRAP STYLE="text-align: center"><font style="font-size: 10pt"><b>(Primary Standard Industrial</b></font></td>
    <TD NOWRAP STYLE="text-align: center"><font style="font-size: 10pt"><b>(I.R.S. Employer</b></font></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="text-align: center"><font style="font-size: 10pt"><b>Incorporation or Organization)</b></font></td>
    <TD NOWRAP STYLE="text-align: center"><font style="font-size: 10pt"><b>Classification Code Number)</b></font></td>
    <TD NOWRAP STYLE="text-align: center"><font style="font-size: 10pt"><b>Identification Number)</b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2575 West Bellfort, Suite 333</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Houston, Texas 77054</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(713) 300-5160</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address, Including Zip Code, and Telephone
Number, Including Area Code, of Registrant&rsquo;s Principal Executive Offices)&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities registered pursuant to Section
12(b) of the Act: Common Stock, par value $0.001</B><BR>
<B>per share</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities registered pursuant to Section
12(g) of the Act: None</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is a well-known seasoned
issuer, as defined in Rule 405 of the Securities Act.&nbsp;&nbsp;&nbsp;&nbsp;YES&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;NO&nbsp;&nbsp;
<FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is not required to
file reports pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Act.&nbsp;&nbsp;&nbsp;&nbsp;YES&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;NO&nbsp;&nbsp;
<FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant (1)&nbsp;has filed
all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter periods as the registrant was required to file such reports) and (2)&nbsp;has been subject to such filing
requirements for the past 90&nbsp;days.&nbsp;&nbsp;&nbsp;&nbsp;YES&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT>&nbsp;&nbsp;&nbsp;&nbsp;NO&nbsp;&nbsp;
<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant has submitted
electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant
to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit
and post such files).&nbsp;&nbsp;&nbsp;&nbsp;YES&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT>&nbsp;&nbsp;&nbsp;&nbsp;NO&nbsp;&nbsp;
<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Indicate by check mark if disclosure
of delinquent filers pursuant to Item&nbsp;405 of Regulation S-K is not contained herein, and will not be contained, to the best
of registrant&rsquo;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form
10-K or any amendment to this Form 10-K.&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &ldquo;large accelerated
filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo; in Rule 12b-2 of the Exchange Act. (check
one)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 24%; text-align: center"><font style="font-size: 10pt">Large accelerated filer&nbsp;&nbsp;&nbsp;<font style="font-family: Wingdings">&uml;</font></font></td>
    <td style="width: 19%; text-align: center"><font style="font-size: 10pt">Accelerated filer&nbsp;&nbsp;&nbsp;<font style="font-family: Wingdings">&uml;</font></font></td>
    <td style="width: 22%; text-align: center"><font style="font-size: 10pt">Non-accelerated filer&nbsp;&nbsp;&nbsp;<font style="font-family: Wingdings">&uml;</font></font></td>
    <td style="width: 35%; text-align: center"><font style="font-size: 10pt">Smaller reporting company&nbsp;&nbsp;&nbsp;<font style="font-family: Wingdings">x</font></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Act).&nbsp;&nbsp;&nbsp;&nbsp;YES&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;NO&nbsp;&nbsp;
<FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9pt 0pt 0">The aggregate market value of the registrant&rsquo;s
voting equity held by non-affiliates of the registrant, computed by reference to the price at which the common stock was last sold
as of the last business day of the registrant&rsquo;s most recently completed second fiscal quarter, was $27,612,783. In determining
the market value of the voting equity held by non-affiliates, securities of the registrant beneficially owned by directors, officers
and 10% or greater shareholders of the registrant have been excluded. This determination of affiliate status is not necessarily
a conclusive determination for other purposes. The number of shares of the registrant&rsquo;s common stock outstanding as of March
24, 2017 was 17,176,872.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DOCUMENTS INCORPORATED BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Portions of this registrant&rsquo;s definitive proxy statement
for its 2017 Annual Meeting of Stockholders to be filed with the SEC no later than 120 days after the end of the registrant&rsquo;s
fiscal year are incorporated herein by reference in Part III of this Annual Report on Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Table of Contents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 92%; text-transform: uppercase; font-weight: bold"><A HREF="#main_001"><font style="font-family: Times New Roman, Times, Serif">PART I</font></A></td>
    <TD STYLE="vertical-align: bottom; width: 8%; text-align: right; text-transform: uppercase; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">2</font></td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-transform: uppercase; font-weight: bold">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: right; text-transform: uppercase; font-weight: bold">&nbsp;</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-transform: uppercase; font-weight: bold"><A HREF="#main_002"><font style="font-family: Times New Roman, Times, Serif">ITEM 1. BUSINESS</font></A></td>
    <TD STYLE="vertical-align: bottom; text-align: right; text-transform: uppercase; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">2</font></td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-transform: uppercase; font-weight: bold">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: right; text-transform: uppercase; font-weight: bold">&nbsp;</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-transform: uppercase; font-weight: bold"><A HREF="#main_003"><font style="font-family: Times New Roman, Times, Serif">ITEM 1A. RISK FACTORS</font></A></td>
    <TD STYLE="vertical-align: bottom; text-align: right; text-transform: uppercase; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">24</font></td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-transform: uppercase; font-weight: bold">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: right; text-transform: uppercase; font-weight: bold">&nbsp;</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-transform: uppercase; font-weight: bold"><A HREF="#main_004"><font style="font-family: Times New Roman, Times, Serif">ITEM 1B. UNRESOLVED STAFF COMMENTS</font></A></td>
    <TD STYLE="vertical-align: bottom; text-align: right; text-transform: uppercase; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">40</font></td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-transform: uppercase; font-weight: bold">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: right; text-transform: uppercase; font-weight: bold">&nbsp;</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-transform: uppercase; font-weight: bold"><A HREF="#main_005"><font style="font-family: Times New Roman, Times, Serif">ITEM 2. PROPERTIES</font></A></td>
    <TD STYLE="vertical-align: bottom; text-align: right; text-transform: uppercase; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">40</font></td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-transform: uppercase; font-weight: bold">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: right; text-transform: uppercase; font-weight: bold">&nbsp;</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-transform: uppercase; font-weight: bold"><A HREF="#main_006"><font style="font-family: Times New Roman, Times, Serif">ITEM 3. LEGAL PROCEEDINGS</font></A></td>
    <TD STYLE="vertical-align: bottom; text-align: right; text-transform: uppercase; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">40</font></td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-transform: uppercase; font-weight: bold">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: right; text-transform: uppercase; font-weight: bold">&nbsp;</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-transform: uppercase; font-weight: bold"><A HREF="#main_007"><font style="font-family: Times New Roman, Times, Serif">ITEM 4. MINE SAFETY DISCLOSURE</font></A></td>
    <TD STYLE="vertical-align: bottom; text-align: right; text-transform: uppercase; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">40</font></td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-transform: uppercase; font-weight: bold">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: right; text-transform: uppercase; font-weight: bold">&nbsp;</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-transform: uppercase; font-weight: bold"><A HREF="#main_009"><font style="font-family: Times New Roman, Times, Serif">ITEM 5. MARKET FOR REGISTRANT&rsquo;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</font></A></td>
    <TD STYLE="vertical-align: bottom; text-align: right; text-transform: uppercase; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">41</font></td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-transform: uppercase; font-weight: bold">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: right; text-transform: uppercase; font-weight: bold">&nbsp;</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-transform: uppercase; font-weight: bold"><A HREF="#main_010"><font style="font-family: Times New Roman, Times, Serif">ITEM 6. SELECTED FINANCIAL DATA</font></A></td>
    <TD STYLE="vertical-align: bottom; text-align: right; text-transform: uppercase; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">43</font></td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-transform: uppercase; font-weight: bold">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: right; text-transform: uppercase; font-weight: bold">&nbsp;</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-transform: uppercase; font-weight: bold"><A HREF="#main_011"><font style="font-family: Times New Roman, Times, Serif">ITEM 7. MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></A></td>
    <TD STYLE="vertical-align: bottom; text-align: right; text-transform: uppercase; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">43</font></td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-transform: uppercase; font-weight: bold">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: right; text-transform: uppercase; font-weight: bold">&nbsp;</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-transform: uppercase; font-weight: bold"><A HREF="#main_012"><font style="font-family: Times New Roman, Times, Serif">ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS</font></A></td>
    <TD STYLE="vertical-align: bottom; text-align: right; text-transform: uppercase; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">53</font></td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-transform: uppercase; font-weight: bold">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: right; text-transform: uppercase; font-weight: bold">&nbsp;</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-transform: uppercase; font-weight: bold"><A HREF="#main_013"><font style="font-family: Times New Roman, Times, Serif">ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</font></A></td>
    <TD STYLE="vertical-align: bottom; text-align: right; text-transform: uppercase; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">53</font></td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-transform: uppercase; font-weight: bold">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: right; text-transform: uppercase; font-weight: bold">&nbsp;</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-transform: uppercase; font-weight: bold"><A HREF="#main_014"><font style="font-family: Times New Roman, Times, Serif">ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</font></A></td>
    <TD STYLE="vertical-align: bottom; text-align: right; text-transform: uppercase; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">53</font></td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-transform: uppercase; font-weight: bold">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: right; text-transform: uppercase; font-weight: bold">&nbsp;</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-transform: uppercase; font-weight: bold"><A HREF="#main_015"><font style="font-family: Times New Roman, Times, Serif">ITEM 9A. CONTROLS AND PROCEDURES</font></A></td>
    <TD STYLE="vertical-align: bottom; text-align: right; text-transform: uppercase; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">54</font></td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-transform: uppercase; font-weight: bold">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: right; text-transform: uppercase; font-weight: bold">&nbsp;</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-transform: uppercase; font-weight: bold"><A HREF="#main_016"><font style="font-family: Times New Roman, Times, Serif">ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</font></A></td>
    <TD STYLE="vertical-align: bottom; text-align: right; text-transform: uppercase; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">56</font></td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-transform: uppercase; font-weight: bold">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: right; text-transform: uppercase; font-weight: bold">&nbsp;</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-transform: uppercase; font-weight: bold"><A HREF="#main_017"><font style="font-family: Times New Roman, Times, Serif">ITEM 11. EXECUTIVE COMPENSATION</font></A></td>
    <TD STYLE="vertical-align: bottom; text-align: right; text-transform: uppercase; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">56</font></td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-transform: uppercase; font-weight: bold">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: right; text-transform: uppercase; font-weight: bold">&nbsp;</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-transform: uppercase; font-weight: bold"><A HREF="#main_018"><font style="font-family: Times New Roman, Times, Serif">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</font></A></td>
    <TD STYLE="vertical-align: bottom; text-align: right; text-transform: uppercase; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">56</font></td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-transform: uppercase; font-weight: bold">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: right; text-transform: uppercase; font-weight: bold">&nbsp;</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-transform: uppercase; font-weight: bold"><A HREF="#main_019"><font style="font-family: Times New Roman, Times, Serif">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</font></A></td>
    <TD STYLE="vertical-align: bottom; text-align: right; text-transform: uppercase; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">56</font></td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-transform: uppercase; font-weight: bold">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: right; text-transform: uppercase; font-weight: bold">&nbsp;</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-transform: uppercase; font-weight: bold"><A HREF="#main_020"><font style="font-family: Times New Roman, Times, Serif">ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</font></A></td>
    <TD STYLE="vertical-align: bottom; text-align: right; text-transform: uppercase; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">56</font></td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-transform: uppercase; font-weight: bold">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: right; text-transform: uppercase; font-weight: bold">&nbsp;</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-transform: uppercase; font-weight: bold"><A HREF="#main_021"><font style="font-family: Times New Roman, Times, Serif">ITEM 15. EXHIBITS AND FINANCIAL STATEMENTS</font></A></td>
    <TD STYLE="vertical-align: bottom; text-align: right; text-transform: uppercase; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">57</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CAUTIONARY NOTE REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Securities and Exchange Commission,
referred to herein as the SEC, encourages companies to disclose forward-looking information so that investors can better understand
a company&rsquo;s future prospects and make informed investment decisions. Certain statements that we may make from time to time,
including, without limitation, statements contained in this report constitute &ldquo;forward- looking statements&rdquo; within
the meaning of the Private Securities Litigation Reform Act of 1995.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We make forward-looking statements under
the &ldquo;Risk Factors,&rdquo; &ldquo;Business,&rdquo; &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition
and Results of Operations&rdquo; and in other sections of this report. In some cases, you can identify these statements by forward-looking
words such as &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;should,&rdquo; &ldquo;would,&rdquo; &ldquo;could,&rdquo; &ldquo;expect,&rdquo;
&ldquo;plan,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;predict,&rdquo;
&ldquo;potential&rdquo; or &ldquo;continue,&rdquo; and the negative of these terms and other comparable terminology. These forward-looking
statements, which are subject to known and unknown risks, uncertainties and assumptions about us, may include projections of our
future financial performance based on our growth strategies and anticipated trends in our business. These statements are only predictions
based on our current expectations and projections about future events. There are important factors that could cause our actual
results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or
achievements expressed or implied by the forward-looking statements. In particular, you should consider the numerous risks and
uncertainties described under &ldquo;Risk Factors.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">While we believe we have identified material
risks, these risks and uncertainties are not exhaustive. Other sections of this report describe additional factors that could
adversely impact our business and financial performance. Moreover, we operate in a very highly regulated, competitive and rapidly
changing environment. New risks and uncertainties emerge from time to time, and it is not possible to predict all risks and uncertainties,
nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may
cause actual results to differ materially from those contained in any forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Although we believe the expectations reflected
in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements.
Moreover, neither we nor any other person assumes responsibility for the accuracy or completeness of any of these forward-looking
statements. You should not rely upon forward-looking statements as predictions of future events. We are under no duty to update
any of these forward-looking statements after the date of this report to conform our prior statements to actual results or revised
expectations, and we do not intend to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Forward-looking statements include, but
are not limited to, statements about:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to obtain additional funding to develop our product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the need to obtain regulatory approval of our product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the success of our clinical trials through all phases of clinical development;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to complete our clinical trials in a timely fashion and within our expected budget;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>compliance with obligations under intellectual property licenses with third parties;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any delays in regulatory review and approval of product candidates in clinical development;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to commercialize our product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>market acceptance of our product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>competition from existing products or new products that may emerge;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>potential product liability claims;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our dependency on third-party manufacturers to supply or manufacture our products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to establish or maintain collaborations, licensing or other arrangements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability and third parties&rsquo; abilities to protect intellectual property rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to adequately support future growth; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to attract and retain key personnel to manage our business effectively.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We caution you not to place undue reliance
on the forward-looking statements, which speak only as of the date of this Form 10-K in the case of forward-looking statements
contained in this Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="main_001"></A>PART I</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>References in this Annual Report on Form
10-K to &ldquo;MBI&rdquo; or &ldquo;the Company&rdquo;, &ldquo;we&rdquo;, &ldquo;our&rdquo; and &ldquo;us&rdquo; are used herein
to refer to Moleculin Biotech, Inc. </I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="main_002"></A>ITEM 1. BUSINESS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">MBI is a preclinical-stage pharmaceutical
company organized as a Delaware corporation in July 2015 to focus on the development of anti-cancer drug candidates, some of which
are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, which we refer
to as MD Anderson. Our lead drug candidate is liposomal Annamycin, which we refer to as Annamycin, an anthracycline being studied
for the treatment of relapsed or refractory acute myeloid leukemia, or AML. Annamycin has been in clinical trials pursuant to an
Investigational New Drug application, or IND, that had been filed with the FDA. Due to a lack of development activity by a prior
drug developer, this IND was terminated. To permit the renewed investigation of Annamycin, we are submitting a new IND augmenting
the data that supported the original IND, with subsequent clinical data and additional information. We have two other drug development
projects in process, one involving a collection of small molecules, which we refer to as the WP1066 Portfolio, focused on the modulation
of key regulatory transcription factors involved in the progression of cancer, and the WP1222 Portfolio, a suite of molecules targeting
the metabolic processes involved in cancer in general and glioblastoma (the most common form of brain tumor) in particular. We
also continue to sponsor ongoing research at MD Anderson in order to improve and expand our drug development pipeline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We have been granted
royalty-bearing, worldwide, exclusive licenses for the patent and technology rights related to our WP1066 Portfolio and WP1122
Portfolio drug technologies, as these patent rights are owned by MD Anderson. The Annamycin drug substance is no longer covered
by any existing patent protection. We intend to submit patent applications for formulation, synthetic process and reconstitution
related to our Annamycin drug product candidate, although there is no assurance that we will be successful in obtaining <FONT STYLE="font-family: Times New Roman, Times, Serif">such
patent protection. Independently from potential patent protection, we have received Orphan Drug designation from the FDA for Annamycin
for the treatment of AML,</FONT> which would entitle us to market exclusivity of 7 years from the date of approval of a New Drug
Application (NDA) in the United States. If we submit and receive approval for a New Drug Application (NDA) for Annamycin for the
treatment of AML, we may then benefit from Orphan Drug exclusivity, during which period FDA generally could not approve another
Annamycin product for the same use. We also intend to apply for similar status in the European Union (EU) where market exclusivity
extends to 10 years from the date of Marketing Authorization Application (MAA). Separately, the FDA may also grant market exclusivity
of 5 years for newly approved new chemical entities (of which Annamycin would be one), but there can be no assurance that such
exclusivity will be granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate History</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We were founded in 2015 by Walter Klemp
(our chairman and CEO), Dr. Don Picker (our President and Chief Operating Officer) and Dr. Waldemar Priebe of MD Anderson (Chairman
of our Scientific Advisory Board) in order to combine and consolidate development efforts that include several MD Anderson anti-cancer
technologies. This effort began with the acquisition of the Annamycin development project from AnnaMed, Inc., or AnnaMed, followed
by the acquisition of the license rights to the WP1122 Portfolio from IntertechBio Corporation, or IntertechBio. Further, we undertook
an effort to gain control of the WP1066 Portfolio, which culminated with the merger of Moleculin, LLC and MBI and the establishment
of a co-development agreement with Houston Pharmaceuticals, Inc., or HPI, coincident with our IPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">AnnaMed was formed in 2012 to take over
the development of Annamycin from a prior drug development company, Callisto Pharmaceuticals, Inc., or Callisto. Callisto ceased
development work on Annamycin, leading to the termination of its IND by the FDA. Callisto disclosed publicly in its Form 10-K
filing for the year ended 2009 that the clinical data relating to acute leukemia patients &ldquo;did not support further clinical
evaluation of L-Annamycin as a single agent to treat relapsed or refractory adult acute leukemia patients.&rdquo; In order to
satisfy unmet license obligations, Callisto agreed to transfer all available Annamycin data to AnnaMed, which data we are using
and have augmented with additional data and information to apply for a new IND. As such, notwithstanding Callisto&rsquo;s determination
to terminate its development of Annamycin, we are utilizing the clinical data from Callisto&rsquo;s trials to apply for a new
IND. The basis for our decision to proceed notwithstanding Callisto&rsquo;s determination is that we believe the actual clinical
data as reported by Dr. Robert Shepard, our Chief Medical Officer and who was Callisto&rsquo;s Chief Medical Officer at the time
of the clinical trials, to the 2009 Annual Meeting of the American Society of Clinical Oncology, and as further reported by the
Principal Investigators of the clinical trials in a peer-reviewed journal article (Clin Lymphoma Myeloma Leuk. 2013 August; 13(4):
430&ndash;434. doi:10.1016/j.clml.2013.03.015.), supports further clinical evaluation. In addition, the conclusion published in
the 2013 Clinical Lymphoma, Myeloma &amp; Leukemia journal article was that &ldquo;Single agent nanomolecular liposomal annamycin
appears to be well-tolerated and evidence of clinical activity as a single agent in refractory adult ALL.&rdquo; As reported in
both the ASCO presentation and the 2013 journal article referenced, the definition of efficacy is based on the following Response
Criteria: &ldquo;Response criteria were achievement of CR defined as &le;5% blasts, granulocyte count of &ge;1&times;109/L, and
a platelet count of &ge;100&times;109/L. Partial remission was defined the same as CR, except for the presence of 6% to 25% blasts.
Hematologic improvement was defined as for CR but platelet count &lt;100&times;109/L.&rdquo; The summary of patient response from
the 2013 journal article reads: &ldquo;After determining the MTD, a 10-patient phase IIA was conducted. Eight of the patients
completed one cycle of the three days of treatment at the MTD. Of these, five (62%) demonstrated encouraging anti-leukemic activity
with complete clearing of circulating peripheral blasts. Three of these subjects also cleared bone marrow blasts with one subsequently
proceeding onto successful stem cell transplantation. The other two developed tumor lysis syndrome and unfortunately expired prior
to response assessment.&rdquo; In the Company&rsquo;s review of these trials, it confirmed that the activity demonstrated in this
summary corresponds with a &ldquo;Partial remission&rdquo; as described in the Response Criteria and that the three subjects who
&ldquo;cleared bone marrow blasts&rdquo; correspond with &ldquo;CR&rdquo; (Complete Response).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In 2012, AnnaMed out-licensed development
rights in a limited territory to a Polish special purpose drug development company called Dermin in exchange for Dermin&rsquo;s
development work based on its successful effort to obtain Polish government grant funding to assist in the development of Annamycin.
Since that time, such grant funding has been used to produce Annamycin in preparation for future clinical trials. In August 2015,
we entered into a rights transfer agreement with AnnaMed pursuant to which, in exchange for 1,431,000 shares of our common stock,
AnnaMed agreed to transfer any and all data it had regarding the development of Annamycin and the Annamycin IND, including all
trade secrets, know-how, confidential information and other intellectual property rights held by AnnaMed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IntertechBio was formed in 2009 to license
and begin development on the WP1122 Portfolio. The WP1122 Portfolio was also out-licensed to Dermin, which was awarded a Polish
government grant to assist in drug development efforts. In August 2015, IntertechBio agreed to assign all license rights to us
in exchange for our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Moleculin, LLC was formed in 2006 and has
been working to develop the WP1066 Portfolio it licensed from MD Anderson. As a part of the formation of Moleculin, LLC, an agreement
was reached with HPI to limit Moleculin, LLC&rsquo;s development efforts to uses in dermatology only, leaving non-dermatology indications
to HPI. From 2006 to 2014, Moleculin, LLC funded its operations through the sale of equity and debt securities and through fees
received from an out-licensing agreement with a Japanese dermatology drug development company, Maruho, Ltd., or Maruho. Beginning
in 2012, Moleculin, LLC conducted a series of clinical trials focused on the topical treatment of psoriasis. Although those trials
demonstrated drug activity, the results were not conclusive enough to warrant full commercialization as a topical dermatology drug.
Additional study was required to determine optimal dosing and scheduling regimens for the topical treatment of psoriatic plaques.
As a result of this additional complexity with regard to the potential treatment of psoriasis, Maruho did not elect to continue
its funding of the psoriasis drug development effort and, therefore, forfeited their license rights to the WP1066 Portfolio that
had been granted to it by Moleculin, LLC. Dermin is planning to clinically evaluate a candidate from the WP1066 Portfolio for the
topical treatment of cutaneous T-cell lymphoma, or CTCL. We do not have control of the clinical plan or timeline for Dermin&rsquo;s
development effort.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Prior to our IPO, Moleculin, LLC was merged
with and into our company. The merger agreement contains mutual representations and warranties between the parties. Pursuant to
the merger agreement, we agreed for a period of six years to indemnify and hold harmless each present and former director and/or
officer of Moleculin, LLC whom Moleculin, LLC would have had the power to indemnify under Delaware law that is made a party or
threatened to be made a party to any threatened, pending or completed proceeding or claim by reason of the fact that he or she
was a director or officer of the Moleculin, LLC prior to the effective time of the merger and arising out of actions or omissions
of the indemnified party in any such capacity occurring at or prior to the effective time of the merger against any losses or damages
reasonably incurred in connection with any claim. To our knowledge, no such proceeding or claim exists or has been threatened on
the date hereof and Moleculin, LLC made representations to this effect in the merger agreement as of the date of such agreement.
As additional consideration payable to the Moleculin, LLC unit holders, we agreed pursuant to the merger agreement that if drugs
for dermatology indications are successfully developed by us (or our successors) using any of the Existing IP Assets, then the
Moleculin, LLC unit holders, in the aggregate, will be entitled to receive a 2.5% royalty on the net revenues generated by such
drugs. Any such net revenues would include a deduction for license fees or royalty obligations payable to MD Anderson for such
Existing IP Assets. The merger agreement defined &ldquo;Existing IP Assets&rdquo; to mean all intellectual property, licensed by
us and Moleculin, LLC as of the time of the merger, including, without limitation, the intellectual property licensed from MD Anderson
under the Patent and Technology License Agreement entered into by and between IntertechBio Corporation and MD Anderson dated April
2, 2012, as amended, and the Patent and Technology License Agreement dated June 21, 2010, as amended, between MD Anderson and Moleculin,
LLC, but excluding any intellectual property relating to Annamycin. The right to receive the contingent royalty payments described
herein are for drugs developed only for dermatology indications, and do not include drugs developed for any other indications.
We have no obligation of any nature to pursue the development of any drugs for dermatology indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">From 2006 through 2015, HPI was engaged
in research related to the use of the WP1066 Portfolio for the treatment of non-dermatology cancers and received grant awards totaling
approximately $4.9 million toward this effort. Prior to our IPO, we entered into a co-development agreement with HPI whereby HPI
is continuing its grant-funded research and making all resulting data available for our use in exchange for a development fee.
We may buy HPI out of its co-development rights in the WP1066 Portfolio at our option. Please see the section &ldquo;Business &ndash;
License Agreements&rdquo; for a description of our agreement with HPI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Neither our founders nor MBI have or will
have any ownership stake in Dermin, our Polish licensee. No Dermin-related grant money is expected to be paid directly to us, but
rather the sublicense agreements require Dermin to share resulting data, which we believe will reduce costs we might otherwise
have to incur directly. There can be no assurance, however, that Dermin will continue to receive the funds they have been awarded
or that such funds will be spent by Dermin in a manner that will benefit MBI. The sublicensed territories granted to Dermin for
the WP1066 Portfolio are Poland, Ukraine, Czech Republic, Hungary, Romania, Slovakia, Belarus, Lithuania, Latvia and Estonia. For
the WP1122 Portfolio, the territory expanded to include Russia and Kazakhstan. For Annamycin, the territory is further expanded
to include Netherlands, Turkey, Belgium, Switzerland, Austria, Sweden, Greece, Portugal, Norway, Denmark, Ireland, Finland, Luxembourg,
Iceland, Uzbekistan, Georgia, Armenia, Azerbaijan and Germany. However, in the case of Germany, this territory may be reclaimed
by us for a payment of $500,000 to Dermin.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following summarizes the transactional
history and common relationships among HPI, IntertechBio, Moleculin, LLC, MBI, Callisto, AnnaMed, MD Anderson, and our officers
and major shareholders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Moleculin,
LLC</I>: Prior to our IPO, Moleculin, LLC was merged with and into our company. Moleculin, LLC was the holder of the license agreement
with MD Anderson covering our WP 1066 Portfolio. As a result of the merger, we issued the equity interests holders of Moleculin,
LLC an aggregate of 999,931 shares of our common stock. Waldemar Priebe, chairman of our Scientific Advisory Board, Walter Klemp,
our chairman and chief executive officer, and Don Picker, our president and chief operating officer, were members of Moleculin,
LLC and received 6,046 shares, 22,795 shares and 6,046 shares, respectively, of our common stock as a result of the merger. In
addition, Walter Klemp and Don Picker were members of the board of Moleculin, LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Houston
Pharmaceuticals, Inc.</I>: Prior to our IPO, MBI on Moleculin, LLC&rsquo;s behalf, entered into a co-development agreement with
HPI whereby HPI is continuing its grant-funded research and making all resulting data available for our use in exchange for a development
fee. Waldemar Priebe, chairman of our Scientific Advisory Board, and Don Picker, our president and chief operating officer, are
shareholders of HPI, and Dr. Priebe has the voting and dispositive power over the shares held by HPI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>IntertechBio
Corporation</I>: In August 2015, in exchange for the issuance of 630,000 shares of common stock, we acquired the rights to the
license agreement with MD Anderson covering our WP1122 Portfolio held by IntertechBio Corporation. Waldemar Priebe, chairman of
our Scientific Advisory Board, and Don Picker, our president and chief operating officer, are shareholders of IntertechBio and
control the voting and dispositive power over the shares held by IntertechBio.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>AnnaMed,
Inc.</I>: In August 2015, in exchange for 1,431,000 shares of our common stock, we acquired the rights to the Annamycin data related
to the original Annamycin IND and the development of Annamycin held by AnnaMed, Inc., a company controlled by Walter Klemp, our
chairman and chief executive officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Callisto
Pharmaceuticals, Inc.</I>: Our president and chief operating officer, Don Picker and our chief medical officer, Robert Shepard,
were chief operating officer and chief medical officer, respectively, of Callisto. Since 2009, neither individual has had any relationship
or ownership with Callisto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>MD
Anderson</I>: Both Moleculin, LLC and IntertechBio entered into license agreements with MD Anderson. See &ldquo;Business &ndash;
Our Licenses Agreements&rdquo; below. Waldemar Priebe, chairman of our Scientific Advisory Board, is a Professor of Medicinal Chemistry,
Department of Experimental Therapeutics, Division of Cancer Medicine, at the University of Texas MD Anderson Cancer Center.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Drug Candidates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Annamycin</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our lead product candidate
is Annamycin, for which FDA has granted Orphan Drug designation <FONT STYLE="font-family: Times New Roman, Times, Serif">for the
treatment of AML</FONT>. We intend to conduct clinical trials for Annamycin as a monotherapy for the treatment of relapsed or refractory
AML. If Annamycin is ultimately approved on this basis, it is possible, with the necessary subsequent testing and approval, that
it could be used in the future in combination with other drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Market for Annamycin</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Leukemia is a cancer of the white blood
cells and acute forms of leukemia can manifest quickly and leave patients with limited treatment options. AML is the most common
type of acute leukemia in adults. It occurs when a clone of leukemic progenitor white blood cells proliferates in the bone marrow,
suppressing the production of normal blood cells. Currently, the only viable option for acute leukemia patients is a bone marrow
transplant, which is successful in a significant number of patients. However, in order to qualify for a bone marrow transplant,
the patient&rsquo;s leukemia cells must be decreased to a sufficiently low level. This usually begins with a therapy of combining
two chemotherapeutic drugs, which almost always includes an anthracycline to induce remission (a complete response, or CR). This
therapy has not improved since it was first used in the 1970s and we estimate that this induction therapy has a success rate of
about 20%, as it has from the time of its initial use. Unfortunately, the current clinically approved anthracyclines are cardiotoxic
(i.e., can damage the heart), which can limit the dosage amount that may be administered to patients. Additionally, the tumor
cells often present de novo or develop resistance to the first line anthracycline, through what is called &ldquo;multidrug resistance,&rdquo;
enabling the tumor cells to purge themselves of the available anthracyclines. Consequently, there remains no effective therapy
for inducing remission in these patients sufficient to enable a curative bone marrow transplant and unfortunately most will succumb
quickly to their leukemia. If a patient&rsquo;s leukemia reappears before they can be prepared for a bone marrow transplant, they
are considered to have &ldquo;relapsed.&rdquo; If a patient fails to achieve a sufficient response from the induction therapy
to qualify for a bone marrow transplant, they are considered to be &ldquo;refractory&rdquo; (resistant to therapy). Together,
this group of relapsed and refractory AML patients constitutes our primary focus for treatment with Annamycin and our intent is
to pursue FDA approval for Annamycin as a second-line induction therapy for adult relapsed and refractory AML patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe that pursuing approval as a
second line induction therapy for adult relapsed or refractory AML patients is the shortest path to regulatory approval, but we
also believe that one of the most important potential uses of Annamycin is in the treatment of children with either AML or ALL
(acute lymphoblastic leukemia, which is more common in children). Accordingly, we also intend to pursue approval for pediatric
use in these conditions when practicable.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Of the estimated 18,860 U.S. cases of acute
myeloid leukemia diagnosed in 2014, an estimated 97% were adult and although exact numbers are not available, we estimate that
70% to 80% (approximately 13,000 to 14,000 patients) were expected to relapse or be resistant to first-line therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Prior Clinical Trials for Annamycin</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Annamycin is a liposome formulated anthracycline (also referred to in literature as &ldquo;L-Annamycin&rdquo;).
It has been tested in 6 clinical trials and 114 patients with little to no reported cardiotoxicity and, in the two clinical trials
focused on leukemia, with fewer dose-limiting toxicities than are normally expected with doxorubicin (one of the leading first-line
anthracyclines used for induction therapy). Each of these trials was conducted by a prior developer of Annamycin, and not by our
company. Annamycin demonstrated significant activity in 8 of 16 patients in a Phase I study in adult relapsed or refractory AML
and ALL patients, with 6 of 14 patients completely clearing leukemic bone marrow blasts. The reason only 14 (rather than 16) patients
were tested for leukemic bone marrow blasts is that 2 of the 16 patients succumbed to their disease before bone marrow testing
could be completed. In a 30 patient dose-ranging Phase I/II study in ALL, 3 of 8 patients treated with the maximum tolerable dose
cleared their leukemic blasts to a level sufficient to qualify for a bone marrow transplant. One of these patients went on to receive
a successful curative bone marrow transplant. The other two of these three patients died of tumor lysis syndrome, a condition resulting
from the overloading of their system with the debris from leukemic blast cells destroyed by the induction therapy. Armed with the
knowledge of this potential, prophylactic pretreatment intended to protect patients from the effects of tumor lysis syndrome will
be deployed where appropriate in future trials. Based on the results of the above clinical trials, we believe Annamycin may be
different from currently approved induction therapy drugs in four key ways: (i) it has demonstrated clinical activity in a patient
population for whom there are currently no effective therapies, (ii) it appears to be capable of avoiding the &ldquo;multi-drug
resistance&rdquo; mechanisms that have been associated with limiting the effectiveness of currently approved anthracyclines; (iii)
it has been shown to be non-cardiotoxic in animal models and little to no cardiotoxicity has been reported from the use of Annamycin
in 114 patients; and (iv) in certain AML cell lines, it has been shown to be more potent than one of the leading approved anthracyclines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Based on initial conversations with the
FDA, because of the serious unmet medical need, we believe Annamycin may qualify for accelerated approval based on our planned
clinical trials. In order to facilitate our communication with the FDA, we requested access to and reviewed in detail the available
data supporting the dose-ranging Phase I/II clinical trial discussed above, which was conducted by a previous developer of Annamycin.
In October 2016, we announced that we had identified some positive findings from this review, which gave rise to a modification
of our own clinical development plan. We had indicated that our plan was to conduct a detailed review of the clinical results generated
by that prior developer, and then to use those results to reestablish an IND in order to continue clinical trials of Annamycin.
However, in the course of our review, we identified that Annamycin may have greater potential for efficacy than we originally believed,
based on an unexpected potential opportunity to increase the drug&rsquo;s Maximum Tolerable Dose (&ldquo;MTD&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In particular, the Dose Limiting Toxicities
(&ldquo;DLTs&rdquo;) reported in the previous trial that led to the establishment of the current MTD of 150 mg/m<SUP>2</SUP> were
all from patients who had an unusually high number of first-line induction therapy failures prior to being treated with Annamycin.
Specifically, of the three patients in the last clinical trial who experienced these DLTs, one of them had failed nineteen prior
induction therapy attempts, another had failed sixteen and the other had failed fifteen before being enrolled in the trial. We
concluded from our review of this data that, if the heavily treated patients are excluded from the data set, the MTD could have
been closer to 250 mg/m<SUP>2</SUP>, substantially higher than the level that was actually set by this previous trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We view this as an encouraging development
because it means we may have an opportunity to increase the MTD for our next trial from 150 mg/m<SUP>2</SUP> to 200 or even 250
mg/m<SUP>2</SUP>. If that turns out to be the case, we believe it could increase the chance for positive outcomes in our next trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">With the discovery that we may be able to
increase our MTD, we determined to adjust our clinical strategy by adding in a Phase I arm to our next Phase II trial, which will
add expense to our development effort. We believe this change in strategy will add several months to the eventual final approval
of the drug, if the drug is approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Because the prior developer of Annamycin
allowed their IND to lapse, we are required to submit a new IND for continued clinical trials with Annamycin. We filed our IND
application for Annamycin, with the clinical strategy of increasing the MTD mentioned above, on February 10, 2017. &nbsp;In subsequent
discussions with us, FDA requested certain revisions to the protocol, additional&nbsp;information, and additional data related
to Chemistry, Manufacturing and Controls (&ldquo;CMC&rdquo;). &nbsp;We have the additional information, have made the requested
revisions to the protocol,&nbsp;and we are working on developing the CMC data. &nbsp;In the interim, we have withdrawn the IND
application in order to resubmit it when the requested data are available. &nbsp;We believe that resubmission of the IND application
will occur in time for the IND to go into effect and the announcement of the beginning of Phase I/II clinical trials in the first
half of 2017. However, if we are unable to obtain the required CMC data on a timely basis, we will be delayed in resubmitting our
IND application, which will delay the commencement of our clinical trials beyond the first half of 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On March 21, 2017 we received notice that
FDA had granted Orphan Drug designation for Annamycin <FONT STYLE="font-family: Times New Roman, Times, Serif">for the treatment
of AML, </FONT>effective March 20, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Little to No Cardiotoxicity</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;One of the key dose-limiting toxicities
associated with currently available anthracyclines is their propensity to induce life-threatening heart damage. This is especially
problematic for pediatric leukemia patients whose life spans can be severely shortened by the very induction therapy designed to
cure them of acute leukemia. In the animal model relied upon by the FDA as an indicator of human cardiotoxicity, the non-liposomal
(free) form of Annamycin has been shown to be significantly less likely than doxorubicin to create heart lesions in mice, and the
liposomal formulation (L-Annamycin) has been shown in these same models to have reduced cardiotoxicity to the point where it is
unlikely to cause harm to human patients. This possible lack of human cardiotoxicity means L-Annamycin may be able to be used more
aggressively in helping patients achieve remission. This would be especially valuable in the case of pediatric acute leukemia (both
AML and ALL) where long-term survival can be greatly impacted by cardiotoxicity. Unless otherwise noted, all of our references
to Annamycin refer to the liposomal form (L-Annamycin).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Circumventing Multidrug Resistance</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;In addition to cardiotoxicity, the
effectiveness of currently approved anthracyclines is limited by their propensity for succumbing to &ldquo;multidrug resistance,&rdquo;
whereby transporters (one type of which is referred to as a &ldquo;P-glycoprotein pump&rdquo;) develop on the outer surface of
cells to expel drugs like anthracyclines as a natural defense mechanism. The dosing of current therapies cannot be increased in
an attempt to overcome multidrug resistance because of the likelihood of cardiotoxicity and other serious side effects. This limitation
prevents adequate dosing of current anthracyclines to produce lasting remission. A laboratory study has suggested that Annamycin
may resist being expelled by P-glycoprotein pumps and other similar tested multidrug resistance transporters, which may mean the
drug circumvents multidrug resistance. This characteristic has been shown in pre-clinical testing to allow for higher drug uptake
in diseased cells, which we believe could allow for more effective induction therapy with less risk to the patient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In order for anthracyclines to
provide effective induction therapy, they must be allowed to accumulate in leukemic cells sufficiently to enter the
cell&rsquo;s nucleus, where they damage the cell&rsquo;s DNA and induce apoptosis (cell death). As induction therapy
progresses, however, the targeted cells can develop a natural defense mechanism to prevent the anthracycline activity. The
graphic below provides a simplified depiction of the formation of a P-glycoprotein pump on the outer surface (membrane) of a
leukemic cell. As typical anthracyclines enter the cell, they are attracted to such pumps and are expelled (referred to as
&ldquo;efflux&rdquo;) before they can accumulate sufficiently to serve their purpose. In contrast, Annamycin appears to avoid
such pumps, thereby being allowed to accumulate sufficiently to destroy the leukemia cell despite the presence of the
multidrug resistance mechanisms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="pg11img1_10k.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The WP1066 Portfolio</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have a license agreement with MD Anderson
pursuant to which we have been granted a royalty-bearing, worldwide, exclusive license for the patent and technology rights related
to our WP1066 Portfolio and its close analogs, molecules targeting the modulation of key oncogenic transcription factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Clinical Testing of WP1066 Portfolio</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>In vitro </I>testing has shown a high
level of activity for WP1066 against a wide range of solid tumors, and <I>in vivo</I> testing has shown significant activity against
head and neck, pancreatic, stomach, and ovarian cancers, as well as metastatic melanoma and glioblastoma, among others. <I>In vivo</I>
testing in mouse tumor models has shown that WP1066 inhibits tumor growth, blocks angiogenesis (a process that provides necessary
blood supply to tumors) and increases survival.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">With respect to our WP1066 Portfolio, we must complete pre-clinical toxicology testing, along with additional
chemistry, manufacturing and control work to fully characterize the drug, establish the desired formulation and develop reference
standards for future drug release, among other things, prior to submitting an application for IND. A clinician at MD Anderson has
advised us that she is proceeding with a physician-sponsored IND for WP1066 treatment of brain tumors. We are not participating
in this IND process. The clinician has submitted an IND to the FDA and has indicated that this IND is on hold until documentation
of Good Manufacturing Process, or GMP, production of WP1066 can be presented to the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">An analog of WP1066, referred to as WP1220,
was previously the subject of an IND (WP1220 was referred to as MOL4239 for purposes of this IND) related to use of the molecule
in the topical treatment of psoriasis. Clinical trials were commenced on WP1220 in the US, but were terminated early due to limited
efficacy in the topical treatment of psoriatic plaques. Notwithstanding its limitations in treating psoriasis, our pre-clinical
research has suggested that WP1220 may be effective in inhibiting cutaneous T-cell lymphoma (CTCL) in multiple CTCL cell lines.
Based on this data, we are collaborating with a Polish drug development company, Dermin, which has received Polish government
grant money to develop WP1220 in Poland for the topical treatment of early stage CTCL patients. CTCL is a potentially deadly form
of skin cancer for which there are limited treatment options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We also conducted a Phase II clinical trial
for WP1066 for the topical treatment of psoriasis, however this trial was terminated early as a significant number of patients
experienced a non-permanent worsening of their psoriatic plaques after extended use of the drug, suggesting that its use as a topical
agent for non-life threatening diseases such as psoriasis will require further study to optimize dosing and scheduling regimens.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Scientific Rationale for WP1066 Portfolio</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Cellular biology depends upon signaling mechanisms to regulate functions such as cell growth, death and
adaptation. Signal &ldquo;transduction&rdquo; is such a mechanism that converts an upstream stimulus to a cell into a specific
cellular response. Signal transduction starts with a signal to a receptor or via a compound capable of passing through the cell
membrane and ends with a change in cell function. The end result of this signal is often the activation of &ldquo;transcription,&rdquo;
whereby genetic information is expressed and, in the case of oncogenic transcription, disease processes are initiated or maintained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Receptors span the cell membrane, with part
of the receptor outside and part inside the cell. When a chemical signal represented by a specific protein binds to the outer portion
of the receptor, it conveys another signal inside the cell. Often there is a cascade of signals within the cell, wherein an upstream
inducer starts a chain of events that resembles a domino effect. Collectively, this sequence is referred to as a &ldquo;signaling
pathway.&rdquo; Eventually, the signal creates a change in the cell function by changing the expression of specific genes and production
of specific proteins within the cell, and again, in the case of tumor development, such expression results in unwanted oncogenic
processes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Importantly, while normal healthy cell function
relies on signaling mechanisms, diseases are capable of co-opting these mechanisms with negative consequences. Oncogenic processes
(including inflammation and proliferation) depend upon signaling pathways that are responsible for coordinating functions such
as cell growth, survival and cell differentiation. A particular class of proteins referred to as Signal Transducers and Activators
of Transcription (such proteins are &ldquo;STATs&rdquo;) regulates the process of disease cell survival and proliferation, angiogenesis
and immune system function and is persistently activated in a large number of human inflammatory processes and in hyper-proliferating
diseases. Because certain of these proteins are known to be co-opted by tumor cells, we refer to them as &ldquo;oncogenic transcription
factors,&rdquo; of which certain STATs are a subset.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Some STATs, such as STAT3, can be activated
by any one of many different upstream inducers, making them very difficult to target by blocking just one or more of these upstream
inducers. We believe that blocking a targeted STAT directly rather than via its multiple upstream inducers should result in greater
efficacy with lower toxicity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the diagram shown below, any one of many
different pathways (categorized as Growth Factor Receptors, Cytokine Receptors and Non-Receptor Tyrosine Kinases) triggers the
activation of STAT3 proteins in a process called &ldquo;phosphorylation&rdquo;. In this process, phosphates attach to corresponding
receptors on STAT3 and, eventually, two phosphorylated STAT3 proteins (&ldquo;p-STAT3&rdquo;) bind together in a pair referred
to as a &ldquo;dimer.&rdquo; Once the dimer is formed, it enters the cell nucleus and triggers gene transcription. Conversely,
if we reduce the presence of p-STAT3 before dimers can be formed, we can prevent the triggering of gene transcription and effectively
inhibit the disease process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="pg13img1_10k.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The upstream effectors shown in the above
diagram (SRC, JAK and ABL) are just some of those capable of activating STAT3 once they themselves are activated by a variety of
signal compounds. The complexity and diversity of pathways capable of activating STAT3 make it very difficult to develop effective
drugs that attempt to target the upstream effectors. Furthermore, many of these upstream pathways are necessary for normal healthy
cell function, so blocking them indiscriminately can lead to unwanted toxicities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Published research has identified STAT3
as a master regulator of a wide range of tumors and linked STAT3 activation with the progression of these tumors. For this reason,
it is believed that direct inhibition of p-STAT3 may be an effective way to reduce or eliminate the progression of these diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Many research efforts have been directed
toward development of specific methods to control activation of STAT3, but most have focused on targeting the upstream effectors
of these pathways like growth factors, cytokines, and specific kinases including Janus kinases (JAKs). However, we believe that
the multifactorial nature of the activation of STAT3 limits the effectiveness of such upstream approaches. Because the activity
of p-STAT3 is a final and determinative step in triggering unwanted transcription, we believe it is preferable to inhibit p-STAT3
more directly and independently from upstream effectors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe the WP1066 Portfolio represents
a novel class of agents capable of hitting multiple targets, including p-STAT3, regardless of their upstream method of activation.
Numerous preclinical tests involving a wide range of tumor cells suggest that by inhibiting the presence of p-STAT3, WP1066 directly
attacks tumor cells. We believe the effectiveness of WP1066 is not only the result of attacking tumors directly, but also indirectly
by stimulating the immune system, increasing the patient&rsquo;s natural ability to fight off tumor development. STAT1 is believed
to stimulate T-cell activity and thereby the immune system responsible for fighting tumors. WP1066 has been shown to increase
the activity of STAT1 at the same time it inhibits the activity of p-STAT3. We believe this dual activity makes WP1066 a uniquely
promising anticancer drug candidate, although we recognize that substantial additional preclinical and clinical research remains
to be done, and may not bear out these early results and our optimism.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe the combination of the
direct and indirect effects of WP1066 may ultimately be shown to provide significant tumor suppression and increased survival
in a number of <I>in vitro</I> cancer models. Below is one example of an animal model suggesting an increase in survival by
treating mice with metastatic melanoma with WP1066.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="pg14img1_10k.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The WP1122 Portfolio</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have a license agreement with MD Anderson
pursuant to which we have been granted a royalty-bearing, worldwide, exclusive license for the patent and technology rights related
to our WP1122 Portfolio and similar molecules targeting the treatment of glioblastoma multiforme (GBM) and related central nervous
system malignancies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe this technology has the potential
to target a wide variety of solid tumors, which eventually become resistant to all treatments, and thereby provide a large and
important opportunity for novel drugs. Notwithstanding this potential, we are focused on the treatment of central nervous system
malignancies and especially GBM. Although less prevalent than some larger categories of solid tumors, cancers of the central nervous
system are particularly aggressive and resistant to treatment. The prognosis for such patients can be particularly grim and the
treatment options available to their physicians are among the most limited of any cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The American Cancer Society has estimated
23,770 new cases of brain and other nervous system cancers will occur in the United States in 2016, resulting in 16,050 deaths.
Despite the severity and poor prognosis of these tumors, there are few FDA-approved drugs on the market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have preliminary preclinical data for
WP1122, including <I>in vitro</I> activity against cancer cell lines, as well as data on survival of animals subjected to xenografts
of human brain tumors, including data regarding biodistribution and pharmacokinetics. In non-optimal doses and treatment regimes,
WP1122 performed equal to or better than the current market leader, temozolomide and provided for superior survival for animals
treated in combination with temozolomide. Notwithstanding these early results, we recognize that substantial additional preclinical
and clinical research remains to be done, and may not support these initial findings or their translation into activity in humans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Scientific Rationale for WP1122</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;Science has recognized that many cancer
cells have a unique metabolism, distinct from that of normal cells. Dubbed the &ldquo;Warburg Effect&rdquo; because of its discoverer,
tumors rely preferentially on glycolysis for the metabolism of glucose, even in the presence of abundant oxygen, for energy (adenosine
triphosphate (ATP)) production. This alternative form of energy production makes cancer cells as much as 17 times more dependent
on glucose than normal cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The fundamental mechanism for imaging actively
growing tumors using positron emission tomography (PET scans) is the Warburg Effect. A radiolabeled glucose decoy called F18DG
accumulates disproportionately in tumors because of their dramatically increased rate of glucose uptake and accumulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Researchers have theorized that if a tumor&rsquo;s
access to glucose could be blocked, the tumor could be starved out of existence. Previous attempts at targeting the metabolism
of tumor cells have failed due to the rapid metabolism and short half-life (minutes) of the drugs being investigated. Efforts to
target tumor metabolism in the brain were further thwarted by the inability to get glycolytic inhibitors into the brain in sufficient/therapeutic
amounts due to the presence of what is called the &ldquo;blood brain barrier.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe WP1122 has the potential for
developing a technology platform for enabling increased cellular uptake, increased drug half-life and, importantly, an increased
ability to cross the blood brain barrier, enabling greater uptake in the brain. Our approach was inspired by the same principle
that distinguishes morphine from heroin. Heroin is chemically the diacetyl ester of morphine. While morphine has a limited ability
to cross the blood brain barrier (making it a good candidate for pain killing without impairing mental function), its diacetyl
form, heroin, has the ability to accumulate in the brain by 10 to 100 times more than morphine. Once across the blood brain barrier,
the acetyl groups are cleaved off by natural enzyme esterases, leaving pure morphine to accumulate in the brain. Similarly, we
believe, based on pre-clinical testing, that WP1122, the diacetyl form of a glucose analog and decoy known as &ldquo;2-DG,&rdquo;
crosses the blood brain barrier where its acetyl groups are cleaved off, allowing the resulting 2-DG to accumulate in the brain
at a much higher rate than free 2-DG can do by itself.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Adding to the difficulty in getting free
2-DG across the blood brain barrier in therapeutic quantities is the relatively short half-life of 2-DG. The free form of 2-DG
is rapidly metabolized and rendered ineffective within minutes of entering the body. In contrast, WP1122 has a half-life of approximately
6 hours, making it much more feasible to deliver quantities adequate for a therapeutic effect. In addition, we believe WP1122 may
represent an improvement to current PET scan diagnostics techniques because of its unique ability to cross the blood brain barrier.
These observations are based only on preliminary data and significant additional development is required to determine if these
findings are valid and if they will translate into the desired activity in humans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On October 25, 2016, we announced promising
initial results of the preclinical toxicology work on WP1122, our unique inhibitor of glucose metabolism, which is an important
driver of glycolytic brain tumor progression and survival. We view this as an important step toward future clinical trials for
WP1122. A similar chemical structure to that which turns morphine into heroine has been used to allow WP1122 to successfully enter
the brain and increase circulation time. We indicated that preliminary escalating single dose toxicity testing in mice (oral administration)
was successfully completed and even at the highest possible dose, no toxic death was observed. In multiple therapeutic doses, WP1122
was well tolerated during intense twice-daily oral dosing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview of the market for our anti-cancer drugs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;Cancer is the second leading cause
of death in the United States behind heart disease. In 2014, an estimated 14.5 million people in the United States were living
with a past or current diagnosis of cancer and, in 2016, the National Institutes of Health estimated that nearly 1.7 million new
cases will be diagnosed and almost 600,000 Americans will die from cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="pg15img1_10k.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Source: American Cancer Society - Cancer Facts
&amp; Figures 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Digestive, reproductive, breast and respiratory
cancers comprise 65% of expected cancer diagnoses in 2016, while cancers like leukemia and brain tumors are considered &ldquo;rare
diseases&rdquo;. Leukemia in particular, can be divided into acute, chronic and other, with acute lymphoblastic leukemia (ALL)
and acute myeloid leukemia (AML) comprising 26,540 of the estimated 60,140 new cases expected in the United States this year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The worldwide cancer drug business has been
estimated to represent approximately $100 billion in annual sales. Our lead drug, Annamycin, is in a class of drugs referred to
as anthracyclines, which are chemotherapy drugs designed to destroy the DNA of targeted cancer cells. The most common approved
anthracyclines are daunorubicin and doxorubicin and, prior to the expansion of their generic equivalents, annual revenues generated
from anthracyclines have been estimated in the range of $600 million. Acute leukemia is one of a number of cancers that are treated
with anthracyclines. One industry report estimates that annual drug revenues generated from the demand for AML-related therapies
in the United States, United Kingdom, France, Germany, Italy and Spain were in the range of $151 million in 2012, and we believe
that this number may increase if and when improved AML treatments are available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our other two active development projects
have applications (among others) in the treatment of brain tumors, another rare disease for which there are few available treatments.
The leading brain tumor drug is temozolomide, a drug introduced under the brand name Temodar. In 2012, one industry source reported
annual revenues of approximately $882 million for Temodar before the expiration of its patent protection, at which point generic
versions of the drug began to enter the market and reduce prices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Orphan Drug Act and other legislative
initiatives provide incentives, including market exclusivity and accelerated approval pathways, for companies that pursue the development
of treatments for rare diseases and serious diseases for which there are few or no acceptable available treatment alternatives.
Over the last 10 years, an increasing number of companies have begun using these designations to obtain new drug approvals for
drugs where patent coverage has expired and/or where accelerated approval appears possible. An IMS Health report estimated that,
in 2013, the sale of drugs with full or partial Orphan Drug exclusivity represented approximately $29 billion in revenue. We consider
obtaining Orphan Drug exclusivity and accelerated approval to be an important part of our development strategy for our drug candidates.
Notwithstanding these potential opportunities, we can provide no assurance that our drugs will receive Orphan Drug designation
(other than Annamycin, which recently received such designation) or, if approved, exclusivity or any other special designation
that could, among other things, provide for accelerated approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our License Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We acquired the rights and obligations under
the Patent and Technology License Agreement entered into by and between IntertechBio and MD Anderson dated April 2, 2012 (the &ldquo;IntertechBio
Agreement&rdquo;). Pursuant to that license agreement and an October 2015 amendment, IntertechBio obtained a royalty-bearing, worldwide,
exclusive license to intellectual property including patent rights related to our WP1122 Portfolio and to our drug product candidate,
WP1122. In consideration, IntertechBio agreed to make payments to MD Anderson, including an up-front payment, license documentation
fee, annual maintenance fee, milestone payments and minimum annual royalty payments for sales of products developed under the license
agreement. Specifically, under the IntertechBio Agreement, IntertechBio agreed to pay a nonrefundable upfront documentation fee
in the amount of $80,000; annual maintenance fee in the amount of $10,000 on the first anniversary of the effective date of the
IntertechBio Agreement, $20,000 on the second anniversary of the effective date of the agreement, $40,000 on the third anniversary
of the effective date of the agreement, $60,000 on the fourth anniversary of the effective date of the agreement, $80,000 on the
fifth anniversary of the effective date of the agreement and $100,000 on the sixth anniversary of the effective date of the agreement
and every anniversary thereafter, except that such payments will no longer be due upon the first sale of a licensed product. Under
the IntertechBio Agreement, IntertechBio also agreed to make a minimum annual royalty in the amount of $200,000 for the first anniversary
following the first sale of a licensed product, $400,000 for the second anniversary following the first sale of a licensed product,
and $600,000 for the third year following the first sale of a licensed product and every anniversary thereafter. IntertechBio also
agreed to make one-time milestone payments in the amount of $200,000 upon commencement of a Phase II study for a licensed product,
$250,000 upon commencement of a Phase III study for a licensed product, $400,000 upon filing of a New Drug Application (&ldquo;NDA&rdquo;)
for a licensed product and $500,000 upon receipt of market approval for sale of a licensed product. MD Anderson has the right to
terminate the agreement upon advance notice in the event of a default by IntertechBio. The agreement will also be terminated immediately
upon IntertechBio&rsquo;s insolvency. Additionally, MD Anderson has the right to terminate the license agreement if (i) a preclinical
toxicology program for a licensed product is not initiated within one year of the of effective date of the amendment, (ii) an investigational
new drug application (IND) is not filed with the Food and Drug Administration (FDA) for a Phase I study for a licensed product
within three years of the effective date of the amendment, or (iii) a Phase I study for a licensed product is not commenced within
five years of the effective date of the amendment. The IntertechBio Agreement will expire upon the expiration of the licensed intellectual
property. In August 2015, the IntertechBio Agreement and amendments thereto were assigned to MBI. Under the assignment, MBI has
assumed the rights and obligations of IntertechBio including, without limitation, the right to manufacture, have manufactured,
use, import, offer to sell and/or sell products worldwide for any indication under the licensed intellectual property with the
right to sublicense. However, the rights obtained pursuant to the assignment of the IntertechBio Agreement are made subject to
the rights of the U.S. government to the extent that the technology covered by the licensed intellectual property was developed
under a funding agreement between MD Anderson and the U.S. government. All out-of-pocket expenses incurred by MD Anderson in filing,
prosecuting and maintaining the licensed patents have been and shall continue to be assumed by MBI. MBI is not required to issue
MD Anderson any equity upon the completion of any milestones. On October 8, 2015, IntertechBio entered into a letter agreement
with MD Anderson where MD Anderson agreed to receive past due maintenance fees and patent expenses of $98,108 owed by IntertechBio
in four installments. The past due amount is related to certain metabolic inhibitor technology license that was assigned to MBI
by IntertechBio and was owed by IntertechBio prior to MBI&rsquo;s acquisition of the license. Pursuant to the letter, IntertechBio
Corporation also agreed to pay $65,504 patent fees to a law firm. In order to have the license in good standing, MBI agreed to
pay MD Anderson the $98,108 and the $65,504 to a law firm on behalf of IntertechBio Corporation; all such payments have been made
in full by MBI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Due to our acquisition of Moleculin, LLC,
we obtained a royalty-bearing, worldwide, exclusive license to intellectual property rights, including patent rights related to
our WP1066 drug product candidate from MD Anderson. Moleculin, LLC entered into a June 2010 Patent and Technology License Agreement
with MD Anderson (the &ldquo;Moleculin Agreement&rdquo;). Under the Moleculin Agreement and an October 2015 amendment, Moleculin,
LLC obtained the right to manufacture, have manufactured, use, import, offer to sell and/or sell products worldwide for any indication
under the licensed intellectual property with the right to sublicense. In consideration, Moleculin, LLC agreed to make payments
to MD Anderson including an up-front payment, milestone payments and minimum annual royalty payments for sales of products developed
under the license agreement. Specifically, under the Moleculin Agreement, Moleculin, LLC agreed to pay a nonrefundable upfront
documentation fee in the amount of $223,585; annual maintenance fee in the amount of $20,000 on the first anniversary of the effective
date of the Moleculin Agreement, which shall increase in $10,000 increments on an annual basis thereafter up to a maximum of $100,000,
except that such payments will no longer be due upon marketing approval in any country of a licensed product. Under the Moleculin
Agreement, Moleculin, LLC also agreed to make a minimum annual royalty payment to MD Anderson in the amount of $200,000 after the
first sale of a licensed product. Moleculin, LLC also agreed to make one-time milestone payments in the amount of $150,000 upon
commencement of the first Phase III study for a licensed product within the United States, Europe, China or Japan; $500,000 upon
submission of the first NDA for a licensed product in the United States; and $600,000 upon receipt of the first marketing approval
for sale of a licensed product in the United States. MD Anderson has the right to terminate the Moleculin Agreement upon advanced
notice in the event of a default by Moleculin, LLC. Moleculin, LLC has the right to terminate the Moleculin Agreement for any reason
upon advance written notice to MD Anderson. The Moleculin Agreement will also be terminated immediately upon Moleculin, LLC&rsquo;s
insolvency. Per the October 2015 amendment to the Moleculin Agreement, MD Anderson relinquished any rights to any equity previously
due MD Anderson in Moleculin, LLC. Upon completion of our acquisition of Moleculin, LLC, we assumed the rights and obligations
of Moleculin, LLC including, without limitation, the right to manufacture, have manufactured, use, import, offer to sell and/or
sell products worldwide for any indication under the licensed intellectual property with the right to sublicense. However, the
rights we have obtained pursuant to the assignment of the Moleculin Agreement are made subject to the rights of the U.S. government
to the extent that the technology covered by the licensed intellectual property was developed under a funding agreement between
MD Anderson and the U.S. government. All out-of-pocket expenses incurred by MD Anderson in filing, prosecuting and maintaining
the licensed patents have been and shall continue to be assumed by us. MBI is not required to issue MD Anderson any equity in our
company upon the completion of any milestones.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On October 8, 2015, Moleculin, LLC entered
into a letter agreement with MD Anderson for Moleculin, LLC&rsquo;s past due fees to MD Anderson in the amount of $691,186 of which
$300,000 had been paid prior to the letter agreement. Pursuant to the letter agreement, MD Anderson agreed to receive the remaining
past due fee in three installments, which payments have been made in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Moleculin, LLC out-licensed certain intellectual
property rights including rights covering the WP1066 drug product candidate to Dermin (&ldquo;Moleculin Out-License Agreement&rdquo;).
The licensed intellectual property includes rights obtained by Moleculin, LLC pursuant to a license agreement with MD Anderson
(&ldquo;Moleculin-MD Anderson Agreement&rdquo;). Under the Moleculin Out-License Agreement, Moleculin, LLC granted Dermin a royalty-bearing,
exclusive license to manufacture, have manufactured, use, import, offer to sell and/or sell products in the field of human therapeutics
under the licensed intellectual property in the countries of Belarus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland,
Romani, Slovakia and Ukraine (&ldquo;licensed territories&rdquo;). Additionally, Moleculin, LLC agreed to develop and provide a
dossier containing data related to the licensed subject matter to Dermin. In consideration, Dermin agreed to make payments to Moleculin,
LLC, including upfront development fees, annual royalty payments, sublicense fee, and milestone payments. Specifically, under the
Moleculin Out-License Agreement, Dermin agreed to make a nonrefundable upfront dossier development payment in the amount of $100,000;
a service fee in the amount of $100,000 for assistance provided to Dermin in securing additional funding; and royalty payments
on sales of any licensed product at a rate of no less than the royalty rate due to MD Anderson under the Moleculin-MD Anderson
Agreement plus 1%. Dermin also agreed to provide a percentage of certain consideration Dermin receives pursuant to sublicense agreements
in the amount of 25% prior to completion of a Phase IIb clinical study in a licensed territory and 10% on or after completion of
a Phase IIb clinical study in a licensed territory, provided, however, if the sublicense fee is less than the sublicense fee due
to MD Anderson under the Moleculin-MD Anderson Agreement, then Dermin shall be obligated to pay no less than the amount due to
MD Anderson plus 5%. Also under the Moleculin Out-License Agreement, Dermin agreed to pay all out-of-pocket expenses incurred by
Moleculin, LLC in filing, prosecuting and maintaining the licensed patents for which the license has been granted. The parties
to the Moleculin Out-License Agreement each have the right to terminate the agreement upon advance notice in the event of a default
by the other party. Dermin has the right to terminate the agreement if (i) Moleculin, LLC fails to timely provide the dossier to
Dermin after Moleculin, LLC&rsquo;s filing of an NDA for a licensed product in the United States; or (ii) Moleculin, LLC does not
cooperate in assisting Dermin to secure funds to develop the licensed subject matter. Upon completion of our acquisition of Moleculin,
LLC, we assumed the rights and obligations of Moleculin, LLC under the Moleculin Out-License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We acquired the rights and obligations
to the Patent and Technology License Agreement entered into by and between IntertechBio and Dermin dated April 15, 2011 (the &ldquo;IntertechBio
Out-License Agreement&rdquo;). Pursuant to that license agreement, IntertechBio exclusively out-licensed intellectual property
rights to Dermin, including rights covering the WP1122 drug product candidate obtained from MD Anderson pursuant to the IntertechBio
Agreement. Under the IntertechBio Out-License Agreement, IntertechBio granted Dermin a royalty-bearing, exclusive license to manufacture,
have manufactured, use, import, offer to sell and/or sell products in the field of human therapeutics under the licensed intellectual
property in the countries of Belarus, Russia, Kazakhstan, Uzbekistan, Turkmenistan, Czech Republic, Estonia, Hungary, Latvia,
Lithuania, Poland, Romania, Slovakia and Ukraine (&ldquo;licensed territories&rdquo;). Additionally, IntertechBio agreed to develop
and provide a dossier containing data related to the licensed subject matter to Dermin. In consideration, Dermin agreed to make
payments to IntertechBio, including upfront development fees, annual royalty payments, sublicense fees, and milestone payments.
Specifically, under the IntertechBio Out-licensing Agreement, Dermin agreed to make a nonrefundable upfront dossier development
fee in the amount of $35,000; a service fee in the amount of $40,000 for assistance provided to Dermin in securing additional
funding; and royalty payments on sales of any licensed product at a rate of no less than the royalty rate due to MD Anderson under
the IntertechBio Agreement plus 2%. Dermin also agreed to provide a percentage of certain consideration Dermin receives pursuant
to sublicense agreements in the amount of 25% prior to completion of a Phase IIb clinical study in a licensed territory and 10%
on or after completion of a Phase IIb clinical study in the licensed territories, provided, if the sublicense fee is less than
the sublicense fee due to MD Anderson under the IntertechBio Agreement, then Dermin shall be obligated to pay not less than the
amount due to MD Anderson plus 5%. Also under the IntertechBio Out-Licensing Agreement, Dermin agreed to pay all out-of-pocket
expenses incurred by IntertechBio in filing, prosecution and maintaining the licensed patents for which the license has been granted.
The parties to the IntertechBio Out-licensing Agreement each have the right to terminate the agreement upon advanced notice in
the event of a default by the other party. Dermin has the right to terminate the agreement if (i) IntertechBio fails to timely
provide the dossier to Dermin after IntertechBio&rsquo;s filing of an NDA for a licensed product in the United States; or (ii)
IntertechBio does not cooperate in assisting Dermin to secure funds to develop the licensed subject matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We entered into a May 2016 out-licensing
agreement with HPI, pursuant to which we granted HPI certain intellectual property rights, including rights covering the potential
drug candidate, WP1066 (&ldquo;HPI Out-Licensing Agreement&rdquo;). Under the HPI Out-Licensing Agreement we are required to make
an upfront $100,000 payment and quarterly payments in the amount of $37,500 for the first four quarters following the effective
date of the HPI Out-Licensing Agreement and $75,000 per quarter for the following eight quarters thereafter in consideration for
the right to development data related to the development of licensed products. Notwithstanding our obligation to make the foregoing
payments, the HPI Out-Licensing Agreement does not obligate HPI to conduct any specific research or to meet any milestones. Upon
payment in the amount of $1,000,000 to HPI within three years of the effective date of the HPI Out-Licensing Agreement we will
regain all rights to the licensed subject matter and rights to any and all development data and any regulatory submissions including
any IND, NDA or ANDA related to the licensed subject matter. In the event that we do not exercise our right to regain our rights
to the licensed subject matter within three years of the effective date of the HPI Out-Licensing Agreement the license granted
to HPI shall convert to an exclusive license upon HPI&rsquo;s written notice and we shall be obligated to transfer all existing
data relating to licensed subject matter including any development data and any IND to HPI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Annamed out-licensed certain intellectual
property rights including rights covering the potential drug product, Annamycin to Dermin pursuant to a Patent and Technology Development
and License Agreement dated June 28, 2012 (the &ldquo;Annamed Agreement&rdquo;). The licensed intellectual property includes rights
obtained by Annamed pursuant to a license agreement with MD Anderson (&ldquo;Annamed-MD Anderson Agreement&rdquo;). Under the Annamed
Agreement, Annamed granted Dermin a royalty-bearing, exclusive license to manufacture, have manufactured, use, import, offer to
sell and/or sell products in the field of human therapeutics under the licensed intellectual property in the countries of Poland,
Ukraine, Czech Republic, Hungary, Romania, Slovakia, Belarus, Lithuania, Latvia, Estonia, Netherlands, Turkey, Belgium, Switzerland,
Austria, Sweden, Greece, Portugal, Norway, Denmark, Ireland, Finland, Luxembourg, Iceland, Kazachstan, Russian Federation, Uzbekistan,
Georgia, Armenia, Azerbaijan and Germany (&ldquo;Annamed licensed territories&rdquo;). Additionally, Annamed agreed to develop
and provide a dossier containing data related to the licensed subject matter to Dermin. In consideration, Annamed agreed to provide
a running royalty at a rate of no less than the royalty due to MD Anderson under the Annamed-MD Anderson Agreement plus 2.5% for
the sale of any licensed product in the Annamed licensed territories excluding Germany and at a rate of 15% for the sale of any
licensed product in Germany. Dermin also agreed to provide a percentage of certain consideration Dermin receives pursuant to sublicense
agreements in the amount of 25% prior to completion of a Phase IIb clinical study in an Annamed licensed territory and 10% on or
after completion of a Phase IIb clinical study in an Annamed licensed territory, provided, however, if the sublicense fee is less
than the sublicense fee due to MD Anderson under the Annamed-MD Anderson Agreement, then Dermin shall be obligated to pay no less
than the amount due to MD Anderson plus 5%. Also under the Annamed Agreement, Dermin agreed to pay all out-of-pocket expenses incurred
by Annamed in filing, prosecuting and maintaining the licensed patents for which the license has been granted. Annamed has the
right to terminate the Annamed Agreement as to any country within the Annamed licensed territories if Dermin fails to provide evidence
of its use of commercially reasonable efforts to commercialize a licensed product in such country within ninety days of Annamed&rsquo;s
written request. The Annamed Agreement may also be terminated by Annamed upon advanced written notice in the event that Dermin
defaults. Dermin has the right to terminate the agreement if (i) Annamed fails to timely provide the documents and information
required for Dermin to prepare a dossier within 30 days of Annamed&rsquo;s filing of an NDA for a licensed product in the United
States; or (ii) Annamed does not cooperate in assisting Dermin to secure funds to develop the licensed subject matter. As of August
2015, we have obtained the rights and obligations of Annamed under the Annamed Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Competition </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We operate in a highly competitive segment
of the pharmaceutical market, which market is highly competitive as a whole. We face competition from numerous sources including
commercial pharmaceutical and biotechnology enterprises, academic institutions, government agencies, and private and public research
institutions. Many of our competitors may have significantly greater financial, product development, manufacturing and marketing
resources. Additionally, many universities and private and public research institutes are active in cancer research, and some may
be in direct competition with us. We may also compete with these organizations to recruit scientists and clinical development personnel.
Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements
with large and established companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The unmet medical need for more effective
cancer therapies is such that anticancer drugs are, by far, the leading class of drugs in development. These include a wide array
of products against cancer targeting many of the same indications as our drug candidates. While the introduction of newer targeted
agents may result in extended overall survival, induction therapy regimens are likely to remain a cornerstone of cancer treatment
in the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There are a number of established therapies
that may be considered competitive for the cancer indications for which we intend to develop our lead product, Annamycin. A key
consideration when treating AML patients is whether the patient is suitable for intensive therapy. The standard of care for the
treatment of newly diagnosed AML patients who can tolerate intensive therapy is cytarabine in combination with an anthracycline
(e.g., doxorubicin or daunorubicin). For some patients, primarily those less than 60 years of age, a stem cell transplant could
also be considered if the induction regimen is effective in attaining a CR (Complete Response). The regimen of cytarabine in combination
with an anthracycline has been the standard of care for decades. A patient not suitable for intensive therapy may be offered the
option for low-intensity therapy such as low-dose cytarabine, azacitidine or decitabine. It should be noted that, in the US, these
are not approved by the FDA for the treatment of AML patients and there remains no effective therapy for these patients or for
relapsed or refractory AML. The initial focus for Annamycin development is in patients for whom the standard induction regimen
has failed. Also, several major pharmaceutical companies and biotechnology companies are aggressively pursuing new cancer development
programs for the treatment of AML.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A number of attempts have been made or are
under way to provide an improved treatment for AML. Recently, Celator Pharmaceuticals reported Phase III clinical trial results
for a new combined formulation of cytarabine and daunorubicin (commonly used induction therapy drugs) they call Vyxeos. This new
liposome formulation provides a 5:1 ratio of cytarabine and daunorubicin in each of three injections. When compared with patients
receiving 7 injections of cytarabine and 3 injections of daunorubicin (traditional 7+3 induction therapy), patients receiving Vyxeos
achieved an average increase in overall survival of approximately 3.5 months (9.5 months compared with 6 months). Despite this
extension of overall survival, Vyxeos did not reduce the toxic side effects of daunorubicin (including cardiotoxicity) and it failed
to qualify a significant majority of patients for curative bone marrow transplant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Drugs attempting to target a subset of AML
patients who present with particular anomalies involving a gene referred to as FLT3 are currently in clinical trials, as well as
other approaches that include immunotherapy relying on other biomarkers, other attempts at improved chemotherapy and alternative
approaches to radiation therapy. Other approaches to improve the effectiveness of induction therapy are in early stage clinical
trials and, although they do not appear to address the underlying problems with anthracyclines, we can provide no assurance that
such improvements, if achieved, would not adversely impact the need for improved anthracyclines. A modified version of doxorubicin
designed to reduce cardiotoxicity is in clinical trials for the treatment of sarcoma and, although this drug does not appear to
address multidrug resistance and is not currently intended for the treatment of acute leukemia, we can provide no assurance that
it will not become a competitive alternative to Annamycin. Although we are not aware of any other single agent therapies in clinical
trials that would directly compete against Annamycin in the treatment of relapsed and refractory AML, we can provide no assurance
that such therapies are not in development, will not receive regulatory approval and will reach market before our drug candidate
Annamycin. In addition, any such competing therapy may be more effective and / or cost-effective than ours.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Government Regulation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Government authorities in the US, at the
federal, state and local level, and in other countries extensively regulate, among other things, the research, development, testing,
manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval
monitoring and reporting, marketing and export and import of products such as those we are developing. The pharmaceutical drug
product candidates that we develop must be approved by the FDA before they may be marketed and distributed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the United States, the FDA regulates
pharmaceutical products under the Federal Food, Drug, and Cosmetic Act, and implementing regulations. Pharmaceutical products are
also subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the
subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial
time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development
process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. FDA and related
enforcement activity could include refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning
letters, product recalls, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals
of government contracts, restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could
have a material adverse effect on us. The process required by the FDA before a pharmaceutical product may be marketed in the US
generally involves the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Completion of preclinical laboratory tests, animal studies and formulation studies according to Good Laboratory Practices
or other applicable regulations;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Submission to the FDA of an Investigational New Drug application, or IND, which must become effective before human clinical
studies may begin;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Performance of adequate and well-controlled human clinical studies according to the FDA&rsquo;s current good clinical practices
(&ldquo;GCP&rdquo;), to establish the safety and efficacy of the proposed pharmaceutical product for its intended use;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Submission to the FDA of an NDA for a new pharmaceutical product;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the pharmaceutical product
is produced, to assess compliance with current good manufacturing practices (&ldquo;cGMP&rdquo;), to assure that the facilities,
methods and controls are adequate to preserve the pharmaceutical product&rsquo;s identity, strength, quality and purity;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Potential FDA audit of the preclinical and clinical study sites that generated the data in support of the NDA; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>FDA review and approval of the NDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The lengthy process of seeking required
approvals and the continuing need for compliance with applicable statutes and regulations require the expenditure of substantial
resources and approvals, and continued compliance are inherently uncertain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Before testing any compounds with potential
therapeutic value in humans, the pharmaceutical product candidate enters the preclinical testing stage. Preclinical tests include
laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety
and activity of the pharmaceutical product candidate. These early proof-of-principle studies are done using sound scientific procedures
and thorough documentation. The conduct of the single and repeat dose toxicology and toxicokinetic studies in animals must comply
with federal regulations and requirements including good laboratory practices. The sponsor must submit the results of the preclinical
tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical
protocol, to the FDA as part of the IND. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA
has concerns and notifies the sponsor. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before
the clinical study can begin. If resolution cannot be reached within the 30-day review period, either the FDA places the IND on
clinical hold or the sponsor withdraws the application. The FDA may also impose clinical holds on a pharmaceutical product candidate
at any time before or during clinical studies for various reasons. Accordingly, we cannot be sure that submission of an IND will
result in the FDA allowing clinical studies to begin, or that, once begun, issues will not arise that suspend or terminate such
clinical study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Clinical studies involve the administration
of the pharmaceutical product candidate to healthy volunteers or patients under the supervision of qualified investigators, generally
physicians not employed by or under the clinical study sponsor&rsquo;s control. Clinical studies are conducted under protocols
detailing, among other things, the objectives of the clinical study, dosing procedures, subject selection and exclusion criteria,
how the results will be analyzed and presented and the parameters to be used to monitor subject safety. Each protocol must be submitted
to the FDA as part of the IND. Clinical studies must be conducted in accordance with GCP. Further, each clinical study must be
reviewed and approved by an independent institutional review board (&ldquo;IRB&rdquo;) at, or servicing, each institution at which
the clinical study will be conducted. An IRB is charged with protecting the welfare and rights of study participants and considers
such items as whether the risks to individuals participating in the clinical studies are minimized and are reasonable in relation
to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical study subject or
his or her legal representative and must monitor the clinical study until completed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Human clinical studies are typically conducted
in three sequential phases that may overlap or be combined:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Phase
1: The pharmaceutical product is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption,
metabolism, distribution and excretion. In the case of some products for severe or life-threatening diseases such as cancer, especially
when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often
conducted in patients, with a goal of characterizing the safety profile of the drug and establishing a maximum tolerable dose (&ldquo;MTD&rdquo;).
Our pharmaceutical products fall into this latter category because its products are intended to treat cancer and contain cytotoxic
agents. Hence, our Phase 1 studies are conducted in late-stage cancer patients whose disease has progressed after treatment with
other agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Phase
2: With the maximum tolerable dose established in a Phase 1 trial, the pharmaceutical product is evaluated in a limited patient
population at the MTD to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product
for specific targeted diseases, to determine dosage tolerance, optimal dosage and dosing schedule and to identify patient populations
with specific characteristics where the pharmaceutical product may be more effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Phase
3: Clinical studies are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population
at geographically dispersed clinical study sites. These clinical studies are intended to establish the overall risk/benefit ratio
of the product and provide an adequate basis for product labeling. The studies must be well controlled and usually include a control
arm for comparison. One or two Phase 3 studies are usually required by the FDA for an NDA approval, depending on the disease severity
and other available treatment options. In some instances, an NDA approval may be obtained based on Phase 2 clinical data with
the understanding that the approved drug can be sold subject to a confirmatory trial to be conducted post-approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Post-approval studies, or Phase 4 clinical
studies, may be conducted after initial marketing approval. These studies are often used to gain additional experience from the
treatment of patients in the intended therapeutic indication. The FDA also may require Phase 4 studies, Risk Evaluation and Mitigation
Strategies (&ldquo;REMS&rdquo;) and post-marketing surveillance, among other things, to monitor the effects of an approved product
or place conditions on an approval that could restrict the distribution or use of the product.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Progress reports detailing the results of
the clinical studies must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA
and the investigators for serious and unexpected adverse events or any finding from tests in laboratory animals that suggests a
significant risk for human subjects. Phase 1, Phase 2 and Phase 3 clinical studies may not be completed successfully within any
specified period, if at all. The FDA or the sponsor or its data safety monitoring board may suspend a clinical study at any time
on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk.
Similarly, an IRB can suspend or terminate approval of a clinical study at its institution if the clinical study is not being conducted
in accordance with the IRB&rsquo;s requirements or if the pharmaceutical product has been associated with unexpected serious harm
to patients.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Concurrent with clinical studies, companies
may complete additional animal studies and must also develop additional information about the chemistry and physical characteristics
of the pharmaceutical product as well as finalize a process for manufacturing the product in commercial quantities in accordance
with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the pharmaceutical
product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final
pharmaceutical product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted
to demonstrate that the pharmaceutical product candidate does not undergo unacceptable deterioration over its shelf life.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The results of product development, preclinical
studies and clinical studies, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry
of the pharmaceutical product, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting
approval to market the product. The submission of an NDA is subject to the payment of substantial user fees. A waiver of such fees
may be obtained under certain limited circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDA reviews all NDAs submitted before it accepts them for filing and may request additional information
rather than accepting an NDA for filing. Once the submission is accepted for filing, the FDA begins an in-depth review of the NDA.
Under the goals and policies agreed to by the FDA under the Prescription Drug User Fee Act (&ldquo;PDUFA&rdquo;), the FDA has 10
months after the 60-day filing date in which to complete its initial review of a standard review NDA and respond to the applicant,
and six months after the 60-day filing date for a priority review NDA. The FDA does not always meet its PDUFA goal dates for standard
and priority NDAs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">After the NDA submission is accepted for
filing, the FDA reviews the NDA application to determine, among other things, whether the proposed product is safe and effective
for its intended use, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&rsquo;s
identity, strength, quality and purity. The FDA may refer applications for novel pharmaceutical products or pharmaceutical products
which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and
other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions.
The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making
decisions. During the pharmaceutical product approval process, the FDA also will determine whether a risk evaluation and mitigation
strategy (&ldquo;REMS&rdquo;) is necessary to assure the safe use of the pharmaceutical product. If the FDA concludes that a REMS
is needed, the sponsor of the NDA must submit a proposed REMS; the FDA will not approve the NDA without a REMS, if required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Before approving an NDA, the FDA will inspect
the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing
processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within
required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites as well
as the site where the pharmaceutical product is manufactured to assure compliance with GCP and cGMP. If the FDA determines the
application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission
and often will request additional testing or information. In addition, the FDA will require the review and approval of product
labeling.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The NDA review and approval process is lengthy
and difficult and the FDA may refuse to approve an NDA if the applicable regulatory criteria are not satisfied or may require additional
clinical data or other data and information. Even if such data and information is submitted, the FDA may ultimately decide that
the NDA does not satisfy the criteria for approval. Data obtained from clinical studies are not always conclusive and the FDA may
interpret data differently than we interpret the same data. The FDA will issue a complete response letter if the agency decides
not to approve the NDA. The complete response letter usually describes all of the specific deficiencies in the NDA identified by
the FDA. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional
clinical studies. Additionally, the complete response letter may include recommended actions that the applicant might take to place
the application in a condition for approval. If a complete response letter is issued, the applicant may either resubmit the NDA,
addressing all of the deficiencies identified in the letter, or withdraw the application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If a product receives regulatory approval,
the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited,
which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings
or precautions be included in the product labeling. In addition, the FDA may require Phase 4 testing which involves clinical studies
designed to further assess pharmaceutical product safety and effectiveness and may require testing and surveillance programs to
monitor the safety of approved products that have been commercialized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Expedited Development and Review Programs
</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDA has a Fast Track program that is
intended to expedite or facilitate the process for reviewing new pharmaceutical products that meet certain criteria. Specifically,
new pharmaceutical products are eligible for Fast Track designation if they are intended to treat a serious condition and demonstrate
the potential to address unmet medical needs for the condition. Fast Track designation applies to the combination of the product
and the specific indication for which it is being studied. Unique to a Fast Track product, the FDA may consider for review sections
of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission
of the sections of the NDA, if the FDA determines that the schedule is acceptable and if the sponsor pays any required user fees
upon submission of the first section of the NDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any product submitted to the FDA for market,
including a Fast Track program, may also be eligible for other FDA programs intended to expedite development and review, such as
priority review and accelerated approval. Any product is eligible for priority review if it is intended to treate a serious condition
and it offers a significant improvement in the treatment, diagnosis or prevention of a disease compared to marketed products. The
FDA will attempt to direct additional resources to the evaluation of an application for a new pharmaceutical product designated
for priority review in an effort to facilitate the review. Additionally, accelerated approval may be available for a product intended
to treat a serious condition that provides meaningful therapeutic benefit over existing treatments, which means the product may
be approved on the basis of adequate and well-controlled clinical studies establishing that the product has an effect on a surrogate
endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on an intermediate clinical endpoint.
As a condition of accelerated approval, the FDA may require the sponsor to perform adequate and well-controlled post-marketing
clinical studies. In addition, the FDA currently requires pre-approval of promotional materials for products receiving accelerated
approval, which could impact the timing of the commercial launch of the product. Fast Track designation, priority review and accelerated
approval do not change the standards for approval but may expedite the development or approval process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Post-Approval Requirements </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any pharmaceutical products for which the
Company receives FDA approvals are subject to continuing regulation by the FDA, including, among other things, cGMP compliance,
record-keeping requirements, reporting of adverse experiences with the product, providing the FDA with updated safety and efficacy
information, product sampling and distribution requirements, complying with certain electronic records and signature requirements
and complying with FDA promotion and advertising requirements, which include, among others, standards for direct-to-consumer advertising,
prohibitions on promoting pharmaceutical products for uses or in patient populations that are not described in the pharmaceutical
product&rsquo;s approved labeling (known as &ldquo;off-label use&rdquo;), industry-sponsored scientific and educational activities
and promotional activities involving the internet. Failure to comply with FDA requirements can have negative consequences, including
adverse publicity, enforcement letters from the FDA, actions by the U.S. Department of Justice and/or U.S. Department of Health
and Human Services&rsquo; Office of Inspector General, mandated corrective advertising or communications with doctors, and civil
or criminal penalties. Although physicians may prescribe legally available pharmaceutical products for off-label uses, manufacturers
may not directly or indirectly market or promote such off-label uses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We rely and expect to continue to rely on
third parties for the production of clinical and commercial quantities of our products. Manufacturers of our products are required
to comply with applicable FDA manufacturing requirements contained in the FDA&rsquo;s cGMP regulations. cGMP regulations require,
among other things, quality control and quality assurance, as well as the corresponding maintenance of records and documentation.
Pharmaceutical product manufacturers and other entities involved in the manufacture and distribution of approved pharmaceutical
products are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced
inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue
to expend time, money and effort in the area of production and quality control to maintain cGMP compliance. Discovery of problems
with a product after approval may result in restrictions on a product, manufacturer or holder of an approved NDA, including withdrawal
of the product from the market. In addition, changes to the manufacturing process generally require prior FDA approval before being
implemented and other types of changes to the approved product, such as adding new indications and additional labeling claims,
are also subject to further FDA review and approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Patent Term Restoration and Marketing
Exclusivity </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Depending upon the timing, duration and
specifics of the FDA approval of the use of our pharmaceutical product candidates, some of our products covered by U.S. patents
may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly
referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as
compensation for patent term lost during product development and the FDA regulatory review process for a product the approval of
which is the first permitted commercial marketing of the active pharmaceutical ingredient. However, patent term restoration cannot
extend the remaining term of a patent beyond a total of 14 years from the product&rsquo;s approval date. The patent term restoration
period is generally one-half the time between the effective date of an IND and the submission date of an NDA plus the time between
the submission date of an NDA and the approval of that application. Only one patent applicable to an approved pharmaceutical product
is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent unless
an extension is obtained. The U.S. Patent and Trademark Office, in consultation with the FDA, reviews and renders a decision on
the application for any patent term extension or restoration. In the future, we may be able to apply for extension of patent term
for one or more of our currently licensed patents or any future owned patents to add patent life beyond its current expiration
date, depending upon the expected length of the clinical studies and other factors involved in the filing of the relevant NDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Market exclusivity provisions under the
U.S. Food, Drug, and Cosmetic Act can also delay the submission or the approval of certain applications of other companies seeking
to reference another company&rsquo;s NDA or seeking approval for a similar product. Pediatric exclusivity adds six months to existing
exclusivity periods and patent terms and may be granted based on the completion of a pediatric clinical study that &ldquo;fairly
responds&rdquo; to an FDA-issued &ldquo;Written Request&rdquo; for such a clinical study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Pharmaceutical Coverage, Pricing and
Reimbursement </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Significant uncertainty exists as to the
coverage and reimbursement status of any pharmaceutical product candidates for which we may obtain regulatory approval. In the
United States and in markets in other countries, sales of any products for which we receive regulatory approval for commercial
sale will depend in part upon the availability of reimbursement from third-party payers. Third-party payers include government
payers such as Medicare and Medicaid, managed care providers, private health insurers and other organizations. The process for
determining whether a payer will provide coverage for a pharmaceutical product may be separate from the process for setting the
price or reimbursement rate that the payer will pay for the pharmaceutical product. Third-party payers may limit coverage to specific
pharmaceutical products on an approved list, or formulary, which might not, and frequently does not, include all of the FDA-approved
pharmaceutical products for a particular indication. Third-party payers are increasingly challenging the price and examining the
medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. A payer&rsquo;s
decision to provide coverage for a pharmaceutical product does not imply that an adequate reimbursement rate will be approved.
Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate
return on our investment in product development. In addition, in the United States there is a growing emphasis on comparative effectiveness
research, both by private payers and by government agencies. We may need to conduct expensive pharmaco-economic studies in order
to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain the FDA
approvals. Our pharmaceutical product candidates may not be considered medically necessary or cost-effective. To the extent other
drugs or therapies are found to be more effective than our products, payers may elect to cover such therapies in lieu of our products
and/or reimburse our products at a lower rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Orphan Drug exclusivity prevents for seven
years the approval of another product with the same active moiety for the same rare disease. If a product is a new chemical entity
(i.e., generally that the moiety has not previously been approved), it may receive five years of exclusivity, during which period
FDA may not accept for review certain NDAs for another product with the same moiety. If approval of a product required new clinical
data, it may convey three years of exclusivity against approval of certain NDAs for similar products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Different pricing and reimbursement schemes
exist in other countries. In the European Community, governments influence the price of pharmaceutical products through their pricing
and reimbursement rules and control of national healthcare systems that fund a large part of the cost of those products to consumers.
Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price
has been agreed upon. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical
studies that compare the cost-effectiveness of a particular pharmaceutical product candidate to currently available therapies.
Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. The downward
pressure on healthcare costs in general, particularly prescription drugs, has become very intense. As a result, increasingly high
barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets
exert a commercial pressure on pricing within a country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The marketability of any pharmaceutical
product candidates for which we may receive regulatory approval for commercial sale may suffer if the government and third-party
payers fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has increased
and we expect this will continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement
rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which
we may receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>International Regulation </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition to regulations in the United
States, there are a variety of foreign regulations governing clinical studies and commercial sales and distribution of our current
and future product candidates. Whether or not FDA approval is obtained for a product, approval of a product must be obtained by
the comparable regulatory authorities of foreign countries, or jurisdictions such as the EU, before clinical studies or marketing
of the product can commence in those countries. The approval process varies from country to country, and the time may be longer
or shorter than that required for FDA approval. The requirements governing the conduct of clinical studies, product licensing,
pricing and reimbursement vary greatly from country to country. In addition, certain regulatory authorities may require us to repeat
previously conducted preclinical and/or clinical studies under specific criteria for approval in their respective country or jurisdictions,
which may delay and/or increase the cost of approval in certain markets targeted for approval by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Subsequent Event</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On February 9, 2017, we entered into an
Underwriting Agreement (the &ldquo;Underwriting Agreement&rdquo;) with Roth Capital Partners, LLC, as representative of the several
underwriters identified therein (collectively, the &ldquo;Underwriters&rdquo;), pursuant to which we sold in a registered public
offering (the &ldquo;Offering&rdquo;), 3,710,000 units, priced at a public offering price of $1.35 per unit, with each unit consisting
of: (i) one share of common stock, (ii) a five-year Series A warrant to purchase 0.50 of a share of common stock, (iii) a 90-day
Series B warrant to purchase one share of common stock, and (iv) a five-year Series C warrant to purchase 0.50 of a share of common
stock. The Series C warrants in a unit may only be exercised to the extent and in proportion to a holder of the Series C warrants
exercising its Series B warrants included in the unit. The Series A and Series C warrant have an exercise price of $1.50 per share
of common stock. The Series B warrant has an exercise price of $1.35 per share of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the terms of the Underwriting Agreement,
we granted the Underwriters a 45-day option to purchase an additional 556,500 shares of common stock and/or an additional 556,500
warrants combinations (comprised of an aggregate of 278,250 Series A warrants, 556,500 Series B warrants and 278,250 Series C warrants),
in any combinations thereof, from us to cover over-allotments at the public offering price per share of $1.349 and public offering
price per warrant combination of $.001, respectively, less the underwriting discounts and commissions. Upon the closing of the
Offering, the Underwriters exercised the over-allotment option with respect to 278,100 warrant combinations. We received approximately
$4.4 million in net proceeds from the Offering, after deducting underwriting discounts and commissions and estimated offering expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Subsequent to March 22, 2017, investors
in the aforementioned offering on February 9, 2017, have excerised approximately 600,000 Series B warrants resulting in approximately
gross proceeds to the Company of $800,000 and approximately 600,000 shares of the Company&rsquo;s common stock being issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Employees </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of December 31, 2016, we had two full-time
employees and four part-time employees, and accordingly, a high percentage of the work performed for our development projects is
outsourced to qualified independent contractors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Legal Proceedings </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are not subject to any litigation.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="main_003"></A>ITEM 1A. RISK FACTORS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>The following risks and uncertainties
should be carefully considered. If any of the following occurs, our business, financial condition or operating results could be
materially harmed. An investment in our securities is speculative in nature, involves a high degree of risk and should not be made
by an investor who cannot bear the economic risk of its investment for an indefinite period of time and who cannot afford the loss
of its entire investment.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Relating to Our Business </B></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will require substantial additional funding,
which may not be available to us on acceptable terms, or at all, and, if not so available, may require us to delay, limit, reduce
or cease our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We intend to use the proceeds from our
previous offerings, as well as the proceeds any possible future offerings, to, among other uses, advance Annamycin through clinical
development. Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is expensive. We
will require substantial additional future capital in order to complete clinical development and commercialize Annamycin. If the
FDA requires that we perform additional nonclinical studies or clinical trials, or if we determine, as we did in October 2016,
that additional clinical trials are required for Annamycin, our expenses would further increase beyond what we currently expect
and the anticipated timing of any potential approval of Annamycin would likely be delayed. In addition, if our current plan to
obtain the required CMC data to be included with our IND application for Annamycin is unsuccessful, we will be required to incur
unexpected costs and a delay in submiting our IND application. Further, there can be no assurance that the costs we will need
to incur to obtain regulatory approval of Annamycin will not increase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We will continue to require substantial
additional capital to continue our clinical development and commercialization activities. Because successful development of our
product candidates is uncertain, we are unable to estimate the actual amount of funding we will require to complete research and
development and commercialize our products under development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The amount and timing of our future funding
requirements will depend on many factors, including but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>whether our updated plan for clinical trials will be completed on a timely basis and, if completed, expect to publicly announce
results from our phase I/II clinical trial until sometime in 2018;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>whether we are successful in obtaining the benefits of FDA&rsquo;s expedited development and review programs related to
Annamycin;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
progress, costs, results of and timing of our clinical trials for Annamycin;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
outcome, costs and timing of seeking and obtaining FDA and any other regulatory approvals;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
costs associated with securing and establishing commercialization and manufacturing capabilities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;market
acceptance of our product candidates;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
costs of acquiring, licensing or investing in businesses, products, product candidates and technologies;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;our
ability to maintain, expand and enforce the scope of our intellectual property portfolio, including the amount and timing of any
payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and
enforcement of any patents or other intellectual property rights;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;our
need and ability to hire additional management and scientific and medical personnel;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
the effect of competing drug candidates and new product approvals;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
our need to implement additional internal systems and infrastructure, including financial and reporting systems; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
the economic and other terms, timing of and success of our existing licensing arrangements and any collaboration, licensing or
other arrangements into which we may enter in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Some of these factors are outside of our
control. Based upon our currently expected level of operating expenditures, we believe that we will be able to fund our operational
plan into the first quarter of 2018, assuming not a significant amount of the warrants in our recent public offering are execised
for cash. This period could be shortened if there are any significant increases in planned spending on development programs or
more rapid progress of development programs than anticipated. We do not believe that our existing capital resources are sufficient
to enable us to complete the development and commercialization of Annamycin, if approved, or to initiate any clinical trials or
additional development work needed for any other drug candidates. Accordingly, we expect that we will need to raise additional
funds in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may seek additional funding through a
combination of equity offerings, debt financings, government or other third-party funding, commercialization, marketing and distribution
arrangements and other collaborations, strategic alliances and licensing arrangements. Additional funding may not be available
to us on acceptable terms or at all. In addition, the terms of any financing may adversely affect the holdings or the rights of
our stockholders. In addition, the issuance of additional shares by us, or the possibility of such issuance, may cause the market
price of our shares to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If we are unable to obtain funding on a
timely basis, we may be required to significantly curtail one or more of our research or development programs. We also could be
required to seek funds through arrangements with collaborative partners or otherwise that may require us to relinquish rights to
some of our technologies or product candidates or otherwise agree to terms unfavorable to us.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have in the past completed related party transactions
that were not conducted on an arm&rsquo;s length basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We acquired the rights to the license agreement
with MD Anderson covering our WP1122 Portfolio held by IntertechBio Corporation, a company affiliated with certain members of our
management and board of directors. We acquired the rights to all data related to the development of Annamycin held by AnnaMed,
Inc., a company affiliated with certain members of our management and board of directors. Prior to our IPO, Moleculin, LLC merged
with and into our company. Moleculin, LLC was affiliated with certain members of our management and board of directors. Prior to
our IPO, we, on Moleculin, LLC&rsquo;s behalf, entered into an agreement with HPI whereby HPI agreed to terminate its option to
sublicense certain rights to the WP1066 Portfolio and entered into a co-development agreement with us. Our largest shareholder
and a member of our management are shareholders of HPI. None of the foregoing transactions were conducted on an arm&rsquo;s length
basis. As such, it is possible that the terms were less favorable to us than in an arm&rsquo;s length transaction.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our ability to retain the development rights to
the WP1066 Portfolio will require us to make up to a total of $1.75 million in future payments to HPI, in addition to payments
of shares of our common stock and cash made in connection with our IPO, pursuant to the development agreement we entered into with
HPI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our acquisition of Moleculin, LLC prior
to our IPO provided us with the rights to the license agreement Moleculin, LLC had with MD Anderson covering the WP1066 Portfolio.
However, Moleculin, LLC previously granted HPI an option to obtain an exclusive sub-license to develop the WP1066 Portfolio in
all non-dermatological fields. Prior to our IPO, we, on Moleculin, LLC&rsquo;s behalf, entered into two agreements with HPI. The
first agreement terminated HPI&rsquo;s option to obtain the aforementioned exclusive sublicense in exchange for a payment of $100,000
and the issuance of 629,000 shares of our common stock. The second agreement, the HPI Out-Licensing Agreement is a technology rights
and development license agreement that provided HPI with a non-exclusive sublicense to develop the WP1066 Portfolio. Pursuant to
this HPI Out-Licensing Agreement, we agreed to make payments to HPI of $750,000 over a three-year period commencing after our IPO
in exchange for HPI allowing us to access any data, information or know-how resulting from the research and development conducted
by HPI, which payments will be expensed when incurred. Notwithstanding our obligation to make the foregoing payments, the HPI Out-Licensing
Agreement does not obligate HPI to conduct any specific research or to meet any milestones. Pursuant to the HPI Out-Licensing Agreement,
we have the right within three years of the date we entered into the agreement to buy-out from HPI all rights granted to HPI under
the agreement for a payment of $1.0 million. If we do not exercise the foregoing buy-out right within three years, the license
granted to HPI shall convert into an exclusive license even as to our company. As such, if we do not exercise the buy-out right
for any reason, we will no longer have access to the non-dermatology uses of the WP1066 Portfolio and all amounts paid to HPI prior
to such date will have value only to the extent that the data, information and know-how may be applicable to dermatology applications
of the WP1066 Portfolio. We do not expect to maintain a reserve of $1.0 million to exercise the buy-out payment and, as such, we
will need to raise additional funds to make the buy-out payment. We cannot assure you that such additional funding, if required,
will be available on satisfactory terms, or at all.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have never been profitable, we have no products
approved for commercial sale, and to date we have not generated any revenue from product sales. As a result, our ability to reduce
our losses and reach profitability is unproven, and we may never achieve or sustain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have never been profitable and do not
expect to be profitable in the foreseeable future. We have not yet submitted any drug candidates for approval by regulatory authorities
in the United States or elsewhere. For the year ended December 31, 2016, we incurred a net loss of $3,926,361. We had an accumulated
deficit of $4,674,721 as of December 31, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To date, we have devoted most of our financial
resources to research and development, including our drug discovery research, preclinical development activities and clinical trial
preparation, as well as corporate overhead. We have not generated any revenues from product sales. We expect to continue to incur
losses for the foreseeable future, and we expect these losses to increase as we continue our development of, and seek regulatory
approvals for Annamycin, prepare for and begin the commercialization of any approved products, and add infrastructure and personnel
to support our continuing product development efforts. We anticipate that any such losses could be significant for the next several
years. If Annamycin or any of our other drug candidates fail in clinical trials or does not gain regulatory approval, or if our
drug candidates do not achieve market acceptance, we may never become profitable. As a result of the foregoing, we expect to continue
to experience net losses and negative cash flows for the foreseeable future. These net losses and negative cash flows have had,
and will continue to have, an adverse effect on our stockholders' equity and working capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Because of the numerous risks and uncertainties
associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses
or when, or if, we will be able to achieve profitability. In addition, our expenses could increase if we are required by the FDA
to perform studies or trials in addition to those currently expected, or if there are any delays in completing our clinical trials
or the development of any of our drug candidates. The amount of future net losses will depend, in part, on the rate of future growth
of our expenses and our ability to generate revenues.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our financial condition would be adversely impacted
if our intangible assets become impaired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As a result of the accounting for our
acquisition of Moleculin, LLC and the agreement we, on Moleculin, LLC&rsquo;s behalf, entered into with Houston
Pharmaceuticals, Inc., we have carried on our balance sheet within intangible assets in-process research and development
(&ldquo;IPR&amp;D&rdquo;) of $11,147,540 as of December 31, 2016. Intangibles are evaluated quarterly and are tested for
impairment at least annually or when events or changes in circumstances indicate the carrying value of each segment, and
collectively our company taken as a whole, might exceed its fair value. We have retained a third party valuation firm to
provide us with a valuation of these intangible assets and have incorporated their final report results in this filing of our
Form 10-K for the year ended December 31, 2016.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Intangible assets related to IPR&amp;D are
considered indefinite-lived intangible assets and are assessed for impairment annually or more frequently if impairment indicators
exist. If the associated research and development effort is abandoned, the related assets will be written-off and the Company will
record a noncash impairment loss on its statement of operations. For those compounds that reach commercialization, if any, the
IPR&amp;D assets will be amortized over their estimated useful lives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If we determine that the value of our intangible
assets is less than the amounts reflected on our balance sheet, we will be required to reflect an impairment of our intangible
assets in the period in which such determination is made. An impairment of our intangible assets would result in our recognizing
an expense in the amount of the impairment in the relevant period, which would also result in the reduction of our intangible
assets and a corresponding reduction in our stockholders&rsquo; equity in the relevant period. As the transactions discussed above
were related party transactions and were not conducted on an arm&rsquo;s length basis, it is possible that the terms were less
favorable to us than what we would have received in an arm&rsquo;s length transaction.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have a limited operating history and we expect
a number of factors to cause our operating results to fluctuate on an annual basis, which may make it difficult to predict our
future performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are a preclinical pharmaceutical company
with a limited operating history. Our operations to date have been limited to acquiring our technology portfolio. We have not yet
commenced any clinical trials or obtained any regulatory approvals for any of our drug candidates. Consequently, any predictions
made about our future success or viability may not be as accurate as they could be if we had a longer operating history or approved
products on the market. Our operating results are expected to significantly fluctuate from quarter-to-quarter or year-to-year due
to a variety of factors, many of which are beyond our control. Factors relating to our business that may contribute to these fluctuations
include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
delays in regulatory review and approval of our product candidates in clinical development, including our ability to receive approval
from the FDA for Annamycin;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;delays
in the commencement, enrollment and timing of clinical trials;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;difficulties
in identifying patients suffering from our target indications;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
success of our clinical trials through all phases of clinical development;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;potential
side effects of our product candidate that could delay or prevent approval or cause an approved drug to be taken off the market;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;our
ability to obtain additional funding to develop drug candidates;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;our
ability to identify and develop additional drug candidates beyond Annamycin and our WP1066 and WP1122 Portfolios;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;competition
from existing products or new products that continue to emerge;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
ability of patients or healthcare providers to obtain coverage or sufficient reimbursement for our products;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;our
ability to adhere to clinical trial requirements directly or with third parties such as contract research organizations (CROs);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;our
dependency on third-party manufacturers to manufacture our products and key ingredients;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;our
ability to establish or maintain collaborations, licensing or other arrangements, particularly with MD Anderson;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;our
ability to defend against any challenges to our intellectual property including, claims of patent infringement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;our
ability to enforce our intellectual property rights against potential competitors;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;our
ability to secure additional intellectual property protection for our developing drug candidates and associated technologies;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;our
ability to attract and retain key personnel to manage our business effectively; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;potential
product liability claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Accordingly, the results of any historical
quarterly or annual periods should not be relied upon as indications of future operating performance.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">We cannot be certain that Annamycin will receive
regulatory approval, and without regulatory approval we will not be able to market Annamycin.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our business currently depends largely on
the successful development and commercialization of Annamycin. Our ability to generate revenue related to product sales, if ever,
will depend on the successful development and regulatory approval of Annamycin for the treatment of relapsed or refractory acute
myeloid leukemia, or AML.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We currently have no products approved for
sale and we cannot guarantee that we will ever have marketable products. The development of a product candidate and issues relating
to its approval and marketing are subject to extensive regulation by the FDA in the United States and regulatory authorities in
other countries, with regulations differing from country to country. We are not permitted to market our product candidates in the
United States until we receive approval of a NDA from the FDA. We have not submitted any marketing applications for any of our
product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">NDAs must include extensive preclinical
and clinical data and supporting information to establish the product candidate&rsquo;s safety and effectiveness for each desired
indication. NDAs must also include significant information regarding the chemistry, manufacturing and controls for the product.
Obtaining approval of a NDA is a lengthy, expensive and uncertain process, and we may not be successful in obtaining approval.
The FDA review processes can take years to complete and approval is never guaranteed. If we submit a NDA to the FDA, the FDA must
decide whether to accept or reject the submission for filing. We cannot be certain that any submissions will be accepted for filing
and review by the FDA. Regulators in other jurisdictions have their own procedures for approval of product candidates. Even if
a product is approved, the FDA may limit the indications for which the product may be marketed, require extensive warnings on the
product labeling or require expensive and time-consuming clinical trials or reporting as conditions of approval. Regulatory authorities
in countries outside of the United States and Europe also have requirements for approval of drug candidates with which we must
comply with prior to marketing in those countries. Obtaining regulatory approval for marketing of a product candidate in one country
does not ensure that we will be able to obtain regulatory approval in any other country. In addition, delays in approvals or rejections
of marketing applications in the United States, Europe or other countries may be based upon many factors, including regulatory
requests for additional analyses, reports, data, preclinical studies and clinical trials, regulatory questions regarding different
interpretations of data and results, changes in regulatory policy during the period of product development and the emergence of
new information regarding our product candidates or other products. Also, regulatory approval for any of our product candidates
may be withdrawn.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If we are unable to obtain approval from
the FDA, or other regulatory agencies, for Annamycin and our other product candidates, or if, subsequent to approval, we are unable
to successfully commercialize Annamycin or our other product candidates, we will not be able to generate sufficient revenue to
become profitable or to continue our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any statements in this report indicating
that Annamycin has demonstrated preliminary evidence of efficacy are our own and are not based on the FDA&rsquo;s or any other
comparable governmental agency&rsquo;s assessment of Annamycin and do not indicate that Annamycin will achieve favorable efficacy
results in any later stage trials or that the FDA or any comparable agency will ultimately determine that Annamycin is effective
for purposes of granting marketing approval.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Delays in the commencement, enrollment and completion
of clinical trials could result in increased costs to us and delay or limit our ability to obtain regulatory approval for Annamycin
and our other product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Delays in the commencement, enrollment and
completion of clinical trials could increase our product development costs or limit the regulatory approval of our product candidates.
We do not know whether any future trials or studies of our other product candidates will begin on time or will be completed on
schedule, if at all. The start or end of a clinical study is often delayed or halted due to changing regulatory requirements, manufacturing
challenges, including delays or shortages in available drug product, required clinical trial administrative actions, slower than
anticipated patient enrollment, changing standards of care, availability or prevalence of use of a comparative drug or required
prior therapy, clinical outcomes or financial constraints. For instance, delays or difficulties in patient enrollment or difficulties
in retaining trial participants can result in increased costs, longer development times or termination of a clinical trial. Clinical
trials of a new product candidate require the enrollment of a sufficient number of patients, including patients who are suffering
from the disease the product candidate is intended to treat and who meet other eligibility criteria. Rates of patient enrollment
are affected by many factors, including the size of the patient population, the eligibility criteria for the clinical trial, that
include the age and condition of the patients and the stage and severity of disease, the nature of the protocol, the proximity
of patients to clinical sites and the availability of effective treatments and/or availability of investigational treatment options
for the relevant disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A product candidate can unexpectedly fail
at any stage of preclinical and clinical development. The historical failure rate for product candidates is high due to scientific
feasibility, safety, efficacy, changing standards of medical care and other variables. The results from preclinical testing or
early clinical trials of a product candidate may not predict the results that will be obtained in later phase clinical trials of
the product candidate. We, the FDA or other applicable regulatory authorities may suspend clinical trials of a product candidate
at any time for various reasons, including, but not limited to, a belief that subjects participating in such trials are being exposed
to unacceptable health risks or adverse side effects, or other adverse initial experiences or findings. We may not have the financial
resources to continue development of, or to enter into collaborations for, a product candidate if we experience any problems or
other unforeseen events that delay or prevent regulatory approval of, or our ability to commercialize, product candidates, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;inability
to obtain sufficient funds required for a clinical trial;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;inability
to reach agreements on acceptable terms with prospective CROs and trial sites, the terms of which can be subject to extensive negotiation
and may vary significantly among different CROs and trial sites;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;negative
or inconclusive results from our clinical trials or the clinical trials of others for product candidates similar to ours, leading
to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
serious and unexpected drug-related side effects experienced by subjects in our clinical trials or by individuals using drugs similar
to our product candidates;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;conditions
imposed by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;delays
in enrolling research subjects in clinical trials;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;high
drop-out rates and high fail rates of research subjects;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;inadequate
supply or quality of product candidate components or materials or other supplies necessary for the conduct of our clinical trials;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;greater
than anticipated clinical trial costs;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;poor
effectiveness of our product candidates during clinical trials; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;unfavorable
FDA or other regulatory agency inspection and review of a clinical trial site or vendor.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have never conducted a clinical trial or submitted
an NDA before, and any product candidate we advance through clinical trials may not have favorable results in later clinical trials
or receive regulatory approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Clinical failure can occur at any stage
of our clinical development. Clinical trials may produce negative or inconclusive results, and our collaborators or we may decide,
or regulators may require us, to conduct additional clinical trials or nonclinical studies. In addition, data obtained from trials
and studies are susceptible to varying interpretations, and regulators may not interpret our data as favorably as we do, which
may delay, limit or prevent regulatory approval. Success in preclinical studies and early clinical trials does not ensure that
subsequent clinical trials will generate the same or similar results or otherwise provide adequate data to demonstrate the efficacy
and safety of a product candidate. A number of companies in the pharmaceutical industry, including those with greater resources
and experience than us, have suffered significant setbacks in clinical trials, even after seeing promising results in earlier clinical
trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, the design of a clinical trial
can determine whether its results will support approval of a product and flaws in the design of a clinical trial may not become
apparent until the clinical trial is well advanced. We may be unable to design and execute a clinical trial to support regulatory
approval. Further, clinical trials of potential products often reveal that it is not practical or feasible to continue development
efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If Annamycin is found to be unsafe or lack
efficacy, we will not be able to obtain regulatory approval for it and our business would be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In some instances, there can be significant
variability in safety and/or efficacy results between different trials of the same product candidate due to numerous factors, including
changes in trial protocols, differences in composition of the patient populations, adherence to the dosing regimen and other trial
protocols and the rate of dropout among clinical trial participants. We do not know whether any clinical trials we or any of our
potential future collaborators may conduct will demonstrate the consistent or adequate efficacy and safety that would be required
to obtain regulatory approval and market any products. If we are unable to bring Annamycin to market, or to acquire other products
that are on the market or can be developed, our ability to create long-term stockholder value will be limited.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our product candidates may have undesirable side
effects that may delay or prevent marketing approval, or, if approval is received, require them to be taken off the market, require
them to include safety warnings or otherwise limit their sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Unforeseen side effects from any of our product candidates could arise either during clinical development or, if
Annamycin is approved, after the approved product has been marketed. For example, in the most recent Phase I/II dose-ranging clinical
trial of Annamycin, two patients succumbed to tumor lysis syndrome (TLS) resulting from the debris created by Annamycin killing
the targeted leukemic blasts more rapidly than anticipated. Now that this potential has been identified, prophylactic measures
intended to protect patients from TLS will be deployed in future clinical trials, but there can be no assurance that such measures
will be effective or that other adverse events may not emerge related to our drug. As another example, we intend to attempt to
increase the maximum tolerable dose (MTD) for Annamycin by conducting another Phase I dose-ranging trial, however, unforeseen side
effects could prevent us from increasing the MTD from the one established in the prior Phase I/II trial. Additional or unforeseen
side effects from Annamycin or any of our other product candidates could arise either during clinical development or, if approved,
after the approved product has been marketed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The range and potential severity of possible
side effects from therapies such as Annamycin are significant. If Annamycin causes undesirable or unacceptable side effects in
the future, this could interrupt, delay or halt clinical trials and result in the failure to obtain or suspension or termination
of marketing approval from the FDA and other regulatory authorities, or result in marketing approval from the FDA and other regulatory
authorities only with restrictive label warnings or other limitations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If any of our product candidates receives
marketing approval and we or others later identify undesirable or unacceptable side effects caused by such products:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;regulatory
authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians
and pharmacies;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;we
may be required to change instructions regarding the way the product is administered, conduct additional clinical trials or change
the labeling of the product;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;we
may be subject to limitations on how we may promote the product;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;sales
of the product may decrease significantly;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;regulatory
authorities may require us to take our approved product off the market;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;we
may be subject to litigation or product liability claims; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;our
reputation may suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any of these events could prevent us or
our potential future collaborators from achieving or maintaining market acceptance of the affected product or could substantially
increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenues from
the sale of our products.<B><I>&nbsp;</I></B></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">If the FDA does not find the manufacturing facilities
of our future contract manufacturers acceptable for commercial production, we may not be able to commercialize any of our product
candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We do not intend to manufacture the pharmaceutical
products that we plan to sell. We are currently utilizing contract manufacturers for the production of the active pharmaceutical
ingredients and the formulation of drug product for our trials of Annamycin that we will need to conduct prior to seeking regulatory
approval. However, we do not have agreements for supplies of Annamycin or any of our other product candidates and we may not be
able to reach agreements with these or other contract manufacturers for sufficient supplies to commercialize Annamycin if it is
approved. Additionally, the facilities used by any contract manufacturer to manufacture Annamycin or any of our other product
candidates must be the subject of a satisfactory inspection before the FDA approves the product candidate manufactured at that
facility. We are completely dependent on these third-party manufacturers for compliance with the requirements of U.S. and non-U.S.
regulators for the manufacture of our finished products. If our manufacturers cannot successfully manufacture material that conform
to our specifications and the FDA&rsquo;s current good manufacturing practice standards, or cGMP, and other requirements of any
governmental agency whose jurisdiction to which we are subject, our product candidates will not be approved or, if already approved,
may be subject to recalls or other negative actions. Reliance on third-party manufacturers entails risks to which we would not
be subject if we manufactured our product candidates, including:<FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
possibility that we are unable to enter into a manufacturing agreement with a third party to manufacture our product candidates;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
possible breach of the manufacturing agreements by the third parties because of factors beyond our control; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
possibility of termination or nonrenewal of the agreements by the third parties before we are able to arrange for a qualified replacement
third-party manufacturer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any of these factors could cause the delay
of approval or commercialization of our product candidates, cause us to incur higher costs or prevent us from commercializing our
product candidates successfully. Furthermore, if any of our product candidates are approved and contract manufacturers fail to
deliver the required commercial quantities of finished product on a timely basis at commercially reasonable prices and we are unable
to find one or more replacement manufacturers capable of production at a substantially equivalent cost, in substantially equivalent
volumes and quality and on a timely basis, we would likely be unable to meet demand for our products and could lose potential revenue.
It may take several years to establish an alternative source of supply for our product candidates and to have any such new source
approved by the government agencies that regulate our products.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have no sales, marketing or distribution experience
and we will have to invest significant resources to develop those capabilities or enter into acceptable third-party sales and marketing
arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have no sales, marketing or distribution
experience. To develop sales, distribution and marketing capabilities, we will have to invest significant amounts of financial
and management resources, some of which will need to be committed prior to any confirmation that Annamycin or any of our other
product candidates will be approved by the FDA. For product candidates where we decide to perform sales, marketing and distribution
functions ourselves or through third parties, we could face a number of additional risks, including that we or our third-party
sales collaborators may not be able to build and maintain an effective marketing or sales force. If we use third parties to market
and sell our products, we may have limited or no control over their sales, marketing and distribution activities on which our future
revenues may depend.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may not be successful in establishing and maintaining
development and commercialization collaborations, which could adversely affect our ability to develop certain of our product candidates
and our financial condition and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Because developing pharmaceutical products,
conducting clinical trials, obtaining regulatory approval, establishing manufacturing capabilities and marketing approved products
are expensive, we may seek to enter into collaborations with companies that have more experience. Additionally, if any of our product
candidates receives marketing approval, we may enter into sales and marketing arrangements with third parties with respect to our
unlicensed territories. If we are unable to enter into arrangements on acceptable terms, if at all, we may be unable to effectively
market and sell our products in our target markets. We expect to face competition in seeking appropriate collaborators. Moreover,
collaboration arrangements are complex and time consuming to negotiate, document and implement and they may require substantial
resources to maintain. We may not be successful in our efforts to establish and implement collaborations or other alternative arrangements
for the development of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">When we collaborate with a third party for
development and commercialization of a product candidate, we can expect to relinquish some or all of the control over the future
success of that product candidate to the third party. For example, we have formed a collaboration with a Polish drug development
company called Dermin, where we have provided them with sub-license rights to our technologies for use in limited territories in
exchange for their use of Polish government grant funding to pay for development costs we would otherwise have to fund ourselves.
With the exception of Annamycin, Dermin&rsquo;s territories are primarily Poland and lesser surrounding countries, but not including
any of the major European markets (UK, Germany, France, Spain and Italy). In the case of Annamycin, Dermin&rsquo;s territories
also include Germany, but we retain the right to repurchase that territory for $500,000 at any time in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We announced in October 2016 that we had
secured an agreement with Dermin to utilize Dermin&rsquo;s supply of Annamycin for our upcoming clinical trial. If Dermin is unable
to provide us with sufficient supply for clinical trials, or if the drug product supplied is unacceptable for use in our clinical
trials, our clinical trials may be delayed or the outcomes may be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">One or more of our collaboration partners
may not devote sufficient resources to the commercialization of our product candidates or may otherwise fail in their commercialization.
The terms of any collaboration or other arrangement that we establish may contain provisions that are not favorable to us. In addition,
any collaboration that we enter into may be unsuccessful in the development and commercialization of our product candidates. In
some cases, we may be responsible for continuing preclinical and initial clinical development of a product candidate or research
program under a collaboration arrangement, and the payment we receive from our collaboration partner may be insufficient to cover
the cost of this development. If we are unable to reach agreements with suitable collaborators for our product candidates, we would
face increased costs, we may be forced to limit the number of our product candidates we can commercially develop or the territories
in which we commercialize them. As a result, we might fail to commercialize products or programs for which a suitable collaborator
cannot be found. If we fail to achieve successful collaborations, our operating results and financial condition could be materially
and adversely affected.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our success depends greatly on the success of Annamycin&rsquo;s
development for the treatment of relapsed or refractory AML, and our pipeline of product candidates beyond this lead indication
is extremely early stage and limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Other than Annamycin, our other two drug
candidates, our WP1066 Portfolio and our WP1122 Portfolio, are each in the early stages of development. In addition, our current
plan is to use a significant portion of our available funds to support our clinical plan for Annamycin, although this cash utilization
may change in the future. As such, we are dependent on the success of Annamycin in the near term. We cannot provide you any assurance
that we will be able to successfully advance any of these indications through the development process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">We face competition from other biotechnology and
pharmaceutical companies and our operating results will suffer if we fail to compete effectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The biotechnology and pharmaceutical industries
are intensely competitive and subject to rapid and significant technological change. We have competitors in the United States,
Europe and other jurisdictions, including major multinational pharmaceutical companies, established biotechnology companies, specialty
pharmaceutical and generic drug companies and universities and other research institutions. Many of our competitors have greater
financial and other resources, such as larger research and development staff and more experienced marketing and manufacturing organizations
than we do. Large pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining regulatory
approvals, recruiting patients and manufacturing pharmaceutical products. These companies also have significantly greater research,
sales and marketing capabilities and collaborative arrangements in our target markets with leading companies and research institutions.
Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license
novel compounds that could make the product candidates that we develop obsolete. As a result of all of these factors, our competitors
may succeed in obtaining patent protection and/or FDA approval or discovering, developing and commercializing drugs for the diseases
that we are targeting before we do or may develop drugs that are deemed to be more effective or gain greater market acceptance
than ours. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements
with large, established companies. In addition, many universities and private and public research institutes may become active
in our target disease areas. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis, technologies
and drug products that are more effective or less costly than any of our product candidates that we are currently developing or
that we may develop, which could render our products obsolete or noncompetitive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A number of attempts have been made or are
under way to provide an improved treatment for AML. Drugs attempting to target a subset of AML patients who present with particular
anomalies involving a gene referred to as FLT3 are currently in clinical trials. Other approaches to improve the effectiveness
of induction therapy are in early stage clinical trials and, although they do not appear to address the underlying problems with
anthracyclines, we can provide no assurance that such improvements, if achieved, would not adversely impact the need for improved
anthracyclines. A modified version of doxorubicin designed to reduce cardiotoxicity is in clinical trials for the treatment of
sarcoma and, although this drug does not appear to address multidrug resistance and is not currently intended for the treatment
of acute leukemia, we can provide no assurance that it will not become a competitive alternative to Annamycin. Although we are
not aware of any other single agent therapies in clinical trials that would directly compete against Annamycin in the treatment
of relapsed and refractory AML, we can provide no assurance that such therapies are not in development, will not receive regulatory
approval and will reach market before our drug candidate Annamycin. In addition, any such competing therapy may be more effective
and / or cost-effective than ours.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If our competitors market products that
are more effective, safer or less expensive or that reach the market sooner than our future products, if any, we may not achieve
commercial success. In addition, because of our limited resources, it may be difficult for us to stay abreast of the rapid changes
in each technology. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological
advances or products developed by our competitors may render our technologies or product candidates obsolete, less competitive
or not economical.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Annamycin does not have any patent protections,
including composition of matter patent protection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On March 21, 2017, we received notice that
we have obtained Orphan Drug designation for Annamycin with the FDA for the treatment of AML. Additionally, we intend to pursue
patents with claims directed to Annamycin drug product formulations and the methods of use of Annamycin to treat relapsed or refractory
AML and other conditions, and methods for its synthesis, as the composition of matter patent protection for Annamycin has expired.
As a result, competitors may be able to offer and sell products so long as these competitors do not infringe any other patents
that third parties or we hold, including formulation, synthesis and method of use patents. However, method of use patents, in
particular, are more difficult to enforce than composition of matter patents because of the risk of off-label sale or use of the
subject compounds. Physicians are permitted to prescribe an approved product for uses that are not described in the product's
labeling. Although off-label prescriptions may infringe our method of use patents, the practice is common across medical specialties
and such infringement is difficult to prevent or prosecute. Off-label sales would limit our ability to generate revenue from the
sale of Annamycin, if approved for commercial sale.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">The intellectual property rights we have licensed
from MD Anderson are subject to the rights of the U.S. government.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have obtained a royalty-bearing, worldwide,
exclusive license to intellectual property rights, including patent rights related to our WP1066 Portfolio and WP1122 Portfolio
drug product candidates from MD Anderson. Some of our licensed intellectual property rights from MD Anderson have been developed
in the course of research funded by the U.S. government. As a result, the U.S. government may have certain rights to intellectual
property embodied in our current or future products pursuant to the Bayh-Dole Act of 1980. Government rights in certain inventions
developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions
for any governmental purpose. In addition, the U.S. government has the right to require us, or an assignee or exclusive licensee
to such inventions, to grant licenses to any of these inventions to a third party if they determine that: (i) adequate steps have
not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; (iii)
government action is necessary to meet requirements for public use under federal regulations; or (iv) the right to use or sell
such inventions is exclusively licensed to an entity within the U.S. and substantially manufactured outside the U.S. without the
U.S. government&rsquo;s prior approval. Additionally, we may be restricted from granting exclusive licenses for the right to use
or sell our inventions created pursuant to such agreements unless the licensee agrees to additional restrictions (e.g., manufacturing
substantially all of the invention in the U.S.). The U.S. government also has the right to take title to these inventions if we
fail to disclose the invention to the government and fail to file an application to register the intellectual property within specified
time limits. In addition, the U.S. government may acquire title in any country in which a patent application is not filed within
specified time limits. Additionally, certain inventions are subject to transfer restrictions during the term of these agreements
and for a period thereafter, including sales of products or components, transfers to foreign subsidiaries for the purpose of the
relevant agreements, and transfers to certain foreign third parties. If any of our intellectual property becomes subject to any
of the rights or remedies available to the U.S. government or third parties pursuant to the Bayh-Dole Act of 1980, this could impair
the value of our intellectual property and could adversely affect our business.<B><I>&nbsp;</I></B></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may incur substantial costs as a result of litigation
or other proceedings relating to patent and other intellectual property rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may from time to time seek to enforce
our intellectual property rights against infringers when we determine that a successful outcome is probable and may lead to an
increase in the value of the intellectual property. If we choose to enforce our patent rights against a party, then that individual
or company has the right to ask the court to rule that such patents are invalid or should not be enforced. Additionally, the validity
of our patents and the patents we have licensed may be challenged if a petition for post grant proceedings such as inter-partes
review and post grant review is filed within the statutorily applicable time with the U.S. Patent and Trademark Office (USPTO).
These lawsuits and proceedings are expensive and would consume time and resources and divert the attention of managerial and scientific
personnel even if we were successful in stopping the infringement of such patents. In addition, there is a risk that the court
will decide that such patents are not valid and that we do not have the right to stop the other party from using the inventions.
There is also the risk that, even if the validity of such patents is upheld, the court will refuse to stop the other party on the
ground that such other party's activities do not infringe our intellectual property rights. In addition, in recent years the U.S.
Supreme Court modified some tests used by the USPTO in granting patents over the past 20 years, which may decrease the likelihood
that we will be able to obtain patents and increase the likelihood of a challenge of any patents we obtain or license.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may be subject to claims that our employees have
wrongfully used or disclosed alleged trade secrets of their former employers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As is common in the biotechnology and pharmaceutical
industries, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our
competitors or potential competitors. We may be subject to claims that these employees, or we, have used or disclosed trade secrets
or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. Even if
we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">If we are not able to adequately prevent disclosure
of trade secrets and other proprietary information, the value of our technology and products could be significantly diminished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We rely on trade secrets to protect our
proprietary technologies, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets
are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators,
sponsored researchers and other advisors to protect our trade secrets and other proprietary information. These agreements may not
effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized
disclosure of confidential information. In addition, others may independently discover our trade secrets and proprietary information.
Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure
to obtain or maintain trade secret protection could adversely affect our competitive business position.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will need to expand our operations and increase
the size of our company, and we may experience difficulties in managing growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of December 31, 2016, we had two full-time
and four part-time employees. As we advance our product candidates through preclinical studies and clinical trials, we will need
to increase our product development, scientific and administrative headcount to manage these programs. In addition, to meet our
obligations as a public company, we may need to increase our general and administrative capabilities. Our management, personnel
and systems currently in place may not be adequate to support this future growth. If we are unable to successfully manage this
growth and increased complexity of operations, our business may be adversely affected.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may not be able to manage our business effectively
if we are unable to attract and retain key personnel and consultants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may not be able to attract or retain
qualified management, finance, scientific and clinical personnel and consultants due to the intense competition for qualified personnel
and consultants among biotechnology, pharmaceutical and other businesses. If we are not able to attract and retain necessary personnel
and consultants to accomplish our business objectives, we may experience constraints that will significantly impede the achievement
of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are highly dependent on the development,
regulatory, commercialization and business development expertise of our management team, key employees and consultants. If we lose
one or more of our executive officers or key employees or consultants, our ability to implement our business strategy successfully
could be seriously harmed. Any of our executive officers or key employees or consultants may terminate their employment at any
time. Replacing executive officers, key employees and consultants may be difficult and may take an extended period of time because
of the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain regulatory
approval of and commercialize products successfully. Competition to hire and retain employees and consultants from this limited
pool is intense, and we may be unable to hire, train, retain or motivate these additional key personnel and consultants. Our failure
to retain key personnel or consultants could materially harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, we have scientific and clinical
advisors and consultants who assist us in formulating our research, development and clinical strategies. These advisors are not
our employees and may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability
to us and typically they will not enter into non-compete agreements with us. If a conflict of interest arises between their work
for us and their work for another entity, we may lose their services. In addition, our advisors may have arrangements with other
companies to assist those companies in developing products or technologies that may compete with ours.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our chief executive officer and our chief operating
officer are currently working for us on a part-time basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Three of our key employees are currently part-time
and provide services for other biotechnology development efforts. Specifically, Walter Klemp, our chairman and chief executive
officer is also the chief executive officer of Soliton, Inc., a medical device development company whose business operations we
do not believe conflict with those of our company, and Donald Picker, our president and chief operating officer, is currently also
serving as chief operating officer of two other biotechnology companies, whose business operations we do not believe conflict with
those of our company. As we progress, if the full-time services of a CEO or COO are required and the current officers cannot provide
that level of commitment, we will need to identify a suitable CEO or COO who can dedicate such time to our company. We can provide
no assurance that we will be able to successfully identify and retain a qualified candidate for this position.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">We do not expect that our insurance policies will
cover all of our business exposures thus leaving us exposed to significant uninsured liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We do not carry insurance for all categories
of risk that our business may encounter. In particular, we do not carry product liability insurance covering any clinical trials
liability that we may incur. Although we intend to obtain such insurance before we commence any clinical trials, there can be no
assurance that we will secure adequate insurance coverage or that any such insurance coverage will be sufficient to protect our
operations to significant potential liability in the future. Any significant uninsured liability may require us to pay substantial
amounts, which would adversely affect our financial position and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Relating to Our Common Stock</B></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our stock price has been and may continue to be
volatile, which could result in substantial losses for investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Since our IPO in June 2016, our stock price
has ranged from a high of $9.58 to a low of $0.95, and the market price of our common stock is likely to continue to be highly
volatile and could fluctuate widely in response to various factors, many of which are beyond our control. In addition, the securities
markets have from time to time experienced significant price and volume fluctuations that are unrelated to the operating performance
of particular companies. These market fluctuations may also significantly affect the market price of our common stock.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Your ownership may be diluted if additional capital
stock is issued to raise capital, to finance acquisitions or in connection with strategic transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We intend to seek to raise additional funds,
finance acquisitions or develop strategic relationships by issuing equity or convertible debt securities, which would reduce the
percentage ownership of our existing stockholders. Our board of directors has the authority, without action or vote of the stockholders,
to issue all or any part of our authorized but unissued shares of common or preferred stock. Our certificate of incorporation authorizes
us to issue up to 75,000,000 shares of common stock and 5,000,000 shares of preferred stock. Future issuances of common or preferred
stock would reduce your influence over matters on which stockholders vote and would be dilutive to earnings per share. In addition,
any newly issued preferred stock could have rights, preferences and privileges senior to those of the common stock. Those rights,
preferences and privileges could include, among other things, the establishment of dividends that must be paid prior to declaring
or paying dividends or other distributions to holders of our common stock or providing for preferential liquidation rights. These
rights, preferences and privileges could negatively affect the rights of holders of our common stock, and the right to convert
such preferred stock into shares of our common stock at a rate or price that would have a dilutive effect on the outstanding shares
of our common stock.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">The concentration of our common stock ownership
by our current management will limit your ability to influence corporate matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our founders, directors and executive officers
beneficially own and are able to vote in the aggregate 48.3% of our outstanding common stock. As such, our founders, directors
and executive officers, as stockholders, will continue to have the ability to exert significant influence over all corporate activities,
including the election or removal of directors and the outcome of tender offers, mergers, proxy contests or other purchases of
common stock that could give our stockholders the opportunity to realize a premium over the then-prevailing market price for their
shares of common stock. This concentrated control will limit your ability to influence corporate matters and, as a result, we may
take actions that our stockholders do not view as beneficial. In addition, such concentrated control could discourage others from
initiating changes of control. In such cases, the perception of our prospects in the market may be adversely affected and the market
price of our common stock may decline.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certain provisions in our organizational documents
could enable our board of directors to prevent or delay a change of control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our organizational documents contain provisions
that may have the effect of discouraging, delaying or preventing a change of control of, or unsolicited acquisition proposals,
that a stockholder might consider favorable. These include provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;prohibiting
the stockholders from acting by written consent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;requiring
advance notice of director nominations and of business to be brought before a meeting of stockholders;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;requiring
a majority vote of the outstanding shares of common stock to amend the bylaws; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;limiting
the persons who may call special stockholders&rsquo; meetings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Furthermore, our board of directors has
the authority to issue shares of preferred stock in one or more series and to fix the rights and preferences of these shares without
stockholder approval. Any series of preferred stock is likely to be senior to our common stock with respect to dividends, liquidation
rights and, possibly, voting rights. The ability of our board of directors to issue preferred stock also could have the effect
of discouraging unsolicited acquisition proposals, thus adversely affecting the market price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, Delaware law makes it difficult
for stockholders that recently have acquired a large interest in a corporation to cause the merger or acquisition of the corporation
against the directors&rsquo; wishes. Under Section&nbsp;203 of the Delaware General Corporation Law, a Delaware corporation may
not engage in any merger or other business combination with an interested stockholder for a period of three years following the
date that the stockholder became an interested stockholder except in limited circumstances, including by approval of the corporation&rsquo;s
board of directors.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have no intention of declaring dividends in the
foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The decision to pay cash dividends on our
common stock rests with our board of directors and will depend on our earnings, unencumbered cash, capital requirements and financial
condition. We do not anticipate declaring any dividends in the foreseeable future, as we intend to use any excess cash to fund
our operations. Investors in our common stock should not expect to receive dividend income on their investment, and investors will
be dependent on the appreciation of our common stock to earn a return on their investment.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Failure to maintain effective internal control over
our financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act could cause our financial reports to be inaccurate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are required pursuant to Section 404
of the Sarbanes-Oxley Act of 2002, or Section 404, to maintain internal control over financial reporting and to assess and report
on the effectiveness of those controls. This assessment includes disclosure of any material weaknesses identified by our management
in our internal control over financial reporting. Our management concluded that our internal controls over financial reporting
were, and continue to be ineffective, and as of the year ended December 31, 2016, identified a material weakness in our internal
controls due to the lack of segregation of duties. While management is working to remediate the material weakness, there is no
assurance that such changes, when economically feasible and sustainable, will remediate the identified material weaknesses or
that the controls will prevent or detect future material weaknesses. If we are not able to maintain effective internal control
over financial reporting, our financial statements, including related disclosures, may be inaccurate, which could have a material
adverse effect on our business.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Failure to continue improving our accounting systems
and controls could impair our ability to comply with the financial reporting and internal controls requirements for publicly traded
companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As a public company, we operate in an increasingly
demanding regulatory environment, which requires us to comply with the Sarbanes-Oxley Act of 2002, and the related rules and regulations
of the SEC. Company responsibilities required by the Sarbanes-Oxley Act include establishing corporate oversight and adequate internal
control over financial reporting and disclosure controls and procedures. Effective internal controls are necessary for us to produce
reliable financial reports and are important to help prevent financial fraud.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Management did elect to perform an annual assessment as of December 31, 2016 of the effectiveness of our
internal control over financial reporting for its first annual report. Our management concluded that our internal control over
financial reporting was, and continues to be, ineffective and as of the year ended December 31, 2016, due to a material weakness
in our internal controls due to the lack of segregation of duties. This annual assessment was performed earlier than required.
Section 404(a) of the Sarbanes-Oxley Act requires annual management assessments of the effectiveness of our internal control over
financial reporting, starting with the second annual report that we would expect to file with the SEC. However, for as long as
we remain an &ldquo;emerging growth company&rdquo; as defined in the JOBS Act, we have and intend to consider to take advantage
of certain exemptions from various reporting requirements that are applicable to other public companies that are not &ldquo;emerging
growth companies&rdquo; including, but not limited to, not being required to comply with the auditor attestation requirements of
Section 404(b) of the Sarbanes-Oxley Act. We may continue to take advantage of these reporting exemptions until we are no longer
an &ldquo;emerging growth company.&rdquo; If we cannot provide reliable financial reports or prevent fraud, our business and results
of operations could be harmed and investors could lose confidence in our reported financial information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On November 14, 2016, our Audit Committee, after discussion with management and our previous independent
registered public accountants, determined that our unaudited financial statements for the quarter ended June 30, 2016, as reported
in our Quarterly Report on Form 10-Q filed on August 15, 2016 should no longer be relied upon due to an error identified therein,
and that a restatement of these financial statements is required. We identified certain non-cash errors due to an error in the
accounting for the business combination of Moleculin, LLC. We filed a Form 10-Q/A for the quarter ended June 30, 2016 on November
21, 2016 reflecting such corrections in errors.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">As an &ldquo;emerging growth company&rdquo; under
the Jumpstart Our Business Startups Act, or JOBS Act, we are permitted to, and intend to, rely on exemptions from certain disclosure
requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As an &ldquo;emerging growth company&rdquo;
under the JOBS Act, we are permitted to, and intend to, rely on exemptions from certain disclosure requirements. We are an emerging
growth company until the earliest of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
last day of the fiscal year during which we have total annual gross revenues of $1 billion or more;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
last day of the fiscal year following the fifth anniversary of our IPO, or December 31, 2021;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
date on which we have, during the previous 3-year period, issued more than $1 billion in non-convertible debt; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
date on which we are deemed a &ldquo;large accelerated issuer&rdquo; as defined under the federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For so long as we remain an emerging growth
company, we will not be required to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;have
an auditor report on our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;comply
with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation
or a supplement to the auditor&rsquo;s report providing additional information about the audit and the financial statements (auditor
discussion and analysis);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;submit
certain executive compensation matters to shareholders advisory votes pursuant to the &ldquo;say on frequency&rdquo; and &ldquo;say
on pay&rdquo; provisions (requiring a non-binding shareholder vote to approve compensation of certain executive officers) and the
&ldquo;say on golden parachute&rdquo; provisions (requiring a non-binding shareholder vote to approve golden parachute arrangements
for certain executive officers in connection with mergers and certain other business combinations) of the Dodd-Frank Wall Street
Reform and Consumer Protection Act of 2010;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;include
detailed compensation discussion and analysis in our filings under the Securities Exchange Act of 1934, as amended, and instead
may provide a reduced level of disclosure concerning executive compensation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;may
present only two years of audited financial statements and only two years of related Management&rsquo;s Discussion and Analysis
of Financial Condition and Results of Operations, or MD&amp;A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We intend to take advantage of all of these
reduced reporting requirements and exemptions. Certain of these reduced reporting requirements and exemptions were already available
to us due to the fact that we also qualify as a &ldquo;smaller reporting company&rdquo; under SEC rules. For instance, smaller
reporting companies are not required to obtain an auditor attestation and report regarding management&rsquo;s assessment of internal
control over financial reporting; are not required to provide a compensation discussion and analysis; are not required to provide
a pay-for-performance graph or CEO pay ratio disclosure; and may present only two years of audited financial statements and related
MD&amp;A disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the JOBS Act, we may take advantage
of the above-described reduced reporting requirements and exemptions until December 31, 2021, or such earlier time that we no longer
meet the definition of an emerging growth company.&nbsp;In this regard, the JOBS Act provides that we would cease to be an &ldquo;emerging
growth company&rdquo; if we have more than $1.0 billion in annual revenues, have more than $700 million in market value of our
common stock held by non-affiliates, or issue more than $1.0 billion in principal amount of non-convertible debt over a three-year
period.&nbsp;Further, under current SEC rules, we will continue to qualify as a &ldquo;smaller reporting company&rdquo; for so
long as we have a public float (i.e., the market value of common equity held by non-affiliates) of less than $75 million as of
the last business day of our most recently completed second fiscal quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We cannot predict if investors will find
our securities less attractive due to our reliance on these exemptions.&nbsp;If investors were to find our common stock less attractive
as a result of our election, we may have difficulty raising capital.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="main_004"></A>ITEM 1B. UNRESOLVED STAFF COMMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There are no unresolved comments from the
staff of the SEC.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="main_005"></A>ITEM 2. PROPERTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our corporate and executive offices are
in located in a leased facility in Houston, Texas. The current lease is month-to-month but is expected to be renegotiated in the
next six months. We believe our facilities are sufficient to meet our current needs and that suitable space will be available as
and when needed. We do not own any real property.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="main_006"></A>ITEM 3. LEGAL PROCEEDINGS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are not a party to any pending legal
proceedings.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="main_007"></A>ITEM 4. MINE SAFETY DISCLOSURE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="main_009"></A>ITEM 5. MARKET FOR REGISTRANT&rsquo;S COMMON EQUITY, RELATED
STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Market Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our common stock has been listed on the NASDAQ Capital Market since June 1, 2016, the date of our initial
public offering, under the symbol &ldquo;MBRX&rdquo;. On March 24, 2017, the closing price reported on the NASDAQ Capital Market
for our common stock was $$1.13.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Year-Ended December 31, 2016</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">High</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Low</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">First Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">n/a</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">n/a</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 66%">Second Quarter (commencing June 1, 2016)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">9.58</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">6.24</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Third Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7.02</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5.50</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Fourth Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5.90</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.46</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of February 23, 2017 there were approximately
229 holders of record of our common stock. In addition, we believe that a significant number of beneficial owners of our common
stock hold their shares in nominee or in &ldquo;street name&rdquo; accounts through brokers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Dividends</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have never declared or paid any cash
dividends on our common stock. We currently intend to retain any future earnings to finance the growth and development of our business.
Therefore, we do not anticipate declaring any cash dividends in the foreseeable future. Any future determination as to the payment
of dividends, if any, will be at the discretion of our board of directors and will depend on then existing conditions, including
our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors
our board of directors may deem relevant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Securities Authorized for Issuance under Equity Compensation
Plans</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table sets forth information
regarding our equity compensation plans at December 31, 2016:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 96%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Plan category</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>Number
                                         of securities to</B><br> <B>be issued upon exercise</B><br> <B>of outstanding options,</B><br>
                                         <B>warrants and rights</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>(a)</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>Weighted-average</B><br>
                                         <B>exercise price of</B><br> <B>outstanding options,</B><br> <B>warrants and rights</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>(b)</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>Number
                                         of securities (by</B><br> <B>class) remaining available</B><br> <B>for future issuance
                                         under</B><br> <B>equity compensation</B><br> <B>plans (excluding</B><br> <B>securities reflected
                                         in</B><br> <B>column (a))</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>(c)</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 37%; text-align: left; text-indent: 0in">Equity compensation plans approved by security holders (1)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 18%; text-align: right">510,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">5.28</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 18%; text-align: right">1,990,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in; padding-bottom: 1pt">Equity compensation plans not approved by security holders
    (2)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">107,802</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">7.50</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&mdash;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-indent: 0in; padding-bottom: 1pt">Total</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">617,802</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt 0">5.67</P>


</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">1,990,000</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: yellow"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>Represents shares of common stock issuable upon exercise of outstanding stock options under our 2015 Stock Plan, as amended.
Our 2015 Stock Plan has been approved by our stockholders.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>Consists of a five-year warrant issued to the underwriters in our initial public offering.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recent Sales of Unregistered Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On various dates from August 31, 2015 through
January 19, 2016, each as amended on March 10, 2016, we issued certain 8% unsecured promissory notes in aggregate principal amount
of $615,000 to certain accredited investors. Upon the completion of the IPO, these notes provided that they be automatically converted
into shares of our common stock at their applicable conversion prices, which were $0.1299 with respect to $250,000 in notes and
$0.20 per share with respect to the remaining $365,000, to the extent and provided that no holder of these notes was or will be
permitted to convert such notes to the extent that the holder or any of its affiliates would beneficially own in excess of 4.99%
of our common stock after such conversion. Due to this 4.99% limitation, the remaining principal and accrued interest amounts of
the effected notes will remain outstanding and will be converted into shares of our common stock at such time as the 4.99% limitation
continues to be met. The IPO was completed on May 31, 2016. On May 31, 2016, pursuant to the conversion feature of the foregoing
notes and with restriction of the 4.99% beneficially owned condition limitation, we issued 1,166,503 common shares in total, reducing
convertible debt principal by $183,356 and accrued interest by $17,699. During the three months ended December 31, 2016, an additional
110,038 common shares were issued due to the number of common shares outstanding allowing for conversion of additional shares under
the 4.99% beneficially owned condition limitation. This reduced the convertible debt principal by $21,577 and accrued interest
by $430. The remaining convertible debt without consideration of accrued interest as of December 31, 2016, if converted on December
31, 2016, would result in an additional 1,821,013 common shares to be issued. See Note 3 of our financial statements for more information
regarding the issuance of the notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe that the issuances were exempt
from registration under the Securities Act in reliance on Section 4(a)(2) of the Securities Act regarding transactions not involving
a public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On May 31, 2016, we completed our initial
public offering, which commenced on May 2, 2016, pursuant to which we sold 1,540,026 shares of our common stock at $6.00 per share
with gross proceeds of $9,240,156 and net proceeds of $8,464,183 after deducting underwriting discounts and commissions and offering
expenses payable by us. The offer and sale of all of the shares in the offering were registered under the Securities Act pursuant
to a registration statement on Form S-1 (File No. 333-209323), which was declared effective by the SEC on May 2, 2016. Bonwick
Capital Partners LLC and Network 1 Financial Securities, Inc. acted as underwriters for the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There has been no material change in the
planned use of proceeds from our IPO as described in our final prospectus filed with the SEC on May 3, 2016 pursuant to Rule 424(b).
No direct or indirect payments were made by us to any of our directors or officers or their associates, to persons owning ten percent
or more of our common stock or to their associates, or to our affiliates, other than payments in the ordinary course of business
to officers for salaries and those payments disclosed in &ldquo;Item 1. Business&rdquo; with regard to the license arrangements
with HPI. Pending the uses described, we intend to invest the net proceeds in short-term, interest-bearing obligations, investment-grade
instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Subsequent Event</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On February 9, 2017, we entered into an
Underwriting Agreement (the &ldquo;Underwriting Agreement&rdquo;) with Roth Capital Partners, LLC, as representative of the several
underwriters identified therein (collectively, the &ldquo;Underwriters&rdquo;), pursuant to which we sold in a registered public
offering (the &ldquo;Offering&rdquo;), 3,710,000 units, priced at a public offering price of $1.35 per unit, with each unit consisting
of: (i) one share of common stock, (ii) a five-year Series A warrant to purchase 0.50 of a share of common stock, (iii) a 90-day
Series B warrant to purchase one share of common stock, and (iv) a five-year Series C warrant to purchase 0.50 of a share of common
stock. The Series C warrants in a unit may only be exercised to the extent and in proportion to a holder of the Series C warrants
exercising its Series B warrants included in the unit. The Series A and Series C warrant have an exercise price of $1.50 per share
of common stock. The Series B warrant has an exercise price of $1.35 per share of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the terms of the Underwriting Agreement,
we granted the Underwriters a 45-day option to purchase an additional 556,500 shares of common stock and/or an additional 556,500
warrants combinations (comprised of an aggregate of 278,250 Series A warrants, 556,500 Series B warrants and 278,250 Series C warrants),
in any combinations thereof, from us to cover over-allotments at the public offering price per share of $1.349 and public offering
price per warrant combination of $.001, respectively, less the underwriting discounts and commissions. Upon the closing of the
Offering, the Underwriters exercised the over-allotment option with respect to 278,100 warrant combinations. We received approximately
$4.4 million in net proceeds from the Offering, after deducting underwriting discounts and commissions and estimated offering expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Subsequent to March 22, 2017, investors
in the aforementioned offering on February 9, 2017, have excerised approximately 600,000 Series B warrants resulting in approximately
gross proceeds to the Company of $800,000 and approximately 600,000 shares of the Company&rsquo;s common stock being issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Purchases of Equity Securities by the Issuer and Affiliated
Purchasers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We did not repurchase any of our equity
securities during the year ended December 31, 2016.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="main_010"></A>ITEM 6. SELECTED FINANCIAL DATA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable to the Company, which is
a smaller reporting company.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="main_011"></A>ITEM 7. MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>This Management&rsquo;s Discussion and
Analysis of Financial Condition and Results of Operations (&ldquo;MD&amp;A&rdquo;) contains certain forward-looking statements.
Historical results may not indicate future performance. Our forward-looking statements reflect our current views about future events,
are based on assumptions and are subject to known and unknown risks and uncertainties that could cause actual results to differ
materially from those contemplated by these statements. Factors that may cause differences between actual results and those contemplated
by forward-looking statements include, but are not limited to, those set forth at the beginning of this report under the section
titled &ldquo;Cautionary Note Regarding Forward-Looking Statements&rdquo; and discussed in &ldquo;Item 1A. Risk Factors.&rdquo;
We undertake no obligation to publicly update or revise any forward-looking statements, including any changes that might result
from any facts, events, or circumstances after the date hereof that may bear upon forward-looking statements. Furthermore, we cannot
guarantee future results, events, levels of activity, performance, or achievements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Highlights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are a preclinical-stage pharmaceutical
development company organized as a Delaware corporation in July 2015 to focus on the development of anti-cancer drug candidates.
We have three drug development projects. Our lead drug candidate is liposomal Annamycin, which is referred to as Annamycin, an
anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia, or AML. Annamycin has been in clinical
trials pursuant to an investigational new drug application, or IND, that had been filed with the U.S. Food and Drug Administration,
or FDA. Due to a lack of development activity by a prior drug developer, this IND was terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We filed our IND application, with a Phase
I/II approach with the intent of increasing the MTD, for Annamycin on February 10, 2017. &nbsp;In subsequent discussions, FDA requested
certain revisions to the protocol, additional&nbsp;information, and additional data related to Chemistry, Manufacturing and Controls
(&ldquo;CMC&rdquo;). &nbsp;We have the additional information, have made the requested revisions to the protocol,&nbsp;and we are
working on developing the CMC data. &nbsp;In the interim, we have withdrawn the IND application, in order to resubmit it when the
requested data are available. &nbsp;We believe that resubmission of the IND application will occur in time for the IND to go into
effect in the first half of 2017. However, if we are unable to obtain the required CMC data on a timely basis, we will be delayed
in resubmitting our IND application, which will delay the commencement of our clinical trials beyond the first half of 2017. Furthermore
on March 21, 2017, we received notice that we have obtained Orphan Drug designation for Annamycin with the FDA for the treatment
of AML.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have two other drug development projects
in progress. One of them involves a collection of small molecules we refer to as the WP1066 Portfolio that was obtained via our
acquisition of Moleculin, LLC and is focused on the modulation of key regulatory transcription factors involved in the progression
of cancer. The other, which we call the WP1122 Portfolio, is a suite of molecules targeting the metabolic processes involved in
cancer in general, and glioblastoma in particular that we acquired from IntertechBio Corporation. Both of these technologies are
licensed on a worldwide exclusive basis from The University of Texas M.D. Anderson Cancer Center, or MD Anderson.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">MBI was founded in 2015 in order to combine
and consolidate the development efforts involving several anti-cancer technologies, some of which are based on license agreements
with MD Anderson. This effort began with the acquisition of the Annamycin development project from AnnaMed, Inc., or AnnaMed, followed
by the acquisition of the license rights to the WP1122 Portfolio from IntertechBio Corporation, or IntertechBio. Further, we, on
Moleculin, LLC&rsquo;s behalf, entered into a co-development agreement with Houston Pharmaceuticals, Inc., or HPI, which culminated
with the merger of Moleculin, LLC into MBI coincident with our initial public offering allowing us to gain control of the WP1066
Portfolio.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">AnnaMed was formed in 2012 to take over
the development of Annamycin from a prior drug development company, Callisto Pharmaceuticals, Inc., or Callisto. Callisto ceased
development work on Annamycin leading to the termination of its IND by the FDA. In order to satisfy unmet license obligations,
Callisto agreed to transfer all available Annamycin data to AnnaMed, which data we used in our initial filing of an IND.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IntertechBio was formed in 2009 to license
and begin development on the WP1122 Portfolio. In August 2015, IntertechBio agreed to assign all license rights to us in exchange
for 630,000 shares of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Moleculin, LLC was formed in 2006 and was
working to develop the WP1066 Portfolio it licensed from MD Anderson. On May&nbsp;2, 2016, Moleculin, LLC was merged with and into
MBI. As a result of the merger, we issued the holders of Moleculin, LLC equity interests and convertible notes an aggregate of
approximately 999,931 shares of our common stock.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Since Moleculin, LLC commenced operations
in 2006, substantially all of its efforts had been focused on research, development and the advancement of the WP1066 Portfolio.
Moleculin, LLC did not generate any revenue from product sales and, as a result, incurred significant losses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Neither Moleculin, LLC nor MBI has manufacturing
facilities and all manufacturing activities are contracted out to third parties. Additionally, Moleculin, LLC utilized third-party
clinical research organizations to carry out clinical trials. Neither Moleculin, LLC nor MBI have a sales organization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recent Business Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Accelerated Plan for Clinical Drug Production
</I>&ndash; We announced on October 7, 2016, that we had secured an agreement with Dermin Sp. Zo. O. (&ldquo;Dermin&rdquo;) to
utilize Dermin&rsquo;s supply of Annamycin for our upcoming clinical trial, substantially reducing the expenditures required for
drug product and shortening the time required to produce clinical supplies. We believe that this is an important agreement and
key milestone to be reached and that it reduces the potential for drug production to negatively impact our clinical timeline. With
this agreement in place, our drug product expense for upcoming clinical trials should be below previous estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Moleculin, LLC previously licensed Annamycin
to Dermin within a limited region in Europe, enabling Dermin to deploy Polish grant funds toward producing Annamycin. The agreement
reached between the two companies allows us to utilize this Annamycin in our upcoming clinical trials rather than having to produce
new Annamycin for its own use. We believe Dermin benefits from a data sharing arrangement giving it access to our clinical data
on a faster timeline than it would be able develop on its own.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Updated Plan for Clinical Trials for
Annamycin </I>&ndash; On October 20, 2016, we announced in a conference call that we had identified some significantly positive
findings from our detailed review of the last clinical trial for Annamycin by a prior developer, which has given rise to a modification
of our own clinical development plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As we previously disclosed, a prior developer
had conducted a clinical trial with Annamycin, but then subsequently failed to maintain their IND with the FDA. We had previously
indicated that our plan was to conduct a detailed review of the clinical results generated by that prior developer. We would then
use those results to reestablish an IND in order to continue clinical trials of Annamycin. However, we announced recently that,
in the course of our review, we identified that Annamycin may have greater potential for efficacy than we originally believed,
based on an unexpected potential opportunity to increase the drug&rsquo;s Maximum Tolerable Dose (&ldquo;MTD&rdquo;).&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In particular, the Dose Limiting Toxicities
(&ldquo;DLTs&rdquo;) reported in that previous trial that led to the establishment of the current MTD of 150 mg/m2 were all from
patients who had an unusually high number of first-line induction therapy failures prior to being treated with Annamycin. Specifically,
of the three patients in the last clinical trial who experienced these DLTs, one of them had failed nineteen prior induction therapy
attempts, another had failed sixteen and the other had failed fifteen before being enrolled in the trial. We concluded from our
review of this data that, if the heavily treated patients are excluded from the data set, the MTD could have been closer to 250
mg/m2, substantially higher than the level that was actually set by this previous trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We view this as an encouraging development
because it means we may have an opportunity to increase the MTD for our next trial from 150 mg/m2 to 200 or even 250 mg/m2. If
that turns out to be the case, we believe it could increase the chance for positive outcomes in our next trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">With the discovery that we may be able to
increase our MTD, we determined to adjust our clinical strategy by adding in a Phase I arm to our next Phase II trial, which will
add some expense to our development effort. We believe this change in strategy will add several months to the eventual final approval
of the drug, however, we believe that we will publicly announce results from our phase I/II clinical trial sometime in 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Filing of an IND for Annamycin &ndash;
</I>We filed our IND application, with the clinical strategy of increasing the MTD mentioned above, for Annamycin on February 10,
2017. &nbsp;In subsequent discussions, FDA requested certain revisions to the protocol, additional&nbsp;information, and additional
data related to Chemistry, Manufacturing and Controls (&ldquo;CMC&rdquo;). &nbsp;We have the additional information, we have made
the requested revisions to the protocol,&nbsp;and we are developing the CMC data. &nbsp;In the interim, we have withdrawn the IND
application, in order to resubmit it when the requested data are available. &nbsp;We believe that resubmission of the IND application
will occur in time for the IND to go into effect and the announcement of the beginning of phase I/II clinical trials in the first
half of 2017. However, if we are unable to obtain the required CMC data on a timely basis, we will be delayed in resubmitting our
IND application, which will delay the commencement of our clinical trials beyond the first half of 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Filing for Orphan Drug Status for Annamycin
&ndash; </I>On March 21, 2017 we received notice that we had obtained Orphan Drug designation for Annamycin for the treatment of
AML with the FDA effective March 20, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Update on WP1066</I> &ndash; A clinician
at MD Anderson has advised us that she is proceeding with a physician-sponsored IND for WP1066 for the treatment of brain tumors.
We are not participating in nor have influence on this IND process. The clinician has submitted an IND to the FDA and has indicated
that this IND is on hold until documentation of Good Manufacturing Process or GMP production of WP1066 can be presented to the
FDA. We expect that this IND will eventually move forward in 2017 and will produce publishable clinical results in 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Advancement of Preclinical Testing for
Brain Tumors with WP1122</I> &ndash; On October 25, 2016, we announced promising initial results of the preclinical toxicology
work on WP1122, our unique inhibitor of glucose metabolism, which is an important driver of glycolytic brain tumor progression
and survival. We view this as an important step toward future clinical trials for WP1122. A similar chemical structure to that
which turns morphine into heroine has been used to allow WP1122 to successfully enter the brain and increase circulation time.
We indicated that preliminary escalating single dose toxicity testing in mice (oral administration) was successfully completed
and even at the highest possible dose, no toxic death was observed. In multiple therapeutic doses, WP1122 was well tolerated during
intense twice-daily oral dosing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe moving forward with preclinical
toxicology is the key to our ability to generate proof of concept in humans. We had previously announced the presentation of promising
preclinical data in July 2016, supporting the potential for using WP1122 as a treatment for glioblastoma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Subsequent Event</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On February 9, 2017, we entered into an
Underwriting Agreement (the &ldquo;Underwriting Agreement&rdquo;) with Roth Capital Partners, LLC, as representative of the several
underwriters identified therein (collectively, the &ldquo;Underwriters&rdquo;), pursuant to which we sold in a registered public
offering (the &ldquo;Offering&rdquo;), 3,710,000 units, priced at a public offering price of $1.35 per unit, with each unit consisting
of: (i) one share of common stock, (ii) a five-year Series A warrant to purchase 0.50 of a share of common stock, (iii) a 90-day
Series B warrant to purchase one share of common stock, and (iv) a five-year Series C warrant to purchase 0.50 of a share of common
stock. The Series C warrants in a unit may only be exercised to the extent and in proportion to a holder of the Series C warrants
exercising its Series B warrants included in the unit. The Series A and Series C warrant have an exercise price of $1.50 per share
of common stock. The Series B warrant has an exercise price of $1.35 per share of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the terms of the Underwriting Agreement,
we granted the Underwriters a 45-day option to purchase an additional 556,500 shares of common stock and/or an additional 556,500
warrants combinations (comprised of an aggregate of 278,250 Series A warrants, 556,500 Series B warrants and 278,250 Series C warrants),
in any combinations thereof, from us to cover over-allotments at the public offering price per share of $1.349 and public offering
price per warrant combination of $.001, respectively, less the underwriting discounts and commissions. Upon the closing of the
Offering, the Underwriters exercised the over-allotment option with respect to 278,100 warrant combinations. We received approximately
$4.4 million in net proceeds from the Offering, after deducting underwriting discounts and commissions and estimated offering expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Subsequent to March 22, 2017, investors
in the aforementioned offering on February 9, 2017, have excerised approximately 600,000 Series B warrants resulting in approximately
gross proceeds to the Company of $800,000 and approximately 600,000 shares of the Company&rsquo;s common stock being issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We were formed on July 28, 2015; therefore,
the financial information for 2015 is not comparable to the financial results of the year ended December 31, 2016. The following
table sets forth, for the periods indicated, data derived from our statement of operations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 96%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 10pt; text-align: center">Year Ended<BR>
 December 31,</TD><TD NOWRAP STYLE="font-size: 10pt">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 10pt; text-align: center">From Inception<BR>
 through<BR>
 December&nbsp;31,</TD><TD NOWRAP STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-size: 10pt">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">Revenue</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Operating expenses:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 50%; font-size: 10pt; text-align: left; padding-left: 0.125in">Research and development</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">1,495,561</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">260,418</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">General and administrative</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,381,424</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">477,810</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt; padding-left: 0.125in">Depreciation</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6,162</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Total operating expense</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,883,147</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">738,228</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Loss from operations</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(3,883,147</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(738,228</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Other expense:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;Interest expense</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(43,214</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(10,132</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in">Net loss</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(3,926,361</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(748,360</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Research and Development Expense.</B>
Research and development (R&amp;D) expense was $1,495,561 and $260,418 for the twelve months ended December&nbsp;31,
2016 and for the period from July 28, 2015 (inception) to December 31, 2015, respectively. The increase of approximately $1,235,000
mainly represents an increase of approximately: $253,000 related to an increase in R&amp;D headcount and associated payroll costs,
$111,000 for sponsored research and related expenses; approximately $660,000 associated with developing and testing drug product
as we prepare for clinical trials; and, $245,000 related to travel, consultants, and other research costs associated in preparing
our IND and Orphan Drug applications with the FDA. This was all offset by an approximate $34,000 reduction in patent prosecution
and other expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>General and Administrative Expense.</B>
General and administrative expense was $2,381,424 and $477,810 for the twelve months ended December 31,
2016 and for the period from July 28, 2015 (inception) to December 31, 2015, respectively. The expense increase of approximately
$1,904,000 was mainly attributable to: (a) the increase in headcount and associated payroll costs of $648,000 including severance
of $118,000 and roughly $254,000 of stock based compensation and deferred salary; (b) approximately $584,000 in legal, accounting,
consulting, and other professional expenses; (c) approximately $389,000 in public company costs; (d) approximately $183,000 in
insurance expense; (e) roughly $50,000 in travel expenses; and (f) approximately $50,000 in occupancy, office and other costs.
All of these increases are directly related to our being fully operational versus this period a year ago.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We utilize outside consultants. Total
wages paid to our employees, including our CEO, CFO, COO, CMO plus two other employees, were approximately $549,000, predominately
in the second half of the year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Interest Expense.</B> Interest expense
included expense accrued on our convertible promissory notes issued in 2015 and 2016 bearing interest at the rate of 8% per annum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Net Loss.</B> The net loss for the twelve
months ended December 31, 2016 was $3,926,361 which included non-cash expenses of approximately $450,000 which included $6,000
for depreciation, $324,000 for stock based compensation and other stock based expenses and a one-time expense of $120,000 related
to the severance of our former Chief Financial Officer. This loss for the period is a significant increase from the loss for the
period from July 28, 2015 (inception) to December 31, 2015 of $748,360 as we had, at that time, just begun operations.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of December 31, 2016, we had $5,007,216 in cash. During the period from January 1, 2016 through May&nbsp;2,
2016, we sold 234,296 of common stock for $702,894. On May 31, 2016, we completed our initial public offering, pursuant to which
we sold 1,540,026 shares of our common stock at $6.00 per share for net proceeds of $8,464,183 after deducting underwriting discounts
and commissions and direct offering expenses payable by us. In February 2017, we completed a public offering of our common stock
and warrants, pursuant to which we received approximately $4.4 million in net proceeds, after deducting underwriting discounts
and commissions and estimated offering expenses. We believe that our existing cash and cash equivalents as of December 31, 2016
along with the cash generated by the February 2017 offering described above will be sufficient to fund our planned operations into
the first quarter of 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We will not generate revenue from product
sales unless and until we successfully complete development of, obtain regulatory approval for and begin to commercialize one or
more of our product candidates, which we expect will take a number of years and is subject to significant uncertainty. Accordingly,
we anticipate that we will need to raise additional capital to fund our future operations. Until such time that we can generate
substantial revenue from product sales, if ever, we expect to finance our operating activities through a combination of equity
offerings and debt financings and we may seek to raise additional capital through strategic collaborations. However, we may be
unable to raise additional funds or enter into such arrangements when needed on favorable terms, or at all, which would have a
negative impact on our financial condition and could force us to delay, limit, reduce or terminate our development programs or
commercialization efforts or grant to others rights to develop or market product candidates that we would otherwise prefer to develop
and market ourselves. Failure to receive additional funding could cause us to cease operations, in part or in full. Furthermore,
even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital due to favorable
market conditions or strategic considerations, which may cause dilution to our existing stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table sets forth the primary
sources and uses of cash of MBI for the period indicated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">For the <BR> Twelve Months<BR> Ended <BR> December 31,<BR> 2016</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">From Inception<BR> through <BR> December&nbsp;31, <BR> 2015</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; font-size: 10pt; text-align: left">Net cash used in operating activities</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 16%; font-size: 10pt; text-align: right">(3,764,905</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 16%; font-size: 10pt; text-align: right">(423,509</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Net cash used in investing activities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(121,108</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Net cash provided by financing activities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">8,865,138</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">451,600</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Net increase in cash and cash equivalents</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">4,979,125</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">28,091</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cash used in operating activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Net cash used in operating activities was $3,764,905 for the twelve months ended December 31, 2016 compared
to $423,509 for the period from inception to December 31, 2015. This increase in use of cash for operations is due to our becoming
operational post IPO in mid-2016. This mainly included payments made for payroll, travel, insurance and professional fees to our
consultants, attorneys and accountants for services related to our becoming a publicly traded company and related filing fees,
along with payments made to MD Anderson for license and maintenance fees. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cash used in investing activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Net cash used in investing activities was $121,108 for the twelve months ended December 31, 2016 and primarily
represents the cash paid as part of the acquisition of Moleculin, LLC. No investing activities were done in the prior period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cash provided by financing activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Net cash provided by financing activities was $8,865,138 for the twelve months ended December 31, 2016 compared
to the prior period of $451,600. We received $8,464,183 net proceeds from our IPO stock issuance, $705,894 from issuance of common
stock at $3.00 per share, and $165,000 from issuance of convertible notes. The prior period financing activities mainly consisted
of the issuance of convertible notes payable. Net cash used in financing activities included approximately $470,000 for payments
of notes payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Since Moleculin, LLC&rsquo;s inception and
through December 31, 2015, Moleculin, LLC funded its operations primarily through the sale and issuance of convertible preferred
units and convertible and non-convertible promissory notes. From May to November 2014, Moleculin, LLC issued various convertible
notes to its creditors. The note proceeds were $1.5 million. These notes bore interest at 8% per annum and were due on the earlier
of June 30, 2016 or the consummation of a liquidation event (which event included the merger between MBI and Moleculin, LLC that
occurred on May 2, 2016), unless earlier converted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Off-Balance Sheet Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We do not engage in off-balance sheet transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>JOBS Act and Recent Accounting Pronouncements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The recently enacted JOBS Act provides that
an &ldquo;emerging growth company&rdquo; can take advantage of the extended transition period provided in Section&nbsp;7(a)(2)(B)
of the Securities Act of 1933, as amended, for complying with new or revised accounting standards. In other words, an &ldquo;emerging
growth company&rdquo; can delay the adoption of certain accounting standards until those standards would otherwise apply to private
companies. We have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt
new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have implemented all new accounting pronouncements
that are in effect and may impact our financial statements and we do not believe that there are any other new accounting pronouncements
that have been issued that might have a material impact on our financial position or results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Critical Accounting Policies and Significant Judgments and
Estimates </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The financial statements have been prepared
in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of these financial statements
requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of
contingent assets and liabilities at the date of the financial statements, as well as the reported expenses incurred during the
reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable
under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities
that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or
conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe that the following accounting
policies are the most critical to aid in fully understanding and evaluating our reported financial results, and they require our
most difficult, subjective or complex judgments, resulting from the need to make estimates about the effect of matters that are
inherently uncertain<B>. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Acquisition</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We acquired Moleculin, LLC on May 2, 2016, and, going forward our financial statements will include the operations
of Moleculin, LLC. We account for acquired businesses using the acquisition method of accounting, which requires, among other things,
that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that
the fair value of acquired in-process research and development (&ldquo;IPR&amp;D&rdquo;) be recorded on the balance sheet. Transaction
costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired
will be recorded as goodwill. The Company obtained input from third-parties regarding its tangible and intangible assets and other
information necessary to measure the fair value of the assets acquired and liabilities assumed in connection with the acquisition
of Moleculin, LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Beneficial Conversion Feature</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">From time to time, we may issue convertible
notes that have conversion prices that create an embedded beneficial conversion feature on the issuance date. A beneficial conversion
feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is
convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion
of the note proceeds to the fair value of any attached equity instruments, if any related equity instruments were granted with
the debt. We estimate the fair value of our common stock using the most recent selling price available. The intrinsic value of
the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid-in capital. The
debt discount is amortized to interest expense over the life of the note using the effective interest method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Research and Development Costs </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We record accrued expenses for
estimated costs of our research and development activities conducted by third-party service providers, which include the
conduct of pre-clinical studies and preparation for clinical trials and contract manufacturing activities. We record the
estimated costs of research and development activities based upon the estimated amount of services provided but not yet
invoiced, and we include these costs in accrued liabilities in the balance sheets and within research and development expense
in the statement of operations. These costs are a significant component of our research and development expenses. We record
accrued expenses for these costs based on the estimated amount of work completed and in accordance with agreements
established with these third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We estimate the amount of work completed
through discussions with internal personnel and external service providers as to the progress or stage of completion of the services
and the agreed-upon fee to be paid for such services. We make significant judgments and estimates in determining the accrued balance
in each reporting period. As actual costs become known, we adjust our accrued estimates. Although we do not expect our estimates
to be materially different from amounts actually incurred, our understanding of the status and timing of services performed may
vary from our estimates and could result in us reporting amounts that are too high or too low in any particular period. Our accrued
expenses are dependent, in part, upon the receipt of timely and accurate reporting from clinical research organizations and other
third-party service providers. To date, there have been no material differences from our accrued expenses to actual expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Impairment of Long-Lived Assets &nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Management reviews long-lived assets for
impairment whenever events or changes in circumstances indicate that the carrying amount may not be realizable or at a minimum
annually during the fourth quarter of the year. If an evaluation is required, the estimated future undiscounted cash flows associated
with the asset are compared to the asset&rsquo;s carrying value to determine if an impairment of such asset is necessary. The effect
of any impairment would be to expense the difference between the fair value of such asset and its carrying value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Components of our Results of Operations and Financial Condition
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Operating expenses </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We classify our operating expenses into
three categories: research and development, general and administrative and depreciation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Research and development</I>. Research
and development expenses consist primarily of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;costs
incurred to conduct research, such as the discovery and development of our product candidates;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;costs
related to production of clinical supplies, including fees paid to contract manufacturers;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;fees paid to clinical consultants, clinical trial sites and vendors, including clinical research organizations,
in preparation for clinical trials and our IND and Orphan Drug applications with the FDA; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;costs
related to compliance with drug development regulatory requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We recognize all research and development
costs as they are incurred. Pre-clinical costs, contract manufacturing and other development costs incurred by third parties are
expensed as the contracted work is performed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We expect our research and development expenses
to increase in the future as we advance our product candidates into and through clinical trials and pursue regulatory approval
of our product candidates in the United States and Europe. The process of conducting the necessary clinical research to obtain
regulatory approval is costly and time-consuming. The actual probability of success for our product candidates may be affected
by a variety of factors including: the quality of our product candidates, early clinical data, investment in our clinical program,
competition, manufacturing capability and commercial viability. We may never succeed in achieving regulatory approval for any of
our product candidates. As a result of the uncertainties discussed above, we are unable to determine the duration and completion
costs of our research and development projects or when and to what extent, if any, we will generate revenue from the commercialization
and sale of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">General and administrative. General and
administrative expense consists of personnel related costs, which include salaries, as well as the costs of professional services,
such as accounting and legal, facilities, information technology and other administrative expenses. We expect our general and administrative
expense to increase due to the anticipated growth of our business and related infrastructure as well as accounting, insurance,
investor relations and other costs associated with becoming a public company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Depreciation. </I>Depreciation expense
consists of depreciation on our property and equipment. We depreciate our assets over their estimated useful life. We estimate
leasehold improvements to have a 1-year life; computer equipment to have a 2-year life; machinery and equipment to have a 5-year
life and furniture and office equipment to have a 7-year life. Property and equipment assets acquired as a result of the acquisition
of Moleculin, LLC were given a 2-year life given the assessment at acquisition of their age and condition and expected useful remaining
life.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Other income (expense), net </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Other income (expense), net consists
of interest expense associated with our notes payable and interest income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Accounting for warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We issued warrants to purchase shares of
common stock related to equity transactions in 2016. We account for our warrants issued in accordance with Accounting Standards
Codification (ASC) Topic 815, Derivatives and Hedging, guidance applicable to derivative instruments, which requires every derivative
instrument within its scope to be recorded on the balance sheet as either an asset or liability measured at its fair value, with
changes in fair value recognized in earnings for liability classified warrants. Based on this guidance, we determined that our
warrants meet the criteria for classification as equity. Accordingly, the warrants were classified as equity and are not subject
to remeasurement at each balance sheet date. The fair value was estimated using the Black-Scholes option pricing model, based on
the market value of the underlying common stock at the measurement date, the contractual term of the warrant, risk-free interest
rates, expected dividends and expected volatility of the price of the underlying common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Stock-based compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Stock based compensation transactions are
recognized as compensation expense in the statement of operations based on their fair values on the date of the grant, with the
compensation expense recognized over the period in which a grantee is required to provide service in exchange for the award. We
estimate the fair value of options granted using the Black-Scholes option valuation model. This estimate uses assumptions regarding
a number of inputs that require us to make significant estimates and judgments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Because we are a relatively new publicly
traded common stock the expected volatility assumption was based on industry peer information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Income taxes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We account for income taxes using ASC 740
Income Taxes. ASC 740 Income Taxes is an asset and liability approach that requires the recognition of deferred tax assets and
liabilities for the expected future tax consequences of events that have been recognized in our financial statements or tax returns.
In estimating future tax consequences, ASC 740 generally considers all expected future events other than enactments of and changes
in the tax law or rates. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefits that,
based on available evidence, are not expected to be realized. Valuation allowances are provided if, considering available evidence,
it is more likely than not that the deferred tax assets will not be realized. ASC 740 clarifies the criteria that must be met prior
to recognition of the financial statement benefit of a position taken in a tax return. ASC 740 provides a benefit recognition model
with a two-step approach consisting of &ldquo;more-likely-than-not&rdquo; recognition criteria, and a measurement attribute that
measures a given tax position as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate
settlement. ASC 740 also requires the recognition of liabilities created by differences between tax positions taken in a tax return
and amounts recognized in the financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recent accounting pronouncements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In May 2014, the FASB issued Accounting
Standard Update (&quot;ASU&quot;) 2014-09, Revenue from Contracts with Customers (Topic 606), which will replace numerous requirements
in U.S. GAAP, including industry-specific requirements, and provide companies with a single revenue recognition model for recognizing
revenue from contracts with customers. The core principle of the new standard is that a company should recognize revenue to depict
the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects
to be entitled in exchange for those goods or services. In August 2015, the FASB approved a proposal to defer the effective date
of the guidance until annual and interim reporting periods beginning after December 15, 2017. The Company is currently evaluating
the impact that this standard will have on its financial statements at the time the Company starts to generate revenue or enters
into other contractual arrangements, which the Company does not expect in the near term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In August 2014, the FASB issued ASU 2014-15,
Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&rsquo;s Ability
to Continue as a Going Concern. Under the new guidance, management will be required to assess an entity&rsquo;s ability to continue
as a going concern, and to provide related footnote disclosures in certain circumstances. The provisions of this ASU are effective
for annual periods ending after December 15, 2016, and for annual and interim periods thereafter; early adoption is permitted.
This disclosure is effective within these financial statements for the year ended December 31, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In January 2016, the FASB issued ASU No.
2016-01, Financial Instruments &ndash; Overall: Recognition and Measurement of Financial Assets and Financial Liabilities (&ldquo;ASU
2016-01&rdquo;).&nbsp;ASU 2016-01 affects the accounting for equity investments, financial liabilities under the fair value option
and the presentation and disclosure requirements of financial instruments.&nbsp;ASU 2016-01 is effective for fiscal years beginning
after December 15, 2017, including interim periods within those fiscal years.&nbsp;The Company is currently evaluating the impact
that this standard will have on its financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>



<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In February 2016, the FASB issued ASU No.
2016-02, Leases (Topic 842) (&ldquo;ASU 2016-02&rdquo;). Under ASU 2016-02, an entity will be required to recognize right-of-use
assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements.&nbsp;ASU 2016-02 offers
specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. Lessees and lessors are required to disclose
qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the
amount, timing and uncertainty of cash flows arising from leases.&nbsp;For public companies, ASU 2016-02 is effective for annual
reporting periods beginning after December 15, 2018, including interim periods within that reporting period, and requires a modified
retrospective adoption, with early adoption permitted.&nbsp;The Company is currently evaluating the impact that this standard will
have on its financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In March 2016, the FASB issued ASU 2016-09,
Compensation-Stock Compensation (Topic 718). The new guidance changes the accounting and simplifies various aspects of the accounting
for share-based payments to employees. The guidance allows for a policy election to account for forfeitures as they occur or based
on an estimated number of awards that are expected to vest. ASU 2016-09 is effective for annual periods beginning after December
15, 2016, with early adoption permitted. The adoption of this standard on January 1, 2017, did not have a significant impact on
the Company&rsquo;s financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In August 2016, the FASB issued ASU, Statement
of Cash Flows (Topic 230). This ASU applies to all entities that are required to present a statement of cash flows under Topic
230. The amendments provide guidance on eight specific cash flow issues and includes clarification on how these items should be
classified in the statement of cash flows and is designed to help eliminate diversity in practice as to where items are classified
in the cash flow statement. Furthermore in November 2016, the FASB issued additional guidance on this Topic that requires amounts
generally described as restricted cash and restricted cash equivalents to be included with cash and cash equivalents when reconciling
the statement of cash flows. This ASU is effective for fiscal years beginning after December 15, 2017, and interim periods within
those fiscal years, with earlier application permitted for all entities. We plan to adopt the provisions of this ASU for our fiscal
year beginning January 1, 2018 and are currently evaluating the impact the adoption of this new accounting standard will have on
our financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On November 20, 2015, the Financial Accounting
Standards Board (&ldquo;FASB&rdquo;) issued Accounting Standards Update (&quot;ASU&quot;) 2015-17, &quot;Balance Sheet Classification
of Deferred Taxes&quot;, requiring all deferred tax assets and liabilities, and any related valuation allowance, to be classified
as non-current on the balance sheet. The classification change for all deferred taxes as non-current simplifies entities&rsquo;
processes as it eliminates the need to separately identify the net current and net non-current deferred tax asset or liability
in each jurisdiction and allocate valuation allowances. The Company elected to adopt the accounting in the fourth quarter of 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company does not believe that any other
recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect
on the accompanying financial statements.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="main_012"></A>ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT
MARKET RISKS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable to us, as we are a smaller
reporting company.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="main_013"></A>ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The financial statements required by this
item are set forth beginning in Item 15 of this report and are incorporated herein by reference.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="main_014"></A>ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON
ACCOUNTING AND FINANCIAL DISCLOSURE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-weight: normal">There
have been no disagreements with our independent registered public accountants on accounting or financial disclosure matters during
our two most recent fiscal years.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="main_015"></A>ITEM 9A. CONTROLS AND PROCEDURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Evaluation of Disclosure Controls and Procedures.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our management, including our principal
executive officer and principal financial officer, has evaluated the effectiveness of the design and operation of our disclosure
controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act), as of the end of the period covered
by this Form 10-K. Based on this evaluation, our Chief Executive Officer (&ldquo;CEO&rdquo;) and our Chief Financial Officer (&ldquo;CFO&rdquo;),
concluded that as a result of the material weakness in our internal controls over financial reporting discussed below, our disclosure
controls and procedures were not effective at ensuring that information required to be disclosed in the reports we file or submit
under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and
Exchange Commission's rules and forms and that such information is accumulated and communicated to our management, including our
principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions
regarding disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Attestation Report of the Registered Public Accounting Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our independent registered public accounting
firm will not be required to formally attest to the effectiveness of our internal controls over financial reporting for as long
as we are an &ldquo;emerging growth company&rdquo; pursuant to the provisions of the Jumpstart Our Business Startups Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Management's Report on Internal Control Over Financial Reporting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our principal executive officer and our
principal accounting and financial officer, are responsible for establishing and maintaining adequate internal control over financial
reporting, as such term is defined in Exchange Act Rules 13a-15(f). Management conducted an assessment of the effectiveness of
our internal control over financial reporting as of December 31, 2016. In making this assessment, management used the criteria
described in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway
Commission (COSO). Our management concluded that our internal controls over financial reporting were, and continue to be ineffective,
as of December 31, 2016 due to a material weakness in our internal controls due to the lack of segregation of duties.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">It should be noted that any system of controls,
however well designed and operated, can provide only reasonable and not absolute assurance that the objectives of the system are
met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of certain events.
Because of these and other inherent limitations of control systems, there can be no assurance that any design will succeed in achieving
its stated goals under all potential future conditions, regardless of how remote.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In light of the material weakness described
below, we performed additional analysis and other post-closing procedures to ensure our financial statements were prepared in accordance
with generally accepted accounting principles. Accordingly, we believe that the financial statements included in this report fairly
present, in all material respects, our financial condition, results of operations and cash flows for the periods presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A material weakness is a control deficiency
(within the meaning of the Public Company Accounting Oversight Board (PCAOB) Auditing Standard 1305) or combination of control
deficiencies that result in more than a remote likelihood that a material misstatement of the annual or interim financial statements
will not be prevented or detected.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During the last quarter of fiscal 2016,
and as our operational activities increased, management determined that it does not have sufficient segregation of duties within
its accounting functions, which is a basic internal control. Due to our size and nature, segregation of all conflicting duties
may not always be possible and may not be economically feasible. However, to the extent possible, the initiation of transactions,
the custody of assets and the recording of transactions should be performed by separate individuals. Management evaluated the impact
of our failure to maintain effective segregation of duties on our assessment of our internal control over financial reporting and
has concluded that the control deficiency represents a material weakness. Management intends to increase its accounting staff,
as soon as economically feasible and sustainable, to remediate this material weakness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In reporting its third quarter results,
we identified a material weakness that since has been remediated. Our accounting for business combinations resulted in an error
that caused a restatement of one of our quarterly reports. To remediate this material weakness, management engaged an outside
firm to assist management with such accounting and will continue to use outside firms as a resource to deal with other non-recurring
or unusual transactions that have occurred since the business combination.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Changes in Internal Control over Financial Reporting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During the last quarter of fiscal 2016,
and as our operational activities increased, management determined that it does not have sufficient segregation of duties within
its accounting functions, which is a basic internal control. Due to our size and nature, segregation of all conflicting duties
may not always be possible and may not be economically feasible. However, to the extent possible, the initiation of transactions,
the custody of assets and the recording of transactions should be performed by separate individuals. Management evaluated the impact
of our failure to maintain effective segregation of duties on our assessment of our internal control over financial reporting and
has concluded that the control deficiency represents a material weakness. Management intends to increase its accounting staff,
as soon as economically feasible and sustainable, to remediate this material weakness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In reporting its third quarter results,
we identified a material weakness that since has been remediated. Our accounting for business combinations resulted in an error
that caused a restatement of one of our quarterly reports. To remediate this material weakness, management engaged an outside firm
to assist management with such accounting and has continued to use this outside firm as a resource to deal with other non-recurring
or unusual transactions that have occurred since the business combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">ITEM 9B. OTHER INFORMATION.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART III</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="main_016"></A>ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information required by this item is
incorporated by reference to our Proxy Statement for the 2017 Annual Meeting of Stockholders to be filed with the Securities and
Exchange Commission within 120 days of the fiscal year ended December 31, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Board of Directors has adopted a written
Code of Business Conduct and Ethics applicable to all officers, directors and employees, which is available on our website (www.moleculin.com)
under &ldquo;Governance Documents&rdquo; within the &ldquo;Corporate Governance&rdquo; section. We intend to satisfy the disclosure
requirement under Item 5.05 of Form 8-K regarding amendment to, or waiver from, a provision of this Code and by posting such information
on the website address and location specified above.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="main_017"></A>ITEM 11. EXECUTIVE COMPENSATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information required by this item is
incorporated by reference to our Proxy Statement for the 2017 Annual Meeting of Stockholders to be filed with the Securities and
Exchange Commission within 120 days of the fiscal year ended December 31, 2016.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="main_018"></A>ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS
AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information required by this item is
incorporated by reference to our Proxy Statement for the 2017 Annual Meeting of Stockholders to be filed with the Securities and
Exchange Commission within 120 days of the fiscal year ended December 31, 2016.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="main_019"></A>ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS,
AND DIRECTOR INDEPENDENCE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information required by this item is
incorporated by reference to our Proxy Statement for the 2017 Annual Meeting of Stockholders to be filed with the Securities and
Exchange Commission within 120 days of the fiscal year ended December 31, 2016.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="main_020"></A>ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information required by this item is
incorporated by reference to our Proxy Statement for the 2017 Annual Meeting of Stockholders to be filed with the Securities and
Exchange Commission within 120 days of the fiscal year ended December 31, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART IV</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="main_021"></A>ITEM 15. EXHIBITS AND FINANCIAL STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>Documents filed as part of this Report</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.</TD><TD>Financial Statements.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">The following  financial statements
and notes thereto which are attached hereto beginning on page F-1 have been included by reference into Item 8 of this part of
the annual report on Form 10-K:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="width: 12%; border-bottom: Black 1pt solid">Page</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>1.</td>
    <TD>Nature of Business and Liquidity</td>
    <TD>F-8</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>2.</td>
    <TD>Summary of Significant Accounting Policies</td>
    <TD>F-9</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>3.</td>
    <TD>&ndash; Intangible Assets</td>
    <TD>F-12</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>4.</td>
    <TD>&ndash; Convertible Notes Payable</td>
    <TD>F-15</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>5.</td>
    <TD>&ndash; Equity</td>
    <TD>F-16</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>6.</td>
    <TD>&ndash; Income Taxes</td>
    <TD>F-18</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>7.</td>
    <TD>Commitments and Contingencies</td>
    <TD>F-20</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>8.</td>
    <TD>Subsequent Events</td>
    <TD>F-24</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial
Statement Schedules</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">All schedules are omitted because they are
inapplicable or not required or the required information is shown in the financial statements or notes thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">The information required by this Item is set
forth in the Exhibit Index that follows the signature page of this Annual Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Moleculin Biotech, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Index to Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 92%">&nbsp;</TD>
    <TD STYLE="width: 8%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">PAGE</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#fin_001"><FONT STYLE="font-size: 10pt">Reports of Independent Registered Public Accounting Firms</FONT></A></TD>
    <TD><FONT STYLE="font-size: 10pt">F-2</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#fin_002"><FONT STYLE="font-size: 10pt">Balance Sheets as of December 31, 2016 and 2015</FONT></A></TD>
    <TD><FONT STYLE="font-size: 10pt">F-4</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#fin_003"><FONT STYLE="font-size: 10pt">Statements of Operations for the periods ended December 31, 2016 and 2015</FONT></A></TD>
    <TD><FONT STYLE="font-size: 10pt">F-5</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="#fin_004">Statements of Cash Flows for the periods ended December 31, 2016 and 2015</A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">F-6</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#fin_005"><FONT STYLE="font-size: 10pt">Statements of Stockholders&rsquo; Equity for the periods ended December 31, 2016 and 2015</FONT></A></TD>
    <TD><FONT STYLE="font-size: 10pt">F-7</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#fin_006"><FONT STYLE="font-size: 10pt">Notes to Financial Statements</FONT></A></TD>
    <TD><FONT STYLE="font-size: 10pt">F-8</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 60; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="fin_001"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Board of Directors and Stockholders</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Moleculin Biotech, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying balance
sheet of Moleculin Biotech, Inc. (a Delaware corporation) (the &ldquo;Company&rdquo;) as of December 31, 2016, and the related
statements of operations, stockholders&rsquo; equity, and cash flows for the year ended December 31, 2016. These financial statements
are the responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion on these financial statements
based on our audit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audit in accordance with
the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform
the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not
engaged to perform an audit of the Company&rsquo;s internal control over financial reporting. Our audit included consideration
of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances,
but not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s internal control over financial reporting.
Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management,
as well as evaluating the overall financial statement presentation. We believe that our audit provide a reasonable basis for our
opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In our opinion, the financial statements
referred to above present fairly, in all material respects, the financial position of Moleculin Biotech, Inc. as of December 31,
2016, and the results of its operations and its cash flows for the year ended December 31, 2016 in conformity with accounting principles
generally accepted in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements have
been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the
Company has incurred an accumulated deficit of $4,674,721 since inception and has not yet generated any revenue from operations.
These conditions, along with other matters as set forth in Note 2, raise substantial doubt about the Company&rsquo;s ability to
continue as a going concern. Management&rsquo;s plans in regard to these matters are also described in Note 2. The financial statements
do not include any adjustments that might result from the outcome of this uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ GRANT THORNTON LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Houston, Texas</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April 3, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the Board of Directors and Stockholders of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Moleculin Biotech, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Houston, Texas</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We have audited the accompanying balance sheet of Moleculin
Biotech, Inc. as of December 31, 2015 and the related statements of operations, stockholders&rsquo; equity (deficit), and cash
flows for the period from July 28, 2015 (Inception) to December 31, 2015. Moleculin Biotech, Inc.&rsquo;s management is responsible
for these financial statements. Our responsibility is to express an opinion on these financial statements based on our audit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We conducted our audit in accordance with the standards of the
Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have,
nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of
internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances,
but not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s internal control over financial reporting.
Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management,
as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our
opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In our opinion, the financial statements referred to
above present fairly, in all material respects, the financial position of Moleculin Biotech, Inc. as of December 31, 2015 and
the results of its operations and cash flows for the period from July 28, 2015 (Inception) to December 31, 2015 in conformity
with accounting principles generally accepted in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The accompanying financial statements
have been prepared assuming that Moleculin Biotech, Inc. will continue as a going concern. As discussed in Note 2   to the
financial statements, Moleculin Biotech, Inc. incurred an accumulated loss and has not yet generated any revenue from
operations that raise substantial doubt about its ability to continue as a going concern. Management&rsquo;s plans in regard
to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from
the outcome of this uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/GBH CPAs, PC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">GBH CPAs, PC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">www.gbhcpas.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Houston, Texas</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">March 21, 2016</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="fin_002"></A>Moleculin Biotech, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Balance Sheets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">December 31,<BR> 2016</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">December 31,<BR> 2015</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: center">Assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Current Assets:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; font-size: 10pt; text-align: left; padding-left: 9pt">Cash and cash equivalents</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">5,007,216</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">28,091</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Prepaid expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">215,052</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Total current assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,222,268</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">28,091</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Long-Term Assets:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Furniture and equipment, net of accumulated depreciation<BR>
 of $6,162 and $0, respectively</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">23,128</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&ndash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Intangible assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">11,147,540</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total Assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">16,392,936</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">28,091</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: center">Liabilities and Stockholders' Equity </TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Current Liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Accounts payable and accrued expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1,048,655</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">322,790</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Convertible notes payable</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">296,412</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">450,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Total current liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,345,067</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">772,790</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Long-term deferred compensation &ndash; related party</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">87,500</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total Liabilities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,432,567</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">772,790</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Commitments and contingencies</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Stockholders' Equity:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Preferred stock, $0.001 par value; 5,000,000 authorized, no shares issued and outstanding</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&ndash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&ndash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Common stock, $0.001 par value; 75,000,000 authorized, 12,164,852 and 6,661,000 shares issued and outstanding, respectively</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">12,165</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,661</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Subscription receivable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(3,000</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Additional paid-in capital</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">19,622,925</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&ndash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Accumulated deficit</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(4,674,721</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(748,360</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total Stockholders' Equity (Deficit)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">14,960,369</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(744,699</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total Liabilities and Stockholders' Equity (Deficit)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">16,392,936</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">28,091</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">See accompanying notes
to the financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="fin_003"></A>Moleculin Biotech, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Statements of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Year<BR> Ended<BR> December 31,</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">From<BR> July&nbsp;28, 2015<BR> (Inception)<BR> Through<BR>
    December 31,</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">Revenue</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Operating expenses:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; font-size: 10pt; text-align: left; padding-left: 9pt">Research and development</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">1,495,561</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">260,418</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">General and administrative</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,381,424</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">477,810</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt; padding-left: 9pt">Depreciation</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6,162</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Total Operating Expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,883,147</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">738,228</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Loss from operations</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(3,883,147</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(738,228</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Other expense:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Interest expense</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(43,214</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(10,132</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(3,926,361</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(748,360</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Net loss per common share - basic and diluted</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.40</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.13</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Weighted average common shares outstanding - basic and diluted</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">9,827,510</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">5,691,803</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">See accompanying notes
to the financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="fin_004"></A>Moleculin Biotech, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Statements of Cash Flows</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Year<BR> Ended<BR> December&nbsp;31,</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">From July&nbsp;28,<BR> 2015<BR> (Inception)<BR> Through<BR> December&nbsp;31,</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Cash Flows from Operating Activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; font-size: 10pt; text-align: left">Net loss</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">(3,926,361</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">(748,360</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 9pt">Depreciation</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,162</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Stock-based compensation</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">323,974</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Deferred CEO compensation</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">87,500</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Stock issued for licenses used for research and development</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,061</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Changes in operating assets and liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Prepaid expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(215,052</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Accounts payable and accrued expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(41,128</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">322,790</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Net Cash Used in Operating Activities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(3,764,905</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(423,509</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Cash Flows from Investing Activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Cash paid for purchase of fixed assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(21,470</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Cash paid for acquisition of Moleculin, LLC, net with cash acquired</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(99,638</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Net Cash Used in Investing Activities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(121,108</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Cash Flows from Financing Activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Proceeds from notes payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">165,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">450,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Payments on notes payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(469,939</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Proceeds from sale of common stock, net of cash stock issuance costs</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">9,170,077</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,600</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Net Cash Provided by Financing Activities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">8,865,138</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">451,600</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Net change in cash and cash equivalents</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,979,125</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">28,091</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Cash and cash equivalents, at beginning of period</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">28,091</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents, at end of period</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">5,007,216</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">28,091</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Supplemental disclosures of cash flow information:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Cash paid for interest</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">4,585</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Cash paid for income taxes</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Supplemental disclosure of non-cash investing and financing activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Common stock issued for the Acquisition of Moleculin, LLC</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">9,773,586</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Common stock issued for conversion of debt</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">363,792</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Warrants issued for services provided</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">374,763</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Common stock issued for services provided</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">157,680</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">Shares subscribed</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">3,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">See accompanying notes
to the financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="fin_005"></A>Moleculin Biotech, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Statements of Stockholders&rsquo; Equity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional Paid-In-Capital</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscriptions Receivable</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated Loss</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders' Equity (Deficit)</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 34%; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock issued for cash and subscription receivable</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,600,000</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,600</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,000</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,600</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock issued for licenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,061,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,061</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,061</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(748,360</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(748,360</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at December 31, 2015</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,661,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,661</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,000</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(748,360</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(744,699</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Private issuance @ $3.00 / share</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">234,297</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">234</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">702,660</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">702,894</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued for Moleculin acquisition</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">999,931</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,998,586</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,999,586</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued for technology</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">629,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">629</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,773,371</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,774,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued for cash - IPO, net of stock issuance costs of $1,150, 736</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,540,026</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,540</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,087,880</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,089,420</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants issued
for services</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">374,763</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">374,763</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock granted for services</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">157,656</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">157,680</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock option expense</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">166,294</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">166,294</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued for convertible debt</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,076,598</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,077</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">361,715</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">363,792</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription agreement
settled for cash</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,926,361</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,926,361</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at December 31, 2016</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,164,852</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,165</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19,622,925</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,674,721</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,960,369</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">See accompanying notes
to the financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="fin_006"></A>Moleculin Biotech, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to the Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">1.</TD><TD STYLE="text-align: justify">Nature of Business and Liquidity</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The terms &ldquo;MBI&rdquo;
or &ldquo;the Company&rdquo;, &ldquo;we&rdquo;, &ldquo;our&rdquo; and &ldquo;us&rdquo; are used herein to refer to Moleculin Biotech,
Inc. MBI is a preclinical pharmaceutical company organized as a Delaware corporation in July 2015 to focus on the development of
anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the
M.D. Anderson Cancer Center, which we refer to as MD Anderson.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our lead drug candidate
is liposomal Annamycin, which we refer to as Annamycin, an anthracycline being studied for the treatment of relapsed or refractory
acute myeloid leukemia, or AML. In August 2015, the Company entered into a rights transfer agreement with AnnaMed, Inc. (&ldquo;AnnaMed&rdquo;),
a company affiliated with certain members of the Company&rsquo;s management and board of directors, pursuant to which, in exchange
for 1,431,000 shares of the Company&rsquo;s common stock, AnnaMed agreed to transfer to MBI any and all data it had regarding the
development of Annamycin and the Annamycin investigative new drug application (&ldquo;IND&rdquo;) with the U.S. Food and Drug Administration
(&ldquo;FDA&rdquo;) , including all trade secrets, know-how, confidential information and other intellectual property rights held
by AnnaMed. Annamycin has been in clinical trials pursuant to an IND that had been filed with the FDA. This IND was terminated
due to a lack of activity by a prior drug developer. However, in the course of our review of that data, we identified that Annamycin
may have greater potential for efficacy than we originally believed, based on an unexpected potential opportunity to increase the
drug&rsquo;s Maximum Tolerable Dose (&ldquo;MTD&rdquo;). We determined to adjust our clinical strategy by adding in a Phase I arm
to our next Phase II trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because the prior developer
of Annamycin allowed their IND to lapse, we are required to submit a new IND for continued clinical trials with Annamycin. We filed
our IND application, with the clinical strategy of increasing the MTD mentioned above, for Annamycin on February 10, 2017. &nbsp;In
subsequent discussions with us, FDA requested certain revisions to the protocol, additional&nbsp;information, and additional data
related to Chemistry, Manufacturing and Controls (&ldquo;CMC&rdquo;). &nbsp;We have the additional information, have made the requested
revisions to the protocol,&nbsp;and we are working on developing the CMC data. &nbsp;In the interim, we have withdrawn the IND
application in order to resubmit it when the requested data are available. &nbsp;We believe that resubmission of the IND application
will occur in time for the IND to go into effect and the announcement of the beginning of Phase I/II clinical trials in the first
half of 2017. However, if we are unable to obtain the required CMC data on a timely basis, we will be delayed in resubmitting our
IND application, which will delay the commencement of our clinical trials beyond the first half of 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Annamycin drug
substance is no longer covered by any existing patent protection. We intend to submit patent applications for formulation, synthetic
process and reconstitution related to our Annamycin drug product candidate, although there is no assurance that we will be successful
in obtaining such patent protection. On March 21, 2017, we received notice that FDA had granted us Orphan Drug designation for
Annamycin <FONT STYLE="font-family: Times New Roman, Times, Serif">for the treatment of AML </FONT>. Orphan Drug status could
entitle us to market exclusivity of up to 7 and 10 years from the date of approval of a New Drug Application (&ldquo;NDA&rdquo;)
or Marketing Authorization Application (&ldquo;MAA&rdquo;), in the US and the European Union (&ldquo;EU&rdquo;), respectively.
Separately, the FDA may also grant market exclusivity of up to five years for newly approved new chemical entities (of which Annamycin
would be one), but there can be no assurance that such exclusivity will be granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have two other drug
development projects in progress, one involving a portfolio of small molecules, which we refer to as the WP1066 Portfolio, focused
on the modulation of key oncogenic transcription factors involved in the progression of cancer, and the WP1122 Portfolio, a suite
of molecules targeting the metabolic processes involved in cancer in general, and glioblastoma (the most common form of brain tumor)
in particular. We have been granted royalty-bearing, worldwide, exclusive licenses for the patent and technology rights related
to our WP1066 Portfolio and WP1122 Portfolio drug technologies, as these patent rights are owned by MD Anderson.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 11, 2015,
the Company entered into a rights transfer agreement for WP1122 with IntertechBio Corporation (&ldquo;IntertechBio&rdquo;), a company
affiliated with certain members of our management, whereby IntertechBio agreed to assign its license or sublicense its license<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT>
to certain metabolic inhibitor technology owned by MD Anderson. In consideration, the Company issued 630,000 common shares to IntertechBio.
IntertechBio<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT> agreed to make payments to MD Anderson including an up-front payment,
license documentation fee, annual maintenance fee, milestone payments and minimum annual royalty payments for sales of products
developed under the license agreement. The Company has assumed the rights and obligations of IntertechBio under the license agreement
with MD Anderson. Therefore, <FONT STYLE="font-size: 10pt">&nbsp;</FONT>all out-of-pocket expenses incurred by MD Anderson in filing,
prosecuting and maintaining the licensed patents have been and shall continue to be assumed <FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT>by
the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with
FASB ASC Topic 280, Segment Reporting, we view our operations and manage our business as principally one segment. As a result,
the financial information disclosed herein represents all of the material financial information related to our principal operating
segment.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company filed
a registration statement on Form S-1 (which was declared effective on May 2, 2016) with respect to the Company&rsquo;s initial
public offering of shares of its common stock (&ldquo;IPO&rdquo;) to fund the development of its technologies. Prior to the declaration
of effectiveness of the registration statement on Form S-1, we acquired Moleculin, LLC which was merged with and into MBI. Moleculin,
LLC was the holder of a license agreement with MD Anderson covering technology referred to as <FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT>the
WP1066 Portfolio, which is focused on the modulation of key oncogenic transcription factors. <FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">2.</TD><TD STYLE="text-align: justify">Summary of Significant Accounting Policies</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying audited
financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United
States of America (&ldquo;U.S. GAAP&rdquo;) for financial information, and in accordance with the rules and regulations of the
United States Securities and Exchange Commission (the &ldquo;SEC&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Use of Estimates
in Financial Statement Presentation -</B> The preparation of these financial statements in conformity with accounting principles
generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during
the reporting period. Actual results could differ from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Acquisition &ndash;
</B>We acquired Moleculin, LLC (&ldquo;Moleculin&rdquo;) on May 2, 2016, and, going forward our financial statements
include the operations of Moleculin, LLC. We account for acquired businesses using the acquisition method of accounting, which
requires, among other things, that assets acquired and liabilities assumed be recognized at their estimated fair values as of the
acquisition date and that the fair value of acquired in-process research and development (&ldquo;IPR&amp;D&rdquo;) be recorded
on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned
values of the net assets acquired will be recorded as goodwill. The Company obtained input from third-parties regarding its tangible
and intangible assets and other information necessary to measure the fair value of the assets acquired and liabilities assumed
in connection with the acquisition of Moleculin, LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Going Concern -
</B>These financial statements have been prepared on a going concern basis, which assumes the Company will continue
to realize its assets and discharge its liabilities in the normal course of business. The continuation of the Company as a going
concern is dependent upon the ability of the Company to obtain continued financial support from its stockholders&rsquo;, necessary
equity financing to continue operations and the attainment of profitable operations. As of December 31, 2016, the Company has incurred
an accumulated deficit of $4,674,721 since inception, and had not yet generated any revenue from operations. Additionally, management
anticipates that its cash on hand as of December 31, 2016 plus the additional cash generated from its equity offering subsequent
to year-end, discussed further within these notes to the financial statements, is sufficient to fund its planned operations into
but not beyond the near term. These factors raise substantial doubt regarding the Company&rsquo;s ability to continue as a going
concern. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts
and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company
may seek additional funding through a combination of equity offerings, debt financings, government or other third-party funding,
commercialization, marketing and distribution arrangements, other collaborations, strategic alliances and licensing arrangements
and delay planned cash outlays or a combination thereof. Management cannot be certain that such events or a combination thereof
can be achieved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Cash and Cash Equivalents
-</B> The Company considers all highly liquid accounts with original maturities of three months or less at the date of acquisition
to be cash equivalents.&nbsp;Periodically, the Company may carry cash balances at financial institutions in excess of the federally
insured limit of $250,000. The amount in excess of the FDIC insurance at December 31, 2016 was $256,836 and $0 as of December 31,
2015. Compensation expense is recognized only for share based payments expected to vest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Property and equipment
-</B> Property and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line depreciation
method as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; text-align: justify; text-indent: 0in">Leasehold improvement</TD>
    <TD STYLE="width: 60%; text-align: justify; text-indent: 0in">Shorter of estimated useful lives or the term of the lease<FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in">Computer equipment</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">2 years*</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in">Machinery and equipment</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">5 years*</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in">Furniture and office equipment</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">7 years*</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">*Property and equipment
assets acquired in the merger with Moleculin, LLC are being depreciated over a 2 year useful life due to their age and condition
and expected remaining life assessed at merger date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Intangible assets
-</B> Intangible assets with finite lives are amortized using the straight-line method over their estimated period of benefit.
If an intangible asset is identified as an in-process research &amp; development asset, then no amortization will occur until the
development is complete. If the associated research and development effort is abandoned, the related assets will be written-off
and the Company will record a noncash impairment loss on its statements of operations. For those compounds that reach commercialization,
the IPR&amp;D assets will be amortized over their estimated useful lives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We evaluate the recoverability
of intangible assets periodically and take into account events or circumstances that warrant revised estimates of useful lives
or that indicate that impairment exists. No material impairments of intangible assets have been identified during any of the periods
presented. Intangible assets are tested for impairment on an annual basis, and between annual tests if indicators of potential
impairment exist, using a fair-value-based approach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Beneficial Conversion
Feature</B> - From time to time, the Company may issue convertible notes that have conversion prices that create an embedded beneficial
conversion feature on the issuance date. A beneficial conversion feature exists on the date a convertible note is issued when the
fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds
of the note after first considering the allocation of a portion of the note proceeds to the fair value of any attached equity instruments,
if any related equity instruments were granted with the debt. The Company estimated the fair value of its common stock on the dates
issued. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to
additional paid-in capital, if any. The debt discount is amortized to interest expense over the life of the note using the effective
interest method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Income Taxes -</B>
The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities
are determined based on the differences between the financial reporting and the tax bases of reported assets and liabilities and
are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company
must then assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when
it is more likely than not that some portion or all of a deferred tax asset will not be realized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company accounts
for uncertain tax positions in accordance with the provisions of ASC 740-10 which prescribes a recognition threshold and measurement
attribute for financial statement disclosure of tax positions taken, or expected to be taken, on its tax return. The Company evaluates
and records any uncertain tax positions based on the amount that management deems is more likely than not to be sustained upon
examination and ultimate settlement with the tax authorities in the tax jurisdictions in which it operates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Stock-based Compensation
-</B> Stock-based compensation expense includes the estimated fair value of equity awards vested during the reporting period. The
expense for equity awards vested during the reporting period is determined based upon the grant date fair value of the award and
is recognized as expense over the applicable vesting period of the stock award using the straight-line method.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Loss Per Common
Share</B> - Basic net loss per common share are computed by dividing net loss available to common shareholders by the weighted-average
number of common shares outstanding during the period. Diluted net loss per common share is determined using the weighted-average
number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods
when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their
inclusion would be anti-dilutive. As of December 31, 2016, the Company&rsquo;s potentially dilutive shares, which were not included
in the calculation of net loss per share, included notes convertible to 1,821,013 common shares, options to purchase 510,000 common
shares and warrants to purchase 107,802 common shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Research and Development
Costs -</B> Research and development costs are expensed as incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Subsequent Events
-</B> The Company&rsquo;s management reviewed all material events through the date these financial statements were issued for
subsequent event disclosure consideration and has noted such events as described in Note 8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Recent Accounting
Pronouncements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2014, the FASB
issued Accounting Standard Update (&quot;ASU&quot;) 2014-09, Revenue from Contracts with Customers (Topic 606), which will replace
numerous requirements in U.S. GAAP, including industry-specific requirements, and provide companies with a single revenue recognition
model for recognizing revenue from contracts with customers. The core principle of the new standard is that a company should recognize
revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which
the company expects to be entitled in exchange for those goods or services. In August 2015, the FASB approved a proposal to defer
the effective date of the guidance until annual and interim reporting periods beginning after December 15, 2017. The Company is
currently evaluating the impact that this standard will have on its financial statements at the time the Company starts to generate
revenue or enters into other contractual arrangements, which the Company does not expect in the near term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2014, the
FASB issued ASU 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about
an Entity&rsquo;s Ability to Continue as a Going Concern. Under the new guidance, management will be required to assess an entity&rsquo;s
ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. The provisions of
this ASU are effective for annual periods ending after December 15, 2016, and for annual and interim periods thereafter; early
adoption is permitted. This disclosure is effective within these financial statements for the year ended December 31, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2016, the
FASB issued ASU No. 2016-01, Financial Instruments &ndash; Overall: Recognition and Measurement of Financial Assets and Financial
Liabilities (&ldquo;ASU 2016-01&rdquo;).&nbsp;ASU 2016-01 affects the accounting for equity investments, financial liabilities
under the fair value option and the presentation and disclosure requirements of financial instruments.&nbsp;ASU 2016-01 is effective
for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years.&nbsp;The Company is currently
evaluating the impact that this standard will have on its financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2016, the
FASB issued ASU No. 2016-02, Leases (Topic 842) (&ldquo;ASU 2016-02&rdquo;). Under ASU 2016-02, an entity will be required to recognize
right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements.&nbsp;ASU
2016-02 offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. Lessees and lessors are
required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements
to assess the amount, timing and uncertainty of cash flows arising from leases.&nbsp;For public companies, ASU 2016-02 is effective
for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, and requires
a modified retrospective adoption, with early adoption permitted.&nbsp;The Company is currently evaluating the impact that this
standard will have on its financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2016, the
FASB issued ASU 2016-09, Compensation-Stock Compensation (Topic 718). The new guidance changes the accounting and simplifies various
aspects of the accounting for share-based payments to employees. The guidance allows for a policy election to account for forfeitures
as they occur or based on an estimated number of awards that are expected to vest. ASU 2016-09 is effective for annual periods
beginning after December 15, 2016, with early adoption permitted. The adoption of this standard on January 1, 2017, did not have
a significant impact on the Company&rsquo;s financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2016, the
FASB issued ASU, Statement of Cash Flows (Topic 230). This ASU applies to all entities that are required to present a statement
of cash flows under Topic 230. The amendments provide guidance on eight specific cash flow issues and includes clarification on
how these items should be classified in the statement of cash flows and is designed to help eliminate diversity in practice as
to where items are classified in the cash flow statement. Furthermore in November 2016, the FASB issued additional guidance on
this Topic that requires amounts generally described as restricted cash and restricted cash equivalents to be included with cash
and cash equivalents when reconciling the statement of cash flows. This ASU is effective for fiscal years beginning after December
15, 2017, and interim periods within those fiscal years, with earlier application permitted for all entities. We plan to adopt
the provisions of this ASU for our fiscal year beginning January 1, 2018 and are currently evaluating the impact the adoption of
this new accounting standard will have on our financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 20, 2015,
the Financial Accounting Standards Board (&ldquo;FASB&rdquo;) issued Accounting Standards Update (&quot;ASU&quot;) 2015-17, &quot;Balance
Sheet Classification of Deferred Taxes&quot;, requiring all deferred tax assets and liabilities, and any related valuation allowance,
to be classified as non-current on the balance sheet. The classification change for all deferred taxes as non-current simplifies
entities&rsquo; processes as it eliminates the need to separately identify the net current and net non-current deferred tax asset
or liability in each jurisdiction and allocate valuation allowances. The Company elected to adopt the accounting in the fourth
quarter of 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company does not
believe that any other recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would
have a material effect on the accompanying financial statements.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">3.</TD><TD STYLE="text-align: justify">Intangible Assets</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in"><B>The
Acquisition of Moleculin, LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 2, 2016, Moleculin,
LLC, a Texas limited liability company, was merged with and into the Company. As a result of the merger, the Company issued to
the holders of Moleculin equity interests an aggregate of 999,931 shares of the Company&rsquo;s common stock valued at $5,999,586,
based on the estimated acquisition-date fair value of our common stock of $6.00 per share, equal to the IPO price announced in
our prospectus filed on that date. These shares contain certain trading restrictions. Prior to the Company&rsquo;s acquisition
of Moleculin, the Company had loaned $57,822 to Moleculin which was treated as part of the consideration paid to acquire Moleculin.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As additional consideration
payable to the Moleculin unit holders, we agreed pursuant to the merger agreement that if drugs for dermatology indications are
successfully developed by us using any of the Existing IP Assets, then the Moleculin, LLC unit holders, in the aggregate, will
be entitled to receive a 2.5% royalty on the net revenues generated by such drugs. Any such net revenues would include a deduction
for license fees or royalty obligations payable to MD Anderson for such Existing IP Assets. The merger agreement defined &ldquo;Existing
IP Assets&rdquo; to mean all intellectual property, licensed by us and Moleculin as of the time of the merger, including, without
limitation, the intellectual property licensed from MD Anderson under the Patent and Technology License Agreement entered into
by and between IntertechBio Corporation and MD Anderson dated April 2, 2012, as amended, and the Patent and Technology License
Agreement dated June 21, 2010, as amended, between MD Anderson and Moleculin, LLC, but excluding any intellectual property relating
to Annamycin. The right to receive the contingent royalty payments described herein is limited to&nbsp;drugs developed only for
dermatology indications, and does not include drugs developed for any other indications. We have no obligation of any nature to
pursue the development of any drugs for dermatology indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our acquisition of
Moleculin, LLC, occurring prior to our IPO offering, provided us with the rights to the license agreement that Moleculin, LLC had
with MD Anderson covering the WP1066 Portfolio. However, Moleculin, LLC had previously granted Houston Pharmaceuticals, Inc. (&ldquo;HPI&rdquo;),
a related party, an option, which could be exercised at any time, to obtain an exclusive sub-license to develop the WP1066 Portfolio
in all non-dermatological fields. Moleculin, LLC had previously pursued development of the WP1066 Portfolio for treatment of psoriasis,
however, psoriasis related clinical trials had been terminated. Because WP1066 has shown significant activity against a wide range
of tumors, Moleculin, LLC&rsquo;s focus prior to the acquisition included the development of drugs for cancer treatment. However,
the exclusive sub-license option held by HPI precluded Moleculin, LLC from pursuing drug development related to non-skin cancers,
in addition to potentially creating significant intellectual property, clinical and commercialization risks associated with drug
development for skin cancers. Re-acquisition of the HPI option was therefore essential for the values of both the WP1066 Portfolio
and Moleculin, LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, the merger
agreement contained mutual representations and warranties between the parties. Pursuant to the merger agreement, we agreed for
a period of six years to indemnify and hold harmless each present and former director and/or officer of Moleculin, LLC whom Moleculin,
LLC would have had the power to indemnify under Delaware law that is made a party or threatened to be made a party to any threatened,
pending or completed proceeding or claim by reason of the fact that he or she was a director or officer of the Moleculin, LLC prior
to the effective time of the merger and arising out of actions or omissions of the indemnified party in any such capacity occurring
at or prior to the effective time of the merger against any losses or damages reasonably incurred in connection with any claim.
To our knowledge, no such proceeding or claim exists or has been threatened on the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
the acquisition of Moleculin, LLC, we also negotiated on behalf of Moleculin, LLC two agreements with HPI. Under the first agreement,
HPI&rsquo;s option to obtain the aforementioned exclusive sublicense was terminated in exchange for a payment of $100,000 and the
issuance of 629,000 shares of our common stock, valued at $6 per share. Under the second agreement (HPI Out-Licensing Agreement),
HPI has received a non-exclusive technology rights and development sublicense under which it may continue its ongoing work to develop
the WP1066 Portfolio related to treatment of non-skin cancer. Pursuant to this HPI Out-Licensing Agreement, we agreed to make payments
to HPI totaling $750,000 over a three-year period, of which $75,000 was paid in calendar year 2016. The Company expenses such costs
as incurred as research and development expense, commencing after the IPO offering in exchange for HPI allowing us to access any
data, information or know-how resulting from the research and development conducted by HPI. As of December 31, 2016, notwithstanding
our obligation to make the foregoing payments, the HPI Out-Licensing Agreement does not obligate HPI to conduct any specific research
or to meet any milestones. Pursuant to the HPI Out-Licensing Agreement, we have the right within three years of the effective date
to buy-out from HPI all rights granted to HPI under the agreement for a payment of $1.0 million. Upon our exercise of the buy-out
we will no longer be obligated to make any payments to HPI remaining from the $750,000 obligation discussed above. If we do not
exercise the foregoing buy-out right within three years, the license granted to HPI shall convert into an exclusive license. As
such, if we do not exercise the buy-out right for any reason, we will no longer have access to the non-skin cancer uses of the
WP1066 Portfolio. As noted above, this will also potentially create risks for the development of skin cancer drugs. We do not intend
to set aside and designate cash and cash equivalents in the amount of $1.0 million to make the buy-out payment. If we ultimately
decide to exercise the buy-out right from HPI, we will need to raise additional
funds to make the buy-out payment. We cannot assure that such additional funding will be available on satisfactory terms, or at
all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The agreements with
HPI were executed on May 2, 2016, simultaneously with the closing of the Moleculin, LLC acquisition, and were non-cancelable but
contingent on the Company&rsquo;s ability to complete the IPO by June 30, 2016. They became effective on May 31, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The termination of
the HPI option was completed on behalf of Moleculin, LLC, which was required to enable the sale of Moleculin, LLC by materializing
the value of its most significant asset, and was non-cancelable by either party. Further, the HPI option termination price was
determined simultaneously with the acquisition on May 2, 2016 as our IPO price was established at that time. Accordingly, we concluded
that this transaction was primarily for the benefit of Moleculin, LLC and its former owners, resulting in control of the underlying
intellectual property and thereby increasing the value of Moleculin, LLC intangible assets immediately prior to the closing of
its acquisition by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The HPI option termination
price amounted to $3,874,000, consisting of 629,000 shares of our common stock valued at the IPO price of $6.00 per share, and
$100,000 paid in cash in July 2016, and was included in acquisition-date liabilities assumed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-align: justify"><B>Purchase Price Allocation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The acquisition price
was allocated to the assets acquired and liabilities assumed based upon their estimated fair values and the information available
to management. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the
acquisition date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 92%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 83%">Cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">362</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,820</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt">Intangibles</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">11,147,540</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total assets acquired</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">11,155,722</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Liability assumed (HPI)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,874,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Other liabilities assumed, including $469,939 of notes payable</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,224,314</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net assets acquired/total consideration transferred</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,057,408</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company obtained
input from third-parties regarding its tangible and intangible assets and other information necessary to measure the fair value
of the assets acquired and liabilities assumed in connection with the acquisition of Moleculin, LLC. Management believes all or
most of the intangible assets are IPR&amp;D related to the WP1066 Portfolio, and, as such, no amortization has been recorded to
date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Intangible assets consisted
of the following at December 31, 2016 and December 31, 2015:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 96%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,<BR> 2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,<BR> 2015</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 66%; padding-left: 18.7pt">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Intangibles acquired from Moleculin, LLC</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">11,147,540</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-align: justify"><B>Unaudited Pro Forma Results
of Operations </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following comparative
table presents the unaudited condensed pro forma results of operations that reflect the acquisition of Moleculin as if the acquisition
had occurred as of the first day of each period presented, adjusted for items that are directly attributable to the acquisition.
This information has been compiled from historical financial statements and is not necessarily indicative of the results that actually
would have been achieved had the transaction already occurred or that may be achieved in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 96%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Pro Forma<BR> For the Year<BR> Ended<BR> December<BR> 31,<BR> 2016</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Pro Forma<BR> For Year Ended<BR> December<BR> 31,<BR> 2015</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 66%; font-size: 10pt; text-align: left">Total operating expenses</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">(3,979,316</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">(688,101</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Net loss</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(3,962,997</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(164,128</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Net loss per common share &ndash; basic and diluted</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(0.42</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(0.04</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Weighted average outstanding common shares &ndash; basic and diluted</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">9,401,028</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,273,239</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The years ended December 31, 2016 and December 31, 2015 are adjusted on a pro forma basis to exclude $145,078
and $422,874, respectively, in net interest expense related to the amortization of deferred financing costs and debt discount amortization
for Moleculin, LLC&rsquo;s convertible notes. The holders of the convertible notes were issued the Company&rsquo;s common shares
upon the Company&rsquo;s acquisition of Moleculin, LLC.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">4.</TD><TD STYLE="text-align: justify">Convertible Notes Payable</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On various dates from
August 31, 2015 through January 19, 2016, each as amended on March 10, 2016, the Company entered into seven unsecured promissory
notes with three separate third party investors. Each note bears interest at 8.0% per annum and was to mature on the earlier of
June 30, 2016 or the completion of an IPO of the Company&rsquo;s securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;Since the completion
of the IPO occurred prior to June 30, 2016, these notes were to be automatically converted according to their terms into shares
of the Company&rsquo;s common stock at applicable conversion price upon the Company&rsquo;s IPO to the extent and provided that
no holder of these notes was or will be permitted to convert such notes to the extent that the holder or any of its affiliates
would beneficially own in excess of 4.99% of our common stock after such conversion. Due to this 4.99% limitation, a portion of
these notes was not converted at the time of the IPO and the remaining unconverted principal and accrued interest amounts of the
effected notes will remain outstanding and will be converted into shares of our common stock at such time as the 4.99% limitation
continues to be met. Until such time as the notes are converted into shares of common stock, the maturity date of the notes will
automatically be extended and we will not be required to repay the notes or the accrued interest relating to the notes in cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The IPO was completed
on May 31, 2016. On May 31, 2016, pursuant to the conversion feature of the foregoing notes and with restriction of the 4.99% beneficially
owned condition limitation, discussed above, the Company issued 1,166,503 <FONT STYLE="font-size: 10pt">&nbsp;</FONT>common shares
in total, reducing convertible debt principal by $183,356 and accrued interest by $17,699. Subsequent to these transactions and
through December 31, 2016, an additional 910,095 common shares were issued due to the number of common shares outstanding allowing
for conversion of additional shares under the 4.99% beneficially owned condition limitation. This reduced the convertible debt
principal by $155,565 and accrued interest by $7,172. The remaining convertible debt without consideration of accrued interest
as of December 31, 2016, if converted on December 31, 2016, would result in an additional 1,821,013 common shares to be issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The convertible notes
were analyzed for a beneficial conversion feature on various issuance dates, at which time it was concluded that a beneficial conversion
feature did not exist.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table below represents
the shares that are convertible at December 31, 2016 relating to the principal amounts of these convertible notes payable and excludes
any shares that are convertible relating to the associated accrued interest:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 96%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid">Issuance Date</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,<BR> 2016 (e)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,<BR> 2015</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Conversion Rate</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Shares<BR> Convertible at<BR> Dec&nbsp;31,<BR> 2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%">August 31, 2015(a)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">38,299</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">125,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">0.1299</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">294,832</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>September 3, 2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">125,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">125,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.1299</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">962,279</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>October 6, 2015(a)(c)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,280</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">147,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">151,402</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>October 6, 2015(b)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>October 28, 2015(b)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>January 14, 2016(d)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt">January 19, 2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">82,500</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">0.20</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">412,500</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">276,079</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">450,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,821,013</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt">(a) Debt partially converted on May 31, 2016 and
on August 19, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt">(b) Debt fully converted to common shares on May
31, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt">(c) Debt partially converted on September 1, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt">(d) Debt fully converted to common shares effective
November 30, 2016&nbsp;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 11.5pt 0pt 18.7pt">(e) Excluded from the $276,079 is $20,333 in
accrued interest on the convertible notes payable which is included in the accompanying balance sheet.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The common shares
relating to the above mentioned convertible notes payable contain the following trading restrictions: (a) beginning 90 days after
the initial closing of our IPO and until the one-year anniversary of the initial closing of the IPO, the holder of the note will
be able to sell 1% of the number of shares of common stock underlying the note on a monthly basis, subject to a maximum sale on
any trading day of 4% of the daily volume; (b) if the common stock price is over $7.00 per share for five consecutive trading
days then the holder of the note can sell up to 3% of the number of shares of common stock underlying the note on a monthly basis,
subject to a maximum sale on any trading day of 4% of the daily volume; (c) if the common stock price is over $10.00 per share
for five consecutive trading days then the holder of the note can sell up to an additional 5% of the number of shares of common
stock underlying the note on a monthly basis, subject to a maximum sale on any trading day of 7% of the daily volume; and (d)
if the common stock price is over $14.00 per share then the holder of the note is not restricted from making any sales until such
time as the common stock price falls back below $14.00 per share; and (b) thereafter, until the two-year anniversary of the initial
closing of IPO, the holder of the note can sell on any trading day 10% of the daily volume; provided that if the common stock
price is over $10.00 per share then the holder of the note is not restricted from making any sales until such time as the common
stock falls back below $10.00 per share. The foregoing lock-up restrictions relate to public sales and do not restrict the transfer
of the shares privately, if permitted by applicable law, provided the acquirer of the shares agrees to comply with the above restrictions
with respect to any public sales.&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">5.</TD><TD STYLE="text-align: justify">Equity</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 2, 2016, the
Company amended and restated its certificate of incorporation to increase the number of shares authorized to 80,000,000 of which
5,000,000 shares of preferred stock are authorized and 75,000,000 shares of common stock are authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-align: justify"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are authorized to
issue up to 5,000,000 shares of preferred stock. Our certificate of incorporation authorizes the board to issue these shares in
one or more series, to determine the designations and the powers, preferences and relative, participating, optional or other special
rights and the qualifications, limitations and restrictions thereof, including the dividend rights, conversion or exchange rights,
voting rights (including the number of votes per share), redemption rights and terms, liquidation preferences, sinking fund provisions
and the number of shares constituting the series. As of December 31, 2016, there was no issued preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 11.5pt 0pt 18.7pt; text-align: justify"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 11.5pt 0pt 18.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 31, 2016, the
Company completed its IPO and sold 1,540,026 shares of the Company&rsquo;s common stock. The IPO price per share was $6.00. The
Company received net cash proceeds of $8,464,183 after deducting underwriting discounts, commissions and direct offering expenses
payable by us. Pursuant to our agreement with our underwriters, as additional compensation, we issued the underwriters warrants
to purchase 107,802 shares of common stock exercisable for a period of 5 years from date of issuance at an exercise price of $7.50
per share. The relative fair value of these warrants was $374,763 and is included in stock issuance costs calculated using the
Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 1.39%
(2) expected life of 5 years, (3) expected volatility of 80.61%, and (4) zero expected dividends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2015, the
Company agreed to issue 4,600,000 shares of common stock to its directors, officers and founders for subscriptions of $4,600 cash
to be received of which $1,600 was received in 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 11, 2015,
the Company was granted an assignment of a license agreement between MD Anderson and IntertechBio in exchange for 630,000 shares
of the Company's common stock. The sublicense gives the Company rights to access certain metabolic inhibitor technology owned by
MD Anderson that had been licensed to IntertechBio. The shares were valued at a total of $630 and the related expense included
in research and development costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On August 21, 2015, the Company acquired
the right to the intellectual property of AnnaMed in exchange for 1,431,000 shares of the Company's common stock. The license
gives the Company full ownership rights to the data package supporting the FDA IND Number 46869, allowing the Company to resubmit
a request for IND to the FDA to begin development work on Annamycin. The shares were valued at a total of $1,431 and the related
expense included in research and development costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the period from
January 1, 2016 through May 2, 2016, the Company sold 234,297 common shares for $702,894. These shares are subject to the following
lock-up agreement, from and after the later of six months after issuance or 90 days from the effective date of our IPO registration
statement until the one-year anniversary thereof, (a) the holder of the shares can sell up to 10% of the purchased shares per month,
subject to a maximum sale on any trading day of 8% of the daily volume of the common stock; (b) if the common stock price is over
$7.00 per share for five consecutive trading days then the holder of the shares can sell up to 20% of the purchased shares per
month, subject to a maximum sale on any trading day of 10% of the daily volume of the common stock; and (c) if the common stock
price is over $12.00 per share then the holder of the shares is not restricted from making any sales until such time as the common
stock price falls back below $12.00 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 20, 2016, the
Company agreed to issue 24,000 shares of common stock to PCG Advisory Group, the Company&rsquo;s investor relations firm, for services
provided. The fair value of these shares was $157,680 based on the market price on the grant date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-align: justify"><B>Adoption of 2015 Stock Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 5, 2015,
the Board of Directors of the Company approved the Company&rsquo;s 2015 Stock Plan, which was amended on April&nbsp;22,&nbsp;2016.
The expiration date of the plan is December 5, 2025 and the total number of underlying shares of the Company&rsquo;s common stock
available for grant to employees, directors and consultants under the plan is 2,500,000 shares. The awards under the 2015 Stock
Plan can be in the form of stock options, stock awards or stock unit awards. The following is a summary of option activities for
the periods ended December 31, 2015 and 2016:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Number of<BR> Shares</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; border-bottom: Black 1pt solid; text-align: center">Weighted Average Grant Date Fair Value</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Weighted<BR> Average<BR> Exercise<BR> Price</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Weighted<BR> Average<BR> Remaining<BR> Contractual<BR> Term<BR> (in years)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Aggregate<BR> Intrinsic<BR> Value</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; font-size: 10pt">Granted&nbsp;- 2015</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; width: 1%">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; width: 10%">200,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">0.14</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">0.20</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">Outstanding, December 31, 2015</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">200,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.14</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.20</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">Granted &nbsp;- 2016</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">460,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3.75</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5.83</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">Cancelled</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(150,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.14</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.20</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">Outstanding, December 31, 2016</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">510,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">$</TD><TD STYLE="font-size: 10pt; text-align: right; padding-bottom: 1pt">3.40</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">$</TD><TD STYLE="font-size: 10pt; text-align: right; padding-bottom: 1pt">5.28</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-bottom: 1pt">9.29</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">$</TD><TD STYLE="font-size: 10pt; text-align: right; padding-bottom: 1pt">275,500</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">Exercisable, December 31, 2016</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">50,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">$</TD><TD STYLE="font-size: 10pt; text-align: right; padding-bottom: 1pt">0.14</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">$</TD><TD STYLE="font-size: 10pt; text-align: right; padding-bottom: 1pt">0.20</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-bottom: 1pt">3.67</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">$</TD><TD STYLE="font-size: 10pt; text-align: right; padding-bottom: 1pt">275,500</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended
December 31, 2016, the Company granted an officer and its board of directors&rsquo; options, in the aggregate, to purchase 460,000
shares of the Company&rsquo;s common stock with an exercise price ranging from $5.71 per share to $5.85 per share, a term of 10
years, and a vesting period of 3 to 4 years.&nbsp;The exercise price was based upon the closing price of the stock on the day of
the grant. The options have an aggregated fair value of $1,772,422 that was calculated using the Black-Scholes option-pricing model.
Variables used in the Black-Scholes option-pricing model include: (1) discount of 1.30% (2) expected lives of 6 to 6.25 years,
(3) expected volatility of 70.18% to 70.44%, and (4) zero expected dividends. The Company, due to the limited number of participants
in the plan and their positions within the Company, uses a 0% estimated forfeiture rate. During the year ended December 31, 2016,
the Company recorded $166,294 in stock-based compensation in relation to these options. As of December 31, 2016, there was $1,565,599
of unrecognized compensation cost, net of estimated forfeitures, related to the Company&rsquo;s non-vested equity awards, which
is expected to be recognized over a weighted average period of 3.7 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair value of each
stock option is estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted in
the above paragraph and table. The expected term of the options was computed using the &ldquo;plain vanilla&rdquo; method as prescribed
by the Securities and Exhange Commission Staff Accounting Bulletin 107 because we do not have suffient data regarding employee
exercise behavior to estimate the expected term. The volatility was determined by referring to the average historical volatility
of a peer group of public companies because we do not have sufficient trading history to determine our historical volatility. The
risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the
time of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company entered
into a separation agreement with its former Chief Financial Officer in October 2016 and as part of the agreement, options to purchase
150,000 shares of common stock issued to the former Chief Financial Officer were cancelled and the vesting was accelerated on
the remaining options to purchase 50,000 shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">6.</TD><TD STYLE="text-align: justify">Income Taxes</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The provision for income
taxes consists of the following components (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">December 31,<BR> 2016</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">December 31,<BR> 2015</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Current Expense (Benefit):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 66%; padding-left: 9pt">Federal</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">0</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">0</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt">State</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Current Income Tax Expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Deferred Expense (Benefit):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">Federal</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt">State</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Deferred Income Tax Expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net Deferred Taxes</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following summarizes
activity related to the Company&rsquo;s valuation allowance (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">December 31,<BR> 2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">December 31,<BR> 2015</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 66%; text-align: left">Valuation Allowance at Beginning of Period</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">155</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">0</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Income Tax Benefit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,242</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">155</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Release of Valuation Allowance</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Valuation Allowance at End of Period</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,397</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">155</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A reconciliation of
the income tax benefit computed using the federal statutory income tax rate to the Company&rsquo;s effective income tax rate is
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; border-bottom: Black 1pt solid; text-align: center">December 31,
    2016</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; border-bottom: Black 1pt solid; text-align: center">December 31,
    2015</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Percent</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Percent</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; width: 48%">Federal Tax Benefit at Statutory Rate</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">1,335</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">34.00</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">%</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">254</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">34.00</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">State Tax Benefit Net of Federal</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">137</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3.48</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.00</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">IPO Costs</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(227</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(5.78</TD><TD STYLE="font-size: 10pt; text-align: left">)%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(99</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(13.24</TD><TD STYLE="font-size: 10pt; text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other Permanent Differences</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(3</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(0.08</TD><TD STYLE="font-size: 10pt; text-align: left">)%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.00</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Increase in Valuation Allowance</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,242</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(31.62</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)%</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(155</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(20.76</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total Tax (Expense) / Benefit</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">0</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">0.00</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">%</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">0</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">0.00</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">%</TD></TR>
</TABLE>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The principal components
of the Company&rsquo;s deferred tax assets and liabilities consist of the following at December 31, 2016 and 2015 (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">December 31,<BR> 2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">December 31,<BR> 2015</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Deferred Tax Assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 66%; text-align: left; padding-left: 9pt">Start Up Costs</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">798</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">67</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Federal Net Operating Loss Carryforwards</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">520</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">89</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">State Tax Loss Carryforwards</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Deferred Compensation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">33</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total Deferred Tax Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,401</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">155</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Less Valuation Allowance</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,397</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(155</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net Deferred Tax Assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Deferred Tax Liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Fixed Assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total Deferred Tax Liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net Deferred Taxes</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has incurred
net operating losses since inception. As of December 31, 2016, the Company had total federal operating loss carry forwards of
approximately $1.53 million which expire commencing in 2035. The value of these carryforwards depends on the Company&rsquo;s ability
to generate taxable income. Additionally, because federal tax laws limit the time during which the net operating loss carryforwards
may be applied against future taxes, if the Company fails to generate taxable income prior to the expiration dates of the carry
forwards the Company may not be able to fully utilize the net operating loss carryforwards to reduce future income taxes. Finally,
the Company has not undertaken a detailed analysis of the application of IRC Section 382 with respect to limitations on the utilization
of net operating loss carryforwards and other deferred tax assets. However, the Company believes that this matter is not material
to the overall tax position within the financial statements due to the full valuation allowance against the net operating losses
and the lack of utilization of the net operating losses during tax years open under statute.</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company conducts
business in various locations and, as a result, files income tax returns in the United States Federal jurisdiction and in multiple
state jurisdictions. As of December 31, 2016, the Company had state operating losses of approximately $1.27 million which expire
commencing in 2036. Since the Company is in a loss carryforward position, the Company is generally subject to examination by the
U.S. federal, state and local income tax authorities for all tax years in which a loss carryforward is available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Management has evaluated
the positive and negative evidence bearing upon the realizability of its deferred tax assets. The Company has cumulative losses
and there is no assurance of future taxable income, therefore, valuation allowances have been recorded to fully offset the deferred
tax asset at December 31, 2016. Management has determined that it is more likely than not that the Company will not recognize the
benefits of its federal and state deferred tax assets, and as a result, a valuation allowance of $1.40 million and $0.16 million
has been established at December 31, 2016 and 2015, respectively. The change in the valuation allowance for the year ended December
31, 2016 was primary due to additional operating losses and capitalized research costs. The Company may be eligible to claim research
and development tax credits in the future, but has not conducted a study to date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no unrecognized
tax benefits from any federal, state or foreign jurisdictions. The only tax year open under statute for the Company is December
31, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&rsquo;s
policy is to recognize interest and penalties related to any unrecognized tax liabilities as additional tax expense. No interest
or penalties have been accrued at December 31, 2016 and 2015, as the Company has not recorded any uncertain tax positions. The
Company believes it has appropriate and adequate support for the income tax positions taken and to be taken on its tax returns
and that its accruals for tax liabilities are adequate for all open years based on an assessment of many factors including past
experience and interpretations of tax law applied to the facts of each matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although the Company
believes its recorded assets and liabilities are reasonable, tax regulations are subject to interpretation and tax litigation is
inherently uncertain; therefore the Company&rsquo;s assessments can involve both a series of complex judgments about future events
and rely heavily on estimates and assumptions. Although the Company believes that the estimates and assumptions supporting its
assessments are reasonable, the final determination of tax audit settlements and any related litigation could be materially different
from that which is reflected in historical income tax provisions and recorded assets and liabilities. If the Company were to settle
an audit or a matter under litigation, it could have a material effect on the income tax provision, net income, or cash flows in
the period or periods for which that determination is made. Any accruals for tax contingencies are provided for in accordance with
U.S. GAAP<I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT>The
Company does not believe that its tax positions will significantly change due to any settlement and/or expiration of statutes of
limitations prior to&nbsp;December&nbsp;31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">7.</TD><TD STYLE="text-align: justify">Commitments and Contingencies</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt"><B>MD Anderson &ndash; IntertechBio Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 11, 2015,
the Company acquired the rights and obligations under the Patent and Technology License Agreement entered into between IntertechBio
and MD Anderson dated April 2, 2012. Pursuant to the agreement, IntertechBio obtained a royalty-bearing, worldwide, exclusive license
to intellectual property including patent rights related to the Company&rsquo;s drug product candidate, WP1122. Under the agreement,
IntertechBio agreed to pay annual maintenance fees in the amount of $10,000 on the first anniversary of the effective date of the
agreement, $20,000 on the second anniversary of the effective date of the agreement, $40,000 on the third anniversary of the effective
date of the agreement, $60,000 on the fourth anniversary of the effective date of the agreement, $80,000 on the fifth anniversary
of the effective date of the agreement and $100,000 on the sixth anniversary of the effective date of the agreement, except that
such payments will no longer be due upon the first sale of a licensed product. Under the agreement, IntertechBio also agreed to
make a minimum annual royalty payment in the amount of $200,000 for the first anniversary following the first sale of a licensed
product, $400,000 for the second anniversary following the first sale of a licensed product, and $600,000 for the third year following
the first sale of a licensed product. IntertechBio also agreed to make certain milestone payments. Pursuant to an amendment on
October 19, 2015, the Company will pay milestone payments as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Phase</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 80%; text-align: left; padding-left: 18.7pt">Commencement of Phase II Study for a licensed product</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">200,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 18.7pt">Commencement of Phase III Study for a licensed product</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">250,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 18.7pt">Filing of a New Drug Application for a licensed product</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">400,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 18.7pt">Receipt of market approval for a licensed product</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Per the October 2015
amendment to the agreement, MD Anderson has the right to terminate the license agreement if (i) a preclinical toxicology program
for a licensed product is not initiated within one year of the effective date of the amendment (which has occurred), (ii) an investigational
new drug application is not filed with the Food and Drug Administration for a Phase I study for a licensed product within three
years of the effective date of the amendment, or (iii) a Phase I study for a licensed product is not commenced within five years
of the effective date of the amendment. The agreement will expire upon the expiration of the licensed intellectual property. The
rights obtained by the Company pursuant to the agreement are made subject to the rights of the U.S. government to the extent that
the technology covered by the licensed intellectual property was developed under a funding agreement between MD Anderson and the
U.S. government. All out-of-pocket expenses incurred by MD Anderson in filing, prosecuting and maintaining the licensed patents
have been and shall continue to be assumed by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 8, 2015,
IntertechBio Corporation entered into a letter agreement with MD Anderson wherein MD Anderson agreed to receive past due maintenance
fees and patent expenses of $98,108 owed by IntertechBio Corporation in four installments. The past due amount is related to certain
metabolic inhibitor technology license that was assigned to the Company by IntertechBio Corporation and was owed by IntertechBio
Corporation prior to the Company&rsquo;s acquisition of the license. Pursuant to the letter, IntertechBio Corporation also agreed
to pay $65,504 in patent fees to a law firm. In order to have the license in good standing, the Company agreed to pay MD Anderson
the $98,108 and the $65,504 in patent fees to a patent law firm on behalf of IntertechBio Corporation. As of December 31, 2015,
$45,000 of the past due amount to MD Anderson and $42,504 in patent fees to a patent law firm were still outstanding and were included
in accounts payable and accrued liabilities. On April 15, 2016, the Company entered into a letter agreement with MD Anderson where
MD Anderson agreed to receive the remaining outstanding amount on or before the earlier of a) May 31, 2016 or b) four days after
the Company&rsquo;s completion of the IPO. These amounts were paid prior to or on May 31, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-align: justify"><B>MD Anderson &ndash; Patent
&amp; Technology License Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the Company&rsquo;s
acquisition of Moleculin, LLC on May 2, 2016, we obtained a royalty-bearing, worldwide, exclusive license to intellectual property
rights, including patent rights related to our WP1066 drug product candidate from MD Anderson through a Patent and Technology License
Agreement Moleculin, LLC entered with MD Anderson on June&nbsp;21, 2010 (the &ldquo;Moleculin License Agreement&rdquo;). Under
the Moleculin License Agreement, Moleculin, LLC obtained the right to manufacture, have manufactured, use, import, offer to sell
or sell products worldwide for any indication under the licensed intellectual property with the right to sublicense. In consideration,
Moleculin, LLC agreed to make payments to MD Anderson including an up-front payment, milestone payments and minimum annual royalty
payments for sales of products developed under the license agreement. Specifically, under the Moleculin License Agreement, Moleculin,
LLC agreed to pay a nonrefundable upfront documentation fee and an annual maintenance fee in the amount of $20,000 on June 21,
2011, which has and shall increase in $10,000 increments on an annual basis thereafter up to a maximum of $100,000, except that
such payments will no longer be due upon marketing approval in any country of a licensed product. Under the Moleculin License Agreement,
Moleculin, LLC also agreed to make a minimum annual royalty payment.<FONT STYLE="font-size: 10pt"> </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon completion of
our acquisition of Moleculin, LLC, we assumed the rights and obligations of Moleculin, LLC. However, the rights we have obtained
pursuant to the assignment of the Moleculin License Agreement are made subject to the rights of the U.S. government to the extent
that the technology covered by the licensed intellectual property was developed under a funding agreement between MD Anderson and
the U.S. government. All out-of-pocket expenses incurred by MD Anderson in filing, prosecuting and maintaining the licensed patents
have been and shall continue to be assumed by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 8, 2015,
Moleculin, LLC entered into a letter agreement with MD Anderson for Moleculin, LLC&rsquo;s past due fees to MD Anderson in the
amount of $691,186 of which $300,000 had been paid prior to the letter agreement. Pursuant to the letter agreement, MD Anderson
agreed to receive the remaining past due fee in three installments: a) $125,000 on October 31, 2015; b) $175,000 on January 31,
2016; and c) $91,186 on April 30, 2016. Moleculin, LLC paid $125,000 to MD Anderson on November 2, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 19, 2015,
the agreement was amended for the milestone payments. The amended milestone payments are as follows: (i) commencement of Phase
III Study for first licensed drug/product within the United States, Europe, China or Japan - $150,000; (ii) submission of the
first NDA within the United States - $500,000; and (iii) receipt of first marketing approval for sale of a license product in
the United States<FONT STYLE="font-size: 10pt">&nbsp;</FONT>- $600,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 28, 2016,
the Company and Moleculin, LLC entered into a letter agreement with MD Anderson where MD Anderson agreed to receive the remaining
outstanding amount on or before the earlier of April 30, 2016 or four days after our IPO. This date was amended and per the amended
agreement, the Company paid the outstanding Moleculin, LLC fees on May 31, 2016 in the amount of $306,186 in cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-align: justify"><B>Bonwick Capital Partners
LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 22, 2016,
as amended on February 15, 2016, the Company entered into a letter agreement with Bonwick Capital Partners LLC. (&ldquo;Bonwick&rdquo;)
to engage Bonwick as an exclusive financial advisor of the Company. Pursuant to the agreement, the Company agreed to: a) pay success
fees equal to 7% of the gross proceeds from any form of financing; and b) issue five-year warrants to purchase 7% of the Company&rsquo;s
equity securities sold with a cashless exercise provision, exercisable at 125% of the price per share of the Company&rsquo;s common
stock paid by investors in the transaction. In addition, the Company agreed to reimburse Bonwick for all of its out-of-pocket expenses
incurred in connection with the offering, not to exceed $25,000, and fees and expenses of their counsel not to exceed $100,000.
Upon completion of the Company&rsquo;s IPO, the Company paid Bonwick a $50,000 advisory fee. In connection with the Company&rsquo;s
IPO, Bonwick received a success fee of $646,872, warrants to purchase 107,802 shares of common stock at an exercise price of $7.50
per share, and $6,266 for reimbursement of expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-align: justify"><B>Houston Pharmaceuticals,
Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our acquisition of
Moleculin, LLC, occurring prior to our IPO offering, provided us with the rights of the license agreement that Moleculin, LLC had
with MD Anderson covering the WP1066 Portfolio. As discussed in Note 2, we are obligated to make payments to HPI totaling $750,000
over a three-year period commencing after the IPO offering in exchange for HPI allowing us to access any data, information or know-how
resulting from the research and development conducted by HPI. Pursuant to the HPI Out-Licensing Agreement, we have the right within
three years of the date we enter into the agreement to buy-out from HPI all rights granted to HPI under the agreement for a payment
of $1.0 million. Upon our exercise of the buy-out we will no longer be obligated to make any payments to HPI remaining from the
$750,000 obligation discussed above. We will need to raise additional funds to make the buy-out payment. We cannot assure that
such additional funding will be available on satisfactory terms, or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.7pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.7pt"><B>Employment
Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.7pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 19, 2016,
the Company entered into an employment agreement with Mr. Jonathan P. Foster pursuant to which Mr. Foster agreed to serve as Chief
Financial Officer and Executive Vice President of the Company commencing on such date for an initial term of three years, which
will be automatically renewed for additional one-year terms unless either party chooses not to renew the agreement. The agreement
provides for an annual salary of $250,000, a potential annual bonus, ten-year options to purchase 400,000 shares at an exercise
price per share equal to the closing price of the Company&rsquo;s common stock on the date of execution of his employment agreement,
which was $5.85. The options vest in four equal installments. Termination payments may be made under certain conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company accepted
the resignation of Mr. Louis Ploth from his position as Chief Financial Officer, effective on August 19, 2016. On October 7, 2016,
the Company entered into a separation agreement with Mr. Louis Ploth (the &ldquo;Separation Agreement&rdquo;), pursuant to which,
among other items, Mr. Ploth generally released the Company from any claims he may have against the Company or its affiliates,
and the Company agreed to pay Mr. Ploth a severance payment of $100,000 over a 12-month period and to pay his medical insurance
premiums until August 31, 2017. Pursuant to the Separation Agreement, Mr. Ploth will be permitted to exercise 25% of the options
to purchase common stock granted to him in December 2015, or 50,000 shares, until May 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 13, 2016,
the Company and its Chief Executive Officer, Walter Klemp, entered into an employment agreement which provides for an annual salary
of $300,000, of which some is deferred, and a potential annual bonus. During the period commencing June 1, 2016 and ending June
1, 2017, $12,500 per month of the compensation is deferred. The deferred compensation shall be payable in a lump sum on the earlier
of the termination of the employment agreement or June 1, 2019. As of December 31, 2016, deferred compensation of $87,500 was
recorded in the accompanying balance sheet. If Mr. Klemp&rsquo;s employment is terminated, his status reverts to a consultant
and payments to him would continue until June 1, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">8.</TD><TD STYLE="text-align: justify">Subsequent Events</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 9, 2017,
we entered into an Underwriting Agreement (the &ldquo;Underwriting Agreement&rdquo;) with Roth Capital Partners, LLC, as representative
of the several underwriters identified therein (collectively, the &ldquo;Underwriters&rdquo;), pursuant to which we sold in a registered
public offering (the &ldquo;Offering&rdquo;), 3,710,000 units, priced at a public offering price of $1.35 per unit, with each unit
consisting of: (i) one share of common stock, (ii) a five-year Series A warrant to purchase 0.50 of a share of common stock, (iii)
a 90-day Series B warrant to purchase one share of common stock, and (iv) a five-year Series C warrant to purchase 0.50 of a share
of common stock. The Series C warrants in a unit may only be exercised to the extent and in proportion to a holder of the Series
C warrants exercising its Series B warrants included in the unit. The Series A and Series C warrant have an exercise price of $1.50
per share of common stock. The Series B warrant has an exercise price of $1.35 per share of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the terms of
the Underwriting Agreement, we granted the Underwriters a 45-day option to purchase an additional 556,500 shares of common stock
and/or an additional 556,500 warrant combinations (comprised of an aggregate of 278,250 Series A warrants, 556,500 Series B warrants
and 278,250 Series C warrants), in any combinations thereof, from us to cover over-allotments at the public offering price per
share of $1.349 and public offering price per warrant combination of $.001, respectively, less the underwriting discounts and
commissions. Upon the closing of the Offering, the Underwriters exercised the over-allotment option with respect to 278,100 warrant
combinations. We received approximately $4.4 million in net proceeds from the Offering, after deducting underwriting discounts
and commissions and estimated offering expenses.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 21, 2017,
we received notice that FDA had granted us Orphan Drug designation for Annamycin for the treatment of AML.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subsequent to March
22, 2017, investors in the aforementioned offering on February 9, 2017, have excerised approximately 600,000 Series B warrants
resulting in approximately gross proceeds to the Company of $800,000 and approximately 600,000 shares of the Company&rsquo;s common
stock being issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 13, 2017,
the Company issued to two of its Science Advisory Board (&ldquo;SAB&rdquo;) members 10,000 options each with an excerise price
of $2.31 with 3-year annual vesting and 79,167 shares to a former SAB member to settle an accounts payable of $237,500 in past
due amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 83 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of Section
13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <td colspan="2">MOLECULIN BIOTECH, INC.</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="width: 55%">&nbsp;</td>
    <TD STYLE="width: 4%">&nbsp;</td>
    <TD STYLE="width: 41%">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>By:</td>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Walter V. Klemp</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>Walter V. Klemp,</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>Chief Executive Officer and Chairman</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: April 3, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, this report has been signed by the following persons on behalf of the Registrant in the capacities and on
the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 35%; border-bottom: Black 1pt solid">Signature</td>
    <TD STYLE="width: 2%">&nbsp;</td>
    <TD STYLE="width: 37%; border-bottom: Black 1pt solid">Title</td>
    <TD STYLE="width: 2%">&nbsp;</td>
    <TD STYLE="width: 24%; border-bottom: Black 1pt solid">Date</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Walter V. Klemp</td>
    <TD>&nbsp;</td>
    <TD>Chief Executive Officer and&nbsp;&nbsp;Chairman</td>
    <TD>&nbsp;</td>
    <TD>April 3, 2017</td></tr>
<tr style="vertical-align: top">
    <TD>Walter Klemp</td>
    <TD>&nbsp;</td>
    <TD>(Principal Executive Officer)</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Jonathan P. Foster</td>
    <TD>&nbsp;</td>
    <TD>Executive Vice President Officer and</td>
    <TD>&nbsp;</td>
    <TD>April 3, 2017</td></tr>
<tr style="vertical-align: top">
    <TD>Jonathan P. Foster</td>
    <TD>&nbsp;</td>
    <TD>Chief Financial Officer</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>(Principal Financial and Accounting Officer)</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Donald Picker</td>
    <TD>&nbsp;</td>
    <TD>President and Chief Operating Officer</td>
    <TD>&nbsp;</td>
    <TD>April 3, 2017</td></tr>
<tr style="vertical-align: top">
    <TD>Donald Picker</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Robert George</td>
    <TD>&nbsp;</td>
    <TD>Director</td>
    <TD>&nbsp;</td>
    <TD>April 3, 2017</td></tr>
<tr style="vertical-align: top">
    <TD>Robert George</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Michael Cannon</td>
    <TD>&nbsp;</td>
    <TD>Director</td>
    <TD>&nbsp;</td>
    <TD>April 3, 2017</td></tr>
<tr style="vertical-align: top">
    <TD>Michael Cannon</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Jacqueline Northcut</td>
    <TD>&nbsp;</td>
    <TD>Director</td>
    <TD>&nbsp;</td>
    <TD>April 3, 2017</td></tr>
<tr style="vertical-align: top">
    <TD>Jacqueline Northcut</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 84; Options: NewSection; Value: 58 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <TD STYLE="vertical-align: bottom; width: 12%; border-bottom: Black 1pt solid; text-align: center"><b>Exhibit</b><br>
<b>Number</b></td>
    <TD STYLE="vertical-align: top; width: 2%; text-align: center">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; width: 86%; border-bottom: Black 1pt solid; text-align: center"><b>Description</b></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">3.1</td>
    <TD>&nbsp;</td>
    <TD>Amended and Restated Certificate of Incorporation of Moleculin Biotech, Inc. (incorporated by reference to exhibit 3.1 of the Form S-1/A filed March 21, 2016)</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">3.2</td>
    <TD>&nbsp;</td>
    <TD>Amended and Restated Bylaws of Moleculin Biotech, Inc. (incorporated by reference to exhibit 3.2 of the Form S-1/A filed March 21, 2016)</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">4.1</td>
    <TD>&nbsp;</td>
    <TD>Form of Series A/B/C Warrant Agreement issued in February 2017 offering (incorporated by reference to Exhibit 4.1 of the Form 8-K filed February 9, 2017)</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">10.1 **</td>
    <TD>&nbsp;</td>
    <TD>Moleculin Biotech, Inc. 2015 Incentive Plan (incorporated by reference to exhibit 10.1 of the Form S-1/A filed March 21, 2016)</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">10.2</td>
    <TD>&nbsp;</td>
    <TD>Rights Transfer Agreement between Moleculin Biotech, Inc. and AnnaMed, Inc. (incorporated by reference to exhibit 10.2 of the Form S-1/A filed March 21, 2016)</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>10.3</td>
    <TD>&nbsp;</td>
    <TD>Patent and Technology License Agreement dated June 21, 2010 by and between The Board of Regents of the University of Texas System and Moleculin, LLC (incorporated by reference to exhibit 10.3 of the Form S-1/A filed March 21, 2016)</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>10.4</td>
    <TD>&nbsp;</td>
    <TD>Amendment No. 1 to the Patent and Technology License Agreement dated June 21, 2010 by and between The Board of Regents of the University of Texas System and Moleculin, LLC (incorporated by reference to exhibit 10.4 of the Form S-1/A filed March 21, 2016)</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>10.5</td>
    <TD>&nbsp;</td>
    <TD>Patent and Technology License Agreement dated April 2, 2012 by and between The Board of Regents of the University of Texas System and IntertechBio Corporation (incorporated by reference to exhibit 10.5 of the Form S-1/A filed March 21, 2016)</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>10.6</td>
    <TD>&nbsp;</td>
    <TD>Amendment No. 1 to the Patent and Technology License Agreement dated June 21, 2010 by and between The Board of Regents of the University of Texas System and IntertechBio Corporation (incorporated by reference to exhibit 10.6 of the Form S-1/A filed March 21, 2016)</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>10.7</td>
    <TD>&nbsp;</td>
    <TD>Patent and Technology Development and License Agreement June 28, 2012 by and between Annamed, Inc. and Dermin Sp. z.o.o (incorporated by reference to exhibit 10.7 of the Form S-1/A filed April 15, 2016)</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>10.8</td>
    <TD>&nbsp;</td>
    <TD>Patent and Technology Development and License Agreement dated April 15, 2011 by and between IntertechBio Corporation and Dermin Sp. z.o.o (incorporated by reference to exhibit 10.8 of the Form S-1/A filed March 21, 2016)</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>10.9</td>
    <TD>&nbsp;</td>
    <TD>Patent and Technology Development and License Agreement dated October 27, 2010 by and between Moleculin, LLC and Dermin Sp. z.o.o (incorporated by reference to exhibit 10.9 of the Form S-1/A filed March 21, 2016)</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>10.10</td>
    <TD>&nbsp;</td>
    <TD>Rights Transfer Agreement dated between Moleculin Biotech, Inc. and IntertechBio Corporation dated August 11, 2015 (incorporated by reference to exhibit 10.10 of the Form S-1/A filed March 21, 2016)</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>10.11</td>
    <TD>&nbsp;</td>
    <TD>Agreement and Plan of Merger between Moleculin Biotech, Inc. and Moleculin, LLC (incorporated by reference to exhibit 10.11 of the Form S-1/A filed March 21, 2016)</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>10.12</td>
    <TD>&nbsp;</td>
    <TD>Technology Rights and Development License Agreement to be entered into by Moleculin Biotech, Inc. and Houston Pharmaceuticals, Inc. (incorporated by reference to exhibit 10.13 of the Form S-1/A filed April 15, 2016)</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>10.13 **</td>
    <TD>&nbsp;</td>
    <TD>Employment Agreement between Moleculin Biotech, Inc. and Jonathan P. Foster dated August 19, 2016 (incorporated by reference to Exhibit 10.1 of the Form 8-K filed August 25, 2016)</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 85; Value: 58 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 12%">10.14 **</td>
    <TD STYLE="width: 2%">&nbsp;</td>
    <TD STYLE="width: 86%">Executive Employment Agreement between Moleculin Biotech, Inc. and Walter Klemp dated October 13, 2016 (incorporated by reference to Exhibit 10.1 of the Form 8-K filed October 13, 2016)</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>10.15 **</td>
    <TD>&nbsp;</td>
    <TD>General Release and Separation Agreement between Moleculin Biotech, Inc. and Louis Ploth dated October 7, 2016 (incorporated by reference to Exhibit 10.2 of the Form 8-K filed October 13, 2016)</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>10.16</td>
    <TD>&nbsp;</td>
    <TD>Development Collaboration Agreement between Moleculin Biotech, Inc. and Dermin Sp. Z o. o. dated September 30, 2016 (incorporated by reference to Exhibit 10.4 of the Form 10-Q filed November 21, 2016)</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>21</td>
    <TD>&nbsp;</td>
    <TD>Subsidiaries of the Registrant (incorporated by reference to exhibit 21 of the Form S-1/A filed April 15, 2016)</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>23.1*</td>
    <TD>&nbsp;</td>
    <TD>Consent of GBH CPAs, PC</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>23.2*</td>
    <TD>&nbsp;</td>
    <TD>Consent of Grant Thornton, LLP</td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>31.1*</TD>
    <TD>&nbsp;</TD>
    <TD>Certification of Principal Executive Officer Pursuant to Section 302 of Sarbanes-&#9;Oxley Act of 2002</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>31.2*</TD>
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certification of Principal Financial Officer Pursuant
to Section 302 of Sarbanes-Oxley Act of 2002</P>



</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>32.1*</TD>
    <TD>&nbsp;</TD>
    <TD>Certification of Principal Executive Officer Pursuant to Section 18 U.S.C. Section 1350, as Adopted Pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>32.2*</TD>
    <TD>&nbsp;</TD>
    <TD>Certification of Principal Financial Officer Pursuant to Section 18 U.S.C. Section 1350, as Adopted Pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002</TD></TR>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>101.INS *</td>
    <TD>&nbsp;</td>
    <TD>XBRL Instance Document</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>101.SCH *</td>
    <TD>&nbsp;</td>
    <TD>XBRL Taxonomy Extension Schema Document</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>101.CAL *</td>
    <TD>&nbsp;</td>
    <TD>XBRL Taxonomy Extension Calculation Linkbase Document</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>101.DEF *</td>
    <TD>&nbsp;</td>
    <TD>XBRL Taxonomy Extension Definition Linkbase Document</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>101.LAB *</td>
    <TD>&nbsp;</td>
    <TD>XBRL Taxonomy Extension Label Linkbase Document</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>101.PRE *</td>
    <TD>&nbsp;</td>
    <TD>XBRL Taxonomy Extension Presentation Linkbase Document</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">*</TD><TD>Filed herewith.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">**</TD><TD>Denotes a management contract or compensatory plan or arrangement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 86; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>v462503_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the Board of Directors<B>, </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We hereby consent to the incorporation by reference in the Registration
Statement on Form S-8 (No. 333-212619) of our report dated March 21, 2016 relating to the financial statements of Moleculin Biotech,
Inc. as of December 31, 2015 and for the period from July 28, 2015 (Inception) to December 31, 2015 which appears in this Annual
Report on Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">/s/ GBH CPAs, PC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">GBH CPAs, PC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">www.gbhcpas.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Houston, Texas</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April 3, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>3
<FILENAME>v462503_ex23-2.htm
<DESCRIPTION>EXHIBIT 23.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 23.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have issued our report dated April 3, 2017, with respect
to the financial statements included in the Annual Report of Moleculin Biotech, Inc. on Form 10-K for the year ended December 31,
2016. We hereby consent to the incorporation by reference of said report in the Registration Statement of Moleculin Biotech, Inc.
on Form S-8 (File No. 333-212619).</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/GRANT THORNTON LLP&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Houston, Texas</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April 3, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>v462503_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>OFFICER&rsquo;S CERTIFICATION PURSUANT
TO</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SECTION 302 OF THE SARBANES-OXLEY
ACT OF 2002</U></B></P>

<P STYLE="color: #000033; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Walter Klemp, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. I have reviewed this Annual Report on
Form 10-K of Moleculin Biotech, Inc.;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Based on my knowledge, this report does
not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. Based on my knowledge, the financial
statements, and other financial information included in this report, fairly present in all material respects the financial condition,
results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. The registrant's other certifying officer
and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">a) Designed such disclosure controls and
procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information
relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">b) Designed such internal control over
financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">c) Evaluated the effectiveness of the registrant's
disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls
and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">d) Disclosed in this report any change
in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal
quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably
likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. The registrant's other certifying officer
and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors
and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">a) All significant deficiencies and material
weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect
the registrant's ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">b) Any fraud, whether or not material,
that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April 3, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>By: /s/ Walter Klemp&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Walter Klemp</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Principal Executive Officer)</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>v462503_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>OFFICER&rsquo;S CERTIFICATION PURSUANT
TO</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SECTION 302 OF THE SARBANES-OXLEY
ACT OF 2002</U></B></P>

<P STYLE="color: #000033; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Jonathan Foster, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. I have reviewed this Annual Report on
Form 10-K of Moleculin Biotech, Inc.;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Based on my knowledge, this report does
not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. Based on my knowledge, the financial
statements, and other financial information included in this report, fairly present in all material respects the financial condition,
results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. The registrant's other certifying officer
and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">a) Designed such disclosure controls and
procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information
relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">b) Designed such internal control over
financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">c) Evaluated the effectiveness of the registrant's
disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls
and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">d) Disclosed in this report any change
in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal
quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably
likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. The registrant's other certifying officer
and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors
and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">a) All significant deficiencies and material
weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect
the registrant's ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">b) Any fraud, whether or not material,
that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April 3, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>By: /s/ Jonathan Foster&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jonathan Foster</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Principal Financial Officer and Principal Accounting Officer)</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>v462503_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTIFICATION PURSUANT TO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">18 U.S.C. SECTION 1350,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AS ADOPTED PURSUANT TO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Annual Report on
Form 10-K for the fiscal year ended December 31, 2016 of Moleculin Biotech, Inc. (the &ldquo;Company&rdquo;) as filed with the
Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Walter Klemp, Chief Executive Officer of the
Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: center; vertical-align: top"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange
Act of 1934 (15 U.S.C 78m or 78o(d)); and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: center; vertical-align: top"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The information contained in the Report fairly presents, in all material respects, the financial
condition and results of operations of the Company.</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: April 3, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>By: /s/ Walter Klemp &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Walter Klemp</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Principal Executive Officer)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>A signed original of this written statement required by Section
906 has been provided to Moleculin Biotech, Inc. and will be retained by Moleculin Biotech, Inc. and furnished to the Securities
and Exchange Commission or its staff upon request.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>v462503_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTIFICATION PURSUANT TO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">18 U.S.C. SECTION 1350,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AS ADOPTED PURSUANT TO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Annual Report on
Form 10-K for the fiscal year ended December 31, 2016 of Moleculin Biotech, Inc. (the &ldquo;Company&rdquo;) as filed with the
Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Jonathan Foster, Chief Financial Officer of
the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: center; vertical-align: top"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange
Act of 1934 (15 U.S.C 78m or 78o(d)); and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: center; vertical-align: top"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The information contained in the Report fairly presents, in all material respects, the financial
condition and results of operations of the Company.</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: April 3, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>By: /s/ Jonathan Foster&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jonathan Foster</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Principal Financial Officer and Principal Accounting Officer)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>A signed original of this written statement required by Section
906 has been provided to Moleculin Biotech, Inc. and will be retained by Moleculin Biotech, Inc. and furnished to the Securities
and Exchange Commission or its staff upon request.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>8
<FILENAME>mbrx-20161231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.9 on 02-Apr-2017 [12:25:26] {PM} EST - www.datatracks.com -->
<!-- Based on XBRL 2.1 -->
<xbrli:xbrl xmlns:mbrx="http://www.moleculin.com/20161231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2016-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr">
  <link:schemaRef xlink:type="simple" xlink:href="mbrx-20161231.xsd" />

<!--Context Section-->
  <xbrli:context id="P01_01_2015To12_31_2015">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>

      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_24_2017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-03-24</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2016To04_22_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-04-01</xbrli:startDate>

      <xbrli:endDate>2016-04-22</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P05_01_2016To05_02_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-05-01</xbrli:startDate>

      <xbrli:endDate>2016-05-02</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P05_01_2016To05_31_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-05-01</xbrli:startDate>

      <xbrli:endDate>2016-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn05_02_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-05-02</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn05_31_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_28_2015To12_31_2015">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-07-28</xbrli:startDate>

      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P10_01_2015To10_19_2015">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-10-01</xbrli:startDate>

      <xbrli:endDate>2015-10-19</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2015">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn07_27_2015">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-07-27</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2014">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

<!--Dimension Section-->
  <xbrli:context id="P01_01_2016To12_31_2016_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_WarrantMemberusgaapClassOfWarrantOrRightAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_UnsecuredPromissoryNotesMemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbrx:UnsecuredPromissoryNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_IPOMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_IPOMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn05_31_2016_IPOMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P05_01_2016To05_31_2016_IPOMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-05-01</xbrli:startDate>

      <xbrli:endDate>2016-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn05_31_2016_WarrantMemberusgaapClassOfWarrantOrRightAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P05_01_2016To05_31_2016_WarrantMemberusgaapClassOfWarrantOrRightAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-05-01</xbrli:startDate>

      <xbrli:endDate>2016-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn04_22_2016_StockPlanMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mbrx:StockPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-04-22</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_EmployeeAndBoardOfDirectorsMemberusgaapTitleOfIndividualAxis_MinimumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mbrx:EmployeeAndBoardOfDirectorsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_EmployeeAndBoardOfDirectorsMemberusgaapTitleOfIndividualAxis_MaximumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mbrx:EmployeeAndBoardOfDirectorsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_EmployeeAndBoardOfDirectorsMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mbrx:EmployeeAndBoardOfDirectorsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn08_31_2015_PatentAndTechnologyLicenseAgreementMembermbrxAgreementAxis_ServicingFeePayableMemberusgaapOtherCommitmentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="mbrx:AgreementAxis">mbrx:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">mbrx:ServicingFeePayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-08-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn08_31_2015_MinimumAnnualRoyaltyMemberusgaapOtherCommitmentsAxis_PatentAndTechnologyLicenseAgreementMembermbrxAgreementAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="mbrx:AgreementAxis">mbrx:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">mbrx:MinimumAnnualRoyaltyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-08-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_CommencementOfPhaseIiStudyForLicensedProductMemberusgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mbrx:CommencementOfPhaseIiStudyForLicensedProductMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_CommencementOfPhaseIiiStudyForLicensedProductMemberusgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mbrx:CommencementOfPhaseIiiStudyForLicensedProductMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_FilingOfNewDrugApplicationForLicensedProductMemberusgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mbrx:FilingOfNewDrugApplicationForLicensedProductMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_ReceiptOfMarketApprovalForLicensedProductMemberusgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mbrx:ReceiptOfMarketApprovalForLicensedProductMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn10_31_2015_MdAndersonMemberusgaapTitleOfIndividualAxis_MinimumFeeAndPatentExpensesMemberusgaapOtherCommitmentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">mbrx:MinimumFeeAndPatentExpensesMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mbrx:MdAndersonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn10_31_2015_MinimumFeeAndPatentExpensesMemberusgaapOtherCommitmentsAxis_PatentLawFirmMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">mbrx:MinimumFeeAndPatentExpensesMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mbrx:PatentLawFirmMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2015_MdAndersonMemberusgaapTitleOfIndividualAxis_MinimumFeeAndPatentExpensesMemberusgaapOtherCommitmentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">mbrx:MinimumFeeAndPatentExpensesMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mbrx:MdAndersonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2015_MinimumFeeAndPatentExpensesMemberusgaapOtherCommitmentsAxis_PatentLawFirmMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">mbrx:MinimumFeeAndPatentExpensesMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mbrx:PatentLawFirmMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn10_08_2015_MdAndersonMemberusgaapTitleOfIndividualAxis_MinimumFeeAndPatentExpensesMemberusgaapOtherCommitmentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mbrx:MdAndersonMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">mbrx:MinimumFeeAndPatentExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-10-08</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn10_08_2015_MdAndersonMemberusgaapTitleOfIndividualAxis_MinimumAnnualRoyaltyMemberusgaapOtherCommitmentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mbrx:MdAndersonMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">mbrx:MinimumAnnualRoyaltyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-10-08</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P05_01_2016To05_02_2016_PatentAndTechnologyLicenseAgreementMembermbrxAgreementAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="mbrx:AgreementAxis">mbrx:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-05-01</xbrli:startDate>

      <xbrli:endDate>2016-05-02</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn10_31_2015_PatentAndTechnologyLicenseAgreementMembermbrxAgreementAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="mbrx:AgreementAxis">mbrx:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn01_31_2016_PatentAndTechnologyLicenseAgreementMembermbrxAgreementAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="mbrx:AgreementAxis">mbrx:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn04_30_2016_PatentAndTechnologyLicenseAgreementMembermbrxAgreementAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="mbrx:AgreementAxis">mbrx:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P11_01_2015To11_02_2015_PatentAndTechnologyLicenseAgreementMembermbrxAgreementAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="mbrx:AgreementAxis">mbrx:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-11-01</xbrli:startDate>

      <xbrli:endDate>2015-11-02</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P10_01_2015To10_08_2015_LetterAgreementMemberusgaapOtherCommitmentsAxis_PatentAndTechnologyLicenseAgreementMembermbrxAgreementAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">mbrx:LetterAgreementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="mbrx:AgreementAxis">mbrx:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-10-01</xbrli:startDate>

      <xbrli:endDate>2015-10-08</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P10_01_2015To10_08_2015_PatentAndTechnologyLicenseAgreementMembermbrxAgreementAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="mbrx:AgreementAxis">mbrx:PatentAndTechnologyLicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-10-01</xbrli:startDate>

      <xbrli:endDate>2015-10-08</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P05_01_2016To05_31_2016_MoleculinLlcMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mbrx:MoleculinLlcMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-05-01</xbrli:startDate>

      <xbrli:endDate>2016-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P02_01_2016To02_29_2016_BonwickCapitalPartnersLlcMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mbrx:BonwickCapitalPartnersLlcMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-02-01</xbrli:startDate>

      <xbrli:endDate>2016-02-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P02_01_2016To02_29_2016_BonwickCapitalPartnersLlcMemberdeiLegalEntityAxis_MaximumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mbrx:BonwickCapitalPartnersLlcMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-02-01</xbrli:startDate>

      <xbrli:endDate>2016-02-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P05_01_2016To05_31_2016_BonwickCapitalPartnersLlcMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mbrx:BonwickCapitalPartnersLlcMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-05-01</xbrli:startDate>

      <xbrli:endDate>2016-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn05_31_2016_BonwickCapitalPartnersLlcMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mbrx:BonwickCapitalPartnersLlcMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P05_01_2016To05_02_2016_CommonStockMemberusgaapStatementEquityComponentsAxis_MoleculinLlcMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mbrx:MoleculinLlcMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-05-01</xbrli:startDate>

      <xbrli:endDate>2016-05-02</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn05_02_2016_CommonStockMemberusgaapStatementEquityComponentsAxis_MoleculinLlcMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mbrx:MoleculinLlcMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-05-02</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn05_02_2016_MoleculinLlcMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mbrx:MoleculinLlcMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-05-02</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn05_02_2016_HoustonPharmaceuticalsIncMemberdeiLegalEntityAxis_LicenseAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MoleculinLlcMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mbrx:MoleculinLlcMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mbrx:HoustonPharmaceuticalsIncMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mbrx:LicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-05-02</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P05_01_2016To05_02_2016_HoustonPharmaceuticalsIncMemberdeiLegalEntityAxis_LicenseAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MoleculinLlcMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mbrx:MoleculinLlcMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mbrx:HoustonPharmaceuticalsIncMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mbrx:LicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-05-01</xbrli:startDate>

      <xbrli:endDate>2016-05-02</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn05_02_2016_HoustonPharmaceuticalsIncMemberdeiLegalEntityAxis_MoleculinLlcMemberusgaapBusinessAcquisitionAxis_OutlincenseAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mbrx:MoleculinLlcMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mbrx:HoustonPharmaceuticalsIncMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mbrx:OutlincenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-05-02</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_HoustonPharmaceuticalsIncMemberdeiLegalEntityAxis_MoleculinLlcMemberusgaapBusinessAcquisitionAxis_OutlincenseAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mbrx:MoleculinLlcMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mbrx:HoustonPharmaceuticalsIncMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mbrx:OutlincenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_HoustonPharmaceuticalsIncMemberdeiLegalEntityAxis_MoleculinLlcMemberusgaapBusinessAcquisitionAxis_OutlincenseAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mbrx:MoleculinLlcMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mbrx:HoustonPharmaceuticalsIncMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mbrx:OutlincenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_HoustonPharmaceuticalsIncMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mbrx:HoustonPharmaceuticalsIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To07_31_2016_HoustonPharmaceuticalsIncMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mbrx:HoustonPharmaceuticalsIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2016-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn07_31_2016_HoustonPharmaceuticalsIncMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mbrx:HoustonPharmaceuticalsIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_MoleculinLlcMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mbrx:MoleculinLlcMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2015_OtherIntangibleAssetsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_OtherIntangibleAssetsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_AcquisitionDateOneMembermbrxPeriodTypeAxis_MoleculinLlcMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mbrx:MoleculinLlcMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="mbrx:PeriodTypeAxis">mbrx:AcquisitionDateOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_SubscriptionsReceivableMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mbrx:SubscriptionsReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_MoleculinLlcMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mbrx:MoleculinLlcMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_ConvertibleDebtSecuritiesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_InvestorMemberusgaapRelatedPartyTransactionAxis_IssueDateAugust312015MemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:InvestorMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbrx:IssueDateAugust312015Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_InvestorBMemberusgaapRelatedPartyTransactionAxis_IssueDateSeptember032015MemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mbrx:InvestorBMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbrx:IssueDateSeptember032015Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_InvestorCMemberusgaapRelatedPartyTransactionAxis_IssueDateOctober062015OneMemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mbrx:InvestorCMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbrx:IssueDateOctober062015OneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_InvestorDMemberusgaapRelatedPartyTransactionAxis_IssueDateOctober062015TwoMemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mbrx:InvestorDMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbrx:IssueDateOctober062015TwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_InvestorEMemberusgaapRelatedPartyTransactionAxis_IssueDateOctober282015MemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mbrx:InvestorEMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbrx:IssueDateOctober282015Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_InvestorFMemberusgaapRelatedPartyTransactionAxis_IssueDateJanuary142016MemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mbrx:InvestorFMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbrx:IssueDateJanuary142016Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_InvestorGMemberusgaapRelatedPartyTransactionAxis_IssueDateJanuary192016MemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mbrx:InvestorGMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbrx:IssueDateJanuary192016Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2015_InvestorMemberusgaapRelatedPartyTransactionAxis_IssueDateAugust312015MemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:InvestorMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbrx:IssueDateAugust312015Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2015_InvestorBMemberusgaapRelatedPartyTransactionAxis_IssueDateSeptember032015MemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mbrx:InvestorBMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbrx:IssueDateSeptember032015Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2015_InvestorCMemberusgaapRelatedPartyTransactionAxis_IssueDateOctober062015OneMemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mbrx:InvestorCMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbrx:IssueDateOctober062015OneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2015_InvestorDMemberusgaapRelatedPartyTransactionAxis_IssueDateOctober062015TwoMemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mbrx:InvestorDMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbrx:IssueDateOctober062015TwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2015_InvestorEMemberusgaapRelatedPartyTransactionAxis_IssueDateOctober282015MemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mbrx:InvestorEMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbrx:IssueDateOctober282015Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2015_InvestorFMemberusgaapRelatedPartyTransactionAxis_IssueDateJanuary142016MemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mbrx:InvestorFMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbrx:IssueDateJanuary142016Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2015_InvestorGMemberusgaapRelatedPartyTransactionAxis_IssueDateJanuary192016MemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mbrx:InvestorGMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbrx:IssueDateJanuary192016Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_15_2017To02_09_2017_SubsequentEventMemberusgaapSubsequentEventTypeAxis_UnderwritingAgreementMembermbrxAgreementTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="mbrx:AgreementTypeAxis">mbrx:UnderwritingAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-15</xbrli:startDate>

      <xbrli:endDate>2017-02-09</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn02_09_2017_SubsequentEventMemberusgaapSubsequentEventTypeAxis_UnderwritingAgreementMembermbrxAgreementTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="mbrx:AgreementTypeAxis">mbrx:UnderwritingAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-02-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn02_09_2017_SeriesWarrantMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_UnderwritingAgreementMembermbrxAgreementTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="mbrx:AgreementTypeAxis">mbrx:UnderwritingAgreementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbrx:SeriesWarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-02-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn02_09_2017_SeriesBWarrantMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_UnderwritingAgreementMembermbrxAgreementTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="mbrx:AgreementTypeAxis">mbrx:UnderwritingAgreementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbrx:SeriesBWarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-02-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn02_09_2017_SeriesCWarrantMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_UnderwritingAgreementMembermbrxAgreementTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="mbrx:AgreementTypeAxis">mbrx:UnderwritingAgreementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbrx:SeriesCWarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-02-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_InvestorMemberusgaapRelatedPartyTransactionAxis_IssueDateAugust312015MemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:InvestorMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbrx:IssueDateAugust312015Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_InvestorBMemberusgaapRelatedPartyTransactionAxis_IssueDateSeptember032015MemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mbrx:InvestorBMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbrx:IssueDateSeptember032015Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_InvestorEMemberusgaapRelatedPartyTransactionAxis_IssueDateOctober282015MemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mbrx:InvestorEMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbrx:IssueDateOctober282015Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_InvestorFMemberusgaapRelatedPartyTransactionAxis_IssueDateJanuary142016MemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mbrx:InvestorFMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbrx:IssueDateJanuary142016Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_InvestorGMemberusgaapRelatedPartyTransactionAxis_IssueDateJanuary192016MemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mbrx:InvestorGMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbrx:IssueDateJanuary192016Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_InvestorDMemberusgaapRelatedPartyTransactionAxis_IssueDateOctober062015TwoMemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mbrx:InvestorDMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbrx:IssueDateOctober062015TwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_InvestorCMemberusgaapRelatedPartyTransactionAxis_IssueDateOctober062015OneMemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mbrx:InvestorCMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbrx:IssueDateOctober062015OneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To03_31_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis_ScienceAdvisoryBoardOneMemberusgaapTitleOfIndividualAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mbrx:ScienceAdvisoryBoardOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To03_31_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis_ScienceAdvisoryBoardTwoMemberusgaapTitleOfIndividualAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mbrx:ScienceAdvisoryBoardTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To03_31_2017_FormerScienceAdvisoryBoardMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbrx:FormerScienceAdvisoryBoardMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis_ScienceAdvisoryBoardOneMemberusgaapTitleOfIndividualAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mbrx:ScienceAdvisoryBoardOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis_ScienceAdvisoryBoardTwoMemberusgaapTitleOfIndividualAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mbrx:ScienceAdvisoryBoardTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2017To03_22_2017_SubsequentEventMemberusgaapSubsequentEventTypeAxis_UsFoodAndDrugAdministrationMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbrx:UsFoodAndDrugAdministrationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-03-01</xbrli:startDate>

      <xbrli:endDate>2017-03-22</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P06_01_2016To06_20_2016_PcgAdvisoryGroupMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbrx:PcgAdvisoryGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-06-01</xbrli:startDate>

      <xbrli:endDate>2016-06-20</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_25_2016To08_19_2016_ChiefFinancialOfficerAndExecutiveVicePresidentMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mbrx:ChiefFinancialOfficerAndExecutiveVicePresidentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-25</xbrli:startDate>

      <xbrli:endDate>2016-08-19</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_25_2016To08_19_2016_ChiefFinancialOfficerAndExecutiveVicePresidentMemberusgaapTitleOfIndividualAxis_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mbrx:ChiefFinancialOfficerAndExecutiveVicePresidentMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-25</xbrli:startDate>

      <xbrli:endDate>2016-08-19</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P09_10_2016To10_07_2016_MrLouisMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbrx:MrLouisMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-09-10</xbrli:startDate>

      <xbrli:endDate>2016-10-07</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P08_01_2015To08_31_2015_AnnamedIncMemberdeiLegalEntityAxis_UseRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:UseRightsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mbrx:AnnamedIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-08-01</xbrli:startDate>

      <xbrli:endDate>2015-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P08_01_2015To08_31_2015_IntertechbioCorporationMemberdeiLegalEntityAxis_UseRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:UseRightsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mbrx:IntertechbioCorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-08-01</xbrli:startDate>

      <xbrli:endDate>2015-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2015To12_31_2015_AcquisitionDateOneMembermbrxPeriodTypeAxis_MoleculinLlcMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mbrx:MoleculinLlcMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="mbrx:PeriodTypeAxis">mbrx:AcquisitionDateOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>

      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2016_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2017To03_22_2017_SeriesBWarrantMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_UsFoodAndDrugAdministrationMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbrx:UsFoodAndDrugAdministrationMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbrx:SeriesBWarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-03-01</xbrli:startDate>

      <xbrli:endDate>2017-03-22</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2015_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P08_01_2015To08_11_2015_IntertechbioCorporationMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mbrx:IntertechbioCorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-08-01</xbrli:startDate>

      <xbrli:endDate>2015-08-11</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P08_01_2015To08_21_2015_AnnamedIncMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mbrx:AnnamedIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-08-01</xbrli:startDate>

      <xbrli:endDate>2015-08-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P10_01_2016To10_31_2016_ChiefFinancialOfficerMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefFinancialOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-10-01</xbrli:startDate>

      <xbrli:endDate>2016-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P08_01_2015To08_31_2015_DirectorAndOfficersMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mbrx:DirectorAndOfficersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-08-01</xbrli:startDate>

      <xbrli:endDate>2015-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_28_2015To12_31_2015_DirectorAndOfficersMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mbrx:DirectorAndOfficersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-07-28</xbrli:startDate>

      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_28_2015To12_31_2015_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-07-28</xbrli:startDate>

      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn07_27_2015_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-07-27</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn07_27_2015_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-07-27</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn07_27_2015_SubscriptionsReceivableMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mbrx:SubscriptionsReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-07-27</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn07_27_2015_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-07-27</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2015_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2015_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2015_SubscriptionsReceivableMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mbrx:SubscriptionsReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2015_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_SubscriptionsReceivableMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mbrx:SubscriptionsReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_28_2015To12_31_2015_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-07-28</xbrli:startDate>

      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_28_2015To12_31_2015_SubscriptionsReceivableMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mbrx:SubscriptionsReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-07-28</xbrli:startDate>

      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:unit id="shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>

  <xbrli:unit id="USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>

  <xbrli:unit id="USD_per_Share">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>

      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>

  <xbrli:unit id="pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>

<!--Element Section-->
  <us-gaap:ConvertibleNotesPayableCurrent contextRef="PAsOn12_31_2016" id="Factid_1" unitRef="USD" decimals="0">296412</us-gaap:ConvertibleNotesPayableCurrent>

  <us-gaap:ConvertibleNotesPayableCurrent contextRef="PAsOn12_31_2015" id="Factid_2" unitRef="USD" decimals="0">450000</us-gaap:ConvertibleNotesPayableCurrent>

  <us-gaap:Liabilities contextRef="PAsOn12_31_2016" id="Factid_3" unitRef="USD" decimals="0">1432567</us-gaap:Liabilities>

  <us-gaap:Liabilities contextRef="PAsOn12_31_2015" id="Factid_4" unitRef="USD" decimals="0">772790</us-gaap:Liabilities>

  <us-gaap:CommonStockValue contextRef="PAsOn12_31_2016" id="Factid_5" unitRef="USD" decimals="0">12165</us-gaap:CommonStockValue>

  <us-gaap:CommonStockValue contextRef="PAsOn12_31_2015" id="Factid_6" unitRef="USD" decimals="0">6661</us-gaap:CommonStockValue>

  <us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable contextRef="PAsOn12_31_2016" id="Factid_7" unitRef="USD" decimals="0">0</us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable>

  <us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable contextRef="PAsOn12_31_2015" id="Factid_8" unitRef="USD" decimals="0">3000</us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable>

  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="PAsOn12_31_2016" id="Factid_9" unitRef="USD" decimals="0">19622925</us-gaap:AdditionalPaidInCapitalCommonStock>

  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="PAsOn12_31_2015" id="Factid_10" unitRef="USD" decimals="0">0</us-gaap:AdditionalPaidInCapitalCommonStock>

  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="PAsOn12_31_2016" id="Factid_11" unitRef="USD" decimals="0">-4674721</us-gaap:RetainedEarningsAccumulatedDeficit>

  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="PAsOn12_31_2015" id="Factid_12" unitRef="USD" decimals="0">-748360</us-gaap:RetainedEarningsAccumulatedDeficit>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2016" id="Factid_13" unitRef="USD" decimals="0">14960369</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2015" id="Factid_14" unitRef="USD" decimals="0">-744699</us-gaap:StockholdersEquity>

  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="PAsOn12_31_2016" id="Factid_15" unitRef="USD" decimals="0">16392936</us-gaap:LiabilitiesAndStockholdersEquity>

  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="PAsOn12_31_2015" id="Factid_16" unitRef="USD" decimals="0">28091</us-gaap:LiabilitiesAndStockholdersEquity>

  <us-gaap:PrepaidExpenseCurrent contextRef="PAsOn12_31_2016" id="Factid_17" unitRef="USD" decimals="0">215052</us-gaap:PrepaidExpenseCurrent>

  <us-gaap:PrepaidExpenseCurrent contextRef="PAsOn12_31_2015" id="Factid_18" unitRef="USD" decimals="0">0</us-gaap:PrepaidExpenseCurrent>

  <us-gaap:AssetsCurrent contextRef="PAsOn12_31_2016" id="Factid_19" unitRef="USD" decimals="0">5222268</us-gaap:AssetsCurrent>

  <us-gaap:AssetsCurrent contextRef="PAsOn12_31_2015" id="Factid_20" unitRef="USD" decimals="0">28091</us-gaap:AssetsCurrent>

  <us-gaap:PropertyPlantAndEquipmentNet contextRef="PAsOn12_31_2016" id="Factid_21" unitRef="USD" decimals="0">23128</us-gaap:PropertyPlantAndEquipmentNet>

  <us-gaap:PropertyPlantAndEquipmentNet contextRef="PAsOn12_31_2015" id="Factid_22" unitRef="USD" decimals="0">0</us-gaap:PropertyPlantAndEquipmentNet>

  <us-gaap:IntangibleAssetsNetIncludingGoodwill contextRef="PAsOn12_31_2016" id="Factid_23" unitRef="USD" decimals="0">11147540</us-gaap:IntangibleAssetsNetIncludingGoodwill>

  <us-gaap:IntangibleAssetsNetIncludingGoodwill contextRef="PAsOn12_31_2015" id="Factid_24" unitRef="USD" decimals="0">0</us-gaap:IntangibleAssetsNetIncludingGoodwill>

  <us-gaap:LiabilitiesCurrent contextRef="PAsOn12_31_2016" id="Factid_25" unitRef="USD" decimals="0">1345067</us-gaap:LiabilitiesCurrent>

  <us-gaap:LiabilitiesCurrent contextRef="PAsOn12_31_2015" id="Factid_26" unitRef="USD" decimals="0">772790</us-gaap:LiabilitiesCurrent>

  <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent contextRef="PAsOn12_31_2016" id="Factid_27" unitRef="USD" decimals="0">87500</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>

  <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent contextRef="PAsOn12_31_2015" id="Factid_28" unitRef="USD" decimals="0">0</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>

  <us-gaap:PreferredStockValue contextRef="PAsOn12_31_2015" id="Factid_29" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>

  <us-gaap:PreferredStockValue contextRef="PAsOn12_31_2016" id="Factid_30" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>

  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="PAsOn12_31_2015" id="Factid_31" unitRef="USD" decimals="0">322790</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>

  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="PAsOn12_31_2016" id="Factid_32" unitRef="USD" decimals="0">1048655</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>

  <us-gaap:Assets contextRef="PAsOn12_31_2015" id="Factid_33" unitRef="USD" decimals="0">28091</us-gaap:Assets>

  <us-gaap:Assets contextRef="PAsOn12_31_2016" id="Factid_34" unitRef="USD" decimals="0">16392936</us-gaap:Assets>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn12_31_2015" id="Factid_35" unitRef="USD" decimals="0">28091</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn12_31_2016" id="Factid_36" unitRef="USD" decimals="0">5007216</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <us-gaap:CommitmentsAndContingencies contextRef="PAsOn12_31_2016" id="Factid_37" unitRef="USD" xsi:nil="true" />

  <us-gaap:DepreciationDepletionAndAmortization contextRef="P01_01_2016To12_31_2016" id="Factid_38" unitRef="USD" decimals="0">6162</us-gaap:DepreciationDepletionAndAmortization>

  <us-gaap:SalesRevenueNet contextRef="P01_01_2016To12_31_2016" id="Factid_39" unitRef="USD" decimals="0">0</us-gaap:SalesRevenueNet>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P01_01_2016To12_31_2016" id="Factid_40" unitRef="USD" decimals="0">1495561</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P01_01_2016To12_31_2016" id="Factid_41" unitRef="USD" decimals="0">2381424</us-gaap:GeneralAndAdministrativeExpense>

  <us-gaap:OperatingExpenses contextRef="P01_01_2016To12_31_2016" id="Factid_42" unitRef="USD" decimals="0">3883147</us-gaap:OperatingExpenses>

  <us-gaap:OperatingIncomeLoss contextRef="P01_01_2016To12_31_2016" id="Factid_43" unitRef="USD" decimals="0">-3883147</us-gaap:OperatingIncomeLoss>

  <us-gaap:InterestExpense contextRef="P01_01_2016To12_31_2016" id="Factid_44" unitRef="USD" decimals="0">43214</us-gaap:InterestExpense>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2016To12_31_2016" id="Factid_45" unitRef="USD" decimals="0">-3926361</us-gaap:NetIncomeLoss>

  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="P01_01_2016To12_31_2016" id="Factid_46" unitRef="USD_per_Share" decimals="2">-0.40</us-gaap:EarningsPerShareBasicAndDiluted>

  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P01_01_2016To12_31_2016" id="Factid_47" unitRef="shares" decimals="INF">9827510</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P07_28_2015To12_31_2015" id="Factid_48" unitRef="USD" decimals="0">477810</us-gaap:GeneralAndAdministrativeExpense>

  <us-gaap:DepreciationDepletionAndAmortization contextRef="P07_28_2015To12_31_2015" id="Factid_49" unitRef="USD" decimals="0">0</us-gaap:DepreciationDepletionAndAmortization>

  <us-gaap:OperatingExpenses contextRef="P07_28_2015To12_31_2015" id="Factid_50" unitRef="USD" decimals="0">738228</us-gaap:OperatingExpenses>

  <us-gaap:OperatingIncomeLoss contextRef="P07_28_2015To12_31_2015" id="Factid_51" unitRef="USD" decimals="0">-738228</us-gaap:OperatingIncomeLoss>

  <us-gaap:InterestExpense contextRef="P07_28_2015To12_31_2015" id="Factid_52" unitRef="USD" decimals="0">10132</us-gaap:InterestExpense>

  <us-gaap:NetIncomeLoss contextRef="P07_28_2015To12_31_2015" id="Factid_53" unitRef="USD" decimals="0">-748360</us-gaap:NetIncomeLoss>

  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="P07_28_2015To12_31_2015" id="Factid_54" unitRef="USD_per_Share" decimals="2">-0.13</us-gaap:EarningsPerShareBasicAndDiluted>

  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P07_28_2015To12_31_2015" id="Factid_55" unitRef="shares" decimals="INF">5691803</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>

  <us-gaap:SalesRevenueNet contextRef="P07_28_2015To12_31_2015" id="Factid_56" unitRef="USD" decimals="0">0</us-gaap:SalesRevenueNet>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P07_28_2015To12_31_2015" id="Factid_57" unitRef="USD" decimals="0">260418</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2016To12_31_2016" id="Factid_58" unitRef="USD" decimals="0">323974</us-gaap:ShareBasedCompensation>

  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="P01_01_2016To12_31_2016" id="Factid_59" unitRef="USD" decimals="0">-41128</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>

  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="P01_01_2016To12_31_2016" id="Factid_60" unitRef="USD" decimals="0">-3764905</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>

  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="P01_01_2016To12_31_2016" id="Factid_61" unitRef="USD" decimals="0">-121108</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>

  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="P01_01_2016To12_31_2016" id="Factid_62" unitRef="USD" decimals="0">8865138</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>

  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="P01_01_2016To12_31_2016" id="Factid_63" unitRef="USD" decimals="0">4979125</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>

  <us-gaap:InterestPaid contextRef="P01_01_2016To12_31_2016" id="Factid_64" unitRef="USD" decimals="0">4585</us-gaap:InterestPaid>

  <us-gaap:IncomeTaxesPaidNet contextRef="P01_01_2016To12_31_2016" id="Factid_65" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxesPaidNet>

  <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="P01_01_2016To12_31_2016" id="Factid_66" unitRef="USD" decimals="0">215052</us-gaap:IncreaseDecreaseInPrepaidExpense>

  <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="P01_01_2016To12_31_2016" id="Factid_67" unitRef="USD" decimals="0">9170077</us-gaap:ProceedsFromIssuanceInitialPublicOffering>

  <us-gaap:StockIssued1 contextRef="P01_01_2016To12_31_2016" id="Factid_68" unitRef="USD" decimals="0">9773586</us-gaap:StockIssued1>

  <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="P01_01_2016To12_31_2016" id="Factid_69" unitRef="USD" decimals="0">363792</us-gaap:DebtConversionConvertedInstrumentAmount1>

  <us-gaap:RepaymentsOfNotesPayable contextRef="P01_01_2016To12_31_2016" id="Factid_70" unitRef="USD" decimals="0">469939</us-gaap:RepaymentsOfNotesPayable>

  <us-gaap:ProceedsFromNotesPayable contextRef="P01_01_2016To12_31_2016" id="Factid_71" unitRef="USD" decimals="0">165000</us-gaap:ProceedsFromNotesPayable>

  <us-gaap:ShareBasedCompensation contextRef="P07_28_2015To12_31_2015" id="Factid_72" unitRef="USD" decimals="0">0</us-gaap:ShareBasedCompensation>

  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="P07_28_2015To12_31_2015" id="Factid_73" unitRef="USD" decimals="0">322790</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>

  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="P07_28_2015To12_31_2015" id="Factid_74" unitRef="USD" decimals="0">-423509</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>

  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="P01_01_2016To12_31_2016" id="Factid_75" unitRef="USD" decimals="0">21470</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>

  <us-gaap:StockIssued1 contextRef="P07_28_2015To12_31_2015" id="Factid_76" unitRef="USD" decimals="0">0</us-gaap:StockIssued1>

  <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="P07_28_2015To12_31_2015" id="Factid_77" unitRef="USD" decimals="0">0</us-gaap:DebtConversionConvertedInstrumentAmount1>

  <us-gaap:ProceedsFromNotesPayable contextRef="P07_28_2015To12_31_2015" id="Factid_78" unitRef="USD" decimals="0">450000</us-gaap:ProceedsFromNotesPayable>

  <us-gaap:RepaymentsOfNotesPayable contextRef="P07_28_2015To12_31_2015" id="Factid_79" unitRef="USD" decimals="0">0</us-gaap:RepaymentsOfNotesPayable>

  <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="P07_28_2015To12_31_2015" id="Factid_80" unitRef="USD" decimals="0">1600</us-gaap:ProceedsFromIssuanceInitialPublicOffering>

  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="P07_28_2015To12_31_2015" id="Factid_81" unitRef="USD" decimals="0">451600</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>

  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="P07_28_2015To12_31_2015" id="Factid_82" unitRef="USD" decimals="0">28091</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn07_27_2015" id="Factid_83" unitRef="USD" decimals="0">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <us-gaap:InterestPaid contextRef="P07_28_2015To12_31_2015" id="Factid_84" unitRef="USD" decimals="0">0</us-gaap:InterestPaid>

  <us-gaap:IncomeTaxesPaidNet contextRef="P07_28_2015To12_31_2015" id="Factid_85" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxesPaidNet>

  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="P07_28_2015To12_31_2015" id="Factid_86" unitRef="USD" decimals="0">0</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>

  <mbrx:SharesSubscribed contextRef="P01_01_2016To12_31_2016" id="Factid_87" unitRef="USD" decimals="0">0</mbrx:SharesSubscribed>

  <mbrx:SharesSubscribed contextRef="P07_28_2015To12_31_2015" id="Factid_88" unitRef="USD" decimals="0">3000</mbrx:SharesSubscribed>

  <mbrx:SharesIssuedForLicensesUsedForResearchAndDevelopment contextRef="P01_01_2016To12_31_2016" id="Factid_89" unitRef="USD" decimals="0">0</mbrx:SharesIssuedForLicensesUsedForResearchAndDevelopment>

  <mbrx:SharesIssuedForLicensesUsedForResearchAndDevelopment contextRef="P07_28_2015To12_31_2015" id="Factid_90" unitRef="USD" decimals="0">-2061</mbrx:SharesIssuedForLicensesUsedForResearchAndDevelopment>

  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="P07_28_2015To12_31_2015" id="Factid_91" unitRef="USD" decimals="0">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>

  <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="P01_01_2016To12_31_2016" id="Factid_92" unitRef="USD" decimals="0">99638</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>

  <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="P07_28_2015To12_31_2015" id="Factid_93" unitRef="USD" decimals="0">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>

  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P01_01_2016To12_31_2016_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis" id="Factid_94" unitRef="shares" decimals="INF">510000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P01_01_2016To12_31_2016_WarrantMemberusgaapClassOfWarrantOrRightAxis" id="Factid_95" unitRef="shares" decimals="INF">107802</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="PAsOn12_31_2016_UnsecuredPromissoryNotesMemberusgaapDebtInstrumentAxis" id="Factid_96" unitRef="pure" decimals="3">0.080</us-gaap:DebtInstrumentInterestRateStatedPercentage>

  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="PAsOn12_31_2016_IPOMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_97" unitRef="pure" decimals="4">0.0499</us-gaap:EquityMethodInvestmentOwnershipPercentage>

  <mbrx:DebtConversionConvertedInstrumentAdditionalSharesIssued contextRef="P01_01_2016To12_31_2016_IPOMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_98" unitRef="shares" decimals="INF">1821013</mbrx:DebtConversionConvertedInstrumentAdditionalSharesIssued>

  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="P05_01_2016To05_31_2016" id="Factid_99" unitRef="shares" decimals="INF">1166503</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>

  <us-gaap:DebtConversionOriginalDebtAmount1 contextRef="P05_01_2016To05_31_2016" id="Factid_100" unitRef="USD" decimals="0">183356</us-gaap:DebtConversionOriginalDebtAmount1>

  <us-gaap:InterestPayableCurrent contextRef="PAsOn05_31_2016" id="Factid_101" unitRef="USD" decimals="0">17699</us-gaap:InterestPayableCurrent>

  <us-gaap:InterestPayableCurrent contextRef="PAsOn12_31_2016" id="Factid_102" unitRef="USD" decimals="0">7172</us-gaap:InterestPayableCurrent>

  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="P01_01_2016To12_31_2016" id="Factid_103" unitRef="shares" decimals="INF">910095</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>

  <us-gaap:DebtConversionOriginalDebtAmount1 contextRef="P01_01_2016To12_31_2016" id="Factid_104" unitRef="USD" decimals="0">155565</us-gaap:DebtConversionOriginalDebtAmount1>

  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="PAsOn05_31_2016_IPOMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_105" unitRef="pure" decimals="4">0.0499</us-gaap:EquityMethodInvestmentOwnershipPercentage>

  <mbrx:SharesAuthorized contextRef="PAsOn05_02_2016" id="Factid_106" unitRef="shares" decimals="INF">80000000</mbrx:SharesAuthorized>

  <us-gaap:CommonStockSharesAuthorized contextRef="PAsOn05_02_2016" id="Factid_107" unitRef="shares" decimals="INF">75000000</us-gaap:CommonStockSharesAuthorized>

  <us-gaap:PreferredStockSharesAuthorized contextRef="PAsOn05_02_2016" id="Factid_108" unitRef="shares" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>

  <mbrx:ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable contextRef="P05_01_2016To05_31_2016" id="Factid_109">P5Y</mbrx:ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable>

  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="PAsOn05_31_2016" id="Factid_110" unitRef="shares" decimals="INF">107802</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn05_31_2016" id="Factid_111" unitRef="USD_per_Share" decimals="2">7.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P05_01_2016To05_31_2016_IPOMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_112" unitRef="shares" decimals="INF">1540026</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:SharesIssuedPricePerShare contextRef="PAsOn05_31_2016_IPOMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_113" unitRef="USD_per_Share" decimals="2">6.00</us-gaap:SharesIssuedPricePerShare>

  <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="P05_01_2016To05_31_2016_IPOMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_114" unitRef="USD" decimals="0">8464183</us-gaap:ProceedsFromIssuanceInitialPublicOffering>

  <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="PAsOn05_31_2016_WarrantMemberusgaapClassOfWarrantOrRightAxis" id="Factid_115" unitRef="USD" decimals="0">374763</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>

  <us-gaap:FairValueInputsDiscountRate contextRef="P05_01_2016To05_31_2016_WarrantMemberusgaapClassOfWarrantOrRightAxis" id="Factid_116" unitRef="pure" decimals="4">0.0139</us-gaap:FairValueInputsDiscountRate>

  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="P05_01_2016To05_31_2016_WarrantMemberusgaapClassOfWarrantOrRightAxis" id="Factid_117">P5Y</us-gaap:FairValueAssumptionsExpectedTerm>

  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="P05_01_2016To05_31_2016_WarrantMemberusgaapClassOfWarrantOrRightAxis" id="Factid_118" unitRef="pure" decimals="4">0.8061</us-gaap:FairValueAssumptionsExpectedVolatilityRate>

  <us-gaap:PreferredStockSharesAuthorized contextRef="PAsOn12_31_2016" id="Factid_119" unitRef="shares" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="P04_01_2016To04_22_2016" id="Factid_120">2025-12-05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="PAsOn04_22_2016_StockPlanMemberusgaapAwardTypeAxis" id="Factid_121" unitRef="shares" decimals="INF">2500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn12_31_2015" id="Factid_122" unitRef="shares" decimals="INF">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn12_31_2016" id="Factid_123" unitRef="shares" decimals="INF">510000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="PAsOn12_31_2015" id="Factid_124" unitRef="USD_per_Share" decimals="1">0.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="P01_01_2016To12_31_2016" id="Factid_125" unitRef="USD_per_Share" decimals="2">5.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="P01_01_2016To12_31_2016" id="Factid_126" unitRef="USD_per_Share" decimals="1">0.2</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="PAsOn12_31_2016" id="Factid_127" unitRef="USD_per_Share" decimals="2">5.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2016To12_31_2016" id="Factid_128">P3Y8M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2016To12_31_2016" id="Factid_129">P9Y3M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2016To12_31_2016" id="Factid_130" unitRef="shares" decimals="INF">460000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="P01_01_2016To12_31_2016" id="Factid_131" unitRef="shares" decimals="INF">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn12_31_2016" id="Factid_132" unitRef="shares" decimals="INF">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="PAsOn12_31_2016" id="Factid_133" unitRef="USD_per_Share" decimals="1">0.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="PAsOn12_31_2016" id="Factid_134" unitRef="USD" decimals="0">275500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="P01_01_2016To12_31_2016" id="Factid_135" unitRef="USD" decimals="0">275500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P01_01_2016To12_31_2016_EmployeeAndBoardOfDirectorsMemberusgaapTitleOfIndividualAxis_MinimumMemberusgaapRangeAxis" id="Factid_136">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P01_01_2016To12_31_2016_EmployeeAndBoardOfDirectorsMemberusgaapTitleOfIndividualAxis_MaximumMemberusgaapRangeAxis" id="Factid_137">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="P01_01_2016To12_31_2016_EmployeeAndBoardOfDirectorsMemberusgaapTitleOfIndividualAxis" id="Factid_138" unitRef="USD" decimals="0">1772422</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="P01_01_2016To12_31_2016_EmployeeAndBoardOfDirectorsMemberusgaapTitleOfIndividualAxis_MinimumMemberusgaapRangeAxis" id="Factid_139" unitRef="USD_per_Share" decimals="2">5.71</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="P01_01_2016To12_31_2016_EmployeeAndBoardOfDirectorsMemberusgaapTitleOfIndividualAxis_MaximumMemberusgaapRangeAxis" id="Factid_140" unitRef="USD_per_Share" decimals="2">5.85</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="P01_01_2016To12_31_2016_EmployeeAndBoardOfDirectorsMemberusgaapTitleOfIndividualAxis" id="Factid_141">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2016To12_31_2016_EmployeeAndBoardOfDirectorsMemberusgaapTitleOfIndividualAxis_MaximumMemberusgaapRangeAxis" id="Factid_142">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="P01_01_2016To12_31_2016_EmployeeAndBoardOfDirectorsMemberusgaapTitleOfIndividualAxis" id="Factid_143" unitRef="pure" decimals="4">0.0130</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2016To12_31_2016_EmployeeAndBoardOfDirectorsMemberusgaapTitleOfIndividualAxis_MinimumMemberusgaapRangeAxis" id="Factid_144">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="P01_01_2016To12_31_2016_EmployeeAndBoardOfDirectorsMemberusgaapTitleOfIndividualAxis_MinimumMemberusgaapRangeAxis" id="Factid_145" unitRef="pure" decimals="4">0.7018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="P01_01_2016To12_31_2016_EmployeeAndBoardOfDirectorsMemberusgaapTitleOfIndividualAxis_MaximumMemberusgaapRangeAxis" id="Factid_146" unitRef="pure" decimals="4">0.7044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2016To12_31_2016_EmployeeAndBoardOfDirectorsMemberusgaapTitleOfIndividualAxis" id="Factid_147" unitRef="shares" decimals="INF">460000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ContractualObligationDueInNextTwelveMonths contextRef="PAsOn08_31_2015_PatentAndTechnologyLicenseAgreementMembermbrxAgreementAxis_ServicingFeePayableMemberusgaapOtherCommitmentsAxis" id="Factid_148" unitRef="USD" decimals="0">10000</us-gaap:ContractualObligationDueInNextTwelveMonths>

  <us-gaap:ContractualObligationDueInSecondYear contextRef="PAsOn08_31_2015_PatentAndTechnologyLicenseAgreementMembermbrxAgreementAxis_ServicingFeePayableMemberusgaapOtherCommitmentsAxis" id="Factid_149" unitRef="USD" decimals="0">20000</us-gaap:ContractualObligationDueInSecondYear>

  <us-gaap:ContractualObligationDueInThirdYear contextRef="PAsOn08_31_2015_PatentAndTechnologyLicenseAgreementMembermbrxAgreementAxis_ServicingFeePayableMemberusgaapOtherCommitmentsAxis" id="Factid_150" unitRef="USD" decimals="0">40000</us-gaap:ContractualObligationDueInThirdYear>

  <us-gaap:ContractualObligationDueInFourthYear contextRef="PAsOn08_31_2015_PatentAndTechnologyLicenseAgreementMembermbrxAgreementAxis_ServicingFeePayableMemberusgaapOtherCommitmentsAxis" id="Factid_151" unitRef="USD" decimals="0">60000</us-gaap:ContractualObligationDueInFourthYear>

  <us-gaap:ContractualObligationDueInFifthYear contextRef="PAsOn08_31_2015_PatentAndTechnologyLicenseAgreementMembermbrxAgreementAxis_ServicingFeePayableMemberusgaapOtherCommitmentsAxis" id="Factid_152" unitRef="USD" decimals="0">80000</us-gaap:ContractualObligationDueInFifthYear>

  <us-gaap:ContractualObligationDueAfterFifthYear contextRef="PAsOn08_31_2015_PatentAndTechnologyLicenseAgreementMembermbrxAgreementAxis_ServicingFeePayableMemberusgaapOtherCommitmentsAxis" id="Factid_153" unitRef="USD" decimals="0">100000</us-gaap:ContractualObligationDueAfterFifthYear>

  <mbrx:ContractualObligationDueInNextFiscalYearAfterProductApproval contextRef="PAsOn08_31_2015_MinimumAnnualRoyaltyMemberusgaapOtherCommitmentsAxis_PatentAndTechnologyLicenseAgreementMembermbrxAgreementAxis" id="Factid_154" unitRef="USD" decimals="0">200000</mbrx:ContractualObligationDueInNextFiscalYearAfterProductApproval>

  <mbrx:ContractualObligationDueInSecondYearAfterProductApproval contextRef="PAsOn08_31_2015_MinimumAnnualRoyaltyMemberusgaapOtherCommitmentsAxis_PatentAndTechnologyLicenseAgreementMembermbrxAgreementAxis" id="Factid_155" unitRef="USD" decimals="0">400000</mbrx:ContractualObligationDueInSecondYearAfterProductApproval>

  <mbrx:ContractualObligationDueInThirdYearAfterProductApproval contextRef="PAsOn08_31_2015_MinimumAnnualRoyaltyMemberusgaapOtherCommitmentsAxis_PatentAndTechnologyLicenseAgreementMembermbrxAgreementAxis" id="Factid_156" unitRef="USD" decimals="0">600000</mbrx:ContractualObligationDueInThirdYearAfterProductApproval>

  <mbrx:MilestonePaymentsLiabilities contextRef="PAsOn12_31_2016_CommencementOfPhaseIiStudyForLicensedProductMemberusgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" id="Factid_157" unitRef="USD" decimals="0">200000</mbrx:MilestonePaymentsLiabilities>

  <mbrx:MilestonePaymentsLiabilities contextRef="PAsOn12_31_2016_CommencementOfPhaseIiiStudyForLicensedProductMemberusgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" id="Factid_158" unitRef="USD" decimals="0">250000</mbrx:MilestonePaymentsLiabilities>

  <mbrx:MilestonePaymentsLiabilities contextRef="PAsOn12_31_2016_FilingOfNewDrugApplicationForLicensedProductMemberusgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" id="Factid_159" unitRef="USD" decimals="0">400000</mbrx:MilestonePaymentsLiabilities>

  <mbrx:MilestonePaymentsLiabilities contextRef="PAsOn12_31_2016_ReceiptOfMarketApprovalForLicensedProductMemberusgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" id="Factid_160" unitRef="USD" decimals="0">500000</mbrx:MilestonePaymentsLiabilities>

  <us-gaap:ContractualObligation contextRef="PAsOn10_31_2015_MdAndersonMemberusgaapTitleOfIndividualAxis_MinimumFeeAndPatentExpensesMemberusgaapOtherCommitmentsAxis" id="Factid_161" unitRef="USD" decimals="0">98108</us-gaap:ContractualObligation>

  <us-gaap:ContractualObligation contextRef="PAsOn10_31_2015_MinimumFeeAndPatentExpensesMemberusgaapOtherCommitmentsAxis_PatentLawFirmMemberdeiLegalEntityAxis" id="Factid_162" unitRef="USD" decimals="0">65504</us-gaap:ContractualObligation>

  <us-gaap:ContractualObligation contextRef="PAsOn12_31_2015_MdAndersonMemberusgaapTitleOfIndividualAxis_MinimumFeeAndPatentExpensesMemberusgaapOtherCommitmentsAxis" id="Factid_163" unitRef="USD" decimals="0">45000</us-gaap:ContractualObligation>

  <us-gaap:ContractualObligation contextRef="PAsOn12_31_2015_MinimumFeeAndPatentExpensesMemberusgaapOtherCommitmentsAxis_PatentLawFirmMemberdeiLegalEntityAxis" id="Factid_164" unitRef="USD" decimals="0">42504</us-gaap:ContractualObligation>

  <us-gaap:ContractualObligation contextRef="PAsOn10_08_2015_MdAndersonMemberusgaapTitleOfIndividualAxis_MinimumFeeAndPatentExpensesMemberusgaapOtherCommitmentsAxis" id="Factid_165" unitRef="USD" decimals="0">98108</us-gaap:ContractualObligation>

  <us-gaap:ContractualObligation contextRef="PAsOn10_08_2015_MdAndersonMemberusgaapTitleOfIndividualAxis_MinimumAnnualRoyaltyMemberusgaapOtherCommitmentsAxis" id="Factid_166" unitRef="USD" decimals="0">65504</us-gaap:ContractualObligation>

  <mbrx:LicenseAgreementMaintenanceFeeMaximumPayablePerYear contextRef="P05_01_2016To05_02_2016_PatentAndTechnologyLicenseAgreementMembermbrxAgreementAxis" id="Factid_167" unitRef="USD" decimals="0">100000</mbrx:LicenseAgreementMaintenanceFeeMaximumPayablePerYear>

  <us-gaap:ContractualObligation contextRef="PAsOn10_31_2015_PatentAndTechnologyLicenseAgreementMembermbrxAgreementAxis" id="Factid_168" unitRef="USD" decimals="0">125000</us-gaap:ContractualObligation>

  <us-gaap:ContractualObligation contextRef="PAsOn01_31_2016_PatentAndTechnologyLicenseAgreementMembermbrxAgreementAxis" id="Factid_169" unitRef="USD" decimals="0">175000</us-gaap:ContractualObligation>

  <us-gaap:ContractualObligation contextRef="PAsOn04_30_2016_PatentAndTechnologyLicenseAgreementMembermbrxAgreementAxis" id="Factid_170" unitRef="USD" decimals="0">91186</us-gaap:ContractualObligation>

  <us-gaap:PaymentsForRoyalties contextRef="P11_01_2015To11_02_2015_PatentAndTechnologyLicenseAgreementMembermbrxAgreementAxis" id="Factid_171" unitRef="USD" decimals="0">125000</us-gaap:PaymentsForRoyalties>

  <us-gaap:PaymentsForFees contextRef="P10_01_2015To10_08_2015_LetterAgreementMemberusgaapOtherCommitmentsAxis_PatentAndTechnologyLicenseAgreementMembermbrxAgreementAxis" id="Factid_172" unitRef="USD" decimals="0">691186</us-gaap:PaymentsForFees>

  <us-gaap:PaymentsForFees contextRef="P10_01_2015To10_08_2015_PatentAndTechnologyLicenseAgreementMembermbrxAgreementAxis" id="Factid_173" unitRef="USD" decimals="0">300000</us-gaap:PaymentsForFees>

  <us-gaap:PaymentsForFees contextRef="P05_01_2016To05_31_2016_MoleculinLlcMemberusgaapBusinessAcquisitionAxis" id="Factid_174" unitRef="USD" decimals="0">306186</us-gaap:PaymentsForFees>

  <mbrx:LicenseAgreementMaintenanceFee contextRef="P05_01_2016To05_02_2016_PatentAndTechnologyLicenseAgreementMembermbrxAgreementAxis" id="Factid_175" unitRef="USD" decimals="0">20000</mbrx:LicenseAgreementMaintenanceFee>

  <mbrx:LicenseAgreementMaintenanceFeeAnnualIncrease contextRef="P05_01_2016To05_02_2016_PatentAndTechnologyLicenseAgreementMembermbrxAgreementAxis" id="Factid_176" unitRef="USD" decimals="0">10000</mbrx:LicenseAgreementMaintenanceFeeAnnualIncrease>

  <mbrx:SuccessFeePercentage contextRef="P02_01_2016To02_29_2016_BonwickCapitalPartnersLlcMemberdeiLegalEntityAxis" id="Factid_177" unitRef="pure" decimals="2">0.07</mbrx:SuccessFeePercentage>

  <mbrx:ClassOfWarrantOrRightPercentageOfSecuritiesCalledByWarrantsOrRights contextRef="P02_01_2016To02_29_2016_BonwickCapitalPartnersLlcMemberdeiLegalEntityAxis" id="Factid_178" unitRef="pure" decimals="2">0.07</mbrx:ClassOfWarrantOrRightPercentageOfSecuritiesCalledByWarrantsOrRights>

  <mbrx:ClassOfWarrantOrRightExercisePricePercentageThreshold contextRef="P02_01_2016To02_29_2016_BonwickCapitalPartnersLlcMemberdeiLegalEntityAxis" id="Factid_179" unitRef="pure" decimals="2">1.25</mbrx:ClassOfWarrantOrRightExercisePricePercentageThreshold>

  <mbrx:ReimbursementPayableOfferingCosts contextRef="P02_01_2016To02_29_2016_BonwickCapitalPartnersLlcMemberdeiLegalEntityAxis_MaximumMemberusgaapRangeAxis" id="Factid_180" unitRef="USD" decimals="0">25000</mbrx:ReimbursementPayableOfferingCosts>

  <mbrx:ReimbursementPayableFeesAndExpensesOfCounsel contextRef="P02_01_2016To02_29_2016_BonwickCapitalPartnersLlcMemberdeiLegalEntityAxis_MaximumMemberusgaapRangeAxis" id="Factid_181" unitRef="USD" decimals="0">100000</mbrx:ReimbursementPayableFeesAndExpensesOfCounsel>

  <us-gaap:PaymentsForUnderwritingExpense contextRef="P02_01_2016To02_29_2016_BonwickCapitalPartnersLlcMemberdeiLegalEntityAxis" id="Factid_182" unitRef="USD" decimals="0">50000</us-gaap:PaymentsForUnderwritingExpense>

  <mbrx:ReimburementOfExpenses contextRef="P05_01_2016To05_31_2016_BonwickCapitalPartnersLlcMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_183" unitRef="USD" decimals="0">6266</mbrx:ReimburementOfExpenses>

  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="P05_01_2016To05_31_2016_BonwickCapitalPartnersLlcMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_184" unitRef="USD" decimals="0">646872</us-gaap:PaymentsOfStockIssuanceCosts>

  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="PAsOn05_31_2016_BonwickCapitalPartnersLlcMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_185" unitRef="shares" decimals="INF">107802</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn05_31_2016_BonwickCapitalPartnersLlcMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_186" unitRef="USD_per_Share" decimals="2">7.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="PAsOn05_31_2016" id="Factid_187" unitRef="USD" decimals="-5">1000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>

  <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="P05_01_2016To05_31_2016" id="Factid_188" unitRef="USD" decimals="0">750000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>

  <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent contextRef="PAsOn12_31_2016_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_189" unitRef="USD" decimals="0">87500</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>

  <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="P05_01_2016To05_02_2016_CommonStockMemberusgaapStatementEquityComponentsAxis_MoleculinLlcMemberusgaapBusinessAcquisitionAxis" id="Factid_190" unitRef="shares" decimals="INF">999931</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>

  <us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned contextRef="PAsOn05_02_2016_CommonStockMemberusgaapStatementEquityComponentsAxis_MoleculinLlcMemberusgaapBusinessAcquisitionAxis" id="Factid_191" unitRef="USD" decimals="0">5999586</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>

  <us-gaap:NotesReceivableRelatedParties contextRef="PAsOn05_02_2016_MoleculinLlcMemberusgaapBusinessAcquisitionAxis" id="Factid_192" unitRef="USD" decimals="0">57822</us-gaap:NotesReceivableRelatedParties>

  <mbrx:RoyaltyOnNetRevenues contextRef="PAsOn05_02_2016_MoleculinLlcMemberusgaapBusinessAcquisitionAxis" id="Factid_193" unitRef="pure" decimals="3">0.025</mbrx:RoyaltyOnNetRevenues>

  <us-gaap:SharePrice contextRef="PAsOn05_02_2016_MoleculinLlcMemberusgaapBusinessAcquisitionAxis" id="Factid_194" unitRef="USD_per_Share" decimals="2">6.00</us-gaap:SharePrice>

  <mbrx:AccruedLicenseAgreementPayment contextRef="PAsOn05_02_2016_HoustonPharmaceuticalsIncMemberdeiLegalEntityAxis_LicenseAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MoleculinLlcMemberusgaapBusinessAcquisitionAxis" id="Factid_195" unitRef="USD" decimals="0">100000</mbrx:AccruedLicenseAgreementPayment>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P05_01_2016To05_02_2016_HoustonPharmaceuticalsIncMemberdeiLegalEntityAxis_LicenseAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MoleculinLlcMemberusgaapBusinessAcquisitionAxis" id="Factid_196" unitRef="shares" decimals="INF">629000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <mbrx:LicencingArrangementsConsiderationPayable contextRef="PAsOn05_02_2016_HoustonPharmaceuticalsIncMemberdeiLegalEntityAxis_MoleculinLlcMemberusgaapBusinessAcquisitionAxis_OutlincenseAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" id="Factid_197" unitRef="USD" decimals="0">750000</mbrx:LicencingArrangementsConsiderationPayable>

  <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="P01_01_2016To12_31_2016_HoustonPharmaceuticalsIncMemberdeiLegalEntityAxis_MoleculinLlcMemberusgaapBusinessAcquisitionAxis_OutlincenseAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" id="Factid_198" unitRef="USD" decimals="-5">1000000</us-gaap:PaymentsToAcquireIntangibleAssets>

  <mbrx:LicencingArrangementsReserve contextRef="PAsOn12_31_2016_HoustonPharmaceuticalsIncMemberdeiLegalEntityAxis_MoleculinLlcMemberusgaapBusinessAcquisitionAxis_OutlincenseAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" id="Factid_199" unitRef="USD" decimals="-5">1000000</mbrx:LicencingArrangementsReserve>

  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="PAsOn12_31_2016_HoustonPharmaceuticalsIncMemberdeiLegalEntityAxis" id="Factid_200" unitRef="USD" decimals="0">3874000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P07_01_2016To07_31_2016_HoustonPharmaceuticalsIncMemberdeiLegalEntityAxis" id="Factid_201" unitRef="shares" decimals="INF">629000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <mbrx:AccruedLicenseAgreementPayment contextRef="PAsOn07_31_2016_HoustonPharmaceuticalsIncMemberdeiLegalEntityAxis" id="Factid_202" unitRef="USD" decimals="0">100000</mbrx:AccruedLicenseAgreementPayment>

  <us-gaap:SharePrice contextRef="PAsOn07_31_2016_HoustonPharmaceuticalsIncMemberdeiLegalEntityAxis" id="Factid_203" unitRef="USD_per_Share" decimals="2">6.00</us-gaap:SharePrice>

  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="PAsOn12_31_2016_MoleculinLlcMemberusgaapBusinessAcquisitionAxis" id="Factid_204" unitRef="USD" decimals="0">6057408</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>

  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="PAsOn12_31_2016_MoleculinLlcMemberusgaapBusinessAcquisitionAxis" id="Factid_205" unitRef="USD" decimals="0">7820</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>

  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="PAsOn12_31_2016_MoleculinLlcMemberusgaapBusinessAcquisitionAxis" id="Factid_206" unitRef="USD" decimals="0">11147540</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>

  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="PAsOn12_31_2016_MoleculinLlcMemberusgaapBusinessAcquisitionAxis" id="Factid_207" unitRef="USD" decimals="0">11155722</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>

  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="PAsOn12_31_2015_OtherIntangibleAssetsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_208" unitRef="USD" decimals="0">0</us-gaap:FiniteLivedIntangibleAssetsGross>

  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="PAsOn12_31_2016_OtherIntangibleAssetsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_209" unitRef="USD" decimals="0">11147540</us-gaap:FiniteLivedIntangibleAssetsGross>

  <mbrx:BusinessAcquistionProFormaOperatingExpenses contextRef="P01_01_2016To12_31_2016" id="Factid_210" unitRef="USD" decimals="0">3979316</mbrx:BusinessAcquistionProFormaOperatingExpenses>

  <mbrx:BusinessAcquistionProFormaOperatingExpenses contextRef="P01_01_2015To12_31_2015" id="Factid_211" unitRef="USD" decimals="0">688101</mbrx:BusinessAcquistionProFormaOperatingExpenses>

  <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="P01_01_2016To12_31_2016" id="Factid_212" unitRef="USD" decimals="0">-3962997</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>

  <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="P01_01_2015To12_31_2015" id="Factid_213" unitRef="USD" decimals="0">-164128</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>

  <mbrx:BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted contextRef="P01_01_2016To12_31_2016" id="Factid_214" unitRef="USD_per_Share" decimals="2">-0.42</mbrx:BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted>

  <mbrx:BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted contextRef="P01_01_2015To12_31_2015" id="Factid_215" unitRef="USD_per_Share" decimals="2">-0.04</mbrx:BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted>

  <mbrx:BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted contextRef="P01_01_2016To12_31_2016" id="Factid_216" unitRef="shares" decimals="INF">9401028</mbrx:BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted>

  <mbrx:BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted contextRef="P01_01_2015To12_31_2015" id="Factid_217" unitRef="shares" decimals="INF">4273239</mbrx:BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted>

  <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="P01_01_2016To12_31_2016_AcquisitionDateOneMembermbrxPeriodTypeAxis_MoleculinLlcMemberusgaapBusinessAcquisitionAxis" id="Factid_218" unitRef="USD" decimals="0">145078</us-gaap:AmortizationOfFinancingCostsAndDiscounts>

  <dei:DocumentType contextRef="P01_01_2016To12_31_2016" id="Factid_219">10-K</dei:DocumentType>

  <dei:AmendmentFlag contextRef="P01_01_2016To12_31_2016" id="Factid_220">false</dei:AmendmentFlag>

  <dei:DocumentPeriodEndDate contextRef="P01_01_2016To12_31_2016" id="Factid_221">2016-12-31</dei:DocumentPeriodEndDate>

  <dei:DocumentFiscalYearFocus contextRef="P01_01_2016To12_31_2016" id="Factid_222">2016</dei:DocumentFiscalYearFocus>

  <dei:DocumentFiscalPeriodFocus contextRef="P01_01_2016To12_31_2016" id="Factid_223">FY</dei:DocumentFiscalPeriodFocus>

  <dei:EntityRegistrantName contextRef="P01_01_2016To12_31_2016" id="Factid_224">Moleculin Biotech, Inc.</dei:EntityRegistrantName>

  <dei:EntityCentralIndexKey contextRef="P01_01_2016To12_31_2016" id="Factid_225">0001659617</dei:EntityCentralIndexKey>

  <dei:CurrentFiscalYearEndDate contextRef="P01_01_2016To12_31_2016" id="Factid_226">--12-31</dei:CurrentFiscalYearEndDate>

  <dei:EntityWellKnownSeasonedIssuer contextRef="P01_01_2016To12_31_2016" id="Factid_227">No</dei:EntityWellKnownSeasonedIssuer>

  <dei:EntityVoluntaryFilers contextRef="P01_01_2016To12_31_2016" id="Factid_228">No</dei:EntityVoluntaryFilers>

  <dei:EntityCurrentReportingStatus contextRef="P01_01_2016To12_31_2016" id="Factid_229">Yes</dei:EntityCurrentReportingStatus>

  <dei:EntityFilerCategory contextRef="P01_01_2016To12_31_2016" id="Factid_230">Smaller Reporting Company</dei:EntityFilerCategory>

  <dei:EntityPublicFloat contextRef="PAsOn06_30_2016" id="Factid_231" unitRef="USD" decimals="0">27612783</dei:EntityPublicFloat>

  <dei:TradingSymbol contextRef="P01_01_2016To12_31_2016" id="Factid_232">MBRX</dei:TradingSymbol>

  <dei:EntityCommonStockSharesOutstanding contextRef="PAsOn03_24_2017" id="Factid_233" unitRef="shares" decimals="INF">17176872</dei:EntityCommonStockSharesOutstanding>

  <us-gaap:CommitmentsAndContingencies contextRef="PAsOn12_31_2015" id="Factid_234" unitRef="USD" xsi:nil="true" />

  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="PAsOn12_31_2016" id="Factid_235" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>

  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="PAsOn12_31_2015" id="Factid_236" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>

  <us-gaap:PreferredStockSharesAuthorized contextRef="PAsOn12_31_2015" id="Factid_237" unitRef="shares" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>

  <us-gaap:PreferredStockSharesIssued contextRef="PAsOn12_31_2016" id="Factid_238" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>

  <us-gaap:PreferredStockSharesIssued contextRef="PAsOn12_31_2015" id="Factid_239" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>

  <us-gaap:PreferredStockSharesOutstanding contextRef="PAsOn12_31_2016" id="Factid_240" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>

  <us-gaap:PreferredStockSharesOutstanding contextRef="PAsOn12_31_2015" id="Factid_241" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>

  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="PAsOn12_31_2016" id="Factid_242" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>

  <us-gaap:CommonStockSharesAuthorized contextRef="PAsOn12_31_2016" id="Factid_243" unitRef="shares" decimals="INF">75000000</us-gaap:CommonStockSharesAuthorized>

  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="PAsOn12_31_2015" id="Factid_244" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>

  <us-gaap:CommonStockSharesAuthorized contextRef="PAsOn12_31_2015" id="Factid_245" unitRef="shares" decimals="INF">75000000</us-gaap:CommonStockSharesAuthorized>

  <us-gaap:CommonStockSharesIssued contextRef="PAsOn12_31_2016" id="Factid_246" unitRef="shares" decimals="INF">12164852</us-gaap:CommonStockSharesIssued>

  <us-gaap:CommonStockSharesOutstanding contextRef="PAsOn12_31_2016" id="Factid_247" unitRef="shares" decimals="INF">12164852</us-gaap:CommonStockSharesOutstanding>

  <us-gaap:CommonStockSharesIssued contextRef="PAsOn12_31_2015" id="Factid_248" unitRef="shares" decimals="INF">6661000</us-gaap:CommonStockSharesIssued>

  <us-gaap:CommonStockSharesOutstanding contextRef="PAsOn12_31_2015" id="Factid_249" unitRef="shares" decimals="INF">6661000</us-gaap:CommonStockSharesOutstanding>

  <mbrx:StockIssuedDuringPeriodValuePrivateIssuances contextRef="P01_01_2016To12_31_2016" id="Factid_250" unitRef="USD" decimals="0">702894</mbrx:StockIssuedDuringPeriodValuePrivateIssuances>

  <mbrx:StockIssuedDuringPeriodValuePrivateIssuances contextRef="P01_01_2016To12_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_251" unitRef="USD" decimals="0">234</mbrx:StockIssuedDuringPeriodValuePrivateIssuances>

  <mbrx:StockIssuedDuringPeriodValuePrivateIssuances contextRef="P01_01_2016To12_31_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_252" unitRef="USD" decimals="0">702660</mbrx:StockIssuedDuringPeriodValuePrivateIssuances>

  <mbrx:StockIssuedDuringPeriodSharesPrivateIssuances contextRef="P01_01_2016To12_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_253" unitRef="shares" decimals="INF">234297</mbrx:StockIssuedDuringPeriodSharesPrivateIssuances>

  <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="P01_01_2016To12_31_2016" id="Factid_254" unitRef="USD" decimals="0">5999586</us-gaap:StockIssuedDuringPeriodValueAcquisitions>

  <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="P01_01_2016To12_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_255" unitRef="USD" decimals="0">1000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>

  <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="P01_01_2016To12_31_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_256" unitRef="USD" decimals="0">5998586</us-gaap:StockIssuedDuringPeriodValueAcquisitions>

  <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="P01_01_2016To12_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_257" unitRef="shares" decimals="INF">999931</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>

  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="P01_01_2016To12_31_2016" id="Factid_258" unitRef="USD" decimals="0">157680</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>

  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="P01_01_2016To12_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_259" unitRef="USD" decimals="0">24</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>

  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="P01_01_2016To12_31_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_260" unitRef="USD" decimals="0">157656</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>

  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="P01_01_2016To12_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_261" unitRef="shares" decimals="INF">24000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P01_01_2016To12_31_2016" id="Factid_262" unitRef="USD" decimals="0">166294</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P01_01_2016To12_31_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_263" unitRef="USD" decimals="0">166294</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="P01_01_2016To12_31_2016" id="Factid_264" unitRef="USD" decimals="0">363792</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>

  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="P01_01_2016To12_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_265" unitRef="USD" decimals="0">2077</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>

  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="P01_01_2016To12_31_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_266" unitRef="USD" decimals="0">361715</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>

  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="P01_01_2016To12_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_267" unitRef="shares" decimals="INF">2076598</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>

  <mbrx:StockholdersEquitySubscriptionsSettledForCash contextRef="P01_01_2016To12_31_2016" id="Factid_268" unitRef="USD" decimals="0">3000</mbrx:StockholdersEquitySubscriptionsSettledForCash>

  <mbrx:StockholdersEquitySubscriptionsSettledForCash contextRef="P01_01_2016To12_31_2016_SubscriptionsReceivableMemberusgaapStatementEquityComponentsAxis" id="Factid_269" unitRef="USD" decimals="0">3000</mbrx:StockholdersEquitySubscriptionsSettledForCash>

  <us-gaap:SharesIssuedPricePerShare contextRef="PAsOn12_31_2016" id="Factid_270" unitRef="USD_per_Share" decimals="2">3.00</us-gaap:SharesIssuedPricePerShare>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="P01_01_2016To12_31_2016" id="Factid_271" unitRef="USD" decimals="0">1150736</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>

  <mbrx:NatureOfBusinessAndLiquidityTextBlock contextRef="P01_01_2016To12_31_2016" id="Factid_272">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;/div&gt; &lt;table style="LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0"&gt; &lt;tr&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.3pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"&gt; &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;1.&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Nature of Business and Liquidity&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The terms &amp;#8220;MBI&amp;#8221; or &amp;#8220;the Company&amp;#8221;, &amp;#8220;we&amp;#8221;, &amp;#8220;our&amp;#8221; and &amp;#8220;us&amp;#8221; are used herein to refer to Moleculin Biotech, Inc. MBI is a preclinical pharmaceutical company organized as a Delaware corporation in July 2015 to focus on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, which we refer to as MD Anderson.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;Our lead drug candidate is liposomal Annamycin, which we refer to as Annamycin, an anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia, or AML. In August 2015, the Company entered into a rights transfer agreement with AnnaMed, Inc. (&amp;#8220;AnnaMed&amp;#8221;), a company affiliated with certain members of the Company&amp;#8217;s management and board of directors, pursuant to which, in exchange for &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,431,000&lt;/font&gt; shares of the Company&amp;#8217;s common stock, AnnaMed agreed to transfer to MBI any and all data it had regarding the development of Annamycin and the Annamycin investigative new drug application (&amp;#8220;IND&amp;#8221;) with the U.S. Food and Drug Administration (&amp;#8220;FDA&amp;#8221;) , including all trade secrets, know-how, confidential information and other intellectual property rights held by AnnaMed. Annamycin has been in clinical trials pursuant to an IND that had been filed with the FDA. This IND was terminated due to a lack of activity by a prior drug developer.&amp;#160;However, in the course of our review of that data, we identified that Annamycin may have greater potential for efficacy than we originally believed, based on an unexpected potential opportunity to increase the drug&amp;#8217;s Maximum Tolerable Dose (&amp;#8220;MTD&amp;#8221;). We determined to adjust our clinical strategy by adding in a Phase I arm to our next Phase II trial.&lt;/div&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Because the prior developer of Annamycin allowed their IND to lapse, we are required to submit a new IND for continued clinical trials with Annamycin. We filed our IND application, with the clinical strategy of increasing the MTD mentioned above, for Annamycin on February 10, 2017. &amp;#160;In subsequent discussions with us, FDA requested certain revisions to the protocol, additional&amp;#160;information, and additional data related to Chemistry, Manufacturing and Controls (&amp;#8220;CMC&amp;#8221;). &amp;#160;We have the additional information, have made the requested revisions to the protocol,&amp;#160;and we are working on developing the CMC data. &amp;#160;In the interim, we have withdrawn the IND application in order to resubmit it when the requested data are available. &amp;#160;We believe that resubmission of the IND application will occur in time for the IND to go into effect and the announcement of the beginning of Phase I/II clinical trials in the first half of 2017. However, if we are unable to obtain the required CMC data on a timely basis, we will be delayed in resubmitting our IND application, which will delay the commencement of our clinical trials beyond the first half of 2017.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;The Annamycin drug substance is no longer covered by any existing patent protection. We intend to submit patent applications for formulation, synthetic process and reconstitution related to our Annamycin drug product candidate, although there is no assurance that we will be successful in obtaining such patent protection. On March 21, 2017, we received notice that FDA had granted us Orphan Drug designation for Annamycin &lt;font style="FONT-FAMILY:Times New Roman, Times, Serif"&gt;for the treatment of AML&lt;/font&gt; . Orphan Drug status could entitle us to market exclusivity of up to 7 and 10 years from the date of approval of a New Drug Application (&amp;#8220;NDA&amp;#8221;) or Marketing Authorization Application (&amp;#8220;MAA&amp;#8221;), in the US and the European Union (&amp;#8220;EU&amp;#8221;), respectively. Separately, the FDA may also grant market exclusivity of up to five years for newly approved new chemical entities (of which Annamycin would be one), but there can be no assurance that such exclusivity will be granted.&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;We have two other drug development projects in progress, one involving a portfolio of small molecules, which we refer to as the WP1066 Portfolio, focused on the modulation of key oncogenic transcription factors involved in the progression of cancer, and the WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer in general, and glioblastoma (the most common form of brain tumor) in particular. We have been granted royalty-bearing, worldwide, exclusive licenses for the patent and technology rights related to our WP1066 Portfolio and WP1122 Portfolio drug technologies, as these patent rights are owned by MD Anderson.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On August 11, 2015, the Company entered into a rights transfer agreement for WP1122 with IntertechBio Corporation (&amp;#8220;IntertechBio&amp;#8221;), a company affiliated with certain members of our management, whereby IntertechBio agreed to assign its license or sublicense its license&amp;#160;&amp;#160; to certain metabolic inhibitor technology owned by MD Anderson. In consideration, the Company issued &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 630,000&lt;/font&gt; common shares to IntertechBio. IntertechBio&amp;#160;&amp;#160; agreed to make payments to MD Anderson including an up-front payment, license documentation fee, annual maintenance fee, milestone payments and minimum annual royalty payments for sales of products developed under the license agreement. The Company has assumed the rights and obligations of IntertechBio under the license agreement with MD Anderson. Therefore, &amp;#160;all out-of-pocket expenses incurred by MD Anderson in filing, prosecuting and maintaining the licensed patents have been and shall continue to be assumed &amp;#160;&amp;#160;by the Company.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In accordance with FASB ASC Topic 280, Segment Reporting, we view our operations and manage our business as principally one segment. As a result, the financial information disclosed herein represents all of the material financial information related to our principal operating segment.&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The Company filed a registration statement on Form S-1 (which was declared effective on May 2, 2016) with respect to the Company&amp;#8217;s initial public offering of shares of its common stock (&amp;#8220;IPO&amp;#8221;) to fund the development of its technologies. Prior to the declaration of effectiveness of the registration statement on Form S-1, we acquired Moleculin, LLC which was merged with and into MBI. Moleculin, LLC was the holder of a license agreement with MD Anderson covering technology referred to as &amp;#160;&amp;#160;the WP1066 Portfolio, which is focused on the modulation of key oncogenic transcription factors.&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</mbrx:NatureOfBusinessAndLiquidityTextBlock>

  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2016To12_31_2016" id="Factid_273">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0"&gt; &lt;tr&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.3pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"&gt; &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;2.&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Summary of Significant Accounting Policies&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The accompanying audited financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&amp;#8220;U.S. GAAP&amp;#8221;) for financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;).&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Use of Estimates in Financial Statement Presentation -&lt;/font&gt;&lt;/b&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The preparation of these financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/font&gt;&lt;/b&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Acquisition &amp;#150;&lt;/b&gt; We acquired Moleculin, LLC (&amp;#8220;Moleculin&amp;#8221;) on May 2, 2016, and, going forward our financial statements include the operations of Moleculin, LLC. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired in-process research and development (&amp;#8220;IPR&amp;amp;D&amp;#8221;) be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired will be recorded as goodwill. The Company obtained input from third-parties regarding its tangible and intangible assets and other information necessary to measure the fair value of the assets acquired and liabilities assumed in connection with the acquisition of Moleculin, LLC.&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;b&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/b&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Going Concern -&lt;/b&gt; These financial statements have been prepared on a going concern basis, which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The continuation of the Company as a going concern is dependent upon the ability of the Company to obtain continued financial support from its stockholders&amp;#8217;, necessary equity financing to continue operations and the attainment of profitable operations. As of December 31, 2016, the Company has incurred an accumulated deficit of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4,674,721&lt;/font&gt; since inception, and had not yet generated any revenue from operations. Additionally, management anticipates that its cash on hand as of December 31, 2016 plus the additional cash generated from its equity offering subsequent to year-end, discussed further within these notes to the financial statements, is sufficient to fund its planned operations into but not beyond the near term. These factors raise substantial doubt regarding the Company&amp;#8217;s ability to continue as a going concern. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company may seek additional funding through a combination of equity offerings, debt financings, government or other third-party funding, commercialization, marketing and distribution arrangements, other collaborations, strategic alliances and licensing arrangements and delay planned cash outlays or a combination thereof. Management cannot be certain that such events or a combination thereof can be achieved.&amp;#160;&amp;#160;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Cash and Cash Equivalents -&lt;/strong&gt; The Company considers all highly liquid accounts with original maturities of three months or less at the date of acquisition to be cash equivalents.&amp;#160;Periodically, the Company may carry cash balances at financial institutions in excess of the federally insured limit of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;250,000&lt;/font&gt;. The amount in excess of the FDIC insurance at December 31, 2016 was $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;256,836&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0&lt;/font&gt; as of December 31, 2015. Compensation expense is recognized only for share based payments expected to vest.&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Property and equipment -&lt;/font&gt;&lt;/b&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Property and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line depreciation method as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 85%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; MARGIN-LEFT: 0.5in; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="85%"&gt; &lt;tr&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 40%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="40%"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Leasehold improvement&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 60%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="60%"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Shorter of estimated useful lives or the term of the lease&lt;/font&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Computer equipment&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2&lt;/font&gt; years*&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Machinery and equipment&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5&lt;/font&gt; years*&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Furniture and office equipment&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;7&lt;/font&gt; years*&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;*Property and equipment assets acquired in the merger with Moleculin, LLC are being depreciated over a &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2&lt;/font&gt; year useful life due to their age and condition and expected remaining life assessed at merger date.&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Intangible assets -&lt;/font&gt;&lt;/b&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Intangible assets with finite lives are amortized using the straight-line method over their estimated period of benefit. If an intangible asset is identified as an in-process research &amp;amp; development asset, then no amortization will occur until the development is complete. If the associated research and development effort is abandoned, the related assets will be written-off and the Company will record a noncash impairment loss on its statements of operations. For those compounds that reach commercialization, the IPR&amp;amp;D assets will be amortized over their estimated useful lives.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;We evaluate the recoverability of intangible assets periodically and take into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists. No material impairments of intangible assets have been identified during any of the periods presented. Intangible assets are tested for impairment on an annual basis, and between annual tests if indicators of potential impairment exist, using a fair-value-based approach.&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Beneficial Conversion Feature&lt;/b&gt; - From time to time, the Company may issue convertible notes that have conversion prices that create an embedded beneficial conversion feature on the issuance date. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of any attached equity instruments, if any related equity instruments were granted with the debt. The Company estimated the fair value of its common stock on the dates issued. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid-in capital, if any. The debt discount is amortized to interest expense over the life of the note using the effective interest method.&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"&gt; &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Income Taxes -&lt;/b&gt; The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of reported assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company must then assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.&amp;#160;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"&gt;The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740-10 which prescribes a recognition threshold and measurement attribute for financial statement disclosure of tax positions taken, or expected to be taken, on its tax return. The Company evaluates and records any uncertain tax positions based on the amount that management deems is more likely than not to be sustained upon examination and ultimate settlement with the tax authorities in the tax jurisdictions in which it operates.&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Stock-based Compensation -&lt;/b&gt; Stock-based compensation expense includes the estimated fair value of equity awards vested during the reporting period. The expense for equity awards vested during the reporting period is determined based upon the grant date fair value of the award and is recognized as expense over the applicable vesting period of the stock award using the straight-line method.&amp;#160;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"&gt; &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;strong&gt;Loss Per Common Share&lt;/strong&gt; - Basic net loss per common share are computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. As of December 31, 2016, the Company&amp;#8217;s potentially dilutive shares, which were not included in the calculation of net loss per share, included notes convertible to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,821,013&lt;/font&gt; common shares, options to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 510,000&lt;/font&gt; common shares and warrants to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 107,802&lt;/font&gt; common shares.&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Research and Development Costs -&lt;/font&gt;&lt;/b&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Research and development costs are expensed as incurred.&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/font&gt;&lt;/b&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;b&gt;Subsequent Events -&lt;/b&gt; The Company&amp;#8217;s management reviewed all material events through the date these financial statements were issued for subsequent event disclosure consideration and has noted such events as described in Note 8.&lt;/div&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Recent Accounting Pronouncements&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"&gt;In May 2014, the FASB issued Accounting Standard Update ("ASU") 2014-09, Revenue from Contracts with Customers (Topic 606), which will replace numerous requirements in U.S. GAAP, including industry-specific requirements, and provide companies with a single revenue recognition model for recognizing revenue from contracts with customers. The core principle of the new standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In August 2015, the FASB approved a proposal to defer the effective date of the guidance until annual and interim reporting periods beginning after December 15, 2017. The Company is currently evaluating the impact that this standard will have on its financial statements at the time the Company starts to generate revenue or enters into other contractual arrangements, which the Company does not expect in the near term.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&amp;#8217;s Ability to Continue as a Going Concern. Under the new guidance, management will be required to assess an entity&amp;#8217;s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. The provisions of this ASU are effective for annual periods ending after December 15, 2016, and for annual and interim periods thereafter; early adoption is permitted. This disclosure is effective within these financial statements for the year ended December 31, 2016.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments &amp;#150; Overall: Recognition and Measurement of Financial Assets and Financial Liabilities (&amp;#8220;ASU 2016-01&amp;#8221;).&amp;#160;ASU 2016-01 affects the accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements of financial instruments.&amp;#160;ASU 2016-01 is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years.&amp;#160;The Company is currently evaluating the impact that this standard will have on its financial statements.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (&amp;#8220;ASU 2016-02&amp;#8221;). Under ASU 2016-02, an entity will be required to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements.&amp;#160;ASU 2016-02 offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases.&amp;#160;For public companies, ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, and requires a modified retrospective adoption, with early adoption permitted.&amp;#160;The Company is currently evaluating the impact that this standard will have on its financial statements.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;In March 2016, the FASB issued ASU 2016-09, Compensation-Stock Compensation (Topic 718). The new guidance changes the accounting and simplifies various aspects of the accounting for share-based payments to employees. The guidance allows for a policy election to account for forfeitures as they occur or based on an estimated number of awards that are expected to vest. ASU 2016-09 is effective for annual periods beginning after December 15, 2016, with early adoption permitted. The adoption of this standard on January 1, 2017, did not have a significant impact on the Company&amp;#8217;s financial statements.&lt;/div&gt; &amp;#160; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"&gt;In August 2016, the FASB issued ASU, Statement of Cash Flows (Topic 230). This ASU applies to all entities that are required to present a statement of cash flows under Topic 230. The amendments provide guidance on eight specific cash flow issues and includes clarification on how these items should be classified in the statement of cash flows and is designed to help eliminate diversity in practice as to where items are classified in the cash flow statement. Furthermore in November 2016, the FASB issued additional guidance on this Topic that requires amounts generally described as restricted cash and restricted cash equivalents to be included with cash and cash equivalents when reconciling the statement of cash flows. This ASU is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years, with earlier application permitted for all entities. We plan to adopt the provisions of this ASU for our fiscal year beginning January 1, 2018 and are currently evaluating the impact the adoption of this new accounting standard will have on our financial statements.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;On November 20, 2015, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update ("ASU") 2015-17, "Balance Sheet Classification of Deferred Taxes", requiring all deferred tax assets and liabilities, and any related valuation allowance, to be classified as non-current on the balance sheet. The classification change for all deferred taxes as non-current simplifies entities&amp;#8217; processes as it eliminates the need to separately identify the net current and net non-current deferred tax asset or liability in each jurisdiction and allocate valuation allowances. The Company elected to adopt the accounting in the fourth quarter of 2016.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The Company does not believe that any other recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect on the accompanying financial statements.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>

  <us-gaap:UseOfEstimates contextRef="P01_01_2016To12_31_2016" id="Factid_274">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Use of Estimates in Financial Statement Presentation -&lt;/font&gt;&lt;/b&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The preparation of these financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:UseOfEstimates>

  <mbrx:GoingConcernPolicyPolicyTextBlock contextRef="P01_01_2016To12_31_2016" id="Factid_275">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"&gt;&lt;b&gt;Going Concern -&lt;/b&gt; These financial statements have been prepared on a going concern basis, which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The continuation of the Company as a going concern is dependent upon the ability of the Company to obtain continued financial support from its stockholders&amp;#8217;, necessary equity financing to continue operations and the attainment of profitable operations. As of December 31, 2016, the Company has incurred an accumulated deficit of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4,674,721&lt;/font&gt; since inception, and had not yet generated any revenue from operations. Additionally, management anticipates that its cash on hand as of December 31, 2016 plus the additional cash generated from its equity offering subsequent to year-end, discussed further within these notes to the financial statements, is sufficient to fund its planned operations into but not beyond the near term. These factors raise substantial doubt regarding the Company&amp;#8217;s ability to continue as a going concern. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company may seek additional funding through a combination of equity offerings, debt financings, government or other third-party funding, commercialization, marketing and distribution arrangements, other collaborations, strategic alliances and licensing arrangements and delay planned cash outlays or a combination thereof. Management cannot be certain that such events or a combination thereof can be achieved.&amp;#160;&amp;#160;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</mbrx:GoingConcernPolicyPolicyTextBlock>

  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="P01_01_2016To12_31_2016" id="Factid_276">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Property and equipment -&lt;/font&gt;&lt;/b&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Property and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line depreciation method as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 85%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; MARGIN-LEFT: 0.5in; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="85%"&gt; &lt;tr&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 40%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="40%"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Leasehold improvement&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 60%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="60%"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Shorter of estimated useful lives or the term of the lease&lt;/font&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Computer equipment&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2&lt;/font&gt; years*&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Machinery and equipment&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5&lt;/font&gt; years*&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Furniture and office equipment&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;7&lt;/font&gt; years*&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;*Property and equipment assets acquired in the merger with Moleculin, LLC are being depreciated over a &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2&lt;/font&gt; year useful life due to their age and condition and expected remaining life assessed at merger date.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>

  <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy contextRef="P01_01_2016To12_31_2016" id="Factid_277">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Intangible assets -&lt;/font&gt;&lt;/b&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Intangible assets with finite lives are amortized using the straight-line method over their estimated period of benefit. If an intangible asset is identified as an in-process research &amp;amp; development asset, then no amortization will occur until the development is complete. If the associated research and development effort is abandoned, the related assets will be written-off and the Company will record a noncash impairment loss on its statements of operations. For those compounds that reach commercialization, the IPR&amp;amp;D assets will be amortized over their estimated useful lives.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;We evaluate the recoverability of intangible assets periodically and take into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists. No material impairments of intangible assets have been identified during any of the periods presented. Intangible assets are tested for impairment on an annual basis, and between annual tests if indicators of potential impairment exist, using a fair-value-based approach.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>

  <mbrx:DebtInstrumentConvertibleBeneficialConversionFeaturePolicyPolicyTextBlock contextRef="P01_01_2016To12_31_2016" id="Factid_278">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"&gt;&lt;b&gt;Beneficial Conversion Feature&lt;/b&gt; - From time to time, the Company may issue convertible notes that have conversion prices that create an embedded beneficial conversion feature on the issuance date. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of any attached equity instruments, if any related equity instruments were granted with the debt. The Company estimated the fair value of its common stock on the dates issued. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid-in capital, if any. The debt discount is amortized to interest expense over the life of the note using the effective interest method.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</mbrx:DebtInstrumentConvertibleBeneficialConversionFeaturePolicyPolicyTextBlock>

  <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2016To12_31_2016" id="Factid_279">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"&gt;&lt;b&gt;Income Taxes -&lt;/b&gt; The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of reported assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company must then assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.&amp;#160;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"&gt;The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740-10 which prescribes a recognition threshold and measurement attribute for financial statement disclosure of tax positions taken, or expected to be taken, on its tax return. The Company evaluates and records any uncertain tax positions based on the amount that management deems is more likely than not to be sustained upon examination and ultimate settlement with the tax authorities in the tax jurisdictions in which it operates.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IncomeTaxPolicyTextBlock>

  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="P01_01_2016To12_31_2016" id="Factid_280">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"&gt;&lt;b&gt;Stock-based Compensation -&lt;/b&gt; Stock-based compensation expense includes the estimated fair value of equity awards vested during the reporting period. The expense for equity awards vested during the reporting period is determined based upon the grant date fair value of the award and is recognized as expense over the applicable vesting period of the stock award using the straight-line method.&amp;#160;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>

  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="P01_01_2016To12_31_2016" id="Factid_281">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Research and Development Costs -&lt;/font&gt;&lt;/b&gt; &lt;font style="FONT-SIZE: 10pt"&gt; Research and development costs are expensed as incurred.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>

  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2016To12_31_2016" id="Factid_282">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Recent Accounting Pronouncements&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"&gt;In May 2014, the FASB issued Accounting Standard Update ("ASU") 2014-09, Revenue from Contracts with Customers (Topic 606), which will replace numerous requirements in U.S. GAAP, including industry-specific requirements, and provide companies with a single revenue recognition model for recognizing revenue from contracts with customers. The core principle of the new standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In August 2015, the FASB approved a proposal to defer the effective date of the guidance until annual and interim reporting periods beginning after December 15, 2017. The Company is currently evaluating the impact that this standard will have on its financial statements at the time the Company starts to generate revenue or enters into other contractual arrangements, which the Company does not expect in the near term.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&amp;#8217;s Ability to Continue as a Going Concern. Under the new guidance, management will be required to assess an entity&amp;#8217;s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. The provisions of this ASU are effective for annual periods ending after December 15, 2016, and for annual and interim periods thereafter; early adoption is permitted. This disclosure is effective within these financial statements for the year ended December 31, 2016.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments &amp;#150; Overall: Recognition and Measurement of Financial Assets and Financial Liabilities (&amp;#8220;ASU 2016-01&amp;#8221;).&amp;#160;ASU 2016-01 affects the accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements of financial instruments.&amp;#160;ASU 2016-01 is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years.&amp;#160;The Company is currently evaluating the impact that this standard will have on its financial statements.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (&amp;#8220;ASU 2016-02&amp;#8221;). Under ASU 2016-02, an entity will be required to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements.&amp;#160;ASU 2016-02 offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases.&amp;#160;For public companies, ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, and requires a modified retrospective adoption, with early adoption permitted.&amp;#160;The Company is currently evaluating the impact that this standard will have on its financial statements.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;In March 2016, the FASB issued ASU 2016-09, Compensation-Stock Compensation (Topic 718). The new guidance changes the accounting and simplifies various aspects of the accounting for share-based payments to employees. The guidance allows for a policy election to account for forfeitures as they occur or based on an estimated number of awards that are expected to vest. ASU 2016-09 is effective for annual periods beginning after December 15, 2016, with early adoption permitted. The adoption of this standard on January 1, 2017, did not have a significant impact on the Company&amp;#8217;s financial statements.&lt;/div&gt; &amp;#160; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"&gt;In August 2016, the FASB issued ASU, Statement of Cash Flows (Topic 230). This ASU applies to all entities that are required to present a statement of cash flows under Topic 230. The amendments provide guidance on eight specific cash flow issues and includes clarification on how these items should be classified in the statement of cash flows and is designed to help eliminate diversity in practice as to where items are classified in the cash flow statement. Furthermore in November 2016, the FASB issued additional guidance on this Topic that requires amounts generally described as restricted cash and restricted cash equivalents to be included with cash and cash equivalents when reconciling the statement of cash flows. This ASU is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years, with earlier application permitted for all entities. We plan to adopt the provisions of this ASU for our fiscal year beginning January 1, 2018 and are currently evaluating the impact the adoption of this new accounting standard will have on our financial statements.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;On November 20, 2015, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update ("ASU") 2015-17, "Balance Sheet Classification of Deferred Taxes", requiring all deferred tax assets and liabilities, and any related valuation allowance, to be classified as non-current on the balance sheet. The classification change for all deferred taxes as non-current simplifies entities&amp;#8217; processes as it eliminates the need to separately identify the net current and net non-current deferred tax asset or liability in each jurisdiction and allocate valuation allowances. The Company elected to adopt the accounting in the fourth quarter of 2016.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The Company does not believe that any other recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect on the accompanying financial statements.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>

  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2016To12_31_2016_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_283">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>

  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2016To12_31_2016_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_284">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>

  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2016To12_31_2016_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_285">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>

  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2016To12_31_2016_MoleculinLlcMemberusgaapBusinessAcquisitionAxis" id="Factid_286">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>

  <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="P01_01_2016To12_31_2016_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_287">Shorter of estimated usefule lives or the term of the lease</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>

  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P01_01_2016To12_31_2016_ConvertibleDebtSecuritiesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_288" unitRef="shares" decimals="INF">1821013</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

  <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="P01_01_2016To12_31_2016" id="Factid_289">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The acquisition price was allocated to the assets acquired and liabilities assumed based upon their estimated fair values and the information available to management. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.25in; WIDTH: 92%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="76%"&gt; &lt;div&gt;Cash&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;362&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="76%"&gt; &lt;div&gt;Property and equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;7,820&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="76%"&gt; &lt;div&gt;Intangibles&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;11,147,540&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="76%"&gt; &lt;div&gt;Total assets acquired&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;11,155,722&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="76%"&gt; &lt;div&gt;Liability assumed (HPI)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;(3,874,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="76%"&gt; &lt;div&gt;Other liabilities assumed, including $469,939 of notes payable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;(1,224,314)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="76%"&gt; &lt;div&gt;Net assets acquired/total consideration transferred&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;6,057,408&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>

  <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="P01_01_2016To12_31_2016" id="Factid_290">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Intangible assets consisted of the following at December 31, 2016 and December 31, 2015:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 96%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"&gt; &lt;div&gt;Intangibles acquired from Moleculin, LLC&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;11,147,540&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;&amp;#150;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>

  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="PAsOn12_31_2016_MoleculinLlcMemberusgaapBusinessAcquisitionAxis" id="Factid_291" unitRef="USD" decimals="0">362</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>

  <mbrx:LicencingArrangementsConsiderationPayable contextRef="PAsOn12_31_2016_HoustonPharmaceuticalsIncMemberdeiLegalEntityAxis_MoleculinLlcMemberusgaapBusinessAcquisitionAxis_OutlincenseAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" id="Factid_292" unitRef="USD" decimals="0">750000</mbrx:LicencingArrangementsConsiderationPayable>

  <mbrx:ConvertibleNotesPayableDisclosureTextBlock contextRef="P01_01_2016To12_31_2016" id="Factid_293">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0"&gt; &lt;tr&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.3pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"&gt; &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;4.&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Convertible Notes Payable&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On various dates from August 31, 2015 through January 19, 2016, each as amended on March 10, 2016, the Company entered into seven unsecured promissory notes with three separate third party investors. Each note bears interest at &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 8.0&lt;/font&gt;% per annum and was to mature on the earlier of June 30, 2016 or the completion of an IPO of the Company&amp;#8217;s securities.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;Since the completion of the IPO occurred prior to June 30, 2016, these notes were to be automatically converted according to their terms into shares of the Company&amp;#8217;s common stock at applicable conversion price upon the Company&amp;#8217;s IPO to the extent and provided that no holder of these notes was or will be permitted to convert such notes to the extent that the holder or any of its affiliates would beneficially own in excess of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 4.99&lt;/font&gt;% of our common stock after such conversion. Due to this 4.99% limitation, a portion of these notes was not converted at the time of the IPO and the remaining unconverted principal and accrued interest amounts of the effected notes will remain outstanding and will be converted into shares of our common stock at such time as the 4.99% limitation continues to be met. Until such time as the notes are converted into shares of common stock, the maturity date of the notes will automatically be extended and we will not be required to repay the notes or the accrued interest relating to the notes in cash.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The IPO was completed on May 31, 2016. On May 31, 2016, pursuant to the conversion feature of the foregoing notes and with restriction of the &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 4.99&lt;/font&gt;% beneficially owned condition limitation, discussed above, the Company issued &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,166,503&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt; common shares in total, reducing convertible debt principal by $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;183,356&lt;/font&gt; and accrued interest by $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;17,699&lt;/font&gt;. Subsequent to these transactions and through December 31, 2016, an additional &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 910,095&lt;/font&gt; common shares were issued due to the number of common shares outstanding allowing for conversion of additional shares under the 4.99% beneficially owned condition limitation. This reduced the convertible debt principal by $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;155,565&lt;/font&gt; and accrued interest by $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;7,172&lt;/font&gt;. The remaining convertible debt without consideration of accrued interest as of December 31, 2016, if converted on December 31, 2016, would result in an additional &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,821,013&lt;/font&gt; common shares to be issued.&lt;/div&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The convertible notes were analyzed for a beneficial conversion feature on various issuance dates, at which time it was concluded that a beneficial conversion feature did not exist.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The table below represents the shares that are convertible at December 31, 2016 relating to the principal amounts of these convertible notes payable and excludes any shares that are convertible relating to the associated accrued interest:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt; size: 8.5in 11.0in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 96%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;Shares&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;Convertible&amp;#160;at&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;Dec&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"&gt; &lt;div&gt;Issuance&amp;#160;Date&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;2016 (e)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;Conversion&amp;#160;Rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="33%"&gt; &lt;div&gt;August 31, 2015(a)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;38,299&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;125,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;0.1299&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;294,832&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"&gt; &lt;div&gt;September 3, 2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;125,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;125,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;0.1299&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;962,279&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"&gt; &lt;div&gt;October 6, 2015(a)(c)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;30,280&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;147,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;0.20&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;151,402&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"&gt; &lt;div&gt;October 6, 2015(b)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;&amp;#150;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;3,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;0.20&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;&amp;#150;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"&gt; &lt;div&gt;October 28, 2015(b)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;&amp;#150;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;50,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;0.20&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;&amp;#150;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"&gt; &lt;div&gt;January 14, 2016(d)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;&amp;#150;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;&amp;#150;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;0.20&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;&amp;#150;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"&gt; &lt;div&gt;January 19, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;82,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;&amp;#150;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;0.20&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;412,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"&gt; &lt;div&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;276,079&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;450,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;1,821,013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt; size: 8.5in 11.0in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 18.7pt; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in"&gt; (a) Debt partially converted on May 31, 2016 and on August 19, 2016.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 18.7pt; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in"&gt; (b) Debt fully converted to common shares on May 31, 2016.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 18.7pt; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in"&gt; (c) Debt partially converted on September 1, 2016.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 18.7pt; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in"&gt; (d) Debt fully converted to common shares effective November 30, 2016.&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 11.5pt 0pt 18.7pt; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in"&gt; (e) Excluded from the $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;276,079&lt;/font&gt; is $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;20,333&lt;/font&gt; in accrued interest on the convertible notes payable which is included in the accompanying balance sheet.&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 18.7pt; size: 8.5in 11.0in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 18.7pt; size: 8.5in 11.0in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;The common shares relating to the above mentioned convertible notes payable contain the following trading restrictions: (a) beginning 90 days after the initial closing of our IPO and until the one-year anniversary of the initial closing of the IPO, the holder of the note will be able to sell 1% of the number of shares of common stock underlying the note on a monthly basis, subject to a maximum sale on any trading day of 4% of the daily volume; (b) if the common stock price is over $7.00 per share for five consecutive trading days then the holder of the note can sell up to 3% of the number of shares of common stock underlying the note on a monthly basis, subject to a maximum sale on any trading day of 4% of the daily volume; (c) if the common stock price is over $10.00 per share for five consecutive trading days then the holder of the note can sell up to an additional 5% of the number of shares of common stock underlying the note on a monthly basis, subject to a maximum sale on any trading day of 7% of the daily volume; and (d) if the common stock price is over $14.00 per share then the holder of the note is not restricted from making any sales until such time as the common stock price falls back below $14.00 per share; and (b) thereafter, until the two-year anniversary of the initial closing of IPO, the holder of the note can sell on any trading day 10% of the daily volume; provided that if the common stock price is over $10.00 per share then the holder of the note is not restricted from making any sales until such time as the common stock falls back below $10.00 per share. The foregoing lock-up restrictions relate to public sales and do not restrict the transfer of the shares privately, if permitted by applicable law, provided the acquirer of the shares agrees to comply with the above restrictions with respect to any public sales.&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</mbrx:ConvertibleNotesPayableDisclosureTextBlock>

  <us-gaap:ConvertibleDebtTableTextBlock contextRef="P01_01_2016To12_31_2016" id="Factid_294">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The table below represents the shares that are convertible at December 31, 2016 relating to the principal amounts of these convertible notes payable and excludes any shares that are convertible relating to the associated accrued interest:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt; size: 8.5in 11.0in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 96%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;Shares&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;Convertible&amp;#160;at&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;Dec&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"&gt; &lt;div&gt;Issuance&amp;#160;Date&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;2016 (e)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;Conversion&amp;#160;Rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="33%"&gt; &lt;div&gt;August 31, 2015(a)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;38,299&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;125,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;0.1299&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;294,832&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"&gt; &lt;div&gt;September 3, 2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;125,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;125,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;0.1299&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;962,279&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"&gt; &lt;div&gt;October 6, 2015(a)(c)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;30,280&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;147,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;0.20&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;151,402&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"&gt; &lt;div&gt;October 6, 2015(b)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;&amp;#150;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;3,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;0.20&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;&amp;#150;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"&gt; &lt;div&gt;October 28, 2015(b)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;&amp;#150;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;50,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;0.20&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;&amp;#150;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"&gt; &lt;div&gt;January 14, 2016(d)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;&amp;#150;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;&amp;#150;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;0.20&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;&amp;#150;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"&gt; &lt;div&gt;January 19, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;82,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;&amp;#150;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;0.20&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;412,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"&gt; &lt;div&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;276,079&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;450,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;1,821,013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt; size: 8.5in 11.0in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 18.7pt; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in"&gt; (a) Debt partially converted on May 31, 2016 and on August 19, 2016.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 18.7pt; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in"&gt; (b) Debt fully converted to common shares on May 31, 2016.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 18.7pt; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in"&gt; (c) Debt partially converted on September 1, 2016.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 18.7pt; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in"&gt; (d) Debt fully converted to common shares effective November 30, 2016.&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 11.5pt 0pt 18.7pt; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in"&gt; (e) Excluded from the $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;276,079&lt;/font&gt; is $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;20,333&lt;/font&gt; in accrued interest on the convertible notes payable which is included in the accompanying balance sheet.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ConvertibleDebtTableTextBlock>

  <us-gaap:ConvertibleNotesPayableCurrent contextRef="PAsOn12_31_2016_InvestorMemberusgaapRelatedPartyTransactionAxis_IssueDateAugust312015MemberusgaapDebtInstrumentAxis" id="Factid_295" unitRef="USD" decimals="0">38299</us-gaap:ConvertibleNotesPayableCurrent>

  <us-gaap:ConvertibleNotesPayableCurrent contextRef="PAsOn12_31_2016_InvestorBMemberusgaapRelatedPartyTransactionAxis_IssueDateSeptember032015MemberusgaapDebtInstrumentAxis" id="Factid_296" unitRef="USD" decimals="0">125000</us-gaap:ConvertibleNotesPayableCurrent>

  <us-gaap:ConvertibleNotesPayableCurrent contextRef="PAsOn12_31_2016_InvestorCMemberusgaapRelatedPartyTransactionAxis_IssueDateOctober062015OneMemberusgaapDebtInstrumentAxis" id="Factid_297" unitRef="USD" decimals="0">30280</us-gaap:ConvertibleNotesPayableCurrent>

  <us-gaap:ConvertibleNotesPayableCurrent contextRef="PAsOn12_31_2016_InvestorDMemberusgaapRelatedPartyTransactionAxis_IssueDateOctober062015TwoMemberusgaapDebtInstrumentAxis" id="Factid_298" unitRef="USD" decimals="0">0</us-gaap:ConvertibleNotesPayableCurrent>

  <us-gaap:ConvertibleNotesPayableCurrent contextRef="PAsOn12_31_2016_InvestorEMemberusgaapRelatedPartyTransactionAxis_IssueDateOctober282015MemberusgaapDebtInstrumentAxis" id="Factid_299" unitRef="USD" decimals="0">0</us-gaap:ConvertibleNotesPayableCurrent>

  <us-gaap:ConvertibleNotesPayableCurrent contextRef="PAsOn12_31_2016_InvestorFMemberusgaapRelatedPartyTransactionAxis_IssueDateJanuary142016MemberusgaapDebtInstrumentAxis" id="Factid_300" unitRef="USD" decimals="0">0</us-gaap:ConvertibleNotesPayableCurrent>

  <us-gaap:ConvertibleNotesPayableCurrent contextRef="PAsOn12_31_2016_InvestorGMemberusgaapRelatedPartyTransactionAxis_IssueDateJanuary192016MemberusgaapDebtInstrumentAxis" id="Factid_301" unitRef="USD" decimals="0">82500</us-gaap:ConvertibleNotesPayableCurrent>

  <us-gaap:ConvertibleNotesPayableCurrent contextRef="PAsOn12_31_2015_InvestorMemberusgaapRelatedPartyTransactionAxis_IssueDateAugust312015MemberusgaapDebtInstrumentAxis" id="Factid_302" unitRef="USD" decimals="0">125000</us-gaap:ConvertibleNotesPayableCurrent>

  <us-gaap:ConvertibleNotesPayableCurrent contextRef="PAsOn12_31_2015_InvestorBMemberusgaapRelatedPartyTransactionAxis_IssueDateSeptember032015MemberusgaapDebtInstrumentAxis" id="Factid_303" unitRef="USD" decimals="0">125000</us-gaap:ConvertibleNotesPayableCurrent>

  <us-gaap:ConvertibleNotesPayableCurrent contextRef="PAsOn12_31_2015_InvestorCMemberusgaapRelatedPartyTransactionAxis_IssueDateOctober062015OneMemberusgaapDebtInstrumentAxis" id="Factid_304" unitRef="USD" decimals="0">147000</us-gaap:ConvertibleNotesPayableCurrent>

  <us-gaap:ConvertibleNotesPayableCurrent contextRef="PAsOn12_31_2015_InvestorDMemberusgaapRelatedPartyTransactionAxis_IssueDateOctober062015TwoMemberusgaapDebtInstrumentAxis" id="Factid_305" unitRef="USD" decimals="0">3000</us-gaap:ConvertibleNotesPayableCurrent>

  <us-gaap:ConvertibleNotesPayableCurrent contextRef="PAsOn12_31_2015_InvestorEMemberusgaapRelatedPartyTransactionAxis_IssueDateOctober282015MemberusgaapDebtInstrumentAxis" id="Factid_306" unitRef="USD" decimals="0">50000</us-gaap:ConvertibleNotesPayableCurrent>

  <us-gaap:ConvertibleNotesPayableCurrent contextRef="PAsOn12_31_2015_InvestorFMemberusgaapRelatedPartyTransactionAxis_IssueDateJanuary142016MemberusgaapDebtInstrumentAxis" id="Factid_307" unitRef="USD" decimals="0">0</us-gaap:ConvertibleNotesPayableCurrent>

  <us-gaap:ConvertibleNotesPayableCurrent contextRef="PAsOn12_31_2015_InvestorGMemberusgaapRelatedPartyTransactionAxis_IssueDateJanuary192016MemberusgaapDebtInstrumentAxis" id="Factid_308" unitRef="USD" decimals="0">0</us-gaap:ConvertibleNotesPayableCurrent>

  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="PAsOn12_31_2016_InvestorMemberusgaapRelatedPartyTransactionAxis_IssueDateAugust312015MemberusgaapDebtInstrumentAxis" id="Factid_309" unitRef="USD_per_Share" decimals="4">0.1299</us-gaap:DebtInstrumentConvertibleConversionPrice1>

  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="PAsOn12_31_2016_InvestorBMemberusgaapRelatedPartyTransactionAxis_IssueDateSeptember032015MemberusgaapDebtInstrumentAxis" id="Factid_310" unitRef="USD_per_Share" decimals="4">0.1299</us-gaap:DebtInstrumentConvertibleConversionPrice1>

  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="PAsOn12_31_2016_InvestorCMemberusgaapRelatedPartyTransactionAxis_IssueDateOctober062015OneMemberusgaapDebtInstrumentAxis" id="Factid_311" unitRef="USD_per_Share" decimals="2">0.20</us-gaap:DebtInstrumentConvertibleConversionPrice1>

  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="PAsOn12_31_2016_InvestorDMemberusgaapRelatedPartyTransactionAxis_IssueDateOctober062015TwoMemberusgaapDebtInstrumentAxis" id="Factid_312" unitRef="USD_per_Share" decimals="2">0.20</us-gaap:DebtInstrumentConvertibleConversionPrice1>

  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="PAsOn12_31_2016_InvestorEMemberusgaapRelatedPartyTransactionAxis_IssueDateOctober282015MemberusgaapDebtInstrumentAxis" id="Factid_313" unitRef="USD_per_Share" decimals="2">0.20</us-gaap:DebtInstrumentConvertibleConversionPrice1>

  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="PAsOn12_31_2016_InvestorFMemberusgaapRelatedPartyTransactionAxis_IssueDateJanuary142016MemberusgaapDebtInstrumentAxis" id="Factid_314" unitRef="USD_per_Share" decimals="2">0.20</us-gaap:DebtInstrumentConvertibleConversionPrice1>

  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="PAsOn12_31_2016_InvestorGMemberusgaapRelatedPartyTransactionAxis_IssueDateJanuary192016MemberusgaapDebtInstrumentAxis" id="Factid_315" unitRef="USD_per_Share" decimals="2">0.20</us-gaap:DebtInstrumentConvertibleConversionPrice1>

  <mbrx:NumberOfUnitsIssued contextRef="P01_15_2017To02_09_2017_SubsequentEventMemberusgaapSubsequentEventTypeAxis_UnderwritingAgreementMembermbrxAgreementTypeAxis" id="Factid_316" unitRef="shares" decimals="INF">3710000</mbrx:NumberOfUnitsIssued>

  <mbrx:PricePerUnit contextRef="PAsOn02_09_2017_SubsequentEventMemberusgaapSubsequentEventTypeAxis_UnderwritingAgreementMembermbrxAgreementTypeAxis" id="Factid_317" unitRef="USD_per_Share" decimals="2">1.35</mbrx:PricePerUnit>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn02_09_2017_SeriesWarrantMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_UnderwritingAgreementMembermbrxAgreementTypeAxis" id="Factid_318" unitRef="USD_per_Share" decimals="2">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn02_09_2017_SeriesBWarrantMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_UnderwritingAgreementMembermbrxAgreementTypeAxis" id="Factid_319" unitRef="USD_per_Share" decimals="2">1.35</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn02_09_2017_SeriesCWarrantMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_UnderwritingAgreementMembermbrxAgreementTypeAxis" id="Factid_320" unitRef="USD_per_Share" decimals="2">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <us-gaap:SaleOfStockDescriptionOfTransaction contextRef="P01_15_2017To02_09_2017_SubsequentEventMemberusgaapSubsequentEventTypeAxis_UnderwritingAgreementMembermbrxAgreementTypeAxis" id="Factid_321">purchase one share of common stock, and (iv) a five-year Series C warrant to purchase 0.50 of a share of common stock.</us-gaap:SaleOfStockDescriptionOfTransaction>

  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="PAsOn02_09_2017_SubsequentEventMemberusgaapSubsequentEventTypeAxis_UnderwritingAgreementMembermbrxAgreementTypeAxis" id="Factid_322" unitRef="shares" decimals="INF">556500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>

  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="PAsOn02_09_2017_SeriesWarrantMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_UnderwritingAgreementMembermbrxAgreementTypeAxis" id="Factid_323" unitRef="shares" decimals="INF">278250</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>

  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="PAsOn02_09_2017_SeriesBWarrantMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_UnderwritingAgreementMembermbrxAgreementTypeAxis" id="Factid_324" unitRef="shares" decimals="INF">556500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>

  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="PAsOn02_09_2017_SeriesCWarrantMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_UnderwritingAgreementMembermbrxAgreementTypeAxis" id="Factid_325" unitRef="shares" decimals="INF">278250</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>

  <mbrx:ClassOfWarrantOrRightsWarrantExercised contextRef="P01_15_2017To02_09_2017_SubsequentEventMemberusgaapSubsequentEventTypeAxis_UnderwritingAgreementMembermbrxAgreementTypeAxis" id="Factid_326" unitRef="shares" decimals="INF">278100</mbrx:ClassOfWarrantOrRightsWarrantExercised>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_15_2017To02_09_2017_SubsequentEventMemberusgaapSubsequentEventTypeAxis_UnderwritingAgreementMembermbrxAgreementTypeAxis" id="Factid_327" unitRef="shares" decimals="INF">556500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:SharePrice contextRef="PAsOn02_09_2017_SubsequentEventMemberusgaapSubsequentEventTypeAxis_UnderwritingAgreementMembermbrxAgreementTypeAxis" id="Factid_328" unitRef="USD_per_Share" decimals="3">1.349</us-gaap:SharePrice>

  <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="P01_15_2017To02_09_2017_SubsequentEventMemberusgaapSubsequentEventTypeAxis_UnderwritingAgreementMembermbrxAgreementTypeAxis" id="Factid_329" unitRef="USD" decimals="-5">4400000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn02_09_2017_SubsequentEventMemberusgaapSubsequentEventTypeAxis_UnderwritingAgreementMembermbrxAgreementTypeAxis" id="Factid_330" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <mbrx:DebtInstrumentConvertibleNumberOfCommonShares contextRef="P01_01_2016To12_31_2016_InvestorMemberusgaapRelatedPartyTransactionAxis_IssueDateAugust312015MemberusgaapDebtInstrumentAxis" id="Factid_331" unitRef="shares" decimals="INF">294832</mbrx:DebtInstrumentConvertibleNumberOfCommonShares>

  <mbrx:DebtInstrumentConvertibleNumberOfCommonShares contextRef="P01_01_2016To12_31_2016_InvestorBMemberusgaapRelatedPartyTransactionAxis_IssueDateSeptember032015MemberusgaapDebtInstrumentAxis" id="Factid_332" unitRef="shares" decimals="INF">962279</mbrx:DebtInstrumentConvertibleNumberOfCommonShares>

  <mbrx:DebtInstrumentConvertibleNumberOfCommonShares contextRef="P01_01_2016To12_31_2016_InvestorEMemberusgaapRelatedPartyTransactionAxis_IssueDateOctober282015MemberusgaapDebtInstrumentAxis" id="Factid_333" unitRef="shares" decimals="INF">0</mbrx:DebtInstrumentConvertibleNumberOfCommonShares>

  <mbrx:DebtInstrumentConvertibleNumberOfCommonShares contextRef="P01_01_2016To12_31_2016_InvestorFMemberusgaapRelatedPartyTransactionAxis_IssueDateJanuary142016MemberusgaapDebtInstrumentAxis" id="Factid_334" unitRef="shares" decimals="INF">0</mbrx:DebtInstrumentConvertibleNumberOfCommonShares>

  <mbrx:DebtInstrumentConvertibleNumberOfCommonShares contextRef="P01_01_2016To12_31_2016_InvestorGMemberusgaapRelatedPartyTransactionAxis_IssueDateJanuary192016MemberusgaapDebtInstrumentAxis" id="Factid_335" unitRef="shares" decimals="INF">412500</mbrx:DebtInstrumentConvertibleNumberOfCommonShares>

  <mbrx:DebtInstrumentConvertibleNumberOfCommonShares contextRef="P01_01_2016To12_31_2016_InvestorDMemberusgaapRelatedPartyTransactionAxis_IssueDateOctober062015TwoMemberusgaapDebtInstrumentAxis" id="Factid_336" unitRef="shares" decimals="INF">0</mbrx:DebtInstrumentConvertibleNumberOfCommonShares>

  <mbrx:DebtInstrumentConvertibleNumberOfCommonShares contextRef="P01_01_2016To12_31_2016_InvestorCMemberusgaapRelatedPartyTransactionAxis_IssueDateOctober062015OneMemberusgaapDebtInstrumentAxis" id="Factid_337" unitRef="shares" decimals="INF">151402</mbrx:DebtInstrumentConvertibleNumberOfCommonShares>

  <us-gaap:DebtInstrumentIssuanceDate1 contextRef="P01_01_2016To12_31_2016_InvestorMemberusgaapRelatedPartyTransactionAxis_IssueDateAugust312015MemberusgaapDebtInstrumentAxis" id="Factid_338">2015-08-31</us-gaap:DebtInstrumentIssuanceDate1>

  <us-gaap:DebtInstrumentIssuanceDate1 contextRef="P01_01_2016To12_31_2016_InvestorBMemberusgaapRelatedPartyTransactionAxis_IssueDateSeptember032015MemberusgaapDebtInstrumentAxis" id="Factid_339">2015-09-03</us-gaap:DebtInstrumentIssuanceDate1>

  <us-gaap:DebtInstrumentIssuanceDate1 contextRef="P01_01_2016To12_31_2016_InvestorCMemberusgaapRelatedPartyTransactionAxis_IssueDateOctober062015OneMemberusgaapDebtInstrumentAxis" id="Factid_340">2015-10-06</us-gaap:DebtInstrumentIssuanceDate1>

  <us-gaap:DebtInstrumentIssuanceDate1 contextRef="P01_01_2016To12_31_2016_InvestorDMemberusgaapRelatedPartyTransactionAxis_IssueDateOctober062015TwoMemberusgaapDebtInstrumentAxis" id="Factid_341">2015-10-06</us-gaap:DebtInstrumentIssuanceDate1>

  <us-gaap:DebtInstrumentIssuanceDate1 contextRef="P01_01_2016To12_31_2016_InvestorEMemberusgaapRelatedPartyTransactionAxis_IssueDateOctober282015MemberusgaapDebtInstrumentAxis" id="Factid_342">2015-10-28</us-gaap:DebtInstrumentIssuanceDate1>

  <us-gaap:DebtInstrumentIssuanceDate1 contextRef="P01_01_2016To12_31_2016_InvestorFMemberusgaapRelatedPartyTransactionAxis_IssueDateJanuary142016MemberusgaapDebtInstrumentAxis" id="Factid_343">2016-01-14</us-gaap:DebtInstrumentIssuanceDate1>

  <us-gaap:DebtInstrumentIssuanceDate1 contextRef="P01_01_2016To12_31_2016_InvestorGMemberusgaapRelatedPartyTransactionAxis_IssueDateJanuary192016MemberusgaapDebtInstrumentAxis" id="Factid_344">2016-01-19</us-gaap:DebtInstrumentIssuanceDate1>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2017To03_31_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis_ScienceAdvisoryBoardOneMemberusgaapTitleOfIndividualAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_345" unitRef="shares" decimals="INF">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2017To03_31_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis_ScienceAdvisoryBoardTwoMemberusgaapTitleOfIndividualAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_346" unitRef="shares" decimals="INF">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="P01_01_2017To03_31_2017_FormerScienceAdvisoryBoardMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_347" unitRef="shares" decimals="INF">79167</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="PAsOn03_31_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis_ScienceAdvisoryBoardOneMemberusgaapTitleOfIndividualAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_348" unitRef="USD_per_Share" decimals="2">2.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P01_01_2017To03_31_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis_ScienceAdvisoryBoardOneMemberusgaapTitleOfIndividualAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_349">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="PAsOn03_31_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis_ScienceAdvisoryBoardTwoMemberusgaapTitleOfIndividualAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_350" unitRef="USD_per_Share" decimals="2">2.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P01_01_2017To03_31_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis_ScienceAdvisoryBoardTwoMemberusgaapTitleOfIndividualAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_351">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>

  <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="P01_01_2017To03_31_2017_FormerScienceAdvisoryBoardMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_352" unitRef="USD" decimals="0">237500</us-gaap:DebtConversionConvertedInstrumentAmount1>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P03_01_2017To03_22_2017_SubsequentEventMemberusgaapSubsequentEventTypeAxis_UsFoodAndDrugAdministrationMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_353" unitRef="shares" decimals="INF">600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:InterestPayableCurrent contextRef="PAsOn12_31_2016_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis" id="Factid_354" unitRef="USD" decimals="0">20333</us-gaap:InterestPayableCurrent>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P05_01_2016To05_02_2016" id="Factid_355" unitRef="shares" decimals="INF">234297</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P05_01_2016To05_02_2016" id="Factid_356" unitRef="USD" decimals="0">702894</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <mbrx:CommonStockLockupAndLeakoutAgreementsDescription contextRef="P01_01_2016To12_31_2016" id="Factid_357">These shares are subject to the following lock-up agreement, from and after the later of six months after issuance or 90 days from the effective date of our IPO registration statement until the one-year anniversary thereof, (a) the holder of the shares can sell up to 10% of the purchased shares per month, subject to a maximum sale on any trading day of 8% of the daily volume of the common stock; (b) if the common stock price is over $7.00 per share for five consecutive trading days then the holder of the shares can sell up to 20% of the purchased shares per month, subject to a maximum sale on any trading day of 10% of the daily volume of the common stock; and (c) if the common stock price is over $12.00 per share then the holder of the shares is not restricted from making any sales until such time as the common stock price falls back below $12.00 per share.</mbrx:CommonStockLockupAndLeakoutAgreementsDescription>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P06_01_2016To06_20_2016_PcgAdvisoryGroupMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_358" unitRef="shares" decimals="INF">24000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P06_01_2016To06_20_2016_PcgAdvisoryGroupMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_359" unitRef="USD" decimals="0">157680</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2016To12_31_2016_EmployeeAndBoardOfDirectorsMemberusgaapTitleOfIndividualAxis" id="Factid_360" unitRef="USD" decimals="0">166294</us-gaap:ShareBasedCompensation>

  <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="P01_01_2016To12_31_2016" id="Factid_361">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The provision for income taxes consists of the following components (in thousands):&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both; size: 8.5in 11.0in" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Current Expense (Benefit):&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Federal&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;State&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Current Income Tax Expense&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Deferred Expense (Benefit):&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Federal&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;State&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Deferred Income Tax Expense&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Net Deferred Taxes&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>

  <us-gaap:SummaryOfValuationAllowanceTextBlock contextRef="P01_01_2016To12_31_2016" id="Factid_362">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The following summarizes activity related to the Company&amp;#8217;s valuation allowance (in thousands):&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both; size: 8.5in 11.0in" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Valuation Allowance at Beginning of Period&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;155&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Income Tax Benefit&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;1,242&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;155&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Release of Valuation Allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Valuation Allowance at End of Period&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;1,397&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;155&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>

  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="P01_01_2016To12_31_2016" id="Factid_363">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"&gt;A reconciliation of the income tax benefit computed using the federal statutory income tax rate to the Company&amp;#8217;s effective income tax rate is as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%" colspan="5"&gt; &lt;div&gt;December&amp;#160;31,&amp;#160;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%" colspan="5"&gt; &lt;div&gt;December&amp;#160;31,&amp;#160;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Amount&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Percent&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Amount&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Percent&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Federal Tax Benefit at Statutory Rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,335&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;34.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;254&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;34.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;State Tax Benefit Net of Federal&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;137&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3.48&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; BACKGROUND: #ffffff; COLOR: #000000; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;IPO Costs&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(227)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(5.78)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; BACKGROUND: #cceeff; COLOR: #000000; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(99)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(13.24)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Other Permanent Differences&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(3)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(0.08)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Increase in Valuation Allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(1,242)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(31.62)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(155)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(20.76)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Total Tax (Expense) / Benefit&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>

  <mbrx:PatentAndTechnologyLicenseAgreementMilestonePaymentsTableTextBlock contextRef="P01_01_2016To12_31_2016" id="Factid_364">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Pursuant to an amendment on October 19, 2015, the Company will pay milestone payments as follows:&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0px:auto; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Phase&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Amount&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="57%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Commencement of Phase II Study for a licensed product&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;200,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Commencement of Phase III Study for a licensed product&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;250,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Filing of a New Drug Application for a licensed product&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;400,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Receipt of market approval for a licensed product&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;500,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</mbrx:PatentAndTechnologyLicenseAgreementMilestonePaymentsTableTextBlock>

  <mbrx:LetterAgreementsTerms contextRef="P02_01_2016To02_29_2016_BonwickCapitalPartnersLlcMemberdeiLegalEntityAxis" id="Factid_365">the Company agreed to: a) pay success fees equal to 7% of the gross proceeds from any form of financing; and b) issue five-year warrants to purchase 7% of the Companys equity securities sold with a cashless exercise provision, exercisable at 125% of the price per share of the Companys common stock paid by investors in the transaction. In addition, the Company agreed to reimburse Bonwick for all of its out-of-pocket expenses incurred in connection with the offering, not to exceed $25,000, and fees and expenses of their counsel not to exceed $100,000.</mbrx:LetterAgreementsTerms>

  <us-gaap:OfficersCompensation contextRef="P07_25_2016To08_19_2016_ChiefFinancialOfficerAndExecutiveVicePresidentMemberusgaapTitleOfIndividualAxis" id="Factid_366" unitRef="USD" decimals="0">250000</us-gaap:OfficersCompensation>

  <us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued contextRef="P07_25_2016To08_19_2016_ChiefFinancialOfficerAndExecutiveVicePresidentMemberusgaapTitleOfIndividualAxis_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis" id="Factid_367" unitRef="shares" decimals="INF">400000</us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued>

  <us-gaap:DeferredCompensationArrangementWithIndividualExercisePrice contextRef="P07_25_2016To08_19_2016_ChiefFinancialOfficerAndExecutiveVicePresidentMemberusgaapTitleOfIndividualAxis_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis" id="Factid_368" unitRef="USD_per_Share" decimals="2">5.85</us-gaap:DeferredCompensationArrangementWithIndividualExercisePrice>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="P07_25_2016To08_19_2016_ChiefFinancialOfficerAndExecutiveVicePresidentMemberusgaapTitleOfIndividualAxis_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis" id="Factid_369">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>

  <us-gaap:SeveranceCosts1 contextRef="P09_10_2016To10_07_2016_MrLouisMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_370" unitRef="USD" decimals="0">100000</us-gaap:SeveranceCosts1>

  <mbrx:SeparationAgreementDescription contextRef="P09_10_2016To10_07_2016_MrLouisMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_371">Pursuant to the Separation Agreement, Mr. Ploth will be permitted to exercise 25% of the options to purchase common stock granted to him in December 2015, or 50,000 shares, until May 2020.</mbrx:SeparationAgreementDescription>

  <mbrx:DeferredTaxAssetsStartUpCosts contextRef="PAsOn12_31_2016" id="Factid_372" unitRef="USD" decimals="-3">798000</mbrx:DeferredTaxAssetsStartUpCosts>

  <mbrx:DeferredTaxAssetsStartUpCosts contextRef="PAsOn12_31_2015" id="Factid_373" unitRef="USD" decimals="-3">67000</mbrx:DeferredTaxAssetsStartUpCosts>

  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="PAsOn12_31_2016" id="Factid_374" unitRef="USD" decimals="-3">520000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>

  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="PAsOn12_31_2015" id="Factid_375" unitRef="USD" decimals="-3">89000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>

  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="PAsOn12_31_2016" id="Factid_376" unitRef="USD" decimals="-3">50000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>

  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="PAsOn12_31_2015" id="Factid_377" unitRef="USD" decimals="-3">0</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>

  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="PAsOn12_31_2016" id="Factid_378" unitRef="USD" decimals="-3">33000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>

  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="PAsOn12_31_2015" id="Factid_379" unitRef="USD" decimals="-3">0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>

  <us-gaap:DeferredTaxAssetsGross contextRef="PAsOn12_31_2016" id="Factid_380" unitRef="USD" decimals="-3">1401000</us-gaap:DeferredTaxAssetsGross>

  <us-gaap:DeferredTaxAssetsGross contextRef="PAsOn12_31_2015" id="Factid_381" unitRef="USD" decimals="-3">155000</us-gaap:DeferredTaxAssetsGross>

  <us-gaap:DeferredTaxAssetsNet contextRef="PAsOn12_31_2016" id="Factid_382" unitRef="USD" decimals="-3">4000</us-gaap:DeferredTaxAssetsNet>

  <us-gaap:DeferredTaxAssetsNet contextRef="PAsOn12_31_2015" id="Factid_383" unitRef="USD" decimals="-3">0</us-gaap:DeferredTaxAssetsNet>

  <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="PAsOn12_31_2016" id="Factid_384" unitRef="USD" decimals="-3">4000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>

  <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="PAsOn12_31_2015" id="Factid_385" unitRef="USD" decimals="-3">0</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>

  <us-gaap:DeferredTaxLiabilities contextRef="PAsOn12_31_2016" id="Factid_386" unitRef="USD" decimals="-3">4000</us-gaap:DeferredTaxLiabilities>

  <us-gaap:DeferredTaxLiabilities contextRef="PAsOn12_31_2015" id="Factid_387" unitRef="USD" decimals="-3">0</us-gaap:DeferredTaxLiabilities>

  <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="PAsOn12_31_2016" id="Factid_388" unitRef="USD" decimals="-3">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>

  <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="PAsOn12_31_2015" id="Factid_389" unitRef="USD" decimals="-3">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>

  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="P01_01_2016To12_31_2016" id="Factid_390" unitRef="USD" decimals="0">1335</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>

  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="P01_01_2015To12_31_2015" id="Factid_391" unitRef="USD" decimals="0">254</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>

  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="P01_01_2016To12_31_2016" id="Factid_392" unitRef="pure" decimals="4">0.3400</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>

  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="P01_01_2015To12_31_2015" id="Factid_393" unitRef="pure" decimals="4">0.3400</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>

  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="P01_01_2016To12_31_2016" id="Factid_394" unitRef="USD" decimals="0">137</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>

  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="P01_01_2015To12_31_2015" id="Factid_395" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>

  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="P01_01_2016To12_31_2016" id="Factid_396" unitRef="pure" decimals="4">0.0348</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>

  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="P01_01_2015To12_31_2015" id="Factid_397" unitRef="pure" decimals="2">0.00</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>

  <mbrx:EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost contextRef="P01_01_2016To12_31_2016" id="Factid_398" unitRef="USD" decimals="0">-227</mbrx:EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost>

  <mbrx:EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost contextRef="P01_01_2015To12_31_2015" id="Factid_399" unitRef="USD" decimals="0">-99</mbrx:EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost>

  <mbrx:EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent contextRef="P01_01_2016To12_31_2016" id="Factid_400" unitRef="pure" decimals="4">-0.0578</mbrx:EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent>

  <mbrx:EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent contextRef="P01_01_2015To12_31_2015" id="Factid_401" unitRef="pure" decimals="4">-0.1324</mbrx:EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent>

  <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="P01_01_2016To12_31_2016" id="Factid_402" unitRef="USD" decimals="0">-3</us-gaap:IncomeTaxReconciliationOtherAdjustments>

  <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="P01_01_2015To12_31_2015" id="Factid_403" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxReconciliationOtherAdjustments>

  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="P01_01_2016To12_31_2016" id="Factid_404" unitRef="pure" decimals="4">-0.0008</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>

  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="P01_01_2015To12_31_2015" id="Factid_405" unitRef="pure" decimals="2">0.00</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>

  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="P01_01_2016To12_31_2016" id="Factid_406" unitRef="USD" decimals="0">-1242</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>

  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="P01_01_2015To12_31_2015" id="Factid_407" unitRef="USD" decimals="0">-155</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>

  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="P01_01_2016To12_31_2016" id="Factid_408" unitRef="pure" decimals="4">-0.3162</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>

  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="P01_01_2015To12_31_2015" id="Factid_409" unitRef="pure" decimals="4">-0.2076</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>

  <us-gaap:IncomeTaxExpenseBenefit contextRef="P01_01_2016To12_31_2016" id="Factid_410" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>

  <us-gaap:IncomeTaxExpenseBenefit contextRef="P01_01_2015To12_31_2015" id="Factid_411" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>

  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="P01_01_2016To12_31_2016" id="Factid_412" unitRef="pure" decimals="2">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>

  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="P01_01_2015To12_31_2015" id="Factid_413" unitRef="pure" decimals="2">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>

  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="PAsOn12_31_2015" id="Factid_414" unitRef="USD" decimals="-3">155000</us-gaap:DeferredTaxAssetsValuationAllowance>

  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="PAsOn12_31_2014" id="Factid_415" unitRef="USD" decimals="-3">0</us-gaap:DeferredTaxAssetsValuationAllowance>

  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="P01_01_2016To12_31_2016" id="Factid_416" unitRef="USD" decimals="-3">1242000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>

  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="P01_01_2015To12_31_2015" id="Factid_417" unitRef="USD" decimals="-3">155000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>

  <mbrx:DeferredTaxAssetsValuationAllowanceReleases contextRef="P01_01_2016To12_31_2016" id="Factid_418" unitRef="USD" decimals="-3">0</mbrx:DeferredTaxAssetsValuationAllowanceReleases>

  <mbrx:DeferredTaxAssetsValuationAllowanceReleases contextRef="P01_01_2015To12_31_2015" id="Factid_419" unitRef="USD" decimals="-3">0</mbrx:DeferredTaxAssetsValuationAllowanceReleases>

  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="PAsOn12_31_2016" id="Factid_420" unitRef="USD" decimals="-3">1397000</us-gaap:DeferredTaxAssetsValuationAllowance>

  <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="P01_01_2016To12_31_2016" id="Factid_421" unitRef="USD" decimals="-3">0</us-gaap:CurrentFederalTaxExpenseBenefit>

  <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="P01_01_2015To12_31_2015" id="Factid_422" unitRef="USD" decimals="-3">0</us-gaap:CurrentFederalTaxExpenseBenefit>

  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="P01_01_2016To12_31_2016" id="Factid_423" unitRef="USD" decimals="-3">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>

  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="P01_01_2015To12_31_2015" id="Factid_424" unitRef="USD" decimals="-3">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>

  <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="P01_01_2016To12_31_2016" id="Factid_425" unitRef="USD" decimals="-3">0</us-gaap:CurrentIncomeTaxExpenseBenefit>

  <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="P01_01_2015To12_31_2015" id="Factid_426" unitRef="USD" decimals="-3">0</us-gaap:CurrentIncomeTaxExpenseBenefit>

  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="P01_01_2016To12_31_2016" id="Factid_427" unitRef="USD" decimals="-3">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>

  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="P01_01_2015To12_31_2015" id="Factid_428" unitRef="USD" decimals="-3">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>

  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="P01_01_2016To12_31_2016" id="Factid_429" unitRef="USD" decimals="-3">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>

  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="P01_01_2015To12_31_2015" id="Factid_430" unitRef="USD" decimals="-3">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>

  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="P01_01_2016To12_31_2016" id="Factid_431" unitRef="USD" decimals="-3">0</us-gaap:DeferredIncomeTaxExpenseBenefit>

  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="P01_01_2015To12_31_2015" id="Factid_432" unitRef="USD" decimals="-3">0</us-gaap:DeferredIncomeTaxExpenseBenefit>

  <us-gaap:OperatingLossCarryforwards contextRef="PAsOn12_31_2016" id="Factid_433" unitRef="USD" decimals="-4">1530000</us-gaap:OperatingLossCarryforwards>

  <mbrx:OperatingLossCarryforwardsExpirationPeriod contextRef="P01_01_2016To12_31_2016" id="Factid_434">2035</mbrx:OperatingLossCarryforwardsExpirationPeriod>

  <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets contextRef="P08_01_2015To08_31_2015_AnnamedIncMemberdeiLegalEntityAxis_UseRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_435" unitRef="shares" decimals="INF">1431000</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>

  <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets contextRef="P08_01_2015To08_31_2015_IntertechbioCorporationMemberdeiLegalEntityAxis_UseRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_436" unitRef="shares" decimals="INF">630000</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>

  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P01_01_2016To12_31_2016" id="Factid_437">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The following is a summary of option activities for the periods ended December 31, 2015 and 2016:&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Remaining&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Contractual&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Aggregate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Number&amp;#160;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Weighted&amp;#160;Average&amp;#160;Grant&amp;#160;Date&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Term&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Intrinsic&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Shares&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Fair&amp;#160;Value&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;(in years)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Value&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="39%"&gt; &lt;div&gt;Granted - 2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;200,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.14&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.20&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="39%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"&gt; &lt;div&gt;Outstanding, December 31, 2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;200,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.14&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.20&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"&gt; &lt;div&gt;Granted - 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;460,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3.75&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5.83&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"&gt; &lt;div&gt;Cancelled&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(150,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.14&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.20&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"&gt; &lt;div&gt;Outstanding, December 31, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;510,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3.40&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5.28&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;9.29&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;275,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"&gt; &lt;div&gt;Exercisable, December 31, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;50,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.14&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.20&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3.67&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;275,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>

  <us-gaap:BusinessAcquisitionProFormaInformationTextBlock contextRef="P01_01_2016To12_31_2016" id="Factid_438">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;This information has been compiled from historical financial statements and is not necessarily indicative of the results that actually would have been achieved had the transaction already occurred or that may be achieved in the future.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 96%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;Pro&amp;#160;Forma&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;For&amp;#160;the&amp;#160;Year&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;Pro&amp;#160;Forma&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;Ended&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;For&amp;#160;Year Ended&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;December&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;December&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="64%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"&gt; &lt;div&gt;Total operating expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;(3,979,316)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;(688,101)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"&gt; &lt;div&gt;Net loss&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;(3,962,997)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;(164,128)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"&gt; &lt;div&gt;Net loss per common share &amp;#150; basic and diluted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;(0.42)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;(0.04)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"&gt; &lt;div&gt;Weighted average outstanding common shares &amp;#150; basic and diluted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;9,401,028&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;4,273,239&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>

  <us-gaap:DeferredCompensationArrangementWithIndividualMaximumContractualTerm1 contextRef="P07_25_2016To08_19_2016_ChiefFinancialOfficerAndExecutiveVicePresidentMemberusgaapTitleOfIndividualAxis" id="Factid_439">P3Y</us-gaap:DeferredCompensationArrangementWithIndividualMaximumContractualTerm1>

  <mbrx:MilestonePaymentDescription contextRef="P10_01_2015To10_19_2015" id="Factid_440">The amended milestone payments are as follows: (i) commencement of Phase III Study for first licensed drug/product within the United States, Europe, China or Japan - $150,000; (ii) submission of the first NDA within the United States - $500,000; and (iii) receipt of first marketing approval for sale of a license product in the United States - $600,000.</mbrx:MilestonePaymentDescription>

  <us-gaap:SharesIssuedPricePerShare contextRef="PAsOn05_02_2016_HoustonPharmaceuticalsIncMemberdeiLegalEntityAxis_LicenseAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MoleculinLlcMemberusgaapBusinessAcquisitionAxis" id="Factid_441" unitRef="USD_per_Share" decimals="0">6</us-gaap:SharesIssuedPricePerShare>

  <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="P05_01_2016To05_02_2016_HoustonPharmaceuticalsIncMemberdeiLegalEntityAxis_LicenseAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MoleculinLlcMemberusgaapBusinessAcquisitionAxis" id="Factid_442" unitRef="USD" decimals="-6">75000000000</us-gaap:PaymentsToAcquireIntangibleAssets>

  <us-gaap:CashFDICInsuredAmount contextRef="PAsOn12_31_2016" id="Factid_443" unitRef="USD" decimals="0">250000</us-gaap:CashFDICInsuredAmount>

  <mbrx:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock contextRef="P01_01_2016To12_31_2016" id="Factid_444">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Property and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line depreciation method as follows:&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 85%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; MARGIN-LEFT: 0.5in; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="85%"&gt; &lt;tr&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 40%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="40%"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Leasehold improvement&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 60%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="60%"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Shorter of estimated useful lives or the term of the lease&lt;/font&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Computer equipment&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2&lt;/font&gt; years*&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Machinery and equipment&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5&lt;/font&gt; years*&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Furniture and office equipment&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;7&lt;/font&gt; years*&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;*Property and equipment assets acquired in the merger with Moleculin, LLC are being depreciated over a &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2&lt;/font&gt; year useful life due to their age and condition and expected remaining life assessed at merger date.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</mbrx:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock>

  <us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense contextRef="P01_01_2016To12_31_2016" id="Factid_445" unitRef="USD" decimals="0">87500</us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>

  <mbrx:WarrantsIssuedForServices contextRef="P01_01_2016To12_31_2016" id="Factid_446" unitRef="USD" decimals="0">374763</mbrx:WarrantsIssuedForServices>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="P01_01_2016To12_31_2016" id="Factid_447" unitRef="USD" decimals="0">374763</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="P01_01_2016To12_31_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_448" unitRef="USD" decimals="0">374763</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>

  <us-gaap:BusinessCombinationsPolicy contextRef="P01_01_2016To12_31_2016" id="Factid_449">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/font&gt;&lt;/b&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;b&gt;Acquisition &amp;#150;&lt;/b&gt; We acquired Moleculin, LLC (&amp;#8220;Moleculin&amp;#8221;) on May 2, 2016, and, going forward our financial statements include the operations of Moleculin, LLC. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired in-process research and development (&amp;#8220;IPR&amp;amp;D&amp;#8221;) be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired will be recorded as goodwill. The Company obtained input from third-parties regarding its tangible and intangible assets and other information necessary to measure the fair value of the assets acquired and liabilities assumed in connection with the acquisition of Moleculin, LLC.&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BusinessCombinationsPolicy>

  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P01_01_2016To12_31_2016" id="Factid_450">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;strong&gt;Cash and Cash Equivalents -&lt;/strong&gt; The Company considers all highly liquid accounts with original maturities of three months or less at the date of acquisition to be cash equivalents.&amp;#160;Periodically, the Company may carry cash balances at financial institutions in excess of the federally insured limit of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;250,000&lt;/font&gt;. The amount in excess of the FDIC insurance at December 31, 2016 was $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;256,836&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0&lt;/font&gt; as of December 31, 2015. Compensation expense is recognized only for share based payments expected to vest.&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>

  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther contextRef="PAsOn12_31_2016_MoleculinLlcMemberusgaapBusinessAcquisitionAxis" id="Factid_451" unitRef="USD" decimals="0">1224314</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther>

  <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="P01_01_2015To12_31_2015_AcquisitionDateOneMembermbrxPeriodTypeAxis_MoleculinLlcMemberusgaapBusinessAcquisitionAxis" id="Factid_452" unitRef="USD" decimals="0">422874</us-gaap:AmortizationOfFinancingCostsAndDiscounts>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="PAsOn12_31_2015" id="Factid_453" unitRef="USD_per_Share" decimals="2">0.14</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="P01_01_2015To12_31_2015" id="Factid_454" unitRef="USD_per_Share" decimals="2">0.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="P01_01_2016To12_31_2016" id="Factid_455" unitRef="USD_per_Share" decimals="2">3.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue contextRef="P01_01_2016To12_31_2016" id="Factid_456" unitRef="USD_per_Share" decimals="2">0.14</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="PAsOn12_31_2016" id="Factid_457" unitRef="USD_per_Share" decimals="2">3.40</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>

  <mbrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue contextRef="P01_01_2016To12_31_2016" id="Factid_458" unitRef="USD_per_Share" decimals="2">0.14</mbrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2015To12_31_2015" id="Factid_459" unitRef="shares" decimals="INF">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="P01_01_2015To12_31_2015" id="Factid_460" unitRef="USD_per_Share" decimals="2">0.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>

  <mbrx:DebtConversionConvertedInstrumentCommonStockSharesIssuedTradingRestrictionsDescription contextRef="P01_01_2016To12_31_2016" id="Factid_461">The common shares relating to the above mentioned convertible notes payable contain the following trading restrictions: (a) beginning 90 days after the initial closing of our IPO and until the one-year anniversary of the initial closing of the IPO, the holder of the note will be able to sell 1% of the number of shares of common stock underlying the note on a monthly basis, subject to a maximum sale on any trading day of 4% of the daily volume; (b) if the common stock price is over $7.00 per share for five consecutive trading days then the holder of the note can sell up to 3% of the number of shares of common stock underlying the note on a monthly basis, subject to a maximum sale on any trading day of 4% of the daily volume; (c) if the common stock price is over $10.00 per share for five consecutive trading days then the holder of the note can sell up to an additional 5% of the number of shares of common stock underlying the note on a monthly basis, subject to a maximum sale on any trading day of 7% of the daily volume; and (d) if the common stock price is over $14.00 per share then the holder of the note is not restricted from making any sales until such time as the common stock price falls back below $14.00 per share; and (b) thereafter, until the two-year anniversary of the initial closing of IPO, the holder of the note can sell on any trading day 10% of the daily volume; provided that if the common stock price is over $10.00 per share then the holder of the note is not restricted from making any sales until such time as the common stock falls back below $10.00 per share. The foregoing lock-up restrictions relate to public sales and do not restrict the transfer of the shares privately, if permitted by applicable law, provided the acquirer of the shares agrees to comply with the above restrictions with respect to any public sales.</mbrx:DebtConversionConvertedInstrumentCommonStockSharesIssuedTradingRestrictionsDescription>

  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2016To12_31_2016" id="Factid_462">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0"&gt; &lt;tr&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.3pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"&gt; &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;7.&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Commitments and Contingencies&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 18.7pt"&gt; &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 18.7pt"&gt; &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;MD Anderson &amp;#150; IntertechBio Agreement&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On August 11, 2015, the Company acquired the rights and obligations under the Patent and Technology License Agreement entered into between IntertechBio and MD Anderson dated April 2, 2012. Pursuant to the agreement, IntertechBio obtained a royalty-bearing, worldwide, exclusive license to intellectual property including patent rights related to the Company&amp;#8217;s drug product candidate, WP1122. Under the agreement, IntertechBio agreed to pay annual maintenance fees in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;10,000&lt;/font&gt; on the first anniversary of the effective date of the agreement, $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;20,000&lt;/font&gt; on the second anniversary of the effective date of the agreement, $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;40,000&lt;/font&gt; on the third anniversary of the effective date of the agreement, $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;60,000&lt;/font&gt; on the fourth anniversary of the effective date of the agreement, $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;80,000&lt;/font&gt; on the fifth anniversary of the effective date of the agreement and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;100,000&lt;/font&gt; on the sixth anniversary of the effective date of the agreement, except that such payments will no longer be due upon the first sale of a licensed product. Under the agreement, IntertechBio also agreed to make a minimum annual royalty payment in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;200,000&lt;/font&gt; for the first anniversary following the first sale of a licensed product, $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;400,000&lt;/font&gt; for the second anniversary following the first sale of a licensed product, and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;600,000&lt;/font&gt; for the third year following the first sale of a licensed product. IntertechBio also agreed to make certain milestone payments. &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Pursuant to an amendment on October 19, 2015, the Company will pay milestone payments as follows:&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0px:auto; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Phase&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Amount&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="57%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Commencement of Phase II Study for a licensed product&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;200,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Commencement of Phase III Study for a licensed product&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;250,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Filing of a New Drug Application for a licensed product&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;400,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Receipt of market approval for a licensed product&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;500,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Per the October 2015 amendment to the agreement, MD Anderson has the right to terminate the license agreement if (i) a preclinical toxicology program for a licensed product is not initiated within one year of the effective date of the amendment (which has occurred), (ii) an investigational new drug application is not filed with the Food and Drug Administration for a Phase I study for a licensed product within three years of the effective date of the amendment, or (iii) a Phase I study for a licensed product is not commenced within five years of the effective date of the amendment. The agreement will expire upon the expiration of the licensed intellectual property. The rights obtained by the Company pursuant to the agreement are made subject to the rights of the U.S. government to the extent that the technology covered by the licensed intellectual property was developed under a funding agreement between MD Anderson and the U.S. government. All out-of-pocket expenses incurred by MD Anderson in filing, prosecuting and maintaining the licensed patents have been and shall continue to be assumed by the Company.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On October 8, 2015, IntertechBio Corporation entered into a letter agreement with MD Anderson wherein MD Anderson agreed to receive past due maintenance fees and patent expenses of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;98,108&lt;/font&gt; owed by IntertechBio Corporation in four installments. The past due amount is related to certain metabolic inhibitor technology license that was assigned to the Company by IntertechBio Corporation and was owed by IntertechBio Corporation prior to the Company&amp;#8217;s acquisition of the license. Pursuant to the letter, IntertechBio Corporation also agreed to pay $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;65,504&lt;/font&gt; in patent fees to a law firm. In order to have the license in good standing, the Company agreed to pay MD Anderson the $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;98,108&lt;/font&gt; and the $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;65,504&lt;/font&gt; in patent fees to a patent law firm on behalf of IntertechBio Corporation. As of December 31, 2015, $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;45,000&lt;/font&gt; of the past due amount to MD Anderson and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;42,504&lt;/font&gt; in patent fees to a patent law firm were still outstanding and were included in accounts payable and accrued liabilities. On April 15, 2016, the Company entered into a letter agreement with MD Anderson where MD Anderson agreed to receive the remaining outstanding amount on or before the earlier of a) May 31, 2016 or b) four days after the Company&amp;#8217;s completion of the IPO. These amounts were paid prior to or on May 31, 2016.&lt;/font&gt;&lt;/div&gt; &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 18.7pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;MD Anderson &amp;#150; Patent &amp;amp; Technology License Agreement&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Upon the Company&amp;#8217;s acquisition of Moleculin, LLC on May 2, 2016, we obtained a royalty-bearing, worldwide, exclusive license to intellectual property rights, including patent rights related to our WP1066 drug product candidate from MD Anderson through a Patent and Technology License Agreement Moleculin, LLC entered with MD Anderson on June&amp;#160;21, 2010 (the &amp;#8220;Moleculin License Agreement&amp;#8221;). Under the Moleculin License Agreement, Moleculin, LLC obtained the right to manufacture, have manufactured, use, import, offer to sell or sell products worldwide for any indication under the licensed intellectual property with the right to sublicense. In consideration, Moleculin, LLC agreed to make payments to MD Anderson including an up-front payment, milestone payments and minimum annual royalty payments for sales of products developed under the license agreement. Specifically, under the Moleculin License Agreement, Moleculin, LLC agreed to pay a nonrefundable upfront documentation fee and an annual maintenance fee in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;20,000&lt;/font&gt; on June 21, 2011, which has and shall increase in $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;10,000&lt;/font&gt; increments on an annual basis thereafter up to a maximum of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;100,000&lt;/font&gt;, except that such payments will no longer be due upon marketing approval in any country of a licensed product. Under the Moleculin License Agreement, Moleculin, LLC also agreed to make a minimum annual royalty payment.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Upon completion of our acquisition of Moleculin, LLC, we assumed the rights and obligations of Moleculin, LLC. However, the rights we have obtained pursuant to the assignment of the Moleculin License Agreement are made subject to the rights of the U.S. government to the extent that the technology covered by the licensed intellectual property was developed under a funding agreement between MD Anderson and the U.S. government. All out-of-pocket expenses incurred by MD Anderson in filing, prosecuting and maintaining the licensed patents have been and shall continue to be assumed by us.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On October 8, 2015, Moleculin, LLC entered into a letter agreement with MD Anderson for Moleculin, LLC&amp;#8217;s past due fees to MD Anderson in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;691,186&lt;/font&gt; of which $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;300,000&lt;/font&gt; had been paid prior to the letter agreement. Pursuant to the letter agreement, MD Anderson agreed to receive the remaining past due fee in three installments: a) $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;125,000&lt;/font&gt; on October 31, 2015; b) $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;175,000&lt;/font&gt; on January 31, 2016; and c) $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;91,186&lt;/font&gt; on April 30, 2016. Moleculin, LLC paid $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;125,000&lt;/font&gt; to MD Anderson on November 2, 2015.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On October 19, 2015, the agreement was amended for the milestone payments. The amended milestone payments are as follows: (i) commencement of Phase III Study for first licensed drug/product within the United States, Europe, China or Japan - $150,000; (ii) submission of the first NDA within the United States - $500,000; and (iii) receipt of first marketing approval for sale of a license product in the United States - $600,000.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On January 28, 2016, the Company and Moleculin, LLC entered into a letter agreement with MD Anderson where MD Anderson agreed to receive the remaining outstanding amount on or before the earlier of April 30, 2016 or four days after our IPO. This date was amended and per the amended agreement, the Company paid the outstanding Moleculin, LLC fees on May 31, 2016 in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;306,186&lt;/font&gt; in cash.&lt;/font&gt;&lt;/div&gt; &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 18.7pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Bonwick Capital Partners LLC&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On January 22, 2016, as amended on February 15, 2016, the Company entered into a letter agreement with Bonwick Capital Partners LLC. (&amp;#8220;Bonwick&amp;#8221;) to engage Bonwick as an exclusive financial advisor of the Company. Pursuant to the agreement, &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;the Company agreed to: a) pay success fees equal to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 7&lt;/font&gt;% of the gross proceeds from any form of financing; and b) issue five-year warrants to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;7&lt;/font&gt;% of the Company&amp;#8217;s equity securities sold with a cashless exercise provision, exercisable at &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 125&lt;/font&gt;% of the price per share of the Company&amp;#8217;s common stock paid by investors in the transaction. In addition, the Company agreed to reimburse Bonwick for all of its out-of-pocket expenses incurred in connection with the offering, not to exceed $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;25,000&lt;/font&gt;, and fees and expenses of their counsel not to exceed $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;100,000&lt;/font&gt;.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; Upon completion of the Company&amp;#8217;s IPO, the Company paid Bonwick a $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;50,000&lt;/font&gt; advisory fee. In connection with the Company&amp;#8217;s IPO, Bonwick received a success fee of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;646,872&lt;/font&gt;, warrants to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 107,802&lt;/font&gt; shares of common stock at an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;7.50&lt;/font&gt; per share, and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;6,266&lt;/font&gt; for reimbursement of expenses.&lt;/font&gt;&lt;/div&gt; &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 18.7pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Houston Pharmaceuticals, Inc.&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Our acquisition of Moleculin, LLC, occurring prior to our IPO offering, provided us with the rights of the license agreement that Moleculin, LLC had with MD Anderson covering the WP1066 Portfolio. As discussed in Note 2, we are obligated to make payments to HPI totaling $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;750,000&lt;/font&gt; over a three-year period commencing after the IPO offering in exchange for HPI allowing us to access any data, information or know-how resulting from the research and development conducted by HPI. Pursuant to the HPI Out-Licensing Agreement, we have the right within three years of the date we enter into the agreement to buy-out from HPI all rights granted to HPI under the agreement for a payment of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.0&lt;/font&gt; million. Upon our exercise of the buy-out we will no longer be obligated to make any payments to HPI remaining from the $750,000 obligation discussed above. We will need to raise additional funds to make the buy-out payment. We cannot assure that such additional funding will be available on satisfactory terms, or at all.&lt;/font&gt;&lt;/div&gt; &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.7pt; MARGIN: 0in 0in 0pt 0.25in" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Employment Agreements&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.7pt; MARGIN: 0in 0in 0pt 0.25in"&gt; &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On August 19, 2016, the Company entered into an employment agreement with Mr. Jonathan P. Foster pursuant to which Mr. Foster agreed to serve as Chief Financial Officer and Executive Vice President of the Company commencing on such date for an initial term of three years, which will be automatically renewed for additional one-year terms unless either party chooses not to renew the agreement. The agreement provides for an annual salary of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;250,000&lt;/font&gt;, a potential&amp;#160;annual bonus, ten-year options to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 400,000&lt;/font&gt; shares at an exercise price per share equal to the closing price of the Company&amp;#8217;s common stock on the date of execution of his employment agreement, which was $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5.85&lt;/font&gt;. The options vest in four equal installments. Termination payments may be made under certain conditions.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The Company accepted the resignation of Mr. Louis Ploth from his position as Chief Financial Officer, effective on August 19, 2016. On October 7, 2016, the Company entered into a separation agreement with Mr. Louis Ploth (the &amp;#8220;Separation Agreement&amp;#8221;), pursuant to which, among other items, Mr. Ploth generally released the Company from any claims he may have against the Company or its affiliates, and the Company agreed to pay Mr. Ploth a severance payment of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;100,000&lt;/font&gt; over a 12-month period and to pay his medical insurance premiums until August 31, 2017. &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;Pursuant to the Separation Agreement, Mr. Ploth will be permitted to exercise 25% of the options to purchase common stock granted to him in December 2015, or 50,000 shares, until May 2020.&lt;/font&gt;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;On October 13, 2016, the Company and its Chief Executive Officer, Walter Klemp, entered into an employment agreement which provides for an annual salary of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;300,000&lt;/font&gt;, of which some is deferred, and a potential annual bonus. During the period commencing June 1, 2016 and ending June 1, 2017, $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;12,500&lt;/font&gt; per month of the compensation is deferred. The deferred compensation shall be payable in a lump sum on the earlier of the termination of the employment agreement or June 1, 2019. As of December 31, 2016, deferred compensation of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;87,500&lt;/font&gt; was recorded in the accompanying balance sheet. If Mr. Klemp&amp;#8217;s employment is terminated, his status reverts to a consultant and payments to him would continue until June 1, 2019.&amp;#160;&amp;#160;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>

  <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent contextRef="PAsOn06_30_2016_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_463" unitRef="USD" decimals="0">12500</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>

  <us-gaap:OfficersCompensation contextRef="P01_01_2016To12_31_2016_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_464" unitRef="USD" decimals="0">300000</us-gaap:OfficersCompensation>

  <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2016To12_31_2016" id="Factid_465">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"&gt; &lt;tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0in"&gt;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 0.5in"&gt; &lt;div&gt;8.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div&gt;Subsequent Events&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On February 9, 2017, we entered into an Underwriting Agreement (the &amp;#8220;Underwriting Agreement&amp;#8221;) with Roth Capital Partners, LLC, as representative of the several underwriters identified therein (collectively, the &amp;#8220;Underwriters&amp;#8221;), pursuant to which we sold in a registered public offering (the &amp;#8220;Offering&amp;#8221;), &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 3,710,000&lt;/font&gt; units, priced at a public offering price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.35&lt;/font&gt; per unit, with each unit consisting of: (i) one share of common stock, (ii) a five-year Series A warrant to purchase 0.50 of a share of common stock, (iii) a 90-day Series B warrant to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;purchase one share of common stock, and (iv) a five-year Series C warrant to purchase 0.50 of a share of common stock.&lt;/font&gt; The Series C warrants in a unit may only be exercised to the extent and in proportion to a holder of the Series C warrants exercising its Series B warrants included in the unit. The Series A and Series C warrant have an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.50&lt;/font&gt;&lt;/font&gt; per share of common stock. The Series B warrant has an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.35&lt;/font&gt; per share of common stock.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Under the terms of the Underwriting Agreement, we granted the Underwriters a 45-day option to purchase an additional &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 556,500&lt;/font&gt; shares of common stock and/or an additional &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 556,500&lt;/font&gt; warrant combinations (comprised of an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 278,250&lt;/font&gt; Series A warrants, &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 556,500&lt;/font&gt; Series B warrants and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 278,250&lt;/font&gt; Series C warrants), in any combinations thereof, from us to cover over-allotments at the public offering price per share of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.349&lt;/font&gt; and public offering price per warrant combination of $.001, respectively, less the underwriting discounts and commissions. Upon the closing of the Offering, the Underwriters exercised the over-allotment option with respect to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 278,100&lt;/font&gt; warrant combinations. We received approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4.4&lt;/font&gt; million in net proceeds from the Offering, after deducting underwriting discounts and commissions and estimated offering expenses.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;On March 21, 2017, we received notice that FDA had granted us Orphan Drug designation for Annamycin for the treatment of AML.&lt;/div&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;Subsequent to March 22, 2017, investors in the aforementioned offering on February 9, 2017, have excerised approximately &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 600,000&lt;/font&gt; Series B warrants resulting in approximately gross proceeds to the Company of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;800,000&lt;/font&gt; and approximately &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 600,000&lt;/font&gt; shares of the Company&amp;#8217;s common stock being issued.&lt;/div&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;On January 13, 2017, the Company issued to two of its Science Advisory Board (&amp;#8220;SAB&amp;#8221;) members &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 10,000&lt;/font&gt;&lt;/font&gt; options each with an excerise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2.31&lt;/font&gt;&lt;/font&gt; with &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 3&lt;/font&gt;&lt;/font&gt;-year annual vesting and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 79,167&lt;/font&gt; shares to a former SAB member to settle an accounts payable of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;237,500&lt;/font&gt; in past due amounts.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SubsequentEventsTextBlock>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="P03_01_2017To03_22_2017_SeriesBWarrantMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_UsFoodAndDrugAdministrationMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_466" unitRef="shares" decimals="INF">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>

  <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="P03_01_2017To03_22_2017_SubsequentEventMemberusgaapSubsequentEventTypeAxis_UsFoodAndDrugAdministrationMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_467" unitRef="USD" decimals="0">800000</us-gaap:ProceedsFromIssuanceOfWarrants>

  <us-gaap:CashUninsuredAmount contextRef="PAsOn12_31_2016" id="Factid_468" unitRef="USD" decimals="0">256836</us-gaap:CashUninsuredAmount>

  <us-gaap:CashUninsuredAmount contextRef="PAsOn12_31_2015" id="Factid_469" unitRef="USD" decimals="0">0</us-gaap:CashUninsuredAmount>

  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="P01_01_2016To12_31_2016" id="Factid_470">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;strong&gt;Loss Per Common Share&lt;/strong&gt; - Basic net loss per common share are computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. As of December 31, 2016, the Company&amp;#8217;s potentially dilutive shares, which were not included in the calculation of net loss per share, included notes convertible to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,821,013&lt;/font&gt; common shares, options to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 510,000&lt;/font&gt; common shares and warrants to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 107,802&lt;/font&gt; common shares.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>

  <us-gaap:SubsequentEventsPolicyPolicyTextBlock contextRef="P01_01_2016To12_31_2016" id="Factid_471">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/font&gt;&lt;/b&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;b&gt;Subsequent Events -&lt;/b&gt; The Company&amp;#8217;s management reviewed all material events through the date these financial statements were issued for subsequent event disclosure consideration and has noted such events as described in Note 8.&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>

  <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="P01_01_2016To12_31_2016" id="Factid_472">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0"&gt; &lt;tr&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.3pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"&gt; &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;3.&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Intangible Assets&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 18.7pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The Acquisition of Moleculin, LLC&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On May 2, 2016, Moleculin, LLC, a Texas limited liability company, was merged with and into the Company. As a result of the merger, the Company issued to the holders of Moleculin equity interests an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 999,931&lt;/font&gt; shares of the Company&amp;#8217;s common stock valued at $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5,999,586&lt;/font&gt;, based on the estimated acquisition-date fair value of our common stock of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;6.00&lt;/font&gt; per share, equal to the IPO price announced in our prospectus filed on that date. These shares contain certain trading restrictions. Prior to the Company&amp;#8217;s acquisition of Moleculin, the Company had loaned $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;57,822&lt;/font&gt; to Moleculin which was treated as part of the consideration paid to acquire Moleculin.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;As additional consideration payable to the Moleculin unit holders, we agreed pursuant to the merger agreement that if drugs for dermatology indications are successfully developed by us using any of the Existing IP Assets, then the Moleculin, LLC unit holders, in the aggregate, will be entitled to receive a &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 2.5&lt;/font&gt;% royalty on the net revenues generated by such drugs. Any such net revenues would include a deduction for license fees or royalty obligations payable to MD Anderson for such Existing IP Assets. The merger agreement defined &amp;#8220;Existing IP Assets&amp;#8221; to mean all intellectual property, licensed by us and Moleculin as of the time of the merger, including, without limitation, the intellectual property licensed from MD Anderson under the Patent and Technology License Agreement entered into by and between IntertechBio Corporation and MD Anderson dated April 2, 2012, as amended, and the Patent and Technology License Agreement dated June 21, 2010, as amended, between MD Anderson and Moleculin, LLC, but excluding any intellectual property relating to Annamycin. The right to receive the contingent royalty payments described herein is limited to&amp;#160;drugs developed only for dermatology indications, and does not include drugs developed for any other indications. We have no obligation of any nature to pursue the development of any drugs for dermatology indications.&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;Our acquisition of Moleculin, LLC, occurring prior to our IPO offering, provided us with the rights to the license agreement that Moleculin, LLC had with MD Anderson covering the WP1066 Portfolio. However, Moleculin, LLC had previously granted Houston Pharmaceuticals, Inc. (&amp;#8220;HPI&amp;#8221;), a related party, an option, which could be exercised at any time, to obtain an exclusive sub-license to develop the WP1066 Portfolio in all non-dermatological fields. Moleculin, LLC had previously pursued development of the WP1066 Portfolio for treatment of psoriasis, however, psoriasis related clinical trials had been terminated. Because WP1066 has shown significant activity against a wide range of tumors, Moleculin, LLC&amp;#8217;s focus prior to the acquisition included the development of drugs for cancer treatment. However, the exclusive sub-license option held by HPI precluded Moleculin, LLC from pursuing drug development related to non-skin cancers, in addition to potentially creating significant intellectual property, clinical and commercialization risks associated with drug development for skin cancers. Re-acquisition of the HPI option was therefore essential for the values of both the WP1066 Portfolio and Moleculin, LLC.&lt;/div&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;Additionally, the merger agreement contained mutual representations and warranties between the parties. Pursuant to the merger agreement, we agreed for a period of six years to indemnify and hold harmless each present and former director and/or officer of Moleculin, LLC whom Moleculin, LLC would have had the power to indemnify under Delaware law that is made a party or threatened to be made a party to any threatened, pending or completed proceeding or claim by reason of the fact that he or she was a director or officer of the Moleculin, LLC prior to the effective time of the merger and arising out of actions or omissions of the indemnified party in any such capacity occurring at or prior to the effective time of the merger against any losses or damages reasonably incurred in connection with any claim. To our knowledge, no such proceeding or claim exists or has been threatened on the date hereof.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;In connection with the acquisition of Moleculin, LLC, we also negotiated on behalf of Moleculin, LLC two agreements with HPI. Under the first agreement,&amp;#160;HPI&amp;#8217;s option to obtain the aforementioned exclusive sublicense was terminated in exchange for a payment of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;100,000&lt;/font&gt; and the issuance of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 629,000&lt;/font&gt; shares of our common stock, valued at $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;6&lt;/font&gt; per share. Under the second agreement (HPI Out-Licensing Agreement), HPI has received a non-exclusive technology rights and development sublicense under which it may continue its ongoing work to develop the WP1066 Portfolio related to treatment of non-skin cancer. Pursuant to this HPI Out-Licensing Agreement, we agreed to make payments to HPI totaling $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;750,000&lt;/font&gt; over a three-year period, of which $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;75,000&lt;/font&gt; was paid in calendar year 2016. The Company expenses such costs as&amp;#160;incurred as research and development expense, commencing after the IPO offering in exchange for HPI allowing us to access any data, information or know-how resulting from the research and development conducted by HPI. As of December 31, 2016, notwithstanding our obligation to make the foregoing payments, the HPI Out-Licensing Agreement does not obligate HPI to conduct any specific research or to meet any milestones. Pursuant to the HPI Out-Licensing Agreement, we have the right within three years of the effective date to buy-out from HPI all rights granted to HPI under the agreement for a payment of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.0&lt;/font&gt; million. Upon our exercise of the buy-out we will no longer be obligated to make any payments to HPI remaining from the $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;750,000&lt;/font&gt; obligation discussed above. If we do not exercise the foregoing buy-out right within three years, the license granted to HPI shall convert into an exclusive license. As such, if we do not exercise the buy-out right for any reason, we will no longer have access to the non-skin cancer uses of the WP1066 Portfolio. As noted above, this will also potentially create risks for the development of skin cancer drugs. We do not intend to set aside and designate cash and cash equivalents in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.0&lt;/font&gt; million to make the buy-out payment. If we ultimately decide to exercise the buy-out right from HPI, we will need to raise additional funds to make the buy-out payment. We cannot assure that such additional funding will be available on satisfactory terms, or at all.&lt;/div&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The agreements with HPI were executed on May 2, 2016, simultaneously with the closing of the Moleculin, LLC acquisition, and were non-cancelable but contingent on the Company&amp;#8217;s ability to complete the IPO by June 30, 2016. They became effective on May 31, 2016.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The termination of the HPI option was completed on behalf of Moleculin, LLC, which&amp;#160;was required to enable the sale of Moleculin, LLC by materializing the value of its most significant asset, and was non-cancelable by either party. Further, the HPI option termination price was determined simultaneously with the acquisition on May 2, 2016 as our IPO price was established at that time. Accordingly, we concluded that this transaction was primarily for the benefit of Moleculin, LLC and its former owners, resulting in control of the underlying intellectual property and thereby increasing the value of Moleculin, LLC intangible assets immediately prior to the closing of its acquisition by us.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The HPI option termination price amounted to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3,874,000&lt;/font&gt;, consisting of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 629,000&lt;/font&gt; shares of our common stock valued at the IPO price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;6.00&lt;/font&gt; per share, and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;100,000&lt;/font&gt; paid in cash in July 2016, and was included in acquisition-date liabilities assumed.&lt;/font&gt;&lt;/div&gt; &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 18.7pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Purchase Price Allocation&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The acquisition price was allocated to the assets acquired and liabilities assumed based upon their estimated fair values and the information available to management. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.25in; WIDTH: 92%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="76%"&gt; &lt;div&gt;Cash&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;362&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="76%"&gt; &lt;div&gt;Property and equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;7,820&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="76%"&gt; &lt;div&gt;Intangibles&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;11,147,540&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="76%"&gt; &lt;div&gt;Total assets acquired&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;11,155,722&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="76%"&gt; &lt;div&gt;Liability assumed (HPI)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;(3,874,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="76%"&gt; &lt;div&gt;Other liabilities assumed, including $469,939 of notes payable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;(1,224,314)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="76%"&gt; &lt;div&gt;Net assets acquired/total consideration transferred&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;6,057,408&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 18.7pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The Company obtained input from third-parties regarding its tangible and intangible assets and other information necessary to measure the fair value of the assets acquired and liabilities assumed in connection with the acquisition of Moleculin, LLC. Management believes all or most of the intangible assets are IPR&amp;amp;D related to the WP1066 Portfolio, and, as such, no amortization has been recorded to date.&lt;/div&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Intangible assets consisted of the following at December 31, 2016 and December 31, 2015:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 96%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"&gt; &lt;div&gt;Intangibles acquired from Moleculin, LLC&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;11,147,540&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;&amp;#150;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 18.7pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Unaudited Pro Forma Results of Operations&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 18.7pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The following comparative table presents the unaudited condensed pro forma results of operations that reflect the acquisition of Moleculin as if the acquisition had occurred as of the first day of each period presented, adjusted for items that are directly attributable to the acquisition. &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;This information has been compiled from historical financial statements and is not necessarily indicative of the results that actually would have been achieved had the transaction already occurred or that may be achieved in the future.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 96%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;Pro&amp;#160;Forma&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;For&amp;#160;the&amp;#160;Year&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;Pro&amp;#160;Forma&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;Ended&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;For&amp;#160;Year Ended&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;December&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;December&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="64%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"&gt; &lt;div&gt;Total operating expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;(3,979,316)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;(688,101)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"&gt; &lt;div&gt;Net loss&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;(3,962,997)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;(164,128)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"&gt; &lt;div&gt;Net loss per common share &amp;#150; basic and diluted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;(0.42)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;(0.04)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"&gt; &lt;div&gt;Weighted average outstanding common shares &amp;#150; basic and diluted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;9,401,028&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;4,273,239&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The years ended December 31, 2016 and December 31, 2015 are adjusted on a pro forma basis to exclude $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;145,078&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;422,874&lt;/font&gt;, respectively, in net interest expense related to the amortization of deferred financing costs and debt discount amortization for Moleculin, LLC&amp;#8217;s convertible notes. The holders of the convertible notes were issued the Company&amp;#8217;s common shares upon the Company&amp;#8217;s acquisition of Moleculin, LLC.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>

  <us-gaap:ConvertibleNotesPayableCurrent contextRef="PAsOn12_31_2015_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis" id="Factid_473" unitRef="USD" decimals="0">450000</us-gaap:ConvertibleNotesPayableCurrent>

  <us-gaap:ConvertibleNotesPayableCurrent contextRef="PAsOn12_31_2016_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis" id="Factid_474" unitRef="USD" decimals="0">276079</us-gaap:ConvertibleNotesPayableCurrent>

  <mbrx:DebtInstrumentConvertibleNumberOfCommonShares contextRef="P01_01_2016To12_31_2016_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis" id="Factid_475" unitRef="shares" decimals="INF">1821013</mbrx:DebtInstrumentConvertibleNumberOfCommonShares>

  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="PAsOn12_31_2016" id="Factid_476" unitRef="USD" decimals="0">6162</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>

  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="PAsOn12_31_2015" id="Factid_477" unitRef="USD" decimals="0">0</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>

  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="PAsOn12_31_2016" id="Factid_478" unitRef="USD" decimals="0">1565599</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>

  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P01_01_2016To12_31_2016" id="Factid_479">P3Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>

  <mbrx:EstimatedForfeitureRatePercentage contextRef="PAsOn12_31_2016" id="Factid_480" unitRef="pure" decimals="0">0</mbrx:EstimatedForfeitureRatePercentage>

  <us-gaap:OperatingLossCarryforwards contextRef="PAsOn12_31_2016_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" id="Factid_481" unitRef="USD" decimals="-4">1270000</us-gaap:OperatingLossCarryforwards>

  <mbrx:OperatingLossCarryforwardsExpirationPeriod contextRef="P01_01_2016To12_31_2016_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" id="Factid_482">2036</mbrx:OperatingLossCarryforwardsExpirationPeriod>

  <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets contextRef="P08_01_2015To08_11_2015_IntertechbioCorporationMemberdeiLegalEntityAxis" id="Factid_483" unitRef="shares" decimals="INF">630000</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>

  <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets contextRef="P08_01_2015To08_11_2015_IntertechbioCorporationMemberdeiLegalEntityAxis" id="Factid_484" unitRef="USD" decimals="0">630</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>

  <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets contextRef="P08_01_2015To08_21_2015_AnnamedIncMemberdeiLegalEntityAxis" id="Factid_485" unitRef="shares" decimals="INF">1431000</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>

  <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets contextRef="P08_01_2015To08_21_2015_AnnamedIncMemberdeiLegalEntityAxis" id="Factid_486" unitRef="USD" decimals="0">1431</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="P10_01_2016To10_31_2016_ChiefFinancialOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_487" unitRef="shares" decimals="INF">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber contextRef="P10_01_2016To10_31_2016_ChiefFinancialOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_488" unitRef="shares" decimals="INF">50000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P08_01_2015To08_31_2015_DirectorAndOfficersMemberusgaapTitleOfIndividualAxis" id="Factid_489" unitRef="shares" decimals="INF">4600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P08_01_2015To08_31_2015_DirectorAndOfficersMemberusgaapTitleOfIndividualAxis" id="Factid_490" unitRef="USD" decimals="0">4600</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="P07_28_2015To12_31_2015_DirectorAndOfficersMemberusgaapTitleOfIndividualAxis" id="Factid_491" unitRef="USD" decimals="0">1600</us-gaap:ProceedsFromIssuanceOfCommonStock>

  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2016To12_31_2016" id="Factid_492">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0"&gt; &lt;tr&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.3pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"&gt; &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;5.&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; Equity&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On May 2, 2016, the Company amended and restated its certificate of incorporation to increase the number of shares authorized to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 80,000,000&lt;/font&gt; of which &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 5,000,000&lt;/font&gt; shares of preferred stock are authorized and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 75,000,000&lt;/font&gt; shares of common stock are authorized.&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0in 0.3in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/strong&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0in 0.3in" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Preferred Stock&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 18.7pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;We are authorized to issue up to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 5,000,000&lt;/font&gt; shares of preferred stock. Our certificate of incorporation authorizes the board to issue these shares in one or more series, to determine the designations and the powers, preferences and relative, participating, optional or other special rights and the qualifications, limitations and restrictions thereof, including the dividend rights, conversion or exchange rights, voting rights (including the number of votes per share), redemption rights and terms, liquidation preferences, sinking fund provisions and the number of shares constituting the series. As of December 31, 2016, there was no issued preferred stock.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0in 0.3in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Common Stock&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;On May 31, 2016, the Company completed its IPO and sold &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,540,026&lt;/font&gt; shares of the Company&amp;#8217;s common stock. The IPO price per share was $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;6.00&lt;/font&gt;. The Company received net cash proceeds of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;8,464,183&lt;/font&gt; after deducting underwriting discounts, commissions and direct offering expenses payable by us. Pursuant to our agreement with our underwriters, as additional compensation, we issued the underwriters warrants to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 107,802&lt;/font&gt; shares of common stock exercisable for a period of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5&lt;/font&gt; years from date of issuance at an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;7.50&lt;/font&gt; per share. The relative fair value of these warrants was $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;374,763&lt;/font&gt;&amp;#160;and is included in stock issuance costs calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1.39&lt;/font&gt;% (2) expected life of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5&lt;/font&gt; years, (3) expected volatility of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 80.61&lt;/font&gt;%, and (4) zero expected dividends.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;In August 2015, the Company agreed to issue &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 4,600,000&lt;/font&gt; shares of common stock to its directors, officers and founders for subscriptions of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4,600&lt;/font&gt; cash to be received of which $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,600&lt;/font&gt; was received in 2015.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;On August 11, 2015, the Company was granted an assignment of a license agreement between MD Anderson and IntertechBio in exchange for &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 630,000&lt;/font&gt; shares of the Company's common stock. The sublicense gives the Company rights to access certain metabolic inhibitor technology owned by MD Anderson that had been licensed to IntertechBio. The shares were valued at a total of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;630&lt;/font&gt; and the related expense included in research and development costs.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; On August 21, 2015, the Company acquired the right to the intellectual property of AnnaMed in exchange for &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,431,000&lt;/font&gt; shares of the Company's common stock. The license gives the Company full ownership rights to the data package supporting the FDA IND Number 46869, allowing the Company to resubmit a request for IND to the FDA to begin development work on Annamycin. The shares were valued at a total of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,431&lt;/font&gt; and the related expense included in research and development costs.&lt;/div&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;During the period from January 1, 2016 through May 2, 2016, the Company sold &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 234,297&lt;/font&gt; common shares for $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;702,894&lt;/font&gt;. &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;These shares are subject to the following lock-up agreement, from and after the later of six months after issuance or 90 days from the effective date of our IPO registration statement until the one-year anniversary thereof, (a) the holder of the shares can sell up to 10% of the purchased shares per month, subject to a maximum sale on any trading day of 8% of the daily volume of the common stock; (b) if the common stock price is over $7.00 per share for five consecutive trading days then the holder of the shares can sell up to 20% of the purchased shares per month, subject to a maximum sale on any trading day of 10% of the daily volume of the common stock; and (c) if the common stock price is over $12.00 per share then the holder of the shares is not restricted from making any sales until such time as the common stock price falls back below $12.00 per share.&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On June 20, 2016, the Company agreed to issue &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 24,000&lt;/font&gt; shares of common stock to PCG Advisory Group, the Company&amp;#8217;s investor relations firm, for services provided. The fair value of these shares was $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;157,680&lt;/font&gt; based on the market price on the grant date.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0in 0.5in" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 18.7pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Adoption of 2015 Stock Plan&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On December 5, 2015, the Board of Directors of the Company approved the Company&amp;#8217;s 2015 Stock Plan, which was amended on April&amp;#160;22,&amp;#160;2016. The expiration date of the plan is &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;December 5, 2025&lt;/font&gt; and the total number of underlying shares of the Company&amp;#8217;s common stock available for grant to employees, directors and consultants under the plan is &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 2,500,000&lt;/font&gt; shares. The awards under the 2015 Stock Plan can be in the form of stock options, stock awards or stock unit awards. &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;The following is a summary of option activities for the periods ended December 31, 2015 and 2016:&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Remaining&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Contractual&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Aggregate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Number&amp;#160;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Weighted&amp;#160;Average&amp;#160;Grant&amp;#160;Date&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Term&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Intrinsic&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Shares&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Fair&amp;#160;Value&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;(in years)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Value&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="39%"&gt; &lt;div&gt;Granted - 2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;200,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.14&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.20&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="39%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"&gt; &lt;div&gt;Outstanding, December 31, 2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;200,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.14&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.20&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"&gt; &lt;div&gt;Granted - 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;460,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3.75&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5.83&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"&gt; &lt;div&gt;Cancelled&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(150,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.14&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.20&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"&gt; &lt;div&gt;Outstanding, December 31, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;510,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3.40&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5.28&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;9.29&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;275,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"&gt; &lt;div&gt;Exercisable, December 31, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;50,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.14&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.20&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3.67&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;275,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;During the year ended December 31, 2016, the Company granted an officer and its board of directors&amp;#8217; options, in the aggregate, to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 460,000&lt;/font&gt; shares of the Company&amp;#8217;s common stock with an exercise price ranging from $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5.71&lt;/font&gt; per share to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5.85&lt;/font&gt; per share, a term of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;10&lt;/font&gt; years, and a vesting period of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3&lt;/font&gt; to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4&lt;/font&gt; years.&amp;#160;The exercise price was based upon the closing price of the stock on the day of the grant. The options have an aggregated fair value of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,772,422&lt;/font&gt; that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1.30&lt;/font&gt;% (2) expected lives of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;6&lt;/font&gt; to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 6.25&lt;/font&gt; years, (3) expected volatility of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 70.18&lt;/font&gt;% to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 70.44&lt;/font&gt;%, and (4) zero expected dividends. The Company, due to the limited number of participants in the plan and their positions within the Company, uses a &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0&lt;/font&gt;% estimated forfeiture rate. During the year ended December 31, 2016, the Company recorded $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;166,294&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt; in stock-based compensation in relation to these options. As of December 31, 2016, there was $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,565,599&lt;/font&gt; of unrecognized compensation cost, net of estimated forfeitures, related to the Company&amp;#8217;s non-vested equity awards, which is expected to be recognized over a weighted average period of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 3.7&lt;/font&gt; years. &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The fair value of each stock option is estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted in the above paragraph and table. The expected term of the options was computed using the &amp;#8220;plain vanilla&amp;#8221; method as prescribed by the Securities and Exhange Commission Staff Accounting Bulletin 107 because we do not have suffient data regarding employee exercise behavior to estimate the expected term. The volatility was determined by referring to the average historical volatility of a peer group of public companies because we do not have sufficient trading history to determine our historical volatility. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The Company entered into a separation agreement with its former Chief Financial Officer in October 2016 and as part of the agreement, options to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 150,000&lt;/font&gt; shares of common stock issued to the former Chief Financial Officer were cancelled and the vesting was accelerated on the remaining options to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 50,000&lt;/font&gt; shares of common stock.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>

  <us-gaap:NetIncomeLoss contextRef="P07_28_2015To12_31_2015_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" id="Factid_493" unitRef="USD" decimals="0">-748360</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2016To12_31_2016_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" id="Factid_494" unitRef="USD" decimals="0">-3926361</us-gaap:NetIncomeLoss>

  <us-gaap:StockholdersEquity contextRef="PAsOn07_27_2015" id="Factid_495" unitRef="USD" xsi:nil="true" />

  <us-gaap:StockholdersEquity contextRef="PAsOn07_27_2015_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_496" unitRef="USD" xsi:nil="true" />

  <us-gaap:StockholdersEquity contextRef="PAsOn07_27_2015_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_497" unitRef="USD" xsi:nil="true" />

  <us-gaap:StockholdersEquity contextRef="PAsOn07_27_2015_SubscriptionsReceivableMemberusgaapStatementEquityComponentsAxis" id="Factid_498" unitRef="USD" xsi:nil="true" />

  <us-gaap:StockholdersEquity contextRef="PAsOn07_27_2015_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" id="Factid_499" unitRef="USD" xsi:nil="true" />

  <us-gaap:SharesOutstanding contextRef="PAsOn07_27_2015" id="Factid_500" unitRef="shares" xsi:nil="true" />

  <us-gaap:SharesOutstanding contextRef="PAsOn07_27_2015_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_501" unitRef="shares" xsi:nil="true" />

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2015_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_502" unitRef="USD" decimals="0">6661</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2015_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_503" unitRef="USD" decimals="0">0</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2015_SubscriptionsReceivableMemberusgaapStatementEquityComponentsAxis" id="Factid_504" unitRef="USD" decimals="0">-3000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2015_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" id="Factid_505" unitRef="USD" decimals="0">-748360</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_506" unitRef="USD" decimals="0">12165</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_507" unitRef="USD" decimals="0">19622925</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2016_SubscriptionsReceivableMemberusgaapStatementEquityComponentsAxis" id="Factid_508" unitRef="USD" decimals="0">0</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2016_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" id="Factid_509" unitRef="USD" decimals="0">-4674721</us-gaap:StockholdersEquity>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2015_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_510" unitRef="shares" decimals="INF">6661000</us-gaap:SharesOutstanding>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_511" unitRef="shares" decimals="INF">12164852</us-gaap:SharesOutstanding>

  <mbrx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable contextRef="PAsOn12_31_2016_MoleculinLlcMemberusgaapBusinessAcquisitionAxis" id="Factid_512" unitRef="USD" decimals="0">469939</mbrx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable>

  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="P01_01_2016To12_31_2016" id="Factid_513">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;The principal components of the Company&amp;#8217;s deferred tax assets and liabilities consist of the following at December 31, 2016 and 2015 (in thousands):&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both; size: 8.5in 11.0in" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Deferred Tax Assets:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Start Up Costs&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;798&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;67&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Federal Net Operating Loss Carryforwards&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;520&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;89&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;State Tax Loss Carryforwards&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;50&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Deferred Compensation&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;33&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Total Deferred Tax Assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;1,401&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;155&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Less Valuation Allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;(1,397)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;(155)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Net Deferred Tax Assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;4&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Deferred Tax Liabilities:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Fixed Assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;(4)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Total Deferred Tax Liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;(4)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Net Deferred Taxes&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>

  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2016To12_31_2016" id="Factid_514">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"&gt; &lt;table style="LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0"&gt; &lt;tr&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.3pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"&gt; &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;6.&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Income Taxes&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The provision for income taxes consists of the following components (in thousands):&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both; size: 8.5in 11.0in" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Current Expense (Benefit):&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Federal&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;State&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Current Income Tax Expense&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Deferred Expense (Benefit):&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Federal&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;State&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Deferred Income Tax Expense&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Net Deferred Taxes&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The following summarizes activity related to the Company&amp;#8217;s valuation allowance (in thousands):&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both; size: 8.5in 11.0in" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Valuation Allowance at Beginning of Period&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;155&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Income Tax Benefit&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;1,242&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;155&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Release of Valuation Allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Valuation Allowance at End of Period&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;1,397&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;155&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;A reconciliation of the income tax benefit computed using the federal statutory income tax rate to the Company&amp;#8217;s effective income tax rate is as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%" colspan="5"&gt; &lt;div&gt;December&amp;#160;31,&amp;#160;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%" colspan="5"&gt; &lt;div&gt;December&amp;#160;31,&amp;#160;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Amount&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Percent&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Amount&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Percent&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Federal Tax Benefit at Statutory Rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,335&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;34.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;254&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;34.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;State Tax Benefit Net of Federal&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;137&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3.48&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; BACKGROUND: #ffffff; COLOR: #000000; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;IPO Costs&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(227)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(5.78)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; BACKGROUND: #cceeff; COLOR: #000000; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(99)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(13.24)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Other Permanent Differences&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(3)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(0.08)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Increase in Valuation Allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(1,242)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(31.62)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(155)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(20.76)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Total Tax (Expense) / Benefit&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;The principal components of the Company&amp;#8217;s deferred tax assets and liabilities consist of the following at December 31, 2016 and 2015 (in thousands):&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both; size: 8.5in 11.0in" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Deferred Tax Assets:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Start Up Costs&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;798&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;67&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Federal Net Operating Loss Carryforwards&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;520&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;89&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;State Tax Loss Carryforwards&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;50&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Deferred Compensation&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;33&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Total Deferred Tax Assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;1,401&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;155&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Less Valuation Allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;(1,397)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;(155)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Net Deferred Tax Assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;4&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Deferred Tax Liabilities:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Fixed Assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;(4)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Total Deferred Tax Liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;(4)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Net Deferred Taxes&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"&gt;The Company has incurred net operating losses since inception. As of December 31, 2016, the Company had total federal operating loss carry forwards of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.53&lt;/font&gt; million which expire commencing in &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 2035&lt;/font&gt;. The value of these carryforwards depends on the Company&amp;#8217;s ability to generate taxable income. Additionally, because federal tax laws limit the time during which the net operating loss carryforwards may be applied against future taxes, if the Company fails to generate taxable income prior to the expiration dates of the carry forwards the Company may not be able to fully utilize the net operating loss carryforwards to reduce future income taxes. Finally, the Company has not undertaken a detailed analysis of the application of IRC Section 382 with respect to limitations on the utilization of net operating loss carryforwards and other deferred tax assets. However, the Company believes that this matter is not material to the overall tax position within the financial statements due to the full valuation allowance against the net operating losses and the lack of utilization of the net operating losses during tax years open under statute.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The Company conducts business in various locations and, as a result, files income tax returns in the United States Federal jurisdiction and in multiple state jurisdictions. As of December 31, 2016, the Company had state operating losses of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.27&lt;/font&gt; million which expire commencing in &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 2036&lt;/font&gt;. Since the Company is in a loss carryforward position, the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which a loss carryforward is available.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Management has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. The Company has cumulative losses and there is no assurance of future taxable income, therefore, valuation allowances have been recorded to fully offset the deferred tax asset at December 31, 2016. Management has determined that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets, and as a result, a valuation allowance of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.40&lt;/font&gt; million and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.16&lt;/font&gt; million has been established at December 31, 2016 and 2015, respectively. The change in the valuation allowance for the year ended December 31, 2016 was primary due to additional operating losses and capitalized research costs. The Company may be eligible to claim research and development tax credits in the future, but has not conducted a study to date.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;There are no unrecognized tax benefits from any federal, state or foreign jurisdictions. The only tax year open under statute for the Company is December 31, 2015.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The Company&amp;#8217;s policy is to recognize interest and penalties related to any unrecognized tax liabilities as additional tax expense. No interest or penalties have been accrued at December 31, 2016 and 2015, as the Company has not recorded any uncertain tax positions. The Company believes it has appropriate and adequate support for the income tax positions taken and to be taken on its tax returns and that its accruals for tax liabilities are adequate for all open years based on an assessment of many factors including past experience and interpretations of tax law applied to the facts of each matter.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;Although the Company believes its recorded assets and liabilities are reasonable, tax regulations are subject to interpretation and tax litigation is inherently uncertain; therefore the Company&amp;#8217;s assessments can involve both a series of complex judgments about future events and rely heavily on estimates and assumptions. Although the Company believes that the estimates and assumptions supporting its assessments are reasonable, the final determination of tax audit settlements and any related litigation could be materially different from that which is reflected in historical income tax provisions and recorded assets and liabilities. If the Company were to settle an audit or a matter under litigation, it could have a material effect on the income tax provision, net income, or cash flows in the period or periods for which that determination is made. Any accruals for tax contingencies are provided for in accordance with U.S. GAAP&lt;i&gt;.&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt; The Company does not believe that its tax positions will significantly change due to any settlement and/or expiration of statutes of limitations prior to&amp;#160;December&amp;#160;31, 2017.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IncomeTaxDisclosureTextBlock>

  <mbrx:StockIssuedDuringPeriodSharesForCashAndSubscriptionReceivable contextRef="P07_28_2015To12_31_2015_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_515" unitRef="shares" decimals="INF">4600000</mbrx:StockIssuedDuringPeriodSharesForCashAndSubscriptionReceivable>

  <mbrx:StockIssuedDuringPeriodValueForCashAndSubscriptionReceivable contextRef="P07_28_2015To12_31_2015" id="Factid_516" unitRef="USD" decimals="0">1600</mbrx:StockIssuedDuringPeriodValueForCashAndSubscriptionReceivable>

  <mbrx:StockIssuedDuringPeriodValueForCashAndSubscriptionReceivable contextRef="P07_28_2015To12_31_2015_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_517" unitRef="USD" decimals="0">4600</mbrx:StockIssuedDuringPeriodValueForCashAndSubscriptionReceivable>

  <mbrx:StockIssuedDuringPeriodValueForCashAndSubscriptionReceivable contextRef="P07_28_2015To12_31_2015_SubscriptionsReceivableMemberusgaapStatementEquityComponentsAxis" id="Factid_518" unitRef="USD" decimals="0">-3000</mbrx:StockIssuedDuringPeriodValueForCashAndSubscriptionReceivable>

  <mbrx:StockIssuedDuringPeriodSharesForLicenses contextRef="P07_28_2015To12_31_2015_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_519" unitRef="shares" decimals="INF">2061000</mbrx:StockIssuedDuringPeriodSharesForLicenses>

  <mbrx:StockIssuedDuringPeriodValueForLicenses contextRef="P07_28_2015To12_31_2015" id="Factid_520" unitRef="USD" decimals="0">2061</mbrx:StockIssuedDuringPeriodValueForLicenses>

  <mbrx:StockIssuedDuringPeriodValueForLicenses contextRef="P07_28_2015To12_31_2015_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_521" unitRef="USD" decimals="0">2061</mbrx:StockIssuedDuringPeriodValueForLicenses>

  <mbrx:StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts contextRef="P01_01_2016To12_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_522" unitRef="shares" decimals="INF">1540026</mbrx:StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts>

  <mbrx:StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts contextRef="P01_01_2016To12_31_2016" id="Factid_523" unitRef="USD" decimals="0">8089420</mbrx:StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts>

  <mbrx:StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts contextRef="P01_01_2016To12_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_524" unitRef="USD" decimals="0">1540</mbrx:StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts>

  <mbrx:StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts contextRef="P01_01_2016To12_31_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_525" unitRef="USD" decimals="0">8087880</mbrx:StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts>

  <mbrx:StockIssuedDuringPeriodSharesForTechnology contextRef="P01_01_2016To12_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_526" unitRef="shares" decimals="INF">629000</mbrx:StockIssuedDuringPeriodSharesForTechnology>

  <mbrx:StockIssuedDuringPeriodValueForTechnology contextRef="P01_01_2016To12_31_2016" id="Factid_527" unitRef="USD" decimals="0">3774000</mbrx:StockIssuedDuringPeriodValueForTechnology>

  <mbrx:StockIssuedDuringPeriodValueForTechnology contextRef="P01_01_2016To12_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_528" unitRef="USD" decimals="0">629</mbrx:StockIssuedDuringPeriodValueForTechnology>

  <mbrx:StockIssuedDuringPeriodValueForTechnology contextRef="P01_01_2016To12_31_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_529" unitRef="USD" decimals="0">3773371</mbrx:StockIssuedDuringPeriodValueForTechnology>

<!--FootNote Section Ref-->

  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="#Factid_283" xlink:type="locator" xlink:label="loc_1" />

    <link:footnote xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:type="resource" xlink:label="FN_1">Property and equipment assets acquired in the merger with Moleculin, LLC are being depreciated over a 2 year useful life due to their age and condition and expected remaining life assessed at merger date.</link:footnote>

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_284" xlink:type="locator" xlink:label="loc_3" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_285" xlink:type="locator" xlink:label="loc_4" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_295" xlink:type="locator" xlink:label="loc_5" />

    <link:footnote xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:type="resource" xlink:label="FN_5">Debt partially converted on May 31, 2016 and on August 19, 2016.</link:footnote>

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_5" xlink:from="loc_5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:footnote xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:type="resource" xlink:label="FN_6">Excluded from the $276,079 is $20,333 in accrued interest on the convertible notes payable which is included in the accompanying balance sheet.</link:footnote>

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_6" xlink:from="loc_5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_296" xlink:type="locator" xlink:label="loc_8" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_6" xlink:from="loc_8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_297" xlink:type="locator" xlink:label="loc_9" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_5" xlink:from="loc_9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_6" xlink:from="loc_9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:footnote xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:type="resource" xlink:label="FN_9">Debt partially converted on September 1, 2016.</link:footnote>

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_9" xlink:from="loc_9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_298" xlink:type="locator" xlink:label="loc_11" />

    <link:footnote xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:type="resource" xlink:label="FN_11">Debt fully converted to common shares on May 31, 2016.</link:footnote>

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_11" xlink:from="loc_11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_6" xlink:from="loc_11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_299" xlink:type="locator" xlink:label="loc_13" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_11" xlink:from="loc_13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_6" xlink:from="loc_13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_300" xlink:type="locator" xlink:label="loc_14" />

    <link:footnote xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:type="resource" xlink:label="FN_14">Debt fully converted to common shares effective November 30, 2016 .</link:footnote>

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_14" xlink:from="loc_14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_6" xlink:from="loc_14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_301" xlink:type="locator" xlink:label="loc_16" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_6" xlink:from="loc_16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_302" xlink:type="locator" xlink:label="loc_17" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_5" xlink:from="loc_17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_304" xlink:type="locator" xlink:label="loc_18" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_5" xlink:from="loc_18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_9" xlink:from="loc_18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_305" xlink:type="locator" xlink:label="loc_19" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_11" xlink:from="loc_19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_306" xlink:type="locator" xlink:label="loc_20" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_11" xlink:from="loc_20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_307" xlink:type="locator" xlink:label="loc_21" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_14" xlink:from="loc_21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_309" xlink:type="locator" xlink:label="loc_22" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_5" xlink:from="loc_22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_311" xlink:type="locator" xlink:label="loc_23" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_5" xlink:from="loc_23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_9" xlink:from="loc_23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_312" xlink:type="locator" xlink:label="loc_24" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_11" xlink:from="loc_24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_313" xlink:type="locator" xlink:label="loc_25" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_11" xlink:from="loc_25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_314" xlink:type="locator" xlink:label="loc_26" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_14" xlink:from="loc_26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_331" xlink:type="locator" xlink:label="loc_27" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_5" xlink:from="loc_27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_333" xlink:type="locator" xlink:label="loc_28" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_11" xlink:from="loc_28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_334" xlink:type="locator" xlink:label="loc_29" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_14" xlink:from="loc_29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_336" xlink:type="locator" xlink:label="loc_30" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_11" xlink:from="loc_30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_337" xlink:type="locator" xlink:label="loc_31" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_5" xlink:from="loc_31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_9" xlink:from="loc_31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_338" xlink:type="locator" xlink:label="loc_32" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_5" xlink:from="loc_32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_340" xlink:type="locator" xlink:label="loc_33" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_5" xlink:from="loc_33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_9" xlink:from="loc_33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_341" xlink:type="locator" xlink:label="loc_34" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_11" xlink:from="loc_34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_343" xlink:type="locator" xlink:label="loc_35" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_14" xlink:from="loc_35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
  </link:footnoteLink>
</xbrli:xbrl>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>mbrx-20161231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.9 on 02-Apr-2017 [12:25:26] {PM} EST - www.datatracks.com -->
<schema targetNamespace="http://www.moleculin.com/20161231" elementFormDefault="qualified" xmlns:mbrx="http://www.moleculin.com/20161231" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:country="http://xbrl.sec.gov/country/2016-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.moleculin.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>101 - Document - Document And Entity Information</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.moleculin.com/role/BalanceSheets" id="BalanceSheets">
        <link:definition>102 - Statement - Balance Sheets</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.moleculin.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
        <link:definition>103 - Statement - Balance Sheets (Parenthetical)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.moleculin.com/role/StatementsOfOperations" id="StatementsOfOperations">
        <link:definition>104 - Statement - Statements of Operations</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.moleculin.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
        <link:definition>105 - Statement - Statements of Cash Flows</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.moleculin.com/role/StatementsOfStockholdersEquity" id="StatementsOfStockholdersEquity">
        <link:definition>106 - Statement - Statements of Stockholders&#8217; Equity</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.moleculin.com/role/StatementsOfStockholdersEquityParenthetical" id="StatementsOfStockholdersEquityParenthetical">
        <link:definition>107 - Statement - Statements of Stockholders&#8217; Equity (Parenthetical)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.moleculin.com/role/NatureOfBusinessAndLiquidity" id="NatureOfBusinessAndLiquidity">
        <link:definition>108 - Disclosure - Nature of Business and Liquidity</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.moleculin.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>109 - Disclosure - Summary of Significant Accounting Policies</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.moleculin.com/role/IntangibleAssets" id="IntangibleAssets">
        <link:definition>110 - Disclosure - Intangible Assets</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.moleculin.com/role/ConvertibleNotesPayable" id="ConvertibleNotesPayable">
        <link:definition>111 - Disclosure - Convertible Notes Payable</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.moleculin.com/role/Equity" id="Equity">
        <link:definition>112 - Disclosure - Equity</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.moleculin.com/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>113 - Disclosure - Income Taxes</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.moleculin.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>114 - Disclosure - Commitments and Contingencies</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.moleculin.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>115 - Disclosure - Subsequent Events</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>116 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>117 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.moleculin.com/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
        <link:definition>118 - Disclosure - Intangible Assets (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.moleculin.com/role/ConvertibleNotesPayableTables" id="ConvertibleNotesPayableTables">
        <link:definition>119 - Disclosure - Convertible Notes Payable (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.moleculin.com/role/EquityTables" id="EquityTables">
        <link:definition>120 - Disclosure - Equity (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.moleculin.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
        <link:definition>121 - Disclosure - Income Taxes (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.moleculin.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
        <link:definition>122 - Disclosure - Commitments and Contingencies (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.moleculin.com/role/NatureOfBusinessAndLiquidityDetailsTextual" id="NatureOfBusinessAndLiquidityDetailsTextual">
        <link:definition>123 - Disclosure - Nature of Business and Liquidity (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" id="SummaryOfSignificantAccountingPoliciesDetailsTextual">
        <link:definition>124 - Disclosure - Summary of Significant Accounting Policies (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.moleculin.com/role/IntangibleAssetsDetails" id="IntangibleAssetsDetails">
        <link:definition>125 - Disclosure - Intangible Assets (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.moleculin.com/role/IntangibleAssetsDetails1" id="IntangibleAssetsDetails1">
        <link:definition>126 - Disclosure - Intangible Assets (Details 1)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.moleculin.com/role/IntangibleAssetsDetails2" id="IntangibleAssetsDetails2">
        <link:definition>127 - Disclosure - Intangible Assets (Details 2)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.moleculin.com/role/IntangibleAssetsDetailsTextual" id="IntangibleAssetsDetailsTextual">
        <link:definition>128 - Disclosure - Intangible Assets (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.moleculin.com/role/ConvertibleNotesPayableDetails" id="ConvertibleNotesPayableDetails">
        <link:definition>129 - Disclosure - Convertible Notes Payable (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.moleculin.com/role/ConvertibleNotesPayableDetailsTextual" id="ConvertibleNotesPayableDetailsTextual">
        <link:definition>130 - Disclosure - Convertible Notes Payable (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.moleculin.com/role/EquityDetails" id="EquityDetails">
        <link:definition>131 - Disclosure - Equity (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.moleculin.com/role/EquityDetailsTextual" id="EquityDetailsTextual">
        <link:definition>132 - Disclosure - Equity (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.moleculin.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
        <link:definition>133 - Disclosure - Income Taxes (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.moleculin.com/role/IncomeTaxesDetails1" id="IncomeTaxesDetails1">
        <link:definition>134 - Disclosure - Income Taxes (Details 1)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.moleculin.com/role/IncomeTaxesDetails2" id="IncomeTaxesDetails2">
        <link:definition>135 - Disclosure - Income Taxes (Details 2)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.moleculin.com/role/IncomeTaxesDetails3" id="IncomeTaxesDetails3">
        <link:definition>136 - Disclosure - Income Taxes (Details 3)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.moleculin.com/role/IncomeTaxesDetailsTextual" id="IncomeTaxesDetailsTextual">
        <link:definition>137 - Disclosure - Income Taxes (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.moleculin.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
        <link:definition>138 - Disclosure - Commitments and Contingencies (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.moleculin.com/role/CommitmentsAndContingenciesDetailsTextual" id="CommitmentsAndContingenciesDetailsTextual">
        <link:definition>139 - Disclosure - Commitments and Contingencies (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.moleculin.com/role/SubsequentEventsDetailsTextual" id="SubsequentEventsDetailsTextual">
        <link:definition>140 - Disclosure - Subsequent Events (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:linkbaseRef xlink:type="simple" xlink:href="mbrx-20161231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />

      <link:linkbaseRef xlink:type="simple" xlink:href="mbrx-20161231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />

      <link:linkbaseRef xlink:type="simple" xlink:href="mbrx-20161231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />

      <link:linkbaseRef xlink:type="simple" xlink:href="mbrx-20161231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>

  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />

  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />

  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />

  <import namespace="http://fasb.org/us-gaap/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/country/2016-01-31" schemaLocation="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/currency/2016-01-31" schemaLocation="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/exch/2016-01-31" schemaLocation="http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />

  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />

  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />

  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />

  <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />

  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />

  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />

  <import namespace="http://fasb.org/us-types/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd" />

  <element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_DocumentAndEntityInformationAbstract" />

  <element name="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" />

  <element name="GoingConcernPolicyPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_GoingConcernPolicyPolicyTextBlock" />

  <element name="DebtInstrumentConvertibleBeneficialConversionFeaturePolicyPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_DebtInstrumentConvertibleBeneficialConversionFeaturePolicyPolicyTextBlock" />

  <element name="ConvertibleNotesPayableAbstractAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_ConvertibleNotesPayableAbstractAbstract" />

  <element name="ConvertibleNotesPayableDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_ConvertibleNotesPayableDisclosureTextBlock" />

  <element name="InvestorBMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_InvestorBMember" />

  <element name="InvestorCMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_InvestorCMember" />

  <element name="IssueDateAugust312015Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_IssueDateAugust312015Member" />

  <element name="IssueDateSeptember032015Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_IssueDateSeptember032015Member" />

  <element name="IssueDateOctober062015OneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_IssueDateOctober062015OneMember" />

  <element name="IssueDateOctober062015TwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_IssueDateOctober062015TwoMember" />

  <element name="IssueDateOctober282015Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_IssueDateOctober282015Member" />

  <element name="IssueDateJanuary142016Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_IssueDateJanuary142016Member" />

  <element name="IssueDateJanuary192016Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_IssueDateJanuary192016Member" />

  <element name="DirectorAndOfficersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_DirectorAndOfficersMember" />

  <element name="StockPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_StockPlanMember" />

  <element name="PatentAndTechnologyLicenseAgreementMilestonePaymentsTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_PatentAndTechnologyLicenseAgreementMilestonePaymentsTableTextBlock" />

  <element name="CommitmentsAndContingenciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="mbrx_CommitmentsAndContingenciesTable" />

  <element name="CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_CommitmentsAndContingenciesLineItems" />

  <element name="CommencementOfPhaseIiStudyForLicensedProductMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_CommencementOfPhaseIiStudyForLicensedProductMember" />

  <element name="CommencementOfPhaseIiiStudyForLicensedProductMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember" />

  <element name="FilingOfNewDrugApplicationForLicensedProductMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_FilingOfNewDrugApplicationForLicensedProductMember" />

  <element name="ReceiptOfMarketApprovalForLicensedProductMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_ReceiptOfMarketApprovalForLicensedProductMember" />

  <element name="AgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="mbrx_AgreementAxis" />

  <element name="AnniversaryDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_AnniversaryDomain" />

  <element name="AnniversaryAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="mbrx_AnniversaryAxis" />

  <element name="MdAndersonMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_MdAndersonMember" />

  <element name="AgreementDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_AgreementDomain" />

  <element name="PatentAndTechnologyLicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_PatentAndTechnologyLicenseAgreementMember" />

  <element name="PatentLawFirmMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_PatentLawFirmMember" />

  <element name="BonwickCapitalPartnersLlcMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_BonwickCapitalPartnersLlcMember" />

  <element name="LetterAgreementsTerms" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_LetterAgreementsTerms" />

  <element name="OperatingLossCarryforwardsExpirationPeriod" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_OperatingLossCarryforwardsExpirationPeriod" />

  <element name="InvestorDMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_InvestorDMember" />

  <element name="InvestorEMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_InvestorEMember" />

  <element name="DebtConversionConvertedInstrumentCommonStockSharesIssuedTradingRestrictionsDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_DebtConversionConvertedInstrumentCommonStockSharesIssuedTradingRestrictionsDescription" />

  <element name="ServicingFeePayableMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_ServicingFeePayableMember" />

  <element name="MinimumFeeAndPatentExpensesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_MinimumFeeAndPatentExpensesMember" />

  <element name="MinimumAnnualRoyaltyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_MinimumAnnualRoyaltyMember" />

  <element name="SuccessFeePercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_SuccessFeePercentage" />

  <element name="ClassOfWarrantOrRightPercentageOfSecuritiesCalledByWarrantsOrRights" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_ClassOfWarrantOrRightPercentageOfSecuritiesCalledByWarrantsOrRights" />

  <element name="ClassOfWarrantOrRightExercisePricePercentageThreshold" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_ClassOfWarrantOrRightExercisePricePercentageThreshold" />

  <element name="ReimbursementPayableOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="mbrx_ReimbursementPayableOfferingCosts" />

  <element name="ReimbursementPayableFeesAndExpensesOfCounsel" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="mbrx_ReimbursementPayableFeesAndExpensesOfCounsel" />

  <element name="RevenueRecognitionMilestoneMethodAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="mbrx_RevenueRecognitionMilestoneMethodAxis" />

  <element name="AgreementTypeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="mbrx_AgreementTypeAxis" />

  <element name="DebtConversionConvertedInstrumentAdditionalSharesIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_DebtConversionConvertedInstrumentAdditionalSharesIssued" />

  <element name="MilestonePaymentsLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="mbrx_MilestonePaymentsLiabilities" />

  <element name="DebtInstrumentConvertibleNumberOfCommonShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_DebtInstrumentConvertibleNumberOfCommonShares" />

  <element name="ContractualObligationDueInNextFiscalYearAfterProductApproval" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="mbrx_ContractualObligationDueInNextFiscalYearAfterProductApproval" />

  <element name="ContractualObligationDueInSecondYearAfterProductApproval" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="mbrx_ContractualObligationDueInSecondYearAfterProductApproval" />

  <element name="ContractualObligationDueInThirdYearAfterProductApproval" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="mbrx_ContractualObligationDueInThirdYearAfterProductApproval" />

  <element name="ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable" />

  <element name="CommonStockLockupAndLeakoutAgreementsDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_CommonStockLockupAndLeakoutAgreementsDescription" />

  <element name="BusinessAcquistionProFormaOperatingExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="mbrx_BusinessAcquistionProFormaOperatingExpenses" />

  <element name="BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" />

  <element name="BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted" />

  <element name="MoleculinLlcMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_MoleculinLlcMember" />

  <element name="HoustonPharmaceuticalsIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_HoustonPharmaceuticalsIncMember" />

  <element name="LicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_LicenseAgreementMember" />

  <element name="OutlincenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_OutlincenseAgreementMember" />

  <element name="LicenseAgreementMaintenanceFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="mbrx_LicenseAgreementMaintenanceFee" />

  <element name="LicenseAgreementMaintenanceFeeAnnualIncrease" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="mbrx_LicenseAgreementMaintenanceFeeAnnualIncrease" />

  <element name="RevenueRecognitionMilestoneMethodDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_RevenueRecognitionMilestoneMethodDomain" />

  <element name="LetterAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_LetterAgreementMember" />

  <element name="ReimburementOfExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="mbrx_ReimburementOfExpenses" />

  <element name="LicencingArrangementsConsiderationPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="mbrx_LicencingArrangementsConsiderationPayable" />

  <element name="LicencingArrangementsReserve" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="mbrx_LicencingArrangementsReserve" />

  <element name="UnsecuredPromissoryNotesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_UnsecuredPromissoryNotesMember" />

  <element name="SharesAuthorized" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="mbrx_SharesAuthorized" />

  <element name="PcgAdvisoryGroupMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_PcgAdvisoryGroupMember" />

  <element name="PeriodTypeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="mbrx_PeriodTypeAxis" />

  <element name="RoyaltyOnNetRevenues" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="mbrx_RoyaltyOnNetRevenues" />

  <element name="AccruedLicenseAgreementPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="mbrx_AccruedLicenseAgreementPayment" />

  <element name="LicenseAgreementMaintenanceFeeMaximumPayablePerYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="mbrx_LicenseAgreementMaintenanceFeeMaximumPayablePerYear" />

  <element name="EmployeeAndBoardOfDirectorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_EmployeeAndBoardOfDirectorsMember" />

  <element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" />

  <element name="SharesIssuedForLicensesUsedForResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="mbrx_SharesIssuedForLicensesUsedForResearchAndDevelopment" />

  <element name="WarrantsIssuedForServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="mbrx_WarrantsIssuedForServices" />

  <element name="PeriodTypeDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_PeriodTypeDomain" />

  <element name="AcquisitionDateOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_AcquisitionDateOneMember" />

  <element name="SubscriptionsReceivableMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_SubscriptionsReceivableMember" />

  <element name="StockIssuedDuringPeriodValueForCashAndSubscriptionReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="mbrx_StockIssuedDuringPeriodValueForCashAndSubscriptionReceivable" />

  <element name="StockIssuedDuringPeriodSharesForCashAndSubscriptionReceivable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_StockIssuedDuringPeriodSharesForCashAndSubscriptionReceivable" />

  <element name="StockIssuedDuringPeriodValueForLicenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="mbrx_StockIssuedDuringPeriodValueForLicenses" />

  <element name="StockIssuedDuringPeriodSharesForLicenses" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_StockIssuedDuringPeriodSharesForLicenses" />

  <element name="StockIssuedDuringPeriodValuePrivateIssuances" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="mbrx_StockIssuedDuringPeriodValuePrivateIssuances" />

  <element name="StockIssuedDuringPeriodSharesPrivateIssuances" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_StockIssuedDuringPeriodSharesPrivateIssuances" />

  <element name="StockIssuedDuringPeriodValueForTechnology" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="mbrx_StockIssuedDuringPeriodValueForTechnology" />

  <element name="StockIssuedDuringPeriodSharesForTechnology" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_StockIssuedDuringPeriodSharesForTechnology" />

  <element name="StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="mbrx_StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts" />

  <element name="StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts" />

  <element name="NatureOfBusinessAndLiquidityTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_NatureOfBusinessAndLiquidityTextBlock" />

  <element name="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" />

  <element name="NumberOfUnitsIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_NumberOfUnitsIssued" />

  <element name="PricePerUnit" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="mbrx_PricePerUnit" />

  <element name="AgreementTypeDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_AgreementTypeDomain" />

  <element name="UnderwritingAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_UnderwritingAgreementMember" />

  <element name="InvestorFMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_InvestorFMember" />

  <element name="InvestorGMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_InvestorGMember" />

  <element name="SeriesWarrantMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_SeriesWarrantMember" />

  <element name="SeriesBWarrantMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_SeriesBWarrantMember" />

  <element name="SeriesCWarrantMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_SeriesCWarrantMember" />

  <element name="ClassOfWarrantOrRightsWarrantExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_ClassOfWarrantOrRightsWarrantExercised" />

  <element name="ScienceAdvisoryBoardOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_ScienceAdvisoryBoardOneMember" />

  <element name="ScienceAdvisoryBoardTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_ScienceAdvisoryBoardTwoMember" />

  <element name="FormerScienceAdvisoryBoardMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_FormerScienceAdvisoryBoardMember" />

  <element name="UsFoodAndDrugAdministrationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_UsFoodAndDrugAdministrationMember" />

  <element name="ChiefFinancialOfficerAndExecutiveVicePresidentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_ChiefFinancialOfficerAndExecutiveVicePresidentMember" />

  <element name="MrLouisMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_MrLouisMember" />

  <element name="SeparationAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_SeparationAgreementDescription" />

  <element name="DeferredTaxAssetsValuationAllowanceReleases" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="mbrx_DeferredTaxAssetsValuationAllowanceReleases" />

  <element name="EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost" />

  <element name="EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent" />

  <element name="DeferredTaxAssetsStartUpCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="mbrx_DeferredTaxAssetsStartUpCosts" />

  <element name="AnnamedIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_AnnamedIncMember" />

  <element name="IntertechbioCorporationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_IntertechbioCorporationMember" />

  <element name="MilestonePaymentDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_MilestonePaymentDescription" />

  <element name="ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="mbrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" />

  <element name="SharesSubscribed" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="mbrx_SharesSubscribed" />

  <element name="EstimatedForfeitureRatePercentage" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="mbrx_EstimatedForfeitureRatePercentage" />

  <element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="mbrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable" />

  <element name="StockholdersEquitySubscriptionsSettledForCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="mbrx_StockholdersEquitySubscriptionsSettledForCash" />
</schema>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>mbrx-20161231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.9 on 02-Apr-2017 [12:25:26] {PM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#BalanceSheets" roleURI="http://www.moleculin.com/role/BalanceSheets" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#StatementsOfCashFlows" roleURI="http://www.moleculin.com/role/StatementsOfCashFlows" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#StatementsOfOperations" roleURI="http://www.moleculin.com/role/StatementsOfOperations" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#ConvertibleNotesPayable" roleURI="http://www.moleculin.com/role/ConvertibleNotesPayable" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#Equity" roleURI="http://www.moleculin.com/role/Equity" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#IncomeTaxes" roleURI="http://www.moleculin.com/role/IncomeTaxes" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#IntangibleAssets" roleURI="http://www.moleculin.com/role/IntangibleAssets" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#IncomeTaxesDetails" roleURI="http://www.moleculin.com/role/IncomeTaxesDetails" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#IncomeTaxesDetails2" roleURI="http://www.moleculin.com/role/IncomeTaxesDetails2" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#IncomeTaxesDetails3" roleURI="http://www.moleculin.com/role/IncomeTaxesDetails3" />

  <calculationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/StatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" use="optional" order="30" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" order="50" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" use="optional" order="60" weight="1" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_SharesIssuedForLicensesUsedForResearchAndDevelopment" xlink:label="loc_mbrx_SharesIssuedForLicensesUsedForResearchAndDevelopment" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_mbrx_SharesIssuedForLicensesUsedForResearchAndDevelopment" use="optional" order="70" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromNotesPayable" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable" use="optional" order="20" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="10" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" use="optional" order="20" weight="-1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/StatementsOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_SalesRevenueNet" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" use="optional" order="20" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_InterestExpense" use="optional" order="20" weight="-1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/BalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" use="optional" order="30" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/BalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:label="loc_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" use="optional" order="30" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="50" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/IncomeTaxesDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost" xlink:label="loc_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" use="optional" order="50" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/IncomeTaxesDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent" xlink:label="loc_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" use="optional" order="50" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/IncomeTaxesDetails3">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxAssetsNet" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsGross" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_DeferredTaxAssetsStartUpCosts" xlink:label="loc_mbrx_DeferredTaxAssetsStartUpCosts" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_mbrx_DeferredTaxAssetsStartUpCosts" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance" use="optional" order="20" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxLiabilities" use="optional" order="20" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" use="optional" order="10" weight="1" />
  </calculationLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>mbrx-20161231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.9 on 02-Apr-2017 [12:25:26] {PM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#DocumentAndEntityInformation" roleURI="http://www.moleculin.com/role/DocumentAndEntityInformation" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#BalanceSheets" roleURI="http://www.moleculin.com/role/BalanceSheets" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#StatementsOfCashFlows" roleURI="http://www.moleculin.com/role/StatementsOfCashFlows" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#SummaryOfSignificantAccountingPoliciesDetailsTextual" roleURI="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#BalanceSheetsParenthetical" roleURI="http://www.moleculin.com/role/BalanceSheetsParenthetical" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#StatementsOfOperations" roleURI="http://www.moleculin.com/role/StatementsOfOperations" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#ConvertibleNotesPayableDetails" roleURI="http://www.moleculin.com/role/ConvertibleNotesPayableDetails" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#ConvertibleNotesPayableDetailsTextual" roleURI="http://www.moleculin.com/role/ConvertibleNotesPayableDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#EquityDetailsTextual" roleURI="http://www.moleculin.com/role/EquityDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#SubsequentEventsDetailsTextual" roleURI="http://www.moleculin.com/role/SubsequentEventsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#CommitmentsAndContingenciesDetails" roleURI="http://www.moleculin.com/role/CommitmentsAndContingenciesDetails" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#CommitmentsAndContingenciesDetailsTextual" roleURI="http://www.moleculin.com/role/CommitmentsAndContingenciesDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#IncomeTaxesDetailsTextual" roleURI="http://www.moleculin.com/role/IncomeTaxesDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#IntangibleAssetsDetails" roleURI="http://www.moleculin.com/role/IntangibleAssetsDetails" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#IntangibleAssetsDetails2" roleURI="http://www.moleculin.com/role/IntangibleAssetsDetails2" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#IntangibleAssetsDetailsTextual" roleURI="http://www.moleculin.com/role/IntangibleAssetsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#IntangibleAssetsDetails1" roleURI="http://www.moleculin.com/role/IntangibleAssetsDetails1" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#EquityDetails" roleURI="http://www.moleculin.com/role/EquityDetails" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#StatementsOfStockholdersEquity" roleURI="http://www.moleculin.com/role/StatementsOfStockholdersEquity" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#StatementsOfStockholdersEquityParenthetical" roleURI="http://www.moleculin.com/role/StatementsOfStockholdersEquityParenthetical" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#IncomeTaxesDetails" roleURI="http://www.moleculin.com/role/IncomeTaxesDetails" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#IncomeTaxesDetails1" roleURI="http://www.moleculin.com/role/IncomeTaxesDetails1" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#IncomeTaxesDetails2" roleURI="http://www.moleculin.com/role/IncomeTaxesDetails2" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#IncomeTaxesDetails3" roleURI="http://www.moleculin.com/role/IncomeTaxesDetails3" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#NatureOfBusinessAndLiquidityDetailsTextual" roleURI="http://www.moleculin.com/role/NatureOfBusinessAndLiquidityDetailsTextual" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />

  <definitionLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_3" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentInformationTable_3" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_966" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_966" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_967" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_966" xlink:to="loc_us-gaap_ClassOfStockDomain_967" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_967_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_966" xlink:to="loc_us-gaap_ClassOfStockDomain_967_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_721" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentType_721" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_722" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_AmendmentFlag_722" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_723" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentPeriodEndDate_723" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_724" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentFiscalYearFocus_724" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_725" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentFiscalPeriodFocus_725" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_726" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityRegistrantName_726" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_727" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityCentralIndexKey_727" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_728" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_CurrentFiscalYearEndDate_728" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_729" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_729" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_730" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityVoluntaryFilers_730" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_731" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityCurrentReportingStatus_731" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_732" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityFilerCategory_732" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_733" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityPublicFloat_733" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_734" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_TradingSymbol_734" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_735" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_735" use="optional" order="19" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/BalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_18" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_21" xlink:to="loc_us-gaap_StatementTable_18" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_19" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_18" xlink:to="loc_us-gaap_StatementClassOfStockAxis_19" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_20" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_19" xlink:to="loc_us-gaap_ClassOfStockDomain_20" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_20_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_19" xlink:to="loc_us-gaap_ClassOfStockDomain_20_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_30" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_21" xlink:to="loc_us-gaap_AssetsAbstract_30" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_22" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_30" xlink:to="loc_us-gaap_AssetsCurrentAbstract_22" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_38" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_22" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_38" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_422" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_22" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_422" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_423" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_22" xlink:to="loc_us-gaap_AssetsCurrent_423" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_426" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_30" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_426" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_424" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_426" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_424" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_429" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_426" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_429" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_43" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_30" xlink:to="loc_us-gaap_Assets_43" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_50" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_21" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_50" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_51" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_50" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_51" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_52" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_51" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_52" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_53" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_51" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_53" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_431" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_51" xlink:to="loc_us-gaap_LiabilitiesCurrent_431" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_432" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_50" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_432" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_55" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_50" xlink:to="loc_us-gaap_Liabilities_55" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_59" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_50" xlink:to="loc_us-gaap_CommitmentsAndContingencies_59" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_60" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_50" xlink:to="loc_us-gaap_StockholdersEquityAbstract_60" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_569" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_60" xlink:to="loc_us-gaap_PreferredStockValue_569" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_61" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_60" xlink:to="loc_us-gaap_CommonStockValue_61" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:label="loc_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_62" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_60" xlink:to="loc_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_62" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_63" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_60" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_63" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_64" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_60" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_64" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_65" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_60" xlink:to="loc_us-gaap_StockholdersEquity_65" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_66" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_50" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_66" use="optional" order="29" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/StatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_25" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_28" xlink:to="loc_us-gaap_StatementTable_25" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_26" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_25" xlink:to="loc_us-gaap_StatementClassOfStockAxis_26" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_27" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_26" xlink:to="loc_us-gaap_ClassOfStockDomain_27" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_27_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_26" xlink:to="loc_us-gaap_ClassOfStockDomain_27_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_31" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_31" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_32" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_31" xlink:to="loc_us-gaap_NetIncomeLoss_32" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_33" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_31" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_33" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_444" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_33" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_444" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_34" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_33" xlink:to="loc_us-gaap_ShareBasedCompensation_34" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_974" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_33" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_974" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_SharesIssuedForLicensesUsedForResearchAndDevelopment" xlink:label="loc_mbrx_SharesIssuedForLicensesUsedForResearchAndDevelopment_700" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_33" xlink:to="loc_mbrx_SharesIssuedForLicensesUsedForResearchAndDevelopment_700" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_35" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_33" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_35" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_448" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_35" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_448" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_36" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_35" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_36" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_37" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_31" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_37" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_40" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_40" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_635" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_40" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_635" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_449" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_40" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_449" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_42" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_40" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_42" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_44" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_44" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_626" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_44" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_626" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_453" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_44" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_453" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_451" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_44" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_451" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_47" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_44" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_47" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_48" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_48" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_49" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_49" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_56" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_56" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_57" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_56" xlink:to="loc_us-gaap_InterestPaid_57" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_58" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_56" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_58" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_455" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_455" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_456" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_455" xlink:to="loc_us-gaap_StockIssued1_456" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_459" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_455" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_459" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_WarrantsIssuedForServices" xlink:label="loc_mbrx_WarrantsIssuedForServices_975" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_455" xlink:to="loc_mbrx_WarrantsIssuedForServices_975" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_976" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_455" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_976" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_SharesSubscribed" xlink:label="loc_mbrx_SharesSubscribed_702" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_455" xlink:to="loc_mbrx_SharesSubscribed_702" use="optional" order="35" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual">
    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_800" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_71" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_800" xlink:to="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_71" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_73" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_71" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_73" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_83" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_73" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_83" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_83_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_73" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_83_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_72" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_71" xlink:to="loc_dei_LegalEntityAxis_72" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_74" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_72" xlink:to="loc_dei_EntityDomain_74" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_74_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_72" xlink:to="loc_dei_EntityDomain_74_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_82" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_71" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_82" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_86" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_82" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_86" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_86_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_82" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_86_default" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_87" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_86" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_87" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_85" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_71" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_85" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_577" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_85" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_577" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_577_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_85" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_577_default" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_578" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_577" xlink:to="loc_us-gaap_EmployeeStockOptionMember_578" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_576" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_71" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_576" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_580" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_576" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_580" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_580_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_576" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_580_default" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_581" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_580" xlink:to="loc_us-gaap_WarrantMember_581" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_579" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_71" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_579" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_664" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_579" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_664" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_664_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_579" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_664_default" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_663" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_71" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_663" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_790" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_663" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_790" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_790_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_663" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_790_default" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_791" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_790" xlink:to="loc_us-gaap_ComputerEquipmentMember_791" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_792" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_790" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_792" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_793" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_790" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_793" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_798" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_790" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_798" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_789" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_71" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_789" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_795" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_789" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_795" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_795_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_789" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_795_default" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_MoleculinLlcMember" xlink:label="loc_mbrx_MoleculinLlcMember_796" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_795" xlink:to="loc_mbrx_MoleculinLlcMember_796" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_794" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_71" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_794" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanAssetCategoriesDomain" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_801" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_794" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_801" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanAssetCategoriesDomain" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_801_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_794" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_801_default" use="optional" order="36" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_80" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_800" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_80" use="optional" order="37" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_81" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_800" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_81" use="optional" order="38" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaap_CashUninsuredAmount_526" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_800" xlink:to="loc_us-gaap_CashUninsuredAmount_526" use="optional" order="39" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaap_CashFDICInsuredAmount_634" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_800" xlink:to="loc_us-gaap_CashFDICInsuredAmount_634" use="optional" order="40" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_788" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_800" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_788" use="optional" order="41" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_797" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_800" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_797" use="optional" order="42" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/BalanceSheetsParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_94" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_91" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_94" xlink:to="loc_us-gaap_StatementTable_91" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_92" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_91" xlink:to="loc_us-gaap_StatementClassOfStockAxis_92" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_93" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_92" xlink:to="loc_us-gaap_ClassOfStockDomain_93" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_93_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_92" xlink:to="loc_us-gaap_ClassOfStockDomain_93_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_990" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_94" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_990" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_570" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_94" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_570" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_571" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_94" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_571" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_574" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_94" xlink:to="loc_us-gaap_PreferredStockSharesIssued_574" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_575" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_94" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_575" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_95" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_94" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_95" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_96" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_94" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_96" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_97" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_94" xlink:to="loc_us-gaap_CommonStockSharesIssued_97" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_98" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_94" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_98" use="optional" order="13" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/StatementsOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_104" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_101" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_104" xlink:to="loc_us-gaap_StatementTable_101" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_102" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_101" xlink:to="loc_us-gaap_StatementClassOfStockAxis_102" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_103" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_102" xlink:to="loc_us-gaap_ClassOfStockDomain_103" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_103_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_102" xlink:to="loc_us-gaap_ClassOfStockDomain_103_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_105" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_104" xlink:to="loc_us-gaap_SalesRevenueNet_105" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_106" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_104" xlink:to="loc_us-gaap_OperatingExpensesAbstract_106" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_107" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_106" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_107" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_108" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_106" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_108" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_441" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_106" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_441" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_109" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_106" xlink:to="loc_us-gaap_OperatingExpenses_109" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_110" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_104" xlink:to="loc_us-gaap_OperatingIncomeLoss_110" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_111" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_104" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_111" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_112" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_111" xlink:to="loc_us-gaap_InterestExpense_112" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_113" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_104" xlink:to="loc_us-gaap_NetIncomeLoss_113" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_114" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_104" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_114" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_115" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_104" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_115" use="optional" order="16" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/ConvertibleNotesPayableDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_987" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_165" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_987" xlink:to="loc_us-gaap_StatementTable_165" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_166" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_165" xlink:to="loc_us-gaap_StatementClassOfStockAxis_166" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_167" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_166" xlink:to="loc_us-gaap_ClassOfStockDomain_167" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_167_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_166" xlink:to="loc_us-gaap_ClassOfStockDomain_167_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_168" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_165" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_168" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_170" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_168" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_170" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_170_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_168" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_170_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaap_InvestorMember_172" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_170" xlink:to="loc_us-gaap_InvestorMember_172" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_InvestorBMember" xlink:label="loc_mbrx_InvestorBMember_171" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_170" xlink:to="loc_mbrx_InvestorBMember_171" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_InvestorCMember" xlink:label="loc_mbrx_InvestorCMember_173" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_170" xlink:to="loc_mbrx_InvestorCMember_173" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_InvestorDMember" xlink:label="loc_mbrx_InvestorDMember_349" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_170" xlink:to="loc_mbrx_InvestorDMember_349" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_InvestorEMember" xlink:label="loc_mbrx_InvestorEMember_350" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_170" xlink:to="loc_mbrx_InvestorEMember_350" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_InvestorFMember" xlink:label="loc_mbrx_InvestorFMember_809" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_170" xlink:to="loc_mbrx_InvestorFMember_809" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_InvestorGMember" xlink:label="loc_mbrx_InvestorGMember_811" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_170" xlink:to="loc_mbrx_InvestorGMember_811" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_169" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_165" xlink:to="loc_us-gaap_DebtInstrumentAxis_169" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_175" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_169" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_175" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_175_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_169" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_175_default" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_IssueDateAugust312015Member" xlink:label="loc_mbrx_IssueDateAugust312015Member_176" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_175" xlink:to="loc_mbrx_IssueDateAugust312015Member_176" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_IssueDateSeptember032015Member" xlink:label="loc_mbrx_IssueDateSeptember032015Member_177" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_175" xlink:to="loc_mbrx_IssueDateSeptember032015Member_177" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_IssueDateOctober062015OneMember" xlink:label="loc_mbrx_IssueDateOctober062015OneMember_178" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_175" xlink:to="loc_mbrx_IssueDateOctober062015OneMember_178" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_IssueDateOctober062015TwoMember" xlink:label="loc_mbrx_IssueDateOctober062015TwoMember_179" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_175" xlink:to="loc_mbrx_IssueDateOctober062015TwoMember_179" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_IssueDateOctober282015Member" xlink:label="loc_mbrx_IssueDateOctober282015Member_180" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_175" xlink:to="loc_mbrx_IssueDateOctober282015Member_180" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_IssueDateJanuary142016Member" xlink:label="loc_mbrx_IssueDateJanuary142016Member_181" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_175" xlink:to="loc_mbrx_IssueDateJanuary142016Member_181" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_IssueDateJanuary192016Member" xlink:label="loc_mbrx_IssueDateJanuary192016Member_182" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_175" xlink:to="loc_mbrx_IssueDateJanuary192016Member_182" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_174" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_165" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_174" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_988" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_174" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_988" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_988_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_174" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_988_default" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_989" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_988" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_989" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentIssuanceDate1" xlink:label="loc_us-gaap_DebtInstrumentIssuanceDate1_183" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_987" xlink:to="loc_us-gaap_DebtInstrumentIssuanceDate1_183" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_184" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_987" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_184" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_351" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_987" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_351" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_DebtInstrumentConvertibleNumberOfCommonShares" xlink:label="loc_mbrx_DebtInstrumentConvertibleNumberOfCommonShares_400" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_987" xlink:to="loc_mbrx_DebtInstrumentConvertibleNumberOfCommonShares_400" use="optional" order="32" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/ConvertibleNotesPayableDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_841" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_188" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_841" xlink:to="loc_us-gaap_StatementTable_188" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_189" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_188" xlink:to="loc_us-gaap_StatementClassOfStockAxis_189" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_190" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_189" xlink:to="loc_us-gaap_ClassOfStockDomain_190" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_190_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_189" xlink:to="loc_us-gaap_ClassOfStockDomain_190_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_191" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_188" xlink:to="loc_us-gaap_DebtInstrumentAxis_191" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_193" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_191" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_193" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_193_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_191" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_193_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_UnsecuredPromissoryNotesMember" xlink:label="loc_mbrx_UnsecuredPromissoryNotesMember_564" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_193" xlink:to="loc_mbrx_UnsecuredPromissoryNotesMember_564" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_192" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_188" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_192" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_197" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_192" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_197" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_197_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_192" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_197_default" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_196" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_188" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_196" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_200" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_196" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_200" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_200_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_196" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_200_default" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_201" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_200" xlink:to="loc_us-gaap_IPOMember_201" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_199" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_188" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_199" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_842" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_199" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_842" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_842_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_199" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_842_default" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_843" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_842" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_843" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_202" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_841" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_202" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_203" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_841" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_203" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_206" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_841" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_206" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_DebtConversionConvertedInstrumentCommonStockSharesIssuedTradingRestrictionsDescription" xlink:label="loc_mbrx_DebtConversionConvertedInstrumentCommonStockSharesIssuedTradingRestrictionsDescription_352" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_841" xlink:to="loc_mbrx_DebtConversionConvertedInstrumentCommonStockSharesIssuedTradingRestrictionsDescription_352" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_DebtConversionConvertedInstrumentAdditionalSharesIssued" xlink:label="loc_mbrx_DebtConversionConvertedInstrumentAdditionalSharesIssued_387" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_841" xlink:to="loc_mbrx_DebtConversionConvertedInstrumentAdditionalSharesIssued_387" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_445" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_841" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_445" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_446" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_841" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_446" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_447" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_841" xlink:to="loc_us-gaap_InterestPayableCurrent_447" use="optional" order="27" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/EquityDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_994" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_218" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_218" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_220" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_218" xlink:to="loc_us-gaap_TitleOfIndividualAxis_220" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_223" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_220" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_223" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_223_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_220" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_223_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_DirectorAndOfficersMember" xlink:label="loc_mbrx_DirectorAndOfficersMember_224" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_223" xlink:to="loc_mbrx_DirectorAndOfficersMember_224" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_EmployeeAndBoardOfDirectorsMember" xlink:label="loc_mbrx_EmployeeAndBoardOfDirectorsMember_656" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_223" xlink:to="loc_mbrx_EmployeeAndBoardOfDirectorsMember_656" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ChiefFinancialOfficerMember" xlink:label="loc_us-gaap_ChiefFinancialOfficerMember_1001" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_223" xlink:to="loc_us-gaap_ChiefFinancialOfficerMember_1001" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_222" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_218" xlink:to="loc_us-gaap_AwardTypeAxis_222" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_227" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_222" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_227" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_227_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_222" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_227_default" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_StockPlanMember" xlink:label="loc_mbrx_StockPlanMember_228" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_227" xlink:to="loc_mbrx_StockPlanMember_228" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_226" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_218" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_226" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_232" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_226" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_232" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_232_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_226" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_232_default" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_230" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_218" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_230" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_439" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_230" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_439" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_439_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_230" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_439_default" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_440" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_439" xlink:to="loc_us-gaap_IPOMember_440" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_438" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_218" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_438" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_590" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_438" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_590" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_590_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_438" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_590_default" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_591" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_590" xlink:to="loc_us-gaap_WarrantMember_591" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_589" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_218" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_589" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_594" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_589" xlink:to="loc_us-gaap_RelatedPartyDomain_594" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_594_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_589" xlink:to="loc_us-gaap_RelatedPartyDomain_594_default" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_PcgAdvisoryGroupMember" xlink:label="loc_mbrx_PcgAdvisoryGroupMember_595" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_594" xlink:to="loc_mbrx_PcgAdvisoryGroupMember_595" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_593" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_218" xlink:to="loc_us-gaap_RangeAxis_593" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_658" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_593" xlink:to="loc_us-gaap_RangeMember_658" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_658_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_593" xlink:to="loc_us-gaap_RangeMember_658_default" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_659" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_658" xlink:to="loc_us-gaap_MaximumMember_659" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_660" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_658" xlink:to="loc_us-gaap_MinimumMember_660" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_657" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_218" xlink:to="loc_dei_LegalEntityAxis_657" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_995" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_657" xlink:to="loc_dei_EntityDomain_995" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_995_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_657" xlink:to="loc_dei_EntityDomain_995_default" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_IntertechbioCorporationMember" xlink:label="loc_mbrx_IntertechbioCorporationMember_996" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_995" xlink:to="loc_mbrx_IntertechbioCorporationMember_996" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_AnnamedIncMember" xlink:label="loc_mbrx_AnnamedIncMember_999" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_995" xlink:to="loc_mbrx_AnnamedIncMember_999" use="optional" order="36" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_237" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_237" use="optional" order="37" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_238" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_238" use="optional" order="38" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_242" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_242" use="optional" order="39" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_344" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_344" use="optional" order="40" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_346" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_346" use="optional" order="41" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_354" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_354" use="optional" order="42" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_355" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_ShareBasedCompensation_355" use="optional" order="43" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable" xlink:label="loc_mbrx_ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable_433" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_mbrx_ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable_433" use="optional" order="44" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_434" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_434" use="optional" order="45" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_435" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_435" use="optional" order="46" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_436" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_436" use="optional" order="47" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_437" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_437" use="optional" order="48" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_CommonStockLockupAndLeakoutAgreementsDescription" xlink:label="loc_mbrx_CommonStockLockupAndLeakoutAgreementsDescription_442" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_mbrx_CommonStockLockupAndLeakoutAgreementsDescription_442" use="optional" order="49" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_SharesAuthorized" xlink:label="loc_mbrx_SharesAuthorized_583" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_mbrx_SharesAuthorized_583" use="optional" order="50" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_584" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_584" use="optional" order="51" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_585" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_585" use="optional" order="52" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="loc_us-gaap_FairValueInputsDiscountRate_586" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_FairValueInputsDiscountRate_586" use="optional" order="53" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_587" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_587" use="optional" order="54" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_588" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_588" use="optional" order="55" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_644" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_644" use="optional" order="56" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_645" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_645" use="optional" order="57" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_647" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_647" use="optional" order="58" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_649" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_649" use="optional" order="59" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_650" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_650" use="optional" order="60" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_651" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_651" use="optional" order="61" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_652" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_652" use="optional" order="62" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_654" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_654" use="optional" order="63" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_691" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_691" use="optional" order="64" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_991" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_991" use="optional" order="65" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_EstimatedForfeitureRatePercentage" xlink:label="loc_mbrx_EstimatedForfeitureRatePercentage_992" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_mbrx_EstimatedForfeitureRatePercentage_992" use="optional" order="66" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_997" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_997" use="optional" order="67" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_998" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_998" use="optional" order="68" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_1000" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_1000" use="optional" order="69" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1002" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1002" use="optional" order="70" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/SubsequentEventsDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_835" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_250" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_835" xlink:to="loc_us-gaap_SubsequentEventTable_250" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_251" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_250" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_251" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_255" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_251" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_255" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_255_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_251" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_255_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_256" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_255" xlink:to="loc_us-gaap_SubsequentEventMember_256" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_254" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_250" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_254" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_259" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_254" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_259" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_259_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_254" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_259_default" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_258" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_250" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_258" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_273" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_258" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_273" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_273_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_258" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_273_default" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_272" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_250" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_272" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_385" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_272" xlink:to="loc_us-gaap_RelatedPartyDomain_385" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_385_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_272" xlink:to="loc_us-gaap_RelatedPartyDomain_385_default" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_FormerScienceAdvisoryBoardMember" xlink:label="loc_mbrx_FormerScienceAdvisoryBoardMember_831" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_385" xlink:to="loc_mbrx_FormerScienceAdvisoryBoardMember_831" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_UsFoodAndDrugAdministrationMember" xlink:label="loc_mbrx_UsFoodAndDrugAdministrationMember_838" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_385" xlink:to="loc_mbrx_UsFoodAndDrugAdministrationMember_838" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_AgreementTypeAxis" xlink:label="loc_mbrx_AgreementTypeAxis_384" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_250" xlink:to="loc_mbrx_AgreementTypeAxis_384" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_AgreementTypeDomain" xlink:label="loc_mbrx_AgreementTypeDomain_807" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_mbrx_AgreementTypeAxis_384" xlink:to="loc_mbrx_AgreementTypeDomain_807" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_AgreementTypeDomain" xlink:label="loc_mbrx_AgreementTypeDomain_807_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_mbrx_AgreementTypeAxis_384" xlink:to="loc_mbrx_AgreementTypeDomain_807_default" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_UnderwritingAgreementMember" xlink:label="loc_mbrx_UnderwritingAgreementMember_808" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbrx_AgreementTypeDomain_807" xlink:to="loc_mbrx_UnderwritingAgreementMember_808" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_806" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_250" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_806" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_813" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_806" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_813" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_813_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_806" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_813_default" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_SeriesWarrantMember" xlink:label="loc_mbrx_SeriesWarrantMember_816" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_813" xlink:to="loc_mbrx_SeriesWarrantMember_816" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_SeriesBWarrantMember" xlink:label="loc_mbrx_SeriesBWarrantMember_817" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_813" xlink:to="loc_mbrx_SeriesBWarrantMember_817" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_SeriesCWarrantMember" xlink:label="loc_mbrx_SeriesCWarrantMember_818" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_813" xlink:to="loc_mbrx_SeriesCWarrantMember_818" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_812" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_250" xlink:to="loc_us-gaap_AwardTypeAxis_812" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_821" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_812" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_821" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_821_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_812" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_821_default" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_820" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_250" xlink:to="loc_us-gaap_TitleOfIndividualAxis_820" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_828" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_820" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_828" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_828_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_820" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_828_default" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ScienceAdvisoryBoardOneMember" xlink:label="loc_mbrx_ScienceAdvisoryBoardOneMember_829" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_828" xlink:to="loc_mbrx_ScienceAdvisoryBoardOneMember_829" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ScienceAdvisoryBoardTwoMember" xlink:label="loc_mbrx_ScienceAdvisoryBoardTwoMember_830" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_828" xlink:to="loc_mbrx_ScienceAdvisoryBoardTwoMember_830" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_827" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_250" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_827" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_836" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_827" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_836" use="optional" order="36" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_836_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_827" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_836_default" use="optional" order="37" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_837" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_836" xlink:to="loc_us-gaap_EmployeeStockOptionMember_837" use="optional" order="38" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_252" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_835" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_252" use="optional" order="39" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_261" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_835" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_261" use="optional" order="40" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_270" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_835" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_270" use="optional" order="41" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_271" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_835" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_271" use="optional" order="42" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_NumberOfUnitsIssued" xlink:label="loc_mbrx_NumberOfUnitsIssued_804" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_835" xlink:to="loc_mbrx_NumberOfUnitsIssued_804" use="optional" order="43" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_PricePerUnit" xlink:label="loc_mbrx_PricePerUnit_805" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_835" xlink:to="loc_mbrx_PricePerUnit_805" use="optional" order="44" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaap_SaleOfStockDescriptionOfTransaction_822" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_835" xlink:to="loc_us-gaap_SaleOfStockDescriptionOfTransaction_822" use="optional" order="45" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ClassOfWarrantOrRightsWarrantExercised" xlink:label="loc_mbrx_ClassOfWarrantOrRightsWarrantExercised_823" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_835" xlink:to="loc_mbrx_ClassOfWarrantOrRightsWarrantExercised_823" use="optional" order="46" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_824" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_835" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_824" use="optional" order="47" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_825" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_835" xlink:to="loc_us-gaap_SharePrice_825" use="optional" order="48" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_826" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_835" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_826" use="optional" order="49" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_832" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_835" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_832" use="optional" order="50" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_833" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_835" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_833" use="optional" order="51" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_834" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_835" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_834" use="optional" order="52" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_839" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_835" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_839" use="optional" order="53" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_840" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_835" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_840" use="optional" order="54" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/CommitmentsAndContingenciesDetails">
    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_CommitmentsAndContingenciesLineItems" xlink:label="loc_mbrx_CommitmentsAndContingenciesLineItems_287" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_CommitmentsAndContingenciesTable" xlink:label="loc_mbrx_CommitmentsAndContingenciesTable_284" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mbrx_CommitmentsAndContingenciesLineItems_287" xlink:to="loc_mbrx_CommitmentsAndContingenciesTable_284" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_285" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mbrx_CommitmentsAndContingenciesTable_284" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_285" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_288" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_285" xlink:to="loc_us-gaap_ProjectMember_288" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_288_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_285" xlink:to="loc_us-gaap_ProjectMember_288_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_CommencementOfPhaseIiStudyForLicensedProductMember" xlink:label="loc_mbrx_CommencementOfPhaseIiStudyForLicensedProductMember_289" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_288" xlink:to="loc_mbrx_CommencementOfPhaseIiStudyForLicensedProductMember_289" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember" xlink:label="loc_mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember_290" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_288" xlink:to="loc_mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember_290" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_FilingOfNewDrugApplicationForLicensedProductMember" xlink:label="loc_mbrx_FilingOfNewDrugApplicationForLicensedProductMember_291" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_288" xlink:to="loc_mbrx_FilingOfNewDrugApplicationForLicensedProductMember_291" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ReceiptOfMarketApprovalForLicensedProductMember" xlink:label="loc_mbrx_ReceiptOfMarketApprovalForLicensedProductMember_292" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_288" xlink:to="loc_mbrx_ReceiptOfMarketApprovalForLicensedProductMember_292" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_MilestonePaymentsLiabilities" xlink:label="loc_mbrx_MilestonePaymentsLiabilities_389" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbrx_CommitmentsAndContingenciesLineItems_287" xlink:to="loc_mbrx_MilestonePaymentsLiabilities_389" use="optional" order="9" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/CommitmentsAndContingenciesDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_882" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_295" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_LossContingenciesTable_295" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_AgreementAxis" xlink:label="loc_mbrx_AgreementAxis_305" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_295" xlink:to="loc_mbrx_AgreementAxis_305" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_AgreementDomain" xlink:label="loc_mbrx_AgreementDomain_309" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_mbrx_AgreementAxis_305" xlink:to="loc_mbrx_AgreementDomain_309" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_AgreementDomain" xlink:label="loc_mbrx_AgreementDomain_309_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_mbrx_AgreementAxis_305" xlink:to="loc_mbrx_AgreementDomain_309_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_PatentAndTechnologyLicenseAgreementMember" xlink:label="loc_mbrx_PatentAndTechnologyLicenseAgreementMember_310" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbrx_AgreementDomain_309" xlink:to="loc_mbrx_PatentAndTechnologyLicenseAgreementMember_310" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_297" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_295" xlink:to="loc_us-gaap_TitleOfIndividualAxis_297" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_306" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_297" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_306" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_306_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_297" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_306_default" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_MdAndersonMember" xlink:label="loc_mbrx_MdAndersonMember_307" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_306" xlink:to="loc_mbrx_MdAndersonMember_307" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaap_ChiefExecutiveOfficerMember_711" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_306" xlink:to="loc_us-gaap_ChiefExecutiveOfficerMember_711" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ChiefFinancialOfficerAndExecutiveVicePresidentMember" xlink:label="loc_mbrx_ChiefFinancialOfficerAndExecutiveVicePresidentMember_874" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_306" xlink:to="loc_mbrx_ChiefFinancialOfficerAndExecutiveVicePresidentMember_874" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_AnniversaryAxis" xlink:label="loc_mbrx_AnniversaryAxis_296" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_295" xlink:to="loc_mbrx_AnniversaryAxis_296" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_AnniversaryDomain" xlink:label="loc_mbrx_AnniversaryDomain_298" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_mbrx_AnniversaryAxis_296" xlink:to="loc_mbrx_AnniversaryDomain_298" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_AnniversaryDomain" xlink:label="loc_mbrx_AnniversaryDomain_298_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_mbrx_AnniversaryAxis_296" xlink:to="loc_mbrx_AnniversaryDomain_298_default" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_308" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_295" xlink:to="loc_dei_LegalEntityAxis_308" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_315" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_308" xlink:to="loc_dei_EntityDomain_315" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_315_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_308" xlink:to="loc_dei_EntityDomain_315_default" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_PatentLawFirmMember" xlink:label="loc_mbrx_PatentLawFirmMember_316" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_315" xlink:to="loc_mbrx_PatentLawFirmMember_316" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_BonwickCapitalPartnersLlcMember" xlink:label="loc_mbrx_BonwickCapitalPartnersLlcMember_323" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_315" xlink:to="loc_mbrx_BonwickCapitalPartnersLlcMember_323" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_314" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_295" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_314" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_320" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_314" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_320" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_320_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_314" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_320_default" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaap_OtherCommitmentsAxis_319" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_295" xlink:to="loc_us-gaap_OtherCommitmentsAxis_319" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaap_OtherCommitmentsDomain_361" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_319" xlink:to="loc_us-gaap_OtherCommitmentsDomain_361" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaap_OtherCommitmentsDomain_361_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_319" xlink:to="loc_us-gaap_OtherCommitmentsDomain_361_default" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ServicingFeePayableMember" xlink:label="loc_mbrx_ServicingFeePayableMember_362" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_361" xlink:to="loc_mbrx_ServicingFeePayableMember_362" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_MinimumFeeAndPatentExpensesMember" xlink:label="loc_mbrx_MinimumFeeAndPatentExpensesMember_363" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_361" xlink:to="loc_mbrx_MinimumFeeAndPatentExpensesMember_363" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_MinimumAnnualRoyaltyMember" xlink:label="loc_mbrx_MinimumAnnualRoyaltyMember_371" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_361" xlink:to="loc_mbrx_MinimumAnnualRoyaltyMember_371" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_LetterAgreementMember" xlink:label="loc_mbrx_LetterAgreementMember_542" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_361" xlink:to="loc_mbrx_LetterAgreementMember_542" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_360" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_295" xlink:to="loc_us-gaap_RangeAxis_360" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_380" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_360" xlink:to="loc_us-gaap_RangeMember_380" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_380_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_360" xlink:to="loc_us-gaap_RangeMember_380_default" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_381" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_380" xlink:to="loc_us-gaap_MaximumMember_381" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_RevenueRecognitionMilestoneMethodAxis" xlink:label="loc_mbrx_RevenueRecognitionMilestoneMethodAxis_379" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_295" xlink:to="loc_mbrx_RevenueRecognitionMilestoneMethodAxis_379" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_RevenueRecognitionMilestoneMethodDomain" xlink:label="loc_mbrx_RevenueRecognitionMilestoneMethodDomain_534" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_mbrx_RevenueRecognitionMilestoneMethodAxis_379" xlink:to="loc_mbrx_RevenueRecognitionMilestoneMethodDomain_534" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_RevenueRecognitionMilestoneMethodDomain" xlink:label="loc_mbrx_RevenueRecognitionMilestoneMethodDomain_534_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_mbrx_RevenueRecognitionMilestoneMethodAxis_379" xlink:to="loc_mbrx_RevenueRecognitionMilestoneMethodDomain_534_default" use="optional" order="36" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_533" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_295" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_533" use="optional" order="37" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_545" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_533" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_545" use="optional" order="38" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_545_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_533" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_545_default" use="optional" order="39" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_MoleculinLlcMember" xlink:label="loc_mbrx_MoleculinLlcMember_546" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_545" xlink:to="loc_mbrx_MoleculinLlcMember_546" use="optional" order="40" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_544" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_295" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_544" use="optional" order="41" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_549" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_544" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_549" use="optional" order="42" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_549_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_544" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_549_default" use="optional" order="43" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_550" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_549" xlink:to="loc_us-gaap_IPOMember_550" use="optional" order="44" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_548" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_295" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_548" use="optional" order="45" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_713" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_548" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_713" use="optional" order="46" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_713_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_548" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_713_default" use="optional" order="47" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_712" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_295" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_712" use="optional" order="48" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_879" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_712" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_879" use="optional" order="49" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_879_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_712" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_879_default" use="optional" order="50" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_880" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_879" xlink:to="loc_us-gaap_EmployeeStockOptionMember_880" use="optional" order="51" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_878" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_295" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_878" use="optional" order="52" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_883" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_878" xlink:to="loc_us-gaap_RelatedPartyDomain_883" use="optional" order="53" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_883_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_878" xlink:to="loc_us-gaap_RelatedPartyDomain_883_default" use="optional" order="54" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_MrLouisMember" xlink:label="loc_mbrx_MrLouisMember_884" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_883" xlink:to="loc_mbrx_MrLouisMember_884" use="optional" order="55" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_LetterAgreementsTerms" xlink:label="loc_mbrx_LetterAgreementsTerms_324" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_mbrx_LetterAgreementsTerms_324" use="optional" order="56" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_364" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_364" use="optional" order="57" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="loc_us-gaap_ContractualObligationDueInSecondYear_365" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_ContractualObligationDueInSecondYear_365" use="optional" order="58" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="loc_us-gaap_ContractualObligationDueInThirdYear_366" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_ContractualObligationDueInThirdYear_366" use="optional" order="59" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="loc_us-gaap_ContractualObligationDueInFourthYear_367" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_ContractualObligationDueInFourthYear_367" use="optional" order="60" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInFifthYear" xlink:label="loc_us-gaap_ContractualObligationDueInFifthYear_368" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_ContractualObligationDueInFifthYear_368" use="optional" order="61" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueAfterFifthYear" xlink:label="loc_us-gaap_ContractualObligationDueAfterFifthYear_369" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_ContractualObligationDueAfterFifthYear_369" use="optional" order="62" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_370" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_ContractualObligation_370" use="optional" order="63" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_SuccessFeePercentage" xlink:label="loc_mbrx_SuccessFeePercentage_372" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_mbrx_SuccessFeePercentage_372" use="optional" order="64" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ClassOfWarrantOrRightPercentageOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_mbrx_ClassOfWarrantOrRightPercentageOfSecuritiesCalledByWarrantsOrRights_373" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_mbrx_ClassOfWarrantOrRightPercentageOfSecuritiesCalledByWarrantsOrRights_373" use="optional" order="65" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ClassOfWarrantOrRightExercisePricePercentageThreshold" xlink:label="loc_mbrx_ClassOfWarrantOrRightExercisePricePercentageThreshold_374" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_mbrx_ClassOfWarrantOrRightExercisePricePercentageThreshold_374" use="optional" order="66" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ReimbursementPayableOfferingCosts" xlink:label="loc_mbrx_ReimbursementPayableOfferingCosts_376" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_mbrx_ReimbursementPayableOfferingCosts_376" use="optional" order="67" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ReimbursementPayableFeesAndExpensesOfCounsel" xlink:label="loc_mbrx_ReimbursementPayableFeesAndExpensesOfCounsel_377" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_mbrx_ReimbursementPayableFeesAndExpensesOfCounsel_377" use="optional" order="68" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:label="loc_us-gaap_PaymentsForUnderwritingExpense_378" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_PaymentsForUnderwritingExpense_378" use="optional" order="69" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ContractualObligationDueInNextFiscalYearAfterProductApproval" xlink:label="loc_mbrx_ContractualObligationDueInNextFiscalYearAfterProductApproval_405" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_mbrx_ContractualObligationDueInNextFiscalYearAfterProductApproval_405" use="optional" order="70" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ContractualObligationDueInSecondYearAfterProductApproval" xlink:label="loc_mbrx_ContractualObligationDueInSecondYearAfterProductApproval_406" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_mbrx_ContractualObligationDueInSecondYearAfterProductApproval_406" use="optional" order="71" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ContractualObligationDueInThirdYearAfterProductApproval" xlink:label="loc_mbrx_ContractualObligationDueInThirdYearAfterProductApproval_407" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_mbrx_ContractualObligationDueInThirdYearAfterProductApproval_407" use="optional" order="72" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaap_PaymentsForRoyalties_529" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_PaymentsForRoyalties_529" use="optional" order="73" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_LicenseAgreementMaintenanceFee" xlink:label="loc_mbrx_LicenseAgreementMaintenanceFee_531" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_mbrx_LicenseAgreementMaintenanceFee_531" use="optional" order="74" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_LicenseAgreementMaintenanceFeeAnnualIncrease" xlink:label="loc_mbrx_LicenseAgreementMaintenanceFeeAnnualIncrease_532" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_mbrx_LicenseAgreementMaintenanceFeeAnnualIncrease_532" use="optional" order="75" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaap_PaymentsForFees_547" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_PaymentsForFees_547" use="optional" order="76" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ReimburementOfExpenses" xlink:label="loc_mbrx_ReimburementOfExpenses_551" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_mbrx_ReimburementOfExpenses_551" use="optional" order="77" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_552" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_552" use="optional" order="78" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_553" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_553" use="optional" order="79" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_554" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_554" use="optional" order="80" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_556" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_556" use="optional" order="81" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_565" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_565" use="optional" order="82" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_LicenseAgreementMaintenanceFeeMaximumPayablePerYear" xlink:label="loc_mbrx_LicenseAgreementMaintenanceFeeMaximumPayablePerYear_631" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_mbrx_LicenseAgreementMaintenanceFeeMaximumPayablePerYear_631" use="optional" order="83" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_709" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_OfficersCompensation_709" use="optional" order="84" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_710" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_710" use="optional" order="85" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1_875" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1_875" use="optional" order="86" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued_876" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued_876" use="optional" order="87" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice_877" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice_877" use="optional" order="88" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_881" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_881" use="optional" order="89" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_885" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_SeveranceCosts1_885" use="optional" order="90" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_SeparationAgreementDescription" xlink:label="loc_mbrx_SeparationAgreementDescription_886" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_mbrx_SeparationAgreementDescription_886" use="optional" order="91" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_MilestonePaymentDescription" xlink:label="loc_mbrx_MilestonePaymentDescription_969" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_mbrx_MilestonePaymentDescription_969" use="optional" order="92" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/IncomeTaxesDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_949" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_331" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_949" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_331" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_332" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_331" xlink:to="loc_us-gaap_StatementClassOfStockAxis_332" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_333" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_332" xlink:to="loc_us-gaap_ClassOfStockDomain_333" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_333_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_332" xlink:to="loc_us-gaap_ClassOfStockDomain_333_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_334" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_331" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_334" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_950" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_334" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_950" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_950_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_334" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_950_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_951" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_950" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_951" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_337" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_949" xlink:to="loc_us-gaap_OperatingLossCarryforwards_337" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_OperatingLossCarryforwardsExpirationPeriod" xlink:label="loc_mbrx_OperatingLossCarryforwardsExpirationPeriod_338" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_949" xlink:to="loc_mbrx_OperatingLossCarryforwardsExpirationPeriod_338" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_948" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_949" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_948" use="optional" order="11" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/IntangibleAssetsDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_715" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationSegmentAllocationTable" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationTable_457" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_715" xlink:to="loc_us-gaap_BusinessCombinationSegmentAllocationTable_457" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_458" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationTable_457" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_458" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_558" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_458" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_558" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_558_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_458" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_558_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_MoleculinLlcMember" xlink:label="loc_mbrx_MoleculinLlcMember_559" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_558" xlink:to="loc_mbrx_MoleculinLlcMember_559" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_557" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationTable_457" xlink:to="loc_dei_LegalEntityAxis_557" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_716" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_557" xlink:to="loc_dei_EntityDomain_716" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_716_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_557" xlink:to="loc_dei_EntityDomain_716_default" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_HoustonPharmaceuticalsIncMember" xlink:label="loc_mbrx_HoustonPharmaceuticalsIncMember_717" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_716" xlink:to="loc_mbrx_HoustonPharmaceuticalsIncMember_717" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_461" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_715" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_461" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_600" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_715" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_600" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_601" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_715" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_601" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_464" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_715" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_464" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_465" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_715" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_465" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_978" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_715" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_978" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_466" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_715" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_466" use="optional" order="16" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/IntangibleAssetsDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems_470" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable_469" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems_470" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable_469" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_566" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable_469" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_566" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_567" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_566" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_567" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_567_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_566" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_567_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_BusinessAcquistionProFormaOperatingExpenses" xlink:label="loc_mbrx_BusinessAcquistionProFormaOperatingExpenses_472" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems_470" xlink:to="loc_mbrx_BusinessAcquistionProFormaOperatingExpenses_472" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_478" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems_470" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_478" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" xlink:label="loc_mbrx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_482" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems_470" xlink:to="loc_mbrx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_482" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:label="loc_mbrx_BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted_485" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems_470" xlink:to="loc_mbrx_BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted_485" use="optional" order="8" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/IntangibleAssetsDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_704" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_490" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_704" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_490" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_491" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_490" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_491" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_494" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_491" xlink:to="loc_us-gaap_EquityComponentDomain_494" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_494_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_491" xlink:to="loc_us-gaap_EquityComponentDomain_494_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_495" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_494" xlink:to="loc_us-gaap_CommonStockMember_495" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_493" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_490" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_493" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_497" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_493" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_497" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_497_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_493" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_497_default" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_MoleculinLlcMember" xlink:label="loc_mbrx_MoleculinLlcMember_501" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_497" xlink:to="loc_mbrx_MoleculinLlcMember_501" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_496" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_490" xlink:to="loc_us-gaap_TitleOfIndividualAxis_496" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_507" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_496" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_507" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_507_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_496" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_507_default" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_506" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_490" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_506" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_510" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_506" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_510" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_510_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_506" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_510_default" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_LicenseAgreementMember" xlink:label="loc_mbrx_LicenseAgreementMember_516" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_510" xlink:to="loc_mbrx_LicenseAgreementMember_516" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_OutlincenseAgreementMember" xlink:label="loc_mbrx_OutlincenseAgreementMember_517" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_510" xlink:to="loc_mbrx_OutlincenseAgreementMember_517" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_509" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_490" xlink:to="loc_dei_LegalEntityAxis_509" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_513" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_509" xlink:to="loc_dei_EntityDomain_513" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_513_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_509" xlink:to="loc_dei_EntityDomain_513_default" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_HoustonPharmaceuticalsIncMember" xlink:label="loc_mbrx_HoustonPharmaceuticalsIncMember_515" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_513" xlink:to="loc_mbrx_HoustonPharmaceuticalsIncMember_515" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_512" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_490" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_512" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_620" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_512" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_620" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_620_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_512" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_620_default" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_619" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_490" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_619" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_622" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_619" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_622" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_622_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_619" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_622_default" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_PeriodTypeAxis" xlink:label="loc_mbrx_PeriodTypeAxis_621" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_490" xlink:to="loc_mbrx_PeriodTypeAxis_621" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_PeriodTypeDomain" xlink:label="loc_mbrx_PeriodTypeDomain_705" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_mbrx_PeriodTypeAxis_621" xlink:to="loc_mbrx_PeriodTypeDomain_705" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_PeriodTypeDomain" xlink:label="loc_mbrx_PeriodTypeDomain_705_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_mbrx_PeriodTypeAxis_621" xlink:to="loc_mbrx_PeriodTypeDomain_705_default" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_AcquisitionDateOneMember" xlink:label="loc_mbrx_AcquisitionDateOneMember_706" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbrx_PeriodTypeDomain_705" xlink:to="loc_mbrx_AcquisitionDateOneMember_706" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_492" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_704" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_492" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesReceivableRelatedParties" xlink:label="loc_us-gaap_NotesReceivableRelatedParties_503" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_704" xlink:to="loc_us-gaap_NotesReceivableRelatedParties_503" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_504" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_704" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_504" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_522" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_704" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_522" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_LicencingArrangementsConsiderationPayable" xlink:label="loc_mbrx_LicencingArrangementsConsiderationPayable_561" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_704" xlink:to="loc_mbrx_LicencingArrangementsConsiderationPayable_561" use="optional" order="36" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_LicencingArrangementsReserve" xlink:label="loc_mbrx_LicencingArrangementsReserve_562" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_704" xlink:to="loc_mbrx_LicencingArrangementsReserve_562" use="optional" order="37" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_563" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_704" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_563" use="optional" order="38" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_613" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_704" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_613" use="optional" order="39" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_RoyaltyOnNetRevenues" xlink:label="loc_mbrx_RoyaltyOnNetRevenues_627" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_704" xlink:to="loc_mbrx_RoyaltyOnNetRevenues_627" use="optional" order="40" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_AccruedLicenseAgreementPayment" xlink:label="loc_mbrx_AccruedLicenseAgreementPayment_629" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_704" xlink:to="loc_mbrx_AccruedLicenseAgreementPayment_629" use="optional" order="41" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_703" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_704" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_703" use="optional" order="42" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_719" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_704" xlink:to="loc_us-gaap_SharePrice_719" use="optional" order="43" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_970" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_704" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_970" use="optional" order="44" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable" xlink:label="loc_mbrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable_1003" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_704" xlink:to="loc_mbrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable_1003" use="optional" order="45" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/IntangibleAssetsDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_607" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationSegmentAllocationTable" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationTable_604" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_607" xlink:to="loc_us-gaap_BusinessCombinationSegmentAllocationTable_604" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_605" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationTable_604" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_605" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_608" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_605" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_608" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_608_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_605" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_608_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherIntangibleAssetsMember" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_610" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_608" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_610" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_606" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_607" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_606" use="optional" order="6" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/EquityDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_670" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_666" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_670" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_666" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_668" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_666" xlink:to="loc_us-gaap_StatementClassOfStockAxis_668" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_669" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_668" xlink:to="loc_us-gaap_ClassOfStockDomain_669" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_669_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_668" xlink:to="loc_us-gaap_ClassOfStockDomain_669_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_671" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_670" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_671" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_673" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_670" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_673" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_674" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_670" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_674" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_687" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_670" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_687" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_980" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_670" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_980" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_981" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_670" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_981" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_982" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_670" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_982" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:label="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_986" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_670" xlink:to="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_986" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_675" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_670" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_675" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_677" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_670" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_677" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_678" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_670" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_678" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_688" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_670" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_688" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_679" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_670" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_679" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_689" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_670" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_689" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_684" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_670" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_684" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_690" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_670" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_690" use="optional" order="20" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/StatementsOfStockholdersEquity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_742" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_738" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_us-gaap_StatementTable_738" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_739" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_738" xlink:to="loc_us-gaap_StatementClassOfStockAxis_739" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_740" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_739" xlink:to="loc_us-gaap_ClassOfStockDomain_740" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_740_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_739" xlink:to="loc_us-gaap_ClassOfStockDomain_740_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_741" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_738" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_741" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_743" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_741" xlink:to="loc_us-gaap_EquityComponentDomain_743" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_743_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_741" xlink:to="loc_us-gaap_EquityComponentDomain_743_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_744" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_743" xlink:to="loc_us-gaap_CommonStockMember_744" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_745" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_743" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_745" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_SubscriptionsReceivableMember" xlink:label="loc_mbrx_SubscriptionsReceivableMember_746" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_743" xlink:to="loc_mbrx_SubscriptionsReceivableMember_746" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_747" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_743" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_747" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_752" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_us-gaap_StockholdersEquity_752" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_753" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_us-gaap_SharesOutstanding_753" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_StockIssuedDuringPeriodValueForCashAndSubscriptionReceivable" xlink:label="loc_mbrx_StockIssuedDuringPeriodValueForCashAndSubscriptionReceivable_1005" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_mbrx_StockIssuedDuringPeriodValueForCashAndSubscriptionReceivable_1005" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_StockIssuedDuringPeriodSharesForCashAndSubscriptionReceivable" xlink:label="loc_mbrx_StockIssuedDuringPeriodSharesForCashAndSubscriptionReceivable_1004" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_mbrx_StockIssuedDuringPeriodSharesForCashAndSubscriptionReceivable_1004" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_StockIssuedDuringPeriodValueForLicenses" xlink:label="loc_mbrx_StockIssuedDuringPeriodValueForLicenses_1007" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_mbrx_StockIssuedDuringPeriodValueForLicenses_1007" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_StockIssuedDuringPeriodSharesForLicenses" xlink:label="loc_mbrx_StockIssuedDuringPeriodSharesForLicenses_1006" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_mbrx_StockIssuedDuringPeriodSharesForLicenses_1006" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_StockIssuedDuringPeriodValuePrivateIssuances" xlink:label="loc_mbrx_StockIssuedDuringPeriodValuePrivateIssuances_754" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_mbrx_StockIssuedDuringPeriodValuePrivateIssuances_754" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_StockIssuedDuringPeriodSharesPrivateIssuances" xlink:label="loc_mbrx_StockIssuedDuringPeriodSharesPrivateIssuances_755" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_mbrx_StockIssuedDuringPeriodSharesPrivateIssuances_755" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_756" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_756" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_757" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_757" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_StockIssuedDuringPeriodValueForTechnology" xlink:label="loc_mbrx_StockIssuedDuringPeriodValueForTechnology_1011" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_mbrx_StockIssuedDuringPeriodValueForTechnology_1011" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_StockIssuedDuringPeriodSharesForTechnology" xlink:label="loc_mbrx_StockIssuedDuringPeriodSharesForTechnology_1010" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_mbrx_StockIssuedDuringPeriodSharesForTechnology_1010" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts" xlink:label="loc_mbrx_StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts_1009" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_mbrx_StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts_1009" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts" xlink:label="loc_mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts_1008" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts_1008" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_977" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_977" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_762" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_762" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_763" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_763" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_764" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_764" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_765" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_765" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_766" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_766" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_StockholdersEquitySubscriptionsSettledForCash" xlink:label="loc_mbrx_StockholdersEquitySubscriptionsSettledForCash_767" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_mbrx_StockholdersEquitySubscriptionsSettledForCash_767" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_768" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_us-gaap_NetIncomeLoss_768" use="optional" order="33" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/StatementsOfStockholdersEquityParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_776" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_773" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_776" xlink:to="loc_us-gaap_StatementTable_773" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_774" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_773" xlink:to="loc_us-gaap_StatementClassOfStockAxis_774" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_775" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_774" xlink:to="loc_us-gaap_ClassOfStockDomain_775" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_775_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_774" xlink:to="loc_us-gaap_ClassOfStockDomain_775_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_777" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_776" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_777" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_778" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_776" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_778" use="optional" order="6" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_895" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_892" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_895" xlink:to="loc_us-gaap_StatementTable_892" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_893" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_892" xlink:to="loc_us-gaap_StatementClassOfStockAxis_893" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_894" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_893" xlink:to="loc_us-gaap_ClassOfStockDomain_894" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_894_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_893" xlink:to="loc_us-gaap_ClassOfStockDomain_894_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_911" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_895" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_911" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_912" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_911" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_912" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_913" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_911" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_913" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_914" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_911" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_914" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_915" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_895" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_915" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_916" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_915" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_916" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_917" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_915" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_917" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_918" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_915" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_918" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_919" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_915" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_919" use="optional" order="13" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/IncomeTaxesDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_900" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_897" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_900" xlink:to="loc_us-gaap_StatementTable_897" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_898" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_897" xlink:to="loc_us-gaap_StatementClassOfStockAxis_898" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_899" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_898" xlink:to="loc_us-gaap_ClassOfStockDomain_899" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_899_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_898" xlink:to="loc_us-gaap_ClassOfStockDomain_899_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_920" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_900" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_920" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_921" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_900" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_921" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_DeferredTaxAssetsValuationAllowanceReleases" xlink:label="loc_mbrx_DeferredTaxAssetsValuationAllowanceReleases_922" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_900" xlink:to="loc_mbrx_DeferredTaxAssetsValuationAllowanceReleases_922" use="optional" order="7" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/IncomeTaxesDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_905" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_902" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_905" xlink:to="loc_us-gaap_StatementTable_902" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_903" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_902" xlink:to="loc_us-gaap_StatementClassOfStockAxis_903" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_904" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_903" xlink:to="loc_us-gaap_ClassOfStockDomain_904" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_904_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_903" xlink:to="loc_us-gaap_ClassOfStockDomain_904_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_924" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_905" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_924" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_925" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_905" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_925" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost" xlink:label="loc_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost_926" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_905" xlink:to="loc_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost_926" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_927" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_905" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_927" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_928" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_905" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_928" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_929" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_905" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_929" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_930" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_905" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_930" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_931" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_905" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_931" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent" xlink:label="loc_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent_932" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_905" xlink:to="loc_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent_932" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_933" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_905" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_933" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_934" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_905" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_934" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_935" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_905" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_935" use="optional" order="16" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/IncomeTaxesDetails3">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_910" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_907" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_910" xlink:to="loc_us-gaap_StatementTable_907" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_908" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_907" xlink:to="loc_us-gaap_StatementClassOfStockAxis_908" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_909" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_908" xlink:to="loc_us-gaap_ClassOfStockDomain_909" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_909_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_908" xlink:to="loc_us-gaap_ClassOfStockDomain_909_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_936" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_910" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_936" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_DeferredTaxAssetsStartUpCosts" xlink:label="loc_mbrx_DeferredTaxAssetsStartUpCosts_937" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_936" xlink:to="loc_mbrx_DeferredTaxAssetsStartUpCosts_937" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_938" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_936" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_938" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_939" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_936" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_939" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_940" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_936" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_940" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_941" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_936" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_941" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_942" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_936" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_942" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_943" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_936" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_943" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_944" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_910" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_944" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_945" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_944" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_945" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_946" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_944" xlink:to="loc_us-gaap_DeferredTaxLiabilities_946" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_947" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_944" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_947" use="optional" order="16" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/NatureOfBusinessAndLiquidityDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_962" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_954" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_962" xlink:to="loc_us-gaap_StatementTable_954" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_955" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_954" xlink:to="loc_us-gaap_StatementClassOfStockAxis_955" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_956" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_955" xlink:to="loc_us-gaap_ClassOfStockDomain_956" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_956_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_955" xlink:to="loc_us-gaap_ClassOfStockDomain_956_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_957" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_954" xlink:to="loc_dei_LegalEntityAxis_957" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_960" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_957" xlink:to="loc_dei_EntityDomain_960" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_960_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_957" xlink:to="loc_dei_EntityDomain_960_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_AnnamedIncMember" xlink:label="loc_mbrx_AnnamedIncMember_961" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_960" xlink:to="loc_mbrx_AnnamedIncMember_961" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_IntertechbioCorporationMember" xlink:label="loc_mbrx_IntertechbioCorporationMember_965" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_960" xlink:to="loc_mbrx_IntertechbioCorporationMember_965" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_959" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_954" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_959" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_963" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_959" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_963" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_963_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_959" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_963_default" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseRightsMember" xlink:label="loc_us-gaap_UseRightsMember_964" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_963" xlink:to="loc_us-gaap_UseRightsMember_964" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_958" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_962" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_958" use="optional" order="14" />
  </definitionLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>mbrx-20161231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.9 on 02-Apr-2017 [12:25:26] {PM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />

  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_DocumentAndEntityInformationAbstract" xlink:label="loc_mbrx_DocumentAndEntityInformationAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document And Entity Information [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_DocumentAndEntityInformationAbstract" xlink:to="lab_mbrx_DocumentAndEntityInformationAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationTable" xml:lang="en-US">Document Information [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current Assets:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Cash Flows from Operating Activities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Prepaid expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Used in Operating Activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents, at beginning of period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents, at end of period</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Cash Flows from Investing Activities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Cash paid for purchase of fixed assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid Expense, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Cash Flows from Financing Activities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xml:lang="en-US">Proceeds from Notes Payable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xml:lang="en-US">Proceeds from notes payable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable" xlink:to="lab_us-gaap_ProceedsFromNotesPayable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xml:lang="en-US">Repayments of Notes Payable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xml:lang="en-US">Payments on notes payable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease), Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Net change in cash and cash equivalents</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Stockholders&#39; Equity</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current Liabilities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts payable and accrued expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xml:lang="en-US">Deferred Compensation Liability, Classified, Noncurrent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xml:lang="en-US">Long-term deferred compensation - related party</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental disclosures of cash flow information:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPaid" xml:lang="en-US">Interest Paid, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InterestPaid" xml:lang="en-US">Cash paid for interest</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid" xlink:to="lab_us-gaap_InterestPaid" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xml:lang="en-US">Income Taxes Paid, Net, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xml:lang="en-US">Cash paid for income taxes</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total Liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock, $0.001 par value; 5,000,000 authorized, no shares issued and outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.001 par value; 75,000,000 authorized, 12,164,852 and 6,661,000 shares issued and outstanding, respectively</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Issued on incorporation at par</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:label="loc_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xml:lang="en-US">Common Stock, Share Subscribed but Unissued, Subscriptions Receivable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xml:lang="en-US">Subscription receivable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xml:lang="en-US">Subscription receivable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:to="lab_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional paid-in capital</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit), Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders&#39; Equity Attributable to Parent [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders&#39; Equity:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Description Of Business And Summary Of Significant Accounting Policies [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xml:lang="en-US">Option Indexed to Issuer&#39;s Equity [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xml:lang="en-US">Convertible Debt Securities [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Furniture and equipment</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SalesRevenueNet" xml:lang="en-US">Revenue, Net, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SalesRevenueNet" xml:lang="en-US">Revenue</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNet" xlink:to="lab_us-gaap_SalesRevenueNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss), Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other expense:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest Expense, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Net loss per common share - basic and diluted (in dollars per share)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Net loss per common share-basic and diluted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted average common shares outstanding - basic and diluted (in share)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted average common shares outstanding-basic and diluted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_GoingConcernPolicyPolicyTextBlock" xlink:label="loc_mbrx_GoingConcernPolicyPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_GoingConcernPolicyPolicyTextBlock" xml:lang="en-US">Going Concern, Policy [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_GoingConcernPolicyPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy for going concern.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_GoingConcernPolicyPolicyTextBlock" xlink:to="lab_mbrx_GoingConcernPolicyPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_DebtInstrumentConvertibleBeneficialConversionFeaturePolicyPolicyTextBlock" xlink:label="loc_mbrx_DebtInstrumentConvertibleBeneficialConversionFeaturePolicyPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_DebtInstrumentConvertibleBeneficialConversionFeaturePolicyPolicyTextBlock" xml:lang="en-US">Debt Instrument, Convertible, Beneficial Conversion Feature Policy [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_DebtInstrumentConvertibleBeneficialConversionFeaturePolicyPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy for beneficial conversion feature of debt instrument.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_DebtInstrumentConvertibleBeneficialConversionFeaturePolicyPolicyTextBlock" xlink:to="lab_mbrx_DebtInstrumentConvertibleBeneficialConversionFeaturePolicyPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ConvertibleNotesPayableAbstractAbstract" xlink:label="loc_mbrx_ConvertibleNotesPayableAbstractAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_ConvertibleNotesPayableAbstractAbstract" xml:lang="en-US">Convertible Notes Payable Abstract [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mbrx_ConvertibleNotesPayableAbstractAbstract" xml:lang="en-US">Convertible Notes Payable [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_ConvertibleNotesPayableAbstractAbstract" xlink:to="lab_mbrx_ConvertibleNotesPayableAbstractAbstract" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ConvertibleNotesPayableDisclosureTextBlock" xlink:label="loc_mbrx_ConvertibleNotesPayableDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_ConvertibleNotesPayableDisclosureTextBlock" xml:lang="en-US">Convertible Notes Payable Disclosure [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_ConvertibleNotesPayableDisclosureTextBlock" xml:lang="en-US">The entire disclosure for convertible notes payable.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_ConvertibleNotesPayableDisclosureTextBlock" xlink:to="lab_mbrx_ConvertibleNotesPayableDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xml:lang="en-US">Convertible Debt [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xml:lang="en-US">Related Party Transaction [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xml:lang="en-US">Related Party Transaction [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaap_InvestorMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestorMember" xml:lang="en-US">Investor [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InvestorMember" xml:lang="en-US">Investor A [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestorMember" xlink:to="lab_us-gaap_InvestorMember" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_InvestorBMember" xlink:label="loc_mbrx_InvestorBMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_InvestorBMember" xml:lang="en-US">Investor B [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_InvestorBMember" xlink:to="lab_mbrx_InvestorBMember" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_InvestorCMember" xlink:label="loc_mbrx_InvestorCMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_InvestorCMember" xml:lang="en-US">Investor C [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_InvestorCMember" xlink:to="lab_mbrx_InvestorCMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xml:lang="en-US">Short-term Debt, Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_IssueDateAugust312015Member" xlink:label="loc_mbrx_IssueDateAugust312015Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_IssueDateAugust312015Member" xml:lang="en-US">Issue Date August 31 2015 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_IssueDateAugust312015Member" xlink:to="lab_mbrx_IssueDateAugust312015Member" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_IssueDateSeptember032015Member" xlink:label="loc_mbrx_IssueDateSeptember032015Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_IssueDateSeptember032015Member" xml:lang="en-US">Issue Date September 03 2015 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_IssueDateSeptember032015Member" xlink:to="lab_mbrx_IssueDateSeptember032015Member" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_IssueDateOctober062015OneMember" xlink:label="loc_mbrx_IssueDateOctober062015OneMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_IssueDateOctober062015OneMember" xml:lang="en-US">Issue Date October 06 2015 One [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_IssueDateOctober062015OneMember" xlink:to="lab_mbrx_IssueDateOctober062015OneMember" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_IssueDateOctober062015TwoMember" xlink:label="loc_mbrx_IssueDateOctober062015TwoMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_IssueDateOctober062015TwoMember" xml:lang="en-US">Issue Date October 06 2015 Two [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_IssueDateOctober062015TwoMember" xlink:to="lab_mbrx_IssueDateOctober062015TwoMember" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_IssueDateOctober282015Member" xlink:label="loc_mbrx_IssueDateOctober282015Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_IssueDateOctober282015Member" xml:lang="en-US">Issue Date October 28 2015 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_IssueDateOctober282015Member" xlink:to="lab_mbrx_IssueDateOctober282015Member" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_IssueDateJanuary142016Member" xlink:label="loc_mbrx_IssueDateJanuary142016Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_IssueDateJanuary142016Member" xml:lang="en-US">Issue Date January 14 2016 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_IssueDateJanuary142016Member" xlink:to="lab_mbrx_IssueDateJanuary142016Member" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_IssueDateJanuary192016Member" xlink:label="loc_mbrx_IssueDateJanuary192016Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_IssueDateJanuary192016Member" xml:lang="en-US">Issue Date January 19 2016 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_IssueDateJanuary192016Member" xlink:to="lab_mbrx_IssueDateJanuary192016Member" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentIssuanceDate1" xlink:label="loc_us-gaap_DebtInstrumentIssuanceDate1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentIssuanceDate1" xml:lang="en-US">Debt Instrument, Issuance Date</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentIssuanceDate1" xlink:to="lab_us-gaap_DebtInstrumentIssuanceDate1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleNotesPayableCurrent" xml:lang="en-US">Convertible Notes Payable, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConvertibleNotesPayableCurrent" xml:lang="en-US">Convertible notes payable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableCurrent" xlink:to="lab_us-gaap_ConvertibleNotesPayableCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IPOMember" xml:lang="en-US">IPO [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders&#39; Equity Note Disclosure [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule of Stock by Class [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualAxis" xlink:to="lab_us-gaap_TitleOfIndividualAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Relationship to Entity [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_DirectorAndOfficersMember" xlink:label="loc_mbrx_DirectorAndOfficersMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_DirectorAndOfficersMember" xml:lang="en-US">Director And Officers [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_DirectorAndOfficersMember" xlink:to="lab_mbrx_DirectorAndOfficersMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Equity Award [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_StockPlanMember" xlink:label="loc_mbrx_StockPlanMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_StockPlanMember" xml:lang="en-US">Stock Plan [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mbrx_StockPlanMember" xml:lang="en-US">2015 Stock Plan [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_StockPlanMember" xlink:to="lab_mbrx_StockPlanMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock issued for cash (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock issued for cash</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xml:lang="en-US">Business Acquisition [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_PatentAndTechnologyLicenseAgreementMilestonePaymentsTableTextBlock" xlink:label="loc_mbrx_PatentAndTechnologyLicenseAgreementMilestonePaymentsTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_PatentAndTechnologyLicenseAgreementMilestonePaymentsTableTextBlock" xml:lang="en-US">Patent And Technology License Agreement, Milestone Payments [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_PatentAndTechnologyLicenseAgreementMilestonePaymentsTableTextBlock" xml:lang="en-US">Tabular disclosure of milestone payments under patent and technology license agreement.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_PatentAndTechnologyLicenseAgreementMilestonePaymentsTableTextBlock" xlink:to="lab_mbrx_PatentAndTechnologyLicenseAgreementMilestonePaymentsTableTextBlock" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_CommitmentsAndContingenciesTable" xlink:label="loc_mbrx_CommitmentsAndContingenciesTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_CommitmentsAndContingenciesTable" xml:lang="en-US">Commitments and Contingencies [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_CommitmentsAndContingenciesTable" xlink:to="lab_mbrx_CommitmentsAndContingenciesTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xml:lang="en-US">Project [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_CommitmentsAndContingenciesLineItems" xlink:label="loc_mbrx_CommitmentsAndContingenciesLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_CommitmentsAndContingenciesLineItems" xml:lang="en-US">Commitments and Contingencies [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_CommitmentsAndContingenciesLineItems" xlink:to="lab_mbrx_CommitmentsAndContingenciesLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProjectMember" xml:lang="en-US">Project [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProjectMember" xlink:to="lab_us-gaap_ProjectMember" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_CommencementOfPhaseIiStudyForLicensedProductMember" xlink:label="loc_mbrx_CommencementOfPhaseIiStudyForLicensedProductMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_CommencementOfPhaseIiStudyForLicensedProductMember" xml:lang="en-US">Commencement Of Phase II Study For a Licensed Product [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_CommencementOfPhaseIiStudyForLicensedProductMember" xlink:to="lab_mbrx_CommencementOfPhaseIiStudyForLicensedProductMember" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember" xlink:label="loc_mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember" xml:lang="en-US">Commencement Of Phase III Study For a Licensed Product [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember" xlink:to="lab_mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_FilingOfNewDrugApplicationForLicensedProductMember" xlink:label="loc_mbrx_FilingOfNewDrugApplicationForLicensedProductMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_FilingOfNewDrugApplicationForLicensedProductMember" xml:lang="en-US">Filing Of a New Drug Application For a Licensed Product [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_FilingOfNewDrugApplicationForLicensedProductMember" xlink:to="lab_mbrx_FilingOfNewDrugApplicationForLicensedProductMember" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ReceiptOfMarketApprovalForLicensedProductMember" xlink:label="loc_mbrx_ReceiptOfMarketApprovalForLicensedProductMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_ReceiptOfMarketApprovalForLicensedProductMember" xml:lang="en-US">Receipt Of Market Approval For a Licensed Product [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_ReceiptOfMarketApprovalForLicensedProductMember" xlink:to="lab_mbrx_ReceiptOfMarketApprovalForLicensedProductMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingenciesTable" xml:lang="en-US">Loss Contingencies [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_AgreementAxis" xlink:label="loc_mbrx_AgreementAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_AgreementAxis" xml:lang="en-US">Agreement [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_AgreementAxis" xlink:to="lab_mbrx_AgreementAxis" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_AnniversaryDomain" xlink:label="loc_mbrx_AnniversaryDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_AnniversaryDomain" xml:lang="en-US">Anniversary [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_AnniversaryDomain" xlink:to="lab_mbrx_AnniversaryDomain" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_AnniversaryAxis" xlink:label="loc_mbrx_AnniversaryAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_AnniversaryAxis" xml:lang="en-US">Anniversary [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_AnniversaryAxis" xlink:to="lab_mbrx_AnniversaryAxis" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_MdAndersonMember" xlink:label="loc_mbrx_MdAndersonMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_MdAndersonMember" xml:lang="en-US">MD Anderson [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_MdAndersonMember" xlink:to="lab_mbrx_MdAndersonMember" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_AgreementDomain" xlink:label="loc_mbrx_AgreementDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_AgreementDomain" xml:lang="en-US">Agreement [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_AgreementDomain" xlink:to="lab_mbrx_AgreementDomain" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_PatentAndTechnologyLicenseAgreementMember" xlink:label="loc_mbrx_PatentAndTechnologyLicenseAgreementMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_PatentAndTechnologyLicenseAgreementMember" xml:lang="en-US">Patent and Technology License Agreement [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_PatentAndTechnologyLicenseAgreementMember" xlink:to="lab_mbrx_PatentAndTechnologyLicenseAgreementMember" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_PatentLawFirmMember" xlink:label="loc_mbrx_PatentLawFirmMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_PatentLawFirmMember" xml:lang="en-US">Patent Law Firm [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_PatentLawFirmMember" xlink:to="lab_mbrx_PatentLawFirmMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaap_OtherCommitmentsAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xml:lang="en-US">Other Commitments [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis" xlink:to="lab_us-gaap_OtherCommitmentsAxis" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_BonwickCapitalPartnersLlcMember" xlink:label="loc_mbrx_BonwickCapitalPartnersLlcMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_BonwickCapitalPartnersLlcMember" xml:lang="en-US">Bonwick Capital Partners LLC [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_BonwickCapitalPartnersLlcMember" xlink:to="lab_mbrx_BonwickCapitalPartnersLlcMember" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_LetterAgreementsTerms" xlink:label="loc_mbrx_LetterAgreementsTerms" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_LetterAgreementsTerms" xml:lang="en-US">Letter Agreements Terms</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_LetterAgreementsTerms" xml:lang="en-US">The entire disclosure of agreement terms.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_LetterAgreementsTerms" xlink:to="lab_mbrx_LetterAgreementsTerms" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xml:lang="en-US">Operating Loss Carryforwards [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Authority [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating Loss Carryforwards</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_OperatingLossCarryforwardsExpirationPeriod" xlink:label="loc_mbrx_OperatingLossCarryforwardsExpirationPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_OperatingLossCarryforwardsExpirationPeriod" xml:lang="en-US">Operating Loss Carryforwards Expiration Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_OperatingLossCarryforwardsExpirationPeriod" xml:lang="en-US">Expiration period of each operating loss carryforward included in operating loss carryforward, in CCYY format.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_OperatingLossCarryforwardsExpirationPeriod" xlink:to="lab_mbrx_OperatingLossCarryforwardsExpirationPeriod" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_InvestorDMember" xlink:label="loc_mbrx_InvestorDMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_InvestorDMember" xml:lang="en-US">Investor D [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_InvestorDMember" xlink:to="lab_mbrx_InvestorDMember" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_InvestorEMember" xlink:label="loc_mbrx_InvestorEMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_InvestorEMember" xml:lang="en-US">Investor E [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_InvestorEMember" xlink:to="lab_mbrx_InvestorEMember" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_DebtConversionConvertedInstrumentCommonStockSharesIssuedTradingRestrictionsDescription" xlink:label="loc_mbrx_DebtConversionConvertedInstrumentCommonStockSharesIssuedTradingRestrictionsDescription" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_DebtConversionConvertedInstrumentCommonStockSharesIssuedTradingRestrictionsDescription" xml:lang="en-US">Debt Conversion, Converted Instrument, Common Stock Shares Issued Trading Restrictions Description</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_DebtConversionConvertedInstrumentCommonStockSharesIssuedTradingRestrictionsDescription" xml:lang="en-US">This element represents the restriction terms and conditions trading of the common stock of the shares converted upon debt conversion.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_DebtConversionConvertedInstrumentCommonStockSharesIssuedTradingRestrictionsDescription" xlink:to="lab_mbrx_DebtConversionConvertedInstrumentCommonStockSharesIssuedTradingRestrictionsDescription" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RangeAxis" xml:lang="en-US">Range [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis" xlink:to="lab_us-gaap_RangeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaap_OtherCommitmentsDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xml:lang="en-US">Other Commitments [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain" xlink:to="lab_us-gaap_OtherCommitmentsDomain" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ServicingFeePayableMember" xlink:label="loc_mbrx_ServicingFeePayableMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_ServicingFeePayableMember" xml:lang="en-US">Servicing Fee payable [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_ServicingFeePayableMember" xlink:to="lab_mbrx_ServicingFeePayableMember" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_MinimumFeeAndPatentExpensesMember" xlink:label="loc_mbrx_MinimumFeeAndPatentExpensesMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_MinimumFeeAndPatentExpensesMember" xml:lang="en-US">Minimum Fee and patent Expenses [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_MinimumFeeAndPatentExpensesMember" xlink:to="lab_mbrx_MinimumFeeAndPatentExpensesMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractualObligationDueInNextTwelveMonths" xml:lang="en-US">Contractual Obligation, Due in Next Fiscal Year</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ContractualObligationDueInNextTwelveMonths" xml:lang="en-US">Contractual Obligation, Due First Anniversary April 2, 2013</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:to="lab_us-gaap_ContractualObligationDueInNextTwelveMonths" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="loc_us-gaap_ContractualObligationDueInSecondYear" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractualObligationDueInSecondYear" xml:lang="en-US">Contractual Obligation, Due in Second Year</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ContractualObligationDueInSecondYear" xml:lang="en-US">Contractual Obligation, Due Second Anniversary</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInSecondYear" xlink:to="lab_us-gaap_ContractualObligationDueInSecondYear" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="loc_us-gaap_ContractualObligationDueInThirdYear" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractualObligationDueInThirdYear" xml:lang="en-US">Contractual Obligation, Due in Third Year</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ContractualObligationDueInThirdYear" xml:lang="en-US">Contractual Obligation, Due Third Anniversary</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInThirdYear" xlink:to="lab_us-gaap_ContractualObligationDueInThirdYear" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="loc_us-gaap_ContractualObligationDueInFourthYear" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractualObligationDueInFourthYear" xml:lang="en-US">Contractual Obligation, Due in Fourth Year</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ContractualObligationDueInFourthYear" xml:lang="en-US">Contractual Obligation, Due Fourth Anniversary</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInFourthYear" xlink:to="lab_us-gaap_ContractualObligationDueInFourthYear" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInFifthYear" xlink:label="loc_us-gaap_ContractualObligationDueInFifthYear" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractualObligationDueInFifthYear" xml:lang="en-US">Contractual Obligation, Due in Fifth Year</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ContractualObligationDueInFifthYear" xml:lang="en-US">Contractual Obligation, Due Fifth Anniversary</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInFifthYear" xlink:to="lab_us-gaap_ContractualObligationDueInFifthYear" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueAfterFifthYear" xlink:label="loc_us-gaap_ContractualObligationDueAfterFifthYear" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractualObligationDueAfterFifthYear" xml:lang="en-US">Contractual Obligation, Due after Fifth Year</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ContractualObligationDueAfterFifthYear" xml:lang="en-US">Contractual Obligation, Due Sixth Anniversary</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueAfterFifthYear" xlink:to="lab_us-gaap_ContractualObligationDueAfterFifthYear" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractualObligation" xml:lang="en-US">Contractual Obligation, Total</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="lab_us-gaap_ContractualObligation" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_MinimumAnnualRoyaltyMember" xlink:label="loc_mbrx_MinimumAnnualRoyaltyMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_MinimumAnnualRoyaltyMember" xml:lang="en-US">Minimum Annual Royalty [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_MinimumAnnualRoyaltyMember" xlink:to="lab_mbrx_MinimumAnnualRoyaltyMember" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_SuccessFeePercentage" xlink:label="loc_mbrx_SuccessFeePercentage" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_SuccessFeePercentage" xml:lang="en-US">Success Fee Percentage</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_SuccessFeePercentage" xml:lang="en-US">The percentage of success fee payable.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_SuccessFeePercentage" xlink:to="lab_mbrx_SuccessFeePercentage" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ClassOfWarrantOrRightPercentageOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_mbrx_ClassOfWarrantOrRightPercentageOfSecuritiesCalledByWarrantsOrRights" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_ClassOfWarrantOrRightPercentageOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Class of Warrant or Right, Percentage of Securities Called by Warrants or Rights</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_ClassOfWarrantOrRightPercentageOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Percentage of securities into which the class of warrant or right may be converted.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_ClassOfWarrantOrRightPercentageOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_mbrx_ClassOfWarrantOrRightPercentageOfSecuritiesCalledByWarrantsOrRights" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ClassOfWarrantOrRightExercisePricePercentageThreshold" xlink:label="loc_mbrx_ClassOfWarrantOrRightExercisePricePercentageThreshold" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_ClassOfWarrantOrRightExercisePricePercentageThreshold" xml:lang="en-US">Class of Warrant or Right, Exercise Price Percentage Threshold</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_ClassOfWarrantOrRightExercisePricePercentageThreshold" xml:lang="en-US">Exercise price percentage per share or per unit of warrants or rights outstanding.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_ClassOfWarrantOrRightExercisePricePercentageThreshold" xlink:to="lab_mbrx_ClassOfWarrantOrRightExercisePricePercentageThreshold" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ReimbursementPayableOfferingCosts" xlink:label="loc_mbrx_ReimbursementPayableOfferingCosts" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_ReimbursementPayableOfferingCosts" xml:lang="en-US">Reimbursement Payable, Offering Costs</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_ReimbursementPayableOfferingCosts" xml:lang="en-US">The amount of reimbursement payable related to offering costs.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_ReimbursementPayableOfferingCosts" xlink:to="lab_mbrx_ReimbursementPayableOfferingCosts" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ReimbursementPayableFeesAndExpensesOfCounsel" xlink:label="loc_mbrx_ReimbursementPayableFeesAndExpensesOfCounsel" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_ReimbursementPayableFeesAndExpensesOfCounsel" xml:lang="en-US">Reimbursement Payable, Fees and Expenses of Counsel</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_ReimbursementPayableFeesAndExpensesOfCounsel" xml:lang="en-US">The amount of reimbursement payable related to fees and expenses of counsel.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_ReimbursementPayableFeesAndExpensesOfCounsel" xlink:to="lab_mbrx_ReimbursementPayableFeesAndExpensesOfCounsel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:label="loc_us-gaap_PaymentsForUnderwritingExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForUnderwritingExpense" xml:lang="en-US">Payments for Underwriting Expense</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForUnderwritingExpense" xlink:to="lab_us-gaap_PaymentsForUnderwritingExpense" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_RevenueRecognitionMilestoneMethodAxis" xlink:label="loc_mbrx_RevenueRecognitionMilestoneMethodAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_RevenueRecognitionMilestoneMethodAxis" xml:lang="en-US">Revenue Recognition, Milestone Method [Axis]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_RevenueRecognitionMilestoneMethodAxis" xml:lang="en-US">Revenue Recognition, Milestone Method</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_RevenueRecognitionMilestoneMethodAxis" xlink:to="lab_mbrx_RevenueRecognitionMilestoneMethodAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RangeMember" xml:lang="en-US">Range [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember" xlink:to="lab_us-gaap_RangeMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MaximumMember" xml:lang="en-US">Maximum [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember" xlink:to="lab_us-gaap_MaximumMember" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_AgreementTypeAxis" xlink:label="loc_mbrx_AgreementTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_AgreementTypeAxis" xml:lang="en-US">Agreement Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_AgreementTypeAxis" xlink:to="lab_mbrx_AgreementTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_DebtConversionConvertedInstrumentAdditionalSharesIssued" xlink:label="loc_mbrx_DebtConversionConvertedInstrumentAdditionalSharesIssued" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_DebtConversionConvertedInstrumentAdditionalSharesIssued" xml:lang="en-US">Debt Conversion, Converted Instrument, Additional Shares Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_DebtConversionConvertedInstrumentAdditionalSharesIssued" xml:lang="en-US">The number of additional shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. &#34;Part noncash&#34; refers to that portion of the transaction not resulting in cash receipts or payments in the period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_DebtConversionConvertedInstrumentAdditionalSharesIssued" xlink:to="lab_mbrx_DebtConversionConvertedInstrumentAdditionalSharesIssued" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_MilestonePaymentsLiabilities" xlink:label="loc_mbrx_MilestonePaymentsLiabilities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_MilestonePaymentsLiabilities" xml:lang="en-US">Milestone Payments Liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mbrx_MilestonePaymentsLiabilities" xml:lang="en-US">Milestone Payments Liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_MilestonePaymentsLiabilities" xml:lang="en-US">Carrying amount of expense payable towards milestone payments under Patent and Technology License Agreement.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_MilestonePaymentsLiabilities" xlink:to="lab_mbrx_MilestonePaymentsLiabilities" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_DebtInstrumentConvertibleNumberOfCommonShares" xlink:label="loc_mbrx_DebtInstrumentConvertibleNumberOfCommonShares" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_DebtInstrumentConvertibleNumberOfCommonShares" xml:lang="en-US">Debt Instrument, Convertible, Number Of Common Shares</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mbrx_DebtInstrumentConvertibleNumberOfCommonShares" xml:lang="en-US">Debt Instrument, Convertible, Number of Common Shares</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_DebtInstrumentConvertibleNumberOfCommonShares" xml:lang="en-US">The number of common shares that the holder of the debt instrument would receive if the debt was converted to equity.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_DebtInstrumentConvertibleNumberOfCommonShares" xlink:to="lab_mbrx_DebtInstrumentConvertibleNumberOfCommonShares" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ContractualObligationDueInNextFiscalYearAfterProductApproval" xlink:label="loc_mbrx_ContractualObligationDueInNextFiscalYearAfterProductApproval" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_ContractualObligationDueInNextFiscalYearAfterProductApproval" xml:lang="en-US">Contractual Obligation, Due in Next Fiscal Year After Product Approval</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mbrx_ContractualObligationDueInNextFiscalYearAfterProductApproval" xml:lang="en-US">Contractual Obligation, Due in Next Fiscal Year, After Product Approval</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_ContractualObligationDueInNextFiscalYearAfterProductApproval" xml:lang="en-US">Amount of contractual obligation due in the next fiscal year following the latest fiscal year after product approval.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_ContractualObligationDueInNextFiscalYearAfterProductApproval" xlink:to="lab_mbrx_ContractualObligationDueInNextFiscalYearAfterProductApproval" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ContractualObligationDueInSecondYearAfterProductApproval" xlink:label="loc_mbrx_ContractualObligationDueInSecondYearAfterProductApproval" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_ContractualObligationDueInSecondYearAfterProductApproval" xml:lang="en-US">Contractual Obligation, Due in Second Year After Product Approval</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mbrx_ContractualObligationDueInSecondYearAfterProductApproval" xml:lang="en-US">Contractual Obligation, Due in Second Year, After Product Approval</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_ContractualObligationDueInSecondYearAfterProductApproval" xml:lang="en-US">Amount of contractual obligation due in the second fiscal year following the latest fiscal year after product approval.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_ContractualObligationDueInSecondYearAfterProductApproval" xlink:to="lab_mbrx_ContractualObligationDueInSecondYearAfterProductApproval" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ContractualObligationDueInThirdYearAfterProductApproval" xlink:label="loc_mbrx_ContractualObligationDueInThirdYearAfterProductApproval" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_ContractualObligationDueInThirdYearAfterProductApproval" xml:lang="en-US">Contractual Obligation, Due in Third Year After Product Approval</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mbrx_ContractualObligationDueInThirdYearAfterProductApproval" xml:lang="en-US">Contractual Obligation, Due in Third Year, After Product Approval</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_ContractualObligationDueInThirdYearAfterProductApproval" xml:lang="en-US">Amount of contractual obligation due in the third fiscal year following the latest fiscal year after product approval.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_ContractualObligationDueInThirdYearAfterProductApproval" xlink:to="lab_mbrx_ContractualObligationDueInThirdYearAfterProductApproval" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xml:lang="en-US">Assets, Noncurrent [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xml:lang="en-US">Long-Term Assets:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Furniture and equipment, net of accumulated depreciation of $6,162 and $0, respectively</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total Assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xml:lang="en-US">Intangible assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total Liabilities and Stockholders&#39; Equity (Deficit)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable" xlink:label="loc_mbrx_ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable" xml:lang="en-US">Class of Warrant or Right, Period from which Warrants or Rights Exercisable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable" xml:lang="en-US">Class of Warrant or Right, Period from which Warrants or Rights Exercisable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable" xlink:to="lab_mbrx_ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares Issued, Price Per Share</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Proceeds from sale of common stock, net of cash stock issuance costs</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US">Class of Warrant or Right [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total Operating Expenses</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expense</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_CommonStockLockupAndLeakoutAgreementsDescription" xlink:label="loc_mbrx_CommonStockLockupAndLeakoutAgreementsDescription" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_CommonStockLockupAndLeakoutAgreementsDescription" xml:lang="en-US">Common Stock Lock-Up and Leak-Out Agreements Description</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_CommonStockLockupAndLeakoutAgreementsDescription" xml:lang="en-US">This element represents the restriction terms and conditions on selling the common stock.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_CommonStockLockupAndLeakoutAgreementsDescription" xlink:to="lab_mbrx_CommonStockLockupAndLeakoutAgreementsDescription" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionOriginalDebtAmount1" xml:lang="en-US">Debt Conversion, Original Debt, Amount</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="lab_us-gaap_DebtConversionOriginalDebtAmount1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPayableCurrent" xml:lang="en-US">Interest Payable, Current</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Accounts payable and accrued expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xml:lang="en-US">Cash paid for acquisition of Moleculin, LLC, net with cash acquired</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xml:lang="en-US">Business Combinations [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationSegmentAllocationTable" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationSegmentAllocationTable" xml:lang="en-US">Business Combination, Segment Allocation [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationTable" xlink:to="lab_us-gaap_BusinessCombinationSegmentAllocationTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssued1" xml:lang="en-US">Stock Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssued1" xml:lang="en-US">Common stock issued for the Acquisition of Moleculin, LLC</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xml:lang="en-US">Common stock issued for conversion of debt</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xml:lang="en-US">Cash</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xml:lang="en-US">Property and equipment</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Intangibles</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xml:lang="en-US">Total assets acquired</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xml:lang="en-US">Liability assumed (HPI)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xml:lang="en-US">Other liabilities assumed, including $469,939 of notes payable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationAbstract" xml:lang="en-US">Business Acquisition, Pro Forma Information [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable" xml:lang="en-US">Business Acquisition, Pro Forma Information, Nonrecurring Adjustments [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_BusinessAcquistionProFormaOperatingExpenses" xlink:label="loc_mbrx_BusinessAcquistionProFormaOperatingExpenses" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_BusinessAcquistionProFormaOperatingExpenses" xml:lang="en-US">Business Acquistion Pro Forma Operating Expenses</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_mbrx_BusinessAcquistionProFormaOperatingExpenses" xml:lang="en-US">Total operating expenses</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_BusinessAcquistionProFormaOperatingExpenses" xml:lang="en-US">The proforma operating expenses for a period as if the business combination or combinations had been completed at the beginning of the period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_BusinessAcquistionProFormaOperatingExpenses" xlink:to="lab_mbrx_BusinessAcquistionProFormaOperatingExpenses" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xml:lang="en-US">Net loss</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xml:lang="en-US">Net loss</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" xlink:label="loc_mbrx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Basic And Diluted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mbrx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" xml:lang="en-US">Net loss per common share - basic and diluted (in dollars per share)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mbrx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" xml:lang="en-US">Net loss per common share - basic and diluted (in dollars per share)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" xml:lang="en-US">The pro forma basic and diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" xlink:to="lab_mbrx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:label="loc_mbrx_BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xml:lang="en-US">Business Acquisition, Pro Forma Weighted Average Number of Shares Outstanding, Basic And Diluted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mbrx_BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xml:lang="en-US">Weighted average outstanding common shares - basic and diluted (in shares)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xml:lang="en-US">The pro forma Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:to="lab_mbrx_BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_MoleculinLlcMember" xlink:label="loc_mbrx_MoleculinLlcMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_MoleculinLlcMember" xml:lang="en-US">Moleculin LLC [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_MoleculinLlcMember" xlink:to="lab_mbrx_MoleculinLlcMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesReceivableRelatedParties" xlink:label="loc_us-gaap_NotesReceivableRelatedParties" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotesReceivableRelatedParties" xml:lang="en-US">Notes Receivable, Related Parties</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableRelatedParties" xlink:to="lab_us-gaap_NotesReceivableRelatedParties" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xml:lang="en-US">Equity Interest Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_HoustonPharmaceuticalsIncMember" xlink:label="loc_mbrx_HoustonPharmaceuticalsIncMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_HoustonPharmaceuticalsIncMember" xml:lang="en-US">Houston Pharmaceuticals, Inc [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_HoustonPharmaceuticalsIncMember" xml:lang="en-US">Houston Pharmaceuticals, Inc</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_HoustonPharmaceuticalsIncMember" xlink:to="lab_mbrx_HoustonPharmaceuticalsIncMember" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_LicenseAgreementMember" xlink:label="loc_mbrx_LicenseAgreementMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_LicenseAgreementMember" xml:lang="en-US">License Agreement [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_LicenseAgreementMember" xml:lang="en-US">License Agreement</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_LicenseAgreementMember" xlink:to="lab_mbrx_LicenseAgreementMember" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_OutlincenseAgreementMember" xlink:label="loc_mbrx_OutlincenseAgreementMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_OutlincenseAgreementMember" xml:lang="en-US">Out-Lincense Agreement [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_OutlincenseAgreementMember" xml:lang="en-US">Out-Lincense Agreement</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_OutlincenseAgreementMember" xlink:to="lab_mbrx_OutlincenseAgreementMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaap_CashUninsuredAmount" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashUninsuredAmount" xml:lang="en-US">Cash, Uninsured Amount</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashUninsuredAmount" xlink:to="lab_us-gaap_CashUninsuredAmount" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaap_PaymentsForRoyalties" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForRoyalties" xml:lang="en-US">Payments for Royalties</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRoyalties" xlink:to="lab_us-gaap_PaymentsForRoyalties" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_LicenseAgreementMaintenanceFee" xlink:label="loc_mbrx_LicenseAgreementMaintenanceFee" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_LicenseAgreementMaintenanceFee" xml:lang="en-US">License Agreement, Maintenance Fee</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_LicenseAgreementMaintenanceFee" xml:lang="en-US">The annual maintenance fee under the licensing agreement.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_LicenseAgreementMaintenanceFee" xlink:to="lab_mbrx_LicenseAgreementMaintenanceFee" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_LicenseAgreementMaintenanceFeeAnnualIncrease" xlink:label="loc_mbrx_LicenseAgreementMaintenanceFeeAnnualIncrease" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_LicenseAgreementMaintenanceFeeAnnualIncrease" xml:lang="en-US">License Agreement, Maintenance Fee Annual Increase</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_LicenseAgreementMaintenanceFeeAnnualIncrease" xml:lang="en-US">The rate of increase annualy om the annual maintenance fee under the licensing agreement.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_LicenseAgreementMaintenanceFeeAnnualIncrease" xlink:to="lab_mbrx_LicenseAgreementMaintenanceFeeAnnualIncrease" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_RevenueRecognitionMilestoneMethodDomain" xlink:label="loc_mbrx_RevenueRecognitionMilestoneMethodDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_RevenueRecognitionMilestoneMethodDomain" xml:lang="en-US">Revenue Recognition, Milestone Method [Domain]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_RevenueRecognitionMilestoneMethodDomain" xml:lang="en-US">Revenue Recognition, Milestone Method</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_RevenueRecognitionMilestoneMethodDomain" xlink:to="lab_mbrx_RevenueRecognitionMilestoneMethodDomain" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_LetterAgreementMember" xlink:label="loc_mbrx_LetterAgreementMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_LetterAgreementMember" xml:lang="en-US">Letter Agreement [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_LetterAgreementMember" xlink:to="lab_mbrx_LetterAgreementMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaap_PaymentsForFees" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForFees" xml:lang="en-US">Payments for Other Fees</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForFees" xlink:to="lab_us-gaap_PaymentsForFees" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ReimburementOfExpenses" xlink:label="loc_mbrx_ReimburementOfExpenses" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_ReimburementOfExpenses" xml:lang="en-US">Reimburement of Expenses</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_ReimburementOfExpenses" xml:lang="en-US">The amount of expenses reimbursed to underwriters.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_ReimburementOfExpenses" xlink:to="lab_mbrx_ReimburementOfExpenses" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments of Stock Issuance Costs</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_LicencingArrangementsConsiderationPayable" xlink:label="loc_mbrx_LicencingArrangementsConsiderationPayable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_LicencingArrangementsConsiderationPayable" xml:lang="en-US">Licencing Arrangements Consideration Payable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mbrx_LicencingArrangementsConsiderationPayable" xml:lang="en-US">Licensing Arrangements Consideration Payable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_LicencingArrangementsConsiderationPayable" xml:lang="en-US">Amount to be Paid for Technology Rights And Development of License under out license agreement</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_LicencingArrangementsConsiderationPayable" xlink:to="lab_mbrx_LicencingArrangementsConsiderationPayable" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_LicencingArrangementsReserve" xlink:label="loc_mbrx_LicencingArrangementsReserve" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_LicencingArrangementsReserve" xml:lang="en-US">Licencing Arrangements Reserve</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mbrx_LicencingArrangementsReserve" xml:lang="en-US">Licensing Arrangements Reserve</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_LicencingArrangementsReserve" xml:lang="en-US">The amount of reserve maintained for the payments made against the licensing arrangements.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_LicencingArrangementsReserve" xlink:to="lab_mbrx_LicencingArrangementsReserve" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xml:lang="en-US">Payments to Acquire Intangible Assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_UnsecuredPromissoryNotesMember" xlink:label="loc_mbrx_UnsecuredPromissoryNotesMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_UnsecuredPromissoryNotesMember" xml:lang="en-US">Unsecured Promissory Notes [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_UnsecuredPromissoryNotesMember" xlink:to="lab_mbrx_UnsecuredPromissoryNotesMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems" xml:lang="en-US">Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders&#39; Equity Attributable to Parent, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total Stockholders&#39; Equity (Deficit)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Beginning Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Ending Balances</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Compensation Expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xml:lang="en-US">Deferred CEO compensation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Issued on incorporation at par (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xml:lang="en-US">Option Indexed to Issuer&#39;s Equity, Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US">Class of Warrant or Right [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_SharesAuthorized" xlink:label="loc_mbrx_SharesAuthorized" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_SharesAuthorized" xml:lang="en-US">Shares Authorized</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_SharesAuthorized" xml:lang="en-US">The maximum number of common and preferred shares permitted to be issued by an entity&#39;s charter and bylaws.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_SharesAuthorized" xlink:to="lab_mbrx_SharesAuthorized" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xml:lang="en-US">Warrants Not Settleable in Cash, Fair Value Disclosure</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:to="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="loc_us-gaap_FairValueInputsDiscountRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsDiscountRate" xml:lang="en-US">Fair Value Inputs, Discount Rate</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsDiscountRate" xlink:to="lab_us-gaap_FairValueInputsDiscountRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Fair Value Assumptions, Expected Term</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedTerm" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedTerm" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Fair Value Assumptions, Expected Volatility Rate</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_PcgAdvisoryGroupMember" xlink:label="loc_mbrx_PcgAdvisoryGroupMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_PcgAdvisoryGroupMember" xml:lang="en-US">PCG Advisory Group [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_PcgAdvisoryGroupMember" xlink:to="lab_mbrx_PcgAdvisoryGroupMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xml:lang="en-US">Net assets acquired/total consideration transferred</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xml:lang="en-US">Intangibles acquired from Moleculin, LLC</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationSegmentAllocationLineItems" xml:lang="en-US">Business Combination Segment Allocation [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:to="lab_us-gaap_BusinessCombinationSegmentAllocationLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherIntangibleAssetsMember" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xml:lang="en-US">Other Intangible Assets [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xml:lang="en-US">Equity Interest Issued or Issuable, Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_PeriodTypeAxis" xlink:label="loc_mbrx_PeriodTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_PeriodTypeAxis" xml:lang="en-US">Period Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_PeriodTypeAxis" xlink:to="lab_mbrx_PeriodTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by Financing Activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_RoyaltyOnNetRevenues" xlink:label="loc_mbrx_RoyaltyOnNetRevenues" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_RoyaltyOnNetRevenues" xml:lang="en-US">Royalty On Net Revenues</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_RoyaltyOnNetRevenues" xml:lang="en-US">It represents the royalty percentage on net revenue.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_RoyaltyOnNetRevenues" xlink:to="lab_mbrx_RoyaltyOnNetRevenues" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_AccruedLicenseAgreementPayment" xlink:label="loc_mbrx_AccruedLicenseAgreementPayment" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_AccruedLicenseAgreementPayment" xml:lang="en-US">Accrued license agreement payment</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_AccruedLicenseAgreementPayment" xml:lang="en-US">Amount payable for license agreement payment.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_AccruedLicenseAgreementPayment" xlink:to="lab_mbrx_AccruedLicenseAgreementPayment" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_LicenseAgreementMaintenanceFeeMaximumPayablePerYear" xlink:label="loc_mbrx_LicenseAgreementMaintenanceFeeMaximumPayablePerYear" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_LicenseAgreementMaintenanceFeeMaximumPayablePerYear" xml:lang="en-US">License Agreement, Maintenance Fee - Maximum Payable Per Year</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_LicenseAgreementMaintenanceFeeMaximumPayablePerYear" xml:lang="en-US">Represents the maximum payable amount of annual maintenance fee under the licensing agreement.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_LicenseAgreementMaintenanceFeeMaximumPayablePerYear" xlink:to="lab_mbrx_LicenseAgreementMaintenanceFeeMaximumPayablePerYear" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaap_CashFDICInsuredAmount" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFDICInsuredAmount" xml:lang="en-US">Cash, FDIC Insured Amount</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFDICInsuredAmount" xlink:to="lab_us-gaap_CashFDICInsuredAmount" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Used in Investing Activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Number of Shares, Granted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xml:lang="en-US">Subsequent Events, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Number of Shares, Cancelled</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_EmployeeAndBoardOfDirectorsMember" xlink:label="loc_mbrx_EmployeeAndBoardOfDirectorsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_EmployeeAndBoardOfDirectorsMember" xml:lang="en-US">Employee And Board Of Directors [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_EmployeeAndBoardOfDirectorsMember" xml:lang="en-US">Employee And Board Of Directors</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_EmployeeAndBoardOfDirectorsMember" xlink:to="lab_mbrx_EmployeeAndBoardOfDirectorsMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinimumMember" xml:lang="en-US">Minimum [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember" xlink:to="lab_us-gaap_MinimumMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of Shares, Outstanding Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of Shares, Outstanding Balance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Number of Shares, Exercisable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value, Outstanding Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value, Outstanding Balance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value, Granted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value, Cancelled</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:label="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value, Exercisable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xml:lang="en-US">The weighted average grant-date fair value of options exercisable.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:to="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Outstanding Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Outstanding Balance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/negativeLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Cancelled</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years), Outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_SharesIssuedForLicensesUsedForResearchAndDevelopment" xlink:label="loc_mbrx_SharesIssuedForLicensesUsedForResearchAndDevelopment" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_SharesIssuedForLicensesUsedForResearchAndDevelopment" xml:lang="en-US">Shares Issued For Licenses Used For Research And Development</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_mbrx_SharesIssuedForLicensesUsedForResearchAndDevelopment" xml:lang="en-US">Stock issued for licenses used for research and development</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_SharesIssuedForLicensesUsedForResearchAndDevelopment" xml:lang="en-US">Value of shares issued for licenses used for research and development.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_SharesIssuedForLicensesUsedForResearchAndDevelopment" xlink:to="lab_mbrx_SharesIssuedForLicensesUsedForResearchAndDevelopment" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_WarrantsIssuedForServices" xlink:label="loc_mbrx_WarrantsIssuedForServices" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_WarrantsIssuedForServices" xml:lang="en-US">Warrants Issued For Services</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mbrx_WarrantsIssuedForServices" xml:lang="en-US">Warrants issued for services provided</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_WarrantsIssuedForServices" xml:lang="en-US">Value of Warrants issued for services provided in non cash financing activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_WarrantsIssuedForServices" xlink:to="lab_mbrx_WarrantsIssuedForServices" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_PeriodTypeDomain" xlink:label="loc_mbrx_PeriodTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_PeriodTypeDomain" xml:lang="en-US">Period Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_PeriodTypeDomain" xlink:to="lab_mbrx_PeriodTypeDomain" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_AcquisitionDateOneMember" xlink:label="loc_mbrx_AcquisitionDateOneMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_AcquisitionDateOneMember" xml:lang="en-US">Acquisition Date One [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_AcquisitionDateOneMember" xlink:to="lab_mbrx_AcquisitionDateOneMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OfficersCompensation" xml:lang="en-US">Officers&#39; Compensation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficersCompensation" xlink:to="lab_us-gaap_OfficersCompensation" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaap_ChiefExecutiveOfficerMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ChiefExecutiveOfficerMember" xml:lang="en-US">Chief Executive Officer [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChiefExecutiveOfficerMember" xlink:to="lab_us-gaap_ChiefExecutiveOfficerMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Share Price</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityVoluntaryFilers" xml:lang="en-US">Entity Voluntary Filers</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityPublicFloat" xml:lang="en-US">Entity Public Float</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders&#39; Equity [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_SubscriptionsReceivableMember" xlink:label="loc_mbrx_SubscriptionsReceivableMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_SubscriptionsReceivableMember" xml:lang="en-US">Subscriptions Receivable [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_SubscriptionsReceivableMember" xlink:to="lab_mbrx_SubscriptionsReceivableMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">Accumulated Loss [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Beginning Balance (in shares)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Endind Balances (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_StockIssuedDuringPeriodValueForCashAndSubscriptionReceivable" xlink:label="loc_mbrx_StockIssuedDuringPeriodValueForCashAndSubscriptionReceivable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_StockIssuedDuringPeriodValueForCashAndSubscriptionReceivable" xml:lang="en-US">Stock Issued During Period Value for Cash and Subscription Receivable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mbrx_StockIssuedDuringPeriodValueForCashAndSubscriptionReceivable" xml:lang="en-US">Stock issued for cash and subscription receivable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_StockIssuedDuringPeriodValueForCashAndSubscriptionReceivable" xml:lang="en-US">Value of stock issued for cash and subscription receivable.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_StockIssuedDuringPeriodValueForCashAndSubscriptionReceivable" xlink:to="lab_mbrx_StockIssuedDuringPeriodValueForCashAndSubscriptionReceivable" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_StockIssuedDuringPeriodSharesForCashAndSubscriptionReceivable" xlink:label="loc_mbrx_StockIssuedDuringPeriodSharesForCashAndSubscriptionReceivable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_StockIssuedDuringPeriodSharesForCashAndSubscriptionReceivable" xml:lang="en-US">Stock Issued During Period Shares for Cash and Subscription Receivable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mbrx_StockIssuedDuringPeriodSharesForCashAndSubscriptionReceivable" xml:lang="en-US">Stock issued for cash and subscription receivable (in Shares)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_StockIssuedDuringPeriodSharesForCashAndSubscriptionReceivable" xml:lang="en-US">Number of shares issued for cash and subscription receivable.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_StockIssuedDuringPeriodSharesForCashAndSubscriptionReceivable" xlink:to="lab_mbrx_StockIssuedDuringPeriodSharesForCashAndSubscriptionReceivable" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_StockIssuedDuringPeriodValueForLicenses" xlink:label="loc_mbrx_StockIssuedDuringPeriodValueForLicenses" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_StockIssuedDuringPeriodValueForLicenses" xml:lang="en-US">Stock Issued During Period Value for Licenses</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mbrx_StockIssuedDuringPeriodValueForLicenses" xml:lang="en-US">Stock issued for licenses</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_StockIssuedDuringPeriodValueForLicenses" xml:lang="en-US">Value of stock issued for licenses.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_StockIssuedDuringPeriodValueForLicenses" xlink:to="lab_mbrx_StockIssuedDuringPeriodValueForLicenses" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_StockIssuedDuringPeriodSharesForLicenses" xlink:label="loc_mbrx_StockIssuedDuringPeriodSharesForLicenses" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_StockIssuedDuringPeriodSharesForLicenses" xml:lang="en-US">Stock Issued During Period Shares for Licenses</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mbrx_StockIssuedDuringPeriodSharesForLicenses" xml:lang="en-US">Stock issued for licenses (in shares)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_StockIssuedDuringPeriodSharesForLicenses" xml:lang="en-US">Number of shares issued for licenses.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_StockIssuedDuringPeriodSharesForLicenses" xlink:to="lab_mbrx_StockIssuedDuringPeriodSharesForLicenses" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_StockIssuedDuringPeriodValuePrivateIssuances" xlink:label="loc_mbrx_StockIssuedDuringPeriodValuePrivateIssuances" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_StockIssuedDuringPeriodValuePrivateIssuances" xml:lang="en-US">Stock Issued During the Period, Value, Private Issuances</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mbrx_StockIssuedDuringPeriodValuePrivateIssuances" xml:lang="en-US">Private issuance @ $3.00 / share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_StockIssuedDuringPeriodValuePrivateIssuances" xml:lang="en-US">Equity impact of the value of private issuances during the period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_StockIssuedDuringPeriodValuePrivateIssuances" xlink:to="lab_mbrx_StockIssuedDuringPeriodValuePrivateIssuances" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_StockIssuedDuringPeriodSharesPrivateIssuances" xlink:label="loc_mbrx_StockIssuedDuringPeriodSharesPrivateIssuances" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_StockIssuedDuringPeriodSharesPrivateIssuances" xml:lang="en-US">Stock Issued During the Period, Shares, Private Issuances</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mbrx_StockIssuedDuringPeriodSharesPrivateIssuances" xml:lang="en-US">Private issuance @ $3.00 / share (in shares)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_StockIssuedDuringPeriodSharesPrivateIssuances" xml:lang="en-US">Number of new stock issued during the period in private issuances</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_StockIssuedDuringPeriodSharesPrivateIssuances" xlink:to="lab_mbrx_StockIssuedDuringPeriodSharesPrivateIssuances" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xml:lang="en-US">Issued for Moleculin acquisition</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US">Issued for Moleculin acquisition (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_StockIssuedDuringPeriodValueForTechnology" xlink:label="loc_mbrx_StockIssuedDuringPeriodValueForTechnology" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_StockIssuedDuringPeriodValueForTechnology" xml:lang="en-US">Stock Issued During Period Value for Technology</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mbrx_StockIssuedDuringPeriodValueForTechnology" xml:lang="en-US">Issued for technology</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_StockIssuedDuringPeriodValueForTechnology" xml:lang="en-US">Value of stock issued for technology.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_StockIssuedDuringPeriodValueForTechnology" xlink:to="lab_mbrx_StockIssuedDuringPeriodValueForTechnology" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_StockIssuedDuringPeriodSharesForTechnology" xlink:label="loc_mbrx_StockIssuedDuringPeriodSharesForTechnology" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_StockIssuedDuringPeriodSharesForTechnology" xml:lang="en-US">Stock Issued During Period Shares for Technology</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mbrx_StockIssuedDuringPeriodSharesForTechnology" xml:lang="en-US">Issued for technology (in shares)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_StockIssuedDuringPeriodSharesForTechnology" xml:lang="en-US">Number of shares issued for technology.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_StockIssuedDuringPeriodSharesForTechnology" xlink:to="lab_mbrx_StockIssuedDuringPeriodSharesForTechnology" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts" xlink:label="loc_mbrx_StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts" xml:lang="en-US">Stock Issued During Period Value for Cash Initial Public offering Net of Stock Issuance Costs</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mbrx_StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts" xml:lang="en-US">Issued for cash - IPO, net of stock issuance costs of $1,150,736</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts" xml:lang="en-US">Value of stock issued for Cash IPO Net of Stock Issuance Costs</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts" xlink:to="lab_mbrx_StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts" xlink:label="loc_mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts" xml:lang="en-US">Stock Issued During Period Shares for Cash Initial Public offering Net of Stock Issuance Costs</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts" xml:lang="en-US">Issued for cash - IPO, net of stock issuance costs of $1,150,736 (in shares)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts" xml:lang="en-US">Number of shares issued for cash initial public offering net of stock issuance costs.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts" xlink:to="lab_mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xml:lang="en-US">Warrants issued for services</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_NatureOfBusinessAndLiquidityTextBlock" xlink:label="loc_mbrx_NatureOfBusinessAndLiquidityTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_NatureOfBusinessAndLiquidityTextBlock" xml:lang="en-US">Nature of Business and Liquidity [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_NatureOfBusinessAndLiquidityTextBlock" xml:lang="en-US">The entire disclosure for nature of business and liquidity.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_NatureOfBusinessAndLiquidityTextBlock" xlink:to="lab_mbrx_NatureOfBusinessAndLiquidityTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer Equipment [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xml:lang="en-US">Machinery and Equipment [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and Fixtures [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xml:lang="en-US">Defined Benefit Plan, Asset Categories [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:to="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold Improvements [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Description Of Business And Summary Of Significant Accounting Policies [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanAssetCategoriesDomain" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xml:lang="en-US">Plan Asset Categories [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain" xlink:to="lab_us-gaap_PlanAssetCategoriesDomain" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_NumberOfUnitsIssued" xlink:label="loc_mbrx_NumberOfUnitsIssued" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_NumberOfUnitsIssued" xml:lang="en-US">Number Of Units issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_NumberOfUnitsIssued" xml:lang="en-US">Represents the number of units issued during the period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_NumberOfUnitsIssued" xlink:to="lab_mbrx_NumberOfUnitsIssued" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_PricePerUnit" xlink:label="loc_mbrx_PricePerUnit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_PricePerUnit" xml:lang="en-US">Price Per Unit</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_PricePerUnit" xml:lang="en-US">Represents price per units.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_PricePerUnit" xlink:to="lab_mbrx_PricePerUnit" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_AgreementTypeDomain" xlink:label="loc_mbrx_AgreementTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_AgreementTypeDomain" xml:lang="en-US">Agreement Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_AgreementTypeDomain" xlink:to="lab_mbrx_AgreementTypeDomain" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_UnderwritingAgreementMember" xlink:label="loc_mbrx_UnderwritingAgreementMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_UnderwritingAgreementMember" xml:lang="en-US">Underwriting Agreement [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_UnderwritingAgreementMember" xlink:to="lab_mbrx_UnderwritingAgreementMember" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_InvestorFMember" xlink:label="loc_mbrx_InvestorFMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_InvestorFMember" xml:lang="en-US">Investor F [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_InvestorFMember" xlink:to="lab_mbrx_InvestorFMember" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_InvestorGMember" xlink:label="loc_mbrx_InvestorGMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_InvestorGMember" xml:lang="en-US">Investor G [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_InvestorGMember" xlink:to="lab_mbrx_InvestorGMember" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_SeriesWarrantMember" xlink:label="loc_mbrx_SeriesWarrantMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_SeriesWarrantMember" xml:lang="en-US">Series A Warrant [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_SeriesWarrantMember" xlink:to="lab_mbrx_SeriesWarrantMember" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_SeriesBWarrantMember" xlink:label="loc_mbrx_SeriesBWarrantMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_SeriesBWarrantMember" xml:lang="en-US">Series B Warrant [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_SeriesBWarrantMember" xlink:to="lab_mbrx_SeriesBWarrantMember" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_SeriesCWarrantMember" xlink:label="loc_mbrx_SeriesCWarrantMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_SeriesCWarrantMember" xml:lang="en-US">Series C Warrant [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_SeriesCWarrantMember" xlink:to="lab_mbrx_SeriesCWarrantMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaap_SaleOfStockDescriptionOfTransaction" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockDescriptionOfTransaction" xml:lang="en-US">Sale of Stock, Description of Transaction</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockDescriptionOfTransaction" xlink:to="lab_us-gaap_SaleOfStockDescriptionOfTransaction" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ClassOfWarrantOrRightsWarrantExercised" xlink:label="loc_mbrx_ClassOfWarrantOrRightsWarrantExercised" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_ClassOfWarrantOrRightsWarrantExercised" xml:lang="en-US">Class Of Warrant Or Rights Warrant Exercised</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_ClassOfWarrantOrRightsWarrantExercised" xml:lang="en-US">Represents number of warrants exercised during the period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_ClassOfWarrantOrRightsWarrantExercised" xlink:to="lab_mbrx_ClassOfWarrantOrRightsWarrantExercised" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ScienceAdvisoryBoardOneMember" xlink:label="loc_mbrx_ScienceAdvisoryBoardOneMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_ScienceAdvisoryBoardOneMember" xml:lang="en-US">Science Advisory Board One [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_ScienceAdvisoryBoardOneMember" xlink:to="lab_mbrx_ScienceAdvisoryBoardOneMember" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ScienceAdvisoryBoardTwoMember" xlink:label="loc_mbrx_ScienceAdvisoryBoardTwoMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_ScienceAdvisoryBoardTwoMember" xml:lang="en-US">Science Advisory Board Two [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_ScienceAdvisoryBoardTwoMember" xlink:to="lab_mbrx_ScienceAdvisoryBoardTwoMember" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_FormerScienceAdvisoryBoardMember" xlink:label="loc_mbrx_FormerScienceAdvisoryBoardMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_FormerScienceAdvisoryBoardMember" xml:lang="en-US">Former Science Advisory Board [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_FormerScienceAdvisoryBoardMember" xlink:to="lab_mbrx_FormerScienceAdvisoryBoardMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_UsFoodAndDrugAdministrationMember" xlink:label="loc_mbrx_UsFoodAndDrugAdministrationMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_UsFoodAndDrugAdministrationMember" xml:lang="en-US">U.S. Food and Drug Administration [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_UsFoodAndDrugAdministrationMember" xlink:to="lab_mbrx_UsFoodAndDrugAdministrationMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Proceeds from Issuance of Warrants</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xml:lang="en-US">Short-term Debt, Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xml:lang="en-US">Convertible Notes Payable [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableMember" xlink:to="lab_us-gaap_ConvertibleNotesPayableMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ChiefFinancialOfficerAndExecutiveVicePresidentMember" xlink:label="loc_mbrx_ChiefFinancialOfficerAndExecutiveVicePresidentMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_ChiefFinancialOfficerAndExecutiveVicePresidentMember" xml:lang="en-US">Chief Financial Officer and Executive Vice President [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_ChiefFinancialOfficerAndExecutiveVicePresidentMember" xlink:to="lab_mbrx_ChiefFinancialOfficerAndExecutiveVicePresidentMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Maximum Contractual Term</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Shares Issued</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Exercise Price</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingenciesLineItems" xml:lang="en-US">Loss Contingencies [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_MrLouisMember" xlink:label="loc_mbrx_MrLouisMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_MrLouisMember" xml:lang="en-US">Mr. Louis [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_MrLouisMember" xlink:to="lab_mbrx_MrLouisMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeveranceCosts1" xml:lang="en-US">Severance Costs</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_SeparationAgreementDescription" xlink:label="loc_mbrx_SeparationAgreementDescription" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_SeparationAgreementDescription" xml:lang="en-US">Separation Agreement Description</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_SeparationAgreementDescription" xml:lang="en-US">Represents description regarding separation agreement.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_SeparationAgreementDescription" xlink:to="lab_mbrx_SeparationAgreementDescription" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Current Expense (Benefit):</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xml:lang="en-US">Current Federal Tax Expense (Benefit)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xml:lang="en-US">Federal</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xml:lang="en-US">State</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xml:lang="en-US">Current Income Tax Expense</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Deferred Expense (Benefit):</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xml:lang="en-US">Federal</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xml:lang="en-US">State</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Income Tax Expense</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Net Deferred Taxes</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Total Tax (Expense) / Benefit, Amount</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation Allowance at Beginning of Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation Allowance at End of Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Less Valuation Allowance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US">Income Tax Benefit</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_DeferredTaxAssetsValuationAllowanceReleases" xlink:label="loc_mbrx_DeferredTaxAssetsValuationAllowanceReleases" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_DeferredTaxAssetsValuationAllowanceReleases" xml:lang="en-US">Deferred Tax Assets Valuation Allowance Releases</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mbrx_DeferredTaxAssetsValuationAllowanceReleases" xml:lang="en-US">Release of Valuation Allowance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_DeferredTaxAssetsValuationAllowanceReleases" xml:lang="en-US">The value of valuation allowance released during the reporting period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_DeferredTaxAssetsValuationAllowanceReleases" xlink:to="lab_mbrx_DeferredTaxAssetsValuationAllowanceReleases" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Federal Tax Benefit at Statutory Rate, Amount</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">State Tax Benefit Net of Federal, Amount</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost" xlink:label="loc_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost" xml:lang="en-US">Effective Income Tax Rate Reconciliation Initial Public Offering Cost</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost" xml:lang="en-US">IPO Costs, Amount</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to initial offering costs.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost" xlink:to="lab_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xml:lang="en-US">Other Permanent Differences, Amount</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Increase in Valuation Allowance, Amount</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Federal Tax Benefit at Statutory Rate, Percent</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">State Tax Benefit Net of Federal, percent</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent" xlink:label="loc_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent" xml:lang="en-US">Effective Income Tax Rate Reconciliation Initial Public Offering Cost Percent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent" xml:lang="en-US">IPO Costs, Percent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to initial public offering costs.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent" xlink:to="lab_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xml:lang="en-US">Other Permanent Differences, Percent</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Increase in Valuation Allowance, Percent</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Total Tax (Expense) / Benefit, Percent</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xml:lang="en-US">Deferred Tax Assets:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_DeferredTaxAssetsStartUpCosts" xlink:label="loc_mbrx_DeferredTaxAssetsStartUpCosts" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_DeferredTaxAssetsStartUpCosts" xml:lang="en-US">Deferred Tax Assets Start Up Costs</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mbrx_DeferredTaxAssetsStartUpCosts" xml:lang="en-US">Start Up Costs</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_DeferredTaxAssetsStartUpCosts" xml:lang="en-US">Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, start up costs.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_DeferredTaxAssetsStartUpCosts" xlink:to="lab_mbrx_DeferredTaxAssetsStartUpCosts" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xml:lang="en-US">Federal Net Operating Loss Carryforwards</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xml:lang="en-US">State Tax Loss Carryforwards</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Deferred Compensation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred Tax Assets, Gross</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Total Deferred Tax Assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Net Deferred Tax Assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xml:lang="en-US">Deferred Tax Liabilities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xml:lang="en-US">Fixed Assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xml:lang="en-US">Deferred Tax Liabilities, Net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xml:lang="en-US">Total Deferred Tax Liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Deferred Tax Assets, Net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Net Deferred Taxes</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Authority [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">State and Local Jurisdiction [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xml:lang="en-US">Stock Issued During Period, Shares, Purchase of Assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xml:lang="en-US">Stock issued for licenses / technology (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_AnnamedIncMember" xlink:label="loc_mbrx_AnnamedIncMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_AnnamedIncMember" xml:lang="en-US">AnnaMed, Inc [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_AnnamedIncMember" xlink:to="lab_mbrx_AnnamedIncMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseRightsMember" xlink:label="loc_us-gaap_UseRightsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseRightsMember" xml:lang="en-US">Use Rights [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseRightsMember" xlink:to="lab_us-gaap_UseRightsMember" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_IntertechbioCorporationMember" xlink:label="loc_mbrx_IntertechbioCorporationMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_IntertechbioCorporationMember" xml:lang="en-US">IntertechBio Corporation [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_IntertechbioCorporationMember" xlink:to="lab_mbrx_IntertechbioCorporationMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationLineItems" xml:lang="en-US">Document Information [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_MilestonePaymentDescription" xlink:label="loc_mbrx_MilestonePaymentDescription" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_MilestonePaymentDescription" xml:lang="en-US">Milestone Payment Description</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_MilestonePaymentDescription" xml:lang="en-US">Milestone Payment Description</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_MilestonePaymentDescription" xlink:to="lab_mbrx_MilestonePaymentDescription" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Stock granted for services</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Common stock issued for services provided</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:label="loc_mbrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xml:lang="en-US">Schedule of Property Plant And Equipment Useful life [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xml:lang="en-US">Tabular disclosure of property plant and equipment useful life.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:to="lab_mbrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_SharesSubscribed" xlink:label="loc_mbrx_SharesSubscribed" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_SharesSubscribed" xml:lang="en-US">Shares Subscribed</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mbrx_SharesSubscribed" xml:lang="en-US">Shares subscribed</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_SharesSubscribed" xml:lang="en-US">Value of shares subscribed during the period as a non cash activities.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_SharesSubscribed" xlink:to="lab_mbrx_SharesSubscribed" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Stock granted for services (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years), Exercisable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding Balance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_EstimatedForfeitureRatePercentage" xlink:label="loc_mbrx_EstimatedForfeitureRatePercentage" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_EstimatedForfeitureRatePercentage" xml:lang="en-US">Estimated Forfeiture Rate Percentage</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_EstimatedForfeitureRatePercentage" xml:lang="en-US">It represents the percentage rate of estimated forfeiture.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_EstimatedForfeitureRatePercentage" xlink:to="lab_mbrx_EstimatedForfeitureRatePercentage" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xml:lang="en-US">Stock Issued During Period, Value, Purchase of Assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xml:lang="en-US">Stock issued for licenses / technology</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ChiefFinancialOfficerMember" xlink:label="loc_us-gaap_ChiefFinancialOfficerMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ChiefFinancialOfficerMember" xml:lang="en-US">Chief Financial Officer [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChiefFinancialOfficerMember" xlink:to="lab_us-gaap_ChiefFinancialOfficerMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable" xlink:label="loc_mbrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Notes Payable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable" xml:lang="en-US">Amount of liabilities incurred related to notes payable, assumed at the acquisition date.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable" xlink:to="lab_mbrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Stock option expense</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Issued for convertible debt</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Issued for convertible debt (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_StockholdersEquitySubscriptionsSettledForCash" xlink:label="loc_mbrx_StockholdersEquitySubscriptionsSettledForCash" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mbrx_StockholdersEquitySubscriptionsSettledForCash" xml:lang="en-US">Stockholders&#39; Equity, Subscriptions Settled For Cash</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mbrx_StockholdersEquitySubscriptionsSettledForCash" xml:lang="en-US">Subscription agreement settled for cash</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mbrx_StockholdersEquitySubscriptionsSettledForCash" xml:lang="en-US">Represents subscriptions receivable settled for cash during the period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_StockholdersEquitySubscriptionsSettledForCash" xlink:to="lab_mbrx_StockholdersEquitySubscriptionsSettledForCash" />
  </labelLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>mbrx-20161231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.9 on 02-Apr-2017 [12:25:26] {PM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#DocumentAndEntityInformation" roleURI="http://www.moleculin.com/role/DocumentAndEntityInformation" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.moleculin.com/role/SummaryOfSignificantAccountingPolicies" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#IntangibleAssets" roleURI="http://www.moleculin.com/role/IntangibleAssets" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#ConvertibleNotesPayable" roleURI="http://www.moleculin.com/role/ConvertibleNotesPayable" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#Equity" roleURI="http://www.moleculin.com/role/Equity" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#IncomeTaxes" roleURI="http://www.moleculin.com/role/IncomeTaxes" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#CommitmentsAndContingencies" roleURI="http://www.moleculin.com/role/CommitmentsAndContingencies" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#SubsequentEvents" roleURI="http://www.moleculin.com/role/SubsequentEvents" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#BalanceSheets" roleURI="http://www.moleculin.com/role/BalanceSheets" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesTables" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#IntangibleAssetsTables" roleURI="http://www.moleculin.com/role/IntangibleAssetsTables" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#ConvertibleNotesPayableTables" roleURI="http://www.moleculin.com/role/ConvertibleNotesPayableTables" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#EquityTables" roleURI="http://www.moleculin.com/role/EquityTables" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#IncomeTaxesTables" roleURI="http://www.moleculin.com/role/IncomeTaxesTables" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#CommitmentsAndContingenciesTables" roleURI="http://www.moleculin.com/role/CommitmentsAndContingenciesTables" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#BalanceSheetsParenthetical" roleURI="http://www.moleculin.com/role/BalanceSheetsParenthetical" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#NatureOfBusinessAndLiquidityDetailsTextual" roleURI="http://www.moleculin.com/role/NatureOfBusinessAndLiquidityDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#SummaryOfSignificantAccountingPoliciesDetailsTextual" roleURI="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#IntangibleAssetsDetails" roleURI="http://www.moleculin.com/role/IntangibleAssetsDetails" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#IntangibleAssetsDetails1" roleURI="http://www.moleculin.com/role/IntangibleAssetsDetails1" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#IntangibleAssetsDetails2" roleURI="http://www.moleculin.com/role/IntangibleAssetsDetails2" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#IntangibleAssetsDetailsTextual" roleURI="http://www.moleculin.com/role/IntangibleAssetsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#ConvertibleNotesPayableDetails" roleURI="http://www.moleculin.com/role/ConvertibleNotesPayableDetails" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#ConvertibleNotesPayableDetailsTextual" roleURI="http://www.moleculin.com/role/ConvertibleNotesPayableDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#EquityDetails" roleURI="http://www.moleculin.com/role/EquityDetails" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#StatementsOfOperations" roleURI="http://www.moleculin.com/role/StatementsOfOperations" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#EquityDetailsTextual" roleURI="http://www.moleculin.com/role/EquityDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#IncomeTaxesDetails" roleURI="http://www.moleculin.com/role/IncomeTaxesDetails" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#IncomeTaxesDetails1" roleURI="http://www.moleculin.com/role/IncomeTaxesDetails1" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#IncomeTaxesDetails2" roleURI="http://www.moleculin.com/role/IncomeTaxesDetails2" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#IncomeTaxesDetails3" roleURI="http://www.moleculin.com/role/IncomeTaxesDetails3" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#IncomeTaxesDetailsTextual" roleURI="http://www.moleculin.com/role/IncomeTaxesDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#CommitmentsAndContingenciesDetails" roleURI="http://www.moleculin.com/role/CommitmentsAndContingenciesDetails" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#CommitmentsAndContingenciesDetailsTextual" roleURI="http://www.moleculin.com/role/CommitmentsAndContingenciesDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#StatementsOfCashFlows" roleURI="http://www.moleculin.com/role/StatementsOfCashFlows" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#SubsequentEventsDetailsTextual" roleURI="http://www.moleculin.com/role/SubsequentEventsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#StatementsOfStockholdersEquity" roleURI="http://www.moleculin.com/role/StatementsOfStockholdersEquity" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#StatementsOfStockholdersEquityParenthetical" roleURI="http://www.moleculin.com/role/StatementsOfStockholdersEquityParenthetical" />

  <roleRef xlink:type="simple" xlink:href="mbrx-20161231.xsd#NatureOfBusinessAndLiquidity" roleURI="http://www.moleculin.com/role/NatureOfBusinessAndLiquidity" />

  <presentationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_DocumentAndEntityInformationAbstract" xlink:label="loc_mbrx_DocumentAndEntityInformationAbstract_2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_3" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DocumentAndEntityInformationAbstract_2" xlink:to="loc_dei_DocumentInformationTable_3" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_966" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_966" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_967" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_966" xlink:to="loc_us-gaap_ClassOfStockDomain_967" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_4" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_3" xlink:to="loc_dei_DocumentInformationLineItems_4" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_721" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentType_721" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_722" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_AmendmentFlag_722" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_723" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentPeriodEndDate_723" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_724" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentFiscalYearFocus_724" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_725" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentFiscalPeriodFocus_725" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_726" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityRegistrantName_726" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_727" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityCentralIndexKey_727" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_728" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_CurrentFiscalYearEndDate_728" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_729" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_729" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_730" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityVoluntaryFilers_730" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_731" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityCurrentReportingStatus_731" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_732" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityFilerCategory_732" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_733" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityPublicFloat_733" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_734" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_TradingSymbol_734" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_735" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_735" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/SummaryOfSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_783" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_784" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_783" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_784" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/IntangibleAssets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_483" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_484" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_483" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_484" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/ConvertibleNotesPayable">
    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ConvertibleNotesPayableAbstractAbstract" xlink:label="loc_mbrx_ConvertibleNotesPayableAbstractAbstract_160" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ConvertibleNotesPayableDisclosureTextBlock" xlink:label="loc_mbrx_ConvertibleNotesPayableDisclosureTextBlock_161" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_ConvertibleNotesPayableAbstractAbstract_160" xlink:to="loc_mbrx_ConvertibleNotesPayableDisclosureTextBlock_161" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/Equity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_209" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_212" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_209" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_212" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_327" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_328" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_327" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_328" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/CommitmentsAndContingencies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_277" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_278" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_277" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_278" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_213" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_214" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_213" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_214" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/BalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_18" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_17" xlink:to="loc_us-gaap_StatementTable_18" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_19" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_18" xlink:to="loc_us-gaap_StatementClassOfStockAxis_19" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_20" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_19" xlink:to="loc_us-gaap_ClassOfStockDomain_20" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_21" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_18" xlink:to="loc_us-gaap_StatementLineItems_21" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_30" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_21" xlink:to="loc_us-gaap_AssetsAbstract_30" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_22" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_30" xlink:to="loc_us-gaap_AssetsCurrentAbstract_22" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_38" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_22" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_38" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_422" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_22" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_422" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_423" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_22" xlink:to="loc_us-gaap_AssetsCurrent_423" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_426" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_30" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_426" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_424" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_426" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_424" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_429" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_426" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_429" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_43" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_30" xlink:to="loc_us-gaap_Assets_43" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_50" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_21" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_50" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_51" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_50" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_51" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_52" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_51" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_52" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_53" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_51" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_53" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_431" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_51" xlink:to="loc_us-gaap_LiabilitiesCurrent_431" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_432" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_50" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_432" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_55" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_50" xlink:to="loc_us-gaap_Liabilities_55" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_59" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_50" xlink:to="loc_us-gaap_CommitmentsAndContingencies_59" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_60" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_50" xlink:to="loc_us-gaap_StockholdersEquityAbstract_60" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_569" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_60" xlink:to="loc_us-gaap_PreferredStockValue_569" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_61" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_60" xlink:to="loc_us-gaap_CommonStockValue_61" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:label="loc_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_62" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_60" xlink:to="loc_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_62" use="optional" order="25" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_63" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_60" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_63" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_64" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_60" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_64" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_65" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_60" xlink:to="loc_us-gaap_StockholdersEquity_65" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_66" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_50" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_66" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_118" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_120" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_118" xlink:to="loc_us-gaap_UseOfEstimates_120" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_582" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_118" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_582" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_GoingConcernPolicyPolicyTextBlock" xlink:label="loc_mbrx_GoingConcernPolicyPolicyTextBlock_121" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_118" xlink:to="loc_mbrx_GoingConcernPolicyPolicyTextBlock_121" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_122" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_118" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_122" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_787" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_118" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_787" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_419" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_118" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_419" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_DebtInstrumentConvertibleBeneficialConversionFeaturePolicyPolicyTextBlock" xlink:label="loc_mbrx_DebtInstrumentConvertibleBeneficialConversionFeaturePolicyPolicyTextBlock_123" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_118" xlink:to="loc_mbrx_DebtInstrumentConvertibleBeneficialConversionFeaturePolicyPolicyTextBlock_123" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_129" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_118" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_129" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_124" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_118" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_124" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_125" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_118" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_125" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_126" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_118" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_126" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_127" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_118" xlink:to="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_127" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_128" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_118" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_128" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_786" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:label="loc_mbrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_973" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_786" xlink:to="loc_mbrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_973" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/IntangibleAssetsTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_487" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_499" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_487" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_499" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_599" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_487" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_599" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_500" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_487" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_500" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/ConvertibleNotesPayableTables">
    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ConvertibleNotesPayableAbstractAbstract" xlink:label="loc_mbrx_ConvertibleNotesPayableAbstractAbstract_162" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_163" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_ConvertibleNotesPayableAbstractAbstract_162" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_163" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/EquityTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_639" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_640" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_639" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_640" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_852" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_853" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_852" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_853" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_854" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_852" xlink:to="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_854" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_855" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_852" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_855" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_856" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_852" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_856" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/CommitmentsAndContingenciesTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_280" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_PatentAndTechnologyLicenseAgreementMilestonePaymentsTableTextBlock" xlink:label="loc_mbrx_PatentAndTechnologyLicenseAgreementMilestonePaymentsTableTextBlock_281" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_280" xlink:to="loc_mbrx_PatentAndTechnologyLicenseAgreementMilestonePaymentsTableTextBlock_281" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/BalanceSheetsParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_90" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_91" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_90" xlink:to="loc_us-gaap_StatementTable_91" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_92" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_91" xlink:to="loc_us-gaap_StatementClassOfStockAxis_92" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_93" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_92" xlink:to="loc_us-gaap_ClassOfStockDomain_93" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_94" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_91" xlink:to="loc_us-gaap_StatementLineItems_94" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_990" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_94" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_990" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_570" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_94" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_570" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_571" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_94" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_571" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_574" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_94" xlink:to="loc_us-gaap_PreferredStockSharesIssued_574" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_575" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_94" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_575" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_95" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_94" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_95" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_96" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_94" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_96" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_97" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_94" xlink:to="loc_us-gaap_CommonStockSharesIssued_97" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_98" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_94" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_98" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/NatureOfBusinessAndLiquidityDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_953" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_954" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_953" xlink:to="loc_us-gaap_StatementTable_954" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_955" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_954" xlink:to="loc_us-gaap_StatementClassOfStockAxis_955" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_956" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_955" xlink:to="loc_us-gaap_ClassOfStockDomain_956" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_957" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_954" xlink:to="loc_dei_LegalEntityAxis_957" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_960" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_957" xlink:to="loc_dei_EntityDomain_960" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_AnnamedIncMember" xlink:label="loc_mbrx_AnnamedIncMember_961" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_960" xlink:to="loc_mbrx_AnnamedIncMember_961" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_IntertechbioCorporationMember" xlink:label="loc_mbrx_IntertechbioCorporationMember_965" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_960" xlink:to="loc_mbrx_IntertechbioCorporationMember_965" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_959" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_954" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_959" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_963" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_959" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_963" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseRightsMember" xlink:label="loc_us-gaap_UseRightsMember_964" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_963" xlink:to="loc_us-gaap_UseRightsMember_964" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_962" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_954" xlink:to="loc_us-gaap_StatementLineItems_962" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_958" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_962" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_958" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_70" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_71" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_70" xlink:to="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_71" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_73" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_71" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_73" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_83" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_73" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_83" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_72" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_71" xlink:to="loc_dei_LegalEntityAxis_72" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_74" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_72" xlink:to="loc_dei_EntityDomain_74" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_82" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_71" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_82" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_86" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_82" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_86" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_87" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_86" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_87" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_85" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_71" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_85" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_577" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_85" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_577" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_578" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_577" xlink:to="loc_us-gaap_EmployeeStockOptionMember_578" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_576" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_71" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_576" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_580" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_576" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_580" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_581" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_580" xlink:to="loc_us-gaap_WarrantMember_581" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_579" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_71" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_579" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_664" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_579" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_664" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_663" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_71" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_663" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_790" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_663" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_790" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_791" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_790" xlink:to="loc_us-gaap_ComputerEquipmentMember_791" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_792" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_790" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_792" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_793" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_790" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_793" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_798" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_790" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_798" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_789" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_71" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_789" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_795" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_789" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_795" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_MoleculinLlcMember" xlink:label="loc_mbrx_MoleculinLlcMember_796" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_795" xlink:to="loc_mbrx_MoleculinLlcMember_796" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_794" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_71" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_794" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanAssetCategoriesDomain" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_801" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_794" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_801" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_800" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_71" xlink:to="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_800" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_80" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_800" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_80" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_81" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_800" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_81" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaap_CashUninsuredAmount_526" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_800" xlink:to="loc_us-gaap_CashUninsuredAmount_526" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaap_CashFDICInsuredAmount_634" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_800" xlink:to="loc_us-gaap_CashFDICInsuredAmount_634" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_788" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_800" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_788" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_797" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_800" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_797" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/IntangibleAssetsDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_454" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationSegmentAllocationTable" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationTable_457" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_454" xlink:to="loc_us-gaap_BusinessCombinationSegmentAllocationTable_457" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_458" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationTable_457" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_458" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_558" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_458" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_558" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_MoleculinLlcMember" xlink:label="loc_mbrx_MoleculinLlcMember_559" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_558" xlink:to="loc_mbrx_MoleculinLlcMember_559" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_557" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationTable_457" xlink:to="loc_dei_LegalEntityAxis_557" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_716" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_557" xlink:to="loc_dei_EntityDomain_716" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_HoustonPharmaceuticalsIncMember" xlink:label="loc_mbrx_HoustonPharmaceuticalsIncMember_717" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_716" xlink:to="loc_mbrx_HoustonPharmaceuticalsIncMember_717" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_715" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationTable_457" xlink:to="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_715" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_461" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_715" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_461" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_600" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_715" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_600" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_601" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_715" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_601" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_464" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_715" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_464" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_465" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_715" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_465" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_978" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_715" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_978" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_466" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_715" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_466" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/IntangibleAssetsDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_603" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationSegmentAllocationTable" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationTable_604" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_603" xlink:to="loc_us-gaap_BusinessCombinationSegmentAllocationTable_604" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_605" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationTable_604" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_605" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_608" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_605" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_608" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherIntangibleAssetsMember" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_610" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_608" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_610" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_607" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationTable_604" xlink:to="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_607" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_606" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_607" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_606" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/IntangibleAssetsDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationAbstract_468" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable_469" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationAbstract_468" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable_469" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_566" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable_469" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_566" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_567" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_566" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_567" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems_470" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable_469" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems_470" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_BusinessAcquistionProFormaOperatingExpenses" xlink:label="loc_mbrx_BusinessAcquistionProFormaOperatingExpenses_472" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems_470" xlink:to="loc_mbrx_BusinessAcquistionProFormaOperatingExpenses_472" use="optional" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_478" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems_470" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_478" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" xlink:label="loc_mbrx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_482" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems_470" xlink:to="loc_mbrx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_482" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:label="loc_mbrx_BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted_485" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems_470" xlink:to="loc_mbrx_BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted_485" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/IntangibleAssetsDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_489" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_490" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_489" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_490" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_491" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_490" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_491" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_494" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_491" xlink:to="loc_us-gaap_EquityComponentDomain_494" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_495" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_494" xlink:to="loc_us-gaap_CommonStockMember_495" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_493" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_490" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_493" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_497" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_493" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_497" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_MoleculinLlcMember" xlink:label="loc_mbrx_MoleculinLlcMember_501" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_497" xlink:to="loc_mbrx_MoleculinLlcMember_501" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_496" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_490" xlink:to="loc_us-gaap_TitleOfIndividualAxis_496" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_507" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_496" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_507" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_506" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_490" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_506" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_510" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_506" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_510" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_LicenseAgreementMember" xlink:label="loc_mbrx_LicenseAgreementMember_516" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_510" xlink:to="loc_mbrx_LicenseAgreementMember_516" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_OutlincenseAgreementMember" xlink:label="loc_mbrx_OutlincenseAgreementMember_517" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_510" xlink:to="loc_mbrx_OutlincenseAgreementMember_517" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_509" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_490" xlink:to="loc_dei_LegalEntityAxis_509" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_513" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_509" xlink:to="loc_dei_EntityDomain_513" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_HoustonPharmaceuticalsIncMember" xlink:label="loc_mbrx_HoustonPharmaceuticalsIncMember_515" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_513" xlink:to="loc_mbrx_HoustonPharmaceuticalsIncMember_515" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_512" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_490" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_512" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_620" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_512" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_620" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_619" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_490" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_619" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_622" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_619" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_622" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_PeriodTypeAxis" xlink:label="loc_mbrx_PeriodTypeAxis_621" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_490" xlink:to="loc_mbrx_PeriodTypeAxis_621" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_PeriodTypeDomain" xlink:label="loc_mbrx_PeriodTypeDomain_705" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_PeriodTypeAxis_621" xlink:to="loc_mbrx_PeriodTypeDomain_705" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_AcquisitionDateOneMember" xlink:label="loc_mbrx_AcquisitionDateOneMember_706" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_PeriodTypeDomain_705" xlink:to="loc_mbrx_AcquisitionDateOneMember_706" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_704" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_490" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_704" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_492" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_704" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_492" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesReceivableRelatedParties" xlink:label="loc_us-gaap_NotesReceivableRelatedParties_503" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_704" xlink:to="loc_us-gaap_NotesReceivableRelatedParties_503" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_504" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_704" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_504" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_522" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_704" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_522" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_LicencingArrangementsConsiderationPayable" xlink:label="loc_mbrx_LicencingArrangementsConsiderationPayable_561" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_704" xlink:to="loc_mbrx_LicencingArrangementsConsiderationPayable_561" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_LicencingArrangementsReserve" xlink:label="loc_mbrx_LicencingArrangementsReserve_562" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_704" xlink:to="loc_mbrx_LicencingArrangementsReserve_562" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_563" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_704" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_563" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_613" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_704" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_613" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_RoyaltyOnNetRevenues" xlink:label="loc_mbrx_RoyaltyOnNetRevenues_627" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_704" xlink:to="loc_mbrx_RoyaltyOnNetRevenues_627" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_AccruedLicenseAgreementPayment" xlink:label="loc_mbrx_AccruedLicenseAgreementPayment_629" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_704" xlink:to="loc_mbrx_AccruedLicenseAgreementPayment_629" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_703" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_704" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_703" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_719" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_704" xlink:to="loc_us-gaap_SharePrice_719" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_970" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_704" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_970" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable" xlink:label="loc_mbrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable_1003" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_704" xlink:to="loc_mbrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable_1003" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/ConvertibleNotesPayableDetails">
    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ConvertibleNotesPayableAbstractAbstract" xlink:label="loc_mbrx_ConvertibleNotesPayableAbstractAbstract_164" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_165" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_ConvertibleNotesPayableAbstractAbstract_164" xlink:to="loc_us-gaap_StatementTable_165" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_166" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_165" xlink:to="loc_us-gaap_StatementClassOfStockAxis_166" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_167" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_166" xlink:to="loc_us-gaap_ClassOfStockDomain_167" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_168" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_165" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_168" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_170" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_168" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_170" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaap_InvestorMember_172" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_170" xlink:to="loc_us-gaap_InvestorMember_172" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_InvestorBMember" xlink:label="loc_mbrx_InvestorBMember_171" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_170" xlink:to="loc_mbrx_InvestorBMember_171" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_InvestorCMember" xlink:label="loc_mbrx_InvestorCMember_173" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_170" xlink:to="loc_mbrx_InvestorCMember_173" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_InvestorDMember" xlink:label="loc_mbrx_InvestorDMember_349" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_170" xlink:to="loc_mbrx_InvestorDMember_349" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_InvestorEMember" xlink:label="loc_mbrx_InvestorEMember_350" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_170" xlink:to="loc_mbrx_InvestorEMember_350" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_InvestorFMember" xlink:label="loc_mbrx_InvestorFMember_809" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_170" xlink:to="loc_mbrx_InvestorFMember_809" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_InvestorGMember" xlink:label="loc_mbrx_InvestorGMember_811" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_170" xlink:to="loc_mbrx_InvestorGMember_811" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_169" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_165" xlink:to="loc_us-gaap_DebtInstrumentAxis_169" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_175" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_169" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_175" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_IssueDateAugust312015Member" xlink:label="loc_mbrx_IssueDateAugust312015Member_176" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_175" xlink:to="loc_mbrx_IssueDateAugust312015Member_176" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_IssueDateSeptember032015Member" xlink:label="loc_mbrx_IssueDateSeptember032015Member_177" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_175" xlink:to="loc_mbrx_IssueDateSeptember032015Member_177" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_IssueDateOctober062015OneMember" xlink:label="loc_mbrx_IssueDateOctober062015OneMember_178" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_175" xlink:to="loc_mbrx_IssueDateOctober062015OneMember_178" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_IssueDateOctober062015TwoMember" xlink:label="loc_mbrx_IssueDateOctober062015TwoMember_179" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_175" xlink:to="loc_mbrx_IssueDateOctober062015TwoMember_179" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_IssueDateOctober282015Member" xlink:label="loc_mbrx_IssueDateOctober282015Member_180" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_175" xlink:to="loc_mbrx_IssueDateOctober282015Member_180" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_IssueDateJanuary142016Member" xlink:label="loc_mbrx_IssueDateJanuary142016Member_181" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_175" xlink:to="loc_mbrx_IssueDateJanuary142016Member_181" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_IssueDateJanuary192016Member" xlink:label="loc_mbrx_IssueDateJanuary192016Member_182" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_175" xlink:to="loc_mbrx_IssueDateJanuary192016Member_182" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_174" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_165" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_174" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_988" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_174" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_988" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_989" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_988" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_989" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_987" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_165" xlink:to="loc_us-gaap_StatementLineItems_987" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentIssuanceDate1" xlink:label="loc_us-gaap_DebtInstrumentIssuanceDate1_183" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_987" xlink:to="loc_us-gaap_DebtInstrumentIssuanceDate1_183" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_184" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_987" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_184" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_351" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_987" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_351" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_DebtInstrumentConvertibleNumberOfCommonShares" xlink:label="loc_mbrx_DebtInstrumentConvertibleNumberOfCommonShares_400" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_987" xlink:to="loc_mbrx_DebtInstrumentConvertibleNumberOfCommonShares_400" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/ConvertibleNotesPayableDetailsTextual">
    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ConvertibleNotesPayableAbstractAbstract" xlink:label="loc_mbrx_ConvertibleNotesPayableAbstractAbstract_187" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_188" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_ConvertibleNotesPayableAbstractAbstract_187" xlink:to="loc_us-gaap_StatementTable_188" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_189" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_188" xlink:to="loc_us-gaap_StatementClassOfStockAxis_189" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_190" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_189" xlink:to="loc_us-gaap_ClassOfStockDomain_190" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_191" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_188" xlink:to="loc_us-gaap_DebtInstrumentAxis_191" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_193" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_191" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_193" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_UnsecuredPromissoryNotesMember" xlink:label="loc_mbrx_UnsecuredPromissoryNotesMember_564" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_193" xlink:to="loc_mbrx_UnsecuredPromissoryNotesMember_564" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_192" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_188" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_192" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_197" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_192" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_197" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_196" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_188" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_196" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_200" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_196" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_200" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_201" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_200" xlink:to="loc_us-gaap_IPOMember_201" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_199" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_188" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_199" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_842" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_199" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_842" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_843" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_842" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_843" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_841" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_188" xlink:to="loc_us-gaap_StatementLineItems_841" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_202" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_841" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_202" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_203" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_841" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_203" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_206" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_841" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_206" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_DebtConversionConvertedInstrumentCommonStockSharesIssuedTradingRestrictionsDescription" xlink:label="loc_mbrx_DebtConversionConvertedInstrumentCommonStockSharesIssuedTradingRestrictionsDescription_352" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_841" xlink:to="loc_mbrx_DebtConversionConvertedInstrumentCommonStockSharesIssuedTradingRestrictionsDescription_352" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_DebtConversionConvertedInstrumentAdditionalSharesIssued" xlink:label="loc_mbrx_DebtConversionConvertedInstrumentAdditionalSharesIssued_387" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_841" xlink:to="loc_mbrx_DebtConversionConvertedInstrumentAdditionalSharesIssued_387" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_445" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_841" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_445" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_446" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_841" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_446" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_447" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_841" xlink:to="loc_us-gaap_InterestPayableCurrent_447" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/EquityDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_662" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_666" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_662" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_666" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_668" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_666" xlink:to="loc_us-gaap_StatementClassOfStockAxis_668" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_669" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_668" xlink:to="loc_us-gaap_ClassOfStockDomain_669" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_670" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_666" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_670" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_671" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_670" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_671" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_673" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_670" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_673" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_674" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_670" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_674" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_672" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_670" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_672" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_687" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_670" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_687" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_980" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_670" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_980" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_981" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_670" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_981" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_982" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_670" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_982" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_983" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_670" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_983" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:label="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_986" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_670" xlink:to="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_986" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_675" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_670" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_675" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_677" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_670" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_677" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_678" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_670" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_678" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/negativeLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_676" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_670" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_676" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_688" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_670" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_688" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_679" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_670" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_679" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_689" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_670" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_689" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_684" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_670" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_684" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_690" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_670" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_690" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/StatementsOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_100" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_101" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_100" xlink:to="loc_us-gaap_StatementTable_101" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_102" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_101" xlink:to="loc_us-gaap_StatementClassOfStockAxis_102" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_103" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_102" xlink:to="loc_us-gaap_ClassOfStockDomain_103" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_104" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_101" xlink:to="loc_us-gaap_StatementLineItems_104" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_105" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_104" xlink:to="loc_us-gaap_SalesRevenueNet_105" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_106" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_104" xlink:to="loc_us-gaap_OperatingExpensesAbstract_106" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_107" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_106" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_107" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_108" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_106" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_108" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_441" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_106" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_441" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_109" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_106" xlink:to="loc_us-gaap_OperatingExpenses_109" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_110" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_104" xlink:to="loc_us-gaap_OperatingIncomeLoss_110" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_111" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_104" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_111" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_112" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_111" xlink:to="loc_us-gaap_InterestExpense_112" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_113" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_104" xlink:to="loc_us-gaap_NetIncomeLoss_113" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_114" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_104" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_114" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_115" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_104" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_115" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/EquityDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_217" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_218" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_217" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_218" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_220" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_218" xlink:to="loc_us-gaap_TitleOfIndividualAxis_220" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_223" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_220" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_223" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_DirectorAndOfficersMember" xlink:label="loc_mbrx_DirectorAndOfficersMember_224" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_223" xlink:to="loc_mbrx_DirectorAndOfficersMember_224" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_EmployeeAndBoardOfDirectorsMember" xlink:label="loc_mbrx_EmployeeAndBoardOfDirectorsMember_656" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_223" xlink:to="loc_mbrx_EmployeeAndBoardOfDirectorsMember_656" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ChiefFinancialOfficerMember" xlink:label="loc_us-gaap_ChiefFinancialOfficerMember_1001" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_223" xlink:to="loc_us-gaap_ChiefFinancialOfficerMember_1001" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_222" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_218" xlink:to="loc_us-gaap_AwardTypeAxis_222" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_227" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_222" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_227" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_StockPlanMember" xlink:label="loc_mbrx_StockPlanMember_228" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_227" xlink:to="loc_mbrx_StockPlanMember_228" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_226" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_218" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_226" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_232" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_226" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_232" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_230" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_218" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_230" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_439" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_230" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_439" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_440" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_439" xlink:to="loc_us-gaap_IPOMember_440" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_438" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_218" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_438" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_590" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_438" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_590" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_591" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_590" xlink:to="loc_us-gaap_WarrantMember_591" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_589" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_218" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_589" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_594" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_589" xlink:to="loc_us-gaap_RelatedPartyDomain_594" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_PcgAdvisoryGroupMember" xlink:label="loc_mbrx_PcgAdvisoryGroupMember_595" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_594" xlink:to="loc_mbrx_PcgAdvisoryGroupMember_595" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_593" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_218" xlink:to="loc_us-gaap_RangeAxis_593" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_658" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_593" xlink:to="loc_us-gaap_RangeMember_658" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_659" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_658" xlink:to="loc_us-gaap_MaximumMember_659" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_660" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_658" xlink:to="loc_us-gaap_MinimumMember_660" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_657" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_218" xlink:to="loc_dei_LegalEntityAxis_657" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_995" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_657" xlink:to="loc_dei_EntityDomain_995" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_IntertechbioCorporationMember" xlink:label="loc_mbrx_IntertechbioCorporationMember_996" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_995" xlink:to="loc_mbrx_IntertechbioCorporationMember_996" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_AnnamedIncMember" xlink:label="loc_mbrx_AnnamedIncMember_999" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_995" xlink:to="loc_mbrx_AnnamedIncMember_999" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_994" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_218" xlink:to="loc_us-gaap_ClassOfStockLineItems_994" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_237" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_237" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_238" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_238" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_242" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_242" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_344" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_344" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_346" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_346" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_354" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_354" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_355" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_ShareBasedCompensation_355" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable" xlink:label="loc_mbrx_ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable_433" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_mbrx_ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable_433" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_434" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_434" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_435" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_435" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_436" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_436" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_437" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_437" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_CommonStockLockupAndLeakoutAgreementsDescription" xlink:label="loc_mbrx_CommonStockLockupAndLeakoutAgreementsDescription_442" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_mbrx_CommonStockLockupAndLeakoutAgreementsDescription_442" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_SharesAuthorized" xlink:label="loc_mbrx_SharesAuthorized_583" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_mbrx_SharesAuthorized_583" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_584" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_584" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_585" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_585" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="loc_us-gaap_FairValueInputsDiscountRate_586" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_FairValueInputsDiscountRate_586" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_587" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_587" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_588" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_588" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_644" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_644" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_645" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_645" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_647" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_647" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_649" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_649" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_650" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_650" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_651" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_651" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_652" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_652" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_654" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_654" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_691" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_691" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_991" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_991" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_EstimatedForfeitureRatePercentage" xlink:label="loc_mbrx_EstimatedForfeitureRatePercentage_992" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_mbrx_EstimatedForfeitureRatePercentage_992" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_997" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_997" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_998" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_998" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_1000" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_1000" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1002" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_994" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1002" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_891" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_892" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_891" xlink:to="loc_us-gaap_StatementTable_892" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_893" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_892" xlink:to="loc_us-gaap_StatementClassOfStockAxis_893" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_894" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_893" xlink:to="loc_us-gaap_ClassOfStockDomain_894" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_895" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_892" xlink:to="loc_us-gaap_StatementLineItems_895" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_911" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_895" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_911" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_912" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_911" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_912" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_913" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_911" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_913" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_914" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_911" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_914" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_915" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_895" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_915" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_916" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_915" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_916" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_917" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_915" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_917" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_918" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_915" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_918" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_919" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_915" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_919" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/IncomeTaxesDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_896" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_897" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_896" xlink:to="loc_us-gaap_StatementTable_897" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_898" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_897" xlink:to="loc_us-gaap_StatementClassOfStockAxis_898" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_899" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_898" xlink:to="loc_us-gaap_ClassOfStockDomain_899" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_900" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_897" xlink:to="loc_us-gaap_StatementLineItems_900" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_920" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_900" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_920" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_921" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_900" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_921" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_DeferredTaxAssetsValuationAllowanceReleases" xlink:label="loc_mbrx_DeferredTaxAssetsValuationAllowanceReleases_922" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_900" xlink:to="loc_mbrx_DeferredTaxAssetsValuationAllowanceReleases_922" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_923" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_900" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_923" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/IncomeTaxesDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_901" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_902" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_901" xlink:to="loc_us-gaap_StatementTable_902" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_903" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_902" xlink:to="loc_us-gaap_StatementClassOfStockAxis_903" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_904" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_903" xlink:to="loc_us-gaap_ClassOfStockDomain_904" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_905" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_902" xlink:to="loc_us-gaap_StatementLineItems_905" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_924" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_905" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_924" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_925" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_905" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_925" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost" xlink:label="loc_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost_926" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_905" xlink:to="loc_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost_926" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_927" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_905" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_927" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_928" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_905" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_928" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_929" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_905" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_929" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_930" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_905" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_930" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_931" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_905" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_931" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent" xlink:label="loc_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent_932" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_905" xlink:to="loc_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent_932" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_933" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_905" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_933" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_934" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_905" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_934" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_935" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_905" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_935" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/IncomeTaxesDetails3">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_906" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_907" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_906" xlink:to="loc_us-gaap_StatementTable_907" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_908" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_907" xlink:to="loc_us-gaap_StatementClassOfStockAxis_908" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_909" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_908" xlink:to="loc_us-gaap_ClassOfStockDomain_909" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_910" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_907" xlink:to="loc_us-gaap_StatementLineItems_910" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_936" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_910" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_936" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_DeferredTaxAssetsStartUpCosts" xlink:label="loc_mbrx_DeferredTaxAssetsStartUpCosts_937" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_936" xlink:to="loc_mbrx_DeferredTaxAssetsStartUpCosts_937" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_938" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_936" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_938" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_939" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_936" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_939" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_940" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_936" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_940" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_941" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_936" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_941" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_942" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_936" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_942" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_943" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_936" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_943" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_944" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_910" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_944" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_945" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_944" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_945" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_946" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_944" xlink:to="loc_us-gaap_DeferredTaxLiabilities_946" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_947" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_944" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_947" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/IncomeTaxesDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_330" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_331" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_330" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_331" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_332" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_331" xlink:to="loc_us-gaap_StatementClassOfStockAxis_332" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_333" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_332" xlink:to="loc_us-gaap_ClassOfStockDomain_333" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_334" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_331" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_334" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_950" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_334" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_950" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_951" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_950" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_951" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_949" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_331" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_949" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_337" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_949" xlink:to="loc_us-gaap_OperatingLossCarryforwards_337" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_OperatingLossCarryforwardsExpirationPeriod" xlink:label="loc_mbrx_OperatingLossCarryforwardsExpirationPeriod_338" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_949" xlink:to="loc_mbrx_OperatingLossCarryforwardsExpirationPeriod_338" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_948" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_949" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_948" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/CommitmentsAndContingenciesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_283" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_CommitmentsAndContingenciesTable" xlink:label="loc_mbrx_CommitmentsAndContingenciesTable_284" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_283" xlink:to="loc_mbrx_CommitmentsAndContingenciesTable_284" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_285" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_CommitmentsAndContingenciesTable_284" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_285" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_288" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_285" xlink:to="loc_us-gaap_ProjectMember_288" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_CommencementOfPhaseIiStudyForLicensedProductMember" xlink:label="loc_mbrx_CommencementOfPhaseIiStudyForLicensedProductMember_289" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_288" xlink:to="loc_mbrx_CommencementOfPhaseIiStudyForLicensedProductMember_289" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember" xlink:label="loc_mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember_290" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_288" xlink:to="loc_mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember_290" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_FilingOfNewDrugApplicationForLicensedProductMember" xlink:label="loc_mbrx_FilingOfNewDrugApplicationForLicensedProductMember_291" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_288" xlink:to="loc_mbrx_FilingOfNewDrugApplicationForLicensedProductMember_291" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ReceiptOfMarketApprovalForLicensedProductMember" xlink:label="loc_mbrx_ReceiptOfMarketApprovalForLicensedProductMember_292" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_288" xlink:to="loc_mbrx_ReceiptOfMarketApprovalForLicensedProductMember_292" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_CommitmentsAndContingenciesLineItems" xlink:label="loc_mbrx_CommitmentsAndContingenciesLineItems_287" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_CommitmentsAndContingenciesTable_284" xlink:to="loc_mbrx_CommitmentsAndContingenciesLineItems_287" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_MilestonePaymentsLiabilities" xlink:label="loc_mbrx_MilestonePaymentsLiabilities_389" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_CommitmentsAndContingenciesLineItems_287" xlink:to="loc_mbrx_MilestonePaymentsLiabilities_389" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/CommitmentsAndContingenciesDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_294" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_295" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_294" xlink:to="loc_us-gaap_LossContingenciesTable_295" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_AgreementAxis" xlink:label="loc_mbrx_AgreementAxis_305" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_295" xlink:to="loc_mbrx_AgreementAxis_305" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_AgreementDomain" xlink:label="loc_mbrx_AgreementDomain_309" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_AgreementAxis_305" xlink:to="loc_mbrx_AgreementDomain_309" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_PatentAndTechnologyLicenseAgreementMember" xlink:label="loc_mbrx_PatentAndTechnologyLicenseAgreementMember_310" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_AgreementDomain_309" xlink:to="loc_mbrx_PatentAndTechnologyLicenseAgreementMember_310" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_297" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_295" xlink:to="loc_us-gaap_TitleOfIndividualAxis_297" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_306" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_297" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_306" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_MdAndersonMember" xlink:label="loc_mbrx_MdAndersonMember_307" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_306" xlink:to="loc_mbrx_MdAndersonMember_307" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaap_ChiefExecutiveOfficerMember_711" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_306" xlink:to="loc_us-gaap_ChiefExecutiveOfficerMember_711" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ChiefFinancialOfficerAndExecutiveVicePresidentMember" xlink:label="loc_mbrx_ChiefFinancialOfficerAndExecutiveVicePresidentMember_874" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_306" xlink:to="loc_mbrx_ChiefFinancialOfficerAndExecutiveVicePresidentMember_874" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_AnniversaryAxis" xlink:label="loc_mbrx_AnniversaryAxis_296" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_295" xlink:to="loc_mbrx_AnniversaryAxis_296" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_AnniversaryDomain" xlink:label="loc_mbrx_AnniversaryDomain_298" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_AnniversaryAxis_296" xlink:to="loc_mbrx_AnniversaryDomain_298" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_308" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_295" xlink:to="loc_dei_LegalEntityAxis_308" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_315" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_308" xlink:to="loc_dei_EntityDomain_315" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_PatentLawFirmMember" xlink:label="loc_mbrx_PatentLawFirmMember_316" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_315" xlink:to="loc_mbrx_PatentLawFirmMember_316" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_BonwickCapitalPartnersLlcMember" xlink:label="loc_mbrx_BonwickCapitalPartnersLlcMember_323" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_315" xlink:to="loc_mbrx_BonwickCapitalPartnersLlcMember_323" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_314" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_295" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_314" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_320" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_314" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_320" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaap_OtherCommitmentsAxis_319" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_295" xlink:to="loc_us-gaap_OtherCommitmentsAxis_319" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaap_OtherCommitmentsDomain_361" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_319" xlink:to="loc_us-gaap_OtherCommitmentsDomain_361" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ServicingFeePayableMember" xlink:label="loc_mbrx_ServicingFeePayableMember_362" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_361" xlink:to="loc_mbrx_ServicingFeePayableMember_362" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_MinimumFeeAndPatentExpensesMember" xlink:label="loc_mbrx_MinimumFeeAndPatentExpensesMember_363" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_361" xlink:to="loc_mbrx_MinimumFeeAndPatentExpensesMember_363" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_MinimumAnnualRoyaltyMember" xlink:label="loc_mbrx_MinimumAnnualRoyaltyMember_371" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_361" xlink:to="loc_mbrx_MinimumAnnualRoyaltyMember_371" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_LetterAgreementMember" xlink:label="loc_mbrx_LetterAgreementMember_542" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_361" xlink:to="loc_mbrx_LetterAgreementMember_542" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_360" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_295" xlink:to="loc_us-gaap_RangeAxis_360" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_380" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_360" xlink:to="loc_us-gaap_RangeMember_380" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_381" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_380" xlink:to="loc_us-gaap_MaximumMember_381" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_RevenueRecognitionMilestoneMethodAxis" xlink:label="loc_mbrx_RevenueRecognitionMilestoneMethodAxis_379" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_295" xlink:to="loc_mbrx_RevenueRecognitionMilestoneMethodAxis_379" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_RevenueRecognitionMilestoneMethodDomain" xlink:label="loc_mbrx_RevenueRecognitionMilestoneMethodDomain_534" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_RevenueRecognitionMilestoneMethodAxis_379" xlink:to="loc_mbrx_RevenueRecognitionMilestoneMethodDomain_534" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_533" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_295" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_533" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_545" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_533" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_545" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_MoleculinLlcMember" xlink:label="loc_mbrx_MoleculinLlcMember_546" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_545" xlink:to="loc_mbrx_MoleculinLlcMember_546" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_544" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_295" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_544" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_549" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_544" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_549" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_550" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_549" xlink:to="loc_us-gaap_IPOMember_550" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_548" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_295" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_548" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_713" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_548" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_713" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_712" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_295" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_712" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_879" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_712" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_879" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_880" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_879" xlink:to="loc_us-gaap_EmployeeStockOptionMember_880" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_878" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_295" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_878" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_883" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_878" xlink:to="loc_us-gaap_RelatedPartyDomain_883" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_MrLouisMember" xlink:label="loc_mbrx_MrLouisMember_884" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_883" xlink:to="loc_mbrx_MrLouisMember_884" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_882" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_295" xlink:to="loc_us-gaap_LossContingenciesLineItems_882" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_LetterAgreementsTerms" xlink:label="loc_mbrx_LetterAgreementsTerms_324" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_mbrx_LetterAgreementsTerms_324" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_364" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_364" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="loc_us-gaap_ContractualObligationDueInSecondYear_365" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_ContractualObligationDueInSecondYear_365" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="loc_us-gaap_ContractualObligationDueInThirdYear_366" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_ContractualObligationDueInThirdYear_366" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="loc_us-gaap_ContractualObligationDueInFourthYear_367" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_ContractualObligationDueInFourthYear_367" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInFifthYear" xlink:label="loc_us-gaap_ContractualObligationDueInFifthYear_368" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_ContractualObligationDueInFifthYear_368" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueAfterFifthYear" xlink:label="loc_us-gaap_ContractualObligationDueAfterFifthYear_369" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_ContractualObligationDueAfterFifthYear_369" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_370" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_ContractualObligation_370" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_SuccessFeePercentage" xlink:label="loc_mbrx_SuccessFeePercentage_372" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_mbrx_SuccessFeePercentage_372" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ClassOfWarrantOrRightPercentageOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_mbrx_ClassOfWarrantOrRightPercentageOfSecuritiesCalledByWarrantsOrRights_373" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_mbrx_ClassOfWarrantOrRightPercentageOfSecuritiesCalledByWarrantsOrRights_373" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ClassOfWarrantOrRightExercisePricePercentageThreshold" xlink:label="loc_mbrx_ClassOfWarrantOrRightExercisePricePercentageThreshold_374" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_mbrx_ClassOfWarrantOrRightExercisePricePercentageThreshold_374" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ReimbursementPayableOfferingCosts" xlink:label="loc_mbrx_ReimbursementPayableOfferingCosts_376" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_mbrx_ReimbursementPayableOfferingCosts_376" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ReimbursementPayableFeesAndExpensesOfCounsel" xlink:label="loc_mbrx_ReimbursementPayableFeesAndExpensesOfCounsel_377" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_mbrx_ReimbursementPayableFeesAndExpensesOfCounsel_377" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:label="loc_us-gaap_PaymentsForUnderwritingExpense_378" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_PaymentsForUnderwritingExpense_378" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ContractualObligationDueInNextFiscalYearAfterProductApproval" xlink:label="loc_mbrx_ContractualObligationDueInNextFiscalYearAfterProductApproval_405" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_mbrx_ContractualObligationDueInNextFiscalYearAfterProductApproval_405" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ContractualObligationDueInSecondYearAfterProductApproval" xlink:label="loc_mbrx_ContractualObligationDueInSecondYearAfterProductApproval_406" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_mbrx_ContractualObligationDueInSecondYearAfterProductApproval_406" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ContractualObligationDueInThirdYearAfterProductApproval" xlink:label="loc_mbrx_ContractualObligationDueInThirdYearAfterProductApproval_407" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_mbrx_ContractualObligationDueInThirdYearAfterProductApproval_407" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaap_PaymentsForRoyalties_529" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_PaymentsForRoyalties_529" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_LicenseAgreementMaintenanceFee" xlink:label="loc_mbrx_LicenseAgreementMaintenanceFee_531" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_mbrx_LicenseAgreementMaintenanceFee_531" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_LicenseAgreementMaintenanceFeeAnnualIncrease" xlink:label="loc_mbrx_LicenseAgreementMaintenanceFeeAnnualIncrease_532" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_mbrx_LicenseAgreementMaintenanceFeeAnnualIncrease_532" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaap_PaymentsForFees_547" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_PaymentsForFees_547" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ReimburementOfExpenses" xlink:label="loc_mbrx_ReimburementOfExpenses_551" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_mbrx_ReimburementOfExpenses_551" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_552" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_552" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_553" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_553" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_554" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_554" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_556" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_556" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_565" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_565" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_LicenseAgreementMaintenanceFeeMaximumPayablePerYear" xlink:label="loc_mbrx_LicenseAgreementMaintenanceFeeMaximumPayablePerYear_631" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_mbrx_LicenseAgreementMaintenanceFeeMaximumPayablePerYear_631" use="optional" order="71" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_709" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_OfficersCompensation_709" use="optional" order="72" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_710" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_710" use="optional" order="73" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1_875" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1_875" use="optional" order="74" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued_876" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued_876" use="optional" order="75" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice_877" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice_877" use="optional" order="76" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_881" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_881" use="optional" order="77" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_885" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_us-gaap_SeveranceCosts1_885" use="optional" order="78" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_SeparationAgreementDescription" xlink:label="loc_mbrx_SeparationAgreementDescription_886" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_mbrx_SeparationAgreementDescription_886" use="optional" order="79" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_MilestonePaymentDescription" xlink:label="loc_mbrx_MilestonePaymentDescription_969" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_882" xlink:to="loc_mbrx_MilestonePaymentDescription_969" use="optional" order="80" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/StatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_25" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_24" xlink:to="loc_us-gaap_StatementTable_25" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_26" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_25" xlink:to="loc_us-gaap_StatementClassOfStockAxis_26" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_27" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_26" xlink:to="loc_us-gaap_ClassOfStockDomain_27" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_28" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_25" xlink:to="loc_us-gaap_StatementLineItems_28" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_31" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_31" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_32" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_31" xlink:to="loc_us-gaap_NetIncomeLoss_32" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_33" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_31" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_33" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_444" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_33" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_444" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_34" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_33" xlink:to="loc_us-gaap_ShareBasedCompensation_34" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_974" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_33" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_974" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_SharesIssuedForLicensesUsedForResearchAndDevelopment" xlink:label="loc_mbrx_SharesIssuedForLicensesUsedForResearchAndDevelopment_700" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_33" xlink:to="loc_mbrx_SharesIssuedForLicensesUsedForResearchAndDevelopment_700" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_35" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_33" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_35" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_448" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_35" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_448" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_36" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_35" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_36" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_37" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_31" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_37" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_40" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_40" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_635" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_40" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_635" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_449" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_40" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_449" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_42" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_40" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_42" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_44" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_44" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_626" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_44" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_626" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_453" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_44" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_453" use="optional" order="22" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_451" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_44" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_451" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_47" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_44" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_47" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_48" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_48" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_49" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_49" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_54" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_54" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_56" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_56" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_57" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_56" xlink:to="loc_us-gaap_InterestPaid_57" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_58" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_56" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_58" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_455" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_455" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_456" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_455" xlink:to="loc_us-gaap_StockIssued1_456" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_459" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_455" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_459" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_WarrantsIssuedForServices" xlink:label="loc_mbrx_WarrantsIssuedForServices_975" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_455" xlink:to="loc_mbrx_WarrantsIssuedForServices_975" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_976" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_455" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_976" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_SharesSubscribed" xlink:label="loc_mbrx_SharesSubscribed_702" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_455" xlink:to="loc_mbrx_SharesSubscribed_702" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/SubsequentEventsDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_249" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_250" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_249" xlink:to="loc_us-gaap_SubsequentEventTable_250" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_251" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_250" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_251" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_255" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_251" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_255" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_256" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_255" xlink:to="loc_us-gaap_SubsequentEventMember_256" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_254" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_250" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_254" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_259" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_254" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_259" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_258" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_250" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_258" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_273" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_258" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_273" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_272" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_250" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_272" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_385" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_272" xlink:to="loc_us-gaap_RelatedPartyDomain_385" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_FormerScienceAdvisoryBoardMember" xlink:label="loc_mbrx_FormerScienceAdvisoryBoardMember_831" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_385" xlink:to="loc_mbrx_FormerScienceAdvisoryBoardMember_831" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_UsFoodAndDrugAdministrationMember" xlink:label="loc_mbrx_UsFoodAndDrugAdministrationMember_838" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_385" xlink:to="loc_mbrx_UsFoodAndDrugAdministrationMember_838" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_AgreementTypeAxis" xlink:label="loc_mbrx_AgreementTypeAxis_384" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_250" xlink:to="loc_mbrx_AgreementTypeAxis_384" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_AgreementTypeDomain" xlink:label="loc_mbrx_AgreementTypeDomain_807" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_AgreementTypeAxis_384" xlink:to="loc_mbrx_AgreementTypeDomain_807" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_UnderwritingAgreementMember" xlink:label="loc_mbrx_UnderwritingAgreementMember_808" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_AgreementTypeDomain_807" xlink:to="loc_mbrx_UnderwritingAgreementMember_808" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_806" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_250" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_806" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_813" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_806" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_813" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_SeriesWarrantMember" xlink:label="loc_mbrx_SeriesWarrantMember_816" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_813" xlink:to="loc_mbrx_SeriesWarrantMember_816" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_SeriesBWarrantMember" xlink:label="loc_mbrx_SeriesBWarrantMember_817" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_813" xlink:to="loc_mbrx_SeriesBWarrantMember_817" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_SeriesCWarrantMember" xlink:label="loc_mbrx_SeriesCWarrantMember_818" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_813" xlink:to="loc_mbrx_SeriesCWarrantMember_818" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_812" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_250" xlink:to="loc_us-gaap_AwardTypeAxis_812" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_821" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_812" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_821" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_820" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_250" xlink:to="loc_us-gaap_TitleOfIndividualAxis_820" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_828" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_820" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_828" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ScienceAdvisoryBoardOneMember" xlink:label="loc_mbrx_ScienceAdvisoryBoardOneMember_829" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_828" xlink:to="loc_mbrx_ScienceAdvisoryBoardOneMember_829" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ScienceAdvisoryBoardTwoMember" xlink:label="loc_mbrx_ScienceAdvisoryBoardTwoMember_830" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_828" xlink:to="loc_mbrx_ScienceAdvisoryBoardTwoMember_830" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_827" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_250" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_827" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_836" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_827" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_836" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_837" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_836" xlink:to="loc_us-gaap_EmployeeStockOptionMember_837" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_835" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_250" xlink:to="loc_us-gaap_SubsequentEventLineItems_835" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_252" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_835" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_252" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_261" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_835" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_261" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_270" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_835" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_270" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_271" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_835" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_271" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_NumberOfUnitsIssued" xlink:label="loc_mbrx_NumberOfUnitsIssued_804" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_835" xlink:to="loc_mbrx_NumberOfUnitsIssued_804" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_PricePerUnit" xlink:label="loc_mbrx_PricePerUnit_805" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_835" xlink:to="loc_mbrx_PricePerUnit_805" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaap_SaleOfStockDescriptionOfTransaction_822" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_835" xlink:to="loc_us-gaap_SaleOfStockDescriptionOfTransaction_822" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_ClassOfWarrantOrRightsWarrantExercised" xlink:label="loc_mbrx_ClassOfWarrantOrRightsWarrantExercised_823" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_835" xlink:to="loc_mbrx_ClassOfWarrantOrRightsWarrantExercised_823" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_824" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_835" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_824" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_825" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_835" xlink:to="loc_us-gaap_SharePrice_825" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_826" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_835" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_826" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_832" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_835" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_832" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_833" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_835" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_833" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_834" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_835" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_834" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_839" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_835" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_839" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_840" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_835" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_840" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/StatementsOfStockholdersEquity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_737" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_738" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_737" xlink:to="loc_us-gaap_StatementTable_738" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_739" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_738" xlink:to="loc_us-gaap_StatementClassOfStockAxis_739" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_740" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_739" xlink:to="loc_us-gaap_ClassOfStockDomain_740" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_741" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_738" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_741" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_743" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_741" xlink:to="loc_us-gaap_EquityComponentDomain_743" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_744" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_743" xlink:to="loc_us-gaap_CommonStockMember_744" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_745" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_743" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_745" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_SubscriptionsReceivableMember" xlink:label="loc_mbrx_SubscriptionsReceivableMember_746" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_743" xlink:to="loc_mbrx_SubscriptionsReceivableMember_746" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_747" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_743" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_747" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_742" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_738" xlink:to="loc_us-gaap_StatementLineItems_742" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_752" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_us-gaap_StockholdersEquity_752" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_753" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_us-gaap_SharesOutstanding_753" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_StockIssuedDuringPeriodValueForCashAndSubscriptionReceivable" xlink:label="loc_mbrx_StockIssuedDuringPeriodValueForCashAndSubscriptionReceivable_1005" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_mbrx_StockIssuedDuringPeriodValueForCashAndSubscriptionReceivable_1005" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_StockIssuedDuringPeriodSharesForCashAndSubscriptionReceivable" xlink:label="loc_mbrx_StockIssuedDuringPeriodSharesForCashAndSubscriptionReceivable_1004" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_mbrx_StockIssuedDuringPeriodSharesForCashAndSubscriptionReceivable_1004" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_StockIssuedDuringPeriodValueForLicenses" xlink:label="loc_mbrx_StockIssuedDuringPeriodValueForLicenses_1007" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_mbrx_StockIssuedDuringPeriodValueForLicenses_1007" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_StockIssuedDuringPeriodSharesForLicenses" xlink:label="loc_mbrx_StockIssuedDuringPeriodSharesForLicenses_1006" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_mbrx_StockIssuedDuringPeriodSharesForLicenses_1006" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_StockIssuedDuringPeriodValuePrivateIssuances" xlink:label="loc_mbrx_StockIssuedDuringPeriodValuePrivateIssuances_754" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_mbrx_StockIssuedDuringPeriodValuePrivateIssuances_754" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_StockIssuedDuringPeriodSharesPrivateIssuances" xlink:label="loc_mbrx_StockIssuedDuringPeriodSharesPrivateIssuances_755" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_mbrx_StockIssuedDuringPeriodSharesPrivateIssuances_755" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_756" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_756" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_757" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_757" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_StockIssuedDuringPeriodValueForTechnology" xlink:label="loc_mbrx_StockIssuedDuringPeriodValueForTechnology_1011" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_mbrx_StockIssuedDuringPeriodValueForTechnology_1011" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_StockIssuedDuringPeriodSharesForTechnology" xlink:label="loc_mbrx_StockIssuedDuringPeriodSharesForTechnology_1010" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_mbrx_StockIssuedDuringPeriodSharesForTechnology_1010" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts" xlink:label="loc_mbrx_StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts_1009" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_mbrx_StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts_1009" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts" xlink:label="loc_mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts_1008" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts_1008" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_977" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_977" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_762" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_762" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_763" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_763" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_764" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_764" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_765" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_765" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_766" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_766" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_StockholdersEquitySubscriptionsSettledForCash" xlink:label="loc_mbrx_StockholdersEquitySubscriptionsSettledForCash_767" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_mbrx_StockholdersEquitySubscriptionsSettledForCash_767" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_768" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_us-gaap_NetIncomeLoss_768" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_769" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_us-gaap_StockholdersEquity_769" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_770" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_us-gaap_SharesOutstanding_770" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/StatementsOfStockholdersEquityParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_772" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_773" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_772" xlink:to="loc_us-gaap_StatementTable_773" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_774" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_773" xlink:to="loc_us-gaap_StatementClassOfStockAxis_774" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_775" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_774" xlink:to="loc_us-gaap_ClassOfStockDomain_775" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_776" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_773" xlink:to="loc_us-gaap_StatementLineItems_776" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_777" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_776" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_777" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_778" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_776" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_778" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.moleculin.com/role/NatureOfBusinessAndLiquidity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_780" />

    <loc xlink:type="locator" xlink:href="mbrx-20161231.xsd#mbrx_NatureOfBusinessAndLiquidityTextBlock" xlink:label="loc_mbrx_NatureOfBusinessAndLiquidityTextBlock_781" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_780" xlink:to="loc_mbrx_NatureOfBusinessAndLiquidityTextBlock_781" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>pg11img1_10k.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg11img1_10k.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!2P&\ P$1  (1 0,1 ?_$ 0D  0  !@,! 0
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M31$T1-$31$T1-$31%HX^T7^WTZ3/LR;FKC_J"Q'U7*V!PF"E<F*_AHR>.+>
MIBH(UK)$]/P]<E^7PB50K<RRJ1@$#D+HBU'9IZ@W_P!H;B['_P!IC2.G[)&&
M<(9->/\ %L8;(;R'=SUC&F/5F<1D$[2OF=M(BN6-8%XQ@998XN%V!A["&(8_
MO/A%K$!M+G2)I&ME'::'$"H)QI7;0[?*%Q9]Z+DB=]Q'S39PR/$\;8Y2P%U"
MP5;FI6E6@4KAAO5PXOK6S2HP;$3G:[#'(VJ31:9K]/K\38I-C25&JE<83$ZQ
M:C)2S-D+)(#HJJ&2.)=C;%ULLG(U@Z1TEUG?&]SBT'8,V)RT\OF7@\/B_P T
M6]O'%I-S;VMTV-D4C7QO<Z1L0[#CE]7@DEX!IG. #C4*J)+KOS*P?)3%=>4N
MN/62<@+0T)2(1N5FO-/&C^RR:2'*.BE+6)1HFF]7V$7#8ID>P.T: \-M.<VA
M>\@G\;#R#8,!M_95=GC9SYIM'%]AIS=I<V.23-^5<4!?VGCL%E*C/7* *C[]
M >-I;J ZN8_*DNSC(JB8GE%\MWV>:,D(*IQTDR%5] 1J6XHQT>#B6(9V*8&$
MJ39!0X\(%WU3YVOXN5.4CH+)&R33-R#$$X[3AN'["W3P+T67G_Q,/-SH7LM;
M=W%KE(;4'  D4-3A0=>Y>K>,E(R;CV<O#2+"7BI%NF[CY.,=MW\>^:K% Z+E
MF]:**MG3=4@[E.0QBF#M =<V+Z(+OZ(FB)HB:(FB)HB:(FB)HB:(FB)HB:(F
MB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HBT3=5G5UFRM]574[ARB]25XQK8<8X
M?PO:\!8>H_2HWSRVRI>;M%WE\^A[/+-:/,S1$YR:K[-A[,C-P:C5LL9<%2@(
M' BSMM'6Y7:GC2DA%QU>S%U,6.:Q[C*3Z=L67VG+V*!S7;H5Y(3-5N#MU-OD
M\<P-54@)=60?2H#[(VCE X55>%,Q%CQ9OM%KG%2C">EL-7BB,\3RW4U7^H#$
MCT:M9[+*N\)8MQUD7Z;Q_9X=TY9S-9:Q-Q5?-G"0-EI%NB8IT$E Y12*\EW^
MT$AD,AO,181Q#<,]Y$=V&HU:EH0$[7:O2[1*S&-2YBN+M[=YQ95I68#&F.96
M#=2;I9NJJJ]L+)DW047,KRR*EK!]HI9HEC+/6?2/E]=?$F+(;+W59 S5FH-=
MLW3]6I=[:D21J$6K+/F^4;,6&HTK-)-XMPBV<PB*"Z;@572+<2+L(_:,*NKA
M9G#3IKRFIT^43/D5TZW7J)4F:@E",+;8WM<BH"VP-$+(*W"R8Q3F[?&,)26*
M1NM&.W)B@U73;N%$R*15C[1V\Y&=LX'&71YD>P7&VVO+[#%U=L>2<:TQ.]X[
MP+8TZ5DS+KB4=/Y-.J5(UU>M(R 1>)"]G%70*\MLV(=8"*UZ'VM;6-^N_(EJ
MQ*ZB\(5FI]+H8:?/;75*]<KAEGJ$DK/5E,:70LY.)5FDDA;C7UV[B8=.THQB
MTCW#@ZJI5$2B13VO?:GU"R1MPO(URP('PGC?J/F\I8IHD[C3*D+89W#Y,)S4
M8O1,P5R:^A+&E+P.3D C!;F;(J+N7",@1JLT* D6:'3CU,36:;1EC'%_P_/X
M0RIB$]'D+#3)BT5VZMW%5R7"O9NE3C.RU<WT8+YPC%NV\@P$.8P=MC%!1=(R
M:QR+%>I_:?GEZQ6\I6_I9S!CK!^18K+(8KR5/S5*?.;9;<1UVYVIW7)FG0TF
M\EJ9'9 @\?2Z]6E':BB$FFU**Z;/G(<PBKS,7VBU;Q=*5>L0N'K[D6Y7FD]-
M]LIU;@I2KQ)IA[U-9$EL;4NOK2D[(-(^,6AYB*%>2<JFY*34W$GS#!P"14%!
M?:7V<BTP]R1TCY'QM4JQ;,T8GLUJ7R)C>T(M\UX0QM<\KS]3A(F#D!DYNF3E
M3H[LL;8S%:E4D!*@LR1+NJ!%U7WVI"].Q^^R'E[I0S+BB+L6##=0&%&,W,TZ
M:D,BU!L_JD?-PUN]W7T@UQ!;:F2]1,C,-Y11PT80SA5T9R8S5P@F19K=+N?S
M]2&-%+ZO3 I3EI9)FM.&L==:KDRGS)XD6YT[#0<DTIRYK=WJ4DBZ*"3Q$$%$
MW":R"R*2J)BZ(LC=$31$T1-$31$T1-$73<2,>T<,FCI\S;.I)15&.;.'**+A
M^LBD9PLDR14.51THD@03F*F!A*0!$>P-]$6FWKFZ#NHC[2_H+S/TI]4+G"-1
MN-NZA8F6QW9L5>\KZ,@,(4_+E>GZM+R2EL05?M\I/,>L7B$@5KLR,Z6 A-DC
M&#1%LOJO3GAJGX"K'3'$4:%#"E2H$-C2'I"S5,T:E58*,;Q;!N8I"IF]L*FV
M*J+@HE6%SNJ!@4^=JO;7,]I.VYMW%LS#4$?#9U*TO[&UU.TDL;U@?;2-HX'=
M^P=Q6G/,?V+#P9>0D^G_ "HSCH5^L=<E0R*U>.C1@G,!N2QLL419P\0+MV X
M;\8 ':<P]NO8]&\6I(XFP:S$7A@[);0BO3@<17J)7)_-WW6=-O[Q^H\NW BF
M>ZI:\$'J&9N!IY J,H'V*V392714RWF2M0]>*X35=LZ1'OYF<=)IF*)D6CR9
M0CH^/YR0"7F"FORQ'BX#;;#>ZGXP12,RV%NXNI^,0T?LK :+]U&[FFKS'?1B
MW#A0,!>2.G;E W;2MW>)>G##^%<7KX@HM29M*9),7S*Q(/-GC^V#*,S,)5Y9
MGYBD6DW<DT.8B@CPD*0> A2$ "AXQJ>IWFKW)NKUV:0[!T ;@/@5USRQROHO
M)^F,TG0H1%:L->MQWN/2?B'0%Y,>BCHOSG]@YFVU=0/45=,Q7'H%NN8,H45
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M).'<AT;%6597"&2+'7';*DY7A8:(L+^CV0HIN(N9^@IUNZBY=F1R@5-RW4*
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MKNP2<.FN]:8/>^J?ZQPO_I%K_.ZM>XZU]$?0JWO)R[],/2H#<*@ #QV.',0
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M7F6UR?UH;ZQV%5G]GC54YKJ*9N%$"'+"5&R2!.,-S%75318HG#L';@]I-O\
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M^UJ(O\DT5Q7LL+ZC?F;E^*M5%NBN=FE&7+$!44Q/$.04\AQ/4JQ]W ^KKE<
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M;8ZSP%$3-RJE62$Y%DS4[C6[O7*M:ZW)HOX6Z5N(MU;7,51JXD:_.QS65C)
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ML,T=(R*]BEE%!G+,_P"$WSOH]%O%ILR$_BT>#;M$0UX/S-S5+K\YNHY0]E2
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M"+=KN5TE&D0=--<3',"BI1'N[=6-C:Z@^W<W4'M?:FN<#86UPV^:JVWG+4=
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M76[?6.8 @=%!7?MJMLY;MN7Y-)OGW5U,R^%,C6L)8'5[0>2W9E]7)7';@KD
MD7R&'?\ :\=90SL?-B< S;CM6F0Z>U@?>,DXENY^4'KV[#0J(IE#O'\/QZJ<
M6+>JF1FY1%( [1'\/QZ<6+>F1FY0!,H]P_A^/3BQ;TR,W)RR@.V_;]_X].+%
MO3(S<HBD =X_A^/3BQ;TR,W* )%'MW_#\'PZI3/;D>^O9X3_ -$J2:,Y6%H[
M-7_HJOO9R?5-P[AO]9_'W?\ NAOOY]8_BM]X,]?_ $Y_C%N6']'U.GVS_L"]
M0.OEPONVFB)HB:(FB)HB:(FB)HB:(FB)HB:(O-GU"HB.=\P"!>+?(=H'?_\
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MM*]5<5Q7XB<QVVN<R2:UI1?W>Y>,7!H=2@':#>SA2G6!4XK)'DF =P';LVV
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M7R<U6[[7V^;.\D8.^Q%W$ANWP0BF6IJT-(%*GH*K:/SKX^,YGLW317H@.03
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M:NIDB)8Q@X /F+L8A$3H%<(F[2*'$QBCVZF9;QQNS,P*JQVY:T,<0X#> /P
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M!S8Y* R.90U[)IFI^*[]R>E56N="<S(F2$X=K\7]TVM>T.C9Y5 R/&42B <
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M3J3@/ZP> :<0[TI)U* %5WW O%VA\W;O^#\8H[>?;M\P".P#4XL4=@^XE_E
M33]A5<S'7K+>,&A KY:8_&I;&2\5.).%X.7C)ENT?.XMRYBWS2000DH]86LA
M'+J-%E2H24>\3,FX0-PJ)'^:8I1[-4+287EL)FO:VAQ.]5KNWGLKDQ21N+2
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M IPCN*<DOP^ Z9W? IPCN*<DOP^ Z9W? IPCN*<DOP^ Z9W? IPCN*<DOP^
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MS &1P:VM!@,V&)[.TK"W6@/OY8Q):-M[<-D  /;?PXW.J*N/$. )<P4<<!M
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M$9!@$7(KGD(YJZ,H^8\:AF;T#*&YS<1'D*B)>(P%*.O3FO;T8"B\*?"UKRT
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M ;   ;81 "@!0XN$-N(0+N;?<1,(B([ZR.8CU2:+&26XC=E8<[=_["<@WG]
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M.]8#H.!(H>C%7$W+LNG64DDDD4L8+0',)IFH26X@'"F/159ME0*4 +P#N
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MC3^6=,T[^1:74_*H?P *["1"(I)H(ID101(5-%!(A4T42%#8I4DB 4B90#R
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=G_U=4?[?_IOJ_P +^PJ_^A_^&;?_ )>S\/["_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>pg13img1_10k.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg13img1_10k.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!<@'P P$1  (1 0,1 ?_$ 2$   $"!P$!
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MJ?H=XA_UG_\ (0?C*V&Y9^4LB$,X4R?DC31R(_#@3*<NO+V09@_'[KNQI3)
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MKJ3FQ,N!'%L=WCY1_=5>00$A;=%J;SY3ZU FI/E*GHB*(BB(HB;KK$8 U#T
MM\9+4.<5#L Q=.LL$+]H;*SVD'EVETP;)6 'S%<YZTF9]):;2O-@NA*.&9K2
M!7B*.-15,HRUIJMH[J)G;31_'%8937_5G)L.B5T(U!<\&^/IYAV4-]3HTKH7
M2:\=%IQ<V@1,Q>Z>D%$DQ)=0:UY\;S_%PP\N-U1QKMV\%TRD3[&.ZAD;S7-:
M7#;M)! %=ODJO2,G^:N(@XYO*2NLLAJGZ'Q)WBT;\QH:2T_R&)>8^Q7SV2SU
MTWB63-CE45,G?@U:*/F+@!;M4R(G*L)JAFD^0:JV+V;*NK^P=\2M&E0\U&;2
MQ0FYK67$8Q#&IWO>8.L<C(R?RJ:@V&1*8UQD9C%FCB.C'TFLB=-HNQ3<&2#@
M&4,&ZH:8/.QS34[%.U\):02XR&E.Z[S[DH&B>9<U,KJEBZ.I(Y+#F6=OW.<8
MT]Q19+3IM@@8ZX"%5@YE.,9Q[;+7$UW99<0D7*M^,F9L4MC$9G?=,< I6Q3L
M)=,ZL8X-(21SN,<SD=(:A2Y\=RN9<+ZQYK):&NHN.>2R.%XNIJ?.2DROD\4_
M7,@,IDK(S)S$2-A;)Q2142;I@$JDW-C!Q:ZGG^)7#HV%N9CCB*^R4ITS)<QV
M(2R4!DV5:\2>G*F*1<Z?-L,PR(R74$NI4MBL<H7%!;Q&/F,GA;;(".U5!"/-
MP5A3;+.")CO5(2\]YK3D5J9&MP=FK^Q*22(U#YT]S@Y&76(D<XC\%<Z@S880
MSA9+#V3G'EE'+'#H>(QV?]+9))Y*HD>0>1_I!-NW,H11N@*13GAFD^05'F1_
M*/WCOB2MZ7Y;S'O,SE875(,_DL;?:+Y$_17D,-0QO&8L6QU0QQU.JK-%CRF>
M9)%/"@X(DY;N&R[58%V*13I"-YIXD=>1N<*,#AY:UP\RQFO-S]/W3HI )2PL
M <*5#FFM 2/3N3TN7T#GT5TT$Q3%_P $XHYBFN!P-W<HB!@$"B4U[[+!;HM6
M0U@@:C)F]K-187HFU%ITQ%;OQ=&2X8[ZDI;R] >T'O5B#M6W@Y@'':5&H**Y
MF_RK'_LY=(_^G=RP?NW+J(NE2)_M5&?W/9?N9.B*N-T>/]*-$4U$11$41%$1
M1$41%$11$41%$11$41%$4!Z/=#WPHBD3Z#?YXI^G&B+F2]7K_P!XJ]=+_P D
M7+7_ 'MC*(NG&B*4P='@$!JG)7"GR@H@T]"MLB4%B"W,)MQ=,Q1  N4WG%$2
MG#8/#,78?;\41MMJ;W@6\S'4WJG/:MO+-\1V$4]*;K$:+9KCC(L1AFL64XUC
M+=P\5BH$\'CTJ6*1=NEG:C-N^>LDGBC-)=<P(E5WCD3L43#:];%=:M:74W/N
MH0^<M%2,*T%*TH5SRTZ5UFUB,.GW[K>T#W%L?>PJ23LPQ.*N0Z7ZPC>W,!/V
M$;A?#\7$W@N/ VC5#W[3?S'P_J*[/3W4A;3Z6?6G!_QKS#2[5I$!,;F!G=TH
M !S?-'%"CNAM$-\R(B4*H27UA)*&^XFA_7-/P4Q0=.=06MN7/U5S:#:<P \Y
M<FO9YK_IGIM/+X[G//E!P,PW,._%J1>)2#EL8ERF*NE'L7(HG*(B [X@(#LM
M70=&Z&U[7HL^@Z'<2N#:GO-9W3@#WPW"O"JY3KGB!I/2,]>I^JH+:%[BQA',
MDJX8D$1EY&'$ =M5A'X7O+QO\8?6!X^=P! 0!8<3A!/P3"-TC'+" H5+>&^U
M0"7ZJS/]DOB"!4].W% /ST/XRP/]O'AQL_3:&G[E=?B)R>G:SW5F$^<&F?-R
MCG$(HKN&?8Y#X7))-U"7WDEDT6X*M3&W1MQ2WO>N?:C!)I-R^TU.PE@N6.RN
M:[<> =EH?,2%T[IZ^GZLLH=5Z=ZBCN]/G:71N:7YG $M)+"0\4(([S0E&#2S
M5P!!3^'^<*.[N%/\S\4N!1L-K\$.FP= ;;5BW:AIV4TAV#C7[2VD]/\ 4.6K
MM6>/OACZ5*?3'5X 4*;F!R$H&L7BDQ'% .4;@8#IB*!PWK!;:4VP>BJAOM,Y
M8=R!LVU^UE5&3IOJ.%G-;JSLQ_9?&LMTYTX<8O-S^3Y#E4MF^4S;./C#SLLD
MQ: UA6"[MXUB8MA'-FS5HQ(Z>J*&OQ%5#FN8X@  $E]?Q75K##;1M9$S,<-I
M+J5J=^S#!7_3O2]YI-Q/J&HWCKN:Z#*5)HS)7!H-:5KCY$L7F]H=%^KH[:Q&
M*V^GW*B%K;+6J"4I@BX=H41 " ] @/M#V=-$4>GHVT1%$2"Y9IN]G<Q2R_&L
MQFL(R<(L8*2?1K2.DV,M%MW+AW'-Y..D&SE+>8*N5C(JIF1. JG 1$#6K+6&
MKVTM@^U<S/&'_L7 C T)&(^RJT_4]#+^JH[ZS)C>8*$[JT"L)M+M7.*J<=>)
MHA5E .4WS-Q:QQ P&W@ J [NT ';5:.ZTB:,1SP<V,;6UICNVM-:+ OT#JN&
MZN+F.\Y4;GBCA6M"3P=7%)[J.]R;2G');*<RYF)&&@X-LH]E)1]B^)-FK1%
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MDT?J_.'?3<8!W<N7'^^41TWUD,&Z.NTF(#L$!P;&["'8/G;0J'O6F_FSZ?\
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MR+A@+C1H--YI3!<P/F!ND'? EU#&)8-XABB! (3Z42E* ==?3:>TM-+:+O5
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M4B2TOC,X/KAK7S(9C-\N>3YR&(*RJ,[.XHSYCI]V_P 1R^:.!F3,V- 3A+I
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M"22CE00WE%C[RJAQ$QC"(WHBYT/5Y$*3\HH]=(4H 4H:1\M@@ ; #>CXTPV
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M[2,@@GN/'1+D,(.'JQCNE2D,F&[<UB]737-.KNO^J^MKATG4]VZX)(J &QC
M >RP-'P+K70WA3T)X=F&3HVP;:2PQNC:[,^0AKCF(K(7$U.\XKRYB=7\8T_P
MZ8F)B8:1L3#LG3Z1>.#$(DU:MKGL*BA]U9PZ(02ID+YQC"%JUVPY<7S#/R;S
M0@X[>TXK=;IA,#F;&AV?]LW8?A7#AS&:X/-;M9,VU.<JK ADDF)H@BYC<=O
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MW."9S*)G(8N\2XD$ \!K]%:I=69ADY9"W,:BV1@FC-0M\_*;S:RF*<I<=!A
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M.:[%R_W%1+&%(8IB@%[V[=@@(#U!41-5KLPPRE/<RW9OP3!.?S(L0P7!M/\
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MR$]P8KJ3K,9@'>TH>BB>'Q!_2U-[\.U1]R:K%E#2/:XS/+2?#+'(Q$BL_66
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M7@'*:%B&A"1_P8=1E! +;N9F]T(1N>P;>CSJA:3GZ)>#LYA]05SJ4(_2"/\
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M$-W&!H0SJ):8Y")Q#PG?UUBS,@HHB^*9JHY%,=WS0$.B>+WAQ<]4]4VTVES
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MY04$V#+N[L'?=E4> 8O$*(!OB(6\%0M-<CLX6,$7=;L(%=]=Q5/4^D7ZF\7
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M6$-MC!:];C[Z'V','=>,/,N<3VCV73LKLU92:IYL(4"0T2F&S<C6@ '8 -R
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M\VH$;?\ F-49Y;2-@<Q@Q1C;W/0/.?@D3UB>8YAB#.)B,0Q()63;G='<J8U
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M*KCR42;&%IB-T^R7$H&:0&*:)*NU($44&YS'4;FHB;,7U*6.%  _ZS+UQ(V
M V\^&0C>P6N/^!?340:&J*@F?4PQ4="S#N,]8]ZX:9D6\<Z<L(H>?6<;C)/6
MR)UFL>#E;"^$V!ZN4J8G, @3>WK#:U1;[8/:H//<(6K?U3OY/QJ%R-:O3O,G
MK)S5:JN-0,DRB=R-?1;3/.)0NG:Z$O(NWJ;/5^?>-6Y]79DI7!>]K%9LD%G
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MF""_8%6C@(R;PL?&IER3*6<K,J"QRYCE;-H[GO1C15_#XZZBB-6B*_%7! 1
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M#R;-QOEL?BE1L4/."L=9:W"&N<UH!H?3Z%<R=-SPR7D+I7%MDV!Q!=M$[BT
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M5)&7-LP&"O(,T4RB!4DB%OL**28F,6]K$#= 5  .NP>U70[>'3K&+.QPF$F
M&W+5<2GM[JZ;S>K)#:6]?FN543.?]R)*AXH33-0#:<0J-UCL*^-9W%-7)3=(
M*($ 1MML(E#M"H_1\/!9.RNM7@CRND-?.JUM%M6*14&C9-ND7XB29=PB9?D
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MX-EJINENHJ1V]G=.BXD,K\#E<_1K7LI'+'S>!)^)1X0F*8HD Q3=(;;#U6$
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M_@L8K@AWL+ 8JC ME(N5Q7+Y2<=Z@$?3A3H'C29&G.(F4;*-3%,I$(W-NF$
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M^[K]I1X1O8 _!5/,50[_  1PC>P!^"F8IW^"APC>P!^"F8J(SUV*'#/V>_\
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M9%Z/2&Q)!DFZ,FF]%4 N"9+CLV7'97/-;Z^CZ0U5UEK\,DMI( ^*2,48QA-
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M&GV@Q_-,J/)W?-Y%']._$/\ K!K7\[F_&4I=2];2!8NN>K);"!@$,A; ("!
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M,]K;ZA9D!C+V-N5T+=N>3G%[WDD4[C:X[%C67:"3+"*'+L)?-]0<$4%14DS
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M,_S<YYK7#+Y'A>0:AO-"\"S7EGU,P;E=Q2:" :Y$3'(-CZ)QU^Y=<-!BC+R
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M;;:?9ON()3C/(,(@=]:MI3R'8EP]#:,:-$!:95:ZM:AMP R$-&KG3PR#7+M
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M6!EC)Q<VOE"G%$W:.VU[]=NB^S;:I@)_DN]!4S'Q$T+F^D*'=S=H>S^AJ/\
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M2=GE^A3FGBG)=Q09(G#.6UA, VV7^E-U[*HW#LT#S^M*N8&EKXP?S@^TMQV
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MMU^;9=D.'8YA6G+1Y@YF;3,5ELV7R)D\<3+W2@D2O".HZ,2.LC'16I9CJ(K
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M;N101 $Q 2%3*("%ZJOMO#<1<SF=0Y./(M=O#VT9_;^QG/Y'2SXMG^47=/\
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M6&S:!P$0&]PK7-4Z1ZAT.8S2N+['9V5.S=Y5LNC=3]*ZL!J&DW8?&X4$=6X
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MMI@ZK$O<0 >FVVU5;.X#8#(_@CK8SSB)F\T29'DLGS;>1B-['\<,H9-2:<$
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M'WZUGAIJOA]XAN$C7G.^HDWT./M);L&E@$K4HA>^[N%^-YQQ "D(&T1,8U@
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M$Q^(51&&: <R*(#ND*FD8G17EGP0L]3ZQ\5-4\5=:S/CL@XPP.V&,"@I7#
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MH1RP9+H)!R#D'V9)-F>EF1M"*JI1.#3+4B^8()N"V3:K1*I%.Z$N504'Z6Z
M[;?$3PV^L#J%_P"%W49U&8CJ:2_O&-B.8R93(]L1H"31P."_0?=^"]O#UII>
MF11#]'K>PLY'R MR NA8Z05V$APH:"N"<+ZI?0YBTA<DUV>Q.X?(#EQS"P51
M,=P7&(8RH.G")E/.,,O*G,81^G13):]@KM/U<^BKO0?#-_5>LL,.L7]QS&-<
M1G,9<*G#$85-'4/95:/]8;7X&=06W3FG.#]!B#1F9B,XP RC'@-GG3XN>?F%
M2Y=] LHFF$D@EFF6"?"<$;F4)Q@GYUJ<I)<H@(JJ(PC$5'&SHX90Z3% >A]=
M]72]%=+WVM6PYD\S"(7;RX[,,"*UWT6@='V-UU3US9:'' 'Z='(#*>Z UH]K
M:<:4W K6%ZK3E]B,^E\XU<R6'-(039FZPS'5)1,'!I=Y(@H[S&7!0]P6%Z[
MC<3EV&4*L%Q"]<J^K/TU?V4-YXF:SW]7UK-;YG]XVC!WW2UVT?\ DP&DD5Q%
M%UCQ_P"KHM+OG]%]*FMI80,ESL[N1Q=E)W8TH,!O66-)J;Y;]7 :J=Y%SHUD
M2K95(N^93(]#,M4!<&ZA-IW(Q$<EO-]S>$%H_HW@M7EFVE'U3_K8W-UD?:>&
MG5DF$)[T3)GN YH$?= #A@"VH#MNTK>HK+2_%_P%BGED!UW3V5S '.XL!PQ!
M-7;^-%O"CY./GHAG+1[A&0BI>/9O6;A Y5$';&10*Z;+)'#88BJ9[AUU])Y)
M(-#U:TBUB7)<M+9() "]K<QS-:'-S AU:X&G'%>/-5EYNEQ3RM,=W.3FJ*&$
ML):/2!FPKM6F7F'Q*4TBUGFVL"88A+)WS?5[2QZIOE:L,\AE$5\BC+")0(27
M%0JIT2B '2<+WZ1KYT_6GT_6/"SQ\T/Q\T>U?9ZA/>PPW893)<6^#9'OY>YS
M6C-G=Y0O6GAKJC.O/#RYZ6ZF(;%9V;G6\A[SI9&@EK !F=4G#$!,FYON9)]S
MCZNX)B&(,WC:/B21F(8YCBY%2"EJ7D92(YC*/6I]A302BAFPF$;"FDJ)1,4Y
M:Z9XG:M<>+O673O1W25WSNG[J6.>Z>T/RQ9BUS@:T!#6EPP!QV564\/.CK/I
M/I;4>J>I&MM==A:XVC'EN9]&G+2E<I) &)'F711H3I;#:-:385I[!MTT&>/0
MK1CO 3=57632)WA9R>P%4747$QC& 1 1,->VCI]EI,K=)TZ-L>C6MO%'$X4[
MSFMH_ 8C$ X@5K@O(VHZ]==1W\^KW]1K<LKA,TUP:TTC.;$&HKL<:;Z)7+U&
MK![)P5H*G;M0-NJJ)VJI-%#RVF,UDIBH@-AZNL!N%PL(6$+=%2G$*>"4LB.8
M=]4,E'-9- $5R[H)@(MG"=@?-#=7=U!V$#>VCMZ*NK&^N;24$$Y*K":OI5OJ
M<!:YHYBJ\?R!TR<(P,^H J[HA'RX7!!X #8A#CTE7*&PV]:]=4T?6;:\B+7/
M'-! I0\%POJ/H^]T^42P1?,.:234;0?+78E+!,! !.("80"XD^*-@ZMNVMC+
M2!F.Q:.V,.DY0IS."CP2_5>/Z-29FJ)BH:&E?(C@E\/C^C4,[>*<OR>A'")X
M?']&F=G%.7Y/0H<$//M?:F)0]L3!8.OLJ(D8&N%=K54BB=S64^6$_'&0W<>@
MP[(EEY&A*X!J!KJK^.9WK*]5Z!W=#AK\@?:62U06711%Y'004436412.JE?A
M*G3(91._3PSF 3$OX!"B*8R21S$.=-,YTA$R9C$*8R9A"PB0P@(D$0[*(I[!
MTV]G1[U$1;KZ^B]$4ATTU2&(H0BA#?&(<H'(:UA#>*8! =H410.DDH04U$TS
MIC:Y#D*8@V$!"Y3 )1L(413V#L#HM[G9[6RB*0J*)$Q2(DF1(=X!3*0I4Q ]
M]X!(  4=Z^W9MHB!11%/@BDF*-@+PA(7A[H6L7<MNV"W1:B*<  H 4H
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M+A$* %Z"[NSIKJMAI]S:WCKMKJZ?&:PLW".F( \JYOSXM1D?87 ^=G=G#N!
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MF9EOW,3_ -K'OV.B(^9F6_<Q/_:Q[]CHB/F9EOW,3_VL>_8Z(CYF9;]S$_\
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MF9EOW,3_ -K'OV.B(^9F6_<Q/_:Q[]CHB/F9EOW,3_VL>_8Z(CYF9;]S$_\
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MM4CEM'-#FYJ[*J!Z9OFN:^Z!S9NW9Z$Z2&**,1&$, E,2/:@)1"QBB"!0$!
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GI_O%*;_^3_15$?ME3?L_P7G4P] ?%Z.KH^*/DJ&_>J_^#W;/,O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>pg14img1_10k.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg14img1_10k.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!) %" P$1  (1 0,1 ?_$ -L  0 " @,! 0$
M       '" 8)! 4* P$" 0$!  (# 0$!             0<( @4&! ,)$
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M"Y;L6H6;2<;KL9,U"$8QJ\>_#B=*M[7M9ZA\T7/Z*# & , 8 P!@# & , 8
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M_84WZM^6'"_*;-]W?,*YLY#T?F2M;F9IUBY/P7';CZU?NW%)>0G;/*'LQ@#
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MZ_/X];+Z ;)\DUG_ +S<\K\IOID^+;O:\7W8]E\Z?JY^#,?L.=[T/G\>ME]
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M3?KEG6[',O+F!S%BI+'S\.SD15:T5ZW&XE7IIQ4\AG^=0=V, 8 P!@# & ,
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MY\<,NICBCUH:,+WOIH8-[W]36A!WO?\ Z<<+ZF*KK/[R%& , 8 P!@# & ,
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M/N[^3C9R\=[X78^=-?ZIM,S=<R(, 8 P!@# & , 8 P!@# & , 8 P!@# &
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M2A^E(VMYO"9'& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8!YY_5<J^.3&_F=\>'WT4T)R&HF8L#?ZB3,O7W8>%&^S!26:RJDTN92B:Z,$
M:("/[F,$!=I9OJ+KH.N4=W24V.>EI.&JR/3ZXKS=EB-<0)ND%:%*28=4$250
M6L(\:0^/*)6W06+K')X/;XV4L3&;3#\2<!4#?B ;[!H=:CWD+^9 8U,_P/EG
MXM/OWK58!A% ?J'I/]D=;_F:S97O!+F0# & , 8 P!@&J[U(&Q3&'FBKG:P#
M"MBTD.:SU -?[)B%4AEC(#8M>W74UJ6:UU_Z?V<TD^KO#O:-J/+/>'A)K)PL
MR5N4EUPE#)LJOCMW?M,=<]VY8]W#U6W^O;N--^)J<?T2-H+0YI7IJ;'E"/1B
M)V;T3FC,UO6]&)5Z8M4G'K>O9O0B3=;S=# S+&HX-G4,9UQK]J%R#ZXSBI1?
ME31D*U<C=MQNPVPE%->)JJ.PSZSF, QR82AMA,4DDP> *S&J+LCF_.):!.)6
MM,1M2,Y:H D3!V'9R@91.] #O8==?J[UKKO74:_K6)RYH>9K^H*X\'"QKE^X
MH1XIN%J#G)1BM\FEL6Q5WM+:?AE9%O$QKF5=KZNW!R=%5T2JZ+K->^O5"I3>
MM;]S+&]OM_X,2_\ 5*>F:J?G1[NGM_P[5_LQ?>3Q'S"TG_<W_LA_3.<W^I!"
MI4J"QUU45E367J2E:AMC9:^ L7C4[8C4.CL<-V=I84W(P(6E$<=U-%K1FP:!
MK[86L]AR%]3_ "/S_P UXO*.G8FI6-0S'-6Y7(67#BC"4Z2]5>G**:B_2X>%
M.G$TG4[#3.<M-U3-A@VK=Z-VY6C:C2J5=M)-K=OI3K)BI;F%"+0K:/V+,F95
M3&Y7%ZCGS#%YB^QU[?3X#?C@G8J<DRX4.7OC<V>_4F$>V$)##O$DJTH]&A"#
M81"V3:H>N./&N?W#V7.*9L8KSC)QJMK->R5B]ND[&R^2@B+M/4[N;(GQA;6!
M.V.\,C[BY-R@Q2 IT2-JPQ((_211W:C!FD7Y<<=YF[PR.QRQTR^23]Z?X]%H
MP;'9>W2=6ZQ=GCLB?BG"-ND?1/D?3-\?E[4OVI<4Z1,-$Y)3P&"*/*&)1@G%
M-*(\LDKO#4KNB/E+ SL,@>F,LWJX-K+)U;^AC[FJ)Z=2TCNLBSB62+_>$C,U
M_NY 0.X\P^-;8V-[L?:K,J(=D!;DTHV=LD;^^.J<V3R*&A*;(VQ,SC(7!Q!)
M(>[IAI"4HU9?E*TP1>BDB@9=HP1@/U"N.(U=GM:&6)UCI7B(;NV=3@)XY8+#
M\(X;=)+S$IT((X6,I3"IB!2!*H7$N DZ-0ITGVF!WVU&#*7;G)QQ;Y$ECJ.>
MM[H83,'N*RIV#HYI8(>DC<1M>4OTQ6OC^2U-3["V933;RTJW)H.<$R9V)VF-
M&$P!F@* D=!R7H]RK&17"1/4A-?Q%R\CD[JY-$B9W-B?QG-)"2..<3=F=%+T
MLE=39 WZ0-PD&EKAYBD\,4;I21WD!AZ7FOQ;6'-I!-OL6A.;0K>0FJ&R2I$C
M6!$DE:]0SR9:K9"$<0E_A(*\C+8G4Q&]&Z;%.BTHME"UJT8,$6>HQQ&1'L(Q
M66>8Q/3//G]7+MQ*6)(S%6BNHE$IV\.$P6.3,A5L"!VB$X;7%I4&$"3NJ12
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M#M.7<AL;7\X9;.Z';&-(H.(*-- HR%O,@& , 8 P!@# & , \V?JP7Q=-/\
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M$)+ZB]5ME?G\U6R[#*RI^IK*L/CAR5BG'6'UY KMLZ=(*CCKAI;"9'*9]([
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M;MN-V#K"237B:JC(J::JMS/IG,HP!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@&-3/\  ^6?BT^_>M5@&$4!^H>D_P!D=;_F:S97O!+F0# &
M , 8 P!@# & , UR^IJS:747''<(>IK)8;9KM=.NP$NS(_(![Z_6UL_96O\
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M_P U?FE_>D BI)1QK=I%&E+ D<]+'(%L[2(E0CI*E[@DP6AJ Z-$#6]%#Z*
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MV=F:(\UH61@:FUC96Q.!(VM#.A2MC6WI2_86F0H$11"1(G+UO[4!8 AU];6
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M^VG:-/4O&I6F*$9BV)Q)JA31MM2"#H#>4%D9B=&!#O>C#="'OV[P"0< _D8
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M+B\11'(&<#HN,<EX4YZU4X&:4KC0A,4#\0L'TWO6N@>FOK8!(6 , 8 P!@#
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D,GRWP_;^W[GP?8['7V]GIUSB#ML 8 P!@# & , 8 P!@'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>pg15img1_10k.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg15img1_10k.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $@ =P# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%[$C*[ E;9L997YZ_7 Y'-=CI=T][I5I=2H$>:)790<X)&: +=%%% !1110
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MBCM[>U !UQ5G3Y[FUU"&XLIF@N$.4D!Z#W]15?O^F!6G;0>3&<C+'[W?\/\
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M>7#B."%"[N3T &:S-"T*32'E:66.4"-8(-B;2(U+$;O4_-^E<+\8_$9@M(-
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MID9ID<J2QK(K JW3FL3<DHIB2QR('2164]"IR#3@0<8(Y&10 M%%% !1110
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MY)1AF^7T7CBO:5-L^?E6BMB_)<11GEA[@<U7>]8Y$2[2>,M53/OG/OUH]O\
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M_6H([E7P&^4GN.G^?_K5.#WZ9_+WK2]S-IH.W^?>CD?Y_P _Y_0Z=0<C_/\
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M98I()GAF1HY(V*NC#E37;3GS(\^K3<'Y#?\ .***/QK0R"BBB@ ZTG7M2T4
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MHHHH **** "BBB@ HHHH Q?$&B2:TUDJW#P)"[L[1G#<QLHQP>[5R#^$=;M
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M'AD";&5XA@#<,E#[KTK>QW[T <3J_P -]-O6:6P=K&4_P@;H_P NWX5Q>H^
MM?L22EJ+I!_%"V3^1YKVK&1Z4?3/XUK&K)&4J,'J?.T]G=6K$3VLT9!_BC(J
M#('7'YU]'O&D@PZ*P_VAFJTFEV$GW[&V;ZQ+_A6BQ'=&+PW9GSSN'K^M6(+*
M[NB!;6LTI)X"1DYKWU-+L(^8[&V0^HB6K*1B-=J!5'8!<"DZ_9#6&[L\8T_P
M!K]_@O;K:H?XIS@_D.:[C1OAWI^GJ&O9&O).NUAA ?I78\T 8[DU$JTF:1H0
M70:B)&@5%"J!PH&*<.3FC'%+61L%%%% !1110 4444 %%%% !1110 4444 %
M%%% !S1110 4444 %%%% !1110 4444 %<QXQU:^TJ*R^P2)&\SR!BVP9VH6
M RW Y KIZYC6];2ROI8;ZQMYK**(R[V^8JV/E+ C"Y;Y1W[]* ,Z/QU.)+19
M=/!28\R!L94;5+8/3YB3CK@5$WCZXDM6,-M )/WJAFDRNX#*\ YYJ[I7B6/5
M=5LK:338/WUN9XF7YMK;020V,8.<9'.15-_%$=I<1I-I-HNUF9IHDW)Y8P&P
MV.N2 3TS0!VUK(TUK#*P7<Z*QVG(R1G@^E35CZ!JDNI0RB>V2!X]A41G*E&4
M,OX@&MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0C(QC(]*6B@"M
M)86DA):UB+%=F=H!V]<9],T?8+/"C[)#\LGFJ/+'#_WOK[U9HH CB@B@#"&*
M.,,Q=M@QECU)QU-2"BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH ***,B@ HHR*,T %%)D&ES0 449HR* "BC-)D4 +11FC- !
M11D49H *SSHNGG49=0-JIN90%D8Y.\ 8&1T.!6AFC- &8/#^F*28[18\HL?[
MOY<*#G ]/0XJ*+POHT*Q(EA&$A<O&I)(4GM]. <=*V,T9H J6&FVFF0M#90+
M%&S%B!W)JW29&<?THR,9Y_*@!:*,TF1[_E0 M%!.*3/..>N.E "T4F1[_E2T
M %%%% !1110 444A.,]>!GI0 M%)G'K^5&?KUQTH 6BDW#WZ9Z4$XSUX&>E
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M0EF(P!@]L8&/I4-UX4L+F$%C*UTD+117$LC,R9# ]^^XY'<8]!0!1D\?:5%
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M-:Q1R7$ O&*@X$&W&1[^8"/H177,BNI5E# ]01FH5LK=+U[U8A]H:,1%\_P
MD@>W)H XRV\3:M;-%;W$MM=RW5_<6<1$97RY5D^5' /3RPQSQT'K51?'FIO:
MAXQ8S>;Y?[V,'9;%F==LFY@,_(#R5Z_2N]EL;:>X@N)8E:6!R\9]&(VD^YQQ
M26NGVEE9K:6]NB0*,!,9'XYZT &F3SW6F6T]S$D4\D89T1]R@D=CW%6J0
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MN-)N)[S2;6XNDC2>2,,ZQN&4'V(X-/M--L[*T^RV]NB0<Y3&<Y]<]:LA0H
M  X  Z4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
(0 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>pg1img1_10k.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg1img1_10k.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ *P#) P$1  (1 0,1 ?_$ ,<   (" P$!
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M^P_[/V\,<_<L$DD$*K,5!-/NP)(F8 E.I->A(-!I;W3L#FOCS;_[:KGYKB>
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M4'S&NI&-ODR>.@R,:21I<0I(%<=KJ'4,%=?)A6A'D=44,?\ ]O9&_P#?Y/\
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M.7F^Q.(&M94YR.9C&-;6 (B%CJ[;9IS%,P+[8IP$-:;8O6X)P9#<A3ID4*F
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4&C1HT:-&C1HT:-&C1HT:-&C7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821734032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Mar. 24, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Moleculin Biotech, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001659617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,612,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MBRX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,176,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821877056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 5,007,216<span></span>
</td>
<td class="nump">$ 28,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">215,052<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">5,222,268<span></span>
</td>
<td class="nump">28,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Long-Term Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Furniture and equipment, net of accumulated depreciation of $6,162 and $0, respectively</a></td>
<td class="nump">23,128<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">11,147,540<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">16,392,936<span></span>
</td>
<td class="nump">28,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">1,048,655<span></span>
</td>
<td class="nump">322,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable</a></td>
<td class="nump">296,412<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,345,067<span></span>
</td>
<td class="nump">772,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent', window );">Long-term deferred compensation - related party</a></td>
<td class="nump">87,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">1,432,567<span></span>
</td>
<td class="nump">772,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5,000,000 authorized, no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 75,000,000 authorized, 12,164,852 and 6,661,000 shares issued and outstanding, respectively</a></td>
<td class="nump">12,165<span></span>
</td>
<td class="nump">6,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable', window );">Subscription receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">19,622,925<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(4,674,721)<span></span>
</td>
<td class="num">(748,360)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity (Deficit)</a></td>
<td class="nump">14,960,369<span></span>
</td>
<td class="num">(744,699)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity (Deficit)</a></td>
<td class="nump">$ 16,392,936<span></span>
</td>
<td class="nump">$ 28,091<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of subscription receivable from investors who have been allocated common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Assets<br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6807971776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation, Furniture and equipment</a></td>
<td class="nump">$ 6,162<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">12,164,852<span></span>
</td>
<td class="nump">6,661,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">12,164,852<span></span>
</td>
<td class="nump">6,661,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821839712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">260,418<span></span>
</td>
<td class="nump">1,495,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">477,810<span></span>
</td>
<td class="nump">2,381,424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,162<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total Operating Expenses</a></td>
<td class="nump">738,228<span></span>
</td>
<td class="nump">3,883,147<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(738,228)<span></span>
</td>
<td class="num">(3,883,147)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(10,132)<span></span>
</td>
<td class="num">(43,214)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (748,360)<span></span>
</td>
<td class="num">$ (3,926,361)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share - basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.40)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding - basic and diluted (in share)</a></td>
<td class="nump">5,691,803<span></span>
</td>
<td class="nump">9,827,510<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822061072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (748,360)<span></span>
</td>
<td class="num">$ (3,926,361)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">323,974<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense', window );">Deferred CEO compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_SharesIssuedForLicensesUsedForResearchAndDevelopment', window );">Stock issued for licenses used for research and development</a></td>
<td class="nump">2,061<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(215,052)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">322,790<span></span>
</td>
<td class="num">(41,128)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net Cash Used in Operating Activities</a></td>
<td class="num">(423,509)<span></span>
</td>
<td class="num">(3,764,905)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Cash paid for purchase of fixed assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(21,470)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid for acquisition of Moleculin, LLC, net with cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(99,638)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net Cash Used in Investing Activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(121,108)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from notes payable</a></td>
<td class="nump">450,000<span></span>
</td>
<td class="nump">165,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payments on notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(469,939)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from sale of common stock, net of cash stock issuance costs</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">9,170,077<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net Cash Provided by Financing Activities</a></td>
<td class="nump">451,600<span></span>
</td>
<td class="nump">8,865,138<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">28,091<span></span>
</td>
<td class="nump">4,979,125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, at beginning of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">28,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, at end of period</a></td>
<td class="nump">28,091<span></span>
</td>
<td class="nump">5,007,216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,585<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Common stock issued for the Acquisition of Moleculin, LLC</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,773,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Common stock issued for conversion of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">363,792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_WarrantsIssuedForServices', window );">Warrants issued for services provided</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">374,763<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for services provided</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_SharesSubscribed', window );">Shares subscribed</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_SharesIssuedForLicensesUsedForResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued for licenses used for research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_SharesIssuedForLicensesUsedForResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_SharesSubscribed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares subscribed during the period as a non cash activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_SharesSubscribed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_WarrantsIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of Warrants issued for services provided in non cash financing activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_WarrantsIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The compensation expense recognized during the period pertaining to the deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6409875&amp;loc=d3e20015-108363<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822628752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders&#8217; Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Subscriptions Receivable [Member]</div></th>
<th class="th"><div>Accumulated Loss [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Jul. 27, 2015</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Jul. 27, 2015</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_StockIssuedDuringPeriodValueForCashAndSubscriptionReceivable', window );">Stock issued for cash and subscription receivable</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_StockIssuedDuringPeriodSharesForCashAndSubscriptionReceivable', window );">Stock issued for cash and subscription receivable (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_StockIssuedDuringPeriodValueForLicenses', window );">Stock issued for licenses</a></td>
<td class="nump">2,061<span></span>
</td>
<td class="nump">$ 2,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_StockIssuedDuringPeriodSharesForLicenses', window );">Stock issued for licenses (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,061,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(748,360)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(748,360)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balances at Dec. 31, 2015</a></td>
<td class="num">(744,699)<span></span>
</td>
<td class="nump">$ 6,661<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
<td class="num">(748,360)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Endind Balances (in shares) at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,661,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_StockIssuedDuringPeriodValuePrivateIssuances', window );">Private issuance @ $3.00 / share</a></td>
<td class="nump">702,894<span></span>
</td>
<td class="nump">$ 234<span></span>
</td>
<td class="nump">702,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_StockIssuedDuringPeriodSharesPrivateIssuances', window );">Private issuance @ $3.00 / share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issued for Moleculin acquisition</a></td>
<td class="nump">5,999,586<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">5,998,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issued for Moleculin acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">999,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_StockIssuedDuringPeriodValueForTechnology', window );">Issued for technology</a></td>
<td class="nump">3,774,000<span></span>
</td>
<td class="nump">$ 629<span></span>
</td>
<td class="nump">3,773,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_StockIssuedDuringPeriodSharesForTechnology', window );">Issued for technology (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">629,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts', window );">Issued for cash - IPO, net of stock issuance costs of $1,150,736</a></td>
<td class="nump">8,089,420<span></span>
</td>
<td class="nump">$ 1,540<span></span>
</td>
<td class="nump">8,087,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts', window );">Issued for cash - IPO, net of stock issuance costs of $1,150,736 (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,540,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrants issued for services</a></td>
<td class="nump">374,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">374,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock granted for services</a></td>
<td class="nump">157,680<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">157,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock granted for services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock option expense</a></td>
<td class="nump">166,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issued for convertible debt</a></td>
<td class="nump">363,792<span></span>
</td>
<td class="nump">$ 2,077<span></span>
</td>
<td class="nump">361,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issued for convertible debt (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,076,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_StockholdersEquitySubscriptionsSettledForCash', window );">Subscription agreement settled for cash</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,926,361)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,926,361)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balances at Dec. 31, 2016</a></td>
<td class="nump">$ 14,960,369<span></span>
</td>
<td class="nump">$ 12,165<span></span>
</td>
<td class="nump">$ 19,622,925<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (4,674,721)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Endind Balances (in shares) at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,164,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_StockIssuedDuringPeriodSharesForCashAndSubscriptionReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for cash and subscription receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_StockIssuedDuringPeriodSharesForCashAndSubscriptionReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for cash initial public offering net of stock issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_StockIssuedDuringPeriodSharesForLicenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for licenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_StockIssuedDuringPeriodSharesForLicenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_StockIssuedDuringPeriodSharesForTechnology">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for technology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_StockIssuedDuringPeriodSharesForTechnology</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_StockIssuedDuringPeriodSharesPrivateIssuances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period in private issuances</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_StockIssuedDuringPeriodSharesPrivateIssuances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_StockIssuedDuringPeriodValueForCashAndSubscriptionReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued for cash and subscription receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_StockIssuedDuringPeriodValueForCashAndSubscriptionReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued for Cash IPO Net of Stock Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_StockIssuedDuringPeriodValueForLicenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued for licenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_StockIssuedDuringPeriodValueForLicenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_StockIssuedDuringPeriodValueForTechnology">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued for technology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_StockIssuedDuringPeriodValueForTechnology</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_StockIssuedDuringPeriodValuePrivateIssuances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of private issuances during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_StockIssuedDuringPeriodValuePrivateIssuances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_StockholdersEquitySubscriptionsSettledForCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents subscriptions receivable settled for cash during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_StockholdersEquitySubscriptionsSettledForCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66904339&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65896087&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65896087&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28183637&amp;loc=d3e4724-112606<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Warrant<br> -URI http://asc.fasb.org/extlink&amp;oid=6528364<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=mbrx_SubscriptionsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=mbrx_SubscriptionsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6812427296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Stockholders&#8217; Equity (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share | $ / shares</a></td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | $</a></td>
<td class="nump">$ 1,150,736<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6812635056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_NatureOfBusinessAndLiquidityTextBlock', window );">Nature of Business and Liquidity [Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <table style="LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.3pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <b><font style="FONT-SIZE: 10pt">1.</font></b></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><b><font style="FONT-SIZE: 10pt">Nature of Business and Liquidity</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The terms &#8220;MBI&#8221; or &#8220;the Company&#8221;, &#8220;we&#8221;, &#8220;our&#8221; and &#8220;us&#8221; are used herein to refer to Moleculin Biotech, Inc. MBI is a preclinical pharmaceutical company organized as a Delaware corporation in July 2015 to focus on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, which we refer to as MD Anderson.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Our lead drug candidate is liposomal Annamycin, which we refer to as Annamycin, an anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia, or AML. In August 2015, the Company entered into a rights transfer agreement with AnnaMed, Inc. (&#8220;AnnaMed&#8221;), a company affiliated with certain members of the Company&#8217;s management and board of directors, pursuant to which, in exchange for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,431,000</font> shares of the Company&#8217;s common stock, AnnaMed agreed to transfer to MBI any and all data it had regarding the development of Annamycin and the Annamycin investigative new drug application (&#8220;IND&#8221;) with the U.S. Food and Drug Administration (&#8220;FDA&#8221;) , including all trade secrets, know-how, confidential information and other intellectual property rights held by AnnaMed. Annamycin has been in clinical trials pursuant to an IND that had been filed with the FDA. This IND was terminated due to a lack of activity by a prior drug developer.&#160;However, in the course of our review of that data, we identified that Annamycin may have greater potential for efficacy than we originally believed, based on an unexpected potential opportunity to increase the drug&#8217;s Maximum Tolerable Dose (&#8220;MTD&#8221;). We determined to adjust our clinical strategy by adding in a Phase I arm to our next Phase II trial.</div> <font style="FONT-SIZE: 10pt">&#160;</font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Because the prior developer of Annamycin allowed their IND to lapse, we are required to submit a new IND for continued clinical trials with Annamycin. We filed our IND application, with the clinical strategy of increasing the MTD mentioned above, for Annamycin on February 10, 2017. &#160;In subsequent discussions with us, FDA requested certain revisions to the protocol, additional&#160;information, and additional data related to Chemistry, Manufacturing and Controls (&#8220;CMC&#8221;). &#160;We have the additional information, have made the requested revisions to the protocol,&#160;and we are working on developing the CMC data. &#160;In the interim, we have withdrawn the IND application in order to resubmit it when the requested data are available. &#160;We believe that resubmission of the IND application will occur in time for the IND to go into effect and the announcement of the beginning of Phase I/II clinical trials in the first half of 2017. However, if we are unable to obtain the required CMC data on a timely basis, we will be delayed in resubmitting our IND application, which will delay the commencement of our clinical trials beyond the first half of 2017.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify">The Annamycin drug substance is no longer covered by any existing patent protection. We intend to submit patent applications for formulation, synthetic process and reconstitution related to our Annamycin drug product candidate, although there is no assurance that we will be successful in obtaining such patent protection. On March 21, 2017, we received notice that FDA had granted us Orphan Drug designation for Annamycin <font style="FONT-FAMILY:Times New Roman, Times, Serif">for the treatment of AML</font> . Orphan Drug status could entitle us to market exclusivity of up to 7 and 10 years from the date of approval of a New Drug Application (&#8220;NDA&#8221;) or Marketing Authorization Application (&#8220;MAA&#8221;), in the US and the European Union (&#8220;EU&#8221;), respectively. Separately, the FDA may also grant market exclusivity of up to five years for newly approved new chemical entities (of which Annamycin would be one), but there can be no assurance that such exclusivity will be granted.<font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We have two other drug development projects in progress, one involving a portfolio of small molecules, which we refer to as the WP1066 Portfolio, focused on the modulation of key oncogenic transcription factors involved in the progression of cancer, and the WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer in general, and glioblastoma (the most common form of brain tumor) in particular. We have been granted royalty-bearing, worldwide, exclusive licenses for the patent and technology rights related to our WP1066 Portfolio and WP1122 Portfolio drug technologies, as these patent rights are owned by MD Anderson.&#160;&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On August 11, 2015, the Company entered into a rights transfer agreement for WP1122 with IntertechBio Corporation (&#8220;IntertechBio&#8221;), a company affiliated with certain members of our management, whereby IntertechBio agreed to assign its license or sublicense its license&#160;&#160; to certain metabolic inhibitor technology owned by MD Anderson. In consideration, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 630,000</font> common shares to IntertechBio. IntertechBio&#160;&#160; agreed to make payments to MD Anderson including an up-front payment, license documentation fee, annual maintenance fee, milestone payments and minimum annual royalty payments for sales of products developed under the license agreement. The Company has assumed the rights and obligations of IntertechBio under the license agreement with MD Anderson. Therefore, &#160;all out-of-pocket expenses incurred by MD Anderson in filing, prosecuting and maintaining the licensed patents have been and shall continue to be assumed &#160;&#160;by the Company.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In accordance with FASB ASC Topic 280, Segment Reporting, we view our operations and manage our business as principally one segment. As a result, the financial information disclosed herein represents all of the material financial information related to our principal operating segment.&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company filed a registration statement on Form S-1 (which was declared effective on May 2, 2016) with respect to the Company&#8217;s initial public offering of shares of its common stock (&#8220;IPO&#8221;) to fund the development of its technologies. Prior to the declaration of effectiveness of the registration statement on Form S-1, we acquired Moleculin, LLC which was merged with and into MBI. Moleculin, LLC was the holder of a license agreement with MD Anderson covering technology referred to as &#160;&#160;the WP1066 Portfolio, which is focused on the modulation of key oncogenic transcription factors.&#160;&#160;&#160;</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_NatureOfBusinessAndLiquidityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for nature of business and liquidity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_NatureOfBusinessAndLiquidityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6812439120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.3pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <b><font style="FONT-SIZE: 10pt">2.</font></b></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><b><font style="FONT-SIZE: 10pt">Summary of Significant Accounting Policies</font></b></div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">The accompanying audited financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the &#8220;SEC&#8221;).</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><b><font style="FONT-SIZE: 10pt"> &#160;</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><b><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Use of Estimates in Financial Statement Presentation -</font></b> <font style="FONT-SIZE: 10pt">The preparation of these financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><b><font style="FONT-SIZE: 10pt"> &#160;</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><b><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></font></b> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Acquisition &#150;</b> We acquired Moleculin, LLC (&#8220;Moleculin&#8221;) on May 2, 2016, and, going forward our financial statements include the operations of Moleculin, LLC. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired in-process research and development (&#8220;IPR&amp;D&#8221;) be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired will be recorded as goodwill. The Company obtained input from third-parties regarding its tangible and intangible assets and other information necessary to measure the fair value of the assets acquired and liabilities assumed in connection with the acquisition of Moleculin, LLC.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><b> <font style="FONT-SIZE: 10pt"></font></b> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><b><font style="FONT-SIZE: 10pt"> &#160;</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Going Concern -</b> These financial statements have been prepared on a going concern basis, which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The continuation of the Company as a going concern is dependent upon the ability of the Company to obtain continued financial support from its stockholders&#8217;, necessary equity financing to continue operations and the attainment of profitable operations. As of December 31, 2016, the Company has incurred an accumulated deficit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4,674,721</font> since inception, and had not yet generated any revenue from operations. Additionally, management anticipates that its cash on hand as of December 31, 2016 plus the additional cash generated from its equity offering subsequent to year-end, discussed further within these notes to the financial statements, is sufficient to fund its planned operations into but not beyond the near term. These factors raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company may seek additional funding through a combination of equity offerings, debt financings, government or other third-party funding, commercialization, marketing and distribution arrangements, other collaborations, strategic alliances and licensing arrangements and delay planned cash outlays or a combination thereof. Management cannot be certain that such events or a combination thereof can be achieved.&#160;&#160;</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Cash and Cash Equivalents -</strong> The Company considers all highly liquid accounts with original maturities of three months or less at the date of acquisition to be cash equivalents.&#160;Periodically, the Company may carry cash balances at financial institutions in excess of the federally insured limit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250,000</font>. The amount in excess of the FDIC insurance at December 31, 2016 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">256,836</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font> as of December 31, 2015. Compensation expense is recognized only for share based payments expected to vest.</font>&#160;</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><b><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Property and equipment -</font></b> <font style="FONT-SIZE: 10pt">Property and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line depreciation method as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 85%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; MARGIN-LEFT: 0.5in; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="85%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 40%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="40%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Leasehold improvement</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 60%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="60%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt">Shorter of estimated useful lives or the term of the lease</font>&#160;</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Computer equipment</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2</font> years*</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Machinery and equipment</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5</font> years*</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Furniture and office equipment</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7</font> years*</font></div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">*Property and equipment assets acquired in the merger with Moleculin, LLC are being depreciated over a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2</font> year useful life due to their age and condition and expected remaining life assessed at merger date.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><b><font style="FONT-SIZE: 10pt"> &#160;</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><b><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Intangible assets -</font></b> <font style="FONT-SIZE: 10pt">Intangible assets with finite lives are amortized using the straight-line method over their estimated period of benefit. If an intangible asset is identified as an in-process research &amp; development asset, then no amortization will occur until the development is complete. If the associated research and development effort is abandoned, the related assets will be written-off and the Company will record a noncash impairment loss on its statements of operations. For those compounds that reach commercialization, the IPR&amp;D assets will be amortized over their estimated useful lives.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">We evaluate the recoverability of intangible assets periodically and take into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists. No material impairments of intangible assets have been identified during any of the periods presented. Intangible assets are tested for impairment on an annual basis, and between annual tests if indicators of potential impairment exist, using a fair-value-based approach.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><b><font style="FONT-SIZE: 10pt"> &#160;</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Beneficial Conversion Feature</b> - From time to time, the Company may issue convertible notes that have conversion prices that create an embedded beneficial conversion feature on the issuance date. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of any attached equity instruments, if any related equity instruments were granted with the debt. The Company estimated the fair value of its common stock on the dates issued. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid-in capital, if any. The debt discount is amortized to interest expense over the life of the note using the effective interest method.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Income Taxes -</b> The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of reported assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company must then assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.&#160;</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify">The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740-10 which prescribes a recognition threshold and measurement attribute for financial statement disclosure of tax positions taken, or expected to be taken, on its tax return. The Company evaluates and records any uncertain tax positions based on the amount that management deems is more likely than not to be sustained upon examination and ultimate settlement with the tax authorities in the tax jurisdictions in which it operates.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Stock-based Compensation -</b> Stock-based compensation expense includes the estimated fair value of equity awards vested during the reporting period. The expense for equity awards vested during the reporting period is determined based upon the grant date fair value of the award and is recognized as expense over the applicable vesting period of the stock award using the straight-line method.&#160;</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><strong>Loss Per Common Share</strong> - Basic net loss per common share are computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. As of December 31, 2016, the Company&#8217;s potentially dilutive shares, which were not included in the calculation of net loss per share, included notes convertible to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,821,013</font> common shares, options to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 510,000</font> common shares and warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 107,802</font> common shares.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><b><font style="FONT-SIZE: 10pt"> &#160;</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><b><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Research and Development Costs -</font></b> <font style="FONT-SIZE: 10pt">Research and development costs are expensed as incurred.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><b><font style="FONT-SIZE: 10pt"> &#160;</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><b><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></font></b> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Subsequent Events -</b> The Company&#8217;s management reviewed all material events through the date these financial statements were issued for subsequent event disclosure consideration and has noted such events as described in Note 8.</div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><b><font style="FONT-SIZE: 10pt"> &#160;</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><b><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Recent Accounting Pronouncements</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify">In May 2014, the FASB issued Accounting Standard Update ("ASU") 2014-09, Revenue from Contracts with Customers (Topic 606), which will replace numerous requirements in U.S. GAAP, including industry-specific requirements, and provide companies with a single revenue recognition model for recognizing revenue from contracts with customers. The core principle of the new standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In August 2015, the FASB approved a proposal to defer the effective date of the guidance until annual and interim reporting periods beginning after December 15, 2017. The Company is currently evaluating the impact that this standard will have on its financial statements at the time the Company starts to generate revenue or enters into other contractual arrangements, which the Company does not expect in the near term.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern. Under the new guidance, management will be required to assess an entity&#8217;s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. The provisions of this ASU are effective for annual periods ending after December 15, 2016, and for annual and interim periods thereafter; early adoption is permitted. This disclosure is effective within these financial statements for the year ended December 31, 2016.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments &#150; Overall: Recognition and Measurement of Financial Assets and Financial Liabilities (&#8220;ASU 2016-01&#8221;).&#160;ASU 2016-01 affects the accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements of financial instruments.&#160;ASU 2016-01 is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years.&#160;The Company is currently evaluating the impact that this standard will have on its financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (&#8220;ASU 2016-02&#8221;). Under ASU 2016-02, an entity will be required to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements.&#160;ASU 2016-02 offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases.&#160;For public companies, ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, and requires a modified retrospective adoption, with early adoption permitted.&#160;The Company is currently evaluating the impact that this standard will have on its financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In March 2016, the FASB issued ASU 2016-09, Compensation-Stock Compensation (Topic 718). The new guidance changes the accounting and simplifies various aspects of the accounting for share-based payments to employees. The guidance allows for a policy election to account for forfeitures as they occur or based on an estimated number of awards that are expected to vest. ASU 2016-09 is effective for annual periods beginning after December 15, 2016, with early adoption permitted. The adoption of this standard on January 1, 2017, did not have a significant impact on the Company&#8217;s financial statements.</div> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify">In August 2016, the FASB issued ASU, Statement of Cash Flows (Topic 230). This ASU applies to all entities that are required to present a statement of cash flows under Topic 230. The amendments provide guidance on eight specific cash flow issues and includes clarification on how these items should be classified in the statement of cash flows and is designed to help eliminate diversity in practice as to where items are classified in the cash flow statement. Furthermore in November 2016, the FASB issued additional guidance on this Topic that requires amounts generally described as restricted cash and restricted cash equivalents to be included with cash and cash equivalents when reconciling the statement of cash flows. This ASU is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years, with earlier application permitted for all entities. We plan to adopt the provisions of this ASU for our fiscal year beginning January 1, 2018 and are currently evaluating the impact the adoption of this new accounting standard will have on our financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On November 20, 2015, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update ("ASU") 2015-17, "Balance Sheet Classification of Deferred Taxes", requiring all deferred tax assets and liabilities, and any related valuation allowance, to be classified as non-current on the balance sheet. The classification change for all deferred taxes as non-current simplifies entities&#8217; processes as it eliminates the need to separately identify the net current and net non-current deferred tax asset or liability in each jurisdiction and allocate valuation allowances. The Company elected to adopt the accounting in the fourth quarter of 2016.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">The Company does not believe that any other recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect on the accompanying financial statements.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18861-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18743-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18854-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6608082368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets Disclosure [Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.3pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <strong><font style="FONT-SIZE: 10pt">3.</font></strong></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Intangible Assets</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 18.7pt" align="justify"><strong><font style="FONT-SIZE: 10pt"> &#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt">The Acquisition of Moleculin, LLC</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On May 2, 2016, Moleculin, LLC, a Texas limited liability company, was merged with and into the Company. As a result of the merger, the Company issued to the holders of Moleculin equity interests an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 999,931</font> shares of the Company&#8217;s common stock valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,999,586</font>, based on the estimated acquisition-date fair value of our common stock of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6.00</font> per share, equal to the IPO price announced in our prospectus filed on that date. These shares contain certain trading restrictions. Prior to the Company&#8217;s acquisition of Moleculin, the Company had loaned $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">57,822</font> to Moleculin which was treated as part of the consideration paid to acquire Moleculin.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">As additional consideration payable to the Moleculin unit holders, we agreed pursuant to the merger agreement that if drugs for dermatology indications are successfully developed by us using any of the Existing IP Assets, then the Moleculin, LLC unit holders, in the aggregate, will be entitled to receive a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2.5</font>% royalty on the net revenues generated by such drugs. Any such net revenues would include a deduction for license fees or royalty obligations payable to MD Anderson for such Existing IP Assets. The merger agreement defined &#8220;Existing IP Assets&#8221; to mean all intellectual property, licensed by us and Moleculin as of the time of the merger, including, without limitation, the intellectual property licensed from MD Anderson under the Patent and Technology License Agreement entered into by and between IntertechBio Corporation and MD Anderson dated April 2, 2012, as amended, and the Patent and Technology License Agreement dated June 21, 2010, as amended, between MD Anderson and Moleculin, LLC, but excluding any intellectual property relating to Annamycin. The right to receive the contingent royalty payments described herein is limited to&#160;drugs developed only for dermatology indications, and does not include drugs developed for any other indications. We have no obligation of any nature to pursue the development of any drugs for dermatology indications.</font></div> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Our acquisition of Moleculin, LLC, occurring prior to our IPO offering, provided us with the rights to the license agreement that Moleculin, LLC had with MD Anderson covering the WP1066 Portfolio. However, Moleculin, LLC had previously granted Houston Pharmaceuticals, Inc. (&#8220;HPI&#8221;), a related party, an option, which could be exercised at any time, to obtain an exclusive sub-license to develop the WP1066 Portfolio in all non-dermatological fields. Moleculin, LLC had previously pursued development of the WP1066 Portfolio for treatment of psoriasis, however, psoriasis related clinical trials had been terminated. Because WP1066 has shown significant activity against a wide range of tumors, Moleculin, LLC&#8217;s focus prior to the acquisition included the development of drugs for cancer treatment. However, the exclusive sub-license option held by HPI precluded Moleculin, LLC from pursuing drug development related to non-skin cancers, in addition to potentially creating significant intellectual property, clinical and commercialization risks associated with drug development for skin cancers. Re-acquisition of the HPI option was therefore essential for the values of both the WP1066 Portfolio and Moleculin, LLC.</div> <font style="FONT-SIZE: 10pt">&#160;</font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Additionally, the merger agreement contained mutual representations and warranties between the parties. Pursuant to the merger agreement, we agreed for a period of six years to indemnify and hold harmless each present and former director and/or officer of Moleculin, LLC whom Moleculin, LLC would have had the power to indemnify under Delaware law that is made a party or threatened to be made a party to any threatened, pending or completed proceeding or claim by reason of the fact that he or she was a director or officer of the Moleculin, LLC prior to the effective time of the merger and arising out of actions or omissions of the indemnified party in any such capacity occurring at or prior to the effective time of the merger against any losses or damages reasonably incurred in connection with any claim. To our knowledge, no such proceeding or claim exists or has been threatened on the date hereof.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In connection with the acquisition of Moleculin, LLC, we also negotiated on behalf of Moleculin, LLC two agreements with HPI. Under the first agreement,&#160;HPI&#8217;s option to obtain the aforementioned exclusive sublicense was terminated in exchange for a payment of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">100,000</font> and the issuance of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 629,000</font> shares of our common stock, valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6</font> per share. Under the second agreement (HPI Out-Licensing Agreement), HPI has received a non-exclusive technology rights and development sublicense under which it may continue its ongoing work to develop the WP1066 Portfolio related to treatment of non-skin cancer. Pursuant to this HPI Out-Licensing Agreement, we agreed to make payments to HPI totaling $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">750,000</font> over a three-year period, of which $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">75,000</font> was paid in calendar year 2016. The Company expenses such costs as&#160;incurred as research and development expense, commencing after the IPO offering in exchange for HPI allowing us to access any data, information or know-how resulting from the research and development conducted by HPI. As of December 31, 2016, notwithstanding our obligation to make the foregoing payments, the HPI Out-Licensing Agreement does not obligate HPI to conduct any specific research or to meet any milestones. Pursuant to the HPI Out-Licensing Agreement, we have the right within three years of the effective date to buy-out from HPI all rights granted to HPI under the agreement for a payment of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.0</font> million. Upon our exercise of the buy-out we will no longer be obligated to make any payments to HPI remaining from the $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">750,000</font> obligation discussed above. If we do not exercise the foregoing buy-out right within three years, the license granted to HPI shall convert into an exclusive license. As such, if we do not exercise the buy-out right for any reason, we will no longer have access to the non-skin cancer uses of the WP1066 Portfolio. As noted above, this will also potentially create risks for the development of skin cancer drugs. We do not intend to set aside and designate cash and cash equivalents in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.0</font> million to make the buy-out payment. If we ultimately decide to exercise the buy-out right from HPI, we will need to raise additional funds to make the buy-out payment. We cannot assure that such additional funding will be available on satisfactory terms, or at all.</div> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The agreements with HPI were executed on May 2, 2016, simultaneously with the closing of the Moleculin, LLC acquisition, and were non-cancelable but contingent on the Company&#8217;s ability to complete the IPO by June 30, 2016. They became effective on May 31, 2016.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The termination of the HPI option was completed on behalf of Moleculin, LLC, which&#160;was required to enable the sale of Moleculin, LLC by materializing the value of its most significant asset, and was non-cancelable by either party. Further, the HPI option termination price was determined simultaneously with the acquisition on May 2, 2016 as our IPO price was established at that time. Accordingly, we concluded that this transaction was primarily for the benefit of Moleculin, LLC and its former owners, resulting in control of the underlying intellectual property and thereby increasing the value of Moleculin, LLC intangible assets immediately prior to the closing of its acquisition by us.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The HPI option termination price amounted to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,874,000</font>, consisting of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 629,000</font> shares of our common stock valued at the IPO price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6.00</font> per share, and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">100,000</font> paid in cash in July 2016, and was included in acquisition-date liabilities assumed.</font></div> <strong><font style="FONT-SIZE: 10pt">&#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 18.7pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Purchase Price Allocation</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The acquisition price was allocated to the assets acquired and liabilities assumed based upon their estimated fair values and the information available to management. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.25in; WIDTH: 92%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="76%"> <div>Cash</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>362</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="76%"> <div>Property and equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>7,820</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="76%"> <div>Intangibles</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>11,147,540</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="76%"> <div>Total assets acquired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>11,155,722</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="76%"> <div>Liability assumed (HPI)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(3,874,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="76%"> <div>Other liabilities assumed, including $469,939 of notes payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(1,224,314)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="76%"> <div>Net assets acquired/total consideration transferred</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>6,057,408</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 18.7pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company obtained input from third-parties regarding its tangible and intangible assets and other information necessary to measure the fair value of the assets acquired and liabilities assumed in connection with the acquisition of Moleculin, LLC. Management believes all or most of the intangible assets are IPR&amp;D related to the WP1066 Portfolio, and, as such, no amortization has been recorded to date.</div> <font style="FONT-SIZE: 10pt">&#160;</font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Intangible assets consisted of the following at December 31, 2016 and December 31, 2015:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 96%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Intangibles acquired from Moleculin, LLC</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>11,147,540</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>&#150;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 18.7pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Unaudited Pro Forma Results of Operations</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 18.7pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The following comparative table presents the unaudited condensed pro forma results of operations that reflect the acquisition of Moleculin as if the acquisition had occurred as of the first day of each period presented, adjusted for items that are directly attributable to the acquisition. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>This information has been compiled from historical financial statements and is not necessarily indicative of the results that actually would have been achieved had the transaction already occurred or that may be achieved in the future.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 96%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>Pro&#160;Forma</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>For&#160;the&#160;Year</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>Pro&#160;Forma</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>For&#160;Year Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>December</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>December</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="64%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Total operating expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>(3,979,316)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>(688,101)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Net loss</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>(3,962,997)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>(164,128)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Net loss per common share &#150; basic and diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>(0.42)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>(0.04)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Weighted average outstanding common shares &#150; basic and diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>9,401,028</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>4,273,239</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The years ended December 31, 2016 and December 31, 2015 are adjusted on a pro forma basis to exclude $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">145,078</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">422,874</font>, respectively, in net interest expense related to the amortization of deferred financing costs and debt discount amortization for Moleculin, LLC&#8217;s convertible notes. The holders of the convertible notes were issued the Company&#8217;s common shares upon the Company&#8217;s acquisition of Moleculin, LLC.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final.  May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6812428384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_ConvertibleNotesPayableAbstractAbstract', window );"><strong>Convertible Notes Payable Abstract [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_ConvertibleNotesPayableDisclosureTextBlock', window );">Convertible Notes Payable Disclosure [Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.3pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <strong><font style="FONT-SIZE: 10pt">4.</font></strong></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Convertible Notes Payable</font></strong></div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On various dates from August 31, 2015 through January 19, 2016, each as amended on March 10, 2016, the Company entered into seven unsecured promissory notes with three separate third party investors. Each note bears interest at <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8.0</font>% per annum and was to mature on the earlier of June 30, 2016 or the completion of an IPO of the Company&#8217;s securities.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;Since the completion of the IPO occurred prior to June 30, 2016, these notes were to be automatically converted according to their terms into shares of the Company&#8217;s common stock at applicable conversion price upon the Company&#8217;s IPO to the extent and provided that no holder of these notes was or will be permitted to convert such notes to the extent that the holder or any of its affiliates would beneficially own in excess of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4.99</font>% of our common stock after such conversion. Due to this 4.99% limitation, a portion of these notes was not converted at the time of the IPO and the remaining unconverted principal and accrued interest amounts of the effected notes will remain outstanding and will be converted into shares of our common stock at such time as the 4.99% limitation continues to be met. Until such time as the notes are converted into shares of common stock, the maturity date of the notes will automatically be extended and we will not be required to repay the notes or the accrued interest relating to the notes in cash.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The IPO was completed on May 31, 2016. On May 31, 2016, pursuant to the conversion feature of the foregoing notes and with restriction of the <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4.99</font>% beneficially owned condition limitation, discussed above, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,166,503</font> <font style="FONT-SIZE: 10pt">&#160;</font> common shares in total, reducing convertible debt principal by $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">183,356</font> and accrued interest by $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">17,699</font>. Subsequent to these transactions and through December 31, 2016, an additional <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 910,095</font> common shares were issued due to the number of common shares outstanding allowing for conversion of additional shares under the 4.99% beneficially owned condition limitation. This reduced the convertible debt principal by $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">155,565</font> and accrued interest by $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7,172</font>. The remaining convertible debt without consideration of accrued interest as of December 31, 2016, if converted on December 31, 2016, would result in an additional <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,821,013</font> common shares to be issued.</div> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">The convertible notes were analyzed for a beneficial conversion feature on various issuance dates, at which time it was concluded that a beneficial conversion feature did not exist.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The table below represents the shares that are convertible at December 31, 2016 relating to the principal amounts of these convertible notes payable and excludes any shares that are convertible relating to the associated accrued interest:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 96%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>Convertible&#160;at</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>Dec&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>Issuance&#160;Date</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>2016 (e)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>Conversion&#160;Rate</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="33%"> <div>August 31, 2015(a)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>38,299</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>125,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>0.1299</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>294,832</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>September 3, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>125,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>125,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>0.1299</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>962,279</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>October 6, 2015(a)(c)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>30,280</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>147,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>0.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>151,402</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>October 6, 2015(b)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>&#150;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>3,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>0.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>&#150;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>October 28, 2015(b)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>&#150;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>50,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>0.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>&#150;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>January 14, 2016(d)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>&#150;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>&#150;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>0.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>&#150;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>January 19, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>82,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>&#150;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>0.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>412,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>276,079</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>450,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>1,821,013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 18.7pt; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in"> (a) Debt partially converted on May 31, 2016 and on August 19, 2016.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 18.7pt; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in"> (b) Debt fully converted to common shares on May 31, 2016.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 18.7pt; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in"> (c) Debt partially converted on September 1, 2016.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 18.7pt; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in"> (d) Debt fully converted to common shares effective November 30, 2016.&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 11.5pt 0pt 18.7pt; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in"> (e) Excluded from the $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">276,079</font> is $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">20,333</font> in accrued interest on the convertible notes payable which is included in the accompanying balance sheet.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 18.7pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 18.7pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The common shares relating to the above mentioned convertible notes payable contain the following trading restrictions: (a) beginning 90 days after the initial closing of our IPO and until the one-year anniversary of the initial closing of the IPO, the holder of the note will be able to sell 1% of the number of shares of common stock underlying the note on a monthly basis, subject to a maximum sale on any trading day of 4% of the daily volume; (b) if the common stock price is over $7.00 per share for five consecutive trading days then the holder of the note can sell up to 3% of the number of shares of common stock underlying the note on a monthly basis, subject to a maximum sale on any trading day of 4% of the daily volume; (c) if the common stock price is over $10.00 per share for five consecutive trading days then the holder of the note can sell up to an additional 5% of the number of shares of common stock underlying the note on a monthly basis, subject to a maximum sale on any trading day of 7% of the daily volume; and (d) if the common stock price is over $14.00 per share then the holder of the note is not restricted from making any sales until such time as the common stock price falls back below $14.00 per share; and (b) thereafter, until the two-year anniversary of the initial closing of IPO, the holder of the note can sell on any trading day 10% of the daily volume; provided that if the common stock price is over $10.00 per share then the holder of the note is not restricted from making any sales until such time as the common stock falls back below $10.00 per share. The foregoing lock-up restrictions relate to public sales and do not restrict the transfer of the shares privately, if permitted by applicable law, provided the acquirer of the shares agrees to comply with the above restrictions with respect to any public sales.</font>&#160;</div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_ConvertibleNotesPayableAbstractAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_ConvertibleNotesPayableAbstractAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_ConvertibleNotesPayableDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for convertible notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_ConvertibleNotesPayableDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6701137824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.3pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <strong><font style="FONT-SIZE: 10pt">5.</font></strong></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><strong><font style="FONT-SIZE: 10pt"> Equity</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On May 2, 2016, the Company amended and restated its certificate of incorporation to increase the number of shares authorized to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 80,000,000</font> of which <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5,000,000</font> shares of preferred stock are authorized and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 75,000,000</font> shares of common stock are authorized.</font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0in 0.3in" align="justify"><font style="FONT-SIZE: 10pt"></font><strong><font style="FONT-SIZE: 10pt"></font></strong>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0in 0.3in" align="justify"><strong><font style="FONT-SIZE: 10pt">Preferred Stock</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 18.7pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We are authorized to issue up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5,000,000</font> shares of preferred stock. Our certificate of incorporation authorizes the board to issue these shares in one or more series, to determine the designations and the powers, preferences and relative, participating, optional or other special rights and the qualifications, limitations and restrictions thereof, including the dividend rights, conversion or exchange rights, voting rights (including the number of votes per share), redemption rights and terms, liquidation preferences, sinking fund provisions and the number of shares constituting the series. As of December 31, 2016, there was no issued preferred stock.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0in 0.3in" align="justify"><font style="FONT-SIZE: 10pt"></font><strong><font style="FONT-SIZE: 10pt">Common Stock</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On May 31, 2016, the Company completed its IPO and sold <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,540,026</font> shares of the Company&#8217;s common stock. The IPO price per share was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6.00</font>. The Company received net cash proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8,464,183</font> after deducting underwriting discounts, commissions and direct offering expenses payable by us. Pursuant to our agreement with our underwriters, as additional compensation, we issued the underwriters warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 107,802</font> shares of common stock exercisable for a period of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5</font> years from date of issuance at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7.50</font> per share. The relative fair value of these warrants was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">374,763</font>&#160;and is included in stock issuance costs calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1.39</font>% (2) expected life of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5</font> years, (3) expected volatility of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 80.61</font>%, and (4) zero expected dividends.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In August 2015, the Company agreed to issue <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,600,000</font> shares of common stock to its directors, officers and founders for subscriptions of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4,600</font> cash to be received of which $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,600</font> was received in 2015.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On August 11, 2015, the Company was granted an assignment of a license agreement between MD Anderson and IntertechBio in exchange for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 630,000</font> shares of the Company's common stock. The sublicense gives the Company rights to access certain metabolic inhibitor technology owned by MD Anderson that had been licensed to IntertechBio. The shares were valued at a total of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">630</font> and the related expense included in research and development costs.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> On August 21, 2015, the Company acquired the right to the intellectual property of AnnaMed in exchange for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,431,000</font> shares of the Company's common stock. The license gives the Company full ownership rights to the data package supporting the FDA IND Number 46869, allowing the Company to resubmit a request for IND to the FDA to begin development work on Annamycin. The shares were valued at a total of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,431</font> and the related expense included in research and development costs.</div> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During the period from January 1, 2016 through May 2, 2016, the Company sold <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 234,297</font> common shares for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">702,894</font>. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">These shares are subject to the following lock-up agreement, from and after the later of six months after issuance or 90 days from the effective date of our IPO registration statement until the one-year anniversary thereof, (a) the holder of the shares can sell up to 10% of the purchased shares per month, subject to a maximum sale on any trading day of 8% of the daily volume of the common stock; (b) if the common stock price is over $7.00 per share for five consecutive trading days then the holder of the shares can sell up to 20% of the purchased shares per month, subject to a maximum sale on any trading day of 10% of the daily volume of the common stock; and (c) if the common stock price is over $12.00 per share then the holder of the shares is not restricted from making any sales until such time as the common stock price falls back below $12.00 per share.</font><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On June 20, 2016, the Company agreed to issue <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 24,000</font> shares of common stock to PCG Advisory Group, the Company&#8217;s investor relations firm, for services provided. The fair value of these shares was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">157,680</font> based on the market price on the grant date.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0in 0.5in" align="justify"><strong><font style="FONT-SIZE: 10pt"> &#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 18.7pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Adoption of 2015 Stock Plan</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On December 5, 2015, the Board of Directors of the Company approved the Company&#8217;s 2015 Stock Plan, which was amended on April&#160;22,&#160;2016. The expiration date of the plan is <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">December 5, 2025</font> and the total number of underlying shares of the Company&#8217;s common stock available for grant to employees, directors and consultants under the plan is <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,500,000</font> shares. The awards under the 2015 Stock Plan can be in the form of stock options, stock awards or stock unit awards. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The following is a summary of option activities for the periods ended December 31, 2015 and 2016:</font></div> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Contractual</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Aggregate</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Number&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Weighted&#160;Average&#160;Grant&#160;Date</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Term</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Intrinsic</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Fair&#160;Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>(in years)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="39%"> <div>Granted - 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>200,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.14</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="39%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Outstanding, December 31, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>200,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>0.14</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Granted - 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>460,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>3.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5.83</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Cancelled</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(150,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>0.14</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Outstanding, December 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>510,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>3.40</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5.28</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9.29</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>275,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Exercisable, December 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>50,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>0.14</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3.67</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>275,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During the year ended December 31, 2016, the Company granted an officer and its board of directors&#8217; options, in the aggregate, to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 460,000</font> shares of the Company&#8217;s common stock with an exercise price ranging from $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.71</font> per share to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.85</font> per share, a term of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font> years, and a vesting period of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3</font> to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4</font> years.&#160;The exercise price was based upon the closing price of the stock on the day of the grant. The options have an aggregated fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,772,422</font> that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1.30</font>% (2) expected lives of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6</font> to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6.25</font> years, (3) expected volatility of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 70.18</font>% to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 70.44</font>%, and (4) zero expected dividends. The Company, due to the limited number of participants in the plan and their positions within the Company, uses a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font>% estimated forfeiture rate. During the year ended December 31, 2016, the Company recorded $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">166,294</font><font style="FONT-SIZE: 10pt">&#160;</font> in stock-based compensation in relation to these options. As of December 31, 2016, there was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,565,599</font> of unrecognized compensation cost, net of estimated forfeitures, related to the Company&#8217;s non-vested equity awards, which is expected to be recognized over a weighted average period of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3.7</font> years. <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The fair value of each stock option is estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted in the above paragraph and table. The expected term of the options was computed using the &#8220;plain vanilla&#8221; method as prescribed by the Securities and Exhange Commission Staff Accounting Bulletin 107 because we do not have suffient data regarding employee exercise behavior to estimate the expected term. The volatility was determined by referring to the average historical volatility of a peer group of public companies because we do not have sufficient trading history to determine our historical volatility. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company entered into a separation agreement with its former Chief Financial Officer in October 2016 and as part of the agreement, options to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 150,000</font> shares of common stock issued to the former Chief Financial Officer were cancelled and the vesting was accelerated on the remaining options to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 50,000</font> shares of common stock.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74567-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6812439920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.3pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <strong><font style="FONT-SIZE: 10pt">6.</font></strong></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Income Taxes</font></strong></div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The provision for income taxes consists of the following components (in thousands):</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both; size: 8.5in 11.0in" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Current Expense (Benefit):</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Federal</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>State</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Current Income Tax Expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Deferred Expense (Benefit):</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Federal</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>State</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Deferred Income Tax Expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Net Deferred Taxes</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following summarizes activity related to the Company&#8217;s valuation allowance (in thousands):</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both; size: 8.5in 11.0in" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Valuation Allowance at Beginning of Period</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>155</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Income Tax Benefit</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>1,242</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>155</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Release of Valuation Allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Valuation Allowance at End of Period</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>1,397</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>155</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A reconciliation of the income tax benefit computed using the federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%" colspan="5"> <div>December&#160;31,&#160;2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%" colspan="5"> <div>December&#160;31,&#160;2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Amount</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Percent</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Amount</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Percent</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Federal Tax Benefit at Statutory Rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,335</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>34.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>254</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>34.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"> <div>State Tax Benefit Net of Federal</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>137</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>3.48</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; BACKGROUND: #ffffff; COLOR: #000000; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"> <div>IPO Costs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>(227)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>(5.78)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; BACKGROUND: #cceeff; COLOR: #000000; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>(99)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>(13.24)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Other Permanent Differences</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(3)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(0.08)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Increase in Valuation Allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,242)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(31.62)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(155)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(20.76)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Total Tax (Expense) / Benefit</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> </div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The principal components of the Company&#8217;s deferred tax assets and liabilities consist of the following at December 31, 2016 and 2015 (in thousands):</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both; size: 8.5in 11.0in" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Deferred Tax Assets:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Start Up Costs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>798</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>67</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Federal Net Operating Loss Carryforwards</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>520</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>89</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>State Tax Loss Carryforwards</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>50</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Deferred Compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>33</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Total Deferred Tax Assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>1,401</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>155</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Less Valuation Allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>(1,397)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>(155)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Net Deferred Tax Assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>4</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Deferred Tax Liabilities:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Fixed Assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>(4)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Total Deferred Tax Liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>(4)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Net Deferred Taxes</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify">The Company has incurred net operating losses since inception. As of December 31, 2016, the Company had total federal operating loss carry forwards of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.53</font> million which expire commencing in <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2035</font>. The value of these carryforwards depends on the Company&#8217;s ability to generate taxable income. Additionally, because federal tax laws limit the time during which the net operating loss carryforwards may be applied against future taxes, if the Company fails to generate taxable income prior to the expiration dates of the carry forwards the Company may not be able to fully utilize the net operating loss carryforwards to reduce future income taxes. Finally, the Company has not undertaken a detailed analysis of the application of IRC Section 382 with respect to limitations on the utilization of net operating loss carryforwards and other deferred tax assets. However, the Company believes that this matter is not material to the overall tax position within the financial statements due to the full valuation allowance against the net operating losses and the lack of utilization of the net operating losses during tax years open under statute.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">The Company conducts business in various locations and, as a result, files income tax returns in the United States Federal jurisdiction and in multiple state jurisdictions. As of December 31, 2016, the Company had state operating losses of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.27</font> million which expire commencing in <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2036</font>. Since the Company is in a loss carryforward position, the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which a loss carryforward is available.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">Management has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. The Company has cumulative losses and there is no assurance of future taxable income, therefore, valuation allowances have been recorded to fully offset the deferred tax asset at December 31, 2016. Management has determined that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets, and as a result, a valuation allowance of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.40</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.16</font> million has been established at December 31, 2016 and 2015, respectively. The change in the valuation allowance for the year ended December 31, 2016 was primary due to additional operating losses and capitalized research costs. The Company may be eligible to claim research and development tax credits in the future, but has not conducted a study to date.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">There are no unrecognized tax benefits from any federal, state or foreign jurisdictions. The only tax year open under statute for the Company is December 31, 2015.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company&#8217;s policy is to recognize interest and penalties related to any unrecognized tax liabilities as additional tax expense. No interest or penalties have been accrued at December 31, 2016 and 2015, as the Company has not recorded any uncertain tax positions. The Company believes it has appropriate and adequate support for the income tax positions taken and to be taken on its tax returns and that its accruals for tax liabilities are adequate for all open years based on an assessment of many factors including past experience and interpretations of tax law applied to the facts of each matter.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Although the Company believes its recorded assets and liabilities are reasonable, tax regulations are subject to interpretation and tax litigation is inherently uncertain; therefore the Company&#8217;s assessments can involve both a series of complex judgments about future events and rely heavily on estimates and assumptions. Although the Company believes that the estimates and assumptions supporting its assessments are reasonable, the final determination of tax audit settlements and any related litigation could be materially different from that which is reflected in historical income tax provisions and recorded assets and liabilities. If the Company were to settle an audit or a matter under litigation, it could have a material effect on the income tax provision, net income, or cash flows in the period or periods for which that determination is made. Any accruals for tax contingencies are provided for in accordance with U.S. GAAP<i>.</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font> The Company does not believe that its tax positions will significantly change due to any settlement and/or expiration of statutes of limitations prior to&#160;December&#160;31, 2017.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32718-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6701137824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.3pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <strong><font style="FONT-SIZE: 10pt">7.</font></strong></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Commitments and Contingencies</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 18.7pt"> <strong><font style="FONT-SIZE: 10pt">&#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 18.7pt"> <strong><font style="FONT-SIZE: 10pt">MD Anderson &#150; IntertechBio Agreement</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On August 11, 2015, the Company acquired the rights and obligations under the Patent and Technology License Agreement entered into between IntertechBio and MD Anderson dated April 2, 2012. Pursuant to the agreement, IntertechBio obtained a royalty-bearing, worldwide, exclusive license to intellectual property including patent rights related to the Company&#8217;s drug product candidate, WP1122. Under the agreement, IntertechBio agreed to pay annual maintenance fees in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,000</font> on the first anniversary of the effective date of the agreement, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">20,000</font> on the second anniversary of the effective date of the agreement, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">40,000</font> on the third anniversary of the effective date of the agreement, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">60,000</font> on the fourth anniversary of the effective date of the agreement, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">80,000</font> on the fifth anniversary of the effective date of the agreement and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">100,000</font> on the sixth anniversary of the effective date of the agreement, except that such payments will no longer be due upon the first sale of a licensed product. Under the agreement, IntertechBio also agreed to make a minimum annual royalty payment in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">200,000</font> for the first anniversary following the first sale of a licensed product, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">400,000</font> for the second anniversary following the first sale of a licensed product, and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">600,000</font> for the third year following the first sale of a licensed product. IntertechBio also agreed to make certain milestone payments. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Pursuant to an amendment on October 19, 2015, the Company will pay milestone payments as follows:</font></div> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0px:auto; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div style="CLEAR:both;CLEAR: both">Phase</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Amount</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="57%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div style="CLEAR:both;CLEAR: both">Commencement of Phase II Study for a licensed product</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div style="CLEAR:both;CLEAR: both">200,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div style="CLEAR:both;CLEAR: both">Commencement of Phase III Study for a licensed product</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div style="CLEAR:both;CLEAR: both">250,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div style="CLEAR:both;CLEAR: both">Filing of a New Drug Application for a licensed product</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div style="CLEAR:both;CLEAR: both">400,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div style="CLEAR:both;CLEAR: both">Receipt of market approval for a licensed product</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div style="CLEAR:both;CLEAR: both">500,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Per the October 2015 amendment to the agreement, MD Anderson has the right to terminate the license agreement if (i) a preclinical toxicology program for a licensed product is not initiated within one year of the effective date of the amendment (which has occurred), (ii) an investigational new drug application is not filed with the Food and Drug Administration for a Phase I study for a licensed product within three years of the effective date of the amendment, or (iii) a Phase I study for a licensed product is not commenced within five years of the effective date of the amendment. The agreement will expire upon the expiration of the licensed intellectual property. The rights obtained by the Company pursuant to the agreement are made subject to the rights of the U.S. government to the extent that the technology covered by the licensed intellectual property was developed under a funding agreement between MD Anderson and the U.S. government. All out-of-pocket expenses incurred by MD Anderson in filing, prosecuting and maintaining the licensed patents have been and shall continue to be assumed by the Company.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On October 8, 2015, IntertechBio Corporation entered into a letter agreement with MD Anderson wherein MD Anderson agreed to receive past due maintenance fees and patent expenses of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">98,108</font> owed by IntertechBio Corporation in four installments. The past due amount is related to certain metabolic inhibitor technology license that was assigned to the Company by IntertechBio Corporation and was owed by IntertechBio Corporation prior to the Company&#8217;s acquisition of the license. Pursuant to the letter, IntertechBio Corporation also agreed to pay $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">65,504</font> in patent fees to a law firm. In order to have the license in good standing, the Company agreed to pay MD Anderson the $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">98,108</font> and the $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">65,504</font> in patent fees to a patent law firm on behalf of IntertechBio Corporation. As of December 31, 2015, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">45,000</font> of the past due amount to MD Anderson and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">42,504</font> in patent fees to a patent law firm were still outstanding and were included in accounts payable and accrued liabilities. On April 15, 2016, the Company entered into a letter agreement with MD Anderson where MD Anderson agreed to receive the remaining outstanding amount on or before the earlier of a) May 31, 2016 or b) four days after the Company&#8217;s completion of the IPO. These amounts were paid prior to or on May 31, 2016.</font></div> <strong><font style="FONT-SIZE: 10pt">&#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 18.7pt" align="justify"><strong><font style="FONT-SIZE: 10pt">MD Anderson &#150; Patent &amp; Technology License Agreement</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Upon the Company&#8217;s acquisition of Moleculin, LLC on May 2, 2016, we obtained a royalty-bearing, worldwide, exclusive license to intellectual property rights, including patent rights related to our WP1066 drug product candidate from MD Anderson through a Patent and Technology License Agreement Moleculin, LLC entered with MD Anderson on June&#160;21, 2010 (the &#8220;Moleculin License Agreement&#8221;). Under the Moleculin License Agreement, Moleculin, LLC obtained the right to manufacture, have manufactured, use, import, offer to sell or sell products worldwide for any indication under the licensed intellectual property with the right to sublicense. In consideration, Moleculin, LLC agreed to make payments to MD Anderson including an up-front payment, milestone payments and minimum annual royalty payments for sales of products developed under the license agreement. Specifically, under the Moleculin License Agreement, Moleculin, LLC agreed to pay a nonrefundable upfront documentation fee and an annual maintenance fee in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">20,000</font> on June 21, 2011, which has and shall increase in $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,000</font> increments on an annual basis thereafter up to a maximum of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">100,000</font>, except that such payments will no longer be due upon marketing approval in any country of a licensed product. Under the Moleculin License Agreement, Moleculin, LLC also agreed to make a minimum annual royalty payment.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Upon completion of our acquisition of Moleculin, LLC, we assumed the rights and obligations of Moleculin, LLC. However, the rights we have obtained pursuant to the assignment of the Moleculin License Agreement are made subject to the rights of the U.S. government to the extent that the technology covered by the licensed intellectual property was developed under a funding agreement between MD Anderson and the U.S. government. All out-of-pocket expenses incurred by MD Anderson in filing, prosecuting and maintaining the licensed patents have been and shall continue to be assumed by us.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On October 8, 2015, Moleculin, LLC entered into a letter agreement with MD Anderson for Moleculin, LLC&#8217;s past due fees to MD Anderson in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">691,186</font> of which $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">300,000</font> had been paid prior to the letter agreement. Pursuant to the letter agreement, MD Anderson agreed to receive the remaining past due fee in three installments: a) $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">125,000</font> on October 31, 2015; b) $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">175,000</font> on January 31, 2016; and c) $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">91,186</font> on April 30, 2016. Moleculin, LLC paid $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">125,000</font> to MD Anderson on November 2, 2015.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On October 19, 2015, the agreement was amended for the milestone payments. The amended milestone payments are as follows: (i) commencement of Phase III Study for first licensed drug/product within the United States, Europe, China or Japan - $150,000; (ii) submission of the first NDA within the United States - $500,000; and (iii) receipt of first marketing approval for sale of a license product in the United States - $600,000.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On January 28, 2016, the Company and Moleculin, LLC entered into a letter agreement with MD Anderson where MD Anderson agreed to receive the remaining outstanding amount on or before the earlier of April 30, 2016 or four days after our IPO. This date was amended and per the amended agreement, the Company paid the outstanding Moleculin, LLC fees on May 31, 2016 in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">306,186</font> in cash.</font></div> <strong><font style="FONT-SIZE: 10pt">&#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 18.7pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Bonwick Capital Partners LLC</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On January 22, 2016, as amended on February 15, 2016, the Company entered into a letter agreement with Bonwick Capital Partners LLC. (&#8220;Bonwick&#8221;) to engage Bonwick as an exclusive financial advisor of the Company. Pursuant to the agreement, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>the Company agreed to: a) pay success fees equal to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 7</font>% of the gross proceeds from any form of financing; and b) issue five-year warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7</font>% of the Company&#8217;s equity securities sold with a cashless exercise provision, exercisable at <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 125</font>% of the price per share of the Company&#8217;s common stock paid by investors in the transaction. In addition, the Company agreed to reimburse Bonwick for all of its out-of-pocket expenses incurred in connection with the offering, not to exceed $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25,000</font>, and fees and expenses of their counsel not to exceed $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">100,000</font>.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> Upon completion of the Company&#8217;s IPO, the Company paid Bonwick a $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000</font> advisory fee. In connection with the Company&#8217;s IPO, Bonwick received a success fee of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">646,872</font>, warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 107,802</font> shares of common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7.50</font> per share, and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6,266</font> for reimbursement of expenses.</font></div> <strong><font style="FONT-SIZE: 10pt">&#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 18.7pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Houston Pharmaceuticals, Inc.</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Our acquisition of Moleculin, LLC, occurring prior to our IPO offering, provided us with the rights of the license agreement that Moleculin, LLC had with MD Anderson covering the WP1066 Portfolio. As discussed in Note 2, we are obligated to make payments to HPI totaling $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">750,000</font> over a three-year period commencing after the IPO offering in exchange for HPI allowing us to access any data, information or know-how resulting from the research and development conducted by HPI. Pursuant to the HPI Out-Licensing Agreement, we have the right within three years of the date we enter into the agreement to buy-out from HPI all rights granted to HPI under the agreement for a payment of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.0</font> million. Upon our exercise of the buy-out we will no longer be obligated to make any payments to HPI remaining from the $750,000 obligation discussed above. We will need to raise additional funds to make the buy-out payment. We cannot assure that such additional funding will be available on satisfactory terms, or at all.</font></div> <strong><font style="FONT-SIZE: 10pt">&#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.7pt; MARGIN: 0in 0in 0pt 0.25in" align="justify"><strong><font style="FONT-SIZE: 10pt">Employment Agreements</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.7pt; MARGIN: 0in 0in 0pt 0.25in"> <strong><font style="FONT-SIZE: 10pt">&#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On August 19, 2016, the Company entered into an employment agreement with Mr. Jonathan P. Foster pursuant to which Mr. Foster agreed to serve as Chief Financial Officer and Executive Vice President of the Company commencing on such date for an initial term of three years, which will be automatically renewed for additional one-year terms unless either party chooses not to renew the agreement. The agreement provides for an annual salary of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250,000</font>, a potential&#160;annual bonus, ten-year options to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 400,000</font> shares at an exercise price per share equal to the closing price of the Company&#8217;s common stock on the date of execution of his employment agreement, which was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.85</font>. The options vest in four equal installments. Termination payments may be made under certain conditions.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company accepted the resignation of Mr. Louis Ploth from his position as Chief Financial Officer, effective on August 19, 2016. On October 7, 2016, the Company entered into a separation agreement with Mr. Louis Ploth (the &#8220;Separation Agreement&#8221;), pursuant to which, among other items, Mr. Ploth generally released the Company from any claims he may have against the Company or its affiliates, and the Company agreed to pay Mr. Ploth a severance payment of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">100,000</font> over a 12-month period and to pay his medical insurance premiums until August 31, 2017. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Pursuant to the Separation Agreement, Mr. Ploth will be permitted to exercise 25% of the options to purchase common stock granted to him in December 2015, or 50,000 shares, until May 2020.</font></font><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On October 13, 2016, the Company and its Chief Executive Officer, Walter Klemp, entered into an employment agreement which provides for an annual salary of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">300,000</font>, of which some is deferred, and a potential annual bonus. During the period commencing June 1, 2016 and ending June 1, 2017, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">12,500</font> per month of the compensation is deferred. The deferred compensation shall be payable in a lump sum on the earlier of the termination of the employment agreement or June 1, 2019. As of December 31, 2016, deferred compensation of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">87,500</font> was recorded in the accompanying balance sheet. If Mr. Klemp&#8217;s employment is terminated, his status reverts to a consultant and payments to him would continue until June 1, 2019.&#160;&#160;</div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73718637&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6812438320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0in"></td> <td style="TEXT-ALIGN: left; WIDTH: 0.5in"> <div>8.</div> </td> <td style="TEXT-ALIGN: justify"> <div>Subsequent Events</div> </td> </tr> </table> <font style="FONT-SIZE: 10pt">&#160;</font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On February 9, 2017, we entered into an Underwriting Agreement (the &#8220;Underwriting Agreement&#8221;) with Roth Capital Partners, LLC, as representative of the several underwriters identified therein (collectively, the &#8220;Underwriters&#8221;), pursuant to which we sold in a registered public offering (the &#8220;Offering&#8221;), <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,710,000</font> units, priced at a public offering price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.35</font> per unit, with each unit consisting of: (i) one share of common stock, (ii) a five-year Series A warrant to purchase 0.50 of a share of common stock, (iii) a 90-day Series B warrant to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">purchase one share of common stock, and (iv) a five-year Series C warrant to purchase 0.50 of a share of common stock.</font> The Series C warrants in a unit may only be exercised to the extent and in proportion to a holder of the Series C warrants exercising its Series B warrants included in the unit. The Series A and Series C warrant have an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.50</font></font> per share of common stock. The Series B warrant has an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.35</font> per share of common stock.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Under the terms of the Underwriting Agreement, we granted the Underwriters a 45-day option to purchase an additional <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 556,500</font> shares of common stock and/or an additional <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 556,500</font> warrant combinations (comprised of an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 278,250</font> Series A warrants, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 556,500</font> Series B warrants and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 278,250</font> Series C warrants), in any combinations thereof, from us to cover over-allotments at the public offering price per share of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.349</font> and public offering price per warrant combination of $.001, respectively, less the underwriting discounts and commissions. Upon the closing of the Offering, the Underwriters exercised the over-allotment option with respect to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 278,100</font> warrant combinations. We received approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.4</font> million in net proceeds from the Offering, after deducting underwriting discounts and commissions and estimated offering expenses.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On March 21, 2017, we received notice that FDA had granted us Orphan Drug designation for Annamycin for the treatment of AML.</div> <font style="FONT-SIZE: 10pt">&#160;</font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Subsequent to March 22, 2017, investors in the aforementioned offering on February 9, 2017, have excerised approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 600,000</font> Series B warrants resulting in approximately gross proceeds to the Company of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">800,000</font> and approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 600,000</font> shares of the Company&#8217;s common stock being issued.</div> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On January 13, 2017, the Company issued to two of its Science Advisory Board (&#8220;SAB&#8221;) members <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10,000</font></font> options each with an excerise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.31</font></font> with <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3</font></font>-year annual vesting and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 79,167</font> shares to a former SAB member to settle an accounts payable of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">237,500</font> in past due amounts.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821715664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><b><font style="FONT-SIZE: 10pt">Use of Estimates in Financial Statement Presentation -</font></b> <font style="FONT-SIZE: 10pt">The preparation of these financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><b><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></font></b> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Acquisition &#150;</b> We acquired Moleculin, LLC (&#8220;Moleculin&#8221;) on May 2, 2016, and, going forward our financial statements include the operations of Moleculin, LLC. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired in-process research and development (&#8220;IPR&amp;D&#8221;) be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired will be recorded as goodwill. The Company obtained input from third-parties regarding its tangible and intangible assets and other information necessary to measure the fair value of the assets acquired and liabilities assumed in connection with the acquisition of Moleculin, LLC.</div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_GoingConcernPolicyPolicyTextBlock', window );">Going Concern, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"><b>Going Concern -</b> These financial statements have been prepared on a going concern basis, which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The continuation of the Company as a going concern is dependent upon the ability of the Company to obtain continued financial support from its stockholders&#8217;, necessary equity financing to continue operations and the attainment of profitable operations. As of December 31, 2016, the Company has incurred an accumulated deficit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4,674,721</font> since inception, and had not yet generated any revenue from operations. Additionally, management anticipates that its cash on hand as of December 31, 2016 plus the additional cash generated from its equity offering subsequent to year-end, discussed further within these notes to the financial statements, is sufficient to fund its planned operations into but not beyond the near term. These factors raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company may seek additional funding through a combination of equity offerings, debt financings, government or other third-party funding, commercialization, marketing and distribution arrangements, other collaborations, strategic alliances and licensing arrangements and delay planned cash outlays or a combination thereof. Management cannot be certain that such events or a combination thereof can be achieved.&#160;&#160;</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><strong>Cash and Cash Equivalents -</strong> The Company considers all highly liquid accounts with original maturities of three months or less at the date of acquisition to be cash equivalents.&#160;Periodically, the Company may carry cash balances at financial institutions in excess of the federally insured limit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250,000</font>. The amount in excess of the FDIC insurance at December 31, 2016 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">256,836</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font> as of December 31, 2015. Compensation expense is recognized only for share based payments expected to vest.</font>&#160;</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><b><font style="FONT-SIZE: 10pt">Property and equipment -</font></b> <font style="FONT-SIZE: 10pt">Property and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line depreciation method as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 85%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; MARGIN-LEFT: 0.5in; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="85%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 40%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="40%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Leasehold improvement</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 60%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="60%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt">Shorter of estimated useful lives or the term of the lease</font>&#160;</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Computer equipment</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2</font> years*</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Machinery and equipment</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5</font> years*</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Furniture and office equipment</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7</font> years*</font></div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">*Property and equipment assets acquired in the merger with Moleculin, LLC are being depreciated over a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2</font> year useful life due to their age and condition and expected remaining life assessed at merger date.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><b><font style="FONT-SIZE: 10pt">Intangible assets -</font></b> <font style="FONT-SIZE: 10pt">Intangible assets with finite lives are amortized using the straight-line method over their estimated period of benefit. If an intangible asset is identified as an in-process research &amp; development asset, then no amortization will occur until the development is complete. If the associated research and development effort is abandoned, the related assets will be written-off and the Company will record a noncash impairment loss on its statements of operations. For those compounds that reach commercialization, the IPR&amp;D assets will be amortized over their estimated useful lives.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">We evaluate the recoverability of intangible assets periodically and take into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists. No material impairments of intangible assets have been identified during any of the periods presented. Intangible assets are tested for impairment on an annual basis, and between annual tests if indicators of potential impairment exist, using a fair-value-based approach.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DebtInstrumentConvertibleBeneficialConversionFeaturePolicyPolicyTextBlock', window );">Debt Instrument, Convertible, Beneficial Conversion Feature Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"><b>Beneficial Conversion Feature</b> - From time to time, the Company may issue convertible notes that have conversion prices that create an embedded beneficial conversion feature on the issuance date. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of any attached equity instruments, if any related equity instruments were granted with the debt. The Company estimated the fair value of its common stock on the dates issued. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid-in capital, if any. The debt discount is amortized to interest expense over the life of the note using the effective interest method.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"><b>Income Taxes -</b> The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of reported assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company must then assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.&#160;</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify">The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740-10 which prescribes a recognition threshold and measurement attribute for financial statement disclosure of tax positions taken, or expected to be taken, on its tax return. The Company evaluates and records any uncertain tax positions based on the amount that management deems is more likely than not to be sustained upon examination and ultimate settlement with the tax authorities in the tax jurisdictions in which it operates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"><b>Stock-based Compensation -</b> Stock-based compensation expense includes the estimated fair value of equity awards vested during the reporting period. The expense for equity awards vested during the reporting period is determined based upon the grant date fair value of the award and is recognized as expense over the applicable vesting period of the stock award using the straight-line method.&#160;</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><strong>Loss Per Common Share</strong> - Basic net loss per common share are computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. As of December 31, 2016, the Company&#8217;s potentially dilutive shares, which were not included in the calculation of net loss per share, included notes convertible to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,821,013</font> common shares, options to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 510,000</font> common shares and warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 107,802</font> common shares.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><b><font style="FONT-SIZE: 10pt">Research and Development Costs -</font></b> <font style="FONT-SIZE: 10pt"> Research and development costs are expensed as incurred.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><b><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></font></b> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Subsequent Events -</b> The Company&#8217;s management reviewed all material events through the date these financial statements were issued for subsequent event disclosure consideration and has noted such events as described in Note 8.</div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><b><font style="FONT-SIZE: 10pt">Recent Accounting Pronouncements</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify">In May 2014, the FASB issued Accounting Standard Update ("ASU") 2014-09, Revenue from Contracts with Customers (Topic 606), which will replace numerous requirements in U.S. GAAP, including industry-specific requirements, and provide companies with a single revenue recognition model for recognizing revenue from contracts with customers. The core principle of the new standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In August 2015, the FASB approved a proposal to defer the effective date of the guidance until annual and interim reporting periods beginning after December 15, 2017. The Company is currently evaluating the impact that this standard will have on its financial statements at the time the Company starts to generate revenue or enters into other contractual arrangements, which the Company does not expect in the near term.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern. Under the new guidance, management will be required to assess an entity&#8217;s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. The provisions of this ASU are effective for annual periods ending after December 15, 2016, and for annual and interim periods thereafter; early adoption is permitted. This disclosure is effective within these financial statements for the year ended December 31, 2016.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments &#150; Overall: Recognition and Measurement of Financial Assets and Financial Liabilities (&#8220;ASU 2016-01&#8221;).&#160;ASU 2016-01 affects the accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements of financial instruments.&#160;ASU 2016-01 is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years.&#160;The Company is currently evaluating the impact that this standard will have on its financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (&#8220;ASU 2016-02&#8221;). Under ASU 2016-02, an entity will be required to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements.&#160;ASU 2016-02 offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases.&#160;For public companies, ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, and requires a modified retrospective adoption, with early adoption permitted.&#160;The Company is currently evaluating the impact that this standard will have on its financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In March 2016, the FASB issued ASU 2016-09, Compensation-Stock Compensation (Topic 718). The new guidance changes the accounting and simplifies various aspects of the accounting for share-based payments to employees. The guidance allows for a policy election to account for forfeitures as they occur or based on an estimated number of awards that are expected to vest. ASU 2016-09 is effective for annual periods beginning after December 15, 2016, with early adoption permitted. The adoption of this standard on January 1, 2017, did not have a significant impact on the Company&#8217;s financial statements.</div> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify">In August 2016, the FASB issued ASU, Statement of Cash Flows (Topic 230). This ASU applies to all entities that are required to present a statement of cash flows under Topic 230. The amendments provide guidance on eight specific cash flow issues and includes clarification on how these items should be classified in the statement of cash flows and is designed to help eliminate diversity in practice as to where items are classified in the cash flow statement. Furthermore in November 2016, the FASB issued additional guidance on this Topic that requires amounts generally described as restricted cash and restricted cash equivalents to be included with cash and cash equivalents when reconciling the statement of cash flows. This ASU is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years, with earlier application permitted for all entities. We plan to adopt the provisions of this ASU for our fiscal year beginning January 1, 2018 and are currently evaluating the impact the adoption of this new accounting standard will have on our financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On November 20, 2015, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update ("ASU") 2015-17, "Balance Sheet Classification of Deferred Taxes", requiring all deferred tax assets and liabilities, and any related valuation allowance, to be classified as non-current on the balance sheet. The classification change for all deferred taxes as non-current simplifies entities&#8217; processes as it eliminates the need to separately identify the net current and net non-current deferred tax asset or liability in each jurisdiction and allocate valuation allowances. The Company elected to adopt the accounting in the fourth quarter of 2016.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">The Company does not believe that any other recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect on the accompanying financial statements.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_DebtInstrumentConvertibleBeneficialConversionFeaturePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for beneficial conversion feature of debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_DebtInstrumentConvertibleBeneficialConversionFeaturePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_GoingConcernPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_GoingConcernPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting subsequent events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6812483632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock', window );">Schedule of Property Plant And Equipment Useful life [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><b><font style="FONT-SIZE: 10pt">Property and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line depreciation method as follows:</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 85%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; MARGIN-LEFT: 0.5in; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="85%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 40%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="40%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Leasehold improvement</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 60%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="60%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt">Shorter of estimated useful lives or the term of the lease</font>&#160;</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Computer equipment</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2</font> years*</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Machinery and equipment</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5</font> years*</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Furniture and office equipment</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7</font> years*</font></div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">*Property and equipment assets acquired in the merger with Moleculin, LLC are being depreciated over a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2</font> year useful life due to their age and condition and expected remaining life assessed at merger date.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of property plant and equipment useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6645912688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The acquisition price was allocated to the assets acquired and liabilities assumed based upon their estimated fair values and the information available to management. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.25in; WIDTH: 92%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="76%"> <div>Cash</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>362</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="76%"> <div>Property and equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>7,820</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="76%"> <div>Intangibles</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>11,147,540</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="76%"> <div>Total assets acquired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>11,155,722</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="76%"> <div>Liability assumed (HPI)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(3,874,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="76%"> <div>Other liabilities assumed, including $469,939 of notes payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(1,224,314)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="76%"> <div>Net assets acquired/total consideration transferred</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>6,057,408</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Intangible assets consisted of the following at December 31, 2016 and December 31, 2015:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 96%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Intangibles acquired from Moleculin, LLC</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>11,147,540</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>&#150;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Business Acquisition, Pro Forma Information [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">This information has been compiled from historical financial statements and is not necessarily indicative of the results that actually would have been achieved had the transaction already occurred or that may be achieved in the future.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 96%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>Pro&#160;Forma</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>For&#160;the&#160;Year</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>Pro&#160;Forma</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>For&#160;Year Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>December</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>December</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="64%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Total operating expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>(3,979,316)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>(688,101)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Net loss</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>(3,962,997)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>(164,128)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Net loss per common share &#150; basic and diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>(0.42)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>(0.04)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Weighted average outstanding common shares &#150; basic and diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>9,401,028</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>4,273,239</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)-(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65885119&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6807952176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_ConvertibleNotesPayableAbstractAbstract', window );"><strong>Convertible Notes Payable Abstract [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Convertible Debt [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The table below represents the shares that are convertible at December 31, 2016 relating to the principal amounts of these convertible notes payable and excludes any shares that are convertible relating to the associated accrued interest:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 96%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>Convertible&#160;at</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>Dec&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>Issuance&#160;Date</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>2016 (e)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>Conversion&#160;Rate</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="33%"> <div>August 31, 2015(a)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>38,299</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>125,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>0.1299</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>294,832</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>September 3, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>125,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>125,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>0.1299</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>962,279</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>October 6, 2015(a)(c)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>30,280</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>147,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>0.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>151,402</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>October 6, 2015(b)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>&#150;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>3,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>0.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>&#150;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>October 28, 2015(b)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>&#150;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>50,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>0.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>&#150;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>January 14, 2016(d)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>&#150;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>&#150;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>0.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>&#150;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>January 19, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>82,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>&#150;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>0.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>412,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>276,079</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>450,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>1,821,013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 18.7pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 18.7pt; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in"> (a) Debt partially converted on May 31, 2016 and on August 19, 2016.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 18.7pt; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in"> (b) Debt fully converted to common shares on May 31, 2016.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 18.7pt; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in"> (c) Debt partially converted on September 1, 2016.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 18.7pt; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in"> (d) Debt fully converted to common shares effective November 30, 2016.&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 11.5pt 0pt 18.7pt; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in"> (e) Excluded from the $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">276,079</font> is $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">20,333</font> in accrued interest on the convertible notes payable which is included in the accompanying balance sheet.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_ConvertibleNotesPayableAbstractAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_ConvertibleNotesPayableAbstractAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6812635056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following is a summary of option activities for the periods ended December 31, 2015 and 2016:</font></div> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Contractual</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Aggregate</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Number&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Weighted&#160;Average&#160;Grant&#160;Date</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Term</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Intrinsic</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Fair&#160;Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>(in years)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="39%"> <div>Granted - 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>200,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.14</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="39%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Outstanding, December 31, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>200,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>0.14</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Granted - 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>460,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>3.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5.83</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Cancelled</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(150,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>0.14</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Outstanding, December 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>510,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>3.40</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5.28</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9.29</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>275,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Exercisable, December 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>50,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>0.14</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3.67</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>275,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6812541728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">The provision for income taxes consists of the following components (in thousands):</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both; size: 8.5in 11.0in" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Current Expense (Benefit):</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Federal</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>State</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Current Income Tax Expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Deferred Expense (Benefit):</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Federal</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>State</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Deferred Income Tax Expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Net Deferred Taxes</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Summary of Valuation Allowance [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">The following summarizes activity related to the Company&#8217;s valuation allowance (in thousands):</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both; size: 8.5in 11.0in" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Valuation Allowance at Beginning of Period</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>155</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Income Tax Benefit</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>1,242</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>155</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Release of Valuation Allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Valuation Allowance at End of Period</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>1,397</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>155</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify">A reconciliation of the income tax benefit computed using the federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%" colspan="5"> <div>December&#160;31,&#160;2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%" colspan="5"> <div>December&#160;31,&#160;2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Amount</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Percent</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Amount</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Percent</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Federal Tax Benefit at Statutory Rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,335</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>34.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>254</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>34.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"> <div>State Tax Benefit Net of Federal</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>137</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>3.48</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; BACKGROUND: #ffffff; COLOR: #000000; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"> <div>IPO Costs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>(227)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>(5.78)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; BACKGROUND: #cceeff; COLOR: #000000; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>(99)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>(13.24)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Other Permanent Differences</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(3)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(0.08)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Increase in Valuation Allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,242)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(31.62)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(155)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(20.76)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Total Tax (Expense) / Benefit</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The principal components of the Company&#8217;s deferred tax assets and liabilities consist of the following at December 31, 2016 and 2015 (in thousands):</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both; size: 8.5in 11.0in" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Deferred Tax Assets:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Start Up Costs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>798</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>67</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Federal Net Operating Loss Carryforwards</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>520</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>89</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>State Tax Loss Carryforwards</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>50</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Deferred Compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>33</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Total Deferred Tax Assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>1,401</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>155</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Less Valuation Allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>(1,397)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>(155)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Net Deferred Tax Assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>4</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Deferred Tax Liabilities:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Fixed Assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>(4)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Total Deferred Tax Liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>(4)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Net Deferred Taxes</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Valuation Allowance<br> -URI http://asc.fasb.org/extlink&amp;oid=6528051<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6812498640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_PatentAndTechnologyLicenseAgreementMilestonePaymentsTableTextBlock', window );">Patent And Technology License Agreement, Milestone Payments [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Pursuant to an amendment on October 19, 2015, the Company will pay milestone payments as follows:</font></div> <font style="FONT-SIZE: 10pt">&#160;</font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0px:auto; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div style="CLEAR:both;CLEAR: both">Phase</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Amount</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="57%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div style="CLEAR:both;CLEAR: both">Commencement of Phase II Study for a licensed product</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div style="CLEAR:both;CLEAR: both">200,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div style="CLEAR:both;CLEAR: both">Commencement of Phase III Study for a licensed product</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div style="CLEAR:both;CLEAR: both">250,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div style="CLEAR:both;CLEAR: both">Filing of a New Drug Application for a licensed product</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div style="CLEAR:both;CLEAR: both">400,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div style="CLEAR:both;CLEAR: both">Receipt of market approval for a licensed product</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div style="CLEAR:both;CLEAR: both">500,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_PatentAndTechnologyLicenseAgreementMilestonePaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of milestone payments under patent and technology license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_PatentAndTechnologyLicenseAgreementMilestonePaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6808240816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Liquidity (Details Textual) - shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 11, 2015</div></th>
<th class="th"><div>Aug. 31, 2015</div></th>
<th class="th"><div>Aug. 21, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mbrx_AnnamedIncMember', window );">AnnaMed, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Stock Issued During Period, Shares, Purchase of Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,431,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mbrx_AnnamedIncMember', window );">AnnaMed, Inc [Member] | Use Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Stock Issued During Period, Shares, Purchase of Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,431,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mbrx_IntertechbioCorporationMember', window );">IntertechBio Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Stock Issued During Period, Shares, Purchase of Assets</a></td>
<td class="nump">630,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mbrx_IntertechbioCorporationMember', window );">IntertechBio Corporation [Member] | Use Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Stock Issued During Period, Shares, Purchase of Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">630,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mbrx_AnnamedIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mbrx_AnnamedIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_UseRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_UseRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mbrx_IntertechbioCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mbrx_IntertechbioCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821584992">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit), Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (4,674,721)<span></span>
</td>
<td class="num">$ (748,360)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Cash, Uninsured Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">256,836<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash, FDIC Insured Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mbrx_MoleculinLlcMember', window );">Moleculin LLC [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Shorter of estimated usefule lives or the term of the lease<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">107,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">510,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Debt Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,821,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Property and equipment assets acquired in the merger with Moleculin, LLC are being depreciated over a 2 year useful life due to their age and condition and expected remaining life assessed at merger date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68071081&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mbrx_MoleculinLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mbrx_MoleculinLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6810157408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>May 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSegmentAllocationLineItems', window );"><strong>Business Combination Segment Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Liability assumed (HPI)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,000,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mbrx_HoustonPharmaceuticalsIncMember', window );">Houston Pharmaceuticals, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSegmentAllocationLineItems', window );"><strong>Business Combination Segment Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Liability assumed (HPI)</a></td>
<td class="num">$ (3,874,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mbrx_MoleculinLlcMember', window );">Moleculin LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSegmentAllocationLineItems', window );"><strong>Business Combination Segment Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="nump">362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">7,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangibles</a></td>
<td class="nump">11,147,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="nump">11,155,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther', window );">Other liabilities assumed, including $469,939 of notes payable</a></td>
<td class="num">(1,224,314)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Net assets acquired/total consideration transferred</a></td>
<td class="nump">$ 6,057,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=73531372&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSegmentAllocationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSegmentAllocationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mbrx_HoustonPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mbrx_HoustonPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mbrx_MoleculinLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mbrx_MoleculinLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6646049552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets (Details 1) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSegmentAllocationLineItems', window );"><strong>Business Combination Segment Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangibles acquired from Moleculin, LLC</a></td>
<td class="nump">$ 11,147,540<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSegmentAllocationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSegmentAllocationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821728048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems', window );"><strong>Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_BusinessAcquistionProFormaOperatingExpenses', window );">Total operating expenses</a></td>
<td class="num">$ (3,979,316)<span></span>
</td>
<td class="num">$ (688,101)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,962,997)<span></span>
</td>
<td class="num">$ (164,128)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted', window );">Net loss per common share - basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted', window );">Weighted average outstanding common shares - basic and diluted (in shares)</a></td>
<td class="nump">9,401,028<span></span>
</td>
<td class="nump">4,273,239<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma basic and diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_BusinessAcquistionProFormaOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The proforma operating expenses for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_BusinessAcquistionProFormaOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)-(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65885119&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823411168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 02, 2016</div></th>
<th class="th"><div>Jul. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>May 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">234,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mbrx_HoustonPharmaceuticalsIncMember', window );">Houston Pharmaceuticals, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,874,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">629,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_AccruedLicenseAgreementPayment', window );">Accrued license agreement payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mbrx_MoleculinLlcMember', window );">Moleculin LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableRelatedParties', window );">Notes Receivable, Related Parties</a></td>
<td class="nump">$ 57,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_RoyaltyOnNetRevenues', window );">Royalty On Net Revenues</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">469,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mbrx_MoleculinLlcMember', window );">Moleculin LLC [Member] | Acquisition Date One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of Debt Issuance Costs and Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,078<span></span>
</td>
<td class="nump">$ 422,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mbrx_MoleculinLlcMember', window );">Moleculin LLC [Member] | License Agreement [Member] | Houston Pharmaceuticals, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">629,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Payments to Acquire Intangible Assets</a></td>
<td class="nump">$ 75,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_AccruedLicenseAgreementPayment', window );">Accrued license agreement payment</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mbrx_MoleculinLlcMember', window );">Moleculin LLC [Member] | Out-Lincense Agreement [Member] | Houston Pharmaceuticals, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_LicencingArrangementsConsiderationPayable', window );">Licensing Arrangements Consideration Payable</a></td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_LicencingArrangementsReserve', window );">Licensing Arrangements Reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Payments to Acquire Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Moleculin LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</a></td>
<td class="nump">999,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned</a></td>
<td class="nump">$ 5,999,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_AccruedLicenseAgreementPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount payable for license agreement payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_AccruedLicenseAgreementPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred related to notes payable, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_LicencingArrangementsConsiderationPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount to be Paid for Technology Rights And Development of License under out license agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_LicencingArrangementsConsiderationPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_LicencingArrangementsReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of reserve maintained for the payments made against the licensing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_LicencingArrangementsReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_RoyaltyOnNetRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents the royalty percentage on net revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_RoyaltyOnNetRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from parties associated with the reporting entity as evidenced by a written promise to pay.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Related Parties<br> -URI http://asc.fasb.org/extlink&amp;oid=16382449<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mbrx_HoustonPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mbrx_HoustonPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mbrx_MoleculinLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mbrx_MoleculinLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_PeriodTypeAxis=mbrx_AcquisitionDateOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_PeriodTypeAxis=mbrx_AcquisitionDateOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mbrx_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mbrx_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mbrx_OutlincenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mbrx_OutlincenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823873760">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible Notes Payable, Current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 296,412<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 450,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible Notes Payable, Current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 276,079<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">450,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DebtInstrumentConvertibleNumberOfCommonShares', window );">Debt Instrument, Convertible, Number of Common Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,821,013<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_InvestorMember', window );">Investor A [Member] | Issue Date August 31 2015 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuanceDate1', window );">Debt Instrument, Issuance Date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Aug. 31,  2015<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible Notes Payable, Current</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 38,299<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0.1299<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DebtInstrumentConvertibleNumberOfCommonShares', window );">Debt Instrument, Convertible, Number of Common Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">294,832<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mbrx_InvestorBMember', window );">Investor B [Member] | Issue Date September 03 2015 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuanceDate1', window );">Debt Instrument, Issuance Date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Sep.  03,  2015<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible Notes Payable, Current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.1299<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DebtInstrumentConvertibleNumberOfCommonShares', window );">Debt Instrument, Convertible, Number of Common Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">962,279<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mbrx_InvestorCMember', window );">Investor C [Member] | Issue Date October 06 2015 One [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuanceDate1', window );">Debt Instrument, Issuance Date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[3]</sup></td>
<td class="text">Oct.  06,  2015<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible Notes Payable, Current</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[3]</sup></td>
<td class="nump">$ 30,280<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">147,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[3]</sup></td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DebtInstrumentConvertibleNumberOfCommonShares', window );">Debt Instrument, Convertible, Number of Common Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[3]</sup></td>
<td class="nump">151,402<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mbrx_InvestorDMember', window );">Investor D [Member] | Issue Date October 06 2015 Two [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuanceDate1', window );">Debt Instrument, Issuance Date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">Oct.  06,  2015<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible Notes Payable, Current</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DebtInstrumentConvertibleNumberOfCommonShares', window );">Debt Instrument, Convertible, Number of Common Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mbrx_InvestorEMember', window );">Investor E [Member] | Issue Date October 28 2015 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuanceDate1', window );">Debt Instrument, Issuance Date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Oct. 28,  2015<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible Notes Payable, Current</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DebtInstrumentConvertibleNumberOfCommonShares', window );">Debt Instrument, Convertible, Number of Common Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mbrx_InvestorFMember', window );">Investor F [Member] | Issue Date January 14 2016 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuanceDate1', window );">Debt Instrument, Issuance Date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text">Jan. 14,  2016<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible Notes Payable, Current</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DebtInstrumentConvertibleNumberOfCommonShares', window );">Debt Instrument, Convertible, Number of Common Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mbrx_InvestorGMember', window );">Investor G [Member] | Issue Date January 19 2016 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuanceDate1', window );">Debt Instrument, Issuance Date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Jan. 19,  2016<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible Notes Payable, Current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 82,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DebtInstrumentConvertibleNumberOfCommonShares', window );">Debt Instrument, Convertible, Number of Common Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">412,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Debt partially converted on May 31, 2016 and on August 19, 2016.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Excluded from the $276,079 is $20,333 in accrued interest on the convertible notes payable which is included in the accompanying balance sheet.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Debt partially converted on September 1, 2016.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Debt fully converted to common shares on May 31, 2016.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">Debt fully converted to common shares effective November 30, 2016 .</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_DebtInstrumentConvertibleNumberOfCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of common shares that the holder of the debt instrument would receive if the debt was converted to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_DebtInstrumentConvertibleNumberOfCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIssuanceDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the debt instrument was issued, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIssuanceDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mbrx_IssueDateAugust312015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mbrx_IssueDateAugust312015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mbrx_InvestorBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mbrx_InvestorBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mbrx_IssueDateSeptember032015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mbrx_IssueDateSeptember032015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mbrx_InvestorCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mbrx_InvestorCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mbrx_IssueDateOctober062015OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mbrx_IssueDateOctober062015OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mbrx_InvestorDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mbrx_InvestorDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mbrx_IssueDateOctober062015TwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mbrx_IssueDateOctober062015TwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mbrx_InvestorEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mbrx_InvestorEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mbrx_IssueDateOctober282015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mbrx_IssueDateOctober282015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mbrx_InvestorFMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mbrx_InvestorFMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mbrx_IssueDateJanuary142016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mbrx_IssueDateJanuary142016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mbrx_InvestorGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mbrx_InvestorGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mbrx_IssueDateJanuary192016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mbrx_IssueDateJanuary192016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6810487152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible Notes Payable, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 296,412<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DebtConversionConvertedInstrumentCommonStockSharesIssuedTradingRestrictionsDescription', window );">Debt Conversion, Converted Instrument, Common Stock Shares Issued Trading Restrictions Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The common shares relating to the above mentioned convertible notes payable contain the following trading restrictions: (a) beginning 90 days after the initial closing of our IPO and until the one-year anniversary of the initial closing of the IPO, the holder of the note will be able to sell 1% of the number of shares of common stock underlying the note on a monthly basis, subject to a maximum sale on any trading day of 4% of the daily volume; (b) if the common stock price is over $7.00 per share for five consecutive trading days then the holder of the note can sell up to 3% of the number of shares of common stock underlying the note on a monthly basis, subject to a maximum sale on any trading day of 4% of the daily volume; (c) if the common stock price is over $10.00 per share for five consecutive trading days then the holder of the note can sell up to an additional 5% of the number of shares of common stock underlying the note on a monthly basis, subject to a maximum sale on any trading day of 7% of the daily volume; and (d) if the common stock price is over $14.00 per share then the holder of the note is not restricted from making any sales until such time as the common stock price falls back below $14.00 per share; and (b) thereafter, until the two-year anniversary of the initial closing of IPO, the holder of the note can sell on any trading day 10% of the daily volume; provided that if the common stock price is over $10.00 per share then the holder of the note is not restricted from making any sales until such time as the common stock falls back below $10.00 per share. The foregoing lock-up restrictions relate to public sales and do not restrict the transfer of the shares privately, if permitted by applicable law, provided the acquirer of the shares agrees to comply with the above restrictions with respect to any public sales.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued</a></td>
<td class="nump">1,166,503<span></span>
</td>
<td class="nump">910,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt Conversion, Original Debt, Amount</a></td>
<td class="nump">$ 183,356<span></span>
</td>
<td class="nump">$ 155,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest Payable, Current</a></td>
<td class="nump">$ 17,699<span></span>
</td>
<td class="nump">7,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible Notes Payable, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">276,079<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest Payable, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="nump">4.99%<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DebtConversionConvertedInstrumentAdditionalSharesIssued', window );">Debt Conversion, Converted Instrument, Additional Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,821,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mbrx_UnsecuredPromissoryNotesMember', window );">Unsecured Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_DebtConversionConvertedInstrumentAdditionalSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of additional shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_DebtConversionConvertedInstrumentAdditionalSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_DebtConversionConvertedInstrumentCommonStockSharesIssuedTradingRestrictionsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the restriction terms and conditions trading of the common stock of the shares converted upon debt conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_DebtConversionConvertedInstrumentCommonStockSharesIssuedTradingRestrictionsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mbrx_UnsecuredPromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mbrx_UnsecuredPromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6810155920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Outstanding Balance</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares, Granted</a></td>
<td class="nump">460,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Shares, Cancelled</a></td>
<td class="num">(150,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Outstanding Balance</a></td>
<td class="nump">510,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares, Exercisable</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Outstanding Balance</a></td>
<td class="nump">$ 0.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted</a></td>
<td class="nump">3.75<span></span>
</td>
<td class="nump">$ 0.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Cancelled</a></td>
<td class="nump">0.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Outstanding Balance</a></td>
<td class="nump">3.40<span></span>
</td>
<td class="nump">0.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Exercisable</a></td>
<td class="nump">0.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Balance</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">5.83<span></span>
</td>
<td class="nump">0.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Balance</a></td>
<td class="nump">5.28<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years), Outstanding</a></td>
<td class="text">9 years 3 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in years), Exercisable</a></td>
<td class="text">3 years 8 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding Balance</a></td>
<td class="nump">$ 275,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 275,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828053264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 02, 2016</div></th>
<th class="th"><div>Aug. 11, 2015</div></th>
<th class="th"><div>Oct. 31, 2016</div></th>
<th class="th"><div>Jun. 20, 2016</div></th>
<th class="th"><div>May 31, 2016</div></th>
<th class="th"><div>Apr. 22, 2016</div></th>
<th class="th"><div>Aug. 31, 2015</div></th>
<th class="th"><div>Aug. 21, 2015</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">234,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="nump">$ 702,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,565,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec.  05,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Compensation, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 323,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable', window );">Class of Warrant or Right, Period from which Warrants or Rights Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Issuance Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 9,170,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_CommonStockLockupAndLeakoutAgreementsDescription', window );">Common Stock Lock-Up and Leak-Out Agreements Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">These shares are subject to the following lock-up agreement, from and after the later of six months after issuance or 90 days from the effective date of our IPO registration statement until the one-year anniversary thereof, (a) the holder of the shares can sell up to 10% of the purchased shares per month, subject to a maximum sale on any trading day of 8% of the daily volume of the common stock; (b) if the common stock price is over $7.00 per share for five consecutive trading days then the holder of the shares can sell up to 20% of the purchased shares per month, subject to a maximum sale on any trading day of 10% of the daily volume of the common stock; and (c) if the common stock price is over $12.00 per share then the holder of the shares is not restricted from making any sales until such time as the common stock price falls back below $12.00 per share.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_SharesAuthorized', window );">Shares Authorized</a></td>
<td class="nump">80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">460,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.83<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_EstimatedForfeitureRatePercentage', window );">Estimated Forfeiture Rate Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mbrx_IntertechbioCorporationMember', window );">IntertechBio Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Stock Issued During Period, Shares, Purchase of Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">630,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Stock Issued During Period, Value, Purchase of Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mbrx_AnnamedIncMember', window );">AnnaMed, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Stock Issued During Period, Shares, Purchase of Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,431,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Stock Issued During Period, Value, Purchase of Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mbrx_PcgAdvisoryGroupMember', window );">PCG Advisory Group [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 157,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrants Not Settleable in Cash, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 374,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Fair Value Inputs, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.39%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Fair Value Assumptions, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.61%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,540,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Issuance Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,464,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mbrx_StockPlanMember', window );">2015 Stock Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=mbrx_DirectorAndOfficersMember', window );">Director And Officers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=mbrx_EmployeeAndBoardOfDirectorsMember', window );">Employee And Board Of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Compensation, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">460,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,772,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=mbrx_EmployeeAndBoardOfDirectorsMember', window );">Employee And Board Of Directors [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.44%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=mbrx_EmployeeAndBoardOfDirectorsMember', window );">Employee And Board Of Directors [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.18%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefFinancialOfficerMember', window );">Chief Financial Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Period from which Warrants or Rights Exercisable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_CommonStockLockupAndLeakoutAgreementsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the restriction terms and conditions on selling the common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_CommonStockLockupAndLeakoutAgreementsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_EstimatedForfeitureRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents the percentage rate of estimated forfeiture.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_EstimatedForfeitureRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_SharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common and preferred shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_SharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value.  For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the equity-based award expires, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares for which recognition of compensation cost was accelerated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mbrx_IntertechbioCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mbrx_IntertechbioCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mbrx_AnnamedIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mbrx_AnnamedIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mbrx_PcgAdvisoryGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mbrx_PcgAdvisoryGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=mbrx_StockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=mbrx_StockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=mbrx_DirectorAndOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=mbrx_DirectorAndOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=mbrx_EmployeeAndBoardOfDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=mbrx_EmployeeAndBoardOfDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828096112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current Expense (Benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current Income Tax Expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred Expense (Benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred Income Tax Expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Net Deferred Taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=63044130<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=63044130<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=63044130<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6805286832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation Allowance at Beginning of Period</a></td>
<td class="nump">$ 155<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Income Tax Benefit</a></td>
<td class="nump">1,242<span></span>
</td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DeferredTaxAssetsValuationAllowanceReleases', window );">Release of Valuation Allowance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation Allowance at End of Period</a></td>
<td class="nump">$ 1,397<span></span>
</td>
<td class="nump">$ 155<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_DeferredTaxAssetsValuationAllowanceReleases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of valuation allowance released during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_DeferredTaxAssetsValuationAllowanceReleases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822419536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Federal Tax Benefit at Statutory Rate, Amount</a></td>
<td class="nump">$ 1,335<span></span>
</td>
<td class="nump">$ 254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State Tax Benefit Net of Federal, Amount</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost', window );">IPO Costs, Amount</a></td>
<td class="num">(227)<span></span>
</td>
<td class="num">(99)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other Permanent Differences, Amount</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Increase in Valuation Allowance, Amount</a></td>
<td class="num">(1,242)<span></span>
</td>
<td class="num">(155)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total Tax (Expense) / Benefit, Amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal Tax Benefit at Statutory Rate, Percent</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State Tax Benefit Net of Federal, percent</a></td>
<td class="nump">3.48%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent', window );">IPO Costs, Percent</a></td>
<td class="num">(5.78%)<span></span>
</td>
<td class="num">(13.24%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other Permanent Differences, Percent</a></td>
<td class="num">(0.08%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Increase in Valuation Allowance, Percent</a></td>
<td class="num">(31.62%)<span></span>
</td>
<td class="num">(20.76%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total Tax (Expense) / Benefit, Percent</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to initial offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to initial public offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6811415744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details 3) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred Tax Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DeferredTaxAssetsStartUpCosts', window );">Start Up Costs</a></td>
<td class="nump">$ 798<span></span>
</td>
<td class="nump">$ 67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal Net Operating Loss Carryforwards</a></td>
<td class="nump">520<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State Tax Loss Carryforwards</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Deferred Compensation</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total Deferred Tax Assets</a></td>
<td class="nump">1,401<span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less Valuation Allowance</a></td>
<td class="num">(1,397)<span></span>
</td>
<td class="num">(155)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net Deferred Tax Assets</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred Tax Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed Assets</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total Deferred Tax Liabilities</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net Deferred Taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_DeferredTaxAssetsStartUpCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, start up costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_DeferredTaxAssetsStartUpCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Asset<br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6805269264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 1,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_OperatingLossCarryforwardsExpirationPeriod', window );">Operating Loss Carryforwards Expiration Period</a></td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred Tax Assets, Valuation Allowance</a></td>
<td class="nump">$ 1,397<span></span>
</td>
<td class="nump">$ 155<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 1,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_OperatingLossCarryforwardsExpirationPeriod', window );">Operating Loss Carryforwards Expiration Period</a></td>
<td class="text">2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_OperatingLossCarryforwardsExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration period of each operating loss carryforward included in operating loss carryforward, in CCYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_OperatingLossCarryforwardsExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6810518512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mbrx_CommencementOfPhaseIiStudyForLicensedProductMember', window );">Commencement Of Phase II Study For a Licensed Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_MilestonePaymentsLiabilities', window );">Milestone Payments Liabilities</a></td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember', window );">Commencement Of Phase III Study For a Licensed Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_MilestonePaymentsLiabilities', window );">Milestone Payments Liabilities</a></td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mbrx_FilingOfNewDrugApplicationForLicensedProductMember', window );">Filing Of a New Drug Application For a Licensed Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_MilestonePaymentsLiabilities', window );">Milestone Payments Liabilities</a></td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mbrx_ReceiptOfMarketApprovalForLicensedProductMember', window );">Receipt Of Market Approval For a Licensed Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_MilestonePaymentsLiabilities', window );">Milestone Payments Liabilities</a></td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_MilestonePaymentsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of expense payable towards milestone payments under Patent and Technology License Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_MilestonePaymentsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mbrx_CommencementOfPhaseIiStudyForLicensedProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mbrx_CommencementOfPhaseIiStudyForLicensedProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mbrx_FilingOfNewDrugApplicationForLicensedProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mbrx_FilingOfNewDrugApplicationForLicensedProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mbrx_ReceiptOfMarketApprovalForLicensedProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mbrx_ReceiptOfMarketApprovalForLicensedProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6829806656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 02, 2016</div></th>
<th class="th"><div>Nov. 02, 2015</div></th>
<th class="th"><div>Oct. 08, 2015</div></th>
<th class="th"><div>Oct. 07, 2016</div></th>
<th class="th"><div>Aug. 19, 2016</div></th>
<th class="th"><div>May 31, 2016</div></th>
<th class="th"><div>Feb. 29, 2016</div></th>
<th class="th"><div>Oct. 19, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Apr. 30, 2016</div></th>
<th class="th"><div>Jan. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Oct. 31, 2015</div></th>
<th class="th"><div>Aug. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent', window );">Deferred Compensation Liability, Classified, Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_MilestonePaymentDescription', window );">Milestone Payment Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The amended milestone payments are as follows: (i) commencement of Phase III Study for first licensed drug/product within the United States, Europe, China or Japan - $150,000; (ii) submission of the first NDA within the United States - $500,000; and (iii) receipt of first marketing approval for sale of a license product in the United States - $600,000.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mbrx_MrLouisMember', window );">Mr. Louis [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_SeparationAgreementDescription', window );">Separation Agreement Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Pursuant to the Separation Agreement, Mr. Ploth will be permitted to exercise 25% of the options to purchase common stock granted to him in December 2015, or 50,000 shares, until May 2020.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mbrx_MoleculinLlcMember', window );">Moleculin LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payments for Other Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">306,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mbrx_PatentLawFirmMember', window );">Patent Law Firm [Member] | Minimum Fee and patent Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual Obligation, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,504<span></span>
</td>
<td class="nump">$ 65,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mbrx_BonwickCapitalPartnersLlcMember', window );">Bonwick Capital Partners LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_LetterAgreementsTerms', window );">Letter Agreements Terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company agreed to: a) pay success fees equal to 7% of the gross proceeds from any form of financing; and b) issue five-year warrants to purchase 7% of the Companys equity securities sold with a cashless exercise provision, exercisable at 125% of the price per share of the Companys common stock paid by investors in the transaction. In addition, the Company agreed to reimburse Bonwick for all of its out-of-pocket expenses incurred in connection with the offering, not to exceed $25,000, and fees and expenses of their counsel not to exceed $100,000.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_SuccessFeePercentage', window );">Success Fee Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_ClassOfWarrantOrRightPercentageOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Percentage of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_ClassOfWarrantOrRightExercisePricePercentageThreshold', window );">Class of Warrant or Right, Exercise Price Percentage Threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForUnderwritingExpense', window );">Payments for Underwriting Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mbrx_BonwickCapitalPartnersLlcMember', window );">Bonwick Capital Partners LLC [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_ReimburementOfExpenses', window );">Reimburement of Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 646,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mbrx_BonwickCapitalPartnersLlcMember', window );">Bonwick Capital Partners LLC [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_ReimbursementPayableOfferingCosts', window );">Reimbursement Payable, Offering Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_ReimbursementPayableFeesAndExpensesOfCounsel', window );">Reimbursement Payable, Fees and Expenses of Counsel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=mbrx_MdAndersonMember', window );">MD Anderson [Member] | Minimum Fee and patent Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual Obligation, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="nump">98,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=mbrx_MdAndersonMember', window );">MD Anderson [Member] | Minimum Annual Royalty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual Obligation, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Officers' Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent', window );">Deferred Compensation Liability, Classified, Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,500<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=mbrx_ChiefFinancialOfficerAndExecutiveVicePresidentMember', window );">Chief Financial Officer and Executive Vice President [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Officers' Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1', window );">Deferred Compensation Arrangement with Individual, Maximum Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=mbrx_ChiefFinancialOfficerAndExecutiveVicePresidentMember', window );">Chief Financial Officer and Executive Vice President [Member] | Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued', window );">Deferred Compensation Arrangement with Individual, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice', window );">Deferred Compensation Arrangement with Individual, Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_AgreementAxis=mbrx_PatentAndTechnologyLicenseAgreementMember', window );">Patent and Technology License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual Obligation, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,186<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Payments for Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_LicenseAgreementMaintenanceFee', window );">License Agreement, Maintenance Fee</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_LicenseAgreementMaintenanceFeeAnnualIncrease', window );">License Agreement, Maintenance Fee Annual Increase</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payments for Other Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_LicenseAgreementMaintenanceFeeMaximumPayablePerYear', window );">License Agreement, Maintenance Fee - Maximum Payable Per Year</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_AgreementAxis=mbrx_PatentAndTechnologyLicenseAgreementMember', window );">Patent and Technology License Agreement [Member] | Servicing Fee payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">Contractual Obligation, Due First Anniversary April 2, 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">Contractual Obligation, Due Second Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">Contractual Obligation, Due Third Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFourthYear', window );">Contractual Obligation, Due Fourth Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFifthYear', window );">Contractual Obligation, Due Fifth Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueAfterFifthYear', window );">Contractual Obligation, Due Sixth Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_AgreementAxis=mbrx_PatentAndTechnologyLicenseAgreementMember', window );">Patent and Technology License Agreement [Member] | Minimum Annual Royalty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_ContractualObligationDueInNextFiscalYearAfterProductApproval', window );">Contractual Obligation, Due in Next Fiscal Year, After Product Approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_ContractualObligationDueInSecondYearAfterProductApproval', window );">Contractual Obligation, Due in Second Year, After Product Approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_ContractualObligationDueInThirdYearAfterProductApproval', window );">Contractual Obligation, Due in Third Year, After Product Approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_AgreementAxis=mbrx_PatentAndTechnologyLicenseAgreementMember', window );">Patent and Technology License Agreement [Member] | Letter Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payments for Other Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 691,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_ClassOfWarrantOrRightExercisePricePercentageThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price percentage per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_ClassOfWarrantOrRightExercisePricePercentageThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_ClassOfWarrantOrRightPercentageOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of securities into which the class of warrant or right may be converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_ClassOfWarrantOrRightPercentageOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_ContractualObligationDueInNextFiscalYearAfterProductApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the next fiscal year following the latest fiscal year after product approval.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_ContractualObligationDueInNextFiscalYearAfterProductApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_ContractualObligationDueInSecondYearAfterProductApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the second fiscal year following the latest fiscal year after product approval.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_ContractualObligationDueInSecondYearAfterProductApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_ContractualObligationDueInThirdYearAfterProductApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the third fiscal year following the latest fiscal year after product approval.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_ContractualObligationDueInThirdYearAfterProductApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_LetterAgreementsTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of agreement terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_LetterAgreementsTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_LicenseAgreementMaintenanceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The annual maintenance fee under the licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_LicenseAgreementMaintenanceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_LicenseAgreementMaintenanceFeeAnnualIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The rate of increase annualy om the annual maintenance fee under the licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_LicenseAgreementMaintenanceFeeAnnualIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_LicenseAgreementMaintenanceFeeMaximumPayablePerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum payable amount of annual maintenance fee under the licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_LicenseAgreementMaintenanceFeeMaximumPayablePerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_MilestonePaymentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Description</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_MilestonePaymentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_ReimburementOfExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses reimbursed to underwriters.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_ReimburementOfExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_ReimbursementPayableFeesAndExpensesOfCounsel">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of reimbursement payable related to fees and expenses of counsel.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_ReimbursementPayableFeesAndExpensesOfCounsel</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_ReimbursementPayableOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of reimbursement payable related to offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_ReimbursementPayableOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_SeparationAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents description regarding separation agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_SeparationAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_SuccessFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of success fee payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_SuccessFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueAfterFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueAfterFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The per share price that the individual must pay to acquire shares under the deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum term of the deferred compensation arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6409961&amp;loc=d3e20487-108367<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued pursuant to the terms of a deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenditures for salaries of officers. Does not include allocated share-based compensation, pension and post-retirement benefit expense or other labor-related non-salary expense. For commercial and industrial companies, excludes any direct and overhead labor that is included in cost of goods sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForUnderwritingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash paid for expenses incurred during underwriting activities (the process to review insurance applications, evaluate risks, accept or reject applications, and determine the premiums to be charged) for insurance companies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForUnderwritingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(10)<br> -URI http://asc.fasb.org/extlink&amp;oid=65897934&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mbrx_MrLouisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mbrx_MrLouisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mbrx_MoleculinLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mbrx_MoleculinLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mbrx_PatentLawFirmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mbrx_PatentLawFirmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=mbrx_MinimumFeeAndPatentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=mbrx_MinimumFeeAndPatentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mbrx_BonwickCapitalPartnersLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mbrx_BonwickCapitalPartnersLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=mbrx_MdAndersonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=mbrx_MdAndersonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=mbrx_MinimumAnnualRoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=mbrx_MinimumAnnualRoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=mbrx_ChiefFinancialOfficerAndExecutiveVicePresidentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=mbrx_ChiefFinancialOfficerAndExecutiveVicePresidentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_AgreementAxis=mbrx_PatentAndTechnologyLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_AgreementAxis=mbrx_PatentAndTechnologyLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=mbrx_ServicingFeePayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=mbrx_ServicingFeePayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=mbrx_LetterAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=mbrx_LetterAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6826774640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 02, 2016</div></th>
<th class="th"><div>Mar. 22, 2017</div></th>
<th class="th"><div>Feb. 09, 2017</div></th>
<th class="th"><div>May 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">234,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,166,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">910,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">460,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Issuance Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 9,170,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 363,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Science Advisory Board One [Member] | Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Science Advisory Board Two [Member] | Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Underwriting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">556,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_NumberOfUnitsIssued', window );">Number Of Units issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,710,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_PricePerUnit', window );">Price Per Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Sale of Stock, Description of Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">purchase one share of common stock, and (iv) a five-year Series C warrant to purchase 0.50 of a share of common stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_ClassOfWarrantOrRightsWarrantExercised', window );">Class Of Warrant Or Rights Warrant Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">556,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Issuance Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Underwriting Agreement [Member] | Series A Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Underwriting Agreement [Member] | Series B Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">556,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Underwriting Agreement [Member] | Series C Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Former Science Advisory Board [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 237,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | U.S. Food and Drug Administration [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from Issuance of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | U.S. Food and Drug Administration [Member] | Series B Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_ClassOfWarrantOrRightsWarrantExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of warrants exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_ClassOfWarrantOrRightsWarrantExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_NumberOfUnitsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of units issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_NumberOfUnitsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_PricePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents price per units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_PricePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4582445-111684<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569655-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=mbrx_ScienceAdvisoryBoardOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=mbrx_ScienceAdvisoryBoardOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=mbrx_ScienceAdvisoryBoardTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=mbrx_ScienceAdvisoryBoardTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_AgreementTypeAxis=mbrx_UnderwritingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_AgreementTypeAxis=mbrx_UnderwritingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mbrx_SeriesWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mbrx_SeriesWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mbrx_SeriesBWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mbrx_SeriesBWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mbrx_SeriesCWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mbrx_SeriesCWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mbrx_FormerScienceAdvisoryBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mbrx_FormerScienceAdvisoryBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mbrx_UsFoodAndDrugAdministrationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mbrx_UsFoodAndDrugAdministrationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>59
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M?_A=A7UOW=[]8^.+H&[@UUWH+U!+ P04    " "J/(-*F5R<(Q &  "<)P
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M6W17DZZC>-M?N]!P]UO^ U!+ P04    " "J/(-*;A):OUT#  "A#@  &
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MDR&U&2*#(7WJC#Q2S5@R)TMFL\0&2V95F[H/R1/"&='"2;2PB1*#:&$E"L(
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M"?#_J9'2@+43W=E1Z^Q#7 (&C7';O=VK,(XA,'*87QI9GGOY#U!+ P04
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M'VPV)-0N'!_\V8QC-AH.N^D'L?D;%W\!4$L#!!0    ( *H\@TJ Q->FM0$
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M4/EPO,6S'<9L,+QIQQ_$IF^<OP)02P,$%     @ JCR#2AUER>"V 0  T@,
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M_=E,8S893O?S#R++-R[_ U!+ P04    " "J/(-*'!MFF5@"  "D"   &0
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MX[:W=J_&@1D#([OI+2#S@Y3]!5!+ P04    " "J/(-*-K=^*[<!  #2 P
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MU>29M<<7!1@7\#KY^P!V'"OU"S##.6<N#.F YL4V (Z\*JEM1AOGN@-CMFA
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M!G8$T1U! A-$($'D".([ C+)LL<0AVD<Y@&%[@,KQ:!2#"BE,$$"$B3O]TI
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MQ$4H"5&8S@1YDQO5 +OHX<.=DEY;H;[=272<;T](W<A9?"_GGAE3[S1F:/[
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MW]/9?^>OO%3FW4B4QE*4;?_I+?>M%)6.HH92Y6_#N:C[\T''/[KA#J =X.1
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MK,DPI_L 7TP%)QR!PR+X:"_NBHBT(B9-/&KJ*8LL%DQ/Q92)*%3_<#H"IB-
M.C%V$$$'D4,]D5E/$H=)IM4SR2+'>F*83@S22;1T8B,.2XF%C.- "0R4@$ I
M=I!"!REPH*U(;FHH"K5J@!]F6;(,)I)]? 5S4V,FDAE7F:>4:24]@VB,:8V0
MF1>((FLCL!#3(@21M%LH!R*SL%F4W>03/K#;TN[SL="+?=R:.1"!?)BQ/I2)
MU,8A!E'WQ BLC^468)AE#,$LT[,%(B8L<3"D&**4#IE9%-N[9FI Y,SHP%GD
MW(*8C0S 46_!]2QR[B[,/>8"/F:2+XN)$ELH3#X&T,<BBPO,/N8"/R1BL5X2
M$B669##_F L D<A,!B PI-3H0!<&,@!!D5@[D# $R06"4*37-HO2NS:U$(<P
M <F%@$AD)F,2D$5,A+9\, $)$=#R-YPP <F!@#D2,1V34&1I9,*8) =,YDAD
M)F.R5&]BZ$=O8C(QRNTMC"%*#A#-H<BH*OI$"V/,D@-F<R0RDS%9;%L7C&$"
M&":;"XQA<L#P&HG(]E*%"4LNA$4B<]5,PAJ-Z4)7,NGZSJL&QW#E+G"%(KTL
M_@FX<@Q7[@)7)#*3,>%J6Q?,50ZX2K9J+&_)+EQ%(N)Z-4AD>?SDF*O<A:M(
M9";S,5>1'Z-]N<E5VR7"4.4N4$4BLZ1/0)5CJ'(7J"*1F8PS5#F&*D=0M3S;
M<@Q5[@)5)"++O@O'4.4.4%USDY?I\!ZC-YT+,X$OVU83YJ5PX.5:? *% J-0
M.*!P+4S*"7:W-/>A=-3=SV**"9,]QMM\#D2<+ ]^PK*)Y\",'(G(\K0K,#4$
M H).923BME7%0! .#U Y$G'+<XG =[M =SO7XP"1L=42W.QA5[+=C]\3.F_3
MG.M^>+>_&;U^L\C';7QM?,T>GQD:I\=GI'\2:D*@&=58:H;#&:%F!)R)U$P$
M9V(U$\.91,V,GU^"GZ5/'V_^*-K]L>Z\UZ;OFVK<N]\U32_5NH8/JD\.LMA>
M3TJYZX?#1!VWTT>3Z:1O3O,'H>#Z56KU/U!+ P04    " "J/(-*+U!<.[0"
M  "Z"0  &0   'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6R5EN%NFS 0QU\%
M\0#%!F-"E41J$TV;M$E5IW6?W<1)4 $SVTFZMY]M* 5S;%T^!.S\[^YWE^/P
M\BKDBSIQKH/7JJS5*CQIW=Q&D=J=>,74C6AX;7XY"%DQ;9;R&*E&<K9W1E49
MQ0C1J&)%':Z7;N]!KI?BK,NBY@\R4.>J8O+W/2_%=17B\&WCL3B>M-V(ULN&
M'?EWKG\T#]*LHM[+OJAXK0I1!Y(?5N$=OMWBU!HXQ5/!KVIP']A4GH5XL8LO
M^U6(+!$O^4Y;%\Q<+GS#R])Z,AR_.J=A'],:#N_?O']RR9MDGIGB&U'^+/;Z
MM H78;#G!W8N]:.X?N9=0FD8=-E_Y1=>&KDE,3%VHE3N.]B=E195Y\6@5.RU
MO1:UNUX[_V]FL$'<&<2]05N<68.D,T@^&H%T!N0] G'5:E-QM=DRS=9+*:Z!
M;/_>AMDNPK?$5']G-UVQW6^F/,KL7M9)DBRCBW74:>Y;33S2D+%F,]7@7A$9
M@AXCAC#NXXEY3/T0@&:LV$X520Q3)& Q$F=/AO8H]2A:#76:NJ7(*<$^RE1&
M4F0^, X!<<@4)_%Q( V%@Z1@D!1PD'D-T&K203(84YHBKU$V4UV.$<I3F(>"
M/!3@67@\=%)<O#"EH1X.($O3E,[@9"!.!N#D'DXVC9/1W%-MLDEQ,IS-M.<"
M9%D [3GS7^>@@_P#_9U/,..,HLS+9IO_5W]C! \?]._J;CK1Z(E#PR$UCC0S
MYO T$IF#!4?4'8X!%]@?E9 H]C/ZNV@, T\J#(PJXC^.G6CTW"YBC/!<[> Q
MA($90\B,"WC(8&#*$+_S0)'?W]'@Q59Q>72'!A7LQ+EV)Y;!;G\PN8O=B_%=
MWIYJOC%Y+&H5/ MM7J_N)7@00G/#@FX,R\D<I/I%R0_:WF;F7K:GB7:A1=.=
ME*+^N+;^ U!+ P04    " "J/(-*\\J>& 0#  "+#   &0   'AL+W=O<FMS
M:&5E=',O<VAE970S,2YX;6R55UV/FS 0_"N(]P9L,)!3$NF2JFJE5CJU:OOL
M2YP$'6!JG.3Z[^NOH\0L:7H/ 9O9G=F]>-@L+ER\=$?&9/!:5TVW#(]2M@]1
MU&V/K*;=C+>L44_V7-14JJ4X1%TK&-V9H+J*<!QG44W+)EPMS-Z36"WX259E
MPYY$T)WJFHK?:U;QRS)$X=O&U_)PE'HC6BU:>F#?F/S>/@FUBOHLN[)F35?R
M)A!LOPP?T<,&8QU@$#]*=ND&]X$NY9GS%[WXM%N&L5;$*K:5.@55ES/;L*K2
MF92.7RYIV'/JP.']6_8/IGA5S#/MV(97/\N=/"[#(@QV;$]/E?S*+Q^9*XB$
M@:O^,SNS2L&U$L6QY55G/H/MJ9.\=EF4E)J^VFO9F.O%/LGG+@P.P"X ]P&8
MW Q(7$#2!Z#4%&^5F5+?4TE7"\$O@;#_K9;J+P5Z2%0SMWK3],X\4]5V:O>\
M2M)\$9UU(H=96PP>8%"/B%3VG@)#%&L\"L?7!)LQ(L$P0P(6D9CXY*J( DZ0
M@@E2DR"]2C#WNF QQ& :6T:L_V > O*0,0^)/1XRXDFS*Q[;LS'LEIP,E),!
M<I G)QOQO$-DFB@'B?([^IN/B @"ZA[#;M5=@'(*H&[O.[DNQG*F:>8@S1R@
M23P:BRD&-/$,I3 +BN$C' ,\J7^&+4A?>J9DEA.ONPYVIYX)2T& 'N+K06,]
M-YA 9WE$^(X..Y!7>>H7#J!NZ(%]""6 GLS7D_P7$VQ8"' L,O)M"T+HBFG"
M61'L6 BRK,(G(N.2R*Q(_!X#L&D]L&4AR+-\*W&@.PN'+0L!GC7N< X5C@N_
M< ?#=^F!/0L!II7Y[PX'NI,(=BT$V%;FOQ5 T 0/AFT+ [:5^8<7!$T<%0S;
M$0;L*//MR(&RX6LE)V3*[S'L1QCPH\P__P[T3ZIH,,+53!S,M-L%6WYJI!Z6
M!KO]1/UH!FIO?ZTF;3L7_TUCQ_0O5!S*I@N>N50#IAD#]YQ+IF3&,W58C^J7
M0;^HV%[JVUS="SL>VX7DK1O]H_[WQ^H/4$L#!!0    ( *H\@TK%;_"][P4
M -LB   9    >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;)5:V7+B2!#\%8(/
M,.J[Y<".6%_C:R,<,[&[S[*1#3& 6$FV9_]^)=%F4%<E(>9A0#BKLH_*[ .F
MGT7YLYKG>3WZM5JNJ[/QO*XWIY-)]3+/5UEU4FSR=?.7UZ)<977S6+Y-JDV9
M9[,N:+6<R"2QDU6V6(_/I]UG3^7YM'BOEXMU_E2.JO?5*BO_N\B7Q>?96(R_
M/OB^>)O7[0>3\^DF>\M_Y/5?FZ>R>9KLLLP6JWQ=+8KUJ,Q?S\9_B--'9]J
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MUNW;EJO<_MQB^U 7F_!3DLGN]RSG_P-02P,$%     @ JCR#2CX%-*]$ @
MQ@<  !D   !X;"]W;W)K<VAE971S+W-H965T,S,N>&ULC97;CILP$(9?!?$
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MQ5WOE[F)'7B9LXLD70\'[HD+I9C_JX"PL?!#_Q9X[II6Z@ J\P$W\ OD[^'
MU0K-64X=A5YTK/<XG O_*=SM,XTW@)<.1K&8>]K)D;%7O?A^*OQ "P("M=09
ML!JNL ="="(EX^^4TY]+:N)R?LO^U7A77HY8P)Z1/]U)MH7_R?=.<,87(I_9
M^ TF/ZGO3>9_P!6(@FLEJD;-B#!?K[X(R>B414FA^,V.76_&T>ZD-YJ;$$V$
M:":$V8>$>"+$[X3$F+?*C-4O6.(RYVSTN+VL >M_(MS%ZC!K'31G9_:46Z&B
MUS*)@QQ==:()4UE,M,"$,P*I['.)R%6BBC;TZ+[ ?HN((W>%V&DB-OSDSD2X
M,F$QF<'TUD2:KG1L,8%;1N*4D3ADK*Q6%I,N943)^CP<H(76.R6I4TGJ4!*O
ME*2;(JM[WW^$N!.1.45D#A')2D2VO97X\^-*AP.T.0ZT^.$I\,;T!N'5[-)+
M_6LMHG/[>8KT@UG%*]66;!=Y3V-[VD_,FZX7WI%)]1S-HSDS)D%)#![4*;6J
MC<X+ F>IIX]JSFTSL0O)AJE/HKE9E_\!4$L#!!0    ( *H\@THV<E7)J0(
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MKN:\/^G[A63M<(L)QJO4^C]02P,$%     @ JCR#2NQG?><V @  X 8  !D
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MJHVI"35C$A33?5#;UZBJOPPHU%)W$]7G4^F;!I(-<UG'R[^E^ -02P,$%
M  @ JCR#2H60&=?W!0  T2,  !D   !X;"]W;W)K<VAE971S+W-H965T,SDN
M>&ULE9IM4Z-(%(7_2BH_0.AWL!*K5EVCCC.;FJW=_8R*FIHD9 %U]M\O$)()
MM^^A8#Y,7CQ]3S?=3]]+D]EGEO\HWM*TG/S<K+?%?/I6EKOS("B>WM)-4IQE
MNW1;_>4ERS=)67W,7X-BEZ?)<]-HLPYD&-I@DZRVTXM9\]TROYAE[^5ZM4V7
M^:1XWVR2_+_+=)U]SJ=B>OCB^^KUK:R_""YFN^0U_3,M_]HM\^I3<(SRO-JD
MVV*5;2=Y^C*?_B;.ERZJ&S2*OU?I9W'R?E(/Y3'+?M0?[I[GT[#N4;I.G\HZ
M1%*]?*17Z7I=1ZKZ\6\;='KTK!N>OC]$OVD&7PWF,2G2JVS]S^JY?)M/H^GD
M.7U)WM?E]^SS-FT'9*:3=O0/Z4>ZKN1U3RJ/IVQ=-/]/GMZ+,MNT4:JN;)*?
M^]?5MGG];.,?FO$-9-M 'AL(U=M M0W4KP:ZMX%N&^BA#4S;P P=@VT;V*$.
MKFW@A@XZ:AM$0[L4MPWBH0U$>)BY<.@HQ'&RQ> FA^D6<G"3PX2+P3,N#E,N
M!L^Y.$RZ,(.;'*9=T'D/]I TU%TG97(QR[//2;[?.'9)O3^)\ZI5%;S^MN&X
M^6-%7E%]^W&A(SD+/NI(K>9RKY$G&DDU5[Y&1ZJKN>8TNJOYG=.8KN:&T]BN
M9L'TV1*O6RZ.ZVKN.$W4U=PS7EW%%R9*5_' ^<1=S5=&$X==S3=?HTAG_N#"
MB*YFR0Q)_>IR4*VIX\*2_,*23035<9%\!,5'4$T$?3H41R[)8J\QC6;;:$3H
MHA 8:=Y(^T81N:Z+O28Z,7)GAG<QO(OQ7"1=V8N]QG:&T_SCG2SO9#TG'1,6
M%]:[<,Y@(\<;.<:(+.Q[YPTIJIW(LO55H"<1WY.(Z0FYN'><QO(N,>\2,Q$<
M'Z%.9>Q^&P[G0J ]6S#]B.A&*L!: EX 8R$9KYAZ^2(#C0#MPL==:C ] H L
M](B+"S 5/J<F)-OCHA6=XJ-"*R+47P"J\$DU:.\2@$'A1HP9T"-\-$RH:&:)
MO#%K:4)-LTODK3MK3F7='@'2A(\:C"$!:G($:A*@)GW43$@VEEM6!):"1.F2
M0\A1(TX4 2/ F?0Y,V%,C3@1,@(P2C^M&A%2(TXD@!$@5C+$"DF-_-3:D^\D
M %8RP H%8@!@Y0A@)0!6,L *0N)"^L!::=&Z!"!*!D1!RY96U&%>V\BA>@\
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M)^14*2F^-DW!+1;S6E!>DYUC[4##(2[EA>U&X 8@&,V5#JG #4!<L[<'%G=
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MA2Q]"+$6BP ZJ%IR>&GY<J(U2I;G\9(L=P$NR+@SC$5,)<FEFC(I00V)_E)
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MY50"E(GY0_MJ98A3*=8&":!G)SM:F\61\2C/*U/I"@" _[9G;D,NH+1-97]
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MP'@7;BZN+E0JE?<PF8WCX-$0@F6G"&Z.VK%K>!4X1*:+H>ID8=,1KJC9(9+
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M;?B2;&K5-(&-PPIL(LY/]1)6$9I.[O,4],$?"#=%0W#6P0P4)$%*2#Z8H\E
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M])V)7;2^LB[%\4]Q??&72 ?"4W'05 H>F)0$<PB<L$#5Q$@%$%Z//SMI5?A
M<A!4DJ5'$+^VNKO;B:EA<+G5ZP%TPAL)I .EQ*^7TZD\C6?28- J.!<5Z%(L
M*<J6UOKUEX,2='$\56^-##"FY.ZQCA<AQU1S21]L]GINL5=)5_[Z!7;.P%G*
M _<%F\,OZ86HB)4>1U*)"I1H'W[3GOCU:V^;*%MGBB':MJ6AT7#WZZ''N?9=
M,V!T%ENJL:(SQ1Q;C=0][:@]W:BG@]%)"#.1XLP:KZIK)#+I&7HP-VB7><']
MUV>CV:'C=P*M.H6U8[W!N,!<8C$>:"N%3F&QPP>!5<+(Q>.@E$ LYS-FLV("
MMRJ6L)4#,ZMOTU@I_ Z)YD(U2(15NB.7/+9VN'1WN%0[E+;6.67EB/5$%_2,
M'TRS\429.E1#7NR0B98#DY.I)J2"*5M?04UN0P G=9NCA$+Q?<5]LI12F!KL
MW)/4IM&2AZ6J@3D-=W*=F13KQ3%/4<WM8]5MMEGTC\77UFJ&WF**A&JZ?A>U
MO0#N0B'\G*G;$R=^6R?,CUDK$"%*IS0FFY:AIK0J5',DA?;D2*S!W.6(J%GL
M;"^OVF+YF\A3!K#7!&65E[$UB1)K,!"4V>!6&2Q QIZQNP E;';JV95O2)J^
M5;AOCE"-K=N \UDJ7IDI-V[CD'STX/H37W@$F&-WS-<^VV0Y<&U"+X @5D0
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M@Z YC$!61$[//5S;0NIZ2)QMBMRG2@X ^9;+>Z:J^6@O?>MPFS9?ZRNYVHT
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M[_/[H4IA:[F<R%DX6O0]G'<X"ZD&PXG_X9OX9AA,.A[2L*K.AM<'>=3AH*0
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M[![B9KV3-O T1\ S8?GZ3=QF"E),Z&WT$+Q)BHW/+@*?<>=<?O6U*F'<4_E
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M8F]O:RYX;6S%F4MOXR 41O\*\JJSF01(TX>:2FW:D2)5;:1$LQT1FR2H-J2
MT_;?#]B*BJ?NU6QNNO(+XR-LO@/XZM78YY4QS^2M*K6;9%OO=Y>#@<NWLA+N
MI]E)':ZLC:V$#X=V,W [*T7AME+ZJARPX7 \J(32V?75H:ZY'5Q?Q9W?2KZZ
MC_/QD(C<J[U<BM4D&V:AW" IV%1ZV+9$E_9_F,QZK7)Y9_*ZDMJW4%:6PBNC
MW5;M7$:TJ.0D.Q0A-[H@]]HK_TYFNJTJE,U(\^A9,<EHV/?"AWOVRJE5*3-B
M+U6X8&<%C>!XD+>B%#J79-$T1\+$ "9V3"9R,A<VW+"57N6B_)$P<H"1XS(N
MXG-C&4?,FCSMI&W+)'0C@&YT3+JI<%ORJS2O*=TI0'=Z3+J%-_GSUI2%M.X/
MN7^I$\@Q #G^3LBS!/(,@#S#A7P4OK8R M[63FGI'!$A;![42ZT*Y1/(<P#R
M'+DEZZH2]KUI1K71*MPF8BKFN:E#*B:0%P#D!2[D3'NA-_&9Y,:Y;A32(93/
M0URPJ=%[:7U#]FB\=&0NWD7#\ $("@39(*''!K.E-) Z*+([9CHWE21+\28[
MKQ!2!45VQ=14E?)MEL3N&5ZI5WHC=:ZZD) Q*+8RZI63+W4<K]SO(VH*!LF"
M8ML"B@\Z3C$A75!L7X"8J2\H) R*;(Q/.4=.EC%-7#JNHI M*+(NO@R\EC3%
MA'Q!D871QEY?ZS%(%PQ9%VG^]<)!JF#(J@"#D)RDF.#T ]DAX*B*\103T@K#
MGH) B<-&*28D%H8LEI[$N9->J++[74**8<B*^1J1T XD)!B&+!@ DG4@(;VP
MX^OE +F4;^F$A$&.8=_GF(B;8D*.8<B. 3'Y,%T)@9S#D9US4&%/M^:0;OA1
M9B;=+[#^9P4)\@P_XEREO_7 !2YDO?32=?.00U[AZ%[IX^M$(8>DPM&ETL?'
M.WR03SBZ3_KX^OH()!2.+!1PR,C/4TQ(*!Q=*!#F18H)"84C"^73)/]+/8\@
MH8S:ORF'7RB%7(=1<O$8'N'"^5R4^=R2N&F7@T:G<::VKLMR&LX]Z0<CFI\>
ML8[#_YKKOU!+ P04    " "J/(-*_O=.0Z0!  #=&   &@   'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QSQ=G/;H) $,?Q5S$\0)>9P7^->NK%:]L7(+@"
MD7_9W:;Z]J5<BHDR/9B?%PS!S'Q/'S>X>;=5&LJV\479^=FYKAJ_C8H0NE=C
M?%;8.O4O;6>;_LFQ=74:^EN7FR[-3FEN#<?QPKCQC&BW&<^<[0_;R.T/%,T^
M4Y?;L(W,N3+?K3OYPMK@S?!!+_V"_BN7SOYG?7L\EIE]:[.OVC;A1L7?@LC<
M#N+I((8'R720P(.2Z: $'C2?#IK#@Q;300MXT'(Z: D/6DT'K>!!Z^F@-3R(
M8D7&&)^D88W7FA2N">\U*6 37FQ2R":\V:2@37BU26&;\&Z3 C?AY2:%;L+;
M30K>A->;%;T9KS<K>O,3SMK:81NO-RMZ,UYO5O1FO-ZLZ,UXO5G1F_%ZLZ(W
MX_5F16_&Z\V*WHS76Q2]!:^W*'H+7F]1])8GO"O17I;@]19%;\'K+8K>@M=;
M%+T%K[<H>@M>;U'T%KS>HN@M>+T31>\$KW<RTML7J;.'C^#*)O>/+KD:?K=F
M!+</E\H^/F.8>G?_2.G0;[%FN#[\%VR8^AMAKO[-V/T 4$L#!!0    ( *H\
M@TIQRL[1J $  "X9   3    6T-O;G1E;G1?5'EP97-=+GAM;,V9WV["(!2'
M7\7T=K$(./<GZLVVV\UD>P'6'BVQ+030Z=N/5ETRTR4N:O*[*84#YWQ0\MUT
M_+&UY'N;JJS])"E"L(^,^:R@2OG46*IC9&Y<I4+LN@6S*ENJ!3$Q&(Q89NI
M=>B')D<R'3_37*W*T'O:C3>I)XFRMM29"MK4;%WG1TG[^X2IH[*=XPMM_4V<
MD/1>-C&+CV.3)$9]PDZH<+RPZ<=U;VMR3N?T+S0SG^N,<I.MJK@D]=:1RGU!
M%*HR]85RE+\'I^O%GG>F7'A554S,-B7[-2&]'D?8EM0-T$8N63G$:T%=I=K
M[LG/*GBX#9EQU+<N1EW0'=N+2+,8]:R9>,DM4G-U<LI/*AY37^_#?AFW;-^[
M#OPGZ%G;G'?JE^,0(!P2A&,(PG$+PC$"X;@#X;@'X7@ X> #%! 4HW(4I7(4
MIW(4J7(4JW(4K7(4KW(4L7(4LPH4LPH4LPH4LPH4LPH4LPH4LPH4LPH4LPH4
MLPH4LTH4LTH4LTH4LTH4LTH4LTH4LTH4LTH4LTH4LTH4LPZO:-:V32NEZ[](
M/HU9'NJS]C?)]!M02P$"% ,4    " "J/(-*'R// \     3 @  "P
M        @ $     7W)E;',O+G)E;'-02P$"% ,4    " "J/(-*9O,+8((
M  "Q    $               @ 'I    9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( *H\@TI?BU^M[@   "L"   1              "  9D!  !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( *H\@TJ97)PC$ 8  )PG   3
M          "  ;8"  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
MJCR#2A"V5,*J @  !PH  !@              ( !]P@  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( *H\@TIN$EJ_70,  *$.   8
M          "  =<+  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M    " "J/(-*OXN[UD4"  #U!P  &               @ %J#P  >&PO=V]R
M:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ JCR#2F41M&?  @  N D
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M965T."YX;6Q02P$"% ,4    " "J/(-*Z](O*+8!  #2 P  &
M    @ &$(0  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @
MJCR#2H&6&*FV 0  T@,  !D              ( !<",  'AL+W=O<FMS:&5E
M=',O<VAE970Q,"YX;6Q02P$"% ,4    " "J/(-*J7T$]K<!  #2 P  &0
M            @ %=)0  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4
M Q0    ( *H\@TJ Q->FM0$  -(#   9              "  4LG  !X;"]W
M;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ JCR#2A$Z*L&W 0
MT@,  !D              ( !-RD  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX
M;6Q02P$"% ,4    " "J/(-*'67)X+8!  #2 P  &0              @ $E
M*P  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( *H\@TJC
M^N8HM@$  -(#   9              "  1(M  !X;"]W;W)K<VAE971S+W-H
M965T,34N>&UL4$L! A0#%     @ JCR#2AP;9IE8 @  I @  !D
M     ( !_RX  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *H\@TII$:)-X $   $%   9              "
M 5PY  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ JCR#
M2C7$?%ZW 0  T@,  !D              ( !<SL  'AL+W=O<FMS:&5E=',O
M<VAE970R,BYX;6Q02P$"% ,4    " "J/(-*/MCR./8!   $!@  &0
M        @ %A/0  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0
M   ( *H\@TK/Y\45* ,  !,.   9              "  8X_  !X;"]W;W)K
M<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ JCR#2O)H$LQ0 @  H@<
M !D              ( ![4(  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q0
M2P$"% ,4    " "J/(-* J=Y,[T!   4!   &0              @ %T10
M>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( *H\@TIG7M3"
M-0(  !D&   9              "  6A'  !X;"]W;W)K<VAE971S+W-H965T
M,C<N>&UL4$L! A0#%     @ JCR#2N20*J1U P  81   !D
M ( !U$D  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " "J
M/(-*3SEMMZ8$  "A&@  &0              @ & 30  >&PO=V]R:W-H965T
M<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( *H\@THO4%P[M (  +H)   9
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M970S-"YX;6Q02P$"% ,4    " "J/(-*-G)5R:D"   5"@  &0
M    @ %I8P  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    (
M *H\@TJ[R6YN@@(  %8)   9              "  4EF  !X;"]W;W)K<VAE
M971S+W-H965T,S8N>&UL4$L! A0#%     @ JCR#2NQG?><V @  X 8  !D
M             ( ! FD  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"
M% ,4    " "J/(-*+=9)80,"  !G!@  &0              @ %O:P  >&PO
M=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( *H\@TJ%D!G7]P4
M -$C   9              "  :EM  !X;"]W;W)K<VAE971S+W-H965T,SDN
M>&UL4$L! A0#%     @ JCR#2CJ^KZN4!   *Q@  !D              ( !
MUW,  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " "J/(-*
MH)KE^K93  #E5 $ %               @ &B>   >&PO<VAA<F5D4W1R:6YG
M<RYX;6Q02P$"% ,4    " "J/(-*R#_I;V4"  !@#0  #0
M@ &*S   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( *H\@TH[9)6U*0,  !X:
M   /              "  1K/  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" "J/(-*_O=.0Z0!  #=&   &@              @ %PT@  >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "J/(-*<<K.T:@!   N&0
M$P              @ %,U   6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
..,0 Q $D-   EU@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.7.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>145</ContextCount>
  <ElementCount>279</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>69</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="mbrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>101 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mbrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>102 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/BalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mbrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>103 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mbrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>104 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/StatementsOfOperations</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mbrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>105 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/StatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mbrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>106 - Statement - Statements of Stockholders’ Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/StatementsOfStockholdersEquity</Role>
      <ShortName>Statements of Stockholders’ Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mbrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>107 - Statement - Statements of Stockholders’ Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/StatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>Statements of Stockholders’ Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mbrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>108 - Disclosure - Nature of Business and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/NatureOfBusinessAndLiquidity</Role>
      <ShortName>Nature of Business and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mbrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>109 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mbrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>110 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mbrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>111 - Disclosure - Convertible Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.moleculin.com/role/ConvertibleNotesPayable</Role>
      <ShortName>Convertible Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mbrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>112 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mbrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>113 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mbrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>114 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mbrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>115 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mbrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>116 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="mbrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>117 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="mbrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>118 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/IntangibleAssets</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="mbrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>119 - Disclosure - Convertible Notes Payable (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.moleculin.com/role/ConvertibleNotesPayableTables</Role>
      <ShortName>Convertible Notes Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/ConvertibleNotesPayable</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="mbrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>120 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/Equity</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="mbrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>121 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/IncomeTaxes</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="mbrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>122 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="mbrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>123 - Disclosure - Nature of Business and Liquidity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/NatureOfBusinessAndLiquidityDetailsTextual</Role>
      <ShortName>Nature of Business and Liquidity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/NatureOfBusinessAndLiquidity</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="mbrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>124 - Disclosure - Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="mbrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>125 - Disclosure - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/IntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/IntangibleAssetsTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="mbrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>126 - Disclosure - Intangible Assets (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/IntangibleAssetsDetails1</Role>
      <ShortName>Intangible Assets (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/IntangibleAssetsTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="mbrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>127 - Disclosure - Intangible Assets (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/IntangibleAssetsDetails2</Role>
      <ShortName>Intangible Assets (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/IntangibleAssetsTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="mbrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>128 - Disclosure - Intangible Assets (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/IntangibleAssetsDetailsTextual</Role>
      <ShortName>Intangible Assets (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/IntangibleAssetsTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="mbrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>129 - Disclosure - Convertible Notes Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.moleculin.com/role/ConvertibleNotesPayableDetails</Role>
      <ShortName>Convertible Notes Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/ConvertibleNotesPayableTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="mbrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>130 - Disclosure - Convertible Notes Payable (Details Textual)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.moleculin.com/role/ConvertibleNotesPayableDetailsTextual</Role>
      <ShortName>Convertible Notes Payable (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/ConvertibleNotesPayableTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="mbrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>131 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/EquityTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="mbrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>132 - Disclosure - Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/EquityDetailsTextual</Role>
      <ShortName>Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/EquityTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="mbrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>133 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/IncomeTaxesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="mbrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>134 - Disclosure - Income Taxes (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/IncomeTaxesDetails1</Role>
      <ShortName>Income Taxes (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/IncomeTaxesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="mbrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>135 - Disclosure - Income Taxes (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/IncomeTaxesDetails2</Role>
      <ShortName>Income Taxes (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/IncomeTaxesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="mbrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>136 - Disclosure - Income Taxes (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/IncomeTaxesDetails3</Role>
      <ShortName>Income Taxes (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/IncomeTaxesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="mbrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>137 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/IncomeTaxesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="mbrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>138 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="mbrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>139 - Disclosure - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/CommitmentsAndContingenciesDetailsTextual</Role>
      <ShortName>Commitments and Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="mbrx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>140 - Disclosure - Subsequent Events (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/SubsequentEventsDetailsTextual</Role>
      <ShortName>Subsequent Events (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/SubsequentEvents</ParentRole>
      <Position>40</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>mbrx-20161231.xml</File>
    <File>mbrx-20161231.xsd</File>
    <File>mbrx-20161231_cal.xml</File>
    <File>mbrx-20161231_def.xml</File>
    <File>mbrx-20161231_lab.xml</File>
    <File>mbrx-20161231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>65
<FILENAME>0001144204-17-018352-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-17-018352-xbrl.zip
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M\\C$L8SK*>U?A12H]5*J7LH@5<UBF7:[_8(=T<#+N2 C_P'$TS6Q09K,9F=
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M=)XP4ENW:5Z[3?,ZL[.01HSD0K$O6:/],?;ZA_C=K38X;?:>VDW)UPR]'>X
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MT&HU/W_]<AW^I7Y6'%?^T8<W>!JC]%!#?N25+/O%"5QY9.0CZ=? B_T(3!>
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ML)W7XXGSVD!';6S2F_@@7*:-%8_8Z#BK@W?%D7'!D2"T#0_L,:R:A.#C";&
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M)Q&0DA"R(J%XD4O<%)-5IPZJ9,Y>YXXZG4T^:@IO/WJ\LHGDCX^)P</?\%R
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MJ"+U!XNLU] >-%K#O17/JF6BEHGRR83:ZM:-5LN/;BT4NQ2*YHE:Q8VBFEV
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M1) OM@G[(NSX/DPTT^:X2RJO$U.?('BFS:EBLE=@*&<ZT^RY:3\K(\W2;)T
M@Q#B+_*^^(,:'G38D>,:Q/WE"/9VCBW=XD_59O.OGQ7ZS+&ES9W /QV;;\3X
M?*3HQ,+FQ#K,1]_#OV>:8?"_P_'=\),1;B?R1S?Z*.R GS\%WO&SILU.SR-"
MH"P\XA./Y,W_8CGZ'[_^^4]__I.B_)SR\#<DVAVCV7G@N@26$8CJPZOW9/S+
MT=V9=VNKK:>V^H1B\G0-;WJ^XWZEXA-X.-X]L320MSM0,?-'5[,]#83,L<_>
M3._IVO,"<@$_LWVCK6(Q ?EEA/;:]GPWF,+<^,Z18AK 1#B(\=0:=H^4P#89
M--\?+HX4@^@FF'8>$N_7]J U'*:2(06S+=#AR]J$"%5NL[TV+7J9M%!;7;!7
M]TB,\[6)P<M,-'M(BEN;K$6-?C9G-%N#?1+CXGW$>'QUUB+&(),8^R3$Y::$
M: W6%I!A::EPM385>$JIVL%QUJ!"&QW/DE+AMXVI,%R;"FHF%0:H+'=.B>[.
M-U!0@V7<-+I[V4';S7:YB;'3';3=[&13H]/?+S5VNH6VFRLLS?W28G>[:+N9
M;6:BB.R3$KO<2;--S'U289<[Z99LR_B\TKOLHP<8W+FF3M12>:3M9L+(?)H1
M]^D!(TPR83I &-I0+Z).;GRW2ZB=;KAJL]K$VNV&K*IYJ-5":K6:I:/5;K=K
MM55E6NUP.U?;52;4#G=[M5-E0NW0(%"[NR'4=.2^G7X+$+#;\7>8T*.P&W%Z
M--4GL(L A_ZCTVP]-8?T\]-#,/+(OP.8Z?(%_B7CE_CI<3XCE#+?;8.XKZ[I
MF_;SV;-+R#1\$4$)OQ(O)*@BF\WLQ$DFQ_6W*W B^BJSGI>A%D.=4N..N/C[
M(@_L%==^3@Y03]I=CJV,S8)!;&F>=SO^77.!6?U;]QY37B[?B*N;'J$OAC]Z
M_%<O12QDDA#7)!Y_1R9(ZE24)+NGXB W%;NRE;T)L79%\2\E)WDNXSUDW$J0
M_+S<)&_E<@&VP^4/F@6//?B._L<%\737G.$V>#N6]L1R;B8M]>C76>#J$\TC
MBF,3EL*@..,PI0%Q:M"LG/^?O3?];=Q(&H>_/\#S/Q!^$V3F!UG1+7EF=P"/
MCZSW\8R-&2?!?AJTR9;$#45J>=C6_O5O577S%'6:DDBY%YM$EGA45=?5U76\
M,Y_>:TP;FD_\=,:9JPFVT"ZT9T$?S(2('M8 *N-S6/XCZ_$*K$&\M5@\-'/?
MN1X@/8!CF65QX_,LNW[E,G*MUFJ#WNWVTN<(KR/ 7NE9 0O9:J]>@E8?SW(J
MO 0E-YFMSAL0@[+;T.[!Y(!\]]QGA;HC-,HEW9>UUMB7 >V:T;9L/63G7 U\
M\F>PL,:%,YERL)"TX\:;1@3=YUE\R3V;T=8:#+1Q1V;5^XVH?V/##LETC-]<
MQ_-*2L_^YOI@!\3)I3_YA27S(M;:Y+5IQ]$YRY",\,EB>N\Z.N>&=^TZ$XP:
M8 ;C#;S!9-9]\&B9^MUP"'2R1R7EGR5).J?=DT^=3B-]PK@VOGO8<.V;6.VU
M-D]M#+4U&LV"=D^D!1=&ZT(3<D&[AN\BM3K+:0T1G7QP#GE2UVZNH?G/.H-V
M2VK^C7#>$[7V>ES77F/+<]9KM?IG):;8'L]6VFOL3QHE)M4>3U?::VPCRDRJ
M/9ZOM-?P]CM-D<!86GKM]S2XO8:37V9J[3?/H+V&"]_L-CN-5QG&_'._T(-#
M')HE]1L&X!? /:>-P6F[N>@ ,X7(KG#>K_4_"_$^.VVT#XKW?N6ATY"(-QNG
MC=Y!$=^OVNPT2X/X'KVV3BO&NC4X*-9[=, Z;<*Z=]IHGC8[!\5ZC[Y4IY/
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M4V#9;G]0!+82QGTAO7AU.XWF2J2;[59G!TBOT-\TBO7<P!XRHH_+YNNY)(:
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M3N?BRU94\*RS^ !7JX%9+QN^:JX2!BLG1(W898"''>(R43MV+\LL[H;"[\O
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M8_DPC;AC1W)Z1F+14Y=O-@=C[;D6V!=DFZD69>V;W3XK8%Q669$K8A28PNT
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M1Z3M4PA4!>B[.*-U$":TIK)R+QQWZDBMDBK= 77'?6QNDM1*.,<F(13/V*S
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MHHC1BJ55O)X8^$#MSD!*(KID0S"Y(<JZ]GW*=7,8SA,)MEKD3 L$S79LEV/
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MWV.S5U1N<)>7&-/,=&G@L8060TMR,&U,DS0]<K:@*8T==]6=WZN(&BQ7-.?
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M(=C(%!6 L$I$6H;*GSRK-U##XJ95"Z:%:]!-=5I=NPO<Y08A@EP,[7QTF)O
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MP\"R2 )=;VQ.$S),T5;FPWX,?&^L,/""Z13K8Z0W?WUYKL'J:#*7L=,;],[
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MC61'5F9KSG!HZG ALPW-]#V0(^8:\*UFF"[7?<?U!/<,6LW^1\V9^J9C T!
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M_?M)XR0$CDX*/C0;C9\_"AMZ:K&9$_@?AN8+-SZ>:/]_>]?6VS:2K-\'F/_
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MPZF(XMRA+4;M.[*%=A@1I A2:O".(-4*!Z9<%[;2&K:=]655))<6>VFQE\!
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MI"#)^"RK(!F26*GD"[V4CUM*[LQ]U['$K(K\0V*Y'.P\#>I7:" 0"M,5#F7
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M&3BNR!9X_AR0"GY()Y;06^'/B[1$P++AZ;*42!D6TAHZM_(G$0BCV?)"-P/
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M&-9R/OH"OL#O'X[P$<X)_B\H^']02P,$%     @ JCR#2E"I6RU8$0  T<4
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M=/1U=)2L;PX*(@-%=+1+FUIT'.CH."BAHR 84$3'04M''3HRBTS=8S,U!9&
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ML3%.A-[-M1LTRS =QV]NK%.KI@]SIL M\K:Q37'515.7'+5ATZB?8&_3VXE
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M D$H%C]XP0E5AEP>6&(C5W%5PD,F1.$M0&0"R:/=DJ5"CQ"VIOQ)+;.'.:U
MON;M( H08:9CYG97F:T&FW[K_*!J7-7VJMR(JCL:UQRJFL9NHH/.5<OZEKU:
MF8ZRB TV/5ZEBH>Q8/K70H%0X,TZU5P0PPS*<E:4357MJYS_ET^B6G8'W2Y
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M<7PPA)I\E]ETS5A6@&2:5;8%R!]P=Z<)&V&ZHZ^1PX/A\M&$5V?GB.)QVNU
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M.-@G8.Q?P\!=HS:)U?RQNYOI/*S7)PFP\>/4Y$*EU.HA6?O %[=,1.9P8Z&
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M8WB;$;[@>X*2[#Z)0O\DN=>>Q,V1F@5C,JL7-&"<Z"EVS0M19HAQ0[^6_WV
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MJ,$Y8WDX&;2YXC'#OQ?@ EY@BF,>0#W'LR*]>5M1E(NS@YH.,4*W)P*MX>/
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M0#X 8$K?6;?9ME9Q-J;-]9312H3@5X)G;<'3M057RP2SK.Q-1AA=)5A/ [.
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M5[&T_=!6#7:]5 GJF#,8O%.0Q5Z<"^ZUV:1<D%'8'3'KO$KEY3E,S8?]S-$
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MA&V9'A4I_KIY<[.Z5%#8HK;7 V]W9UBK33_R0Q2YC4UTJUD!S]/DE<'JS"]
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M8J[Z%E1%AK3GD$A[NQ2I!)9QJUQ^]1OR#@Y(9&\QWZV88AQ$W.4J\'$632-
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M&41L)30$8-=Y7K+PHLRB9%JG)JY\M/);]JWZDSS)H4X#WMX^B?V+A$[DAMH
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M,C Q-C$R,S$N>&UL4$L! A0#%     @ JCR#2E"I6RU8$0  T<4  !$
M         ( !E/<  &UB<G@M,C Q-C$R,S$N>'-D4$L! A0#%     @ JCR#
M2CW#NA3W"   I'P  !4              ( !&PD! &UB<G@M,C Q-C$R,S%?
M8V%L+GAM;%!+ 0(4 Q0    ( *H\@TK9)/DJ!TL  )7?!  5
M  "  442 0!M8G)X+3(P,38Q,C,Q7V1E9BYX;6Q02P$"% ,4    " "J/(-*
MYZESX7EH  "8MP4 %0              @ %_70$ ;6)R>"TR,#$V,3(S,5]L
M86(N>&UL4$L! A0#%     @ JCR#2O5 46"#4   6VD% !4
M ( !*\8! &UB<G@M,C Q-C$R,S%?<')E+GAM;%!+!08     !@ & (H!  #A
%%@(    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
